

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:52:18 ON 05 AUG 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 14:53:14 ON 05 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3

DICTIONARY FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\bmcldowell\My Documents\misc\10552426.str



chain nodes :

11

ring nodes :

1 2 3 4 5 6 7 8 9 10

ring/chain nodes :

12

chain bonds :


```

7-12  9-11
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
7-12  9-11
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1 STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:53:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4301 TO ITERATE

46.5% PROCESSED      2000 ITERATIONS      50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   82087 TO   89953
PROJECTED ANSWERS:      13448 TO   16744

```

L2 50 SEA SSS SAM L1

```

=> s l1 sss full
FULL SEARCH INITIATED 14:53:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 87525 TO ITERATE

```

```

100.0% PROCESSED      87525 ITERATIONS      15742 ANSWERS
SEARCH TIME: 00.00.02

```

L3 15742 SEA SSS FUL L1

```
=> d dscan
'DSCAN' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN
```

```
EPROP  - Table of experimental properties
PPROP  - Table of predicted properties
PROP   - EPROP, ETAG, PPROP and SPEC
```

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

```
ABS    -- Abstract
APPS   -- Application and Priority Information
BIB    -- CA Accession Number, plus Bibliographic Data
CAN    -- CA Accession Number
CBIB   -- CA Accession Number, plus Bibliographic Data (compressed)
IND    -- Index Data
IPC    -- International Patent Classification
PATS   -- PI, SO
STD    -- BIB, IPC, and NCL
```

```
IABS   -- ABS, indented, with text labels
IBIB   -- BIB, indented, with text labels
ISTD   -- STD format, indented
```

```
OBIB   ----- AN, plus Bibliographic Data (original)
OIBIB  ----- OBIB, indented with text labels
```

```
SBIB   ----- BIB, no citations
SIBIB  ----- IBIB, no citations
```

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.


The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

```
HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):ide
```

RN 1038038-31-1 REGISTRY
ED Entered STN: 03 Aug 2008
CN INDEX NAME NOT YET ASSIGNED
MF C21 H18 N4 O2
SR Chemical Library
Supplier: UkrOrgSynthesis



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d scan


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-[4-(4-morpholinyl)phenyl]-,
hydrochloride (1:1)
MF C24 H20 Cl2 N4 O . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[3-[4-(2-pyrimidinyl)-1-
 piperazinyl]propyl]-
 MF C24 H26 N8




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Isoleucine, N-(6-bromo-2-phenyl-4-quinazolinyl)-
 MF C20 H20 Br N3 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(3,4-dichlorophenyl)-,
hydrochloride (1:1)
MF C20 H12 Cl3 N3 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, N-(2,6-dimethylphenyl)-2-phenyl-, hydrochloride (1:1)
MF C22 H19 N3 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzeneacetaldehyde, 4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]- α -methyl-
 MF C24 H19 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Methanone, [4-(4-amino-6,7-dimethoxy-5-phenyl-2-quinazolinyl)hexahydro-1H-1,4-diazepin-1-yl][(3S,4S)-3,4-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-1-pyrrolidinyl]-
 MF C38 H60 N6 O5 Si2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C26 H21 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1,5-Pentanediamine, N5-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-
 N1,N1-dimethyl-
 MF C23 H29 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Quinazolinamine, 2-(2-chlorophenyl)-6,7-dimethoxy-N-4-pyridinyl-
 MF C21 H17 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Acetamide, 2-[[5-[4-(1H-indazol-5-ylamino)-6-(2-methoxyethoxy)-2-quinazolinyl]-3-thienyl]oxy]-N-(1-methylethyl)-
 MF C27 H28 N6 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-1H-indazol-5-yl-6-[2-(4-morpholinyl)ethoxy]-
 MF C33 H30 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indazole-1-carboxylic acid, 5-[[2-[3-[(4-piperidinylcarbonyl)amino]phenyl]-4-quinazolinyl]amino]-, 1,1-dimethylethyl ester
 MF C32 H33 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzamide, N-[1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-piperidinyl]-2-ethoxy-
 MF C24 H29 N5 O4
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzenesulfonamide, N-[1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-piperidinyl]-
 MF C21 H25 N5 O4 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzamide, N-[3-(4-amino-6,7-dimethoxy-2-quinazolinyl)-3-
 azabicyclo[3.1.0]hex-6-yl]-2-methoxy-, hydrochloride (1:1)
 MF C23 H25 N5 O4 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzamide, N-[3-(4-amino-6,7-dimethoxy-2-quinazolinyl)-3-
 azabicyclo[3.1.0]hex-6-yl]-3,4-dimethoxy-, hydrochloride (1:1)
 MF C24 H27 N5 O5 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzamide, N-[3-(4-amino-6,7-dimethoxy-2-quinazolinyl)-3-azabicyclo[3.1.0]hex-6-yl]-, hydrochloride (1:1)
 MF C22 H23 N5 O3 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperazinecarboxamide, N-(2-methylphenyl)-4-[2-(4-methylphenyl)-4-quinazolinyl]-
 MF C27 H27 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperazinecarboxamide, 4-[2-(2-furanyl)-4-quinazolinyl]-N-(4-methoxyphenyl)-
 MF C24 H23 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Propanone, 3-[(7-chloro-2-phenyl-4-quinazolinyl)(2-furanylmethyl)amino]-
 1-(4-morpholinyl)-
 MF C26 H25 Cl N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Benzenemethanol, 4-nitro- α -[[2-phenyl-4-quinazolinyl)amino]methyl]-
 MF C22 H18 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Methanone, 1,3-benzodioxol-5-yl[4-[2-(2-thienyl)-4-quinazolinyl]-1-piperazinyl]-
 MF C24 H20 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Methanone, (2-fluorophenyl)[4-[2-(3-pyridinyl)-4-quinazolinyl]-1-
MF piperazinyl]-
C24 H20 F N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Ethanone, 1-(3,5-dimethyl-1-piperidiny1)-2-[4-[2-(2-thienyl)-4-
MF quinazolinyl]-1-piperazinyl]-
C25 H31 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Quinazoline, 4-[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]-2-(2-
 thienyl)-
 MF C25 H26 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Quinazoline, 4-[4-(tetrahydro-1,1-dioxido-3-thienyl)-1-piperazinyl]-2-(3-thienyl)-
MF C20 H22 N4 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Piperidinecarboxamide, 1-[2-(3-pyridinyl)-4-quinazolinyl]-
MF C19 H19 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Acetamide, N-(2-methoxyethyl)-2-[methyl[2-(4-pyridinyl)-4-quinazolinyl]amino]-
MF C19 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Quinazolinamine, 2-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]-
 MF C20 H17 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1-Piperazineacetic acid, α -(2-chlorophenyl)-4-[2-(4-pyridinyl)-4-quinazolinyl]-, methyl ester
 MF C26 H24 Cl N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Methanone, 2-furanyl[4-[[2-(3-thienyl)-4-quinazolinyl]amino]-1-piperidinyl]-
 MF C22 H20 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Quinazolinamine, N-[[6-(4-morpholinyl)-3-pyridinyl]methyl]-2-(3-thienyl)-
 MF C22 H21 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Quinazoline, 2-(3-pyridinyl)-4-[4-[[2-(3-thienyl)-4-thiazolyl]methyl]-1-piperazinyl]-
 MF C25 H22 N6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Quinazoline, 4-[4-(2-phenylethyl)-1-piperazinyl]-2-(3-thienyl)-
MF C24 H24 N4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, N-[(4-fluorophenyl)(1-methyl-1H-imidazol-2-yl)methyl]-2-phenyl-
MF C25 H20 F N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 6-Azabicyclo[3.2.1]octane, 6-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-1,3,3-trimethyl-
MF C24 H25 Cl2 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 15742 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Propanamide, 3-[(2-cyclopropyl-4-quinazolinyl)propylamino]-N-(1-phenylethyl)-
 MF C25 H30 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

181.74

182.16

FILE 'CAPLUS' ENTERED AT 14:55:40 ON 05 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 4 Aug 2008 (20080804/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 14:52:18 ON 05 AUG 2008)

FILE 'REGISTRY' ENTERED AT 14:53:14 ON 05 AUG 2008

L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 15742 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:55:40 ON 05 AUG 2008

=> s l3 and (py<2004)
4872 L3
24005665 PY<2004
L4 3734 L3 AND (PY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	184.76

FILE 'STNGUIDE' ENTERED AT 14:56:33 ON 05 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 1, 2008 (20080801/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	184.94

FILE 'REGISTRY' ENTERED AT 14:58:08 ON 05 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3
DICTIONARY FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Documents and Settings\bmcldowell\My Documents\misc\10552426narrow.str



chain nodes :

11

ring nodes :

1 2 3 4 5 6 7 8 9 10

ring/chain nodes :

12

chain bonds :

7-12 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

7-12 9-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS

Generic attributes :

11:

Saturation : Unsaturated

L5 STRUCTURE UPLOADED

=> s l5 sss full

FULL SEARCH INITIATED 14:58:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 87525 TO ITERATE

100.0% PROCESSED 87525 ITERATIONS

10076 ANSWERS

SEARCH TIME: 00.00.02

L6 10076 SEA SSS FUL L5

=> fil cap

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	363.30

FILE 'CAPLUS' ENTERED AT 14:58:48 ON 05 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2008 VOL 149 ISS 6
 FILE LAST UPDATED: 4 Aug 2008 (20080804/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> s 16 and (py<2004)
      463 L6
      24005665 PY<2004
L7      323 L6 AND (PY<2004)
```

```
=> d 1-50 ibib abs hitstr
```

```
L7  ANSWER 1 OF 323  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2006:544975  CAPLUS
DOCUMENT NUMBER:       145:44367
TITLE:                 Modulation of PDE11A activity for affecting
                        spermatogenesis
INVENTOR(S):           Burslem, Martyn Frank; Harrow, Ian Dennis; Lanfear,
                        Jeremy; Phillips, Stephen Charles; Wayman, Christopher
                        Peter
PATENT ASSIGNEE(S):    UK
SOURCE:                U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.
                        Ser. No. 40,570.
                        CODEN: USXXCO
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20060121550	A1	20060608	US 2002-137498	20020429
US 20030061625	A1	20030327	US 2001-40570	20011101 <--
US 6828473	B2	20041207		
AU 2003246861	A1	20030909	AU 2003-246861	20030212 <--
JP 2004283180	A	20041014	JP 2004-169061	20040607

PRIORITY APPLN. INFO.:


GB 2000-26727	A	20001101
US 2000-255689P	P	20001214
GB 2001-11710	A	20010514
US 2001-293411P	P	20010524
US 2001-40570	A2	20011101
GB 2002-4227	A	20020222
JP 2001-337061	A3	20011101
WO 2003-IB508	W	20030212

AB The invention provides genetically modified non-human mammals and genetically modified animal cells containing a functionally disrupted PDE11A gene. Also provided by the invention are methods of screening for agents that modulate PDE11A to modulate spermatogenesis, methods of treating mammals to modulate spermatogenesis, and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11A. The invention also provides agents and methods relating to the effect of PDE11A modulation (i.e. PDE11A inhibition or stimulation) on ex vivo spermatozoa capacitation and PDE11A stimulation on in vivo spermatozoa capacitation. The invention also relates to the effect of PDE11A modulation on male pro-fertility and female sexual dysfunction (FSD), specifically female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), hypoactive sexual desire disorder (HSDD) or sexual pain disorders. The present invention features genetically-modified animal cells and genetically-modified nonhuman mammals containing a disrupted PDE11A gene, as well as assays for identifying PDE11A function in the cells and tissues that normally express PDE11A. Based upon studies of genetically modified mice homozygous for a PDE11A disruption (PDE11A -/-), we have discovered that PDE11A plays a role in stimulating spermatogenesis. Accordingly, the present invention also provides methods for impacting or affecting, e.g., stimulating or inhibiting, spermatogenesis in a mammal by administering an agent that increases or decreases PDE11A activity, resp.

IT 157863-31-5, 6-Chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, 4-quinazolinamine dihydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modulation of PDE11A activity for affecting spermatogenesis)

RN 157863-31-5 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L7 ANSWER 2 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:878169 CAPLUS

DOCUMENT NUMBER: 141:366218

TITLE: Preparation of substituted (hetero)aromatic compounds that modulate PPAR activity


INVENTOR(S): Bratton, Larry D.; Cheng, Xue-Min; Erasga, Noe; Filzen, Gary F.; Geyer, Andrew G.; Lee, Chitase; Trivedi, Bharat K.; Unangst, Paul C.

PATENT ASSIGNEE(S): Warner Lambert Company LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 90 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040209936	A1	20041021	US 2004-774260	20040206
US 7244763	B2	20070717		
US 20030225158	A1	20031204	US 2003-347749	20030122 <--
US 6875780	B2	20050405		
CA 2522118	A1	20041028	CA 2004-2522118	20040405
WO 2004091604	A1	20041028	WO 2004-IB1178	20040405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620086	A1	20060201	EP 2004-725756	20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009486	A	20060502	BR 2004-9486	20040405
JP 2006524220	T	20061026	JP 2006-506486	20040405
NL 1025961	A1	20041026	NL 2004-1025961	20040416
NL 1025961	C2	20050215		
PRIORITY APPLN. INFO.:			US 2003-463641P	P 20030417
			US 2002-370508P	P 20020405
			US 2002-386026P	P 20020605
			WO 2004-IB1178	W 20040405
OTHER SOURCE(S):			CASREACT 141:366218; MARPAT 141:366218	
GI				




AB Title compds. I [X0-2 = absent, O, S, amino, etc.; Ar1-2 = (hetero)aryl, etc.; V1 = absent, (un)saturated hydrocarbon chain, etc.; T = (un)saturated, (un)substituted hydrocarbon, etc.; R1-3 = H, alkyl, alkoxy, etc.; R7-8 = H, alkyl, halo, etc.; n = 0-5; q = 0-10; p = 0-10] are prepared For instance, [7-[(4-(4-Chlorophenyl)-4-oxobutyl)sulfanyl]indan-4-yloxy]acetic acid is prepared in 5 steps from 4-hydroxyindan-1-one, Me bromoacetate and 4-chloro-1-(4-chlorophenyl)butan-1-one. Compds. of the invention exhibit IC50 < 9,344 nM for PPAR β and IC50 of < 15,000 nM for PPAR α . I are useful for the treatment of dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia.

IT 779193-58-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)


RN 779193-58-7 CAPLUS

CN Acetic acid, 2-[2-methyl-4-[[2-[[3-[(2-phenyl-4-quinazolinyl)amino]propyl]thio]ethyl]thio]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:160406 CAPLUS
 DOCUMENT NUMBER: 141:410887

TITLE: A facile synthesis of 2-phenylquinazoline derivatives
 AUTHOR(S): Issac, Yvette A.; Arsanious, Mona H.; Abd El-Nabi, Hisham A.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt
 SOURCE: Egyptian Journal of Chemistry (2003), Volume Date 2002, 45(5), 929-946
 CODEN: EGJCA3; ISSN: 0449-2285
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:410887
 GI



AB Several 2-phenylquinazoline derivs., e.g., I, were synthesized starting from Et (2-phenylquinazolin-4-oxy)acetate. The structures of the isolated compds. were elucidated by IR, ¹H NMR, ¹³C NMR, MS, and elemental analyses. The antimicrobial activity of some of these compds. against a variety of bacteria and fungi was determined
 IT 512187-97-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of substituted quinazolines via substitution of chloroquinazoline with nucleophiles)
 RN 512187-97-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-thiazolyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 117998-85-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation and antimicrobial activity of substituted quinazolines via substitution of chloroquinazoline with nucleophiles)

RN 117998-85-3 CAPLUS

CN 4(1H)-Quinazolinone, 2-phenyl-, oxime (9CI) (CA INDEX NAME)




IT 474289-64-0P 512188-00-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antimicrobial activity of substituted quinazolines via substitution of chloroquinazoline with nucleophiles)

RN 474289-64-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-2-pyridinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 512188-00-0 CAPLUS

CN Quinazoline, 2-phenyl-4-(2-phenylhydrazinyl)- (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:931342 CAPLUS

DOCUMENT NUMBER: 140:791

TITLE: Treatment of fibroproliferative disorders using TGF- β inhibitors

INVENTOR(S): Chakravarty, Sarvajit; Dugar, Sundeep; Higgins, Linda S.; Kapoun, Ann M.; Liu, David Y.; Schreiner, George F.; Protter, Andrew A.; Tran, Thomas-Toan

PATENT ASSIGNEE(S): Scios, Inc., USA
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097615	A1	20031127	WO 2003-US15514	20030516 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003229305	A1	20031202	AU 2003-229305	20030516 <--
US 20040038856	A1	20040226	US 2003-440428	20030516
EP 1511738	A1	20050309	EP 2003-726892	20030516
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-381720P	P 20020517
			US 2003-440428	A 20030516
			WO 2003-US15514	W 20030516

OTHER SOURCE(S): MARPAT 140:791

AB The invention concerns methods of treating fibroproliferative disorders associated with TGF- β signaling, by administering non-peptide small mol. inhibitors of TGF- β specifically binding to the type I TGF- β receptor (TGF β -R1). Preferably, the inhibitors are quinazoline derivs. The invention also concerns methods for reversing the effect of TGF- β mediated cell activation on the expression of a gene associated with fibrosis, comprising contacting a cell or tissue in which the expression of such gene is altered as a result of TGF- β mediated cell activation, with a non-peptide small mol. inhibitor of TGF- β , specifically binding a TGF β -R1 receptor kinase present in the cell or tissue.

IT 18602-70-5 40288-70-8 54665-94-0
 80858-58-8 157862-99-2 166039-38-9
 181114-32-9 181115-48-0 259870-32-1
 259870-33-2 259870-34-3 259870-35-4
 259870-36-5 259870-37-6 259870-38-7
 259870-39-8 259870-42-3 259870-44-5
 404828-44-0 420831-73-8 422561-07-7
 438247-46-2 446312-97-6 446829-19-2
 474289-37-7 474289-39-9 474289-40-2
 474289-42-4 474289-44-6 474289-50-4
 474289-54-8 474289-60-6 474289-64-0
 474289-68-4 474289-70-8 474289-72-0
 474289-74-2 474289-76-4 474289-79-7
 474289-80-0 474289-82-2 474289-84-4
 474289-87-7 474289-89-9 474289-93-5
 474289-98-0 474290-04-5 474290-06-7
 474290-15-8 474290-17-0 474290-19-2
 474290-23-8 474290-26-1 474290-28-3
 474290-30-7 627535-94-8 627535-96-0
 627535-97-1 627535-99-3 627536-00-9
 627536-01-0 627536-04-3 627536-05-4

627536-06-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(treatment of fibroproliferative disorders using TGF- β inhibitors)


RN 18602-70-5 CAPLUS

CN 4-Quinazolinamine, N-[[2-(4-morpholinyl)ethyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 54665-94-0 CAPLUS

CN Phenol, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 80858-58-8 CAPLUS

CN Quinazoline, 2-phenyl-4-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 157862-99-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 166039-38-9 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 181114-32-9 CAPLUS


CN Quinazoline, 2-phenyl-4-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 181115-48-0 CAPLUS
 CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)




RN 259870-32-1 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 259870-33-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-34-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-35-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-36-5 CAPLUS
 CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 259870-37-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-38-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-39-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-42-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 259870-44-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 404828-44-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 420831-73-8 CAPLUS

CN 4-Quinazolinamine, N-(2-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 422561-07-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 438247-46-2 CAPLUS


CN 4-Quinazolinamine, N-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 446312-97-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 446829-19-2 CAPLUS
 CN Phenol, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-37-7 CAPLUS
 CN 2,3-Pyridinediamine, N2-(phenylmethyl)-N3-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474289-39-9 CAPLUS
 CN 2,4-Pyridinediamine, N2-(phenylmethyl)-N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474289-40-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-[3-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 474289-42-4 CAPLUS
 CN 4-Quinazolinamine, 2-(3-aminophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-44-6 CAPLUS
 CN 4-Quinazolinamine, N,2-di-4-pyridinyl- (CA INDEX NAME)




RN 474289-50-4 CAPLUS
 CN 4-Quinazolinamine, N-4-pyridinyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 474289-54-8 CAPLUS
 CN 1,4-Benzenediamine, N1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474289-60-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-3-pyridinyl- (CA INDEX NAME)



RN 474289-64-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-pyridinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 474289-68-4 CAPLUS
 CN Benzeneethanol, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-70-8 CAPLUS

CN Benzonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-72-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 474289-74-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-76-4 CAPLUS

CN 4-Quinazolinamine, N-[(2,5-difluorophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 474289-79-7 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylpropyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 474289-80-0 CAPLUS

CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-phenyl- (CA INDEX NAME)




RN 474289-82-2 CAPLUS

CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 474289-84-4 CAPLUS

CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-87-7 CAPLUS


CN 4-Quinazolinamine, N-(1-methylethyl)-2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-89-9 CAPLUS
 CN 4-Quinazolinamine, N-[(4-methoxyphenyl)methyl]-2-phenyl-N-4-pyridinyl-
 (CA INDEX NAME)



RN 474289-93-5 CAPLUS
 CN Phenol, 2-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-98-0 CAPLUS
 CN 4-Quinazolinamine, 2-(3-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474290-04-5 CAPLUS

CN 3,4-Pyridinediamine, N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474290-06-7 CAPLUS

CN 4-Quinazolinamine, 2-[2-[(phenylmethyl)amino]phenyl]-N-4-pyridinyl- (CA INDEX NAME)




RN 474290-15-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 474290-17-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 474290-19-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 474290-23-8 CAPLUS


CN 4-Quinazolinamine, N-1H-indol-4-yl-2-phenyl- (CA INDEX NAME)




RN 474290-26-1 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-5-yl-2-phenyl- (CA INDEX NAME)



RN 474290-28-3 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-4-pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 474290-30-7 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 627535-94-8 CAPLUS

CN 4-Quinazolinamine, N-(4-methoxyphenyl)-2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 627535-96-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(aminomethyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 627535-97-1 CAPLUS


CN 4-Quinazolinamine, N-[(4-aminophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 627535-99-3 CAPLUS
 CN 4-Quinazolinamine, N-2-naphthalenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 627536-00-9 CAPLUS
 CN Quinazoline, 2-phenyl-4-[4-(4-pyridinylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 627536-01-0 CAPLUS
 CN 4-Piperidinecarboxamide, 1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 627536-04-3 CAPLUS
 CN 1,2-Benzenediamine, N1-(phenylmethyl)-N2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 627536-05-4 CAPLUS
 CN Benzonitrile, 4-[4-[[2-[(phenylmethyl)amino]phenyl]amino]-2-quinazolinyl]-
 (CA INDEX NAME)



RN 627536-06-5 CAPLUS
 CN Benzonitrile, 3-[[[2-[(2-phenyl-4-quinazolinyl)amino]phenyl]amino]methyl]-
 (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:913005 CAPLUS
 DOCUMENT NUMBER: 139:391384
 TITLE: Use of inhibitors of EGFR-mediated signal transduction
 for the treatment of benign prostatic hyperplasia
 (BPH)/prostatic hypertrophy
 INVENTOR(S): Singer, Thomas; Colbatzky, Florian; Platz, Stefan

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.,
Germany
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094921	A2	20031120	WO 2003-EP4606	20030502 <--
WO 2003094921	A3	20040318		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10221018	A1	20031127	DE 2002-10221018	20020511 <--
AU 2003233223	A1	20031111	AU 2003-233223	20030502 <--
CA 2483590	A1	20031120	CA 2003-2483590	20030502 <--
EP 1505981	A2	20050216	EP 2003-727422	20030502
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005526123	T	20050902	JP 2004-503006	20030502
US 20030225079	A1	20031204	US 2003-431699	20030508 <--
US 20070099918	A1	20070503	US 2006-609407	20061212
PRIORITY APPLN. INFO.:			DE 2002-10221018	A 20020511
			US 2002-389815P	P 20020618
			WO 2003-EP4606	W 20030502
			US 2003-431699	B1 20030508

OTHER SOURCE(S): MARPAT 139:391384

AB The invention discloses the use of EGF-receptor antagonists for the production of a medicament to prevent and/or treat benign prostatic hyperplasia and/or prostatic hypertrophy, as well as a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy involving the administration of an EGF-receptor antagonist, optionally in combination with known compds. for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, and the corresponding pharmaceutical compns. Compds. of the invention include e.g. quinazoline derivs. and monoclonal antibodies. Preparation of

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N-(2-methoxyethyl)-N-methylamino)-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline is described.


IT 210538-44-6, UK 338003

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(EGFR-mediated signal transduction inhibitors for treatment of benign prostatic hyperplasia/prostatic hypertrophy)

RN 210538-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



L7 ANSWER 6 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:892555 CAPLUS

DOCUMENT NUMBER: 139:377257

TITLE: Crystal structure of human Aurora-2 kinase complexes with ligands and their binding sites, and applications in drug screening and drug design

INVENTOR(S): Cheetham, Graham; Knegtel, Ronald; Swenson, Lovorka; Coll, Joyce T.; Renwick, Suzanne; Weber, Peter

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092607	A2	20031113	WO 2003-US13605	20030501 <--
WO 2003092607	A3	20040205		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003231232	A1	20031117	AU 2003-231232	20030501 <--
EP 1549318	A2	20050706	EP 2003-724367	20030501
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20050143402	A1	20050630	US 2004-979375	20041101
US 7361492	B2	20080422		

PRIORITY APPLN. INFO.: US 2002-377510P P 20020501
WO 2003-US13605 W 20030501

AB The present invention provides crystalline mols. or mol. complexes which comprise binding pockets of Aurora-2 kinase or its homologues. The invention also provides crystals comprising Aurora-2. The crystal structures and atomic coordinates of human Aurora-2-inhibitor complexes and the crystal structure and atomic coordinates of the Aurora-2 bound to adenosine are disclosed. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates


of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the mol. or mol. complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compds., including inhibitory compds., that bind to Aurora-2 or homologues thereof.

IT 404828-21-3D, complexes with Aurora-2 606092-72-2D, complexes with Aurora-2
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (crystal structure of human Aurora-2 kinase complexes with ligands and their binding sites, and applications in drug screening and drug design)
 RN 404828-21-3 CAPLUS
 CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 606092-72-2 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-2-thiazolyl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L7 ANSWER 7 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:841844 CAPLUS
 DOCUMENT NUMBER: 140:77101
 TITLE: The design and synthesis of novel orally active inhibitors of AP-1 and NF- κ B mediated transcriptional activation. SAR of In vitro and In vivo studies

AUTHOR(S): Palanki, Moorthy S. S.; Erdman, Paul E.; Ren, Minghuan; Suto, Mark; Bennett, Brydon L.; Manning, Anthony; Ransone, Lynn; Spooner, Cheryl; Desai, Sonal; Ow, Arnie; Totsuka, Ryuichi; Tsao, Peter; Toriumi, Wataru

CORPORATE SOURCE: Celgene, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(22), 4077-4080
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:77101


AB We have developed novel orally active quinazoline analogs as inhibitors of AP-1 and NF- κ B mediated transcriptional activation. Among the derivs. prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described.

IT 219773-55-4P 219773-60-1P 219773-64-5P
219773-68-9P 219773-72-5P 219773-75-8P
219773-78-1P 219773-85-0P 219773-89-4P
640297-60-5P 640297-61-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of quinazoline analogs as orally active inhibitors of AP-1 and NF- κ B mediated transcriptional activation)


RN 219773-55-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-60-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[6-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-64-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[7-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-68-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[8-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-72-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-75-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[6,7,8-trimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 219773-78-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[5-fluoro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-85-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[5-methyl-2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 219773-89-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[7-(dimethylamino)-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 640297-60-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[6-chloro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)



RN 640297-61-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[7-(4-morpholinyl)-2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757702 CAPLUS

DOCUMENT NUMBER: 139:255407

TITLE: Azolylaminoazine compounds as inhibitors of protein kinases, and their therapeutic use

INVENTOR(S): Binch, Hayley; Charrier, Jean-Damien; Everitt, Simon; Golec, Julian M. C.; Kay, David; Knegtel, Ronald; Miller, Andrew; Pierard, Francoise; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078426	A1	20030925	WO 2003-US7904	20030314 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003225800	A1	20030929	AU 2003-225800	20030314 <--
US 20040002496	A1	20040101	US 2003-389709	20030314
US 7179826	B2	20070220		
EP 1485381	A1	20041215	EP 2003-744682	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-364840P	P 20020315
			WO 2003-US7904	W 20030314

OTHER SOURCE(S): MARPAT 139:255407

AB The invention provides azolylaminoazine compds. useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compns. comprising the compds. and methods of using the compns. in the treatment of various diseases, conditions, and disorders.

IT 603932-44-1 603932-49-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(azolylaminoazine compds. as inhibitors of protein kinases, therapeutic use, and use with other agents)


RN 603932-44-1 CAPLUS

CN 7-Quinazolinemethanamine, 4-[(5-ethyl-4-oxazolyl)amino]-N,N-dimethyl-2-phenyl- (CA INDEX NAME)



RN 603932-49-6 CAPLUS

CN 4-Quinazolinamine, 2-(1-naphthalenyl)-N-1,2,4-thiadiazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757700 CAPLUS

DOCUMENT NUMBER: 139:276913

TITLE: Preparation of thiazolylaminopyrimidines and related compounds as inhibitors of protein kinases

INVENTOR(S): Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA; Binch, Hayley; Charrier, Jean-Damien; Everitt, Simon; Golec, Julian M. C.; Kay, David; Knegetel, Ronald; Miller, Andrew; Pierard, Francoise; et al.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003078423	A1	20030925	WO 2003-US7958	20030314 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2003220300	A1	20030929	AU 2003-220300	20030314 <--
US 20030225073	A1	20031204	US 2003-389707	20030314 <--
US 6846928	B2	20050125		
EP 1485376	A1	20041215	EP 2003-716598	20030314
EP 1485376	B1	20070627		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
AT 365733	T	20070715	AT 2003-716598	20030314
ES 2289279	T3	20080201	ES 2003-716598	20030314
PRIORITY APPLN. INFO.:			US 2002-364842P	P 20020315
			WO 2003-US7958	W 20030314
OTHER SOURCE(S):		MARPAT 139:276913		
GI				




AB Title compds. I [X = O, S, (un)substituted NH; Y = N, (un)substituted CH; one of Z1 and Z2 = (un)substituted CH, the other is N; Q = (un)substituted NH, CH2, S, O, bond; D = aryl, heteroaryl] were prepared for use as inhibitors of GSK-3, Aurora-2, or Src protein kinases (no data). Thus, the quinazoline II was obtained by chlorinating 4-quinazolinone and reaction with 2-aminothiazole.

IT 512187-97-2P 606092-70-0P 606092-72-2P
606092-73-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolylaminopyrimidines and related compds. as inhibitors of protein kinases)

RN 512187-97-2 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-2-thiazolyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 606092-70-0 CAPLUS


CN Benzeneacetonitrile, 4-[4-[(5-cyclopropyl-2-oxazolyl)amino]-7-methoxy-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 606092-72-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-2-thiazolyl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 606092-73-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-2-thiazolyl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757527 CAPLUS

DOCUMENT NUMBER: 139:255405

TITLE: Azinylaminoazoles as inhibitors of protein kinases, and their therapeutic use

INVENTOR(S): Bebbington, David; Binch, Hayley; Charrier, Jean-Damien; Everitt, Simon; Golec, Julian M. C.; Kay, David; Knegt, Ronald; Miller, Andrew; Pierard, Françoise

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077921	A1	20030925	WO 2003-US7957	20030314 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003220299	A1	20030929	AU 2003-220299	20030314 <--
US 20040009974	A1	20040115	US 2003-389296	20030314
US 7091343	B2	20060815		
EP 1485100	A1	20041215	EP 2003-716597	20030314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20070179133	A1	20070802	US 2006-504528	20060815
PRIORITY APPLN. INFO.:				
			US 2002-365003P	P 20020315
			US 2003-389296	A3 20030314
			WO 2003-US7957	W 20030314

OTHER SOURCE(S): MARPAT 139:255405

AB The invention provides azinylaminoazole compds. useful as inhibitors of

protein kinases. The invention also provides pharmaceutically acceptable compns. comprising the compds. and methods of using the compns. in the treatment of various diseases, conditions, or disorders.


IT 603932-80-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(azinylaminoazoles as inhibitors of protein kinases, therapeutic use, and use with other agents)

RN 603932-80-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-fluoro-3-methylphenyl)-N-1H-pyrazol-1-yl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:591156 CAPLUS

DOCUMENT NUMBER: 139:149640

TITLE: Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain

INVENTOR(S): Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Caldwell, Timothy M.; De Lombaert, Stephane

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062209	A2	20030731	WO 2003-US1563	20030117 <--
WO 2003062209	A3	20030904		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473796	A1	20030731	CA 2003-2473796	20030117 <--
BR 2003006982	A	20041026	BR 2003-6982	20030117
EP 1471910	A2	20041103	EP 2003-703887	20030117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1627944	A	20050615	CN 2003-802452	20030117
HU 2005000200	A2	20050728	HU 2005-200	20030117
JP 2005526714	T	20050908	JP 2003-562090	20030117
US 20040106616	A1	20040603	US 2003-347210	20030121
US 7074799	B2	20060711		
IN 2004DN01958	A	20050401	IN 2004-DN1958	20040708
MX 2004PA06882	A	20041206	MX 2004-PA6882	20040715
ZA 2004005641	A	20050715	ZA 2004-5641	20040715
NO 2004003411	A	20040924	NO 2004-3411	20040816
US 20060173003	A1	20060803	US 2006-345926	20060201
US 7304059	B2	20071204		
US 20080015183	A1	20080117	US 2007-864987	20070929
PRIORITY APPLN. INFO.:			US 2002-349920P	P 20020117
			US 2002-350527P	P 20020122
			WO 2003-US1563	W 20030117
			US 2003-347210	A3 20030121
			US 2006-345926	A3 20060201

OTHER SOURCE(S): MARPAT 139:149640

GI



AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions associated with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is C0-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered aromatic heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered aromatic carbocycle or heterocycle, (un)substituted with 1-3 LRa;

L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-, -C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-; wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen, cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino, aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph, phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl).


Although the methods of preparation are not claimed, many example preps. and characterization data for >500 examples of I are included.

IT 573678-98-5P, [4-(Trifluoromethyl)phenyl][2-phenyl-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-yl]amine 573683-87-1P, [2-(5H-Tetrazol-5-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-39-2P, [2-Pyridin-4-yl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-40-5P, [2-Pyridin-3-yl-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-41-6P, [2-(6-Methoxypyridin-3-yl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine 573686-42-7P, [2-[6-(Pyrrolidin-1-yl)pyridin-3-yl]-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate and receptor detector; preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain and for detecting receptors)


RN 573678-98-5 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 573683-87-1 CAPLUS

CN 4-Quinazolinamine, 2-(5H-tetrazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 573686-39-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 573686-40-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 573686-41-6 CAPLUS

CN 4-Quinazolinamine, 2-(6-methoxy-3-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 573686-42-7 CAPLUS
 CN 4-Quinazolinamine, 2-[6-(1-pyrrolidinyl)-3-pyridinyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




L7 ANSWER 12 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:491029 CAPLUS
 DOCUMENT NUMBER: 139:63337
 TITLE: Use of selective phosphodiesterase 5 (PDE5) inhibitors in the treatment of pulmonary diseases having a ventilation-perfusion mismatch
 INVENTOR(S): Ghofrani, Ardeschir; Grimminger, Friedrich Josef; Schudt, Christian
 PATENT ASSIGNEE(S): Altana Pharma AG, Germany
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051346	A2	20030626	WO 2002-EP14279	20021214 <--
WO 2003051346	A3	20040212		

W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, HU, ID, IL,

IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN,
 UA, US, VN, YU, ZA, ZW
 RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR
 CA 2470210 A1 20030626 CA 2002-2470210 20021214 <--
 AU 2002361417 A1 20030630 AU 2002-361417 20021214 <--
 EP 1461022 A2 20040929 EP 2002-796635 20021214
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005513060 T 20050512 JP 2003-552279 20021214
 US 20050107394 A1 20050519 US 2005-499215 20050104
 PRIORITY APPLN. INFO.: EP 2001-129951 A 20011217
 EP 2002-9555 A 20020426
 EP 2002-23936 A 20021025
 WO 2002-EP14279 W 20021214

AB The invention discloses the use of PDE5 inhibitors for the treatment of
 patients having a pulmonary disorder in which in which a pulmonary
 ventilation-pulmonary perfusion mismatch is present.
 IT 548735-65-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (phosphodiesterase 5 inhibitors for treatment of pulmonary disease with
 ventilation-perfusion mismatch)
 RN 548735-65-5 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-methoxyethyl)- (CA
 INDEX NAME)



L7 ANSWER 13 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:472388 CAPLUS
 DOCUMENT NUMBER: 139:53030
 TITLE: Pyrimidine-based and quinazoline-based compounds
 useful as GSK-3 inhibitors
 INVENTOR(S): Choquette, Deborah; Davies, Robert J.; Wannamaker,
 Marion W.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049739	A1	20030619	WO 2002-US39190	20021209 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2469316	A1	20030619	CA 2002-2469316	20021209 <--
AU 2002364536	A1	20030623	AU 2002-364536	20021209 <--
US 20030199526	A1	20031023	US 2002-314905	20021209 <--
EP 1474147	A1	20041110	EP 2002-799913	20021209

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005516005	T	20050602	JP 2003-550788	20021209
MX 2004PA05510	A	20060224	MX 2004-PA5510	20040607
ZA 2004005380	A	20050617	ZA 2004-5380	20040706

PRIORITY APPLN. INFO.: US 2001-338857P P 20011207
WO 2002-US39190 W 20021209

OTHER SOURCE(S): MARPAT 139:53030
GI



AB The invention provides a compound of formula I or a pharmaceutically acceptable derivative thereof [wherein: R₁ = (un)substituted 5- to 6-membered monocyclic or 8- to 10-membered bicyclic (hetero)aryl with 0-4 N/O/S atom(s); Q = (un)substituted C1-4 alkylene chain with 0-2 non-adjacent CH₂ optionally replaced by SO₂ or CO; R₂ = certain (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; R₃, R₄ = -T-R₃; or R₃R₄ = atoms to complete fused, partially saturated or aromatic, 5- to 8-membered ring with 0-3 N/O/S atom(s)

and

optionally substituted by oxo, -T-R₃, etc.; T = bond or C1-4 alkylene chain; R₃ = H, halo, OH or derivs., NH₂ or derivs., CN, SH or derivs., CHO or derivs., CO₂H or derivs., etc.; including pharmaceutically acceptable derivs. and prodrugs]. The compds. are inhibitors of protein kinases, particularly GSK-3 (glycogen synthase kinase 3) mammalian protein kinases. The invention also provides pharmaceutically acceptable compns. comprising the compds. of the invention, and methods of utilizing the compds. and compns. in the treatment of various protein kinase-mediated disorders, such as diabetes, cancer, stroke, and Alzheimer's disease. A table of over 200 compds. I is given in claims. Prepns. of 37 compds. are described in detail. For instance, 4-chloro-2-(2-trifluoromethylphenyl)quinazoline was thermally condensed with 6-(2-aminoethylamino)nicotinonitrile (neat, approx. 140°) to give 49% title compound II. In a test for inhibition of GSK-3β in vitro, 17 compds. I, including II, had K_i < 0.1 μM, and 16 compds. had K_i of 0.1 to 1.0 μM.

IT 544676-63-3P, 6-[2-[2-(2,4-Dichlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-64-4P, 6-[2-[2-(4-Chlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-65-5P, 6-[2-[2-(4-Methoxyphenyl)quinazolin-4-

ylamino]ethylamino]nicotinonitrile 544676-66-6P
544676-67-7P 544676-68-8P 544676-69-9P
544676-70-2P, 6-[2-[2-(2-Trifluoromethylphenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-71-3P,
6-[2-(2-Phenylquinazolin-4-ylamino)ethylamino]nicotinonitrile 544676-72-4P, N-(1H-Indazol-3-yl)-N'-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]ethane-1,2-diamine
544676-73-5P, 6-[2-[2-(2-Chlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-74-6P
544676-75-7P 544676-76-8P 544676-77-9P
544676-78-0P 544676-79-1P 544676-80-4P
544676-81-5P, 6-[2-[2-(4-Cyanophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-82-6P
544676-83-7P 544676-84-8P 544676-85-9P
544676-86-0P 544676-87-1P 544676-88-2P
544676-89-3P 544676-90-6P 544676-91-7P,
6-[2-[2-(3-Cyanophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544676-92-8P 544676-93-9P 544676-94-0P,
6-[2-(2-Thiophen-3-ylquinazolin-4-ylamino)ethylamino]nicotinonitrile 544676-95-1P 544676-96-2P 544676-97-3P
544676-98-4P 544676-99-5P 544677-00-1P
544677-01-2P 544677-02-3P 544677-03-4P
544677-04-5P 544677-05-6P 544677-06-7P
544677-07-8P 544677-08-9P 544677-09-0P
544677-10-3P 544677-11-4P 544677-12-5P
544677-13-6P 544677-14-7P 544677-15-8P
544677-16-9P 544677-17-0P 544677-18-1P
544677-19-2P 544677-20-5P 544677-21-6P
544677-22-7P 544677-23-8P, 4-[2-[2-(2,4-Dichlorophenyl)quinazolin-4-ylamino]ethylamino]benzonitrile
544677-24-9P 544677-25-0P, N-[2-(2,4-Dichlorophenyl)quinazolin-4-yl]-N'-phenylethane-1,2-diamine
544677-26-1P, 2-[2-[2-(2,4-Dichlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544677-27-2P
544677-28-3P 544677-29-4P 544677-30-7P
544677-31-8P 544677-32-9P 544677-33-0P
544677-34-1P 544677-35-2P 544677-36-3P
544677-37-4P 544677-38-5P 544677-39-6P
544677-40-9P 544677-41-0P 544677-42-1P
544677-43-2P 544677-44-3P 544677-45-4P
544677-46-5P 544677-47-6P 544677-48-7P
544677-49-8P 544677-50-1P 544677-51-2P
544677-52-3P 544677-53-4P 544677-54-5P
544677-55-6P, 6-[3-[2-(2,4-Dichlorophenyl)quinazolin-4-ylamino]propylamino]nicotinonitrile 544677-56-7P
544677-57-8P 544677-58-9P 544677-59-0P
544677-60-3P 544677-61-4P 544677-62-5P
544677-78-3P 544677-79-4P 544678-39-9P,
6-[2-[2-(2,4-Dimethoxyphenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-40-2P, 6-[2-[2-(2,3,4-Trimethoxyphenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-41-3P,
6-[2-[2-(2-Cyanophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-42-4P, 6-[2-[2-(2-Methoxyphenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-43-5P,
6-[2-[2-(2-Hydroxyphenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-44-6P, 6-[2-[2-(2-Fluorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-45-7P,
6-[2-(2-Thiophen-2-ylquinazolin-4-ylamino)ethylamino]nicotinonitrile 544678-46-8P, 6-[2-[2-(2,3-Dichlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-47-9P,
6-[2-[2-(2,5-Dichlorophenyl)quinazolin-4-ylamino]ethylamino]nicotinonitrile 544678-48-0P, 6-[2-[2-(4-Chlorobiphenyl-2-yl)quinazolin-4-


ylamino]ethylamino]nicotinonitrile 544678-53-7P,
N-(1H-Indazol-3-yl)-N'-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]ethane-
1,2-diamine trifluoroacetic acid salt

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of pyrimidine-based compds. useful as GSK-3
inhibitors)


RN 544676-63-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2,4-dichlorophenyl)-4-
quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-64-4 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-chlorophenyl)-4-
quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-65-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-methoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-66-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-methylphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-67-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(1-naphthalenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-68-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3,5-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-69-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-[4-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-70-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-71-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[(2-phenyl-4-quinazolinyl)amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-72-4 CAPLUS

CN 1,2-Ethanediamine, N1-1H-indazol-3-yl-N2-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)




RN 544676-73-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-chlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-74-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-bromophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-75-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-[2-chloro-5-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-76-8 CAPLUS

CN 1,2-Ethanediamine, N1-[2-[2-chloro-5-(trifluoromethyl)phenyl]-4-quinazolinyl]-N2-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544676-77-9 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2-chloro-4-nitrophenyl)-4-quinazolinyl]-N2-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544676-78-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-amino-2-chlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-79-1 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2-bromophenyl)-4-quinazolinyl]-N2-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544676-80-4 CAPLUS

3-Pyridinecarbonitrile, 6-[[2-[[2-(4-pyridinyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-81-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-cyanophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-82-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-aminophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-83-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-aminophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-84-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-chloro-4-fluorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-85-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(1,3-benzodioxol-5-yl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-86-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-ethoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-87-1 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-phenoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-88-2 CAPLUS

3-Pyridinecarbonitrile, 6-[[2-[[2-(2,4-difluorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-89-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-acetylphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-90-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3,4,5-trimethoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-91-7 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-cyanophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)



RN 544676-92-8 CAPLUS
 CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-pyridinyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-93-9 CAPLUS
 CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(1-isoquinolinyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-94-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(3-thienyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544676-95-1 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[3-[[2-(2-bromophenyl)-4-quinazolinyl]amino]propyl]amino]- (CA INDEX NAME)




RN 544676-96-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]amino]- (CA INDEX NAME)




RN 544676-97-3 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2-chlorophenyl)-4-quinazolinyl]-N4-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544676-98-4 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-1H-indazol-3-yl- (CA INDEX NAME)




RN 544676-99-5 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544677-00-1 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-1H-indol-2-yl- (CA INDEX NAME)




RN 544677-01-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]amino]- (CA INDEX NAME)




RN 544677-02-3 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-2-thiazolyl- (CA INDEX NAME)




RN 544677-03-4 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-3-pyridazinyl- (CA INDEX NAME)




RN 544677-04-5 CAPLUS

CN Benzonitrile, 4-[[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]amino]- (CA INDEX NAME)




RN 544677-05-6 CAPLUS

CN 2,5-Pyridinediamine, N2-[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]- (CA INDEX NAME)




RN 544677-06-7 CAPLUS

CN 3-Pyridineacetonitrile, 6-[[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]amino]- (CA INDEX NAME)




RN 544677-07-8 CAPLUS

CN 3(2H)-Isothiazolone, 5-[[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]butyl]amino]- (CA INDEX NAME)




RN 544677-08-9 CAPLUS

CN 1,4-Butanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N4-(5-nitro-2-pyridinyl)- (CA INDEX NAME)




RN 544677-09-0 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-pyridinyl- (CA INDEX NAME)




RN 544677-10-3 CAPLUS

CN 2,5-Pyridinediamine, N2-[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]- (CA INDEX NAME)




RN 544677-11-4 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-thiazolyl- (CA INDEX NAME)




RN 544677-12-5 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-3-isoxazolyl- (CA INDEX NAME)




RN 544677-13-6 CAPLUS

CN 3(2H)-Isothiazolone, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-14-7 CAPLUS


CN 5-Isoxazolol, 3-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-15-8 CAPLUS
 CN 3H-Pyrazol-3-one, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]-1,2-dihydro- (CA INDEX NAME)




RN 544677-16-9 CAPLUS
 CN 3(2H)-Isoxazolone, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)



RN 544677-17-0 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-indazol-3-yl- (CA INDEX NAME)




RN 544677-18-1 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544677-19-2 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-indol-2-yl- (CA INDEX NAME)




RN 544677-20-5 CAPLUS

CN 1,2-Ethanediamine, N1-1H-benzimidazol-2-yl-N2-[2-(2,4-dichlorophenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 544677-21-6 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-3-pyridazinyl- (CA INDEX NAME)




RN 544677-22-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-23-8 CAPLUS

CN Benzonitrile, 4-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-24-9 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-imidazol-2-yl- (CA INDEX NAME)




RN 544677-25-0 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-phenyl- (CA INDEX NAME)




RN 544677-26-1 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-27-2 CAPLUS

CN 4-Pyridinecarbonitrile, 2-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-28-3 CAPLUS

CN Benzonitrile, 3-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-29-4 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-indol-5-yl- (CA INDEX NAME)




RN 544677-30-7 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)




RN 544677-31-8 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-naphthalenyl- (CA INDEX NAME)




RN 544677-32-9 CAPLUS

CN 1,2-Ethanediamine, N1-2-benzothiazolyl-N2-[2-(2,4-dichlorophenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 544677-33-0 CAPLUS

CN Benzo[b]thiophene-3-carbonitrile, 2-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-34-1 CAPLUS

CN Thieno[3,2-c]pyridine-3-carbonitrile, 2-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-35-2 CAPLUS


CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-(5-nitro-2-pyridinyl)- (CA INDEX NAME)




RN 544677-36-3 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-pyrazinyl- (CA INDEX NAME)



RN 544677-37-4 CAPLUS
 CN 2-Pyrazinecarbonitrile, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-38-5 CAPLUS
 CN 2-Pyrazinecarboxylic acid, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]-, methyl ester (CA INDEX NAME)




RN 544677-39-6 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-pyrimidinyl- (CA INDEX NAME)




RN 544677-40-9 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-indazol-5-yl- (CA INDEX NAME)




RN 544677-41-0 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1H-indazol-6-yl- (CA INDEX NAME)




RN 544677-42-1 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]-1,2-dihydro- (CA INDEX NAME)




RN 544677-43-2 CAPLUS

CN 3-Pyridineacetonitrile, 6-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-44-3 CAPLUS

CN Benzeneacetonitrile, 4-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-45-4 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-46-5 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-3-pyridinyl- (CA INDEX NAME)




RN 544677-47-6 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-[5-(2H-tetrazol-5-yl)-2-pyridinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 544677-48-7 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 544677-49-8 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-9H-purin-6-yl- (CA INDEX NAME)




RN 544677-50-1 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1-isoquinolinyl- (CA INDEX NAME)




RN 544677-51-2 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-1,3,4-oxadiazol-2-yl- (CA INDEX NAME)




RN 544677-52-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[[[2-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544677-53-4 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-2-thienyl-
(CA INDEX NAME)




RN 544677-54-5 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N2-4-
pyridinyl- (CA INDEX NAME)




RN 544677-55-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[3-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]propyl]amino]- (CA INDEX NAME)




RN 544677-56-7 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-2-pyridinyl- (CA INDEX NAME)




RN 544677-57-8 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-2-thiazolyl- (CA INDEX NAME)




RN 544677-58-9 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-3-isoxazolyl- (CA INDEX NAME)




RN 544677-59-0 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-1H-indazol-3-yl- (CA INDEX NAME)




RN 544677-60-3 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 544677-61-4 CAPLUS

CN 1,3-Propanediamine, N1-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N3-1H-indol-2-yl- (CA INDEX NAME)




RN 544677-62-5 CAPLUS

CN 1,3-Propanediamine, N1-1H-benzimidazol-2-yl-N3-[2-(2,4-dichlorophenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 544677-78-3 CAPLUS

CN Methanesulfonamide, 1-[(5-cyano-2-pyridinyl)amino]-N-[2-(2,4-dichlorophenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 544677-79-4 CAPLUS

CN Methanesulfonamide, N-(5-cyano-2-pyridinyl)-1-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 544678-39-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2,4-dimethoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-40-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2,3,4-trimethoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-41-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-cyanophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-42-4 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-cyanophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-43-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-methoxyphenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-44-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-fluorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-45-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2-thienyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-46-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2,3-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-47-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(2,5-dichlorophenyl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)



RN 544678-48-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[[2-[[2-(4-chloro[1,1'-biphenyl]-2-yl)-4-quinazolinyl]amino]ethyl]amino]- (CA INDEX NAME)




RN 544678-53-7 CAPLUS

CN 1,2-Ethanediamine, N1-1H-indazol-3-yl-N2-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 544676-72-4

CMF C24 H19 F3 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:426627 CAPLUS
 DOCUMENT NUMBER: 140:77093
 TITLE: Synthesis of novel quinazoline derivatives for potential anticancer activity
 AUTHOR(S): El-Brollosy, Nasser R.; Abdel-Megeed, Mohamed F.; Genady, Afaf R.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt
 SOURCE: Alexandria Journal of Pharmaceutical Sciences (2003), 17(1), 17-21
 CODEN: AJPSES; ISSN: 1110-1792
 PUBLISHER: University of Alexandria, Faculty of Pharmacy
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:77093
 GI



II



III

AB Several novel quinazolines containing triazole, pyrazole and quinazolone ring systems as well as a carbohydrate moiety were synthesized. Cyclocondensation of (2-p-tolylquinazolin-4-yl)-hydrazine (I) with various aromatic carboxylic acids $\text{RC}_6\text{H}_4\text{CO}_2\text{H}$ ($\text{R} = \text{H}, 4\text{-Me}, 3\text{-Cl}$) in boiling phosphorus oxychloride afforded 3-aryl[1,2,4]triazolo[4,3-c]quinazolines II. Treatment of I with aromatic aldehydes ArCHO ($\text{Ar} = \text{Ph}, 2\text{-HOC}_6\text{H}_4, \text{PhCH:CH}$, etc.) gave the arylidenehydrazino derivs. III. 4-(3,5-Dimethylpyrazol-1-yl)-2-(p-tolyl)quinazoline was obtained via the reaction of I in boiling acetylacetone. The 2-Ar1-3-[2-(p-tolyl)quinazolin-4-yl]aminoquinazolin-4(3H)-ones ($\text{Ar1} = 3\text{-O}_2\text{NC}_6\text{H}_4, 2\text{-ClC}_6\text{H}_4$) were prepared by treating I with 2-Ar1-3,1-benzoxazin-4-ones in boiling acetic acid. Compound I was reacted with equimolar amount of D-glucose to give gluco-[2-(p-tolyl)quinazolin-4-yl]hydrazone, which was acetylated with acetic anhydride in pyridine to afford the corresponding penta-O-acetyl derivative. Anticancer evaluation of some of the prepared compds. revealed significant activities for compds. III ($\text{Ar} = 2\text{-HOC}_6\text{H}_4, \text{PhCH:CH}$).


IT 416880-88-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. by cyclocondensation of 2-(4-methylphenyl)-4-hydrazono-quinazolinone with aryl carboxylic acids or aldehydes, and their anticancer activity)

RN 416880-88-1 CAPLUS

CN Benzaldehyde, 2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazone (CA INDEX NAME)




IT 416875-66-6P 639791-60-9P 639791-65-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of quinazoline derivs. by cyclocondensation of 2-(4-methylphenyl)-4-hydrazono-quinazolinone with aryl carboxylic acids or aldehydes, and their anticancer activity)

RN 416875-66-6 CAPLUS


CN Benzaldehyde, 2-hydroxy-, 2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazone (CA INDEX NAME)




RN 639791-60-9 CAPLUS
 CN 2-Propenal, 3-phenyl-, 2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazone (CA INDEX NAME)



RN 639791-65-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-chlorophenyl)-3-[[2-(4-methylphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




IT 450379-31-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinazoline derivs. by cyclocondensation of
 2-(4-methylphenyl)-4-hydrazone-quinazolinone with aryl carboxylic acids
 or aldehydes, and their anticancer activity)
 RN 450379-31-4 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-(4-methylphenyl)- (CA INDEX NAME)




IT 639791-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinazoline derivs. by cyclocondensation of 2-(4-methylphenyl)-4-hydrazonoquinazolinone with aryl carboxylic acids or aldehydes, and their anticancer activity)
 RN 639791-66-5 CAPLUS
 CN D-Glucose, [2-(4-methylphenyl)-4-quinazolinyl]hydrazono (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




IT 416873-66-0P 639791-61-0P 639791-62-1P
 639791-63-2P 639791-64-3P 639791-67-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of quinazoline derivs. by cyclocondensation of 2-(4-methylphenyl)-4-hydrazonoquinazolinone with aryl carboxylic acids or aldehydes, and their anticancer activity)
 RN 416873-66-0 CAPLUS
 CN Quinazoline, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(4-methylphenyl)- (CA INDEX NAME)




RN 639791-61-0 CAPLUS

CN Benzaldehyde, 4-chloro-, 2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazone
(CA INDEX NAME)




RN 639791-62-1 CAPLUS


CN Benzaldehyde, 2,6-dichloro-, 2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazone (CA INDEX NAME)



RN 639791-63-2 CAPLUS
 CN Acetic acid, 1,2-diacetyl-2-[2-(4-methylphenyl)-4-quinazolinyl]hydrazide
 (CA INDEX NAME)




RN 639791-64-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[[2-(4-methylphenyl)-4-quinazolinyl]amino]-2-(3-nitrophenyl)- (CA INDEX NAME)



RN 639791-67-6 CAPLUS
 CN D-Glucose, [2-(4-methylphenyl)-4-quinazolinyl]hydrazone, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 15 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:376819 CAPLUS

DOCUMENT NUMBER: 138:385173
 TITLE: Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease
 INVENTOR(S): Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
 SOURCE: PCT Int. Appl., 1243 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040096	A2	20030515	WO 2002-US36072	20021108 <--
WO 2003040096	A3	20040506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2466284	A1	20030515	CA 2002-2466284	20021108 <--
WO 2003040096	A2	20030515	WO 2002-XA36072	20021108 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002359376	A1	20030519	AU 2002-359376	20021108 <--
AU 2002359376	B2	20080110		
US 20040171881	A1	20040902	US 2002-291318	20021108
US 7176242	B2	20070213		
EP 1453789	A2	20040908	EP 2002-793909	20021108
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002014035	A	20050426	BR 2002-14035	20021108
JP 2005520791	T	20050714	JP 2003-542142	20021108
CN 1759095	A	20060412	CN 2002-826786	20021108
NZ 533107	A	20070427	NZ 2002-533107	20021108
MX 2004PA04428	A	20040910	MX 2004-PA4428	20040507
ZA 2004003578	A	20051010	ZA 2004-3578	20040511
IN 2004KN00627	A	20060224	IN 2004-KN627	20040514
NO 2004002359	A	20040806	NO 2004-2359	20040607
US 20070213316	A1	20070913	US 2006-636903	20061211
AU 2008201593	A1	20080501	AU 2008-201593	20080410
PRIORITY APPLN. INFO.:			US 2001-337122P	P 20011108
			US 2001-344086P	P 20011228
			US 2002-345635P	P 20020103

AU 2002-359376 A3 20021108
 US 2002-291318 A3 20021108
 WO 2002-US36072 W 20021108

OTHER SOURCE(S): MARPAT 138:385173
 GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R3 = H, alkyl, haloalkyl, alkenyl, etc.; or R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO₂, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxyalkyl, etc.; R5 = R6X (wherein X = CO, SO₂, (un)substituted CH₂; R6 = (un)substituted Ph, naphthyl, indanyl, etc.); R25 = H, alkyl, alkoxy, etc.] which have activity as inhibitors of β -secretase and are therefore useful in treating a variety of disorders such as Alzheimer's disease, were prepared E.g., a multi-step synthesis of (1S,2R)-II, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid, was given. The compds. I showed IC₅₀ of < 20 μ M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.


IT 527714-26-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease)

RN 527714-26-7 CAPLUS

CN Benzenepropanol, 3,5-difluoro- α -[[[(3-methoxyphenyl)methyl]amino]methyl]- β -[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



L7 ANSWER 16 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:319686 CAPLUS

DOCUMENT NUMBER: 138:343870

TITLE: Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline

INVENTOR(S): Davis, John Douglas; Humphrey, Michael John; MacRae, Ross James; Smith, Janet Sarah

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032956	A1	20030424	WO 2002-IB4040	20020930 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2461168	A1	20030424	CA 2002-2461168	20020930 <--
AU 2002341260	A1	20030428	AU 2002-341260	20020930 <--
EP 1434570	A1	20040707	EP 2002-775048	20020930
EP 1434570	B1	20050831		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002013196	A	20040831	BR 2002-13196	20020930

CN 1568180	A	20050119	CN 2002-820042	20020930
JP 2005507909	T	20050324	JP 2003-535760	20020930
AT 303135	T	20050915	AT 2002-775048	20020930
ES 2246017	T3	20060201	ES 2002-775048	20020930
HU 2006000064	A2	20060628	HU 2006-64	20020930
HU 2006000064	A3	20070228		
US 20030133978	A1	20030717	US 2002-269551	20021010 <--
US 7163696	B2	20070116		
ZA 2004001976	A	20040712	ZA 2004-1976	20040311
IN 2004DN00673	A	20051125	IN 2004-DN673	20040317
NO 2004001520	A	20040405	NO 2004-1520	20040405
MX 2004PA03293	A	20040723	MX 2004-PA3293	20040407
PRIORITY APPLN. INFO.:			GB 2001-24455	A 20011011
			US 2001-340717P	P 20011030
			WO 2002-IB4040	W 20020930


AB The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (I), or a salt, and an adjuvant, diluent or carrier characterized in that the formulation is adapted to release at least 50% by weight of the drug after 6 h in Apparatus 1 described in the USP 24. Formulations according to the invention are suitable for the treatment of BPH. Thus, tablets contained I mesylate 3.567, HPMC 40.000, lactose monohydrate 7.608, anhydrous calcium hydrogen phosphate 22.825, adipic acid 25.000, and Mg stearate 1.000 mg/tablet.

IT 210538-44-6 358632-25-4
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled release pharmaceuticals containing
 (methanesulfonamidotetrahydroisoquinolyl)pyridylquinazoline)

RN 210538-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)




RN 358632-25-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]-, methanesulfonate (1:1)
 (CA INDEX NAME)

CM 1

CRN 210538-44-6


CMF C25 H26 N6 O4 S



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:301049 CAPLUS

DOCUMENT NUMBER: 138:321058

TITLE: C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation

INVENTOR(S): Ding, Sheng; Ding, Qiang; Gray, Nathanael S.

PATENT ASSIGNEE(S): IRM LLC, Bermuda; The Scripps Research Institute

SOURCE: PCT Int. Appl., 68 pp., which which which CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031406	A2	20030417	WO 2002-US32680	20021012 <--
WO 2003031406	A3	20060105		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


CA 2463563	A1	20030417	CA 2002-2463563	20021012 <--
AU 2002342051	A1	20030422	AU 2002-342051	20021012 <--
US 20030191312	A1	20031009	US 2002-270030	20021012 <--
US 7176312	B2	20070213		
JP 2005512972	T	20050512	JP 2003-534390	20021012
EP 1578722	A2	20050928	EP 2002-776216	20021012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20060009642	A1	20060112	US 2005-223429	20050909
US 20070191380	A1	20070816	US 2007-673976	20070212
PRIORITY APPLN. INFO.:			US 2001-328763P	P 20011012
			US 2001-331835P	P 20011120
			US 2002-346480P	P 20020107
			US 2002-348089P	P 20020110
			US 2001-328741P	P 20011012
			US 2002-346552P	P 20020107
			US 2002-347037P	P 20020108
			US 2002-170031	A3 20020612
			US 2002-270030	A3 20021012
			WO 2002-US32680	W 20021012
OTHER SOURCE(S):			CASREACT 138:321058; MARPAT 138:321058	
GI				



AB General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls, particularly C2-, C6- and 9-aryl-substituted purines (e.g. 2-(2,4-dimethoxyphenyl)-6-(4-methoxybenzylamino)-9-isopropylpurine), was demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via Pd catalyzed cross-coupling reactions. The 1st claim comprises a method of preparing a C2-substituted purine compound, said method comprising: reacting a C2-halogenated purine with A-X (X = -B(OH)₂, -OH, and -NHR₁; R₁ = H, (un)substituted alkyl; A = (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl) in the presence of a solvent, a base, a carbene ligand and a Pd catalyst. The 2nd claims narrows the 1st claim to purines I wherein R₂ = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X' = direct bond, NR₁ and O; X'' = direct bond, O and NR₃, with the proviso that when X'' is NR₃, Y is R₄ or A', and when X' is O or a direct bond, Y is A'; A' = (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heterocyclyl; R₃ = H, (un)substituted alkyl; and R₄ = (un)substituted alkyl. Similar claims pertain to C6-substituted purines. Also claimed is a method of preparing a 9-aryl substituted purines, the method comprising: reacting a 2,6-dihalogenated purine with Ar-B(OH)₂ (Ar = (un)substituted aryl, and (un)substituted heterocyclyl) in the presence of a solvent and a Cu catalyst. Also claimed is a method for synthesizing a substituted heteroaryl, the method comprising: providing a dihaloheteroaryl scaffold moiety and capturing the dihaloheteroaryl scaffold moiety on a resin by nucleophilic substitution of a 1st halogen by a resin-bound amine nucleophile to afford a resin-bound amine substituted monohaloheteroaryl. Substitution of the 2nd halogen is done by nucleophilic displacement (e.g. by aniline, phenol, amine, boronic acid) or coupling (e.g.

palladium-mediated). An initial substitution (e.g. alkylation, acylation, coupling) can be done prior to substitution of the 1st halogen. Example procedures are included for: boronic acid coupling, aniline coupling, phenol coupling, purine N9 arylation via boronic acids/cupric acetate, reductive amination for synthesis of PAL-resin-bound amine, resin capture of dichloroheterocycles, substitution of remaining chloro group with boronic acids via Suzuki coupling and product cleavage, substitution of remaining chloro group with anilines or amines via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with phenols via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction without base and product cleavage, and substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction with K_{Ot}Bu as base and product cleavage. Tables of purity and yields for various heteroaryl combinatorial libraries are included as validation of the following methods: palladium catalyzed cross-coupling reactions for derivatizing resin-bound 2-chloro-6-aminopurine with boronic acids, anilines, amines and phenols, resin-bound chloroheterocyclic scaffolds which can be derivatized via Suzuki coupling reaction, resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed amination reaction, and resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed C-O bond formation reaction.

IT 406932-46-5P, 4-(4-Methoxybenzylamino)-2-(3-methoxyphenyl)quinazoline
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 (C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation)
 RN 406932-46-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



L7 ANSWER 18 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:282915 CAPLUS
 DOCUMENT NUMBER: 139:254717
 TITLE: Synthesis and biological evaluation of some quinazoline derivatives as antitumor and antiviral agents
 AUTHOR(S): El-Sherbeny, Magda A.; Gineinah, Magdy M.; Nasr, Magda N.; El-Shafeih, Faiza S.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11495, Saudi

SOURCE: Arabia
 Arzneimittel-Forschung (2003), 53(3),
 206-213
 CODEN: ARZNAD; ISSN: 0004-4172
 PUBLISHER: Editio Cantor Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:254717


AB A new series of 4-(4-aryl-1-piperazinyl)quinazolines, 4-(3-substituted-phenylamino)quinazoline derivs., 2-methoxycarbonylphenylaminoquinazoline derivs., 2-hydrazinocarbonylphenylanminoquinazolines, and 2-aryl-1-(substituted-4-quinazolinyl)-1,4-dihydro-5-oxo-5H-1,3,4-benzotriazepines were synthesized and tested for their antitumor and antiviral activities. Among them, several 4-(4-aryl-1-piperazinyl)quinazolines exhibited broad spectrum antitumor activity with full panel median growth inhibition (GI50) at concns. of 3.2, 2.0, 4.8, 4.0 $\mu\text{mol/l}$ and total growth inhibition at concns. of 56.5, 51.0, 63.0 and 73.0 $\mu\text{mol/l}$, resp. Compds. 2-hydrazinocarbonylphenylanminoquinazolines showed moderate selectivity toward leukemia cell line. 2-Aryl-1-(substituted-4-quinazolinyl)-1,4-dihydro-5-oxo-5H-1,3,4-benzotriazepines showed moderate anti HIV-1 potency with EC50 values of 40.5 and 52.8 $\mu\text{mol/l}$, resp. The detailed synthesis, spectroscopic and biol. data are reported.

IT 602333-16-4P 602333-17-5P 602333-18-6P
 602333-19-7P 602333-20-0P 602333-21-1P
 602333-22-2P 602333-23-3P 602333-24-4P
 602333-25-5P 602333-26-6P 602333-27-7P
 602333-28-8P 602333-29-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and biol. evaluation of some quinazoline derivs. as antitumor and antiviral agents)


RN 602333-16-4 CAPLUS

CN 4-Quinazolinamine, 6-bromo-N-(3-bromophenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-17-5 CAPLUS


CN 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-18-6 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(3-chlorophenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-19-7 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-20-0 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(3-nitrophenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-21-1 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(3-nitrophenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-22-2 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(3-methoxyphenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-23-3 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(3-methoxyphenyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-24-4 CAPLUS
 CN Benzoic acid, 2-[[6-bromo-2-(2-thienyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)



RN 602333-25-5 CAPLUS
 CN Benzoic acid, 2-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




RN 602333-26-6 CAPLUS
 CN Benzoic acid, 2-[[6-bromo-2-(2-thienyl)-4-quinazolinyl]amino]-, hydrazide (CA INDEX NAME)




RN 602333-27-7 CAPLUS

CN Benzoic acid, 2-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-, hydrazide (CA INDEX NAME)




RN 602333-28-8 CAPLUS

CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6-bromo-2-(2-thienyl)-4-quinazolinyl]-2-(4-chlorophenyl)-1,4-dihydro- (CA INDEX NAME)



RN 602333-29-9 CAPLUS

CN 5H-1,3,4-Benzotriazepin-5-one, 2-(4-chlorophenyl)-1-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro- (CA INDEX NAME)




IT 602333-10-8P 602333-11-9P 602333-12-0P
 602333-13-1P 602333-14-2P 602333-15-3P
 602333-30-2P 602333-31-3P 602333-32-4P
 602333-33-5P 602333-34-6P 602333-35-7P
 602333-36-8P 602333-37-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis and biol. evaluation of some quinazoline derivs. as
 antitumor and antiviral agents)


RN 602333-10-8 CAPLUS

CN Quinazoline, 6-bromo-4-(4-phenyl-1-piperazinyl)-2-(2-thienyl)- (CA INDEX NAME)



RN 602333-11-9 CAPLUS


CN Quinazoline, 6,7-dimethoxy-4-(4-phenyl-1-piperazinyl)-2-(2-thienyl)- (CA INDEX NAME)



RN 602333-12-0 CAPLUS


CN Quinazoline, 6-bromo-2-(2-thienyl)-4-[4-[3-(trifluoromethyl)phenyl]-1-

piperazinyl]- (CA INDEX NAME)




RN 602333-13-1 CAPLUS

CN Quinazoline, 6,7-dimethoxy-2-(2-thienyl)-4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 602333-14-2 CAPLUS

CN Quinazoline, 6-bromo-4-[4-(2-ethoxyphenyl)-1-piperazinyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-15-3 CAPLUS

CN Quinazoline, 4-[4-(2-ethoxyphenyl)-1-piperazinyl]-6,7-dimethoxy-2-(2-thienyl)- (CA INDEX NAME)




RN 602333-30-2 CAPLUS

CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6-bromo-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 602333-31-3 CAPLUS


CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 602333-32-4 CAPLUS


CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6-bromo-2-(2-thienyl)-4-quinazolinyl]-

1,4-dihydro-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 602333-33-5 CAPLUS

CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 602333-34-6 CAPLUS

CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6-bromo-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 602333-35-7 CAPLUS


CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 602333-36-8 CAPLUS
 CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6-bromo-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(2-thienyl)- (CA INDEX NAME)



RN 602333-37-9 CAPLUS
 CN 5H-1,3,4-Benzotriazepin-5-one, 1-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-1,4-dihydro-2-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:262951 CAPLUS
 DOCUMENT NUMBER: 139:111070
 TITLE: Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK)

AUTHOR(S): Cywin, Charles L.; Zhao, Bao-Ping; McNeil, Daniel W.; Hrapchak, Matt; Prokopowicz, Anthony S.; Goldberg, Daniel R.; Morwick, Tina M.; Gao, Amy; Jakes, Scott; Kashem, Mohammed; Magolda, Ronald L.; Soll, Richard M.; Player, Mark R.; Bobko, Mark A.; Rinker, James; DesJarlais, Renee L.; Winters, Michael P.

CORPORATE SOURCE: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06801-0368, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1415-1418

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:111070

AB The discovery of novel 5,7-disubstituted[1,6]naphthyridines as potent inhibitors of spleen tyrosine kinase is discussed. The SAR reveals the necessity for a 7-aryl group with preference towards para substitution and that this in combination with 5-aminoalkylamino substituents further improved the potency of the compds. The initial SAR as well as a survey of the other positions is discussed in detail.


IT 562050-15-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure activity relations of novel naphthyridines as potent inhibitors of spleen tyrosine kinase)

RN 562050-15-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:221342 CAPLUS

DOCUMENT NUMBER: 139:101096

TITLE: Synthesis and antiinflammatory screening of some quinazoline and quinazoly-4-oxoquinazoline derivatives

AUTHOR(S): Gineinah, Magdy M.; El-Sherbeny, Magda A.; Nasr, Magda N.; Maarouf, Azza R.

CORPORATE SOURCE: Pharmaceutical Organic Chemistry, College of Pharmacy, Mansoura University, Mansoura, 35516, Egypt

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2003), Volume Date 2002, 335(11-12), 556-562

CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:101096

AB Synthesis of some new derivs. of 2-aryl-4-oxo-1-(4-quinazoly)quinazolines is described. Me N-(4-quinazoly)anthranilate was allowed to react with


Ph iso(thio)cyanate to give 3-phenyl-1-(4-quinazolyl)-1,2,3,4-tetrahydro-2,4-dioxo-and 4-oxo-2-thioxoquinazolines. Alternatively, anthranilic acid amide derivs. were subjected to cyclization with aromatic aldehydes to give 2-aryl-4-oxo-1-(4-quinazolyl)-1,2,3,4-tetrahydroquinazolines. On the other hand, 2-chloro-4-(4-substituted 1-piperazinyl)quinazoline derivs. were subjected to the same type of reactions at the 2-position to afford the corresponding quinazoline derivs. Furthermore, an acid amide was cyclized with acid chlorides to give the corresponding 2-aryl-1-(2-chloro-4-quinazolyl)-4-oxo-1,4-dihydroquinazolines, from which triazoloquinazoline derivs. were synthesized through an intermediate hydrazine derivs. Most of the newly synthesized compds. were tested for their antiinflammatory activities. However, some of the novel compds. were found to exhibit good antiinflammatory potencies. Compds. thus prepared included 2,3-dihydro-3-phenyl-2-thioxo[1(4H),4'-biquinazolin]-4-one, 3-phenyl[1,4'(1H,3'H)-biquinazoline]-2,4'-dione, 2,3-dihydro-2-phenyl[1(4H),4'-biquinazolin]-4-one, 2'-chloro-2-(3-chlorophenyl)[1(4H),4'-biquinazolin]-4-one, 2'-chloro-2-(4-bromophenyl)[1(4H),4'-biquinazolin]-4-one, 2-(3-chlorophenyl)-1-[1-(3-nitrophenyl)[1,2,4]triazolo[4,3-a]quinazolin-4-yl]-4(1H)quinazolinone, 2-(4-bromophenyl)-1-[1-(3-nitrophenyl)[1,2,4]triazolo[4,3-a]quinazolin-4-yl]-4(1H)quinazolinone, etc.

IT 561065-22-3P 561065-23-4P 561065-24-5P
 561065-25-6P 561065-29-0P 561065-30-3P
 561065-31-4P 561065-35-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antiinflammatory activity of [biquinazoline]diones, [(thioxo)biquinazolin]ones and [1,2,4]triazolo[4,3-a]quinazolinyl]quinazolinones)


RN 561065-22-3 CAPLUS

CN [1(2H),2'-Biquinazoline]-2,4(3H)-dione, 4'-(4-methyl-1-piperazinyl)-3-phenyl- (CA INDEX NAME)




RN 561065-23-4 CAPLUS

CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-4'-(4-methyl-1-piperazinyl)-3-phenyl-2-thioxo- (CA INDEX NAME)




RN 561065-24-5 CAPLUS

CN [1(2H),2'-Biquinazoline]-2,4(3H)-dione, 3-phenyl-4'-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 561065-25-6 CAPLUS


CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-3-phenyl-4'-(4-phenyl-1-piperazinyl)-2-thioxo- (CA INDEX NAME)




RN 561065-29-0 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2-(4-chlorophenyl)-2,3-dihydro-4'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 561065-30-3 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2-(3,4-dimethoxyphenyl)-2,3-dihydro-4'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 561065-31-4 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-4'-(4-methyl-1-piperazinyl)-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 561065-35-8 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-2-(3-nitrophenyl)-4'-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)



IT 561065-28-9P 561065-32-5P 561065-33-6P
 561065-34-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiinflammatory activity of [biquinazoline]diones,
 [(thioxo)biquinazolin]ones and [1,2,4]triazolo[4,3-
 a]quinazolinyl]quinazolinones)
 RN 561065-28-9 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-4'-(4-methyl-1-piperazinyl)-2-
 phenyl- (CA INDEX NAME)




RN 561065-32-5 CAPLUS
 CN [1(4H),2'-Biquinazolin]-4-one, 2,3-dihydro-2-phenyl-4'-(4-phenyl-1-
 piperazinyl)- (CA INDEX NAME)




RN 561065-33-6 CAPLUS

CN [1(4H),2'-Biquinazolin]-4-one, 2-(4-chlorophenyl)-2,3-dihydro-4'-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)



RN 561065-34-7 CAPLUS


CN [1(4H),2'-Biquinazolin]-4-one, 2-(3,4-dimethoxyphenyl)-2,3-dihydro-4'-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 21 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:147944 CAPLUS
 DOCUMENT NUMBER: 138:193282
 TITLE: Use of α -adrenoceptor antagonist in combination with muscarinic antagonist for medicament
 INVENTOR(S): Wayley, Michael Grant
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 200305261	A	20030226	JP 2001-240717	20010808 <--
PRIORITY APPLN. INFO.:			JP 2001-240717	20010808
AB The invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men, which combinations contain an α -adrenoceptor antagonist and a muscarinic antagonist. The combinations of the invention are particularly suitable for treating moderate or severe LUTS. A combination immediate-release darifenacin/doxazosin tablet containing doxazosin mesylate 4.05, darifenacin hydrobromide 2.976, microcryst. cellulose 125.28, lactose 63.694, sodium starch glycollate 2, magnesium stearate 2 mg was prepared				
IT 210538-44-6 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (use of α -adrenoceptor antagonist in combination with muscarinic antagonist for treatment of benign prostatic hyperplasia)				
RN 210538-44-6 CAPLUS				
CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)				




L7 ANSWER 22 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:133577 CAPLUS
 DOCUMENT NUMBER: 138:183523
 TITLE: Reagent for determining hydrogen peroxide in clinical assay
 INVENTOR(S): Okabe, Kazuaki; Kadota, Akira; Aoki, Kozo; Takahashi, Kazunobu; Sakurada, Masami; Nakamura, Kouki
 PATENT ASSIGNEE(S): Kyowa Medex Co., Ltd., Japan; Fuji Photo Film Co., Ltd.
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014725	A1	20030220	WO 2002-JP7905	20020802 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002323785	A1	20030224	AU 2002-323785	20020802 <--
EP 1424554	A1	20040602	EP 2002-755787	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050130251	A1	20050616	US 2005-485698	20050124
PRIORITY APPLN. INFO.:			JP 2001-234597	A 20010802
			WO 2002-JP7905	W 20020802
OTHER SOURCE(S):			MARPAT 138:183523	
GI				



II



III

AB A reagent for colorimetrically determining hydrogen peroxide in a clin. assay
is


provided, which comprises: (A) a compound represented by the general formula (I): R1-NH-R2 (I) <R1 represents carbamoyl group, etc.; and R2 represents arylamino group, heteroaryl amino group, or a substituent represented by the general formula II: (II) [R3 to R6 each represents X-Y-Ra {Ra represents hydrogen atom, alkyl group, etc.; X represents a single bond, oxygen, etc.; and Y represents a single bond, (C=O), etc.}, cyano group, halogen atom, etc.]; (B) a compound represented by the general formula III: (III) [R9 represents a group eliminable through an oxidative color-developing coupling reaction with the compound (I); and R7, R8, and R10 to R13 each has the same meaning as R3], etc.; and (C) an peroxidn.-active substance (e.g., peroxidase).

IT 497860-99-8 497861-00-4

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(reagent for determining hydrogen peroxide in clin. assay)


RN 497860-99-8 CAPLUS

CN Benzenesulfonic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX
NAME)



RN 497861-00-4 CAPLUS

CN Benzoic acid, 3-[[2-(2-phenyl-4-quinazolinyl)hydrazino]sulfonyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:117799 CAPLUS
 DOCUMENT NUMBER: 138:170247
 TITLE: Process for the production of quinazolines
 INVENTOR(S): Boulton, Lee Terence; Crook, Robert James; Pettman, Alan John; Walton, Robert
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011829	A1	20030213	WO 2002-IB2872	20020719 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451075	A1	20030213	CA 2002-2451075	20020719 <--
AU 2002317442	A1	20030217	AU 2002-317442	20020719 <--
US 20030100753	A1	20030529	US 2002-199755	20020719 <--
US 7026479	B2	20060411		
EP 1412331	A1	20040428	EP 2002-745749	20020719
EP 1412331	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011670	A	20040713	BR 2002-11670	20020719
CN 1533378	A	20040929	CN 2002-814325	20020719
JP 2005501054	T	20050113	JP 2003-517021	20020719
HU 2004001573	A2	20050128	HU 2004-1573	20020719
HU 2004001573	A3	20050628		

RU 2261861	C1	20051010	RU 2004-102692	20020719
AT 323677	T	20060515	AT 2002-745749	20020719
ES 2260457	T3	20061101	ES 2002-745749	20020719
EG 23204	A	20040731	EG 2002-853	20020729
AP 1299	A	20040906	AP 2002-2602	20020801
ZA 2003009043	A	20041122	ZA 2003-9043	20031120
IN 2003MN01088	A	20060505	IN 2003-MN1088	20031127
MX 2004PA00978	A	20040420	MX 2004-PA978	20040130
PRIORITY APPLN. INFO.:			GB 2001-18752	A 20010801
			US 2001-328369P	P 20011009
			WO 2002-IB2872	W 20020719
OTHER SOURCE(S):			CASREACT 138:170247; MARPAT 138:170247	
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a process for the preparation of I [R1 = (fluoro)alkoxy; R2 = H, (fluoro)alkoxy; R3 = 5- or 6-membered (un)substituted heterocyclic ring; R4 = 4-, 5-, 6- or 7-membered optionally fused/substituted heterocyclic ring]. The process is comprised of condensation of II [R1-3 defined above] with R5R6NCN [R5, R6 taken together with the N atom to which they are attached represent a 4-7-membered N-containing optionally fused/substituted heterocyclic ring]. For instance, 6-amino-3,4-dimethoxy-2-(pyridin-2-yl)benzonitrile (preparation given) and N-(2-cyano-1,2,3,4-tetrahydroisoquinolin-5-yl)methanesulfonamide (preparation given) are reacted in DMSO with sodium t-pentoxide below 30° for 2 h. Aqueous work-up affords III (87 g, 87%). The current process is convergent, avoids the use of organostannane reagents and allows easier large-scale processing than prior art methods.

IT 210538-44-6P, 4-Amino-2-(5-(methanesulfonamido)-1,2,3,4-tetrahydroisoquinolin-2-yl)-6,7-dimethoxy-5-(pyridin-2-yl)quinazoline
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (convergent process for the quinazolines by condensation of 2-aminobenzonitriles with N-cyanoamines)

RN 210538-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2003:85794 CAPLUS
 DOCUMENT NUMBER: 139:46345
 TITLE: Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats
 AUTHOR(S): Achira, M.; Totsuka, R.; Kume, T.
 CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd, Saitama, 335-8505, Japan
 SOURCE: Xenobiotica (2002), 32(12), 1139-1149
 CODEN: XENOBH; ISSN: 0049-8254
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB 1. The pharmacokinetics, particularly the hepatobiliary transport of T-5557 ((3-methyl-2-oxo-piperazin-3-yl)-acetic acid N'-(3-thiophen-2-yl-8-methoxy-quinazolin-1-yl)-hydrazide), a novel anti-inflammatory agent, has been examined in normal and adjuvant arthritis (AA) rats. 2. Following oral administration of T-5557, the absolute bioavailability in AA rats was increased by sixfold compared with normal rats. The extent of binding T-5557 to plasma proteins obtained from AA rats was markedly greater than in normal rats (97.0 vs. 88.2%). The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 vs. 5.621 mL min⁻¹ kg⁻¹), and lower intrinsic biliary clearance was also observed in AA rats (40.33 vs. 69.83 mL min⁻¹ kg⁻¹). 3. Concomitant administration of T-5557 with quinidine, a potent P-glycoprotein inhibitor, to normal rats caused a significant decrease in the biliary clearance of T-5557 by 37.9%. Moreover, the transport of T-5557 for the apical-to-basal compartment in a Caco-2 cells' monolayer was fourfold lower than that for the opposite direction, and was increased in the presence of quinidine and verapamil. 4. These results suggest that P-glycoprotein is involved in the biliary excretion of T-5557 and the decrease in the transport activity as well as the increase in plasma protein binding caused the elevated plasma concentration and bioavailability of T-5557 in AA rats.

IT 546113-62-6, T 5557
 RL: DMA (Drug mechanism of action); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral antiinflammatory agent T-5557 pharmacokinetics and hepatobiliary transport in normal and arthritis rats: P-glycoprotein role)


RN 546113-62-6 CAPLUS

CN 2-Piperazineacetic acid, 2-methyl-3-oxo-, 2-[5-methoxy-2-(2-thienyl)-4-quinazolinyl]hydrazide (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:61743 CAPLUS
DOCUMENT NUMBER: 138:401687
TITLE: Reactivity study on 4-morpholinecarbothioic acid
(2-phenyl-3H-quinazolin-4-ylidene)amide
AUTHOR(S): Fathalla, Walid; Cajan, Michal; Marek, Jaromir;
Pazdera, Pavel
CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Science,
Masaryk University, Brno, Czech Rep.
SOURCE: Journal of Heterocyclic Chemistry (2002),
39(6), 1145-1152
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:401687
GI




AB Regioselective reactions of the title compound (I) were studied. I reacts with alkyl halides in basic medium to afford S-substituted isothiurea derivs., with amines to give 1,1-disubstituted 3-(2-phenyl-3H-quinazolin-4-ylidene)thiureas and 1-substituted 3-(2-phenyl-quinazolin-4-yl)thiureas via transamination. Reaction of I with amines in the presence of H₂O₂ provided 4-morpholinecarboximidamides (II; n = 1, 2) via oxidative desulfurization. Estimation of reactivity sites on I was supported by ab initio (HF/6-31G**) quantum chemical calcns. IR, ¹H NMR, ¹³C NMR, and mass spectroscopy and x-ray anal. were used to identify the products.


IT 400053-06-7P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(regioselective reactions of 4-morpholinecarbothioic acid
(2-phenyl-3H-quinazolin-4-ylidene)amide)

RN 400053-06-7 CAPLUS


CN Thiourea, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




IT 1022-44-2P 400053-01-2P 400053-02-3P
 400053-05-6P 400053-07-8P 400053-10-3P
 530159-21-8P 530159-22-9P 530159-23-0P
 530159-24-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective reactions of 4-morpholinecarbothioic acid
 (2-phenyl-3H-quinazolin-4-ylidene)amide)
 RN 1022-44-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 400053-01-2 CAPLUS
 CN Thiourea, N-butyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 400053-02-3 CAPLUS
 CN Thiourea, N-(phenylmethyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-05-6 CAPLUS
 CN Thiourea, N-cyclohexyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-07-8 CAPLUS

CN Thiourea, N-(4-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-10-3 CAPLUS


CN Thiourea, N-(4-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 530159-21-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-morpholinyl-1-piperidinylmethylene)-2-phenyl- (CA INDEX NAME)




RN 530159-22-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-morpholinyl-1-pyrrolidinylmethylene)-2-phenyl- (CA INDEX NAME)



RN 530159-23-0 CAPLUS
 CN 4-Morpholinecarboximidothioic acid, N-(2-phenyl-4-quinazolinyl)-, phenylmethyl ester (CA INDEX NAME)



RN 530159-24-1 CAPLUS
 CN 4-Morpholinecarboximidothioic acid, N-(2-phenyl-4-quinazolinyl)-,
 2-propen-1-yl ester (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:61742 CAPLUS
 DOCUMENT NUMBER: 138:401686
 TITLE: New domino-reaction for the synthesis of
 N4-(5-aryl-1,3-oxathiol-2-yliden)-2-phenylquinazolin-4-
 amines and 4-[4-aryl-5-(2-phenylquinazolin-4-yl)-1,3-
 thiazol-2-yl]morpholine
 AUTHOR(S): Fathalla, Walid; Marek, Jaromir; Pazdera, Pavel
 CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Science,
 Masaryk University, Brno, Czech Rep.
 SOURCE: Journal of Heterocyclic Chemistry (2002),
 39(6), 1139-1144
 CODEN: JHTCAD; ISSN: 0022-152X
 PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:401686
 AB Morpholine-1-carbothioic acid (2-phenyl-3H-quinazolin-4-ylidene) amide
 reacts with phenacyl bromides to afford N4-(5-aryl-1,3-oxathiol-2-yliden)-
 2-phenylquinazolin-4-amines or N4-(4,5-diphenyl-1,3-oxathiol-2-yliden)-2-
 phenyl-4-aminoquinazoline by a thermodynamically controlled reversible
 reaction favoring the enolate intermediate, while 4-[4-aryl-5-(2-

phenylquinazolin-4-yl)-1,3-thiazol-2-yl]morpholine was produced by a kinetically controlled reaction favoring the C-anion intermediate.


IT 400604-97-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(domino-reaction of morpholine-1-carbothioic acid (2-phenyl-3H-quinazolin-4-ylidene) amide with phenacyl bromides)

RN 400604-97-9 CAPLUS

CN 4-Morpholinecarbothioamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



IT 474254-12-1P 531507-49-0P 531507-50-3P


531507-51-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(domino-reaction of morpholine-1-carbothioic acid (2-phenyl-3H-quinazolin-4-ylidene) amide with phenacyl bromides)


RN 474254-12-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(4-methoxyphenyl)-1,3-oxathiol-2-ylidene]-2-phenyl- (CA INDEX NAME)




RN 531507-49-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1,3-oxathiol-2-ylidene)- (CA INDEX NAME)




RN 531507-50-3 CAPLUS

CN 4-Quinazolinamine, N-[5-(4-methylphenyl)-1,3-oxathiol-2-ylidene]-2-phenyl-
(CA INDEX NAME)



RN 531507-51-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(4-chlorophenyl)-1,3-oxathiol-2-ylidene]-2-phenyl-
(CA INDEX NAME)




IT 531507-52-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(domino-reaction of morpholine-1-carbothioic acid (2-phenyl-3H-quinazolin-4-ylidene) amide with phenacyl bromides)

RN 531507-52-5 CAPLUS

CN 4-Quinazolinamine, N-(4,5-diphenyl-1,3-oxathiol-2-ylidene)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:342 CAPLUS

DOCUMENT NUMBER: 138:321230

TITLE: Synthesis of new quinazoline derivatives of expected potential bioresponses

AUTHOR(S): Isaac, Yvette A.; Arsanious, Mona H.; Abd El-Nabi, Hisham A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt

SOURCE: Revue Roumaine de Chimie (2002), Volume Date 2001, 46(12), 1299-1307

CODEN: RRCHAX; ISSN: 0035-3930

PUBLISHER: Editura Academiei Romane

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:321230

AB The reactivity of the novel compound Et (2-phenylquinazolin-4-oxy)acetate towards carbon electrophiles and nitrogen nucleophiles is described. Reaction of (2-phenylquinazolin-4-oxy)acetic hydrazide with carbon electrophiles is also investigated. Furthermore, the behavior of 4-chloro-2-phenylquinazoline towards a variety of nitrogen and carbon nucleophiles is studied.


IT 117998-85-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinazoline derivs. by reaction of Et (phenylquinazolin-oxy)acetate and related compds. with nitrogen and carbon nucleophiles and carbon electrophiles)

RN 117998-85-3 CAPLUS


CN 4(1H)-Quinazolinone, 2-phenyl-, oxime (9CI) (CA INDEX NAME)




IT 474289-64-0P 512187-97-2P 512188-00-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of quinazoline derivs. by reaction of Et
 (phenylquinazolinoxy)acetate and related compds. with nitrogen and
 carbon nucleophiles and carbon electrophiles)
 RN 474289-64-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-pyridinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 512187-97-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-thiazolyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 512188-00-0 CAPLUS
 CN Quinazoline, 2-phenyl-4-(2-phenylhydrazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:906205 CAPLUS

DOCUMENT NUMBER: 138:4608

TITLE: Preparation of quinazolines from fluorobenzonitriles and guanidines.

INVENTOR(S): Ahman, Jens Bertil; Hodgson, Paul Blaise; Lewandowski, Sarah Jane; Walton, Robert

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094815	A1	20021128	WO 2002-IB1748	20020510 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2447233	A1	20021128	CA 2002-2447233	20020510 <--
AU 2002302891	A1	20021203	AU 2002-302891	20020510 <--
EP 1387839	A1	20040211	EP 2002-730579	20020510
EP 1387839	B1	20060308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009861	A	20040615	BR 2002-9861	20020510
JP 2004537519	T	20041216	JP 2002-591488	20020510
AT 319707	T	20060315	AT 2002-730579	20020510
ES 2255615	T3	20060701	ES 2002-730579	20020510
US 20030004339	A1	20030102	US 2002-144337	20020513 <--
US 6734303	B2	20040511		
MX 2003PA10504	A	20040302	MX 2003-PA10504	20031117
US 20040158062	A1	20040812	US 2004-775001	20040209
PRIORITY APPLN. INFO.:			GB 2001-12061	A 20010518
			US 2001-301750P	P 20010628
			WO 2002-IB1748	W 20020510
			US 2002-144337	A3 20020513

OTHER SOURCE(S): CASREACT 138:4608; MARPAT 138:4608

GI




AB Title compds. [I; R1 = alkoxy, fluoroalkoxy; R2 = H, alkoxy, fluoroalkoxy; R3 = 5-6 membered (substituted) heterocyclyl; R4 = 4-7 membered (substituted) (fused) heterocyclyl], were prepared by reaction of fluorobenzonitriles (II; variables as above) with H2NC(:NH)NR5R6 [NR5R6 = 4-7 membered (substituted) (fused) heterocyclyl]. Thus, a mixture of 6-fluoro-3,4-dimethoxy-2-(2-pyridyl)benzonitrile (preparation given), N-(2-amidino-1,2,3,4-tetrahydro-5-isoquinolyl)methanesulfonamide (preparation given), Cs2CO3, and DMSO was heated to 94-97° for 30 h to give 57% 4-amino-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinolin-2-yl)-6,7-dimethoxy-5-(2-pyridyl)quinazoline.

IT 210538-44-6P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of quinazolines from fluorobenzonitriles and guanidines)

RN 210538-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:849586 CAPLUS

DOCUMENT NUMBER: 137:370099

TITLE: Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3β protein and protein complexes

INVENTOR(S): Ter Haar, Ernst; Swenson, Lovorka; Green, Jeremy; Arnost, Michael J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 778 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088078	A2	20021107	WO 2002-US13511	20020429 <--
WO 2002088078	A3	20040506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2444882	A1	20021107	CA 2002-2444882	20020429 <--
AU 2002259071	A1	20021111	AU 2002-259071	20020429 <--
US 20030125332	A1	20030703	US 2002-135255	20020429 <--
US 7390808	B2	20080624		
EP 1435957	A2	20040714	EP 2002-729056	20020429

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2005504731	T	20050217	JP 2002-585380	20020429
MX 2003PA09957	A	20050725	MX 2003-PA9957	20031030

PRIORITY APPLN. INFO.:
 US 2001-287366P P 20010430
 US 2001-297094P P 20010608
 US 2002-361899P P 20020227
 WO 2002-US13511 W 20020429

OTHER SOURCE(S): MARPAT 137:370099
 GI



AB Title compds. [I; R1 = H, RCO, RO2C, (substituted) alipharyl, carbocyclyl, heterocyclyl, heteroaryl, etc.; R2, R3 = H, (substituted) alipharyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2, NRCOR, SR, OR, CF3, halo, NO2, cyano, etc.; R = H, (substituted) alipharyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl], were prepared Thus, 3-chloro-4-cyano-5,6-diphenylpyridazine was refluxed with N2H4 in EtOH to give 3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki≤0.1 μM.

IT 474381-74-3P 474381-77-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (crystal structure determination; preparation of pyrazolopyridazines as inhibitors
 of gsk-3 and crystal structures of gsk-3β protein and protein complexes)

RN 474381-74-3 CAPLUS
 CN Kinase (phosphorylating), glycogen synthetase (human isoenzyme 3β), compd. with N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-4-quinazolinamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 474231-10-2
 CMF Unspecified
 CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 404828-10-0

CMF C17 H14 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 474381-77-6 CAPLUS

CN Kinase (phosphorylating), glycogen synthetase (human isoenzyme 3 β),
compd. with N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]-4-
quinazolinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 474231-10-2

CMF Unspecified


CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 404826-84-2

CMF C22 H14 F3 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L7 ANSWER 30 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN




ACCESSION NUMBER: 2002:845560 CAPLUS

DOCUMENT NUMBER: 137:353051

TITLE: Preparation of quinazolines as TGF- β and/or p38- α kinase inhibitors
 INVENTOR(S): Chakravarty, Sarvajit; Dugar, Sundeep; Perumattam, John J.; Schreiner, George F.; Liu, David Y.; Lewicki, John A.
 PATENT ASSIGNEE(S): Scios, Inc., USA
 SOURCE: U.S., 37 pp., Cont.-in-part of U.S. 6,184,226.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6476031	B1	20021105	US 1999-383825	19990827 <--
US 6184226	B1	20010206	US 1998-141916	19980828 <--
AT 342256	T	20061115	AT 1999-949568	19990827
ES 2274642	T3	20070516	ES 1999-949568	19990827
US 6277989	B1	20010821	US 2000-525034	20000314 <--
US 20030069248	A1	20030410	US 2001-969936	20011002 <--
US 20020161010	A1	20021031	US 2001-972582	20011005 <--
US 6903096	B2	20050607		
US 20050171123	A1	20050804	US 2005-53121	20050207
US 7345045	B2	20080318		
US 20050220784	A1	20051006	US 2005-136242	20050523
PRIORITY APPLN. INFO.:			US 1998-141916	A2 19980828
			US 1999-383825	A3 19990827
			US 2001-969936	B1 20011002
			US 2001-972582	A3 20011005

OTHER SOURCE(S): MARPAT 137:353051
 GI




AB Title compds. I [R3 = (un)substituted aromatic; Ar = (un)substituted monocyclic or polycyclic aromatic; L = S(CR22)m, NR1SO2(CR22)l, SO2(CR22)m, etc.; Z = CR2, N with the provisos that no more than two Z positions in ring A are N and wherein two adjacent Z positions in ring A cannot be N; R2 = H, alkyl, alkenyl, etc.; l = 0-3; m = 0-4; n = 1] and their pharmaceutically acceptable salts were prepared For example, condensation of chloroquinazoline II and 4-aminopyridine afforded claimed quinazoline III. In p38- α kinase inhibition studies, 9-examples of compds. I

exhibited IC50 values in the range of 0.1-1.5 μ M. Also, the specificity of compds. I for p38- α was assessed by their ability to inhibit other kinases, e.g., p38- γ JNK1, PKA, PKC, PK(PKD), cck2 and EGF-R, with IC50 values ranging from 4.2 - >500 μ M. Compds. I are useful anti-inflammatory agents and in the treatment of fibroproliferative diseases.

IT 54665-94-0P 80858-58-8P 157862-99-2P
 166039-38-9P 181114-32-9P 259870-32-1P
 259870-33-2P 259870-34-3P 259870-35-4P
 259870-36-5P 259870-37-6P 259870-38-7P
 259870-39-8P 259870-40-1P 259870-42-3P
 259870-43-4P, 2-(2,6-Dibromophenyl)-4-(4-pyridylamino)quinazoline
 259870-44-5P 259870-45-6P, 2-(2-Fluorophenyl)-4-(4-pyridylamino)-6,7-dimethoxyquinazoline 259870-46-7P,
 2-(4-Fluorophenyl)-4-(4-pyridylamino)-6,7-dimethoxyquinazoline
 259870-47-8P, 2-(2-Fluorophenyl)-4-(4-pyridylamino)-6-nitroquinazoline 259870-48-9P 259870-49-0P
 259870-50-3P 259870-51-4P 259870-52-5P
 308300-05-2P 404828-44-0P 420831-73-8P
 422561-07-7P 438247-46-2P 446312-97-6P
 446829-19-2P 474289-37-7P 474289-39-9P
 474289-40-2P 474289-42-4P 474289-44-6P
 474289-45-7P 474289-50-4P 474289-52-6P
 474289-54-8P 474289-60-6P 474289-64-0P
 474289-68-4P 474289-70-8P 474289-72-0P
 474289-74-2P 474289-76-4P 474289-79-7P
 474289-80-0P 474289-82-2P 474289-84-4P
 474289-87-7P 474289-89-9P 474289-90-2P
 474289-93-5P 474289-95-7P 474289-98-0P
 474290-00-1P 474290-02-3P 474290-04-5P
 474290-06-7P 474290-07-8P 474290-08-9P
 474290-09-0P 474290-15-8P 474290-17-0P
 474290-19-2P 474290-23-8P 474290-26-1P
 474290-28-3P 474290-30-7P 474290-32-9P
 474290-38-5P, 2-(3-Methoxyphenyl)-4-(4-pyridylamino)quinazoline
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of quinazolines as TGF- β and/or p38- α kinase inhibitors)


RN 54665-94-0 CAPLUS

CN Phenol, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 80858-58-8 CAPLUS

CN Quinazoline, 2-phenyl-4-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 157862-99-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 166039-38-9 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 181114-32-9 CAPLUS


CN Quinazoline, 2-phenyl-4-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 259870-32-1 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 259870-33-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-34-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-35-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 259870-36-5 CAPLUS
 CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 259870-37-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-38-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-39-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-40-1 CAPLUS


CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-42-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-43-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-dibromophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-44-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-45-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (CA
 INDEX NAME)




RN 259870-46-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (CA
 INDEX NAME)




RN 259870-47-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6-nitro-N-4-pyridinyl- (CA INDEX
 NAME)




RN 259870-48-9 CAPLUS
 CN 4,7-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-49-0 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(3-methoxyphenyl)methyl]-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-50-3 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(4-methoxyphenyl)methyl]-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-51-4 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-(2-methylpropyl)-N4-4-pyridinyl- (CA INDEX NAME)



RN 259870-52-5 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[[4-(methylthio)phenyl]methyl]-N4-4-pyridinyl- (CA INDEX NAME)




RN 308300-05-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 420831-73-8 CAPLUS

CN 4-Quinazolinamine, N-(2-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 422561-07-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 438247-46-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 446312-97-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 446829-19-2 CAPLUS
 CN Phenol, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN	474289-37-7	CAPLUS	
CN	2,3-Pyridinediamine, N2-(phenylmethyl)-N3-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)		



RN	474289-39-9	CAPLUS	
CN	2,4-Pyridinediamine, N2-(phenylmethyl)-N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)		




RN	474289-40-2	CAPLUS	
CN	4-Quinazolinamine, 2-phenyl-N-[3-(phenylmethoxy)phenyl]-		(CA INDEX NAME)




RN 474289-42-4 CAPLUS

CN 4-Quinazolinamine, 2-(3-aminophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-44-6 CAPLUS

CN 4-Quinazolinamine, N,2-di-4-pyridinyl- (CA INDEX NAME)




RN 474289-45-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-naphthalenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-50-4 CAPLUS

CN 4-Quinazolinamine, N-4-pyridinyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 474289-52-6 CAPLUS

CN Benzamide, N-[2-(2-fluorophenyl)-4-(4-pyridinylamino)-6-quinazolinyl]-4-methoxy- (CA INDEX NAME)




RN 474289-54-8 CAPLUS


CN 1,4-Benzenediamine, N1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474289-60-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-3-pyridinyl- (CA INDEX NAME)



RN 474289-64-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2-pyridinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 474289-68-4 CAPLUS
 CN Benzeneethanol, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-70-8 CAPLUS

CN Benzonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-72-0 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 474289-74-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-76-4 CAPLUS

CN 4-Quinazolinamine, N-[(2,5-difluorophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 474289-79-7 CAPLUS

CN 4-Quinazolinamine, N-[4-(1-methylpropyl)phenyl]-2-phenyl- (CA INDEX NAME)




RN 474289-80-0 CAPLUS

CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-phenyl- (CA INDEX NAME)




RN 474289-82-2 CAPLUS

CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 474289-84-4 CAPLUS

CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-87-7 CAPLUS


CN 4-Quinazolinamine, N-(1-methylethyl)-2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 474289-89-9 CAPLUS
 CN 4-Quinazolinamine, N-[(4-methoxyphenyl)methyl]-2-phenyl-N-4-pyridinyl-
 (CA INDEX NAME)



RN 474289-90-2 CAPLUS
 CN Quinazoline, 2-phenyl-4-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 474289-93-5 CAPLUS
 CN Phenol, 2-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 474289-95-7 CAPLUS

CN 1,3-Benzenediamine, N1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474289-98-0 CAPLUS

CN 4-Quinazolinamine, 2-(3-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 474290-00-1 CAPLUS

CN 4,7-Quinazolinediamine, 2-(4-fluorophenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 474290-02-3 CAPLUS

CN 4,7-Quinazolinediamine, N7-[(3-methoxyphenyl)methyl]-2-(4-methylphenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 474290-04-5 CAPLUS

CN 3,4-Pyridinediamine, N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 474290-06-7 CAPLUS


CN 4-Quinazolinamine, 2-[2-[(phenylmethyl)amino]phenyl]-N-4-pyridinyl- (CA INDEX NAME)




RN 474290-07-8 CAPLUS
 CN 3,4-Pyridinediamine, N3-(phenylmethyl)-N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 474290-08-9 CAPLUS
 CN Benzonitrile, 4-[4-[[3-[(phenylmethyl)amino]-4-pyridinyl]amino]-2-quinazolinyl]- (CA INDEX NAME)




RN 474290-09-0 CAPLUS
 CN Benzonitrile, 4-[[[4-[(2-phenyl-4-quinazolinyl)amino]-3-pyridinyl]amino]methyl]- (CA INDEX NAME)




RN 474290-15-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 474290-17-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyrimidinyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 474290-19-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 474290-23-8 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-4-yl-2-phenyl- (CA INDEX NAME)



RN 474290-26-1 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-5-yl-2-phenyl- (CA INDEX NAME)




RN 474290-28-3 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-4-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 474290-30-7 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-2-pyrimidinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 474290-32-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 474290-38-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:826587 CAPLUS

DOCUMENT NUMBER: 138:233846

TITLE: Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase

AUTHOR(S): Sarver, Ronald W.; Rogers, Joseph M.; Stockman, Brian J.; Epps, Dennis E.; DeZwaan, Jack; Harris, Melissa S.; Baldwin, Eric T.

CORPORATE SOURCE: Structural, Analytical and Medicinal Chemistry, Discovery Technologies Pharmacia Inc., Kalamazoo, MI, 49001, USA

SOURCE: Analytical Biochemistry (2002), 309(2), 186-195

CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several small mols. identified by high-throughput screening (HTS) were evaluated for their ability to bind to a nonstructural protein 3 (NS3) helicase from hepatitis C virus (HCV). Equilibrium dissociation consts. (Kd's) of


the compds. for this helicase were determined using several techniques including an assay measuring the kinetics of isothermal enzyme denaturation at several concns. of the test mol. Effects of two nonhydrolyzable ATP analogs on helicase denaturation were measured as controls using the isothermal denaturation (ITD) assay. Two compds., 4-(2,4-dimethylphenyl)-2,7,8-trimethyl-4,5-quinolinediamine and 2-phenyl-N-(5-piperazin-1-ylpentyl)quinazolin-4-amine, were identified from screening that inhibited the enzyme and had low micromolar dissociation consts. for NS3 helicase in the ITD assay. Low micromolar affinity of the quinolinediamine to helicase was also confirmed by NMR expts. Unfortunately, isothermal titration calorimetry (ITC) expts. indicated that the substituted quinazolinamine as well as a more water-soluble analog bound with a low micromolar affinity to the 47/23-mer oligonucleotide helicase substrate. There was no further interest in these templates as helicase inhibitors due to the nonspecific binding to enzyme and substrate. A combination of phys. methods was required to discern the mode of action of compds. identified by HTS and remove undesirable lead templates from further consideration.

IT 501443-70-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)




(phys. methods address binding mode of putative ligands for hepatitis C virus NS3 helicase)

RN 501443-70-5 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-[5-(1-piperazinyl)pentyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:803365 CAPLUS
DOCUMENT NUMBER: 138:55941
TITLE: A Modified Synthesis of Iodoazidoaryl Prazosin
AUTHOR(S): Andrus, Merritt B.; Mettath, Sashikumar N.; Song, Chun
CORPORATE SOURCE: Department of Chemistry and Biochemistry, Brigham
Young University, Provo, UT, 84602-5700, USA
SOURCE: Journal of Organic Chemistry (2002), 67(23),
8284-8286
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:55941
GI




AB The antihypertension agent iodoazidoaryl prazosin (IAAP, I) has been made

using a convergent route involving addition of an acylated piperazine (II) to a 2-chloroquinazoline (III). IAAP has been shown to function as a multidrug resistance (MDR) reversal agent and bind to P-glycoprotein, a transmembrane transport protein. A study is also reported involving palladium-catalyzed substitution with amine heterocycles. With N,N-bis(2,6-diisopropylphenyl) dihydroimidazolium chloride (10) as the ligand (2 mol %) for palladium(II) acetate (2 mol %) in THF at room temperature, morpholine added to III in 81% yield.

IT 478798-21-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (palladium complex catalyzed amination of 2-chloroquinazoline by nitrogen heterocycles)

RN 478798-21-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy- (CA INDEX NAME)




REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:754382 CAPLUS
 DOCUMENT NUMBER: 137:279209
 TITLE: Preparation of indazolylaminoquinazolines as Rho-kinase inhibitors
 INVENTOR(S): Nagarathnam, Dhanapalan; Wang, Chunguang
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076977	A2	20021003	WO 2002-US8660	20020322 <--
WO 2002076977	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441501	A1	20021003	CA 2002-2441501	20020322 <--
AU 2002245709	A1	20021008	AU 2002-245709	20020322 <--
US 20030087919	A1	20030508	US 2002-103565	20020322 <--
EP 1370552	A2	20031217	EP 2002-713884	20020322 <--
EP 1370552	B1	20070214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2004528314	T	20040916	JP 2002-576235	20020322
AT 353889	T	20070315	AT 2002-713884	20020322
ES 2280517	T3	20070916	ES 2002-713884	20020322
CA 2507381	A1	20040408	CA 2003-2507381	20030924
WO 2004029045	A2	20040408	WO 2003-US29538	20030924
WO 2004029045	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003270785	A1	20040419	AU 2003-270785	20030924
MX 2003PA08659	A	20050408	MX 2003-PA8659	20030924
EP 1542992	A2	20050622	EP 2003-752497	20030924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508068	T	20060309	JP 2004-540124	20030924
HK 1061029	A1	20070824	HK 2004-104114	20040609
MX 2005PA03273	A	20051018	MX 2005-PA3273	20050323
US 20060142313	A1	20060629	US 2006-354977	20060216
US 20060142314	A1	20060629	US 2006-354978	20060216
PRIORITY APPLN. INFO.:				
			US 2001-277974P	P 20010323
			US 2001-315338P	P 20010829
			US 2001-315341P	P 20010829
			US 2002-103565	B1 20020322
			US 2002-103566	B1 20020322
			WO 2002-US8660	W 20020322
			US 2002-252369	A 20020924
			WO 2003-US29538	W 20030924
OTHER SOURCE(S): MARPAT 137:279209				
AB	Six title compds. were prepared for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease (no data). Thus, 4-chloro-2-phenylquinazoline and 5-aminoindazole were heated at 100° in BuOH overnight to give N-[2-(2,4-dichlorophenyl)-4-quinazolinyl]-N-(1H-indazol-5-yl)amine.			
IT	463327-40-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of indazolylaminoquinazolines as Rho-kinase inhibitors)			
RN	463327-40-4 CAPLUS			
CN	4-Quinazolinamine, N-1H-indazol-5-yl-6,7-dimethoxy-2-phenyl- (CA INDEX NAME)			



L7 ANSWER 34 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:754381 CAPLUS

DOCUMENT NUMBER: 137:279208

TITLE: Preparation of (indazol-5-ylamino)quinazolines as
Rho-kinase inhibitors

INVENTOR(S): Nagarathnam, Dhanapalan; Asgari, Davoud; Shao,
Jianxing; Liu, Xiao-Gao; Khire, Uday; Wang, Chunguang;
Hart, Barry; Boyer, Stephen; Weber, Olaf; Lynch, Mark;
Bankston, Donald

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002076976	A2	20021003	WO 2002-US8659	20020322 <--
WO 2002076976	A3	20021212		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2441492	A1	20021003	CA 2002-2441492	20020322 <--
AU 2002250394	A1	20021008	AU 2002-250394	20020322 <--
US 20030125344	A1	20030703	US 2002-103566	20020322 <--
EP 1370553	A2	20031217	EP 2002-719303	20020322 <--
EP 1370553	B1	20060510		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004524350	T	20040812	JP 2002-576234	20020322
AT 325795	T	20060615	AT 2002-719303	20020322
TW 261055	B	20060901	TW 2002-91105591	20020322
PT 1370553	T	20060929	PT 2002-719303	20020322
ES 2264477	T3	20070101	ES 2002-719303	20020322
US 20030220357	A1	20031127	US 2002-252369	20020924 <--
CA 2507381	A1	20040408	CA 2003-2507381	20030924
WO 2004029045	A2	20040408	WO 2003-US29538	20030924
WO 2004029045	A3	20040722		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003270785	A1	20040419	AU 2003-270785	20030924
MX 2003PA08658	A	20050411	MX 2003-PA8658	20030924
EP 1542992	A2	20050622	EP 2003-752497	20030924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006508068	T	20060309	JP 2004-540124	20030924
HK 1061030	A1	20060908	HK 2004-104115	20040609
MX 2005PA03273	A	20051018	MX 2005-PA3273	20050323
US 20060142313	A1	20060629	US 2006-354977	20060216
US 20060142314	A1	20060629	US 2006-354978	20060216
PRIORITY APPLN. INFO.:			US 2001-277974P	P 20010323
			US 2001-315341P	P 20010829
			US 2001-315338P	P 20010829
			US 2002-103565	B1 20020322
			US 2002-103566	B1 20020322
			WO 2002-US8659	W 20020322
			US 2002-252369	A 20020924
			WO 2003-US29538	W 20030924
OTHER SOURCE(S):			CASREACT 137:279208; MARPAT 137:279208	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = N, CR17; X = alkyl, alkoxy, thioalkoxy, amido, etc.; p = 0-3; a, c = CR5, NR6, etc.; b = CR5, N; A = H, halo, carboxy, cyano, alkoxy, etc.; B = (un)substituted up to 3 times in any position by R5; R1,6 = H, alkyl; R2-5 = H, alkyl, alkenyl; R17 = H, alkyl, CN with provisions] were prepared For instance, 2,4-Dichloroquinazoline (preparation given) was reacted with 5-aminoindazole (THF/H2O, KOAc) to give 2-(N-(1H-indazol-5-yl)amino)-4-chloroquinazoline in 92% yield. This was coupled to 2,4-dichlorophenylboronic acid (ethylene glycol di-Me ether, Pd(dppf)Cl2, NaHCO3, reflux) to give II. I are rho-kinase inhibitors and are useful for inhibiting tumor growth, treating erectile dysfunction and coronary heart disease.

IT 461036-81-7P 461036-90-8P, 7-Chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine 461036-91-9P, N-(1H-Indazol-5-yl)-2-(2-quinoxaliny)-4-quinazolinamine 461036-94-2P, 5-Fluoro-N-(1H-indazol-5-yl)-2-(2-methylphenyl)-4-quinazolinamine 461036-95-3P 461037-02-5P 461037-06-9P, N-(3-Ethyl-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine 461037-10-5P, 2-(4-Chlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-11-6P, 1-[4-[4-((1H-Indazol-5-yl)amino)-2-quinazolinyl]phenyl]ethanone 461037-12-7P, N-(1H-Indazol-5-yl)-2-[4-(trifluoromethyl)phenyl]-4-quinazolinamine 461037-13-8P, 2-(3-Chloro-4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-14-9P, 2-(1,3-Benzodioxol-5-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-15-0P, N-(1H-Indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine 461037-16-1P, 2-(3,4-Dichlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-17-2P, N-(1H-Indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine 461037-18-3P, N-(1H-Indazol-5-yl)-2-(3,4,5-trimethoxyphenyl)-4-quinazolinamine 461037-19-4P, N-(1H-Indazol-5-yl)-2-(2-thienyl)-4-quinazolinamine 461037-20-7P, N-(1H-Indazol-5-yl)-2-(3-thienyl)-4-quinazolinamine 461037-21-8P, N-(1H-Indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine 461037-22-9P, N-(1H-Indazol-5-yl)-2-(2-methoxyphenyl)-4-quinazolinamine 461037-23-0P, 2-(4-Ethoxyphenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-24-1P, 2-(3,5-Dimethyl-4-isoxazolyl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-25-2P, 2-(1,1'-Biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-26-3P, 2-[4-(Dimethylamino)phenyl]-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-27-4P, N-(1H-Indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine 461037-28-5P,

4-[4-((1H-Indazol-5-yl)amino)-2-quinazolinyl]phenol 461037-29-6P
461037-30-9P, 7-Chloro-N-(1H-indazol-5-yl)-2-phenyl-4-
quinazolinamine 461037-31-0P, N-(1H-Indazol-5-yl)-6-nitro-2-
phenyl-4-quinazolinamine 461037-32-1P, 2-(4-Fluorophenyl)-N-(1H-
indazol-5-yl)-6-nitro-4-quinazolinamine 461037-33-2P,
6-Chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine
461037-34-3P, 6-Chloro-N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-
quinazolinamine 461037-35-4P, 6-Chloro-2-(4-fluorophenyl)-N-(1H-
indazol-5-yl)-4-quinazolinamine 461037-36-5P,
6-Chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine
461037-37-6P, 2-(4-Bromophenyl)-6-chloro-N-(1H-indazol-5-yl)-4-
quinazolinamine 461037-38-7P, 5-Fluoro-2-(4-fluorophenyl)-N-(1H-
indazol-5-yl)-4-quinazolinamine 461037-39-8P,
2-(3-Chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine
461037-40-1P, 2-(4-Bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-
quinazolinamine 461037-41-2P, 5-Fluoro-N-(1H-indazol-5-yl)-2-(3-
methylphenyl)-4-quinazolinamine hydrochloride 461037-42-3P,
5-Fluoro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine
461037-43-4P, 2-(3-Bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-
quinazolinamine hydrochloride 461037-44-5P, 2-(3-Bromophenyl)-5-
fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine 461037-45-6P,
2-(2-Chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine
461037-46-7P, 5-Fluoro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-
quinazolinamine 461037-47-8P 461037-48-9P,
5-Fluoro-N-(1H-indazol-5-yl)-2-(2-quinoxaliny)-4-quinazolinamine
461037-49-0P 461037-50-3P, 5-Fluoro-N-(1H-indazol-5-yl)-
2-(1-naphthyl)-4-quinazolinamine 461037-51-4P
461037-52-5P, 5-Fluoro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-
quinazolinamine 461037-53-6P 461037-54-7P,
5-Fluoro-N-(1H-indazol-5-yl)-2-(4-pyridinyl)-4-quinazolinamine
461037-55-8P 461037-56-9P, N-(1H-Indazol-5-yl)-7-methyl-
2-(2-quinoxaliny)-4-quinazolinamine 461037-57-0P,
2-(3-Chlorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine
461037-58-1P, 2-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-
quinazolinamine 461037-59-2P, N-(1H-Indazol-5-yl)-7-methyl-2-(4-
methylphenyl)-4-quinazolinamine 461037-60-5P,
2-(4-Bromophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine
461037-61-6P, N-(1H-Indazol-5-yl)-2-(4-methoxyphenyl)-7-methyl-4-
quinazolinamine 461037-62-7P, N-(1H-Indazol-5-yl)-7-methyl-2-(2-
methylphenyl)-4-quinazolinamine 461037-63-8P
461037-64-9P, N-(1H-Indazol-5-yl)-7-methyl-2-(3-methylphenyl)-4-
quinazolinamine 461037-65-0P 461037-66-1P,
N-[2-(3-Fluorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-indazol-5-yl)amine
461037-67-2P 461037-68-3P, 2-(3-Bromophenyl)-N-(1H-
indazol-5-yl)-7-methyl-4-quinazolinamine 461037-69-4P
461037-70-7P, N-[2-(2-Chlorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-
indazol-5-yl)amine 461037-71-8P 461037-72-9P,
N-(1H-Indazol-5-yl)-2-(3-methoxyphenyl)-7-methyl-4-quinazolinamine
461037-73-0P 461037-74-1P, 2-(3-Furyl)-N-(1H-indazol-5-
yl)-7-methyl-4-quinazolinamine 461037-75-2P 461037-76-3P
, N-(1H-Indazol-5-yl)-7-methyl-2-(1-naphthyl)-4-quinazolinamine
461037-77-4P 461037-78-5P, N-(1H-Indazol-5-yl)-7-methyl-
2-(2-naphthyl)-4-quinazolinamine 461037-79-6P
461037-80-9P, N-(1H-Indazol-5-yl)-7-methyl-2-(3-pyridinyl)-4-
quinazolinamine 461037-81-0P 461037-82-1P,
N-(1H-Indazol-5-yl)-7-methyl-2-(4-pyridinyl)-4-quinazolinamine
461037-83-2P 461037-84-3P, 7-Chloro-2-(3-chlorophenyl)-N-
(1H-indazol-5-yl)-4-quinazolinamine 461037-85-4P,
2-(4-Bromophenyl)-7-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine
461037-86-5P, 7-Chloro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-
quinazolinamine hydrochloride 461037-87-6P, 7-Chloro-N-(1H-
indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine 461037-88-7P,


7-Chloro-2-(3-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine
 461037-89-8P 461037-90-1P, 2-(3-Bromophenyl)-7-chloro-N-
 (1H-indazol-5-yl)-4-quinazolinamine 461037-91-2P
 461037-92-3P, 7-Chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-
 quinazolinamine 461037-93-4P 461037-95-6P
 461037-96-7P 461037-97-8P, 7-Chloro-N-(1H-indazol-5-yl)-
 2-(2-quinoxaliny)-4-quinazolinamine 461037-98-9P
 461037-99-0P, 7-Chloro-N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-
 quinazolinamine 461038-00-6P 461038-01-7P,
 7-Chloro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-quinazolinamine
 461038-02-8P 461038-03-9P, 7-Chloro-N-(1H-indazol-5-yl)-
 2-(3-pyridinyl)-4-quinazolinamine 461038-04-0P
 461038-05-1P, 2-(1,1'-Biphenyl-4-yl)-N-(1H-indazol-5-yl)-6,7-
 dimethoxy-4-quinazolinamine 461038-06-2P, N-(1H-Indazol-5-yl)-
 6,7-dimethoxy-2-(3-methoxyphenyl)-4-quinazolinamine 461038-07-3P
 , N-(1H-Indazol-5-yl)-6,7-dimethoxy-2-(4-vinylphenyl)-4-quinazolinamine
 461038-08-4P, 2-(4-Ethoxyphenyl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-
 4-quinazolinamine 461038-33-5P, 2-(3-Aminophenyl)-N-(1H-indazol-
 5-yl)-4-quinazolinamine 461038-34-6P, N-[3-[4-((1H-Indazol-5-
 yl)amino)-2-quinazolinyl]phenyl]isonicotinamide 461038-35-7P,
 N-[3-[4-((1H-Indazol-5-yl)amino)-2-quinazolinyl]phenyl]acetamide
 461038-66-4P, 2-(2,3-Dihydro-1-benzofuran-5-yl)-N-(1H-indazol-5-
 yl)-4-quinazolinamine 461038-69-7P, 2-(2-Fluoro-1,1'-biphenyl-4-
 yl)-N-(1H-indazol-5-yl)-4-quinazolinamine dihydrochloride
 461038-70-0P 461038-71-1P 461038-72-2P
 461038-73-3P 464177-54-6P, 2-(1-Benzofuran-2-yl)-N-(1H-
 indazol-5-yl)-4-quinazolinamine 464177-55-7P,
 2-(1-Benzothien-2-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(rho-kinase inhibitor; preparation of (indazol-5-ylamino)quinazolines as
 Rho-kinase inhibitors)


RN 461036-81-7 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-1H-indazol-5-yl- (CA INDEX
 NAME)




RN 461036-90-8 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(4-methylphenyl)- (CA
 INDEX NAME)




RN 461036-91-9 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(2-methylphenyl)- (CA INDEX NAME)



RN 461036-94-2 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(2-methylphenyl)- (CA INDEX NAME)




RN 461036-95-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-1H-indazol-5-yl-6,7-dimethoxy- (CA INDEX NAME)




RN 461037-02-5 CAPLUS

CN 4-Quinazolinamine, 2-(2-fluoro[1,1'-biphenyl]-4-yl)-N-1H-indazol-5-yl-
(CA INDEX NAME)




RN 461037-06-9 CAPLUS

CN 4-Quinazolinamine, N-(3-ethyl-1H-indazol-5-yl)-2-(4-methoxyphenyl)- (CA
INDEX NAME)




RN 461037-10-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-11-6 CAPLUS
 CN Ethanone, 1-[4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 461037-12-7 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 461037-13-8 CAPLUS
 CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-14-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-15-0 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 461037-16-1 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-17-2 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 461037-18-3 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 461037-19-4 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(2-thienyl)- (CA INDEX NAME)




RN 461037-20-7 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(3-thienyl)- (CA INDEX NAME)




RN 461037-21-8 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 461037-22-9 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(2-methoxyphenyl)- (CA INDEX NAME)




RN 461037-23-0 CAPLUS
CN 4-Quinazolinamine, 2-(4-ethoxyphenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-24-1 CAPLUS
CN 4-Quinazolinamine, 2-(3,5-dimethyl-4-isoxazolyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-25-2 CAPLUS
CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-26-3 CAPLUS
CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-27-4 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 461037-28-5 CAPLUS
 CN Phenol, 4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]- (CA INDEX NAME)




RN 461037-29-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1-dibenzofuranyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-30-9 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-phenyl- (CA INDEX NAME)




RN 461037-31-0 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-6-nitro-2-phenyl- (CA INDEX NAME)




RN 461037-32-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-1H-indazol-5-yl-6-nitro- (CA INDEX NAME)




RN 461037-33-2 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-1H-indazol-5-yl-2-(4-methylphenyl)- (CA
 INDEX NAME)




RN 461037-34-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-1H-indazol-5-yl-2-(4-methoxyphenyl)- (CA
 INDEX NAME)




RN 461037-35-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(4-fluorophenyl)-N-1H-indazol-5-yl- (CA
 INDEX NAME)




RN 461037-36-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-1H-indazol-5-yl-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 461037-37-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-38-7 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-2-(4-fluorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-39-8 CAPLUS
 CN 4-Quinazolinamine, 2-(3-chlorophenyl)-5-fluoro-N-1H-indazol-5-yl- (CA INDEX NAME)



RN 461037-40-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-5-fluoro-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-41-2 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(3-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 461037-42-3 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(3-methylphenyl)- (CA INDEX NAME)




RN 461037-43-4 CAPLUS
 CN 4-Quinazolinamine, 2-(3-bromophenyl)-5-fluoro-N-1H-indazol-5-yl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 461037-44-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-bromophenyl)-5-fluoro-N-1H-indazol-5-yl- (CA INDEX NAME)



RN 461037-45-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-5-fluoro-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-46-7 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 461037-47-8 CAPLUS
 CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 461037-46-7
 CMF C22 H16 F N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-48-9 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(2-quinoxaliny)- (CA INDEX NAME)




RN 461037-49-0 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(2-quinoxaliny)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 461037-48-9


CMF C23 H14 F N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-50-3 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 461037-51-4 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-50-3


CMF C25 H16 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-52-5 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 461037-53-6 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-52-5


CMF C25 H16 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-54-7 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 461037-55-8 CAPLUS

CN 4-Quinazolinamine, 5-fluoro-N-1H-indazol-5-yl-2-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 461037-54-7


CMF C20 H13 F N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 461037-56-9 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(2-quinoxaliny)- (CA INDEX NAME)




RN 461037-57-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-58-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-59-2 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 461037-60-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)



RN 461037-61-6 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(4-methoxyphenyl)-7-methyl- (CA INDEX NAME)




RN 461037-62-7 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(2-methylphenyl)- (CA INDEX NAME)



RN 461037-63-8 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(2-methylphenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-62-7
 CMF C23 H19 N5




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 461037-64-9 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(3-methylphenyl)- (CA INDEX NAME)



RN 461037-65-0 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(3-methylphenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 461037-64-9
CMF C23 H19 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-66-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-fluorophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-67-2 CAPLUS

CN 4-Quinazolinamine, 2-(3-fluorophenyl)-N-1H-indazol-5-yl-7-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-66-1


CMF C22 H16 F N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-68-3 CAPLUS

CN 4-Quinazolinamine, 2-(3-bromophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-69-4 CAPLUS

CN 4-Quinazolinamine, 2-(3-bromophenyl)-N-1H-indazol-5-yl-7-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-68-3


CMF C22 H16 Br N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-70-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-71-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-5-yl-7-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 461037-70-7

CMF C22 H16 Cl N5




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 461037-72-9 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(3-methoxyphenyl)-7-methyl- (CA INDEX NAME)



RN 461037-73-0 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-5-yl-2-(3-methoxyphenyl)-7-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 461037-72-9
CMF C23 H19 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-74-1 CAPLUS

CN 4-Quinazolinamine, 2-(3-furanyl)-N-1H-indazol-5-yl-7-methyl- (CA INDEX NAME)




RN 461037-75-2 CAPLUS

CN 4-Quinazolinamine, 2-(3-furanyl)-N-1H-indazol-5-yl-7-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-74-1


CMF C20 H15 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-76-3 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(1-naphthalenyl)- (CA INDEX NAME)




RN 461037-77-4 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(1-naphthalenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-76-3


CMF C26 H19 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-78-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 461037-79-6 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 461037-78-5


CMF C26 H19 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-80-9 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(3-pyridinyl)- (CA INDEX NAME)




RN 461037-81-0 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(3-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 461037-80-9


CMF C21 H16 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 461037-82-1 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 461037-83-2 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-5-yl-7-methyl-2-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 461037-82-1


CMF C21 H16 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 461037-84-3 CAPLUS

CN 4-Quinazolinamine, 7-chloro-2-(3-chlorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-85-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461037-86-5 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 461037-87-6 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-methylphenyl)- (CA INDEX NAME)




RN 461037-88-7 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(3-fluorophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)



RN 461037-89-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(3-fluorophenyl)-N-1H-indazol-5-yl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-88-7
 CMF C21 H13 Cl F N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461037-90-1 CAPLUS
 CN 4-Quinazolinamine, 2-(3-bromophenyl)-7-chloro-N-1H-indazol-5-yl- (CA
 INDEX NAME)



RN 461037-91-2 CAPLUS
 CN 4-Quinazolinamine, 2-(3-bromophenyl)-7-chloro-N-1H-indazol-5-yl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-90-1
 CMF C21 H13 Br Cl N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461037-92-3 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-methoxyphenyl)- (CA
 INDEX NAME)



RN 461037-93-4 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-methoxyphenyl)-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-92-3
 CMF C22 H16 Cl N5 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461037-95-6 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(2-furanyl)-N-1H-indazol-5-yl- (CA INDEX
 NAME)



RN 461037-96-7 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(2-furanyl)-N-1H-indazol-5-yl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-95-6
 CMF C19 H12 Cl N5 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461037-97-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(2-quinoxaliny)-
 INDEX NAME)



RN 461037-98-9 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(2-quinoxalinyloxy)-,
 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)


CM 1

CRN 461037-97-8
 CMF C23 H14 Cl N7




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461037-99-0 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(1-naphthalenyl)- (CA
 INDEX NAME)



RN 461038-00-6 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(1-naphthalenyl)-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461037-99-0
 CMF C25 H16 Cl N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461038-01-7 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(2-naphthalenyl)- (CA
 INDEX NAME)



RN 461038-02-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(2-naphthalenyl)-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 461038-01-7
 CMF C25 H16 Cl N5




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 461038-03-9 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-pyridinyl)- (CA INDEX
 NAME)



RN 461038-04-0 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-1H-indazol-5-yl-2-(3-pyridinyl)-,
 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)


CM 1

CRN 461038-03-9
 CMF C20 H13 Cl N6




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 461038-05-1 CAPLUS
 CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-1H-indazol-5-yl-6,7-dimethoxy-
 (CA INDEX NAME)




RN 461038-06-2 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-5-yl-6,7-dimethoxy-2-(3-methoxyphenyl)-
 (CA INDEX NAME)



RN 461038-07-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-ethenylphenyl)-N-1H-indazol-5-yl-6,7-dimethoxy-
 (CA INDEX NAME)




RN 461038-08-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-ethoxyphenyl)-N-1H-indazol-5-yl-6,7-dimethoxy-
 (CA INDEX NAME)




RN 461038-33-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-aminophenyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 461038-34-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 461038-35-7 CAPLUS


CN Acetamide, N-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl]- (CA INDEX NAME)



RN 461038-66-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2,3-dihydro-5-benzofuranyl)-N-1H-indazol-5-yl- (CA INDEX NAME)



RN 461038-69-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluoro[1,1'-biphenyl]-4-yl)-N-1H-indazol-5-yl-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 461038-70-0 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluoro[1,1'-biphenyl]-4-yl)-N-1H-indazol-5-yl-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1


CRN 461037-02-5

CMF C27 H18 F N5



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 461038-71-1 CAPLUS
CN 4-Quinazolinamine, 2-(2-fluoro[1,1'-biphenyl]-4-yl)-N-1H-indazol-5-yl-,
benzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 461037-02-5
CMF C27 H18 F N5



CM 2


CRN 98-11-3
CMF C6 H6 O3 S



RN 461038-72-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluoro[1,1'-biphenyl]-4-yl)-N-1H-indazol-5-yl-,
 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 461037-02-5
 CMF C27 H18 F N5



CM 2


CRN 104-15-4
 CMF C7 H8 O3 S



RN 461038-73-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1-dibenzofuranyl)-N-1H-indazol-5-yl-,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 461037-29-6
 CMF C27 H17 N5 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 464177-54-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-benzofuranyl)-N-1H-indazol-5-yl- (CA INDEX NAME)




RN 464177-55-7 CAPLUS


CN 4-Quinazolinamine, 2-benzo[b]thien-2-yl-N-1H-indazol-5-yl- (CA INDEX NAME)



L7 ANSWER 35 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:718030 CAPLUS
 DOCUMENT NUMBER: 138:287611
 TITLE: The synthesis of new N3-aryl-N1-(2-phenylquinazolin-4-yl)thioureas
 AUTHOR(S): Fathalla, Walid; Pazdera, Pavel
 CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Science, Masaryk University, Brno, Czech Rep.
 SOURCE: ARKIVOC (Gainesville, FL, United States) [online computer file] (2002), (1), 7-11
 CODEN: AGFUAR
 URL: <http://www.arkat-usa.org/ark/journal/2002/General/1-283A/1-283A.pdf>
 PUBLISHER: Arkat USA Inc.
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:287611
 AB Domino-reactions between N2-(2-cyanophenyl)-N1-thioxomethylidenebenzene-1-carboximidamide and aryl amines leading to the N3-aryl-N1-(2-phenylquinazolin-4-yl)thioureas are described. FTIR, 1H NMR, 13C NMR, mass spectroscopy and x-ray structural anal. made identity of the synthesized compds.
 IT 400053-06-7P 400053-14-7P 400053-15-8P
 505092-79-5P 505092-80-8P 505092-81-9P
 505092-82-0P 505092-83-1P 505092-84-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of N3-aryl-N1-(2-phenylquinazolin-4-yl)thioureas by domino-reactions)
 RN 400053-06-7 CAPLUS
 CN Thiourea, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-14-7 CAPLUS
 CN Thiourea, N-1-naphthalenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-15-8 CAPLUS

CN Thiourea, N-2-naphthalenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 505092-79-5 CAPLUS

CN Thiourea, N-(4-iodophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 505092-80-8 CAPLUS

CN Thiourea, N-(4-bromophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 505092-81-9 CAPLUS

CN Thiourea, N-(4-hydroxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 505092-82-0 CAPLUS

CN Thiourea, N-(4-acetylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 505092-83-1 CAPLUS

CN Thiourea, N-[4-(2-phenyldiazenyl)phenyl]-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 505092-84-2 CAPLUS
 CN Thiourea, N-(2,4-dichlorophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 36 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:623680 CAPLUS
 DOCUMENT NUMBER: 138:137255
 TITLE: Studies on quinazolines. Part I. Annellation to the quinazoline ring utilizing amino acid esters
 AUTHOR(S): Wasfy, A. A. F.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt
 SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (2002), 177(5), 1349-1358
 CODEN: PSSLEC; ISSN: 1042-6507
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:137255


AB The reaction of quinazoline-4(3H)-thiones with amino acid ester hydrochlorides in boiling solvents, under the basic catalysis, afforded the corresponding substitution products in low yield. The reaction could be improved by carrying it without a solvent yielding products; the compds. thus prepared included imidazo[1,2-c]quinazolin-3(2H)-one, pyrimido[1,2-c]quinazolin-4-one and (quinazolinyl)amino acid ester derivs. The antibacterial and antifungal activities of the prepared compds. were tested.

IT 494802-21-0P 494802-23-2P 494802-24-3P
494802-26-5P 494802-28-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antibacterial and antifungal activity of
imidazo[1,2-c]quinazolin-3(2H)-one, pyrimido[1,2-c]quinazolin-4-one and
(quinazolinyl)amino acid ester derivs.)

RN 494802-21-0 CAPLUS


CN Glycine, N-[2-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-4-quinazolinyl]-,
methyl ester (CA INDEX NAME)



RN 494802-23-2 CAPLUS

CN L-Serine, N-[2-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-4-quinazolinyl]-,
methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 494802-24-3 CAPLUS


CN L-Valine, N-[2-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-4-quinazolinyl]-,
methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 494802-26-5 CAPLUS
 CN L-Leucine, N-[2-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-4-quinazolinyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 494802-28-7 CAPLUS
 CN β -Alanine, N-[2-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-4-quinazolinyl]-,
 methyl ester (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:615578 CAPLUS
 DOCUMENT NUMBER: 137:154942
 TITLE: Preparation of novel quinazoline derivatives for
 preventing or treating inflammatory diseases caused by

bacterial DNA
 INVENTOR(S): Kisanuki, Sumitsugu; Tomizawa, Hideyuki; Isobe, Yoshiaki
 PATENT ASSIGNEE(S): Japan Energy Corp., Japan
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062767	A1	20020815	WO 2002-JP1045	20020207 <--
W: AU, CA, JP, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002230181	A1	20020819	AU 2002-230181	20020207 <--
PRIORITY APPLN. INFO.:			JP 2001-30973	A 20010207
			WO 2002-JP1045	W 20020207
OTHER SOURCE(S):		MARPAT 137:154942		
GI				



AB Disclosed are medicinal compns. for preventing or treating inflammatory diseases caused by bacterial DNA which contain as the active ingredient quinazoline derivs. represented by the following general formula (I) or pharmacol. acceptable salts thereof [wherein R5, R6, R7, R8 = H, substituents selected from a group of substituents A; or two adjacent groups of R5-R8 together represent methylenedioxy or CH:CHCH:CH; wherein substituents A = C1-4 alkyl, halo, OH, C1-4 alkoxy, C1-4 acyloxy, NR13R14 (R13, R14 = H, C1-4 alkyl), NHCOR15 (R15 = H, C1-4 alkyl), Ph, PhO, cyano, C1-4 acyl, CO2H, C2-5 alkoxyacetyl, CONH2, N-(C1-4 alkyl)carbamoyl, N,N-di(C1-4 alkyl)carbamoyl; R2 = (un)substituted aryl or heteroaryl; n = 0, 1; X = a group of the following general formula -P-NR9R10 or Q; wherein P = (un)branched C2-6 alkylene; R9, R10 = H, C1-4 alkyl, C2-4 hydroxyalkyl, C3-6 alkoxyalkyl; Y = CHR11, O, S, NR12 (wherein R11 = H, C1-4 alkyl, OH, hydroxymethyl, methoxycarbonyl, ethoxycarbonyl; R12 = H, C1-4 alkyl, aryl optionally substituted by substituents A); Z = H or OH when Y = CHR11; Z = H when Y = O, S, or NR12]. Also disclosed are medicinal compns. containing I for preventing or treating autoimmune diseases or diseases caused by excessive production of TNF- α or IL-6. These compds. I inhibit the unusual production of TNF- α or IL-6 of macrophage or monocyte activated by bacterial DNA and are useful for treating or preventing diseases caused by unusual increase in cytokines, e.g. chronic articular rheumatism, systemic lupus erythematosus (SLE), septicemia, inflammatory bowel diseases, osteoarthritis, multiple sclerosis, Behcet's disease, rejection of bone marrow transplant, hepatitis, type II diabetes, atrial myxoma, alc. hepatic cirrhosis, myeloma, and mesangium-proliferative nephritis. Thus, mesylation of 4-(4-hydroxybutylamino)-6,7-dimethoxy-2-(2-naphthyl)quinazoline by methanesulfonyl chloride and Et3N

in CH₂Cl₂ under ice-cooling for 1 h and at room temperature for 4 h followed by amination with N-(2-methoxyethyl)ethylamine at room temperature at room temperature

for 2 days gave 6,7-dimethoxy-4-(4-(ethyl-(2-methoxyethyl)amino)butylamino)-2-(2-naphthyl)quinazoline (II). II in vitro inhibited the production of TNF- α in mouse spleen cells with IC₅₀ of 10 nM and that of IL-6 with IC₅₀ of 32 nM.


IT 445401-77-4P 445401-78-5P 445401-79-6P
 445401-80-9P 445401-81-0P 445401-82-1P
 445401-83-2P 445401-84-3P 445401-85-4P
 445401-86-5P 445401-87-6P 445401-88-7P
 445401-89-8P 445401-90-1P 445401-91-2P
 445401-92-3P 445401-93-4P 445401-94-5P
 445401-95-6P 445401-96-7P 445401-97-8P
 445401-98-9P 445401-99-0P 445402-00-6P
 445402-01-7P 445402-02-8P 445402-03-9P
 445402-04-0P 445402-05-1P 445402-06-2P
 445402-07-3P 445402-08-4P 445402-09-5P
 445402-10-8P 445402-11-9P 445402-12-0P
 445402-19-7P 445402-20-0P 445402-21-1P
 445402-22-2P 445402-23-3P 445402-24-4P
 445402-25-5P 445402-26-6P 445402-27-7P
 445402-28-8P 445402-29-9P 445402-30-2P
 445402-31-3P 445402-32-4P 445402-33-5P
 445402-34-6P 445402-35-7P 445402-38-0P
 445402-39-1P 445402-40-4P 445402-41-5P
 445402-42-6P 445402-43-7P 445402-44-8P
 445402-45-9P 445402-46-0P 445402-47-1P
 445402-48-2P 445402-49-3P 445402-50-6P
 445402-51-7P 445402-52-8P 445402-53-9P
 445402-54-0P 445402-55-1P 445402-56-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinazoline derivs. for preventing or treating inflammatory diseases caused by bacterial DNA)


RN 445401-77-4 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-diethyl- (CA INDEX NAME)




RN 445401-78-5 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-79-6 CAPLUS

CN 1,4-Butanediamine, N4-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-80-9 CAPLUS

CN 1,5-Pentanediamine, N5-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-81-0 CAPLUS

CN 1,3-Propanediamine, N3-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-82-1 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(4-methylphenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-83-2 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(1-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-84-3 CAPLUS

CN 1,3-Propanediamine, N3-[2-(2-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-85-4 CAPLUS

CN 1,3-Propanediamine, N3-[2-(3-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-86-5 CAPLUS

CN 1,3-Propanediamine, N3-[2-(4-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-87-6 CAPLUS

CN 1,3-Propanediamine, N3-[2-[4-(1,1-dimethylethyl)phenyl]-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-88-7 CAPLUS

CN 1,3-Propanediamine, N3-(2-[1,1'-biphenyl]-4-yl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-89-8 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(4-phenoxyphenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-90-1 CAPLUS

CN 1,3-Propanediamine, N3-[2-(4-ethylphenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-91-2 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(3-quinolinyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-92-3 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(4-methoxyphenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)



RN 445401-93-4 CAPLUS


CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-naphthalenyl)-N-[4-(1-piperidinyl)butyl]- (CA INDEX NAME)



RN 445401-94-5 CAPLUS


CN 4-Quinazolinamine, 6,7-dimethoxy-N-[4-(4-morpholinyl)butyl]-2-(2-

naphthalenyl)- (CA INDEX NAME)




RN 445401-95-6 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-[4-(4-methyl-1-piperazinyl)butyl]-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 445401-96-7 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(4-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-97-8 CAPLUS


CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-98-9 CAPLUS
 CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(3-thienyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445401-99-0 CAPLUS
 CN 1,3-Propanediamine, N1-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 445402-00-6 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 445402-01-7 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-[3-(4-morpholinyl)propyl]-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 445402-02-8 CAPLUS

CN 1,4-Butanediamine, N4-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-03-9 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-naphthalenyl)-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 445402-04-0 CAPLUS

CN 1,3-Propanediamine, N3-[2-(4-aminophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-05-1 CAPLUS

CN 6-Quinazolinol, 4-[[3-(dimethylamino)propyl]amino]-7-methoxy-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 445402-06-2 CAPLUS

CN 1,4-Butanediamine, N4-[6,7-dimethoxy-2-(4-methylphenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-07-3 CAPLUS

CN 4-Quinazolinamine, N-[4-(4-ethyl-1-piperazinyl)butyl]-6,7-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)




RN 445402-08-4 CAPLUS

CN 1,4-Butanediamine, N4-[2-(4-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-09-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-[4-(4-methyl-1-piperazinyl)butyl]- (CA INDEX NAME)




RN 445402-10-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-[4-(4-morpholinyl)butyl]- (CA INDEX NAME)




RN 445402-11-9 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-[4-(4-morpholinyl)butyl]- (CA INDEX NAME)




RN 445402-12-0 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-naphthalenyl)-N-[4-(4-phenyl-1-piperazinyl)butyl]- (CA INDEX NAME)




RN 445402-19-7 CAPLUS

CN 4,6-Quinazolinediamine, 2-(4-fluorophenyl)-N4-[4-(4-methyl-1-piperazinyl)butyl]- (CA INDEX NAME)




RN 445402-20-0 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(3-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-21-1 CAPLUS


CN 1,3-Propanediamine, N3-[6,7-dimethoxy-2-(6-methyl-3-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-22-2 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(4-fluorophenyl)-N4-[4-(4-morpholinyl)butyl]-
 (CA INDEX NAME)




RN 445402-23-3 CAPLUS
 CN 1,3-Propanediamine, N3-[2-(6-chloro-3-pyridinyl)-6,7-dimethoxy-4-
 quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)



RN 445402-24-4 CAPLUS
 CN 1,6-Hexanediamine, N6-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-
 N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-25-5 CAPLUS
 CN Phenol, 4-[4-[3-(dimethylamino)propyl]amino]-6,7-dimethoxy-2-
 quinazolinyl]- (CA INDEX NAME)




RN 445402-26-6 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-naphthalenyl)-N-[4-(1-piperazinyl)butyl]- (CA INDEX NAME)




RN 445402-27-7 CAPLUS

CN 4,6-Quinazolinediamine, N4-[4-(dimethylamino)butyl]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 445402-28-8 CAPLUS


CN 4,6-Quinazolinediamine, N4-[4-(dimethylamino)butyl]-2-(4-methylphenyl)- (CA INDEX NAME)




RN 445402-29-9 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(4-methylphenyl)-N4-[4-(4-methyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 445402-30-2 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(4-methylphenyl)-N4-[4-(4-morpholinyl)butyl]- (CA INDEX NAME)




RN 445402-31-3 CAPLUS
 CN 1,4-Butanediamine, N1-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N4-methyl- (CA INDEX NAME)




RN 445402-32-4 CAPLUS
 CN 1,3-Propanediamine, N3-[2-(2-benzofuranyl)-6,7-dimethoxy-4-quinazolinyl]-

N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-33-5 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-[2-(2-naphthalenyl)-4-quinazolinyl]-
(CA INDEX NAME)




RN 445402-34-6 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-[6-methyl-2-(2-naphthalenyl)-4-quinazolinyl]-
(CA INDEX NAME)




RN 445402-35-7 CAPLUS

CN 1,3-Propanediamine, N3-[6,7-difluoro-2-(2-naphthalenyl)-4-quinazolinyl]-
N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-38-0 CAPLUS

CN 4,6-Quinazolinediamine, N4-[3-(dimethylamino)propyl]-2-(2-naphthalenyl)-
(CA INDEX NAME)




RN 445402-39-1 CAPLUS

CN 1,3-Propanediamine, N3-[6-chloro-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-40-4 CAPLUS

CN 1,3-Propanediamine, N3-[7-chloro-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-41-5 CAPLUS

CN 1,3-Propanediamine, N3-[6-bromo-2-(2-naphthalenyl)-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-42-6 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-[7-methyl-2-(2-naphthalenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 445402-43-7 CAPLUS

CN Acetamide, N-[4-[[3-(dimethylamino)propyl]amino]-2-(2-naphthalenyl)-6-quinazolinyl]- (CA INDEX NAME)




RN 445402-44-8 CAPLUS

CN 1,3-Propanediamine, N3-[2-[4-(dimethylamino)phenyl]-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-45-9 CAPLUS

CN 4,6-Quinazolinediamine, N4-[3-(dimethylamino)propyl]-N6,N6-dimethyl-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 445402-46-0 CAPLUS

CN 1,3-Propanediamine, N3-[2-(3,4-dimethylphenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-47-1 CAPLUS

CN 1,3-Propanediamine, N3-[2-(3,4-difluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-48-2 CAPLUS

CN 1,3-Propanediamine, N3-[2-(4-fluoro-3-methylphenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 445402-49-3 CAPLUS

CN Ethanol, 2-[[4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]butyl]ethylamino]- (CA INDEX NAME)




RN 445402-50-6 CAPLUS

CN 1,4-Butanediamine, N1-ethyl-N4-[2-(4-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1-(2-methoxyethyl)- (CA INDEX NAME)




RN 445402-51-7 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-naphthalenyl)-N-[4-(4-thiomorpholinyl)butyl]- (CA INDEX NAME)




RN 445402-52-8 CAPLUS

CN 4-Piperidinol, 1-[4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]butyl]- (CA INDEX NAME)




RN 445402-53-9 CAPLUS

CN 4-Piperidinol, 1-[4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]butyl]- (CA INDEX NAME)




RN 445402-54-0 CAPLUS

CN 1,4-Butanediamine, N4-[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]-N1-ethyl-N1-(2-methoxyethyl)- (CA INDEX NAME)




RN 445402-55-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]butyl]-, methyl ester (CA INDEX NAME)




RN 445402-56-2 CAPLUS


CN 3-Piperidinol, 1-[4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]butyl]- (CA INDEX NAME)




IT 445402-70-0P 445402-71-1P 445402-72-2P
 445402-73-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel quinazoline derivs. for preventing or treating
 inflammatory diseases caused by bacterial DNA)
 RN 445402-70-0 CAPLUS
 CN 1-Butanol, 4-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-quinazolinyl]amino]-
 (CA INDEX NAME)




RN 445402-71-1 CAPLUS
 CN Carbamic acid, [3-[[6,7-dimethoxy-2-(2-naphthalenyl)-4-
 quinazolinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
 NAME)



RN 445402-72-2 CAPLUS
 CN 1,3-Propanediamine, N3-[[6,7-dimethoxy-2-(4-nitrophenyl)-4-quinazolinyl]-
 N1,N1-dimethyl- (CA INDEX NAME)



RN 445402-73-3 CAPLUS
 CN 1-Butanol, 4-[[2-(4-methylphenyl)-6-nitro-4-quinazolinyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:543678 CAPLUS

DOCUMENT NUMBER: 138:106650

TITLE: Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines

AUTHOR(S): Ananthan, Subramaniam; Saini, Surendra K.; Khare, Rashmi; Clayton, Sarah D.; Dersch, Christina M.; Rothman, Richard B.

CORPORATE SOURCE: Organic Chemistry Department, Southern Research Institute, Birmingham, AL, 35255, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2225-2228
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:106650


AB In an attempt to identify novel ligands for the dopamine transporter, a series of 4-substituted-2-phenylquinazolines were synthesized and evaluated. Among the compds. studied, 4-[[2-(4-methylphenyl)-6-nitro-4-quinazolinyl]amino]-2-phenylquinazoline was identified as a novel partial inhibitor of [125I]RTI-55 binding to the dopamine transporter and a partial inhibitor of [3H]dopamine uptake.

IT 40288-71-9P 434326-29-1P 487018-23-5P
 488082-02-6P 488082-03-7P 488082-04-8P
 488082-05-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 4-substituted 2-phenylquinazolines as partial inhibitors of dopamine transporter)


RN 40288-71-9 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 434326-29-1 CAPLUS

CN 4-Quinazolinamine, N-(diphenylmethyl)-2-phenyl- (CA INDEX NAME)



RN 487018-23-5 CAPLUS


CN 1,3-Propanediamine, N1,N1-dimethyl-N3-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 488082-02-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 488082-03-7 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 488082-04-8 CAPLUS
 CN 4-Quinazolinamine, N-(2,2-diphenylethyl)-2-phenyl- (CA INDEX NAME)



RN 488082-05-9 CAPLUS
 CN 4-Quinazolinamine, N-(3,3-diphenylpropyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:506001 CAPLUS

DOCUMENT NUMBER: 137:352982

TITLE: Synthesis of new 4-[4-(4-methoxyphenyl)-5-(2-phenylquinazolin-4-yl)-1,3-thiazol-2-yl]morpholine and N4-[5-(4-methoxyphenyl)-1,3-oxathiol-2-ylidene]-2-phenylquinazolin-4-ylamine

AUTHOR(S): Fathalla, Walid; Marek, Jaromir; Pazdera, Pavel
 CORPORATE SOURCE: Department of Organic Chemistry, Masaryk University, Brno, 602 00, Czech Rep.

SOURCE: Heterocyclic Communications (2002), 8(2), 157-160

CODEN: HCOMEX; ISSN: 0793-0283

PUBLISHER: Freund Publishing House Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:352982

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. (I and II, resp.) were prepared by reaction of thiourea derivative III with 4-methoxyphenacyl bromide. II is the kinetically controlled reversible reaction product; I is the thermodynamically controlled product.

IT 400604-97-9

RL: RCT (Reactant); RACT (Reactant or reagent)
((morpholinothiazolyl)quinazoline and oxathiolylidenequinazolinamine derivs. via cyclocondensation of quinazolinylidenethiourea with methoxyphenacyl bromide)

RN 400604-97-9 CAPLUS

CN 4-Morpholinecarbothioamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




IT 474254-12-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
((morpholinothiazolyl)quinazoline and oxathiolylidenequinazolinamine derivs. via cyclocondensation of quinazolinylidenethiourea with methoxyphenacyl bromide)

RN 474254-12-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(4-methoxyphenyl)-1,3-oxathiol-2-ylidene]-2-phenyl- (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:504782 CAPLUS
 DOCUMENT NUMBER: 137:78968
 TITLE: Preparation of aminocarbonylpyrrolidine derivatives as dipeptidyl peptidase IV inhibitors
 INVENTOR(S): Matsuno, Kenji; Ueno, Kimihisa; Iwata, Yasuhiro; Matsumoto, Yuichi; Nakanishi, Satoshi; Takasaki, Kotaro; Kusaka, Hideaki; Nomoto, Yuji; Ogawa, Akira
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 196 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051836	A1	20020704	WO 2001-JP11578	20011227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2433090	A1	20020704	CA 2001-2433090	20011227 <--
AU 2002216425	A1	20020708	AU 2002-216425	20011227 <--
EP 1354882	A1	20031022	EP 2001-271892	20011227 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040180925	A1	20040916	US 2003-465919	20031110
PRIORITY APPLN. INFO.:			JP 2000-398441	A 20001227
			JP 2001-261409	A 20010830
			WO 2001-JP11578	W 20011227

OTHER SOURCE(S): MARPAT 137:78968
 GI



AB Title compds. [I; Q = CH₂, S; R = H, (S)-CN; B = CH₂CO, COCH₂, CO; YXW = NHCH₂CH₂NH, NH(CH₂)₃NH, NHCH₂C(CH₃)₂NH, 1-(4-methyl-piperidine-4-amino)-yl, 1-(1-aminomethylcyclopropyl)amino, 4-NHCH₂C₆H₄CH₂NH, N(CH₃)CH₂CH₂N(CH₃), 1,4-piperazinyl, 1-piperidinyl-4-amino, N(CH₃)CH₂C(CH₃)₂NH; Z = optionally substituted 1-pyrrolidinyl, optionally substituted 3-thiazolidinyl, optionally substituted 1-oxo-3-thiozolidinyl, etc.] and pharmacol. acceptable salts of title compds. are prepared as dipeptidyl peptidase IV inhibitors. Title compds. are useful as antidiabetics, antiaids agents, antiarteriosclerosis, antihyperglycinemia agents, and as remedies for hyperglycinemia, hyperinsulinism, etc. in combination with related remedies as GI-262570, KAD1229, etc. Thus, the title compound II was prepared and in vivo tested for DPP-IV inhibition with IC₅₀ = 11 nmol/L.

IT 440099-77-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminocarbonylpyrrolidine derivs. as dipeptidyl peptidase IV inhibitors)

RN 440099-77-4 CAPLUS


CN 2-Pyrrolidinecarbonitrile, 1-[2-[[2-[[2-(4-pyridinyl)-4-quinazolinyl]amino]ethyl]amino]acetyl]-, (2S)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 440099-76-3

CMF C22 H23 N7 O


Absolute stereochemistry.




CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 380588-03-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aminocarbonylpyrrolidine derivs. as dipeptidyl peptidase IV
 inhibitors)
 RN 380588-03-4 CAPLUS
 CN 1,2-Ethanediamine, N1-[2-(4-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 41 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:465821 CAPLUS
 DOCUMENT NUMBER: 137:47211
 TITLE: Substituted 2-aryl-4-arylaminoquinazolines and analogs
 as activators of caspases and inducers of apoptosis,
 their preparation, and the use thereof as, e.g.,
 anticancer agents
 INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P.
 Sanjeeva; Pervin, Azra
 PATENT ASSIGNEE(S): Cytovia, Inc., USA
 SOURCE: PCT Int. Appl., 210 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047690	A1	20020620	WO 2001-US47498	20011212 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028922	A	20020624	AU 2002-28922	20011212 <--
US 20030069239	A1	20030410	US 2001-12444	20011212 <--
US 6716851	B2	20040406		
EP 1351691	A1	20031015	EP 2001-990048	20011212 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 20040097503 A1 20040520 US 2003-704448 20031110
 US 7226927 B2 20070605
 PRIORITY APPLN. INFO.: US 2000-254581P P 20001212
 US 2001-12444 A3 20011212
 WO 2001-US47498 W 20011212
 OTHER SOURCE(S): MARPAT 137:47211
 GI



AB The invention is directed to substituted 2-aryl-4-(arylamino)pyrimidines I and analogs thereof [Ar1, Ar2 = (independently) optionally substituted aryl or heteroaryl; A = N or C-R2; R1, R2 = (independently) H, halo, haloalkyl, aryl, fused aryl, carbocyclic, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, OH, SH, acyloxy, N3, alkoxy, aryloxy, arylalkoxy, haloalkoxy, CO2H, carbonylamido, or alkylthio; and R3 = H, optionally substituted alkyl or cycloalkyl]. The invention also relates to the discovery that compds. I are activators of caspases and inducers of apoptosis. I may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. In particular, a method of treating disorders responsive to the induction of apoptosis, comprising administration of I, or a pharmaceutically acceptable salt or prodrug thereof, is claimed. Over 200 specific examples of I are described. For instance, condensation of 4-chloro-6-methyl-2-(2-pyridinyl)pyrimidine with 2-chloro-5-methoxyaniline gave title compound II in 44% yield. This compound induced apoptosis and activated caspase cascade in human breast cancer cell lines T-47D and ZR-75-1. Another compound I also showed marked selectivity for human breast cancer cells over other, non-breast cancer cell lines.
 IT 438247-46-2P, 4-(4-Methoxyanilino)-2-phenylquinazoline
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)
 RN 438247-46-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:427673 CAPLUS

DOCUMENT NUMBER: 137:3711

TITLE: Cells and animals homozygous or heterozygous for a knockout of the PDE11A gene and their uses

INVENTOR(S): Burslem, Martin F.; Harrow, Ian Dennis; Lanfear, Jeremy; Phillips, Stephen C.

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1211313	A2	20020605	EP 2001-308959	20011022 <--
EP 1211313	A3	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2360485	A1	20020501	CA 2001-2360485	20011030 <--
JP 2004283180	A	20041014	JP 2004-169061	20040607
PRIORITY APPLN. INFO.:			GB 2000-26727	A 20001101
			GB 2001-11710	A 20010514
			JP 2001-337061	A3 20011101


AB Animal cells and animals carrying a knockout of the gene for the cyclic nucleotide phosphodiesterase PDE11 are described for use in anal. of the role of the enzyme, especially in spermatogenesis and in the screening of drugs for regulation of spermatogenesis. Heterozygous knockout mice show lowered levels of spermatogenesis. The effect of the knockout on patterns of gene expression was analyzed by microarray hybridization. Known inhibitors of cyclic nucleotide phosphodiesterases were tested for their ability to inhibit PDE11. The pattern of inhibition was similar to, but distinct from, that for PDE5. Array hybridization was used to analyze the effects of PDE11 knockout on gene expression in testis. Twenty-four genes (18 down-regulated and 6 up-regulated) were identified. These gene products may themselves be therapeutic targets for PDE11-related disease (no data).

IT 157863-31-5

RL: PAC (Pharmacological activity); BIOL (Biological study)

(as inhibitor of PDE11; cells and animals homozygous or heterozygous for knockout of PDE11A gene and their uses)

RN 157863-31-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 43 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:314395 CAPLUS
 DOCUMENT NUMBER: 136:335540
 TITLE: Use of PDE V inhibitors for improved fecundity in mammals
 INVENTOR(S): Westbrook, Simon Lempriere; Zanzinger, Johannes Friedrich
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199070	A2	20020424	EP 2001-308684	20011011 <--
EP 1199070	A3	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2359383	A1	20020420	CA 2001-2359383	20011018 <--
US 20030018036	A1	20030123	US 2001-982445	20011018 <--
US 6548508	B2	20030415		
AU 2001081523	A	20020502	AU 2001-81523	20011019 <--
HU 2001004406	A2	20020729	HU 2001-4406	20011019 <--
HU 2001004406	A3	20050728		
JP 2002220346	A	20020809	JP 2001-322195	20011019 <--
JP 3842104	B2	20061108		
ZA 2001008617	A	20030422	ZA 2001-8617	20011019 <--
NZ 514947	A	20050324	NZ 2001-514947	20011019
US 20030018037	A1	20030123	US 2002-229534	20020827 <--
US 6743799	B2	20040601		
US 20040167095	A1	20040826	US 2004-778866	20040212
AU 2004233509	A1	20041223	AU 2004-233509	20041126
PRIORITY APPLN. INFO.:				
			GB 2000-25782	A 20001020
			US 2000-253338P	P 20001128
			US 2001-982445	A1 20011018
			AU 2001-81523	A3 20011019
			US 2002-229534	A1 20020827

AB The invention relates to the use of a cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate


or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity. I.v. and tablet formulations are exemplified. Formulations and packs containing the PDE V inhibitors for pharmaceutical or veterinary use are claimed.

IT 150450-79-6 150450-80-9 150451-88-0
150451-89-1 150452-96-3

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of PDE V inhibitors for improved fecundity in mammals)


RN 150450-79-6 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150450-80-9 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150451-88-0 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 150451-89-1 CAPLUS

CN 6-Quinazolinecarbonitrile, 4-[(1,3-benzodioxol-5-yl)methyl]amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 150452-96-3 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-tetrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 44 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:240746 CAPLUS

DOCUMENT NUMBER: 136:279468

TITLE: Preparation of 4-amino-quinazolines useful as

glycoprotein IbIX antagonists, and their use for control of thrombotic disorders

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Vickers, James; Cezanne, Bertram; Dhanoa, Daljit; Zhao, Bao-Ping; Rinker, James; Player, Mark R.; Jaeger, Edward; Soll, Richard

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024667	A1	20020328	WO 2001-EP10705	20010917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422488	A1	20020328	CA 2001-2422488	20010917 <--
AU 2001093817	A	20020402	AU 2001-93817	20010917 <--
EP 1318984	A1	20030618	EP 2001-974258	20010917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001014020	A	20030722	BR 2001-14020	20010917 <--
HU 2003002221	A2	20031028	HU 2003-2221	20010917 <--
HU 2003002221	A3	20040128		
JP 2004509876	T	20040402	JP 2002-529077	20010917
MX 2003PA02410	A	20030619	MX 2003-PA2410	20030319 <--
IN 2003KN00448	A	20050311	IN 2003-KN448	20030410
ZA 2003003062	A	20040719	ZA 2003-3062	20030417
US 20060019974	A1	20060126	US 2005-380908	20050630
PRIORITY APPLN. INFO.:			US 2000-666908	A 20000920
			US 2000-304188P	P 20000920
			WO 2001-EP10705	W 20010917
OTHER SOURCE(S):			MARPAT 136:279468	
GI				



AB The preparation of 4-amino-quinazolines [I; wherein R, R1, independently = H, (C1-C6)alkyl, OH, (C1-C6)alkoxy, amino, nitro, cyano, etc.; R2, R3, independently = H, (C1-C6)alkyl, cycloalkyl, mono- or bicycloheterocyclic radical, etc.; R4 = aryl (e.g., Ph, naphthyl, biphenyl, etc.), or thiophen-2-yl substituted with aryl (as described supra) or heterocyclic radical, etc.; each of R, R1-R4 with many provisos] is described. Thus,

[2-(4-bromophenyl)-7-chloroquinazolin-4-yl]-phenylamine was prepared by a multistep synthesis. The prepared compds. are useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders and sequelae deriving thereof.


IT 405932-32-3P 405932-33-4P 405932-34-5P
 405932-35-6P 405932-36-7P 405932-37-8P
 405932-39-0P 405932-41-4P 405932-43-6P
 405932-45-8P 405932-46-9P 405932-47-0P
 405932-48-1P 405932-49-2P 405932-50-5P
 405932-51-6P 405932-53-8P 405932-54-9P
 405932-55-0P 405932-57-2P 405932-59-4P
 405932-61-8P 405932-63-0P 405932-64-1P
 405932-66-3P 405932-68-5P 405932-70-9P
 405932-71-0P 405932-72-1P 405932-73-2P
 405932-74-3P 405932-75-4P 405932-77-6P
 405932-78-7P 405932-79-8P 405932-80-1P
 405932-81-2P 405932-82-3P 405932-83-4P
 405932-84-5P 405932-85-6P 405932-86-7P
 405932-87-8P 405932-88-9P 405932-89-0P
 405932-90-3P 405932-91-4P 405932-92-5P
 405932-93-6P 405932-94-7P 405932-96-9P
 405932-97-0P 405932-98-1P 405932-99-2P
 405933-00-8P 405933-01-9P 405933-02-0P
 405933-04-2P 405933-06-4P 405933-08-6P
 405933-10-0P 405933-12-2P 405933-14-4P
 405933-16-6P 405933-18-8P 405933-20-2P
 405933-22-4P 405933-23-5P 405933-25-7P
 405933-26-8P 405933-28-0P 405933-29-1P
 405933-31-5P 405933-33-7P 405933-35-9P
 405933-37-1P 405933-39-3P 405933-41-7P
 405933-43-9P 405933-44-0P 405933-45-1P
 405933-46-2P 405933-48-4P 405933-49-5P
 405933-51-9P 405933-52-0P 405933-53-1P
 405933-55-3P 405933-56-4P 405933-57-5P
 405933-58-6P 405933-59-7P 405933-60-0P
 405933-61-1P 405933-62-2P 405933-63-3P
 405933-64-4P 405933-65-5P 405933-66-6P
 405933-67-7P 405933-68-8P 405933-69-9P
 405933-70-2P 405933-71-3P 405933-72-4P
 405933-73-5P 405933-74-6P 405933-75-7P
 405933-76-8P 405933-77-9P 405933-78-0P
 405933-79-1P 405933-80-4P 405933-81-5P
 405933-82-6P 405933-83-7P 405933-84-8P
 405933-85-9P 405933-86-0P 405933-87-1P
 405933-88-2P 405933-89-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino-quinazolines useful as glycoprotein IbIX antagonists)

RN 405932-32-3 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-phenyl- (CA INDEX NAME)




RN 405932-33-4 CAPLUS
 CN 3H-Pyrazol-3-one, 2-[4-[[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]amino]phenyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)



RN 405932-34-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(cyclopentyloxy)phenyl]- (CA INDEX NAME)




RN 405932-35-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[4-(cyclopentyloxy)phenyl]- (CA INDEX NAME)




RN 405932-36-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(4-morpholinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 405932-37-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]amino]-N,N-diethyl- (CA INDEX NAME)




RN 405932-39-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(4,6-dimethoxy-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 405932-41-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[4-(4,6-dimethoxy-2-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 405932-43-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[4-(4-morpholinyl)phenyl]-
(CA INDEX NAME)




RN 405932-45-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(2-ethylphenyl)- (CA
INDEX NAME)



RN 405932-46-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(3-ethylphenyl)- (CA
INDEX NAME)



RN 405932-47-0 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(4-ethylphenyl)- (CA

INDEX NAME)




RN 405932-48-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[4-(1-methylethyl)phenyl]-
(CA INDEX NAME)




RN 405932-49-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(4-propylphenyl)- (CA
INDEX NAME)




RN 405932-50-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(4-butylphenyl)-7-chloro- (CA
INDEX NAME)




RN 405932-51-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(3-phenoxyphenyl)- (CA
INDEX NAME)




RN 405932-53-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(4-phenoxyphenyl)- (CA
INDEX NAME)




RN 405932-54-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]- (CA INDEX NAME)




RN 405932-55-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-5-isoquinolinyl- (CA INDEX NAME)




RN 405932-57-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(phenylmethyl)- (CA INDEX NAME)




RN 405932-59-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 405932-61-8 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(2-chlorophenyl)methyl]-
 (CA INDEX NAME)




RN 405932-63-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(2-fluorophenyl)methyl]-
 (CA INDEX NAME)




RN 405932-64-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(3-fluorophenyl)methyl]-
 (CA INDEX NAME)



RN 405932-66-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(4-fluorophenyl)methyl]-
 (CA INDEX NAME)




RN 405932-68-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(2-methoxyphenyl)methyl]-
 (CA INDEX NAME)




RN 405932-70-9 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(2-chloro-6-

methylphenyl)methyl]- (CA INDEX NAME)




RN 405932-71-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(2,4-dichlorophenyl)methyl]- (CA INDEX NAME)




RN 405932-72-1 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(3,4-dichlorophenyl)methyl]- (CA INDEX NAME)




RN 405932-73-2 CAPLUS
CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(4-chlorophenyl)methyl]-
(CA INDEX NAME)



RN 405932-74-3 CAPLUS
CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(4-methoxyphenyl)methyl]-
(CA INDEX NAME)




RN 405932-75-4 CAPLUS
CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 405932-77-6 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(4-bromophenyl)-7-chloro- (CA INDEX NAME)




RN 405932-78-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(1-phenylethyl)- (CA INDEX NAME)




RN 405932-79-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[1-(2-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 405932-80-1 CAPLUS
 CN 4-Quinazolinamine, N-[2-(1,3-benzodioxol-5-yloxy)ethyl]-2-(4-bromophenyl)-7-chloro- (CA INDEX NAME)



RN 405932-81-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]- (CA INDEX NAME)





RN 405932-82-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(2'-fluoro[1,1'-biphenyl]-4-yl)butyl]- (CA INDEX NAME)




RN 405932-83-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(4'-fluoro[1,1'-
 biphenyl]-4-yl)butyl]- (CA INDEX NAME)

PAGE 1-A







RN 405932-84-5 CAPLUS
 CN 4-Quinazolinamine, N-(3-[1,1'-biphenyl]-4-ylbutyl)-2-(4-bromophenyl)-7-chloro- (CA INDEX NAME)



RN 405932-85-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 405932-86-7 CAPLUS
 CN 4-Quinazolinamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-2-(4-bromophenyl)-7-chloro- (CA INDEX NAME)




RN 405932-87-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(3-methoxyphenyl)ethyl]-
(CA INDEX NAME)




RN 405932-88-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(2-thienyl)ethyl]- (CA
INDEX NAME)




RN 405932-89-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(4-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 405932-90-3 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(2-pyridinyl)ethyl]-
(CA INDEX NAME)




RN 405932-91-4 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]amino]propyl]- (CA INDEX NAME)




RN 405932-92-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(4-morpholinyl)ethyl]-
(CA INDEX NAME)




RN 405932-93-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(1-piperidiny)ethyl]-
(CA INDEX NAME)




RN 405932-94-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 405932-96-9 CAPLUS

CN 1,2-Ethanediamine, N2-[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 405932-97-0 CAPLUS


CN 1,3-Propanediamine, N3-[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 405932-98-1 CAPLUS
 CN 1,2-Ethanediamine, N2-[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]-N1,N1-diethyl- (CA INDEX NAME)




RN 405932-99-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 405933-00-8 CAPLUS
 CN 1,3-Propanediamine, N1-[2-(4-bromophenyl)-7-chloro-4-quinazolinyl]-N3-(2-methylpropyl)- (CA INDEX NAME)




RN 405933-01-9 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 405933-02-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(4-morpholinyl)propyl]-
(CA INDEX NAME)




RN 405933-04-2 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[2-(octahydro-1-methyl-1H-indol-3-yl)ethyl]-
(CA INDEX NAME)




RN 405933-06-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-butyl-7-chloro- (CA INDEX NAME)




RN 405933-08-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-pentyl- (CA INDEX NAME)



RN 405933-10-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-7-chloro-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 405933-12-2 CAPLUS
 CN 2-Pyrrolidinone, 1-[3-[[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]amino]propyl]- (CA INDEX NAME)




RN 405933-14-4 CAPLUS

CN Benzenemethanol, 2-[[2-[[[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]amino]methyl]phenyl]thio]- (CA INDEX NAME)




RN 405933-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[3-(2-methyl-1-piperidinyl)propyl]- (CA INDEX NAME)




RN 405933-18-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 405933-20-2 CAPLUS

CN Quinazoline, 2-(4-bromophenyl)-6-methyl-4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 405933-22-4 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methyl- (CA INDEX NAME)




RN 405933-23-5 CAPLUS
 CN 4-Piperidinol, 1-[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]-4-(phenylmethyl)- (CA INDEX NAME)



RN 405933-25-7 CAPLUS
 CN Quinazoline, 2-(4-bromophenyl)-6-methyl-4-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 405933-26-8 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 405933-28-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[2-(1-methyl-2-pyrrolidiny)ethyl]- (CA INDEX NAME)




RN 405933-29-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 405933-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-methyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 405933-33-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-[(2-fluorophenyl)methyl]-6-methyl-
 (CA INDEX NAME)




RN 405933-35-9 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N,6-dimethyl-N-(phenylmethyl)- (CA
 INDEX NAME)




RN 405933-37-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N,6-dimethyl-N-[(1-methyl-4-
 piperidinyl)methyl]- (CA INDEX NAME)




RN 405933-39-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-cyclohexyl-N,6-dimethyl- (CA INDEX NAME)



RN 405933-41-7 CAPLUS
 CN 1,2-Ethanediamine, N2-[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 405933-43-9 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-butyl-N,6-dimethyl- (CA INDEX NAME)




RN 405933-44-0 CAPLUS

CN 1,3-Propanediamine, N1-[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]-
N1,N3,N3-trimethyl- (CA INDEX NAME)




RN 405933-45-1 CAPLUS

CN Quinazoline, 2-(4-bromophenyl)-6-methyl-4-[4-(phenylmethyl)-1-piperidinyl]-
(CA INDEX NAME)




RN 405933-46-2 CAPLUS

CN 1,4-Pentanediamine, N4-[2-(4-bromophenyl)-6-methyl-4-quinazolinyl]-N1,N1-
diethyl- (CA INDEX NAME)




RN 405933-48-4 CAPLUS

CN 1,4-Pentanediamine, N4-[2-(4-bromophenyl)-6-chloro-4-quinazolinyl]-N1,N1-diethyl- (CA INDEX NAME)




RN 405933-49-5 CAPLUS

CN Quinazoline, 2-(4-bromophenyl)-6-chloro-4-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 405933-51-9 CAPLUS


CN 1,3-Propanediamine, N1-[2-(4-bromophenyl)-6-chloro-4-quinazolinyl]-N1,N3,N3-trimethyl- (CA INDEX NAME)




RN 405933-52-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-butyl-6-chloro-N-methyl- (CA INDEX NAME)




RN 405933-53-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-cyclohexyl-N-methyl- (CA INDEX NAME)




RN 405933-55-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-methyl-N-[(1-methyl-4-piperidinyl)methyl]- (CA INDEX NAME)




RN 405933-56-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-methyl-N-(phenylmethyl)-
 (CA INDEX NAME)



RN 405933-57-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[(2-fluorophenyl)methyl]-
 (CA INDEX NAME)




RN 405933-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[(3,4,5-
 trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 405933-59-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 405933-60-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 405933-61-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[3-(4-morpholinyl)propyl]-
(CA INDEX NAME)



RN 405933-62-2 CAPLUS


CN Quinazoline, 2-(4-bromophenyl)-6-chloro-4-(4-phenyl-1-piperazinyl)- (CA
INDEX NAME)



RN 405933-63-3 CAPLUS


CN 4-Piperidinol, 1-[2-(4-bromophenyl)-6-chloro-4-quinazolinyl]-4-

(phenylmethyl)- (CA INDEX NAME)




RN 405933-64-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 405933-65-5 CAPLUS


CN Quinazoline, 2-(4-bromophenyl)-6-chloro-4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 405933-66-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[2-(2-pyridinyl)ethyl]-

(CA INDEX NAME)




RN 405933-67-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-[3-(2-methyl-1-piperidinyl)propyl]- (CA INDEX NAME)




RN 405933-68-8 CAPLUS

CN Benzenemethanol, 2-[[2-[[[2-(4-bromophenyl)-6-chloro-4-quinazolinyl]amino]methyl]phenyl]thio]- (CA INDEX NAME)




RN 405933-69-9 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(4-bromophenyl)-6-chloro-4-quinazolinyl]amino]propyl]- (CA INDEX NAME)




RN 405933-70-2 CAPLUS

CN Benzenemethanol, 2-[[2-[[[2-(4-bromophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]methyl]phenyl]thio]- (CA INDEX NAME)




RN 405933-71-3 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[3-(2-methyl-1-piperidinyl)propyl]- (CA INDEX NAME)




RN 405933-72-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 405933-73-5 CAPLUS

CN Quinazoline, 2-(4-bromophenyl)-6,7-dimethoxy-4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 405933-74-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6,7-dimethoxy- (CA INDEX NAME)




RN 405933-75-7 CAPLUS

CN 4-Piperidinol, 1-[2-(4-bromophenyl)-6,7-dimethoxy-4-quinazolinyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 405933-76-8 CAPLUS

CN Quinazoline, 2-(4-bromophenyl)-6,7-dimethoxy-4-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 405933-77-9 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 405933-78-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 405933-79-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 405933-80-4 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 405933-81-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-[(2-fluorophenyl)methyl]-6,7-dimethoxy- (CA INDEX NAME)




RN 405933-82-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 405933-83-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-6,7-dimethoxy-N-methyl-N-[(1-methyl-4-piperidinyl)methyl]- (CA INDEX NAME)




RN 405933-84-8 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-cyclohexyl-6,7-dimethoxy-N-methyl- (CA INDEX NAME)




RN 405933-85-9 CAPLUS


CN 1,2-Ethanediamine, N2-[2-(4-bromophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 405933-86-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-butyl-6,7-dimethoxy-N-methyl- (CA INDEX NAME)




RN 405933-87-1 CAPLUS
 CN 1,3-Propanediamine, N1-[2-(4-bromophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N3,N3-trimethyl- (CA INDEX NAME)



RN 405933-88-2 CAPLUS
 CN Quinazoline, 2-(4-bromophenyl)-6,7-dimethoxy-4-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 405933-89-3 CAPLUS
 CN 1,4-Pentanediamine, N4-[2-(4-bromophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-diethyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220584 CAPLUS

DOCUMENT NUMBER: 136:247584

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegt, Ronald; Golec, Julian M. C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 356 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022608	A1	20020321	WO 2001-US42152	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				



	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,	
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2422380	A1 20020321	CA 2001-2422380 20010914 <--
AU 2001096871	A 20020326	AU 2001-96871 20010914 <--
US 20030055044	A1 20030320	US 2001-953505 20010914 <--
US 6638926	B2 20031028	
US 20030064981	A1 20030403	US 2001-952836 20010914 <--
US 6613776	B2 20030902	
US 20030064982	A1 20030403	US 2001-952875 20010914 <--
US 20030073687	A1 20030417	US 2001-952671 20010914 <--
US 6660731	B2 20031209	
US 20030078166	A1 20030424	US 2001-955601 20010914 <--
US 6696452	B2 20040224	
US 20030083327	A1 20030501	US 2001-952833 20010914 <--
US 6610677	B2 20030826	
EP 1317452	A1 20030611	EP 2001-977779 20010914 <--
EP 1317452	B1 20060517	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
ZA 2003001701	A 20040301	ZA 2003-1701 20010914
ZA 2003001703	A 20040302	ZA 2003-1703 20010914
JP 2004509118	T 20040325	JP 2002-526861 20010914
US 20040097501	A1 20040520	US 2001-953471 20010914
US 7115739	B2 20061003	
HU 2004001819	A2 20041228	HU 2004-1819 20010914
US 20050004110	A1 20050106	US 2001-952878 20010914
US 7098330	B2 20060829	
ES 2242771	T3 20051116	ES 2001-971006 20010914
AT 326458	T 20060615	AT 2001-970969 20010914
AT 327990	T 20060615	AT 2001-970971 20010914
AT 327992	T 20060615	AT 2001-971082 20010914
AT 327991	T 20060615	AT 2001-973050 20010914
AT 326459	T 20060615	AT 2001-977779 20010914
EP 1698627	A1 20060906	EP 2006-10798 20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
PT 1318997	T 20061031	PT 2001-971082 20010914
AT 346064	T 20061215	AT 2001-975210 20010914
ES 2266258	T3 20070301	ES 2001-970971 20010914
ES 2266259	T3 20070301	ES 2001-971082 20010914
AT 363284	T 20070615	AT 2001-977783 20010914
NZ 545284	A 20070629	NZ 1984-5452 20010914
CA 2432303	A1 20020829	CA 2001-2432303 20011219 <--
AU 2002255452	A1 20020904	AU 2002-255452 20011219 <--
AU 2002255452	B2 20060608	
CA 2432223	A1 20020906	CA 2001-2432223 20011219 <--
CA 2432223	C 20080520	
AU 2001297619	A1 20020912	AU 2001-297619 20011219 <--
AU 2001297619	B2 20060608	
EP 1345922	A1 20030924	EP 2001-271061 20011219 <--
EP 1345922	B1 20060531	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
EP 1355905	A1 20031029	EP 2001-273861 20011219 <--
EP 1355905	B1 20070221	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
NZ 526472	A 20040430	NZ 2001-526472 20011219
JP 2004518743	T 20040624	JP 2002-565976 20011219
JP 2004519479	T 20040702	JP 2002-567928 20011219
HU 2004000842	A2 20040728	HU 2004-842 20011219
NZ 526473	A 20050624	NZ 2001-526473 20011219

EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
IN 2003KN00294	A	20050311	IN 2003-KN294	20030310
NO 2003001188	A	20030513	NO 2003-1188	20030314 <--
MX 2003PA02299	A	20030606	MX 2003-PA2299	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
HK 1057888	A1	20061124	HK 2003-108639	20031126
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US42152	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219

JP 2002-557938	A3 20011219
US 2001-26966	A1 20011219
WO 2001-US49139	W 20011219
WO 2001-US50312	W 20011219
US 2001-34019	A3 20011220
US 2001-34683	A1 20011220
US 2003-624800	A3 20030722

OTHER SOURCE(S): MARPAT 136:247584

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆CONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliphatic), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliphatic), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliphatic group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepared as protein kinase inhibitors, especially

as


inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 = CR₉; Z2 and Z3 = N; Z4 = CR_y]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-3 β , Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited K_i values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine

404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclic pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-

methylphenyl)quinazolin-4-yl]amine 404826-61-5P,
[2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P,
[2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P,
[2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P,
[2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine
404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-
3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-
Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-
Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-
4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P,
(5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P,
(4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P,
(2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-
fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-
Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P
, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazoli
n-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-
(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine
404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-
yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-
4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine
404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-
indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-
yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-

yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,

[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
yl)quinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-
yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-
2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P,
(5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-
yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P,
[5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-
yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P,
(5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-
pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P,
(2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine
404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-
pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P,
[5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-
yl](2-phenylquinazolin-4-yl)amine 404828-79-1P,
[5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-


yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 46 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220583 CAPLUS

DOCUMENT NUMBER: 136:247583

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Bebbington, David; Knegt, Ronald; Wannamaker, Marion; Li, Pan; Forester, Cornelia;



PATENT ASSIGNEE(S): Pierce, Albert; Kay, David
 SOURCE: Vertex Pharmaceuticals Incorporated, USA
 PCT Int. Appl., 373 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022607	A1	20020321	WO 2001-US28940	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422379	A1	20020321	CA 2001-2422379	20010914 <--
AU 2001091013	A	20020326	AU 2001-91013	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
BR 2001014088	A	20030617	BR 2001-14088	20010914 <--
EP 1318997	A1	20030618	EP 2001-971082	20010914 <--
EP 1318997	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002173	A2	20030929	HU 2003-2173	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509117	T	20040325	JP 2002-526860	20010914
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
NZ 525008	A	20041224	NZ 2001-525008	20010914
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914
CN 1926132	A	20070307	CN 2001-817434	20010914

AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
IN 2003KN00295	A	20060922	IN 2003-KN295	20030310
NO 2003001191	A	20030513	NO 2003-1191	20030314 <--
MX 2003PA02291	A	20030606	MX 2003-PA2291	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
HK 1058356	A1	20061201	HK 2003-109140	20031215
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321

AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US28940	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
			US 2003-624800	A3 20030722

OTHER SOURCE(S): MARPAT 136:247583
GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂S0-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR,

NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially


as

inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring C]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl(2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P,
(7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P,
[2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P
404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P,
(4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P,
(1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
(6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P,
(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenyl)quinazolin-4-yl]amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-

yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P,
(7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-
Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-
Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-
Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine
404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-25-7P, [2-(4-
Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-
yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-

pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-


yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404872-88-4P
 404872-89-5P 404872-90-8P 404872-93-1P
 404872-94-2P 404872-99-7P 404873-39-8P
 404873-40-1P 404873-41-2P 404873-42-3P
 404873-43-4P 404873-44-5P 404873-45-6P
 404873-46-7P 404873-47-8P 404873-48-9P
 404873-49-0P 404873-50-3P 404873-51-4P
 404873-52-5P 404873-53-6P 404873-54-7P
 404873-55-8P 404873-56-9P 404873-57-0P
 404873-58-1P 404873-59-2P 404873-60-5P
 404873-61-6P 404873-62-7P 404873-63-8P
 404873-64-9P 404873-65-0P 404873-66-1P
 404873-67-2P 404873-68-3P 404873-69-4P
 404873-70-7P 404873-71-8P 404873-72-9P
 404873-73-0P 404873-74-1P 404873-75-2P
 404873-76-3P 404873-77-4P 404873-78-5P
 404873-79-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-78-4 CAPLUS

CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS
 CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS
 CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-81-9 CAPLUS
 CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 404826-82-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-84-2 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1


CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 404827-24-3 CAPLUS
CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-26-5 CAPLUS
CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 404827-27-6 CAPLUS
CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS

CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-


quinazolinyl]amino]-, methyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA


INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS

CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-phenyldimethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-65-5 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(CA INDEX NAME)




RN 404828-70-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)



RN 404828-71-3 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-72-4 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-73-5 CAPLUS
 CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 404828-74-6 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl) [5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-83-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-


isoquinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)


NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-


phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-88-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-89-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-(4-methyl-1-piperazinyl)-
2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-90-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-93-1 CAPLUS


CN 4,8-Quinazolinediamine, N8-(2-aminoethyl)-N4-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-94-2 CAPLUS


CN 4,6-Quinazolinodiamine, N4-(7-fluoro-1H-indazol-3-yl)-N6-[2-(methylamino)ethyl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404872-99-7 CAPLUS


CN 4-Quinazolinamine, 8-(2-aminoethoxy)-N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-39-8 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-40-1 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-41-2 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-42-3 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(1-isoquinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-43-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-44-5 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-45-6 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-46-7 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-47-8 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-48-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-isoquinolinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-49-0 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-50-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-51-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-52-5 CAPLUS


CN Benzamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-53-6 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(1-methylethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-54-7 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(1-methylethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-55-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-56-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-57-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methoxyphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-58-1 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(2-methoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-59-2 CAPLUS


CN Phenol, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-60-5 CAPLUS


CN Phenol, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-61-6 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-62-7 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-63-8 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(4-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-64-9 CAPLUS


CN Benzamide, 2-[4-[(5-fluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-65-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-66-1 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-67-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-68-3 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-69-4 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-dihydro-4-isobenzofuranyl)-N-1H-indazol-3-yl-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-70-7 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-1-naphthalenyl)-N-1H-indazol-3-yl- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-71-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chloro-1-naphthalenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-72-9 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-nitrophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-73-0 CAPLUS


CN Benzonitrile, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-74-1 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]-5-methoxy- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-75-2 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(2-nitrophenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-76-3 CAPLUS


CN Benzenesulfonamide, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-77-4 CAPLUS


CN Benzenesulfonamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-78-5 CAPLUS


CN Benzenesulfonamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404873-79-6 CAPLUS

CN Benzenesulfonamide, 2-[4-[(5-fluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]-N,N-dimethyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-


carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 47 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220582 CAPLUS

DOCUMENT NUMBER: 136:247582

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Binch, Hayley; Knegt, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier,


PATENT ASSIGNEE(S): Jean-Damien; Kay, David; Davies, Robert; Li, Pan;
 SOURCE: Wannamaker, Marion; Forster, Cornelia; Pierce, Albert
 Vertex Pharmaceuticals Incorporated, USA
 PCT Int. Appl., 355 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022606	A1	20020321	WO 2001-US28803	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422378	A1	20020321	CA 2001-2422378	20010914 <--
AU 2001090944	A	20020326	AU 2001-90944	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317448	A1	20030611	EP 2001-971006	20010914 <--
EP 1317448	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002411	A2	20031128	HU 2003-2411	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509116	T	20040325	JP 2002-526859	20010914
JP 4105949	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
AT 294797	T	20050515	AT 2001-971006	20010914
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914

AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
IN 2003KN00293	A	20050311	IN 2003-KN293	20030310
NO 2003001189	A	20030513	NO 2003-1189	20030314 <--
MX 2003PA02293	A	20030606	MX 2003-PA2293	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
HK 1057890	A1	20051216	HK 2003-108726	20031128
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321

AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US28803	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
			US 2003-624800	A3 20030722

OTHER SOURCE(S): MARPAT 136:247582
GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂S0-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR,

NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially


as

inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring D]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl(2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P,
(7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P,
[2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P
404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P,
(4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P,
(1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
(6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P,
(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenyl)quinazolin-4-yl]amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-

yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P,
(7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-
Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-
Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-
Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine
404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-25-7P, [2-(4-
Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-
yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-

pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-


yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-93-3 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS
CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-96-6 CAPLUS
CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 48 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220581 CAPLUS

DOCUMENT NUMBER: 136:247581

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Golec, Julian M. C.; Charrier, Jean-Damien; Knegt, Ronald; Bebbington, David; Davies, Robert; Li, Pan

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 357 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022605	A1	20020321	WO 2001-US28793	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422377	A1	20020321	CA 2001-2422377	20010914 <--
AU 2001092670	A	20020326	AU 2001-92670	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317449	A1	20030611	EP 2001-973050	20010914 <--
EP 1317449	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509115	T	20040325	JP 2002-526858	20010914
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
NZ 525014	A	20050930	NZ 2001-525014	20010914
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914
AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--

AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
MX 2003PA02289	A	20030606	MX 2003-PA2289	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
HK 1057887	A1	20061215	HK 2003-108524	20031121
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125

PRIORITY APPLN. INFO.:

US 2000-232795P	P	20000915
US 2000-257887P	P	20001221
US 2001-286949P	P	20010427
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	A3	20010914
AU 2001-96875	A3	20010914
EP 2001-971082	A3	20010914
JP 2002-526860	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
WO 2001-US28793	W	20010914
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-557938	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US50312	W	20011219
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220
US 2003-624800	A3	20030722

OTHER SOURCE(S): MARPAT 136:247581
GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z¹ = N or CR₉; Z² = N or CH; Z³ = N or CR_x; Z⁴ = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO₂, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliphatic), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliphatic), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliphatic group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepared as protein kinase inhibitors, especially


as

inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrazolamines and indazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N; at least one of Z1 or Z3 = N]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl(2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P,
(7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P,
[2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P
404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P,
(4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P,
(1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
(6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P,
(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenyl)quinazolin-4-yl]amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-

yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P,
(7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-
Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-
Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-
Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine
404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-25-7P, [2-(4-
Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-
yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-

pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-


yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-93-3 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS
CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-96-6 CAPLUS
CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
 CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
 CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
 CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-,
2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220580 CAPLUS

DOCUMENT NUMBER: 136:247606

TITLE: Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.

INVENTOR(S): Davies, Robert; Bebbington, David; Binch, Haley;


PATENT ASSIGNEE(S): Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay;
 SOURCE: Charrier, Jean-Damien; Kay, David; Davies, Robert
 Vertex Pharmaceuticals Incorporated, USA
 PCT Int. Appl., 357 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022604	A1	20020321	WO 2001-US28792	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422371	A1	20020321	CA 2001-2422371	20010914 <--
AU 2001094558	A	20020326	AU 2001-94558	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317450	A1	20030611	EP 2001-975210	20010914 <--
EP 1317450	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002172	A2	20030929	HU 2003-2172	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004512277	T	20040422	JP 2002-526857	20010914
JP 4105948	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
NZ 525009	A	20050527	NZ 2001-525009	20010914
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914


AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
IN 2003KN00289	A	20050311	IN 2003-KN289	20030307
NO 2003001190	A	20030513	NO 2003-1190	20030314 <--
MX 2003PA02292	A	20030606	MX 2003-PA2292	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
HK 1057748	A1	20070615	HK 2003-108588	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321

AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US28792	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
			US 2003-624800	A3 20030722


OTHER SOURCE(S): MARPAT 136:247606
GI



I



II




III


AB The preparation of title compds. I and their pharmaceutically acceptable salts

or prodrugs is described [wherein: R1, R2 = dependently form (un)substituted fused, unsatd. or partially unsatd., 5-8 membered carbocyclo ring; R3, R4 = independently H, aliphatic, aryl, heteroaryl, heterocyclyl, or wide variety of functionalized sidechains; or dependently form a fused, 5-8 membered, unsatd. or partially unsatd. ring having 0-3 ring heteroatoms (N, S, O); R5 = fused, (un)substituted 5-7 membered monocyclic ring or 8-10 membered bicyclic ring (aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms (N, S, O))]. For example, chlorination of quinazoline II with phosphorus oxychloride, followed by condensation with 3-amino-5-methylpyrazole afforded claimed compound III. Compds. I are inhibitors of GSK-3 and Aurora-2 protein kinases. The invention also relates to methods of treating diseases associated with these protein kinases, such as diabetes, cancer and Alzheimer's disease. In bioassays, compds. I inhibited the following kinases with Kis reported < 100 nM: GSK-3 β (163 compds.), AURORA-2 (65 compds.), CDK-2 (no data), ERK2 (8 compds.), AKT (no data), and Human Src kinase (21 compds.). Claims included 146 specific compds., and 188 examples were given. The syntheses of 6 compds. and 46 intermediates are described.

IT 404826-21-7P 404827-06-1P 404827-25-4P
 404828-54-2P 404828-58-6P 404828-61-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)
 RN 404826-21-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404827-06-1 CAPLUS
 CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT	404826-20-6P	404826-22-8P	404826-23-9P
	404826-60-4P	404826-61-5P	404826-63-7P
	404826-64-8P	404826-65-9P	404826-66-0P
	404826-67-1P	404826-68-2P	404826-69-3P
	404826-70-6P	404826-71-7P	404826-72-8P
	404826-73-9P	404826-74-0P	404826-75-1P
	404826-76-2P	404826-77-3P	404826-78-4P
	404826-79-5P	404826-80-8P	404826-81-9P
	404826-82-0P	404826-83-1P	404826-84-2P
	404826-85-3P	404826-86-4P	404826-87-5P
	404826-88-6P	404826-89-7P	404826-90-0P
	404826-91-1P	404826-92-2P	404826-93-3P
	404826-94-4P	404826-95-5P	404826-96-6P
	404826-97-7P	404826-98-8P	404826-99-9P
	404827-00-5P	404827-01-6P	404827-02-7P
	404827-03-8P	404827-04-9P	404827-05-0P
	404827-07-2P	404827-08-3P	404827-09-4P
	404827-10-7P	404827-11-8P	404827-12-9P
	404827-14-1P	404827-15-2P	404827-16-3P


404827-24-3P 404827-26-5P 404827-27-6P
 404827-28-7P 404827-29-8P 404827-31-2P
 404827-54-9P 404827-55-0P 404827-56-1P
 404828-07-5P 404828-10-0P 404828-11-1P
 404828-12-2P 404828-14-4P 404828-15-5P
 404828-16-6P 404828-17-7P 404828-18-8P
 404828-19-9P 404828-20-2P 404828-21-3P
 404828-22-4P 404828-23-5P 404828-24-6P
 404828-25-7P 404828-26-8P 404828-27-9P
 404828-28-0P 404828-29-1P 404828-31-5P
 404828-32-6P 404828-34-8P 404828-35-9P
 404828-36-0P 404828-37-1P 404828-38-2P
 404828-39-3P 404828-40-6P 404828-41-7P
 404828-42-8P 404828-43-9P 404828-44-0P
 404828-45-1P 404828-46-2P 404828-47-3P
 404828-48-4P 404828-49-5P 404828-50-8P
 404828-51-9P 404828-52-0P 404828-53-1P
 404828-55-3P 404828-56-4P 404828-57-5P
 404828-59-7P 404828-60-0P 404828-62-2P
 404828-63-3P 404828-64-4P 404828-65-5P
 404828-66-6P 404828-67-7P 404828-69-9P
 404828-71-3P 404828-72-4P 404828-73-5P
 404828-74-6P 404828-75-7P 404828-76-8P
 404828-77-9P 404828-78-0P 404828-79-1P
 404828-80-4P 404828-82-6P 404828-83-7P
 404828-84-8P 404828-98-4P 404829-00-1P
 404829-01-2P 404829-03-4P 404829-16-9P
 404829-17-0P 404829-18-1P 404829-19-2P
 404829-21-6P 404829-22-7P 404829-23-8P
 404829-24-9P 404829-71-6P 404829-72-7P
 404829-73-8P 404829-74-9P 404829-75-0P
 404844-79-7P 404844-80-0P 404844-82-2P
 404844-83-3P 404844-85-5P 404844-86-6P
 404844-88-8P 404844-89-9P 404844-90-2P
 404844-91-3P 404844-92-4P 404844-93-5P
 404844-94-6P 404844-95-7P 404844-96-8P
 404844-99-1P 404845-00-7P 404845-01-8P
 404845-02-9P 404845-06-3P 404845-07-4P
 404845-08-5P 404845-09-6P 404845-10-9P
 404845-11-0P 404845-12-1P 404845-18-7P
 404845-28-9P 404845-29-0P 404845-30-3P
 404845-31-4P 404845-32-5P 404845-34-7P
 404845-35-8P 404845-36-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase
 inhibitors)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-81-9 CAPLUS


CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-

quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-(trifluoromethyl)phenyl)-2-[2-(4,7-difluorophenyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-10-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-11-1 CAPLUS

CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-


(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-76-8 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 404828-77-9 CAPLUS
 CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
 yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl) [5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-83-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-


isoquinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404844-79-7 CAPLUS

CN 4-Quinazolinamine, 7-chloro-2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-80-0 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-82-2 CAPLUS
 CN Acetamide, N-[2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-7-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404844-83-3 CAPLUS
 CN Ethanone, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-7-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-85-5 CAPLUS


CN 4,7-Quinazolinodiamine, 2-(4-chlorophenyl)-N7-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-86-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-88-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(1H-pyrrol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-89-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-90-2 CAPLUS


CN 4-Quinazolinamine, 8-ethoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-91-3 CAPLUS


CN 7-Quinazolinol, 2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-92-4 CAPLUS


CN 7-Quinazolinecarbonitrile, 2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-93-5 CAPLUS


CN 4-Quinazolinamine, 7-methoxy-8-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-94-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-7-methoxy-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-95-7 CAPLUS


CN 7-Quinazolinecarboxamide, N-methyl-2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-96-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-7-(methylsulfonyl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404844-99-1 CAPLUS


CN 1(2H)-Isoquinolinone, 3,4-dihydro-2-methyl-3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404845-00-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404845-01-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404845-02-9 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N,N-dipropyl- (CA INDEX NAME)




RN 404845-06-3 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-[5-(trifluoromethyl)-2H-indazol-3-yl]- (CA INDEX NAME)




RN 404845-07-4 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-2H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404845-08-5 CAPLUS
CN 4-Quinazolinamine, N-(5-fluoro-2H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404845-09-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-2H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404845-10-9 CAPLUS
 CN 4-Quinazolinamine, N-2H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404845-11-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-2H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)




RN 404845-12-1 CAPLUS
 CN 4-Quinazolinamine, N-2H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 404845-18-7 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404845-28-9 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 404827-17-4


CMF C23 H16 F3 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-29-0 CAPLUS
CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 404827-19-6
CMF C23 H15 F4 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-30-3 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 404827-21-0
CMF C23 H15 F4 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-31-4 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 404827-22-1
CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404845-32-5 CAPLUS


CN 4-Quinazolinamine, N-(4,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-34-7 CAPLUS


CN 4-Quinazolinamine, 8-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-35-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-8-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404845-36-9 CAPLUS

CN 4-Quinazolinamine, 8-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 50 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220579 CAPLUS

DOCUMENT NUMBER: 136:247580

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 406 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022603	A1	20020321	WO 2001-US28738	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422367	A1	20020321	CA 2001-2422367	20010914 <--
AU 2001090912	A	20020326	AU 2001-90912	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		

US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317447	A1	20030611	EP 2001-970969	20010914 <--
EP 1317447	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
JP 2004525075	T	20040819	JP 2002-526856	20010914
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914
AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
MX 2003PA02295	A	20030606	MX 2003-PA2295	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609

ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
HK 1057747	A1	20061201	HK 2003-108474	20031120
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US28738	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
			US 2003-624800	A3 20030722
OTHER SOURCE(S):		MARPAT 136:247580		
GI				



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR₆; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)2O, C(R₆)2S0-2, C(R₆)2NR₆, CO, CO2, CR6OCO, CR6OCONR₆, C(R₆)2NR6CO, C(R₆)2NR6CO2, CR₆:NNR₆, CR₆:NO, C(R₆)2NR6NR₆, C(R₆)2NR6SO2NR₆, C(R₆)2NR6CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially

as


inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (triazinyl)pyrazolamines and indazolamines I [wherein Z1, Z2, and Z3 = N; Z4 = CR_y]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-β3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited K_i values of < 0.1 μM for glycogen synthetase kinase 3β (GSK-3β) and 0.1-1.0 μM for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl) [2-(2-

methylphenyl)quinazolin-4-yl]amine 404826-61-5P,
[2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P,
[2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P,
[2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P,
[2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine
404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-
3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-
Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-
Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine
404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-
4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P,
(5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P,
(4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P,
(2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-
fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-
Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P
, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazoli
n-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-
(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine
404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-
yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-
4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-
yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-
trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine
404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-
indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-
yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-

yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,

[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-yl)quinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
yl)quinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-yl)quinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-
yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-
2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P,
(5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-
yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P,
[5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-
yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P,
(5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-
pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P,
(2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine
404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-
pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P,
[5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-
yl](2-phenylquinazolin-4-yl)amine 404828-79-1P,
[5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-


yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
 CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
 CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
 CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-,
2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d 51-100 ibib abs hitstr
```

L7 ANSWER 51 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220578 CAPLUS

DOCUMENT NUMBER: 136:263164

TITLE: Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and




INVENTOR(S): Alzheimer's disease
 Bebbington, David; Knegtel, Ronald; Binch, Haley;
 Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 377 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022602	A2	20020321	WO 2001-US42162	20010914 <--
WO 2002022602	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422299	A1	20020321	CA 2001-2422299	20010914 <--
AU 2001096875	A	20020326	AU 2001-96875	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1318814	A2	20030618	EP 2001-977783	20010914 <--
EP 1318814	B1	20070530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509114	T	20040325	JP 2002-526855	20010914
JP 4105947	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914

AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
MX 2003PA02297	A	20030606	MX 2003-PA2297	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
HK 1057702	A1	20071102	HK 2003-108682	20031127
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321

AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			JP 2002-526860	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US42162	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
			US 2003-624800	A3 20030722


OTHER SOURCE(S): MARPAT 136:263164
GI



AB Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRY; Rx and Ry = independently

TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2S0-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 1.0-20 μ M for Aurora-2.


IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
 RN 404826-20-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P,
[4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P,
(5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P,
(4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P,
(2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P,
(7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P,
[2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P
404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine
404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P,
(4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P,
(1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P
, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P,
(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester
404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P,
(7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine
404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine

404828-43-9P, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine

404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine
 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404889-28-7P


404889-29-8P 404889-30-1P 404889-31-2P
 404889-32-3P 404889-33-4P 404889-34-5P
 404889-35-6P 404889-36-7P 404889-37-8P
 404889-38-9P 404889-39-0P 404889-40-3P
 404889-41-4P 404889-42-5P 404889-43-6P
 404889-44-7P 404889-45-8P 404889-46-9P
 404889-47-0P 404889-48-1P 404889-49-2P
 404889-50-5P 404889-51-6P 404889-52-7P
 404889-53-8P 404889-54-9P 404889-55-0P
 404889-56-1P 404889-58-3P 404889-59-4P
 404889-60-7P 404889-61-8P 404889-62-9P
 404889-63-0P 404889-79-8P 404889-80-1P
 404889-86-7P 404890-88-6P 404890-89-7P
 404890-90-0P 404890-91-1P 404890-92-2P
 404890-94-4P 404891-05-0P 404891-06-1P
 404891-07-2P 404891-08-3P 404891-09-4P
 404891-10-7P 404891-12-9P 404891-13-0P
 404891-14-1P 404891-15-2P 404891-18-5P
 404891-19-6P 404891-21-0P 404891-23-2P
 404891-25-4P 404891-26-5P 404891-28-7P
 404891-29-8P 404891-31-2P 404891-32-3P
 404891-34-5P 404891-35-6P 404891-36-7P
 404891-38-9P 404891-39-0P 404891-41-4P
 404891-42-5P 404891-43-6P 404891-64-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-28-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-29-8 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-30-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dimethoxyphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-31-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-32-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-33-4 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethoxyphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-34-5 CAPLUS


CN Ethanone, 1-[2-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-quinazolininyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-35-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-36-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-37-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-38-9 CAPLUS


CN Phenol, 2-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-39-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-40-3 CAPLUS


CN 4-Quinazolinamine, N-[3-(2-thienyl)-1H-1,2,4-triazol-5-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-41-4 CAPLUS


CN 4-Quinazolinamine, N-(3-phenyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-42-5 CAPLUS


CN 4-Quinazolinamine, N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-43-6 CAPLUS


CN 4-Quinazolinamine, N-[3-(cyclopropylmethyl)-1H-1,2,4-triazol-5-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-44-7 CAPLUS


CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-45-8 CAPLUS


CN 4-Quinazolinamine, N-[3-(methoxymethyl)-1H-1,2,4-triazol-5-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404889-46-9 CAPLUS

CN 1H-1,2,4-Triazole-3-acetonitrile, 5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-47-0 CAPLUS
CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-48-1 CAPLUS
CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(3-cyclohexyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404889-49-2 CAPLUS
CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[3-(1,1-dimethylethyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-50-5 CAPLUS


CN Benzonitrile, 2-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404889-51-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-52-7 CAPLUS
 CN 4-Quinazolinamine, 2-[4-fluoro-2-(trifluoromethyl)phenyl]-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-53-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404889-54-9 CAPLUS
 CN 4-Quinazolinamine, 8-methoxy-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-55-0 CAPLUS


CN 4-Quinazolinamine, 7-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-56-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-58-3 CAPLUS


CN 4-Quinazolinamine, 2-(4-chloro-3-pyridinyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-59-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-60-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-61-8 CAPLUS


CN 4-Quinazolinamine, 8-methyl-N-(3-phenyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-62-9 CAPLUS


CN 4-Quinazolinamine, N-[3-(2-furanyl)-1H-1,2,4-triazol-5-yl]-8-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-63-0 CAPLUS


CN 4-Quinazolinamine, 8-ethyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-79-8 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-8-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-80-1 CAPLUS


CN 4-Quinazolinamine, 8-(4-methyl-1-piperazinyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404889-86-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-88-6 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-89-7 CAPLUS


CN 4-Quinazolinamine, N-(3-ethyl-1H-1,2,4-triazol-5-yl)-2-(1-naphthalenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-90-0 CAPLUS


CN 4-Quinazolinamine, N-[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]-2-(1-naphthalenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-91-1 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-92-2 CAPLUS


CN 4-Quinazolinamine, N-(3-ethyl-1H-1,2,4-triazol-5-yl)-2-(1-isoquinolinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404890-94-4 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-[3-(1-methylethyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-05-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-06-1 CAPLUS


CN Benzamide, 2-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-07-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1-methylethyl)phenyl]-N-(3-methyl-1H-1,2,4-
triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-08-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-09-4 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-10-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-12-9 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-13-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-dihydro-4-isobenzofuranyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-14-1 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-2-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-15-2 CAPLUS


CN Benzonitrile, 2-[4-[[3-(2-methylpropyl)-1H-1,2,4-triazol-5-yl]amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-18-5 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-19-6 CAPLUS


CN Ethanone, 1-[4-[(3-methyl-1H-1,2,4-triazol-5-yl)amino]-2-phenyl-7-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-21-0 CAPLUS


CN 4,7-Quinazolinediamine, 2-(4-chlorophenyl)-N7-ethyl-N4-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-23-2 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-7-methyl-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)-7-(1H-pyrrol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-26-5 CAPLUS


CN 4-Quinazolinamine, 8-ethoxy-N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-28-7 CAPLUS


CN 7-Quinazolinol, 2-(4-chlorophenyl)-4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-29-8 CAPLUS


CN 4-Quinazolinamine, N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-31-2 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-32-3 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(3-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-34-5 CAPLUS


CN 4-Quinazolinamine, N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-(3-phenoxyphenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-35-6 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-(3-thienyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-36-7 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-38-9 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-39-0 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-41-4 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-42-5 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-43-6 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-methyl-N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404891-64-1 CAPLUS

CN 4-Quinazolinamine, N-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404892-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404892-28-0 CAPLUS

CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-(2-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, 2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



L7 ANSWER 52 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:220577 CAPLUS

DOCUMENT NUMBER: 136:247579

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Knegtel, Ronald; Bebbington, David; Binch, Hayley; Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA


SOURCE: PCT Int. Appl., 376 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022601	A1	20020321	WO 2001-US28740	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422354	A1	20020321	CA 2001-2422354	20010914 <--
AU 2001090914	A	20020326	AU 2001-90914	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317444	A1	20030611	EP 2001-970971	20010914 <--
EP 1317444	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509113	T	20040325	JP 2002-526854	20010914
JP 4111824	B2	20080702		
US 20040097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-971006	20010914
AT 326458	T	20060615	AT 2001-970969	20010914
AT 327990	T	20060615	AT 2001-970971	20010914
AT 327992	T	20060615	AT 2001-971082	20010914
AT 327991	T	20060615	AT 2001-973050	20010914
AT 326459	T	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1318997	T	20061031	PT 2001-971082	20010914
AT 346064	T	20061215	AT 2001-975210	20010914
ES 2266258	T3	20070301	ES 2001-970971	20010914
ES 2266259	T3	20070301	ES 2001-971082	20010914
AT 363284	T	20070615	AT 2001-977783	20010914
NZ 545284	A	20070629	NZ 1984-5452	20010914
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		


CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
HU 2004000842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
MX 2003PA02294	A	20050908	MX 2003-PA2294	20030317
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003PA05609	A	20031006	MX 2003-PA5609	20030620 <--
MX 2003PA05610	A	20031006	MX 2003-PA5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
HK 1057543	A1	20061215	HK 2003-108309	20031114
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 20060258658	A1	20061116	US 2006-492450	20060725
JP 2008115195	A	20080522	JP 2008-15681	20080125
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915

US 2000-257887P	P	20001221
US 2001-286949P	P	20010427
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	A3	20010914
AU 2001-96875	A3	20010914
EP 2001-971082	A3	20010914
JP 2002-526860	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
WO 2001-US28740	W	20010914
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-557938	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US50312	W	20011219
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220
US 2003-624800	A3	20030722

OTHER SOURCE(S) : MARPAT 136:247579
GI




I



II


AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR₉; Z2 = N or CH; Z3 = N or CR_x; Z4 = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂S₀₋₂, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆OCONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₀₋₂R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliphatic), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliphatic), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliphatic group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR,



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)




RN 404828-58-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-61-1 CAPLUS
 CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P,
(6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P,
(4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P,
[2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P,
(7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P,
[2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P
404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate
404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P,
(4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P,
(1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P,
(6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-54-9P,
(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404828-07-5P, (1H-Indazol-3-yl)(2-phenyl)quinazolin-4-yl]amine 404828-10-0P, (5-Methyl-2H-pyrazol-3-

yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P,
(7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-
Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-17-7P, [2-(3,5-
Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-19-9P, [2-(3-Iodophenyl)quinazolin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-22-4P, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-23-5P, [2-(4-
Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine
404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404828-25-7P, [2-(4-
Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-26-8P, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-
yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-31-5P, [2-(3,5-
Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-32-6P, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-
3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine
404828-35-9P, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404828-36-0P, [2-(3-
Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-37-1P, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-
4-yl)amine 404828-38-2P, [2-(3-Acetylphenyl)quinazolin-4-yl](5-
methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-
Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404828-40-6P, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-
(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine
404828-43-9P 404828-44-0P, (2-Phenylquinazolin-4-yl)(2H-
pyrazol-3-yl)amine 404828-45-1P, (2H-Pyrazol-3-yl)(2-pyridin-4-
ylquinazolin-4-yl)amine 404828-46-2P, (5-Ethyl-2H-pyrazol-3-
yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine
404828-48-4P, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-
pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P,
(5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-52-0P, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-
yl)amine 404828-53-1P, (5-Carboxy-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-55-3P, (5-Hydroxymethyl-2H-
pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P,
(5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine
404828-57-5P, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-
phenylquinazolin-4-yl)amine 404828-59-7P, [5-(3-Methoxypropyl)-
2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P,
[5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine
404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-
phenylquinazolin-4-yl)amine 404828-63-3P, (5-Allylcarbamoyl-2H-

pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P,
[5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-98-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404829-00-1P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-03-4P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-11-4P, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-

yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-


yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-93-3 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-94-4 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-95-5 CAPLUS
CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404826-96-6 CAPLUS
CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N3-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-02-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 404827-19-6
 CMF C23 H15 F4 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 404827-21-0 CAPLUS
 CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-23-2 CAPLUS
 CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404827-56-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-07-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-21-3 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-
3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (CA
INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-53-1 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-55-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-56-4 CAPLUS
 CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-57-5 CAPLUS
 CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-59-7 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-60-0 CAPLUS
 CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (CA
 INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-62-2 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propen-1-yl- (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Methanone, [(3S)-3-(methoxymethyl)-1-pyrrolidinyl][5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Methanone, 4-morpholinyl[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-01-2 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-


indol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-13-6 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-14-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-15-8 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-5-yl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-5-yl-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(3-methyl-1H-1,2,4-triazol-5-yl)-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404829-75-0 CAPLUS

CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-,
2,5-dioxo-1-pyrrolidinyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 53 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:178111 CAPLUS

DOCUMENT NUMBER: 137:15994

TITLE: Studies of the biogenic amine transporters. VIII:
identification of a novel partial inhibitor of
dopamine uptake and dopamine transporter binding

AUTHOR(S): Rothman, Richard B.; Dersch, Christina M.; Carroll, F. Ivy; Ananthan, Subramaniam


CORPORATE SOURCE: Clinical Psychopharmacology Section, Intramural
Research Program, National Institute on Drug Abuse,
National Institutes of Health, Baltimore, MD, 21224,
USA
SOURCE: Synapse (New York, NY, United States) (2002
) , 43(4), 268-274
CODEN: SYNAET; ISSN: 0887-4476
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Using [125I]RTI-55 to label the dopamine transporter (DAT), our laboratory has consistently detected one binding site as well as one component of [3H]DA uptake. We report here the identification of a novel partial inhibitor of [3H]DA uptake and DAT binding (SoRI-9804). [125I]RTI-55 binding to the DAT (mouse caudate, rat caudate, HEK cells expressing the cloned DAT), the 5-HT transporter (rat brain), and [3H]DA uptake (rat caudate synaptosomes) were conducted using published procedures. 4-[(Diphenylmethyl)amino]-2-phenylquinazoline (SoRI-9804) was essentially inactive at SERT binding and resolved two DAT binding components in all three tissues, having high affinity (mean K_i of 465 nM) for about 40% of the binding sites and an essentially immeasurable K_i ($> 100 \mu\text{M}$) for the remaining 60% of the binding sites. The [3H]DA uptake expts. indicated that about 50% of uptake was SoRI-9804-sensitive. Saturation binding expts. showed that SoRI-9804 competitively inhibited [125I]RTI-55 binding to the SoRI-9804-sensitive binding component. To determine if the two binding sites discriminated by SoRI-9804 were regulated by the MAP kinase pathway, rat caudate synaptosomes were incubated in the absence or presence of $10 \mu\text{M}$ of PD98059, which inhibits activation of the MAP kinase pathway. The results indicated that inhibition of MAPK/ERK kinase decreased the total B_{max} of the DAT by 90%. Treatment with PD98059 increased the proportion of the SoRI-9804-sensitive binding component from 68-80% of the total B_{max} . The PD98059 expts. suggest that inhibition of MAP kinase cannot explain the differential interaction of SoRI-9804 with the DAT. Viewed collectively, the present results indicate that SoRI-9804 discriminates two components of the DA transporter. Further studies will be needed to determine the underlying mechanism of this effect and if partial inhibition of DA uptake results in any unique behavioral effects.

IT 434326-29-1, SoRI 9804
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(novel partial inhibitor of dopamine uptake and dopamine transporter
binding)

RN 434326-29-1 CAPLUS

CN 4-Quinazolinamine, N-(diphenylmethyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:158388 CAPLUS



DOCUMENT NUMBER: 136:200203

TITLE: Preparation of 4-aminoquinazolines for use in
inhibiting neoplastic cells and related conditions

INVENTOR(S): Pamukcu, Rifat; Piazza, Gary
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont. of U.S. Ser. No. 60,444, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020025968	A1	20020228	US 2001-952769	20010914 <--
PRIORITY APPLN. INFO.:			US 1998-60444	B1 19980415
OTHER SOURCE(S):	MARPAT 136:200203			

GI




- AB Title compds. I [wherein R1 = H or alkyl; Y = alkylene; A = ORa or S(O)pRa; Ra = alkylhydroxy; p = 0-2; Z = single bond, methylene, ethylene, vinylene, or ethynylene; CyB = heterocyclic ring; R3 = H, alkyl, alkoxy, halo, or CF3; R4 = H, alkyl, alkoxy, CO2H, carboxy ester, alkanoylamino, alkylsulfonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, ethynyl, hydroxymethyl, acetyl, or (un)substituted sulfamoyl, carbamoyl, etc.; m and n = independently 1-2; or pharmaceutically acceptable salts or hydrates thereof] were prepared for inhibiting neoplastic cells and related conditions. For example, amination of 2,4-dichloro-6-(2-triethylsilylethynyl)quinazolin-2,4-dione (preparation given) with 2-methoxyethylamine in CHCl3, followed by addition of imidazole in EtOH and deprotection using NBu4F, afforded II. I are useful in the treatment of precancerous and cancerous lesions, including malignant melanomas, breast cancer, and colon cancer (no data).
- IT 157863-90-6P, 4-[(1,1-Dimethyl-2-methoxyethyl)amino]-2-(1-imidazolyl)quinazoline 157864-00-1P, 6-Hydroxy-4-Phenylmethylamino-2-(1-Imidazolyl)Quinazoline 157864-03-4P 157864-08-9P 171661-62-4P, 6-Chloro-4-(2-Ethoxyethyl)Amino-2-(3-Pyridyl)Quinazoline
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (antineoplastic agent; preparation of aminoquinazolines for use in

inhibiting neoplastic cells and related conditions)


RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-
(CA INDEX NAME)




RN 157864-00-1 CAPLUS

CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-03-4 CAPLUS

CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-08-9 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)- (CA INDEX NAME)




RN 171661-62-4 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(2-ethoxyethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



IT 157862-69-6P, 4-Phenylmethylamino-7-Fluoro-2-(3-Pyridyl)Quinazoline 157862-70-9P, 4-Phenylmethylamino-7-Fluoro-2-(3-Pyridyl)Quinazoline Dihydrochloride 157863-23-5P, 6-Acetylamino-4-Phenylmethylamino-2-(3-Pyridyl)Quinazoline 157863-24-6P, 4-Phenylmethylamino-2-(1-Imidazolyl)Quinazoline 157863-68-8P 157863-73-5P 157863-91-7P 157864-04-5P, 4-[[2-(2-Hydroxyethyloxy)ethyl]amino]-6-methylsulfinyl-2-(1-imidazolyl)quinazoline Dihydrochloride 157864-09-0P 157864-10-3P, 6-Methylsulfonyl-4-phenylmethylamino-2-(1-imidazolyl)quinazoline hydrochloride 157864-11-4P, 6-Hydroxymethyl-4-Phenylmethylamino-2-(1-Imidazolyl)Quinazoline 157864-13-6P 157864-14-7P 157864-15-8P 157864-16-9P, 6-Ethynyl-4-(2-Methoxyethyl)Amino-2-(1-Imidazolyl)Quinazoline 157864-17-0P 157864-19-2P, 6-Acetyl-4-(2-Methoxyethyl)Amino-2-(1-Imidazolyl)Quinazoline 157864-20-5P 157941-29-2P 171661-64-6P 171661-66-8P 401520-93-2P, 6-Chloro-4-[(2-ethoxyethyl)amino]-2-(3-pyridyl)quinazoline hydrochloride 401520-94-3P, 6-Hydroxy-4-phenylmethylamino-2-(1-imidazolyl)quinazoline hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antineoplastic agent; preparation of aminoquinazolines for use in inhibiting neoplastic cells and related conditions)
 RN 157862-69-6 CAPLUS
 CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-70-9 CAPLUS
 CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157863-23-5 CAPLUS
 CN Acetamide, N-[4-[(phenylmethyl)amino]-2-(3-pyridinyl)-6-quinazolinyl]-
 (CA INDEX NAME)




RN 157863-24-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-68-8 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157863-73-5 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-, methyl ester (CA INDEX NAME)



RN 157863-91-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157864-04-5 CAPLUS


CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157864-09-0 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 157864-10-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 157864-11-4 CAPLUS
 CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-13-6 CAPLUS
 CN 6-Quinazolinemethanol, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 157864-14-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-[2-(triethylsilyl)ethynyl]- (CA INDEX NAME)




RN 157864-15-8 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-16-9 CAPLUS
 CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 157864-17-0 CAPLUS
 CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 157864-19-2 CAPLUS
 CN Ethanone, 1-[2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-6-quinazolinyl]- (CA INDEX NAME)




RN 157864-20-5 CAPLUS
 CN Ethanone, 1-[4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-6-quinazolinyl]- (CA INDEX NAME)




RN 157941-29-2 CAPLUS


CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]-
(CA INDEX NAME)




RN 171661-64-6 CAPLUS
CN Ethanol, 2-[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-
(CA INDEX NAME)



RN 171661-66-8 CAPLUS
CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 401520-93-2 CAPLUS
CN 4-Quinazolinamine, 6-chloro-N-(2-ethoxyethyl)-2-(3-pyridinyl)-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 401520-94-3 CAPLUS
CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 157863-09-7, 4-Phenylmethylamino-6-nitro-2-(3-pyridyl)quinazoline
 157863-29-1, 6-Ethoxycarbonyl-4-phenylmethylamino-2-(1-imidazolyl)quinazoline 157863-30-4, 4-Phenylmethylamino-2-(1-imidazolyl)quinazoline dihydrochloride 157863-36-0, 6-Methoxy-4-phenylmethylamino-2-(1-imidazolyl)quinazoline dihydrochloride 157863-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of aminoquinazolines for use in inhibiting neoplastic cells and related conditions)
 RN 157863-09-7 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157863-29-1 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 157863-30-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-36-0 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(phenylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-66-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-
 (CA INDEX NAME)



L7 ANSWER 55 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:142666 CAPLUS
 DOCUMENT NUMBER: 136:200479
 TITLE: Preparation of proline derivatives as dipeptidyl
 peptidase IV (DPP-IV) inhibitors and use thereof as
 drugs
 INVENTOR(S): Kitajima, Hiroshi; Sakashita, Hiroshi; Akahoshi,
 Fumihiko; Hayashi, Yoshiharu
 PATENT ASSIGNEE(S): Welfide Corporation, Japan
 SOURCE: PCT Int. Appl., 340 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002014271	A1	20020221	WO 2001-JP6906	20010810 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418656	A1	20020221	CA 2001-2418656	20010810 <--
AU 2001077754	A	20020225	AU 2001-77754	20010810 <--
EP 1308439	A1	20030507	EP 2001-955660	20010810 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013146	A	20030624	BR 2001-13146	20010810 <--
HU 2003000746	A2	20031028	HU 2003-746	20010810 <--
HU 2003000746	A3	20050928		
NZ 524618	A	20040827	NZ 2001-524618	20010810
AU 2001277754	B2	20050929	AU 2001-277754	20010810
EP 1930319	A1	20080611	EP 2008-1977	20010810
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
JP 4101053	B2	20080611	JP 2002-519416	20010810
EP 1950199	A1	20080730	EP 2008-1976	20010810
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
NO 2003000619	A	20030226	NO 2003-619	20030207 <--
US 20040106655	A1	20040603	US 2003-344255	20030210
US 7074794	B2	20060711		
KR 817378	B1	20080327	KR 2003-701924	20030210
US 20050245538	A1	20051103	US 2005-142523	20050602
US 7060722	B2	20060613		
US 20060173056	A1	20060803	US 2006-351118	20060210
NO 2008000138	A	20030226	NO 2008-138	20080108 <--
NO 2008000139	A	20030226	NO 2008-139	20080108 <--
PRIORITY APPLN. INFO.:				
			JP 2000-243217	A 20000810
			JP 2000-400296	A 20001228
			EP 2001-955660	A3 20010810
			WO 2001-JP6906	W 20010810
			US 2003-344255	A3 20030210
			US 2005-142523	A3 20050602
OTHER SOURCE(S): MARPAT 136:200479				
GI				



AB The title compds. [I; X = NR₁R₂, NR₃COR₄, NR₅COR₄, NR₅CH₂CH₂NR₆R₇, NR₈SO₂R₉, OR₁₀, O₂CR₁₁; wherein R₁, R₂ = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or they are linked to each other to form a heterocyclyl containing 1 or 2 N atoms or O which may be a spiro ring and is optionally fused to an (un)substituted

aromatic ring; R3, R4 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl; R5, R6, R7 = H, alkyl, acyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, or which is optionally fused to an (un)substituted aromatic ring; R8, R9, R10, R11 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] or pharmacol. acceptable salts thereof are prepared These compds. are useful for the treatment of DPP-IV related diseases such as diabetes, obesity, HIV infection, cancer metastasis, skin diseases, prostatic hypertrophy (prostatomegaly), pericementitis, or autoimmune diseases. Thus, a solution of 0.924 g (S)-1-[(2S,4S)-4-amino-1-tert-butoxycarbonyl-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine (preparation given), 1.7 mL diisopropylethylamine, and 0.78 g 2-chloro-4-fluorobenzonitrile in 10 mL N-methyl-2-pyrrolidone were stirred at 80° for 4 h to give 0.94 g (S)-1-[(2S,4S)-1-tert-butoxycarbonyl-4-(3-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine which (0.93 g) was treated with HCl/EtOAc at room temperature for 15 h to give (S)-1-[(2S,4S)-4-(3-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine hydrochloride (II). II showed IC50 of 0.13 and 0.15 nM against human blood plasma DPP-IV and rat blood plasma DPP-IV, resp.

IT 401563-79-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of proline derivs. as dipeptidyl peptidase IV (DPP-IV) inhibitors for treating DPP-IV related diseases)

RN 401563-79-9 CAPLUS

CN Methanone, [(2S,4S)-4-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]-2-pyrrolidinyl]-3-thiazolidinyl-, hydrochloride (1:3) (CA INDEX NAME)

Absolute stereochemistry.




IT 181115-48-0P 401568-01-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of proline derivs. as dipeptidyl peptidase IV (DPP-IV) inhibitors for treating DPP-IV related diseases)


RN 181115-48-0 CAPLUS

CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)



RN 401568-01-2 CAPLUS
 CN Methanone, [(2S,4S)-4-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]-2-pyrrolidinyl]-3-thiazolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:122770 CAPLUS
 DOCUMENT NUMBER: 136:178015
 TITLE: Drugs for incontinence - salified and nonsalified nitric oxide-donors and phosphodiesterase inhibitors
 INVENTOR(S): Del Soldato, Piero; Benedini, Francesca
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011707	A2	20020214	WO 2001-EP8734	20010727 <--
WO 2002011707	A3	20021205		

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ,

EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT,
 LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA,
 US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT 2000MI1848 A1 20020208 IT 2000-MI1848 20000808 <--
 IT 1318674 B1 20030827
 AU 2001091691 A 20020218 AU 2001-91691 20010727 <--
 EP 1307184 A2 20030507 EP 2001-971798 20010727 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004511436 T 20040415 JP 2002-517044 20010727
 US 20030203899 A1 20031030 US 2003-343330 20030206 <--
 PRIORITY APPLN. INFO.: IT 2000-MI1848 A 20000808
 WO 2001-EP8734 W 20010727


OTHER SOURCE(S): MARPAT 136:178015

AB Use in the incontinence of one or more of the following classes of drugs
 selected from the following: (B) salified and nonsalified nitric
 oxide-donor drugs, of formula: A - X1 - N(O)z, (B') nitrate salts of drugs
 used for the incontinence, and which do not contain in the mol. a nitric
 oxide donor group; (C) organic or inorg. salts of compds. inhibiting
 phosphodiesterases.

IT 157864-16-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (salified and nonsalified nitric oxide-donors and phosphodiesterase
 inhibitors for treatment of incontinence)

RN 157864-16-9 CAPLUS

CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)- (CA
 INDEX NAME)



L7 ANSWER 57 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:122769 CAPLUS

DOCUMENT NUMBER: 136:189342

TITLE: Drugs for treatment of sexual dysfunction

INVENTOR(S): Del Soldato, Piero

PATENT ASSIGNEE(S): Nicox S.A., Fr.

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011706	A2	20020214	WO 2001-EP8733	20010727 <--
WO 2002011706	A3	20030918		
W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ,			
	EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT,			
	LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA,			

US, UZ, VN, YU, ZA
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

IT 2000MI1847	A1	20020208	IT 2000-MI1847	20000808 <--
IT 1318673	B1	20030827		
AU 2001091690	A	20020218	AU 2001-91690	20010727 <--
EP 1363628	A2	20031126	EP 2001-971797	20010727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR				
JP 2004506619	T	20040304	JP 2002-517043	20010727
US 20030171393	A1	20030911	US 2003-333927	20030204 <--
PRIORITY APPLN. INFO.:			IT 2000-MI1847	A 20000808
			WO 2001-EP8733	W 20010727

OTHER SOURCE(S): MARPAT 136:189342

AB Pharmaceuticals containing nitric oxide-donor drugs or inorg. salts of compds. inhibiting phosphodiesterases are useful for the treatment of sexual dysfunction. Thus, a formulation contained 2-(acetyloxy)benzoic acid 6-(nitroxy-methyl)-2-methylpyridyl ester-HCl (NCX 4050) 4.2, white petrolatum 24, Polysorbate-60 4.8, glycerin 9.5, and water 48 g. NCX 4050 showed vasorelaxing activity on the aortas.

IT 398460-39-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drugs for treatment of sexual dysfunction)


RN 398460-39-4 CAPLUS

CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, nitrate (1:?) (CA INDEX NAME)

CM 1

CRN 157864-16-9


CMF C16 H15 N5 O



CM 2

CRN 7697-37-2

CMF H N O3



L7 ANSWER 58 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2002:96165 CAPLUS

DOCUMENT NUMBER: 136:294745

TITLE: A combinatorial scaffold approach toward
 kinase-directed heterocycle libraries

AUTHOR(S): Ding, Sheng; Gray, Nathanael S.; Wu, Xu; Ding, Qiang;


Schultz, Peter G.
 CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for
 Chemical Biology, The Scripps Research Institute, La
 Jolla, CA, 92037, USA
 SOURCE: Journal of the American Chemical Society (2002
), 124(8), 1594-1596
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:294745
 GI



AB A novel strategy for efficient synthesis of various substituted
 nitrogen-heterocycles, e.g., I, as kinase-directed combinatorial libraries
 is described. The general scheme involves capture of various
 dichloroheterocycles onto solid support and further elaborations by aromatic
 substitution with amines at elevated temperature or by anilines, boronic acids,
 and phenols via palladium-catalyzed cross-coupling reactions, thus the
 scaffold itself is transformed into a diversity element within the
 combinatorial scheme. Libraries consisting of discrete and highly diverse
 heterocyclic small mols. constructed with these chemistries are currently
 being evaluated in a variety of cell and protein-based assays.

IT 406932-46-5P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP
 (Preparation)
 (derivatization of resin-bound chloroheterocyclic scaffolds via Suzuki
 coupling reaction with aryl boronic acid and subsequent cleavage of
 substituted heterocyclic product)

RN 406932-46-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (CA
 INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 59 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:51984 CAPLUS
 DOCUMENT NUMBER: 136:96106
 TITLE: Method for stimulating liver regeneration by use of
 nitric oxide donor
 INVENTOR(S): Lautt, Wilfred Wayne
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020006930	A1	20020117	US 2001-888171	20010622 <--
CA 2351250	A1	20011222	CA 2001-2351250	20010622 <--

PRIORITY APPLN. INFO.: US 2000-213514P P 20000622

AB The present invention provides an NO donor for use in regenerating the liver. Also provided is a pharmaceutical for liver regeneration including an effective amount of the chemical which promotes liver regeneration and a pharmaceutically acceptable carrier. Also provided is a method of stimulating liver regeneration by administering an effective amount of an NO donor or a chemical which stimulates cGMP production


IT 211117-00-9, ONO 1505
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitric oxide donors for liver regeneration)

RN 211117-00-9 CAPLUS

CN Ethanol, 2-[2-[[6-methoxy-2-(1H-pyrrol-1-yl)-4-quinazolinyl]amino]ethoxy]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 211116-99-3
 CMF C17 H20 N4 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S



L7 ANSWER 60 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:910337 CAPLUS

DOCUMENT NUMBER: 136:55220

TITLE: Metal-containing azo compounds and their use in optical recording media with good light resistance and long service life

INVENTOR(S): Nagataki, Yoshiyuki; Sakurai, Tomokazu; Takasawa, Koji; Iinuma, Yoshiharu; Taniguchi, Masatoshi; Ueda, Atsuko

PATENT ASSIGNEE(S): Hitachi Maxell Ltd., Japan; Yamada Chemical Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001348501	A	20011218	JP 2000-167711	20000605 <--
TW 518590	B	20030121	TW 2001-90113469	20010604 <--
US 20020015915	A1	20020207	US 2001-873260	20010605 <--
PRIORITY APPLN. INFO.:			JP 2000-167711	A 20000605

OTHER SOURCE(S): MARPAT 136:55220


AB The compds. are obtained from azo compds. of R1N:NR2 [R1 = optionally substituted or fused 1,3-pyrimidin-4-yl group; R2 = optionally substituted 2-hydroxy(or carboxy or sulfonamido or carbonylamido or amino)-4-aminophenyl group] (I) and metal salts, and are useful for optical recording media recordable by laser light, e.g., DVD-R. Thus, dissolving 0.71 g 4-hydrazino-2-phenylquinazoline and 0.66 g 3-(N,N-dibutylamino)phenol in 5 mL DMF, mixing with 2 mL AcOH and 0.061 g I, dropping 4.8 g a 5% H2O2 water over 90 min, mixing at room temperature for 1 h and working up gave a compound I (R1 = phenylquinazoliny1; R2 = 2-hydroxy-4-dibutylaminophenyl), 0.1 g of which was dissolved in 10 mL MeOH, combined with 0.27 g Ni acetate tetrahydrate, mixed at reflux for 4 h and worked up to give a corresponding Ni phenolate expressing a λ_{\max} of 551 nm after cast into a thin film.

IT 381688-50-2P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; metal-containing azo compds. and use in optical recording
media with good light resistance and long service life)

RN 381688-50-2 CAPLUS

CN Phenol, 5-(dibutylamino)-2-[2-(2-phenyl-4-quinazolinyl)diazenyl]- (CA
INDEX NAME)




IT 6484-29-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for azo dye; metal-containing azo compds. and use in optical
recording media with good light resistance and long service life)

RN 6484-29-3 CAPLUS

CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



L7 ANSWER 61 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:889138 CAPLUS

DOCUMENT NUMBER: 137:169477

TITLE: Synthesis of agonists and antagonists of H3-receptors
of histamine in quinazoline derivative series

AUTHOR(S): Tonkikh, Nataiia; Rizanova, Kristina; Petrova, Marina;
Strakovs, Andris

CORPORATE SOURCE: Faculty of Material Science and Applied Chemistry,
Riga Technical University, Riga, LV 1048, Latvia

SOURCE: Rigas Tehniskas Universitates Zinatniskie Raksti,
Serija 1: Materialzinatne un Lietiska Kimija (2001), (2), 115-118

CODEN: RTUZAL


PUBLISHER: Izdevnieciba RTU

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:169477


GI




I



II



III



IV


AB In reactions of 2-phenyl-4-chloroquinazolines with histamine, 3-(1-imidazolyl)propylamine, 3-(4-morpholyl)propylamine and 2-aminomethylpyridine the corresponding 4-amino-2-phenylquinazolines I-IV have been obtained.

IT 307545-94-4P 446312-95-4P 446312-96-5P
446312-97-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation H3-receptor agonist and antagonist aminoquinazolines via substitution of phenylchloroquinazoline with corresponding amines)


RN 307545-94-4 CAPLUS

CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-phenyl- (CA INDEX NAME)




RN 446312-95-4 CAPLUS


CN 4-Quinazolinamine, N-[2-(1H-imidazol-5-yl)ethyl]-2-phenyl- (CA INDEX NAME)



RN 446312-96-5 CAPLUS
 CN 4-Quinazolinamine, N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl- (CA INDEX NAME)




RN 446312-97-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 62 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:819481 CAPLUS
 DOCUMENT NUMBER: 137:125128


TITLE: Synthesis and behavior of a static benzoxazinone derivative towards nitrogen and sulphur nucleophiles
 AUTHOR(S): Kassab, E. A.; El-Hashash, M. A.; Soliman, F. M. A.; Ali, R. S.
 CORPORATE SOURCE: Industrial Education College, Cairo, Egypt
 SOURCE: Egyptian Journal of Chemistry (2001), 44(1-3), 169-179
 CODEN: EGJCA3; ISSN: 0449-2285
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:125128
 GI



I

AB 2-[2-(4-Bromohydroxyiminobenzyl)phenyl]-4(H)-3,1-benzoxazin-4-one (I) was prepared via the interaction of 1-(4-bromophenyl)-4(H)-3,2-benzoxazin-4-one with anthranilic acid in which hetero-ring opening takes place followed by cyclization. Reactions of I with nitrogen and sulfur nucleophiles were evaluated. The hitherto unknown reaction of the hetero-ring fission of I with aliphatic amino acids was studied. When compound I was treated with glutamic acid in aqueous pyridine, 2-(4-bromo-hydroxyiminobenzyl)benzoylamino-N-(1,3-dicarboxypropyl)benzamide was obtained. The phthalazinone derivative, 2-[2-(carboxy-thiomethoxycarbonyl)phenyl]-4-(4-bromophenyl)phthalazin-1-one, was obtained when I was allowed to react with thioglycolic acid in boiling n-butanol.
 IT 444334-47-8P 444334-48-9P 444334-50-3P
 444334-51-4P 444334-52-5P 444334-54-7P
 444334-55-8P 444334-56-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and N- and S-nucleophile reactions of
 bromohydroxyiminobenzylphenylbenzoxazinone via ring opening/cyclization
 sequence with anthranilic acid)
 RN 444334-47-8 CAPLUS
 CN D-Glucose, [2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 444334-48-9 CAPLUS

CN D-Galactose, [2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 444334-50-3 CAPLUS

CN D-Mannose, [2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 444334-51-4 CAPLUS

CN D-Fructose, [2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 444334-52-5 CAPLUS


CN D-Xylose, [2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 444334-54-7 CAPLUS

CN Benzaldehyde, 4-methoxy-, 2-[2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 444334-55-8 CAPLUS

CN 1,3-Benzodioxole-5-carboxaldehyde, 2-[2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazide (CA INDEX NAME)



RN 444334-56-9 CAPLUS

CN 2-Furancarboxaldehyde, 2-[2-[2-[(4-bromophenyl)(hydroxyimino)methyl]phenyl]-4-quinazolinyl]hydrazone (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 63 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:816643 CAPLUS

DOCUMENT NUMBER: 135:344500

TITLE: Preparation of condensed heteroaryl derivatives as phosphatidylinositol 3-kinase inhibitors and anticancer agents

INVENTOR(S): Hayakawa, Masahiko; Kaizawa, Hiroyuki; Moritomo, Hiroyuki; Kawaguchi, Ken-ichi; Koizumi, Tomonobu; Yamano, Mayumi; Matsuda, Koyo; Okada, Minoru; Ohta, Mitsuaki

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Ludwig Institute for Cancer Research; Imperial Cancer Research Technology Ltd.

SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083456	A1	20011108	WO 2001-JP3650	20010426 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407593	A1	20011108	CA 2001-2407593	20010426 <--
AU 2001052610	A	20011112	AU 2001-52610	20010426 <--
US 20020151544	A1	20021017	US 2001-843615	20010426 <--
US 6608053	B2	20030819		
EP 1277738	A1	20030122	EP 2001-925981	20010426 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 3649395	B2	20050518	JP 2001-580885	20010426
CN 1629145	A	20050622	CN 2004-10055760	20010426
US 6608056	B1	20030819	US 2002-243416	20020913 <--
KR 774855	B1	20071108	KR 2002-714412	20021025
US 20030236271	A1	20031225	US 2003-459002	20030610 <--
US 6838457	B2	20050104		
US 20040009978	A1	20040115	US 2003-459220	20030610
US 6770641	B2	20040803		
US 20050014771	A1	20050120	US 2004-918094	20040813
US 7037915	B2	20060502		
JP 2005120102	A	20050512	JP 2004-332225	20041116
JP 3810017	B2	20060816		
US 20060058321	A1	20060316	US 2005-250782	20051014
US 7173029	B2	20070206		
US 20070037805	A1	20070215	US 2006-544144	20061006
PRIORITY APPLN. INFO.:			JP 2000-128472	A 20000427
			US 2000-200537P	P 20000427
			US 2000-200481P	P 20000428
			JP 2001-580885	A3 20010426
			US 2001-843615	A3 20010426
			WO 2001-JP3650	W 20010426
			US 2002-243416	A3 20020913
			US 2003-459002	A1 20030610
			US 2004-918094	A1 20040813
			US 2005-250782	A1 20051014

OTHER SOURCE(S): MARPAT 135:344500
GI



AB The title compds, e.g. I [n = 0 - 3; R1 = alkyl, etc.; R2, R3 = H, alkyl,


etc; further detail on R2 and R3 is given; R4 = (un)substituted aryl, etc.; X = N, CH; Y = O, S, NH], are prepared Several compds. of this invention in vitro showed IC50 values of $\leq 1 \mu\text{M}$ against phosphatidylinositol 3-kinase (p110 α subtype). The antitumor activity of compds. of this invention is also demonstrated.

IT 307544-21-4P 371937-75-6P 371937-80-3P
 371937-89-2P 371937-94-9P 371937-98-3P
 371938-03-3P 371938-08-8P 371938-13-5P
 371938-18-0P 371938-26-0P 371938-30-6P
 371938-35-1P 371938-40-8P 371938-45-3P
 371938-50-0P 371938-61-3P 371938-71-5P
 371938-76-0P 371938-79-3P 371938-83-9P
 371938-87-3P 371938-92-0P 371938-97-5P
 371939-08-1P 371939-13-8P 371939-18-3P
 371939-28-5P 371939-33-2P 371939-38-7P
 371939-43-4P 371939-48-9P 371939-52-5P
 371939-57-0P 371939-62-7P 371939-67-2P
 371939-71-8P 371939-76-3P 371939-81-0P
 371939-85-4P 371939-95-6P 371940-00-0P
 371940-05-5P 371940-10-2P 371940-15-7P
 371940-19-1P 371940-24-8P 371940-28-2P
 371940-32-8P 371940-36-2P 371940-40-8P
 371940-44-2P 371940-48-6P 371940-52-2P
 371940-56-6P 371940-60-2P 371940-64-6P
 371940-68-0P 371940-72-6P 371940-75-9P
 371940-79-3P 371940-83-9P 371940-87-3P
 371940-91-9P 371940-95-3P 371940-99-7P
 371941-03-6P 371941-07-0P 371941-11-6P
 371941-15-0P 371941-19-4P 371941-24-1P
 371941-28-5P 371941-32-1P 371942-11-9P
 371942-16-4P 371942-20-0P 371942-24-4P
 371942-27-7P 371942-31-3P 371942-35-7P
 371942-39-1P 371942-43-7P 371942-47-1P
 371942-51-7P 371942-55-1P 371942-65-3P
 371943-01-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of condensed heteroaryl derivs. as phosphatidylinositol 3-kinase inhibitors and anticancer agents)


RN 307544-21-4 CAPLUS

CN Quinazoline, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371937-75-6 CAPLUS


CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371937-80-3 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371937-89-2 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-6-nitro-2-phenyl- (CA INDEX NAME)




RN 371937-94-9 CAPLUS
 CN Acetamide, N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (CA INDEX NAME)




RN 371937-98-3 CAPLUS
 CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 371938-03-3 CAPLUS
 CN Acetamide, N-[4-(4-morpholinyl)-2-(3-nitrophenyl)-6-quinazolinyl]- (CA INDEX NAME)




RN 371938-08-8 CAPLUS
 CN Quinazoline, 6-methoxy-2-phenyl-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 371938-13-5 CAPLUS
 CN Ethanol, 2-[(6-methoxy-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 371938-18-0 CAPLUS
 CN Methanesulfonamide, N-[4-(4-morpholinyl)-2-(3-nitrophenyl)-6-quinazolinyl]- (CA INDEX NAME)




RN 371938-26-0 CAPLUS
 CN 7-Quinazolinol, 6-methoxy-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371938-30-6 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 371938-35-1 CAPLUS
 CN 6-Quinazolinol, 4-[(2-hydroxyethyl)amino]-2-phenyl- (CA INDEX NAME)




RN 371938-40-8 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 371938-45-3 CAPLUS
 CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371938-50-0 CAPLUS
 CN Formamide, N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (CA INDEX NAME)




RN 371938-61-3 CAPLUS
 CN 4-Piperidinone, 1-(6-hydroxy-2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 371938-71-5 CAPLUS
 CN 6-Quinazolinol, 4-(4-hydroxy-1-piperidiny)-2-phenyl- (CA INDEX NAME)




RN 371938-76-0 CAPLUS
 CN 6-Quinazolinol, 4-(2,6-dimethyl-4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371938-79-3 CAPLUS
 CN 6-Quinazolinol, 4-[bis(2-methoxyethyl)amino]-2-phenyl- (CA INDEX NAME)




RN 371938-83-9 CAPLUS
 CN Acetamide, N-methyl-N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (CA INDEX NAME)




RN 371938-87-3 CAPLUS
 CN Benzenesulfonamide, 4-methyl-N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (CA INDEX NAME)



RN 371938-92-0 CAPLUS
 CN 6-Quinazolinamine, N,N-dimethyl-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371938-97-5 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(4-thiomorpholinyl)-, hydrochloride (2:1) (CA INDEX NAME)




● 1/2 HCl


RN 371939-08-1 CAPLUS
 CN 7-Quinazolinol, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 371939-13-8 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 371939-18-3 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3-nitrophenyl)- (CA INDEX NAME)




RN 371939-28-5 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 371939-33-2 CAPLUS
 CN 6-Quinazolinol, 2-(2-furanyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-38-7 CAPLUS
 CN Benzoic acid, 4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-, methyl ester (CA INDEX NAME)




RN 371939-43-4 CAPLUS
 CN Benzoic acid, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-, methyl ester (CA INDEX NAME)




RN 371939-48-9 CAPLUS
 CN 6-Quinazolinol, 2-(3-hydroxyphenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-52-5 CAPLUS
 CN 1,3-Benzenediol, 5-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371939-57-0 CAPLUS
 CN 6-Quinazolinol, 2-(2-fluorophenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-62-7 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(5-nitro-3-thienyl)- (CA INDEX NAME)




RN 371939-67-2 CAPLUS
 CN 6-Quinazolinol, 2-(3,4-dimethoxyphenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-71-8 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 371939-76-3 CAPLUS
 CN 6-Quinazolinol, 2-(4-hydroxy-3-methoxyphenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-81-0 CAPLUS
 CN 6-Quinazolinol, 2-(2-benzofuranyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371939-85-4 CAPLUS
 CN Benzamide, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-N-phenyl- (CA INDEX NAME)




RN 371939-95-6 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(2-pyrazinyl)- (CA INDEX NAME)




RN 371940-00-0 CAPLUS
CN 6-Quinazolinol, 2-(4-aminophenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371940-05-5 CAPLUS
CN Benzoic acid, 4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371940-10-2 CAPLUS
CN Benzoic acid, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371940-15-7 CAPLUS
CN 6-Quinazolinol, 2-[3-(hydroxymethyl)phenyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371940-19-1 CAPLUS
 CN 6-Quinazolinol, 2-(3-aminophenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 371940-24-8 CAPLUS
 CN Methanesulfonamide, N-[2-(3-aminophenyl)-4-(4-morpholinyl)-6-quinazolinyl]-
 (CA INDEX NAME)




RN 371940-28-2 CAPLUS
 CN Methanesulfonamide, N-[3-[6-amino-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-
 (CA INDEX NAME)




RN 371940-32-8 CAPLUS
CN Benzamide, 3-[6-amino-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371940-36-2 CAPLUS
CN Benzamide, 4-[6-amino-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371940-40-8 CAPLUS
CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-[4-(4-morpholinyl)-3-nitrophenyl]- (CA INDEX NAME)




RN 371940-44-2 CAPLUS
CN Acetamide, N-[4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-48-6 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-[(phenylmethyl)amino]phenyl]- (CA INDEX NAME)



RN 371940-52-2 CAPLUS
 CN Benzenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-56-6 CAPLUS
 CN Ethenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 371940-60-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-64-6 CAPLUS

CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(phenylsulfonyl)amino]phenyl]-6-quinazolinyl]- (CA INDEX NAME)




RN 371940-68-0 CAPLUS


CN Benzenesulfonamide, N-[3-[6-[(methylsulfonyl)amino]-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-72-6 CAPLUS
 CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(2-thienylsulfonyl)amino]phenyl]-6-quinazolinyl]- (CA INDEX NAME)



RN 371940-75-9 CAPLUS
 CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(1-naphthalenylsulfonyl)amino]phenyl]-6-quinazolinyl]- (CA INDEX NAME)




RN 371940-79-3 CAPLUS
 CN Urea, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 371940-83-9 CAPLUS

CN Carbamic acid, [3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 371940-87-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-91-9 CAPLUS

CN Cyclohexanecarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371940-95-3 CAPLUS

CN Benzeneacetamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-
(CA INDEX NAME)




RN 371940-99-7 CAPLUS

CN 2-Furancarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371941-03-6 CAPLUS

CN Benzamide, 2-chloro-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371941-07-0 CAPLUS

CN Benzamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 371941-11-6 CAPLUS

CN Benzamide, 4-cyano-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371941-15-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 371941-19-4 CAPLUS

CN Benzamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-4-methyl- (CA INDEX NAME)




RN 371941-24-1 CAPLUS

CN Acetic acid, 2-[[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]amino]-2-oxo-, ethyl ester (CA INDEX NAME)




RN 371941-28-5 CAPLUS


CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl-N-2-thiazolyl- (CA INDEX NAME)




RN 371941-32-1 CAPLUS
 CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl-N-(4-phenyl-2-thiazolyl)-
 (CA INDEX NAME)



RN 371942-11-9 CAPLUS
 CN Phenol, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




RN 371942-16-4 CAPLUS
 CN Phenol, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 371942-20-0 CAPLUS
 CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 371942-24-4 CAPLUS
 CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-(3-nitrophenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 371942-27-7 CAPLUS
 CN Benzenamine, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 371942-31-3 CAPLUS
 CN Acetamide, N-[3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 371942-35-7 CAPLUS


CN Benzenesulfonamide, N-[3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 371942-39-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-amino-N-[3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 371942-43-7 CAPLUS

CN Phenol, 3-[6-methoxy-4-(4-morpholinyl)-2-quinazolinyl]-, hydrochloride


(1:1) (CA INDEX NAME)



● HCl

RN 371942-47-1 CAPLUS


CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 371942-51-7 CAPLUS


CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 371942-55-1 CAPLUS


CN Phenol, 3-[4-(4-morpholinyl)-2-quinazolinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 371942-65-3 CAPLUS


CN Phenol, 3-[4-(4-morpholinyl)-6-[2-(4-morpholinyl)ethoxy]-2-quinazolinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 371943-01-0 CAPLUS

CN Phenol, 3-[6-methoxy-4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)




IT 371949-21-2P 371949-26-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of condensed heteroaryl derivs. as phosphatidylinositol 3-kinase inhibitors and anticancer agents)

RN 371949-21-2 CAPLUS
CN 6-Quinazolinol, 2-phenyl-4-(4-thiomorpholinyl)-, 6-(4-methylbenzenesulfonate) (CA INDEX NAME)



RN 371949-26-7 CAPLUS
CN Thiourea, N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 64 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:727667 CAPLUS
DOCUMENT NUMBER: 136:183778
TITLE: One-pot quinazolin-4-ylthiourea synthesis via N-(2-cyanophenyl)benzimidoyl isothiocyanate
AUTHOR(S): Fathalla, W.; Cajan, M.; Marek, J.; Pazdera, P.
CORPORATE SOURCE: Dep. Org. Chem., Faculty Science, Masaryk Univ., Brno, Czech Rep.
SOURCE: Molecules [online computer file] (2001), 6(7), 588-602
CODEN: MOLEFW; ISSN: 1420-3049
URL: <http://www.mdpi.org/molecules/papers/60700588.pdf>
PUBLISHER: Molecular Diversity Preservation International
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:183778


AB 1-Substituted-3-(2-phenylquinazolin-4-yl) thioureas were produced by an intramol. cycloaddn. reaction of 1-substituted-3-[(2-cyanophenylimino)phenylmethyl] thioureas. These compds. in turn were prepared by the reaction of N-(2-cyanophenyl)benzimidoyl isothiocyanate with primary amines. The structures were confirmed by FTIR, 1H-NMR, 13C-NMR, mass spectroscopy and x-ray crystallog.

IT 400053-06-7P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of (phenylquinazolinyl) thioureas by intramol. cycloaddn. reaction of [(cyanophenylimino)phenylmethyl] thioureas)


RN 400053-06-7 CAPLUS
CN Thiourea, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




IT 400053-01-2P 400053-02-3P 400053-03-4P
 400053-04-5P 400053-05-6P 400053-07-8P
 400053-08-9P 400053-09-0P 400053-10-3P
 400053-11-4P 400053-12-5P 400053-13-6P
 400053-14-7P 400053-15-8P 400053-16-9P
 400053-17-0P 400053-18-1P 400053-19-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (phenylquinazolinyl) thioureas by intramol. cycloaddn.
 reaction of [(cyanophenylimino)phenylmethyl] thioureas)
 RN 400053-01-2 CAPLUS
 CN Thiourea, N-butyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-02-3 CAPLUS
 CN Thiourea, N-(phenylmethyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-03-4 CAPLUS
 CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-2-propen-1-yl- (CA INDEX NAME)




RN 400053-04-5 CAPLUS
 CN Thiourea, N-(2-methylpropyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 400053-05-6 CAPLUS
 CN Thiourea, N-cyclohexyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-07-8 CAPLUS
 CN Thiourea, N-(4-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-08-9 CAPLUS

CN Thiourea, N-(3-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-09-0 CAPLUS

CN Thiourea, N-(2-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-10-3 CAPLUS

CN Thiourea, N-(4-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-11-4 CAPLUS

CN Thiourea, N-(4-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-12-5 CAPLUS

CN Thiourea, N-(3-nitrophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-13-6 CAPLUS

CN Thiourea, N-(4-chlorophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-14-7 CAPLUS

CN Thiourea, N-1-naphthalenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400053-15-8 CAPLUS

CN Thiourea, N-2-naphthalenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 400053-16-9 CAPLUS


CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-2-pyridinyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 400053-17-0 CAPLUS

CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-tricyclo[3.3.1.1.3,7]dec-1-yl- (CA INDEX NAME)




RN 400053-18-1 CAPLUS

CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-tricyclo[4.3.1.1.3,8]undec-3-yl- (CA INDEX NAME)




RN 400053-19-2 CAPLUS
 CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-(tricyclo[3.3.1.1.3,7]dec-1-ylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 65 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:727295 CAPLUS
 DOCUMENT NUMBER: 136:183777
 TITLE: One-pot quinazolin-4-ylidenethiourea synthesis via N-(2-cyanophenyl)benzimidoyl isothiocyanate
 AUTHOR(S): Fathalla, Walid M.; Cajan, Michal; Marek, Jaromir; Pazdera, Pavel
 CORPORATE SOURCE: Dep. Org. Chem., Faculty of Science, Masaryk Univ., Brno, Czech Rep.
 SOURCE: Molecules [online computer file] (2001), 6(7), 574-587
 CODEN: MOLEFW; ISSN: 1420-3049
 URL: <http://www.mdpi.org/molecules/papers/60700574.pdf>
 PUBLISHER: Molecular Diversity Preservation International
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:183777
 GI




AB 1,1-Disubstituted 3-(2-phenyl-3H-quinazolin-4-ylidene)thioureas (I; NR2 = morpholino, piperidino, 1-pyrrolidinyl, 4-methyl-1-piperazinyl, NBu2, NPh2) were synthesized in a one pot reaction of N-(2-cyanophenyl)benzimidoyl isothiocyanate with secondary amines. The products underwent transamination reactions.

IT 400604-99-1P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (one-pot quinazolin-4-ylidenethiourea synthesis via
 N-(2-cyanophenyl)benzimidoyl isothiocyanate)

RN 400604-99-1 CAPLUS


CN 1-Pyrrolidinecarbothioamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



IT 400604-97-9P 400604-98-0P 400605-00-7P
 400605-01-8P 400605-02-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (one-pot quinazolin-4-ylidenethiourea synthesis via
 N-(2-cyanophenyl)benzimidoyl isothiocyanate)


RN 400604-97-9 CAPLUS

CN 4-Morpholinecarbothioamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400604-98-0 CAPLUS


CN 1-Piperidinecarbothioamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 400605-00-7 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-methyl-N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 400605-01-8 CAPLUS
 CN Thiourea, N,N-dibutyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 400605-02-9 CAPLUS
 CN Thiourea, N,N-diphenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 66 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:661418 CAPLUS
 DOCUMENT NUMBER: 135:216011
 TITLE: preparation of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
 INVENTOR(S): Basford, Patricia Ann; Hodgson, Paul Blaise
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064672	A1	20010907	WO 2001-IB244	20010223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2398963	A1	20010907	CA 2001-2398963	20010223 <--
CA 2398963	C	20061024		
BR 2001008910	A	20021224	BR 2001-8910	20010223 <--
EP 1268468	A1	20030102	EP 2001-908029	20010223 <--
EP 1268468	B1	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000006	A2	20030528	HU 2003-6	20010223 <--
HU 2003000006	A3	20060130		
JP 2003525289	T	20030826	JP 2001-563512	20010223 <--
JP 3857919	B2	20061213		
AT 253570	T	20031115	AT 2001-908029	20010223 <--
PT 1268468	T	20040130	PT 2001-908029	20010223
EE 200200496	A	20040216	EE 2002-496	20010223
ES 2208565	T3	20040616	ES 2001-908029	20010223
NZ 519672	A	20040625	NZ 2001-519672	20010223
AU 779118	B2	20050106	AU 2001-35888	20010223
US 20020010188	A1	20020124	US 2001-797112	20010301 <--
US 6683085	B2	20040127		
BG 106869	A	20021229	BG 2002-106869	20020624 <--
ZA 2002007016	A	20030902	ZA 2002-7016	20020902 <--

NO 2002004195	A	20020903	NO 2002-4195	20020903 <--
MX 2002PA08665	A	20030224	MX 2002-PA8665	20020903 <--
HK 1053655	A1	20051209	HK 2003-106016	20030822

PRIORITY APPLN. INFO.:

GB 2000-5200	A	20000303
GB 2000-15900	A	20000628
US 2000-192912P	P	20000329
US 2000-218188P	P	20000714
WO 2001-IB244	W	20010223

AB The polymorphs of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate (I) are disclosed. The invention also relates to substantially pure anhydrous crystalline

polymorphic forms of the free base. The compds. are particularly useful in the treatment of benign prostatic hyperplasia. Thus, polymorphs I were prepared by the reaction of 4-amino-6,7-dimethoxy-2-chloro-5-(2-pyridyl)quinazoline with N-(1,2,3,4-tetrahydro-5-isoquinolyl)methanesulfonamide-HCl in the presence of Et3N.

IT 358632-25-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminomethanesulfonamido(tetrahydroisoquinolyl)(pyridyl)quinazoline mesylate and polymorphs)


RN 358632-25-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 210538-44-6


CMF C25 H26 N6 O4 S




CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 210538-44-6P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminomethanesulfonamido(tetrahydroisoquinolyl)(pyridyl)quina
 zoline mesylate and polymorphs)
 RN 210538-44-6 CAPLUS
 CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-
 quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 67 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:600056 CAPLUS
 DOCUMENT NUMBER: 136:167344
 TITLE: Synthesis of some new substituted quinazoline
 derivatives and their antimicrobial screening
 AUTHOR(S): Abdel-Hamide, Sami G.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, College of
 Pharmacy, King Saud University, Riyadh, 11451, Saudi
 Arabia
 SOURCE: Saudi Pharmaceutical Journal (2001), 9(2),
 72-84
 CODEN: SPJOEM; ISSN: 1319-0164
 PUBLISHER: Saudi Pharmaceutical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:167344
 AB A new series of 4-oxo-6-iodo-3H-quinazoline and its fused heterocyclic
 analogs were prepared and screened for their antimicrobial activity. Some
 of the compds. showed remarkable broad spectrum antimicrobial activity.
 The fused heterocycles 1,2,4-triazino[3,4-c]quinazoline,
 1,2,4-triazolo[2,3-c]quinazoline and pyrazolo[1,5-c]quinazoline proved to
 contribute for activity. The detailed synthesis and their antimicrobial
 screening are reported.
 IT 257624-41-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antimicrobial activity of quinazolines)

RN 257624-41-2 CAPLUS
CN Quinazoline, 4-hydrazinyl-6-iodo-2-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 68 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:594376 CAPLUS
DOCUMENT NUMBER: 135:185453
TITLE: Pharmaceutical combinations for treating lower urinary tract disfunctions
INVENTOR(S): Wyllie, Michael Grant
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1123705	A1	20010816	EP 2001-301085	20010207 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TW 287448	B	20071001	TW 2001-90102380	20010205
HU 2001000586	A2	20011128	HU 2001-586	20010206 <--
ZA 2001001012	A	20020806	ZA 2001-1012	20010206 <--
CA 2334460	A1	20010809	CA 2001-2334460	20010207 <--
US 20010044438	A1	20011122	US 2001-778290	20010207 <--
NZ 509807	A	20020927	NZ 2001-509807	20010208 <--
KR 2004032141	A	20040414	KR 2004-20671	20040326
US 20050222165	A1	20051006	US 2005-140723	20050531
US 7138405	B2	20061121		
AU 2006202176	A1	20060615	AU 2006-202176	20060523
PRIORITY APPLN. INFO.:				
			US 2000-181310P	P 20000209
			AU 2001-18329	A3 20010207
			US 2001-778290	A1 20010207
			KR 2001-6417	A3 20010209
AB	Pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia in men contain an α -adrenoceptor antagonist and a muscarinic antagonist. The combinations of the invention are particularly suitable for treating moderate or severe lower urinary tract symptoms. Thus, tablet contained doxazosin mesylate 4.05, microcryst. cellulose 125.28, lactose 66.67, sodium starch glycolate 2.00, and Mg stearate 2.00% by weight			
IT	210538-44-6 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical combinations for treating lower urinary tract disfunctions)			
RN	210538-44-6 CAPLUS			
CN	Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-			


quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 69 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:521903 CAPLUS
 DOCUMENT NUMBER: 135:107335
 TITLE: Preparation of 2,4-diaminoquinazolines for treating a patient having precancerous lesions
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
 SOURCE: U.S., 44 pp., Cont. of U.S. Ser. No. 477,227, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6262059	B1	20010717	US 1998-55829	19980406 <--
US 20010031760	A1	20011018	US 2001-850685	20010507 <--
PRIORITY APPLN. INFO.:			US 1995-477227	B1 19950607
			US 1998-55829	A1 19980406
OTHER SOURCE(S):	MARPAT 135:107335			
GI				



AB The title compds. [I; R1-R4 = H, halo, alkoxy, CN; R5, R6 = piperidino; R7 = H, alkyl; R8 = (un)substituted CH2Ph; Y = (CH2)q; q = 0-8], useful for the treatment of patients having precancerous lesions (no data), were prepared and formulated. Thus, reacting 2-chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline with morpholine in iso-PrOH


afforded 80% I [R1, R3, R4 = H; R2 = CN; NR5R6 = morpholino; R7 = H; Y = a bond; R8 = 3,4-methylenedioxybenzyl]. The compds. I are also useful to inhibit growth of neoplastic cells.

IT 150451-88-0P 150451-89-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-diaminoquinazolines for treating a patient having precancerous lesions)


RN 150451-88-0 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 150451-89-1 CAPLUS

CN 6-Quinazolinecarbonitrile, 4-[(1,3-benzodioxol-5-ylmethyl)amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 70 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:471952 CAPLUS

DOCUMENT NUMBER: 135:56058

TITLE: Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy, and combinations with apoptosis-inducing agents

INVENTOR(S): Mignani, Serge; Debussche, Laurent; Maratrat, Michel

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1110552	A1	20010627	EP 1999-403247	19991222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			EP 1999-403247	19991222
OTHER SOURCE(S): MARPAT 135:56058				

AB The invention provides a combination product comprising at least one compound with affinity for the mitochondrial benzodiazepine receptor, and to at least one apoptosis-inducing agent for simultaneous or sep. use or for use spread out over time, which is intended for the treatment of cancer. Another aspect of the invention relates to the use of the the compound and/or of the combination product for the manufacture of a medicinal product intended to facilitate the induction of apoptosis. Preparation of the dextrorotatory isomer of 2-methyl-3-(2-phenyl-4-quinazolinyl)propionic acid is described.


IT 189064-74-2 189064-76-4 228118-83-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compound with affinity for mitochondrial benzodiazepine receptor for cancer therapy, and combination with apoptosis-inducing agent)


RN 189064-74-2 CAPLUS

CN Glycine, N-[6-chloro-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 189064-76-4 CAPLUS

CN Glycine, N-[6-bromo-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 228118-83-0 CAPLUS

CN Glycine, N-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]- (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 71 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:380582 CAPLUS
 DOCUMENT NUMBER: 134:366898
 TITLE: Novel pyrimidine-, quinazoline-, and purine-based thiazolidinedione derivatives as antidiabetic agents
 INVENTOR(S): Mourelle Mancini, Marisabel; Del Castillo Nieto, Juan Carlos; De Ramon Amat, Elisabet
 PATENT ASSIGNEE(S): Vita-Invest, S. A., Spain
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036416	A1	20010525	WO 2000-ES432	20001115 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ES 2156574	A1	20010616	ES 1999-2533	19991118 <--
ES 2156574	B1	20020201		
CA 2391913	A1	20010525	CA 2000-2391913	20001115 <--
AU 2001012815	A	20010530	AU 2001-12815	20001115 <--
AU 770045	B2	20040212		
BR 2000015613	A	20020723	BR 2000-15613	20001115 <--
EP 1231211	A1	20020814	EP 2000-974559	20001115 <--
EP 1231211	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003478	A2	20030228	HU 2002-3478	20001115 <--
JP 2003514817	T	20030422	JP 2001-538905	20001115 <--
AT 241622	T	20030615	AT 2000-974559	20001115 <--
EE 200200254	A	20030616	EE 2002-254	20001115 <--
PT 1231211	T	20030930	PT 2000-974559	20001115 <--
NZ 519264	A	20031031	NZ 2000-519264	20001115 <--
ES 2199878	T3	20040301	ES 2000-974559	20001115
AP 1330	A	20041125	AP 2002-2512	20001115
IN 2002MN00607	A	20040228	IN 2002-MN607	20020513
BG 106699	A	20030228	BG 2002-106699	20020514 <--
NO 2002002336	A	20020709	NO 2002-2336	20020515 <--

ZA 2002003906	A	20040326	ZA 2002-3906	20020516
MX 2002PA05011	A	20031014	MX 2002-PA5011	20020517 <--
US 7001910	B1	20060221	US 2002-130576	20020517
IN 2005MN00155	A	20050923	IN 2005-MN155	20050223
IN 2005MN00232	A	20051202	IN 2005-MN232	20050328
PRIORITY APPLN. INFO.:			ES 1999-2533	A 19991118
			WO 2000-ES432	W 20001115
			IN 2002-MN607	A3 20020513
OTHER SOURCE(S):		MARPAT 134:366898		
GI				



AB The invention relates to compds. of general formula I, and to their possible pharmaceutically acceptable salts and tautomeric forms [wherein: R₁ = H, alkyl; R₂ = H, alkyl, halo, OR₅, SR₅, NR₅R₆, NO₂, Ph; R₃ = H, alkyl, halo, OR₅, SR₅, NR₅R₆, NO₂, Ph; R₄ = H, alkyl, halo, OR₅, NR₅R₆, Ph; or R₃R₄ = fused rings containing CH:CHCH:CH, N:CR₇NR₈, or NR₈CR₇:N; R₅, R₆ = H, alkyl; R₇ = H, NH₂; R₈ = H, alkyl, tetrahydropyran-2-yl, ribosyl]. The invention also relates to a method for obtaining said compds., and to their utilization as antidiabetic and hypolipidemic agents (by themselves or combined with other antidiabetic agents such as sulfonylureas or biguanides). The invention furthermore relates to utilization of the compds. in the treatment of complications associated with insulin resistance, such as hypertension, hyperuricemia, or other cardiovascular, metabolic, and endocrine disorders, or other disorders associated with diabetes. Over 20 synthetic examples are given. Thus, condensation of 5-[4-(2-methylaminoethoxy)benzyl]thiazolidine-2,4-dione with 2-amino-4,6-dichloropyrimidine in DMF at 80° gave 62% title compound II. In a test for reduction of blood glucose in diabetic mice, II gave 47% reduction at 1 mg/kg p.o., vs. only 38% by troglitazone at 100 mg/kg p.o.

IT 340742-41-8P, 5-[4-[2-[(Methyl)(2-phenylquinazolin-4-yl)amino]ethoxy]benzyl]thiazolidine-2,4-dione


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel pyrimidine-, quinazoline-, and purine-based thiazolidinedione derivs. as antidiabetic agents)


RN 340742-41-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-[methyl(2-phenyl-4-quinazolinyl)amino]ethoxy]phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 72 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:321158 CAPLUS
DOCUMENT NUMBER: 135:137456
TITLE: Quinazolines as cyclin dependent kinase inhibitors
AUTHOR(S): Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C.-H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P.
CORPORATE SOURCE: The DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(9), 1157-1160
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:137456
GI




AB Quinazolines have been identified as inhibitors of CDK4/D1 and CDK2/E. Aspects of the SAR were investigated using solution-phase, parallel synthesis. An X-ray crystal structure was obtained of quinazoline (I) bound in CDK2 and key interactions within the ATP binding pocket are defined.

IT 106185-26-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and activity of quinazolines as cyclin dependent kinase inhibitors)

RN 106185-26-6 CAPLUS

CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 73 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:235559 CAPLUS

DOCUMENT NUMBER: 134:266319

TITLE: CD40 function inhibitors containing (hetero)aryl compounds and their preparation

INVENTOR(S): Saito, Shoichi; Akane, Katsura; Fujimoto, Katsumi; Shiraishi, Akio; Kurakata, Shinichi; Maeda, Hiroaki; Tatsuta, Toru

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 139 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089452	A	20010403	JP 1999-267909	19990922 <--
PRIORITY APPLN. INFO.:			JP 1999-267909	19990922

OTHER SOURCE(S): MARPAT 134:266319
GI



AB Title inhibitors, useful for prevention and treatment of allergy, rheumatoid, autoimmune disease, and arteriosclerosis, contain aromatic compds. I [R1, R3, R4 = H, OH, halo, C1-15 alkyl(oxy), C1-15 alkylthio, (un)substituted (hetero)aryl, etc.; R2 = NO2, nitrile, CO2H, C2-6 alkoxy carbonyl; R1CCR2 may form (un)substituted (hetero)aryl; X, Y = N, CH] or their salts as active ingredients. Thus, MeOCPh:C(CO2Et)2 was refluxed with benzamidine HCl salt and NaH in EtOH for 5 h, evaporated, neutralized, extracted with AcOEt, the organic phase concentrated, and treated

with


POCl3 and morpholine to give 52% I (R1 = R4 = Ph, R2 = CO2Et, R3 = 4-morpholino, X = Y = N), which at 25 μ M inhibited 88% formation of IL-12.

IT 307544-21-4P 332071-25-7P 332071-30-4P
332071-31-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)aryl compds. as CD40 function inhibitors)


RN 307544-21-4 CAPLUS

CN Quinazoline, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 332071-25-7 CAPLUS


CN Quinazoline, 2-phenyl-4-(1-piperidinyl)- (CA INDEX NAME)



RN 332071-30-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-(2-phenyl-4-quinazolinyl)-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RN 332071-31-5 CAPLUS
 CN Quinazoline, 2-phenyl-4-(1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

L7 ANSWER 74 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:218638 CAPLUS
 DOCUMENT NUMBER: 135:122351
 TITLE: The oxidative rearrangement of furan-2-carboximidamides: preparation and properties of 2-acylaminofurans
 AUTHOR(S): Bobosikova, Maria; Clegg, William; Coles, Simon J.; Dandarova, Miloslava; Hursthouse, Michael B.; Kiss, Tibor; Krutosikova, Alzbeta; Liptaj, Tibor; Pronayova, Nad'a; Ramsden, Christopher A.
 CORPORATE SOURCE: Department of Organic Chemistry and Central Research Laboratories, Slovak University of Technology, Bratislava, SK 812 37, Slovakia
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1 (2001), (7), 680-689
 CODEN: JCSPCE; ISSN: 1472-7781
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:122351


AB Oxidation of furan-2-carboximidamides by (dicarboxyiodo)benzenes gives N1-acyl-N1-(2-furyl)ureas via rearrangement to a carbodiimide. Thermolysis of eleven ureas gave the corresponding 2-acylamino-furans which cannot be made from the free amines owing to their high instability. When oxidation of the corresponding benzo[b]furan derivs. was investigated a new type of product was isolated, in addition to the expected ureas, and these were shown to be benzo[4,5]furo[2,3-d]pyrimidine derivs. The mechanism of formation of these products must involve reaction of the carbodiimide intermediate with the amidine precursor and cyclization of the resulting guanidine derivs. The corresponding tetraphenylguanidine was prepared and underwent thermal cyclization but the quinazoline derivative obtained was shown to be formed via an alternative cyclization mechanism. The structures of cyclization products were confirmed by X-ray crystallog. N-(2-Furyl)acetamide readily undergoes cycloaddn. reactions with electron-deficient alkynes to give phenols after spontaneous ring opening. Observed regioselectivity is in agreement with the results of AM1 MO calcns. Reaction of N-(2-furyl)acetamide with Lawesson's reagent gave the thioamide.

IT 40288-70-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-acylamino-furans via oxidative rearrangement of furan-2-carboximidamides)

RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 75 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:177412 CAPLUS

DOCUMENT NUMBER: 135:40402

TITLE: Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF- α production and T Cell proliferation

AUTHOR(S): Tobe, M.; Isobe, Y.; Tomizawa, H.; Matsumoto, M.; Obara, F.; Nagasaki, T.; Hayashi, H.

CORPORATE SOURCE: Pharmaceuticals and Biotechnology Laboratory, Japan Energy Corporation, Toda-shi, Saitama, 335-8502, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(4), 545-548



CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB We synthesized 4-chlorophenethylaminoquinazoline derivs. and evaluated their inhibitory activities toward both TNF- α production and T cell proliferation responses. I, with a piperazine ring at the C(7)-position of the quinazoline ring, was more potent than the lead compound II. A smaller N-substituent in the piperazine ring was required for inhibition of TNF- α production

IT 344455-16-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and structure-activity relationships of quinazoline derivs. as dual-acting compds. with inhibitory activities toward both TNF- α production and T Cell proliferation)

RN 344455-16-9 CAPLUS

CN 4-Quinazolinamine, N-[2-(4-chlorophenyl)ethyl]-2-phenyl- (CA INDEX NAME)



L7 ANSWER 76 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:168635 CAPLUS

DOCUMENT NUMBER: 135:174649

TITLE: Biological activity of some 4-anilinoquinazolines:
cytotoxic, genotoxic and antiprotease effects,
induction of necrosis and changes of actin
cytoskeletonAUTHOR(S): Jantova, S.; Urbancikova, M.; Maliar, T.; Mikulasova,
M.; Rauko, P.; Cipak, L'; Kubikova, J.; Stankovsky,
S.; Spirkova, K.CORPORATE SOURCE: Department of Biochemistry and Microbiology, Faculty
of Chemical Technology, Slovak University of
Technology, Bratislava, 812 37, Slovakia

SOURCE: Neoplasma (2001), 48(1), 52-60

CODEN: NEOLA4; ISSN: 0028-2685

PUBLISHER: VEDA

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Fourteen substituted 4-anilinoquinazolines have been tested for cytotoxic effect and structure activity relationships. The most active derivs. were substituted by chlorine or bromine group in the aromatic ring, in the pyrimidine ring by morpholine group and in the aniline skeleton by nitro group in position 4 or 2. Derivs. 6-bromo-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline, 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline, 2-(morpholin-1-yl)-4-(4'-bromoanilino)-quinazoline and 6-chloro-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline inhibited growth of tumor cell lines HeLa, B16 and L1210. Mutagenic data provided by Ames test showed, that the compds. 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline and 2-(morpholin-1-yl)-4-(4'-bromoanilino)quinazoline did not exhibit the mutagenic effect, whereas the compds. 6-bromo-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline and 6-chloro-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline increased slightly the number of revertants of the strain TA 98 without metabolic activation. Concentration 26 $\mu\text{mol/L}$ of 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline induced necrosis of tumor cells B16. Concentration 5.2 $\mu\text{mol/l}$ induced a significant increase of filamentous actin in the transformed HepG2 cells. Derivs. 6-bromo-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline, 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline, 2-(morpholin-1-yl)-4-(4'-bromoanilino)quinazoline and 6-chloro-2-(morpholin-1-yl)-4-(4'-nitroanilino)quinazoline exhibited antiprotease effect on plasmin. This results could be relevant for the anticancer properties of these compds.

IT 40288-70-8 94078-50-9 94078-54-3


94078-57-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(biol. activity of 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton)

RN 40288-70-8 CAPLUS


CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 94078-50-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 94078-54-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-chlorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)



RN 94078-57-6 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 77 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:151153 CAPLUS

DOCUMENT NUMBER: 134:340476

TITLE: A convenient synthesis of 4-aminoquinazoline derivatives

AUTHOR(S): Shibuya, Isao; Gama, Yasuo; Shimizu, Masao

CORPORATE SOURCE: National Institute of Materials and Chemical Research, Tsukuba, 305-8565, Japan

SOURCE: Heterocycles (2001), 55(2), 381-386

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:340476


AB 2-Substituted 4-(N,N-disubstituted amino)quinazolines were newly synthesized through cyclodesulfurization of N-(thiocarbonyl)arylamines with AgClO₄ in the presence of N,N-disubstituted cyanamides.

IT 139474-19-4P 282538-15-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of quinazolinamines)

RN 139474-19-4 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 282538-15-2 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl-, perchlorate (1:1) (CA INDEX NAME)

CM 1

CRN 139474-19-4


CMF C16 H15 N3



CM 2

CRN 7601-90-3

CMF C1 H O4



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 78 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:58784 CAPLUS

DOCUMENT NUMBER: 134:252311

TITLE: Traceless Solid-Phase Synthesis of 2,4-Diaminoquinazolines

AUTHOR(S): Wilson, Lawrence J.

CORPORATE SOURCE: Healthcare Research Center, Procter & Gamble Pharmaceuticals, Mason, OH, 45040, USA

SOURCE: Organic Letters (2001), 3(4), 585-588

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:252311


AB The solid-phase synthesis of 2,4-diaminoquinazolines is presented. The chemical involves the sequential condensation of 2-aminobenzonitriles and amines starting from an acyl isothiocyanate resin via a traceless cleavage and cyclization. The α -1 antagonist prazosin was synthesized, as well as several other examples, in good yields and purity.

IT 331258-44-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(traceless solid-phase synthesis of diaminoquinazolines)


RN 331258-44-7 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 79 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:44770 CAPLUS
DOCUMENT NUMBER: 134:252299
TITLE: Thiazole and thiadiazole analogs as a novel class of adenosine receptor antagonists
AUTHOR(S): van Muijlwijk-Koezen, Jacqueline E.; Timmerman, Hendrik; Vollinga, Roeland C.; von Kuenzel, Jacobien Frijtag; de Groote, Miriam; Visser, Sven; IJzerman, Adriaan P.
CORPORATE SOURCE: Department of Pharmacochimistry Division of Medicinal Chemistry Leiden/Amsterdam Center for Drug Research, Vrije Universiteit, Amsterdam, 1081 HV, Neth.
SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 749-762
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:252299
GI



AB Novel classes of heterocyclic compds., e.g., I (X = CH, Y = N, R = Ph, cyclopentyl, 3-ClC₆H₄, etc.; X = N, Y = CH, R = 4-ClC₆H₄, Ph, 3-Me-4-MeOC₆H₃, etc.), as adenosine antagonists were developed based on a template approach. Structure-affinity relationships revealed insights for extended knowledge of the receptor-ligand interaction. The authors replaced the bicyclic heterocyclic ring system of earlier described isoquinoline and quinazoline adenosine A₃ receptor ligands by several monocyclic rings and investigated the influence thereof on adenosine receptor affinity. The thiazole or thiadiazole derivs. seemed most promising, so the authors continued their investigations with these two classes of compds. The large difference between a pyridine and isoquinoline ring in binding adenosine A₁ and A₃ receptors showed the importance of the second ring of the isoquinoline ligands. The authors prepared several N-[4-(2-pyridyl)thiazol-2-yl]benzamides, and these compds. showed adenosine affinities in the micromolar range. Most surprising in the series of the N-[4-(2-pyridyl)thiazol-2-yl]amides were the retained adenosine affinities by introduction of a cyclopentanamide instead of the benzamide. A second series of compds., the thiadiazolobenzamide series of compds., revealed potent and selective adenosine receptor antagonists, especially N-(3-phenyl-1,2,4-thiadiazol-5-yl)-4-hydroxybenzamide I (LUF5437, II) (X = N; R = 4-HOC₆H₄) showing a K_i value of 7 nM at the adenosine A₁ receptor and N-(3-phenyl-1,2,4-thiadiazol-5-yl)-4-methoxybenzamide I (LUF5417, III) (X = N; R = 4-MeOC₆H₄) with a K_i value of 82 nM at the adenosine A₃ receptor. 4-Hydroxybenzamide II is the most potent adenosine A₁ receptor antagonist of this new class of compds. Structure-affinity relationships showed the existence of a steric restriction at the para-position of the benzamide ring for binding adenosine A₁ and A₃

receptors. The electronic nature of the 4-substituents played an important role in binding the adenosine A3 receptor. Cis- and trans-4-substituted cyclohexyl derivs. were made next to the 4-substituted benzamide analogs. The authors used them to study the proposed specific interaction between the adenosine A1 receptor and the 4-hydroxy group of this class of thiadiazolo compds., as well as a suggested special role for the 4-methoxy group in binding the A3 receptor. Both the adenosine A1 and A3 receptor slightly preferred the trans-analogs over the cis-analogs, while all compds. showed low affinities at the adenosine A2A receptor. The investigations provided the potent and highly selective adenosine A1 antagonist N-(3-phenyl-1,2,4-thiadiazol-5-yl)-trans-4-hydroxycyclohexanamide (VUF5472) showing a Ki value of 20 nM. A third series of compds. was formed by urea analogs, N-substituted with thiazolo and thiadiazolo heterocycles. The SAR of this class of compds. was not commensurate with the SAR of the previously described quinazoline urea. On the basis of these findings the authors suggest the existence of a special interaction between adenosine receptors and a region of high electron d. positioned between the thia(dia)zole ring and phenyl(pyridyl) ring. Mol. electrostatic potential contour plots showed that for this reason the ligands need either a thiadiazole ring instead of a thiazole or a 2-pyridyl group instead of a Ph. The derived novel classes of antagonists will be useful for a better understanding of the mol. recognition at the adenosine receptors.


IT 94078-82-7P 331472-24-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, adenosine antagonist activity, and structure-activity relationship of thiazole and thiadiazole analogs)


RN 94078-82-7 CAPLUS

CN Benzamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 331472-24-3 CAPLUS

CN Benzamide, 4-methoxy-N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 80 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:10086 CAPLUS

DOCUMENT NUMBER: 134:86277

TITLE: 1,3-Diazines with platelet-derived growth factor receptor inhibitory activity

INVENTOR(S): Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: U.S., 127 pp., Cont.-in-part of PCT 9814431.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6169088	B1	20010102	US 1998-88199	19980601 <--
WO 9814431	A1	19980409	WO 1997-JP3510	19971001 <--
W: AU, BG, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6207667	B1	20010327	US 2000-481544	20000112 <--
US 20020068734	A1	20020606	US 2000-734918	20001213 <--
US 6472391	B2	20021029		
PRIORITY APPLN. INFO.:			JP 1996-260743	A 19960110
			WO 1997-JP3510	A2 19971001
			US 1998-88199	A3 19980601
			US 2000-481544	A3 20000112

OTHER SOURCE(S): MARPAT 134:86277

GI




AB 1,3-Diazines and related N heterocycles [I; wherein V = O or S; W = 1,4-piperazinediyl or 1,4-homopiperazinediyl which may be substituted with unsubstituted alkyl on the ring; X = N or CR⁹; Y = N or CR⁸; Z = N or CR⁷, with at least one of X, Y and Z being N; R¹ = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl, etc.; R² = substituted alkyl, (un)substituted cycloalkyl, aryl, heterocyclyl, etc.; R³, R⁴, R⁵, R⁶ = H, halo, (un)substituted alkyl, NO₂, cyano, (un)substituted OH or NH₂, etc.; R⁷, R⁸ = R¹ groups, halo, etc.; R⁹ = H, CO₂H or derivs.] and their pharmacol. acceptable salts are prepared These compds. inhibit the phosphorylation of PDGF receptors and the abnormal proliferation or migration of cells, and so are effective in preventing or treating cell proliferative diseases such as arteriosclerosis, vascular reocclusion diseases, cancer, and glomerulosclerosis. Thus, 6,7-dimethoxy-4-(1-piperazinyl)quinazoline reacted with Ph isocyanate in refluxing EtOH to give invention compound II [R = CONHPh] in 44% isolated yield. The analog II [R = Q] showed an IC₅₀ of 0.03 μ M for inhibiting the phosphorylation of PDGF receptor in vitro. Pharmaceutical formulations, e.g. tablets containing II [R = N-(p-nitrophenyl)carbamoyl], were prepared

IT 205255-49-8P 205255-50-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-diazines with platelet-derived growth factor receptor inhibitory activity)


RN 205255-49-8 CAPLUS

CN 1-Piperazinecarboxamide, N-(4-nitrophenyl)-4-(2-phenyl-4-quinazolinyl)-
(CA INDEX NAME)



RN 205255-50-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (CA INDEX NAME)




IT 181115-48-0 205259-64-9 205259-65-0

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 1,3-diazines with platelet-derived growth factor receptor inhibitory activity)

RN 181115-48-0 CAPLUS


CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)



RN 205259-64-9 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)




RN 205259-65-0 CAPLUS
 CN Quinazoline, 4-(hexahydro-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-2-phenyl-
 (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 81 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:882543 CAPLUS
 DOCUMENT NUMBER: 134:252285
 TITLE: Some unusual reactions of 3-(phenylamino)isoxazol-
 5(2H)-ones
 AUTHOR(S): Khalafy, J.; Prager, R. H.
 CORPORATE SOURCE: Chemistry Department, Urmia University, Urmia, 57154,
 Iran
 SOURCE: Journal of Sciences, Islamic Republic of Iran (
 2000), 11(1), 32-38
 CODEN: JSIIEN; ISSN: 1016-1104
 PUBLISHER: National Center for Scientific Research
 DOCUMENT TYPE: Journal

LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:252285
 AB 3-(Phenylamino)isoxazol-5(2H)-ones substituted on nitrogen with an isoquinoline or quinazoline group react with tertiary amine bases to give imidazo-annelated compds. When the N-substituent is a nitropyridine, 2-aminoindole derivs. are formed instead. Evidence is presented that the reactions proceed by initial addition of the tertiary amine to C-4.
 IT 153704-59-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (unusual reactions of 3-(phenylamino)isoxazol-5(2H)-ones)
 RN 153704-59-7 CAPLUS
 CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-3-methyl-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



IT 331229-33-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (unusual reactions of 3-(phenylamino)isoxazol-5(2H)-ones)
 RN 331229-33-5 CAPLUS
 CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-5-oxo-3-(phenylamino)-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 82 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:872652 CAPLUS
 DOCUMENT NUMBER: 134:202418
 TITLE: Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines

AUTHOR(S): Wright, S. W.; Hageman, D. L.; McClure, L. D.; Carlo, A. A.; Treadway, J. L.; Mathiowetz, A. M.; Withka, J. M.; Bauer, P. H.

CORPORATE SOURCE: Pfizer Central Research, Groton, CT, 06340, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), Volume Date 2001, 11(1), 17-21
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Anilinoquinazolines currently of interest as inhibitors of tyrosine kinases have been found to be allosteric inhibitors of the enzyme fructose 1,6-bisphosphatase. These represent a new approach to inhibition of F16BPase and serve as leads for further drug design. Enzyme inhibition is achieved by binding at an unidentified allosteric site.

IT 328528-80-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(allosteric inhibition of fructose bisphosphatase by anilinoquinazolines)

RN 328528-80-9 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-6,7-diethoxy-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 83 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:861644 CAPLUS

DOCUMENT NUMBER: 134:29705

TITLE: Preparation of squaric acid derivatives as cell adhesion molecules

INVENTOR(S): Langham, Barry John; Alexander, Rikki Peter; Head, John Clifford; Linsley, Janeen Marsha; Porter, John Robert; Archibald, Sarah Catherine; Warrelow, Graham John

PATENT ASSIGNEE(S): Celltech Chiroscience Limited, UK

SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073260	A1	20001207	WO 2000-GB2020	20000526 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


US 6518283 B1 20030211 US 2000-579317 20000525 <--
CA 2375218 A1 20001207 CA 2000-2375218 20000526 <--
EP 1181266 A1 20020227 EP 2000-935341 20000526 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003500467 T 20030107 JP 2000-621327 20000526 <--
AU 776704 B2 20040916 AU 2000-50889 20000526
US 20030162799 A1 20030828 US 2002-319272 20021213 <--

PRIORITY APPLN. INFO.: GB 1999-12640 A 19990528
GB 2000-2858 A 20000208
US 2000-579317 A3 20000525
WO 2000-GB2020 W 20000526

OTHER SOURCE(S): MARPAT 134:29705
GI




I

AB Squaric acid derivs. I [R1 is an integrin binding group; R2 is a hydrogen atom or a C1-6 alkyl group; L1 is a covalent bond or a linker atom or group; n = 0, 1; Alk1 is an optionally substituted aliphatic chain; R3 is H or an optionally substituted heteroaliph., cycloaliph., heterocycloaliph., polycycloaliph., polyheterocycloaliph., aromatic or heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepared as inhibitors of the binding of integrins to their ligands. Thus, treatment of Et (S)-3-(4-aminophenyl)-2-(tert-butoxycarbonylamino)propionate with 3,5-dichloro-4-pyridinecarboxylic acid, deprotection, reaction with 3,4-diisopropoxy-3-cyclobutene-1,2-dione, propylamination, and saponification afforded (S)-3-[4-(3,5-dichloro-4-pyridylcarboxamido)phenyl]-2-(2-propylamino-3,4-dioxocyclobut-1-enylamino)propanoic acid. Compds. of the invention in which R1 is an $\alpha 4$ integrin binding group generally have IC50 values <1 μ M in the $\alpha 4\beta 1$ and $\alpha 4\beta 7$ assays.

IT 312292-67-4P 312292-68-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of squaric acid derivs. as cell adhesion mols.)

RN 312292-67-4 CAPLUS
CN L-Phenylalanine, N-[2-(1-methylethoxy)-3,4-dioxo-1-cyclobuten-1-yl]-4-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 312292-68-5 CAPLUS

CN L-Phenylalanine, N-[2-(diethylamino)-3,4-dioxo-1-cyclobuten-1-yl]-4-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 312292-69-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of squaric acid derivs. as cell adhesion mols.)

RN 312292-69-6 CAPLUS


CN L-Phenylalanine, N-[2-(diethylamino)-3,4-dioxo-1-cyclobuten-1-yl]-4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




IT 312295-46-8P 312295-47-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of squaric acid derivs. as cell adhesion mols.)
 RN 312295-46-8 CAPLUS
 CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[(2-phenyl-4-
 quinazolinyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 312295-47-9 CAPLUS
 CN L-Phenylalanine, 4-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA
 INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

L7 ANSWER 84 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:803540 CAPLUS

DOCUMENT NUMBER: 134:147558

TITLE: Synthesis of 4-Arylaminoquinazolines and
2-Aryl-4-arylaminoquinazolines from
2-Aminobenzonitrile, Anilines and Formic Acid or
Benzaldehydes

AUTHOR(S): Szczepankiewicz, W.; Suwinski, J.; Bujok, R.

CORPORATE SOURCE: Institute of Organic Chemistry and Technology,
Silesian University of Technology, Gliwice, 44-100,
Pol.

SOURCE: Tetrahedron (2000), 56(47), 9343-9349

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:147558

AB 2-Aminobenzonitrile treated with anilines in the presence of aluminum
chloride gave resp. 2-amino-N-arylbenzamidines. 4-Arylaminoquinazolines
lacking a substituent at the 2 position were obtained directly by heating
2-amino-N-arylbenzamidines in formic acid; in similar conditions other
carboxylic acids did not react with the amidines. The latter when treated
with aldehydes afforded 2-aryl-4-arylmino-1H-2,3-dihydroquinazolines
readily oxidizable by potassium permanganate to 2-aryl-4-
arylaminoquinazolines.

IT 40288-70-8P 324521-78-0P 324521-79-1P

324521-80-4P 324521-81-5P 324521-82-6P


324521-83-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of (aryl)aminoquinazolines from aminobenzonitrile, anilines and
formic acid or benzaldehydes)


RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 324521-78-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-phenyl- (CA INDEX NAME)




RN 324521-79-1 CAPLUS

CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-phenyl- (CA INDEX NAME)




RN 324521-80-4 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-2-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 324521-81-5 CAPLUS

CN 4-Quinazolinamine, N-(2-bromophenyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 324521-82-6 CAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 324521-83-7 CAPLUS
 CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 85 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:784873 CAPLUS

DOCUMENT NUMBER: 134:222685

TITLE: Synthesis of some new quinazoline derivatives

AUTHOR(S): Abdel-Hamide, S. G.

CORPORATE SOURCE: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

SOURCE: Indian Journal of Heterocyclic Chemistry (2000), 10(1), 59-64

CODEN: IJCHEI; ISSN: 0971-1627

PUBLISHER: Prof. R. S. Varma

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:222685


AB A series of 4-(3H)quinazolinones and imidazoquinazoline, pyrimidoquinazoline, triazoloquinazoline, and triazinoquinazoline derivs. have been synthesized starting from 2-phenyl-6-iodo-3,1-benzoxazin-4-one. The structures of all the products were established on the basis of elemental analyses and spectral data.

IT 257624-41-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of some new quinazoline derivs.)

RN 257624-41-2 CAPLUS

CN Quinazoline, 4-hydrazinyl-6-iodo-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 86 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:780209 CAPLUS

DOCUMENT NUMBER: 134:56895

TITLE: Synthesis and antimicrobial activities of novel sugar (2-phenylquinazolin-4-yl)hydrazones and their osazones
 AUTHOR(S): El-Hiti, Gamal A.; Abdel-Megeed, Mohamed F.; Mahmoud, Yehia A-G.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2000), 39B(5), 368-376

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication, CSIR

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:56895

AB Condensation of equimolar amts. of 4-hydrazino-2-phenylquinazoline and a number of monosaccharides (D-glucose, D-galactose, D-xylose, D-arabinose and D-ribose) affords the corresponding hydrazones in good yields. However, when three molar equivalents of 4-hydrazino-2-phenylquinazoline is allowed to react with the monosaccharides in the presence of glacial acetic acid, the corresponding osazones are obtained in fair yields. Acetylation of the hydrazones and osazones gives the corresponding acetyl derivs. The products obtained have been characterized by spectral data and elemental analyses. Some of the compds. show antifungal and antibacterial activities.

IT 314020-18-3P 314020-19-4P 314020-20-7P
 314020-21-8P 314020-22-9P 314020-28-5P
 314020-29-6P 314020-30-9P 314020-31-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and antimicrobial activities of novel sugar phenylquinazolinylhydrazones and their osazones)

RN 314020-18-3 CAPLUS

CN D-Glucose, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 314020-19-4 CAPLUS
 CN D-Galactose, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-20-7 CAPLUS
 CN D-Xylose, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-21-8 CAPLUS
 CN D-Arabinose, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-22-9 CAPLUS
 CN D-Ribose, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-28-5 CAPLUS
 CN D-arabino-Hexos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone] (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 314020-29-6 CAPLUS
 CN D-lyxo-Hexos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 314020-30-9 CAPLUS

CN D-threo-Pentos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 314020-31-0 CAPLUS


CN D-erythro-Pentos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 314020-23-0P 314020-24-1P 314020-25-2P
 314020-26-3P 314020-27-4P 314020-32-1P
 314020-33-2P 314020-34-3P 314020-35-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and antimicrobial activities of novel sugar phenylquinazolinylhydrazones and their osazones)
 RN 314020-23-0 CAPLUS
 CN D-Glucose, (2-phenyl-4-quinazolinyl)hydrazone, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-24-1 CAPLUS
 CN D-Galactose, (2-phenyl-4-quinazolinyl)hydrazone, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-25-2 CAPLUS
 CN D-Xylose, (2-phenyl-4-quinazolinyl)hydrazone, 2,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-26-3 CAPLUS
 CN D-Arabinose, (2-phenyl-4-quinazolinyl)hydrazone, 2,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 314020-27-4 CAPLUS
 CN D-Ribose, (2-phenyl-4-quinazolinyl)hydrazone, 2,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 314020-32-1 CAPLUS
 CN D-arabino-Hexos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone], 3,4,5,6-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 314020-33-2 CAPLUS

CN D-lyxo-Hexos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone],
3,4,5,6-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 314020-34-3 CAPLUS


CN D-threo-Pentos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone],
3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 314020-35-4 CAPLUS
CN D-erythro-Pentos-2-ulose, bis[(2-phenyl-4-quinazolinyl)hydrazone],
3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 6484-29-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and antimicrobial activities of novel sugar
phenylquinazolinylhydrazones and their osazones)
RN 6484-29-3 CAPLUS
CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 87 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:724339 CAPLUS
DOCUMENT NUMBER: 134:17462
TITLE: Synthesis and basicity of 4-amino-2-phenylquinazolines
AUTHOR(S): Zielinski, Wojciech; Kudelko, Agnieszka
CORPORATE SOURCE: Institute of Organic Chemistry and Technology,
Silesian University of Technology, Gliwice, PL-44101,
Pol.
SOURCE: Monatshefte fuer Chemie (2000), 131(8),
895-899
CODEN: MOCMB7; ISSN: 0026-9247
PUBLISHER: Springer-Verlag Wien
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:17462
AB A new group of 6- and 7-substituted compds. of 4-amino-2-phenylquinazoline
were synthesized in 25-82% yields by reaction of N-arylbenzimidoyl
chlorides XC6H4NHCOPh (X = H, 3- and 4-Me, 3- and 4-OMe, 3- and 4-O2N,

4-Br, 4-Cl) with cyanamide in the presence of TiCl₄. The products were identified by spectroscopic methods, and their dissociation consts. were determined

and are discussed. Quinazolines with electron-withdrawing substituents occur both in the amino and imino forms, indicating possible tautomeric equilibrium

IT 1022-44-2P 93716-83-7P 310440-96-1P


310440-97-2P 310440-98-3P 310440-99-4P

310441-00-0P 310441-01-1P 310441-02-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and basicity of)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 93716-83-7 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-phenyl- (CA INDEX NAME)




RN 310440-96-1 CAPLUS

CN 4-Quinazolinamine, 6-methyl-2-phenyl- (CA INDEX NAME)




RN 310440-97-2 CAPLUS

CN 4-Quinazolinamine, 7-methyl-2-phenyl- (CA INDEX NAME)




RN 310440-98-3 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-2-phenyl- (CA INDEX NAME)




RN 310440-99-4 CAPLUS
CN 4-Quinazolinamine, 7-methoxy-2-phenyl- (CA INDEX NAME)




RN 310441-00-0 CAPLUS
CN 4-Quinazolinamine, 6-nitro-2-phenyl- (CA INDEX NAME)



RN 310441-01-1 CAPLUS
CN 4-Quinazolinamine, 7-nitro-2-phenyl- (CA INDEX NAME)



RN 310441-02-2 CAPLUS
CN 4-Quinazolinamine, 6-chloro-2-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 88 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:612064 CAPLUS

DOCUMENT NUMBER: 133:193165
 TITLE: Preparation of imidazoquinazolines and cyclic
 guanosine 3',5'-monophosphate-specific
 phosphodiesterase inhibitors
 INVENTOR(S): Onoda, Yasuo; Machii, Daisuke; Nomoto, Yuji; Takai,
 Haruki; Ono, Satoshi; Ichimura, Michiaki
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000239277	A	20000905	JP 1999-41567	19990219 <--
PRIORITY APPLN. INFO.:			JP 1999-41567	19990219
OTHER SOURCE(S):	MARPAT	133:193165		

GI




AB Title compds. I [R1 = lower alkyl cycloalkyl, lower alkenyl, aralkyl, aryl, etc.; R2, R3 = H, alkyl, cycloalkyl, lower alkenyl, aralkyl, aryl, etc.; X = O, S; Y = OR4, SR5, NR6R7; R4, R5 = lower alkyl, cycloalkyl, lower alkenyl, aralkyl, etc.; R6, R7 = H, lower alkyl, cycloalkyl, alkenyl, aralkyl, aryl, etc.; R6R7 = N-containing heterocyclic ring].
 7-Ethylamino-6-nitro-2-propylamino-4-(4-pyridylmethylamino)quinazoline was hydrogenated with Pd/C in EtOH-THF mixture for 8 h and reacted with CS2 in the presence of Et3N in EtOH at room temperature overnight to give 65% 3-ethyl-6-propylamino-8-(4-pyridylmethylamino)-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione, which was treated with HCl in AcOEt to give their HCl salt showing good antihypertensive activity.


IT 289660-43-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazoquinazolines and cyclic guanosine monophosphate-specific phosphodiesterase inhibitors)
 RN 289660-43-1 CAPLUS
 CN 4-Piperidinemethanol, 1-[2-[[[7-(ethylamino)-2-(1H-imidazol-1-yl)-6-nitro-4-quinazolinyl]amino]methyl]phenyl]- (CA INDEX NAME)




L7 ANSWER 89 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:557933 CAPLUS
 DOCUMENT NUMBER: 133:281483
 TITLE: Concerning the basicity of 4-dimethylaminoquinazoline derivatives
 AUTHOR(S): Zielinski, Wojciech; Kudelko, Agnieszka
 CORPORATE SOURCE: Institute of Organic Chemistry and Technology,
 Silesian University of Technology, Gliwice, PL-44101,
 Pol.
 SOURCE: Monatshefte fuer Chemie (2000), 131(7),
 733-738
 CODEN: MOCMB7; ISSN: 0026-9247
 PUBLISHER: Springer-Verlag Wien
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two series of selected 4-(N,N-dimethylamino)-2-phenylquinazoline and
 2-(N,N-diethylamino)-4-(N,N-dimethylamino)quinazoline derivs. obtained in
 the reaction of substituted N-phenylbenzimidoyl chlorides or
 N1,N1-diethyl-N2-phenylchlorocarboxyamidines with N,N-dimethylcyanamide in
 the presence of TiCl4 were examined in order to detect the protonation
 center. The atypical correlations between pKa and σ were supported
 by MNDO calcns. and single crystal X-ray diffraction data and point to a
 protonation of the ring-N-atoms with delocalization of the pos. charge
 into the N,N-dimethylamino group.
 IT 139474-19-4, 4-(Dimethylamino)-2-phenylquinazoline
 158832-77-0, 6-Methyl-4-(Dimethylamino)-2-phenylquinazoline
 158832-79-2, 6-Bromo-4-(Dimethylamino)-2-phenylquinazoline
 158832-81-6, 7-Methyl-4-(Dimethylamino)-2-phenylquinazoline
 158832-82-7, 7-Methoxy-4-(Dimethylamino)-2-phenylquinazoline
 RL: PRP (Properties)
 (LFER anal. of the basicity of 4-(dimethylamino)quinazoline derivs.)
 RN 139474-19-4 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-77-0 CAPLUS
 CN 4-Quinazolinamine, N,N,6-trimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-79-2 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-81-6 CAPLUS
 CN 4-Quinazolinamine, N,N,7-trimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-82-7 CAPLUS
 CN 4-Quinazolinamine, 7-methoxy-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




IT 299196-54-6P, 6-Methoxy-4-(Dimethylamino)-2-phenylquinazoline
 299196-55-7P, 7-Nitro-4-(Dimethylamino)-2-phenylquinazoline
 299196-60-4P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (LFER anal. of the basicity of 4-(dimethylamino)quinazoline derivs.)
 RN 299196-54-6 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N,N-dimethyl-2-phenyl- (CA INDEX NAME)



RN 299196-55-7 CAPLUS
CN 4-Quinazolinamine, N,N-dimethyl-7-nitro-2-phenyl- (CA INDEX NAME)



RN 299196-60-4 CAPLUS
CN 4-Quinazolinamine, 6-methoxy-N,N-dimethyl-2-phenyl-, hydrochloride (1:1)
(CA INDEX NAME)





● HCl

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 90 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:522557 CAPLUS
DOCUMENT NUMBER: 133:105049
TITLE: Preparation of quinazolines
INVENTOR(S): Shibuya, Isao; Kaba, Yasuo; Shimizu, Masao; Ohishi, Akihiro
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Tokkyo Koho, 7 pp.
CODEN: JTXXFF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 3018185	B1	20000313	JP 1999-33843	19990212 <--
JP 2000229950	A	20000822		
PRIORITY APPLN. INFO.:			JP 1999-33843	19990212
OTHER SOURCE(S):			CASREACT 133:105049; MARPAT 133:105049	
GI				




AB Quinazolines I (R1 = inactive substituent; R2, R3 = hydrocarbyl, etc.; n = 0, 1-4) are prepared by reaction of N-arylthiocarbomoyl compds. II with R32NCN in the presence of metal salts. Thus, refluxing thiobenzanilide with dimethylcyanamide in MeCN in the presence of silver perchlorate gave, after treatment with aqueous NaOH, 78% 2-phenyl-4-dimethylaminoquinazoline.

IT 139474-19-4P 282538-15-2P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of quinazolines by cyclization of N-arylthiocarbomoyl compds. with cyanamides)

RN 139474-19-4 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 282538-15-2 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl-, perchlorate (1:1) (CA INDEX NAME)

CM 1

CRN 139474-19-4


CMF C16 H15 N3



CM 2

CRN 7601-90-3

CMF C1 H 04



L7 ANSWER 91 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:475943 CAPLUS

DOCUMENT NUMBER: 133:89540

TITLE: Pyridopyrimidinones and benzisothiazole dioxides for use in the prophylaxis and therapy of cerebral ischemia

INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Lubisch, Wilfried; Holzenkamp, Uta; Starck, Dorothea; Szabo, Laszlo; Emling, Franz; Garcia-Ladona, Francisco Javi; Hofmann, Hans-Peter; Unger, Liliane

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 90 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900544	A1	20000713	DE 1999-19900544	19990111 <--
CA 2359390	A1	20000720	CA 1999-2359390	19991222 <--
WO 2000041697	A1	20000720	WO 1999-EP10275	19991222 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140099	A1	20011010	EP 1999-966990	19991222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916888	A	20011120	BR 1999-16888	19991222 <--
TR 200102009	T2	20020121	TR 2001-2009	19991222 <--
HU 2002000520	A2	20020729	HU 2002-520	19991222 <--
HU 2002000520	A3	20030428		
JP 2002534467	T	20021015	JP 2000-593308	19991222 <--
ZA 2001005473	A	20021003	ZA 2001-5473	20010703 <--
MX 2001PA06966	A	20020410	MX 2001-PA6966	20010709 <--
NO 2001003408	A	20010821	NO 2001-3408	20010710 <--
BG 105688	A	20020228	BG 2001-105688	20010710 <--
PRIORITY APPLN. INFO.:			DE 1999-19900544	A 19990111
			WO 1999-EP10275	W 19991222

OTHER SOURCE(S): MARPAT 133:89540

GI



AB Title compds. I and II [A = substituted alkylene, alkenylene; B = 4-substituted piperidino, 1,2,3,6-tetrahydropyridino, piperazino, or their 7-membered analogs; R = (un)substituted Ph, naphthyl, indanyl, anthryl, heteroarom.; X = CH₂, Y = (un)substituted NH; X = (un)substituted NH, Y = CH₂; R₁, R₂ = alkyl; R₃, R₄ = H, (un)substituted alkyl, NH₂, CO₂H, OH, alkoxy, F, Cl, Br, I, CF₃, NO₂, CN, pyrrolyl, (un)substituted phenylalkyl] were prepared for use in treating cerebral ischemia and stroke (no data). Thus, Me N-benzyl-4-oxo-3-piperidinecarboxylate was treated with formamidine hydrochloride to give 3,5,7,8-tetrahydro-4-oxo-6-benzylpyrido[4,3-d]pyrimidine which was treated with 1-(2-methoxyphenyl)-4-(2-chloroethyl)piperazine to give the title compound III.


IT 223586-67-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridopyrimidinones and benzisothiazole dioxides for use in the prophylaxis and therapy of cerebral ischemia)

RN 223586-67-2 CAPLUS

CN Quinazoline, 4-[4-[3-(3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-2(3H)-yl)propyl]-1-piperazinyl]-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L7 ANSWER 92 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:441612 CAPLUS
DOCUMENT NUMBER: 133:63991
TITLE: cGMP phosphodiesterase 5 inhibitors for inhalation in
the treatment of sexual dysfunction
INVENTOR(S): Naef, Reto
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037061	A2	20000629	WO 1999-EP10250	19991221 <--
WO 2000037061	A3	20001026		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2355368	A1	20000629	CA 1999-2355368	19991221 <--
EP 1140044	A2	20011010	EP 1999-964644	19991221 <--
EP 1140044	B1	20060315		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
JP 2002532542	T	20021002	JP 2000-589172	19991221 <--
AT 320247	T	20060415	AT 1999-964644	19991221
PT 1140044	T	20060731	PT 1999-964644	19991221
ES 2260952	T3	20061101	ES 1999-964644	19991221
US 20010055570	A1	20011227	US 2001-883572	20010618 <--
US 20040214831	A1	20041028	US 2004-851603	20040521
US 20070197560	A1	20070823	US 2006-644659	20061222
PRIORITY APPLN. INFO.:			GB 1998-28340	A 19981222
			WO 1999-EP10250	W 19991221
			US 2001-883572	A1 20010618

AB Treatment of sexual dysfunction is carried out by inhalation of a cGMP PDE 5 inhibitor, especially, 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (I), 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)pyrazolo[3,4-d]pyrimidin-4-one. Gelatin capsules suitable for use in a capsule inhaler are prepared, each capsule containing a dry powder consisting of 10 mg I, which had been ground to a mean particle diameter of 1-5 μ m, and 10 mg of lactose monohydrate having a particle diameter below 212 μ m. These capsules are used in the treatment of erectile dysfunction patients by inserting a capsule into the capsule chamber of an inhaler.

IT 157862-73-2 157863-27-9
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (cGMP phosphodiesterase inhibitors for inhalation in treatment of sexual dysfunction)


RN 157862-73-2 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157863-27-9 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



L7 ANSWER 93 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:343282 CAPLUS

DOCUMENT NUMBER: 133:159627

TITLE: The ad hoc supermolecule approach to receptor ligand design

AUTHOR(S): De Benedetti, P. G.; Fanelli, F.; Menziani, M. C.; Cocchi, M.

CORPORATE SOURCE: Dipartimento di Chimica, Universita di Modena e Reggio Emilia, Modena, 41100, Italy

SOURCE: THEOCHEM (2000), 503(1-2), 1-16

CODEN: THEODJ; ISSN: 0166-1280

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Among the ligand design methods based on the theor. QSAR paradigm, the simple ad hoc supermol. approach is presented and applied to a highly non-congeneric set of α 1-adrenergic receptor antagonists. The performance of the approach is satisfactory and highlights its (semi)quant. ligand design potentiality.

IT 139644-60-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(ad hoc supermol. approach to receptor ligand design)

RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 94 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:304988 CAPLUS

DOCUMENT NUMBER: 133:89495

TITLE: Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3 Receptor

AUTHOR(S): Van Muijlwijk-Koezen, Jacqueline E.; Timmerman, Henk; Van der Goot, Henk; Menge, Wiro M. P. B.; Von Kuenzel, Jacobien Frijtag; De Groote, Miriam; IJzerman, Adriaan P.

CORPORATE SOURCE: Leiden/Amsterdam Center for Drug Research Division of Medicinal Chemistry Department of Pharmacochimistry, Vrije Universiteit, Amsterdam, 1081 HV, Neth.

SOURCE: Journal of Medicinal Chemistry (2000), 43(11), 2227-2238

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Isoquinoline and quinazoline urea derivs. were found to bind to human adenosine A3 receptors. Series of N-phenyl-N'-quinazolin-4-ylurea derivs. and N-phenyl-N'-isoquinolin-1-ylurea derivs. were synthesized and tested in radioligand binding assays on their adenosine receptor affinities. A structure-affinity anal. indicated that on the 2-position of the quinazoline ring or the equivalent 3-position of the isoquinoline ring a Ph or heteroaryl substituent increased the adenosine A3 receptor affinity in comparison to unsubstituted or aliphatic derivs. Furthermore, the structure-affinity relationship of substituted phenylurea analogs was investigated. Substituents such as electron-withdrawing or electron-donating groups were introduced at different positions of the benzene ring to probe electronic and positional effects of substitution. Substitution on the 3- or 4-position of the Ph ring decreased the adenosine A3 receptor affinity. Substitution at position 2 with an electron-donating substituent, such as Me or methoxy, increased human adenosine A3 receptor affinity, whereas substitution on the 2-position with an electron-withdrawing substituent did not influence affinity. Combination of the optimal substituents in the two series had an additive effect, which led to the potent human adenosine A3 receptor antagonist N-(2-methoxyphenyl)-N'-(2-(3-pyridyl)quinazolin-4-yl)urea (VUF5574, I) showing a K_i value of 4 nM and being at least 2500-fold selective vs. A1 and A2A receptors. Compound I competitively antagonized the effect of an agonist in a functional A3 receptor assay, i.e., inhibition of cAMP production in cells expressing the human adenosine A3 receptor; a pA_2 value of 8.1 was derived from a Schild plot. In conclusion, compound I is a potent and selective human adenosine A3 receptor antagonist and might be a useful tool in further characterization of the human A3 receptor.

IT 280138-91-2P 280138-92-3P 280138-93-4P
280138-95-6P 280138-96-7P 280138-97-8P
280138-98-9P 280138-99-0P 280139-00-6P


280139-05-1P 280139-06-2P 280139-07-3P
280139-08-4P 280139-09-5P 280139-10-8P
280139-11-9P 280570-45-8P, VUF 5574 280570-81-2P
, VUF 5386

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of isoquinoline and quinazoline urea analogs as antagonists for human adenosine A3 receptor)


RN 280138-91-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280138-92-3 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 280138-93-4 CAPLUS

CN Urea, N-phenyl-N'-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 280138-95-6 CAPLUS

CN Urea, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280138-96-7 CAPLUS

CN Urea, N-phenyl-N'-[2-(3-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 280138-97-8 CAPLUS

CN Urea, N-phenyl-N'-[2-(4-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 280138-98-9 CAPLUS


CN Urea, N-[2-(6-methyl-2-pyridinyl)-4-quinazolinyl]-N'-phenyl- (CA INDEX NAME)




RN 280138-99-0 CAPLUS
 CN Urea, N-[2-(4,6-dimethyl-2-pyrimidinyl)-4-quinazolinyl]-N'-phenyl- (CA INDEX NAME)



RN 280139-00-6 CAPLUS
 CN Urea, N-[2-(2-furanyl)-4-quinazolinyl]-N'-phenyl- (CA INDEX NAME)




RN 280139-05-1 CAPLUS
 CN Urea, N-(4-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280139-06-2 CAPLUS

CN Urea, N-(3,4-dichlorophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280139-07-3 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280139-08-4 CAPLUS

CN Urea, N-(3-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 280139-09-5 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 280139-10-8 CAPLUS


CN Urea, N-(2-methylphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 280139-11-9 CAPLUS


CN Urea, N-(2-methylphenyl)-N'-[2-(3-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)

NAME)




RN 280570-45-8 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[2-(3-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 280570-81-2 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




IT 40172-82-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of isoquinoline and quinazoline urea analogs as antagonists for human adenosine A3 receptor)

RN 40172-82-5 CAPLUS

CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)



IT 1022-44-2P 40172-85-8P 273408-89-2P


273408-90-5P 280139-12-0P 280139-13-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoquinoline and quinazoline urea analogs as antagonists for human adenosine A3 receptor)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 40172-85-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-furanyl)- (CA INDEX NAME)




RN 273408-89-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-pyridinyl)- (CA INDEX NAME)




RN 273408-90-5 CAPLUS


CN 4-Quinazolinamine, 2-(3-pyridinyl)- (CA INDEX NAME)



RN 280139-12-0 CAPLUS
 CN 4-Quinazolinamine, 2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 280139-13-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4,6-dimethyl-2-pyrimidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 95 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:248619 CAPLUS
 DOCUMENT NUMBER: 133:30698
 TITLE: Microwave-enhanced synthesis of 4-aminoquinazolines
 AUTHOR(S): Seijas, Julio A.; Vazquez-Tato, M. Pilar; Martinez, M. Montserrat
 CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de Ciencias, Universidad de Santiago de Compostela, Lugo, 27080, Spain
 SOURCE: Tetrahedron Letters (2000), 41(13), 2215-2217
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:30698
 GI




AB Aromatic nitriles react with anthranilonitrile in a domestic microwave oven to afford good yields of the corresponding 4-aminoquinazolines, e.g. I, in a very short irradiation time.

IT 1022-44-2P 16288-67-8P 40172-82-5P
 40172-85-8P 94098-58-5P 273408-87-0P
 273408-88-1P 273408-89-2P 273408-90-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (microwave enhanced preparation of aminoquinazolines)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 16288-67-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-aminophenyl)- (CA INDEX NAME)




RN 40172-82-5 CAPLUS

CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)




RN 40172-85-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-furanyl)- (CA INDEX NAME)




RN 94098-58-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 273408-87-0 CAPLUS
 CN Benzonitrile, 3-(4-amino-2-quinazolinyl)- (CA INDEX NAME)




RN 273408-88-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-thienyl)- (CA INDEX NAME)



RN 273408-89-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-pyridinyl)- (CA INDEX NAME)



RN 273408-90-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)- (CA INDEX NAME)





REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 96 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:220729 CAPLUS
 DOCUMENT NUMBER: 132:251161
 TITLE: Preparation of 4-aminoquinazolines for treating a patient having a precancerous lesions
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
 SOURCE: U.S., 54 pp., Cont. of U.S. Ser. No. 475,197, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6046206	A	20000404	US 1997-846593	19970430 <--
PRIORITY APPLN. INFO.:			US 1995-475197	B1 19950607
OTHER SOURCE(S):	MARPAT	132:251161		


GI



AB The title compds. [I; R1-R4 = H, alkoxy, hydroxyalkyl, etc.; R5 = H, halo, OH, etc.; R6 = H, alkyl, acyl, etc.; R7 = H, OH, CN, etc.; Y = (un)substituted (CH2)q (q = 1-8), CO], useful for the treatment of patients having precancerous lesions, and also for inhibiting the growth of neoplastic cells (no data), were prepared Thus, reacting 4-chloro-6,7,8-trimethoxyquinazoline with piperonylamine in the presence of Na2CO3 in iso-PrOH afforded 69% II.

IT 150452-96-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-aminoquinazolines for treating a patient having a precancerous lesions)

RN 150452-96-3 CAPLUS
 CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-tetrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 122 THERE ARE 122 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 97 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:209898 CAPLUS

DOCUMENT NUMBER: 132:236799

TITLE: Preparation of nitroethenamine derivatives or salts thereof as active constituent in medical composition

INVENTOR(S): Kato, Fuminori; Miyata, Keizo; Kimura, Hirohiko; Yamamoto, Kazuhiro; Ikegami, Hiroyuki; Takeo, Hiromi

PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha Ltd., Japan

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000016766	A1	20000330	WO 1999-JP5148	19990921 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2342607	A1	20000330	CA 1999-2342607	19990921 <--
AU 9956543	A	20000410	AU 1999-56543	19990921 <--
EP 1116486	A1	20010718	EP 1999-943445	19990921 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6451792	B1	20020917	US 2001-805781	20010320 <--
US 20020198184	A1	20021226	US 2002-133752	20020429 <--
US 6596863	B2	20030722		
PRIORITY APPLN. INFO.:			JP 1998-286074	A 19980922
			JP 1998-377076	A 19981228
			WO 1999-JP5148	W 19990921
			US 2001-805781	A3 20010320

OTHER SOURCE(S): MARPAT 132:236799
GI



AB Title compds. N2N(R6)C:C(NR4R5)N(R1)NR2R3 [I; wherein R1 is a hydrogen atom, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or a cyano group; R2 and R3 may be each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, or A-R7 (wherein A is S, SO, SO2, SO3, CO or CO2, and R7 is a hydrogen atom, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group), or may form N=CR8R9 (wherein R8 and R9 are each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy or aryloxy group, a cyano group, a nitro group, or A-R7); R4 and R5 may be each a hydrogen atom, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy group, an amino group, an aryloxy group, A-R7, a cyano group, an ester group or a hydroxyl group, or may form N=CR8R9; R6 is a hydrogen atom, a nitro group, a cyano, A-R7, an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group, an alkoxy group, an amino group, or a halogen atom; and further R1, R2, R3, R4 and R5 may form a ring containing or not containing a heteroatom] and salts thereof are

prepared as

active constituent in medical composition The title compds. II and III were prepared and tested for MMP-9 inhibition activity.


IT 262275-96-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitroethenamine derivs. or salts thereof as active constituent in medical composition)

RN 262275-96-7 CAPLUS


CN Ethenamine, N-methyl-2-nitro-1-[2-(2-phenyl-4-quinazolinyl)hydrazinyl]-
(CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 98 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:191092 CAPLUS
 DOCUMENT NUMBER: 132:222659
 TITLE: Preparation of aminoalkylphosphonic ester derivatives as cell adhesion inhibitors
 INVENTOR(S): Kono, Yasushi; Sawada, Takayuki; Nomura, Masahiro; Takahashi, Yukie; Tsubuki, Takeshi; Sakoe, Yasuhiko; Kuriyama, Kazuhiko
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015645	A1	20000323	WO 1999-JP4913	19990910 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9956485	A1	20000403	AU 1999-56485	19990910 <--
PRIORITY APPLN. INFO.:			JP 1998-258841	A 19980911
			WO 1999-JP4913	W 19990910
OTHER SOURCE(S):			MARPAT 132:222659	
GI				



AB Phosphonic ester derivs. represented by general formula [I; W = thiazole ring, (un)substituted benzothiazole, pyridothiazole, pyridine, quinoline, pyridazine, phthalazine, quinoxaline, pyrimidine, quinazoline, thienopyrimidine, benzimidazole, purine, or indole ring; X = NH(CH2)m (wherein m = 0-2), CONH; Y = (un)substituted benzene, or naphthalene, pyridine, or quinoline, or benzofuran, coumarin, chroman, or chromanone, 1,3-thiazole ring; Z = (CH2)q (wherein q = 0-2), CH:CH, OCH2, OCM2, SCH2,

SOCH₂, SO₂CH₂, NHCO(CH₂)_r (wherein r = 02); R₁ = H, C1-4 alkoxycarbonyl, CO₂H, C1-4 alkoxyphosphoryl; R₂ = C1-4 alkyl; n = 0-2] and pharmacol. acceptable salts thereof are prepared These compds. have an activity of inhibiting a ICAM-1 or VCAM-1 mediated binding of cell adhesion mols. without inhibiting the expression of cell adhesion mols. and thus, are useful as immunosuppressants, anti-inflammatory agents, antiallergic agents and tumor metastasis inhibitors. Thus, 4'-(benzothiazol-2-yl)cinnamic acid was condensed with aminomethanephosphonic acid di-Et ester using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in the presence of 4-dimethylaminopyridine and Et₃N in DMF at room temperature for 10 h to give [4'-(benzothiazol-2-yl)cinnamoyl]aminomethanephosphonic di-Et ester. A title compound (II) in vitro inhibited by 88% the binding of U937 cell to human umbilical vein endothelial cells (HUVEC) which were treated with human interleukin-1 β to induce ICAM-1 and VCAM-1.

IT 261616-41-5P 261616-42-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkylphosphonic ester derivs. as cell adhesion inhibitors and drugs)

RN 261616-41-5 CAPLUS

CN Phosphonic acid, [[[2E)-1-oxo-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2-propenyl]amino]methyl]-, diethyl ester (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 261616-42-6 CAPLUS

CN Phosphonic acid, [2-[[[(2E)-1-oxo-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2-propenyl]amino]ethyl]-, diethyl ester (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 99 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:161275 CAPLUS

DOCUMENT NUMBER: 132:194387

TITLE: Preparation of quinazolines as p38- α kinase and TGF- β inhibitors

INVENTOR(S): Chakravarty, Sarvajit; Dugar, Sundeep; Perumattam, John J.; Schreiner, George F.; Liu, David Y.; Lewicki, John A.

PATENT ASSIGNEE(S): Scios Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012497	A2	20000309	WO 1999-US19846	19990827 <--
WO 2000012497	A3	20000629		
W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6184226	B1	20010206	US 1998-141916	19980828 <--
CA 2342250	A1	20000309	CA 1999-2342250	19990827 <--
AU 9962413	A	20000321	AU 1999-62413	19990827 <--
AU 771947	B2	20040408		
EP 1107959	A2	20010620	EP 1999-949568	19990827 <--
EP 1107959	B1	20061011		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
BR 9913648	A	20020102	BR 1999-13648	19990827 <--
JP 2002523502	T	20020730	JP 2000-567525	19990827 <--
AT 342256	T	20061115	AT 1999-949568	19990827
ES 2274642	T3	20070516	ES 1999-949568	19990827
MX 2001PA02175	A	20030714	MX 2001-PA2175	20010228 <--
HK 1035897	A1	20070601	HK 2001-106212	20010904
PRIORITY APPLN. INFO.:			US 1998-141916	A 19980828
			WO 1999-US19846	W 19990827

OTHER SOURCE(S): MARPAT 132:194387
GI



AB Title compds. [I; R = ZR1; R1 = (un)substituted cyclic (hetero)aliphatic group, -(hetero)aryl; R3 = noninterfering substituent (sic); R4R5 = atoms to complete a 6-membered aromatic ring containing 0, 1, or 2 nonadjacent N atoms


and noninterfering substituent(s) (sic); z = bond or linker (sic); Z3 = CR2 or N; R2 = noninterfering substituent (sic)] were prepared. Thus, prepn of, e.g., 4-(4-pyridinylamino)-2-phenylquinazoline was described. Data for biol. activity of I were given.

IT 259870-32-1P 259870-33-2P 259870-34-3P
259870-35-4P 259870-36-5P 259870-37-6P
259870-38-7P 259870-39-8P 259870-40-1P
259870-42-3P 259870-43-4P 259870-44-5P
259870-45-6P 259870-46-7P 259870-47-8P
259870-48-9P 259870-49-0P 259870-50-3P
259870-51-4P 259870-52-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines as p38- α kinase and TGF- β inhibitors)


RN 259870-32-1 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 259870-33-2 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-34-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-35-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-36-5 CAPLUS
 CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 259870-37-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-38-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-39-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-40-1 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-42-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-43-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-dibromophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-44-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-45-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-46-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-47-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6-nitro-N-4-pyridinyl- (CA INDEX NAME)




RN 259870-48-9 CAPLUS
 CN 4,7-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-49-0 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(3-methoxyphenyl)methyl]-N4-4-pyridinyl- (CA INDEX NAME)




RN 259870-50-3 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(4-methoxyphenyl)methyl]-N4-4-pyridinyl- (CA INDEX NAME)



RN 259870-51-4 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-(2-methylpropyl)-N4-4-pyridinyl- (CA INDEX NAME)



RN 259870-52-5 CAPLUS
 CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[[4-(methylthio)phenyl]methyl]-N4-4-pyridinyl- (CA INDEX NAME)




L7 ANSWER 100 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:114014 CAPLUS
 DOCUMENT NUMBER: 132:260432
 TITLE: Modulation of nitric oxide-dependent vascular and platelet function in-vitro by the novel phosphodiesterase type-V inhibitor, ONO-1505
 AUTHOR(S): Laight, David W.; Anggard, Erik E.; Carrier, Martin J.
 CORPORATE SOURCE: The William Harvey Research Institute, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, EC1M 6BQ, UK
 SOURCE: Journal of Pharmacy and Pharmacology (1999), 51(12), 1429-1433
 CODEN: JPPMAB; ISSN: 0022-3573
 PUBLISHER: Royal Pharmaceutical Society of Great Britain
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We have characterized the in-vitro modulation of both nitric oxide (NO)-dependent vasodilator activity and anti-platelet function by the novel type-V phosphodiesterase inhibitor, ONO-1505 (4-[2-(2-hydroxyethoxy)ethylamino]-2-(1H-imidazol-1-yl)-6-methoxy-qu inazoline methanesulfonate). ONO-1505 elicited vasorelaxation in the rat isolated aorta. If the concentration of ONO-1505 was $\leq 10 \mu\text{M}$ the vasorelaxation was abolished by NG-nitro-L-arginine Me ester (L-NAME), by methylene blue, and by endothelial denudation. Furthermore, pretreatment of the rat isolated aorta for 10min with ONO-1505 in the presence of L-NAME potentiated vasorelaxation to the NO-donor, sodium nitroprusside. Similarly, ONO-1505, although having no effect on ADP-induced rat platelet aggregation in-vitro, augmented established anti-aggregatory effects of sodium nitroprusside. The data therefore show that the novel phosphodiesterase V inhibitor ONO-1505 augments endogenous and exogenous nitrovasodilator activity in-vitro; they also imply modulation of the NO pathway in the hemodynamic actions of this compound, previously reported in-vivo.
 IT 211117-00-9, ONO-1505
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphodiesterase V inhibitor ONO-1505 modulation of nitric oxide-dependent vascular and platelet function)
 RN 211117-00-9 CAPLUS
 CN Ethanol, 2-[2-[[6-methoxy-2-(1H-pyrrol-1-yl)-4-quinazolinyl]amino]ethoxy]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 211116-99-3


CMF C17 H20 N4 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 101-323 ibib abs hitstr

L7 ANSWER 101 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:9434 CAPLUS

DOCUMENT NUMBER: 132:146156

TITLE: Relevance of theoretical molecular descriptors in quantitative structure-activity relationship analysis of α 1-adrenergic receptor antagonists

AUTHOR(S): Menziani, M. C.; Montorsi, M.; De Benedetti, P. G.; Karelson, M.

CORPORATE SOURCE: Department of Chemistry, University of Modena and Reggio Emilia, Modena, 41100, Italy

SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(11), 2437-2451

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A quant. structure-activity relationship (QSAR) study of a wide series of structurally diverse α 1-adrenergic receptor antagonists was performed using the CODESSA (Comprehensive Descriptors for Structural and Statistical Anal.) technique. Theor. descriptors derived on a single structure and ad hoc defined size and shape descriptors were considered in the attempt of describing information relevant to receptor interaction. The relative effectiveness of these two classes of parameters in developing QSAR models for native (α 1A and α 1B) and cloned (α 1a, α 1b, and α 1d) adrenergic receptor binding affinity, functional activity of vascular and lower urinary tract tissues, and in vitro and in vivo selectivity was evaluated.


IT 139644-60-3 173059-56-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(relevance of theor. mol. descriptors in QSAR anal. of

α 1-adrenergic receptor antagonists)


RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



RN 173059-56-8 CAPLUS

CN 4-Quinazolinamine, 2-[1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 102 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:700927 CAPLUS

DOCUMENT NUMBER: 132:151765

TITLE: Synthesis and biological activity of 4-substituted quinazolines

AUTHOR(S): Abdel-Hamide, S. G.

CORPORATE SOURCE: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

SOURCE: Indian Journal of Heterocyclic Chemistry (1999), 9(1), 63-68

CODEN: IJCHEI; ISSN: 0971-1627

PUBLISHER: Prof. R. S. Varma

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new series of quinazoline derivs. were synthesized using the corresponding 4-chloro-2-phenyl-6-iodo-quinazoline as starting material. On screening, some of them were found to exhibit good antibacterial activity.

IT 257624-30-9P 257624-32-1P 257624-35-4P
257624-42-3P 257624-44-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)

(preparation and biol. activity of 4-substituted quinazolines)


RN 257624-30-9 CAPLUS

CN Ethanol, 2-[(6-iodo-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 257624-32-1 CAPLUS

CN Benzo[b]thiophene-3-carbonitrile, 4,5,6,7-tetrahydro-2-[(6-iodo-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 257624-35-4 CAPLUS

CN Ethanone, 1-[4-[(6-iodo-2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 257624-42-3 CAPLUS


CN 1,4-Phthalazinedione, 2,3-dihydro-2-(6-iodo-2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 257624-44-5 CAPLUS
 CN Acetic acid, 2-(6-iodo-2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




IT 257624-41-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and biol. activity of 4-substituted quinazolines)
 RN 257624-41-2 CAPLUS
 CN Quinazoline, 4-hydrazinyl-6-iodo-2-phenyl- (CA INDEX NAME)




IT 257624-31-0P 257624-34-3P 257624-38-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 257624-31-0 CAPLUS
 CN 1-Propanol, 3-[(6-iodo-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 257624-34-3 CAPLUS
 CN Phenol, 3-[(6-iodo-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 257624-38-7 CAPLUS
 CN Benzoic acid, 2-[(6-iodo-2-phenyl-4-quinazolinyl)amino]-, methyl ester
 (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 103 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:699078 CAPLUS
 DOCUMENT NUMBER: 131:317778
 TITLE: Phosphate derivatives for treatment of nephritis
 INVENTOR(S): Miyata, Kazuyoshi; Tsuda, Yoshihiko; Koji, Yasuo; Kuroki, Morihisa; Sakai, Yasuhiro; Mukai, Kiyoshi; Hashimoto, Kinji; Kori, Hideaki
 PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11302177	A	19991102	JP 1998-116645	19980427 <--
PRIORITY APPLN. INFO.:			JP 1998-116645	19980427
OTHER SOURCE(S):	MARPAT 131:317778			
AB	Phosphate derivs. (Markush's structures given) are claimed for treatment of nephritis. The derivs. inhibited mesangium cell proliferation in vitro. Examples of tablets, capsules, and granules were formulated.			
IT	166394-39-4			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES			

(Uses)

(phosphate derivs. for treatment of nephritis)

RN 166394-39-4 CAPLUS

CN Phosphonic acid, [[4-[4-(methylamino)-2-quinazolinyl]phenyl]methyl]-,
diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 104 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:665375 CAPLUS

DOCUMENT NUMBER: 131:293259

TITLE: Silver halide photographic material and its processing

INVENTOR(S): Miura, Norio; Komamura, Tawara

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11288057	A	19991019	JP 1998-93366	19980406 <--
JP 4026735	B2	20071226		

PRIORITY APPLN. INFO.: JP 1998-93366 19980406

OTHER SOURCE(S): MARPAT 131:293259

AB The material is characterized by 0.01-0.10 of maximum d. summation at maximum absorption wavelength of a dye formed with a coupler and a developer. The material may contain a developer. Liquid developing or heat developing of the material is also claimed. The material shows neutral black or blue black image tone and less time variability of photog. properties.


IT 192515-19-8

RL: DEV (Device component use); USES (Uses)

(photog. film containing coupler and developer suitable for liquid and heat developing processes)


RN 192515-19-8 CAPLUS

CN Hydrazinecarboxamide, N-[4-(dodecyloxy)phenyl]-2-(2-phenyl-4-quinazolinyl)-
(CA INDEX NAME)



Me—(CH₂)₁₁—O

L7 ANSWER 105 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:654218 CAPLUS
 DOCUMENT NUMBER: 131:351295
 TITLE: Thermal ring contraction of 3H-1,4-benzodiazepines into quinazolines
 AUTHOR(S): Kaname, Mamoru; Tsuchiya, Takashi; Sashida, Haruki
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, 920-1181, Japan
 SOURCE: Heterocycles (1999), 51(10), 2407-2413
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:351295
 AB The thermolysis of the 5-methoxy- and 5-diethylamino-3H-1,4-benzodiazepines resulted in a ring transformation to give the 4-methoxy- and 4-diethylaminoquinazolines, resp. For example, heating 5-methoxy-3H-1,4-benzodiazepine in Ph₂O at 160-170° for 6 h gave 44% 4-methoxyquinazoline. The mechanism of this ring contraction was also described.
 IT 250643-74-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (thermal ring contraction of 3H-1,4-benzodiazepines into quinazolines)
 RN 250643-74-4 CAPLUS
 CN 4-Quinazolinamine, N,N-diethyl-2-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 106 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1999:640854 CAPLUS
 DOCUMENT NUMBER: 131:257578
 TITLE: Preparation of quinazoline derivatives for treatment of digestive diseases
 INVENTOR(S): Karasawa, Akira; Koshimura, Hirokazu; Suzuki, Koji; Kumazawa, Toshiaki; Takai, Haruki; Yokoyama, Toshihide; Kusaka, Hideaki; Nosaka, Chihiro; Ichimura, Michio; Watanabe, Fumiko; Kishibayashi, Nobuyuki
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan; et al.
 SOURCE: PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950264	A1	19991007	WO 1999-JP1626	19990330 <--
W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9929605	A	19991018	AU 1999-29605	19990330 <--
PRIORITY APPLN. INFO.:			JP 1998-83434	A 19980330
			WO 1999-JP1626	W 19990330
OTHER SOURCE(S):		MARPAT 131:257578		
GI				




AB The title compds. I [Z = A(CY)a; R1 and R2 each represents hydrogen, lower alkyl, lower alkoxyalkyl, etc.; R3 represents hydrogen, lower alkyl, optionally substituted amino, etc.; R4 represents hydrogen, lower alkyl, etc.; R5 and R6 each represents hydrogen or lower alkyl; X represents a single bond, lower alkylene, etc.; CY represents CHOH, CO, etc.; a is 0 or 1; and A represents aryl, heterocycle, aralkyl, etc.] are prepared. The compds. have affinity for serotonin 4 receptor and are useful as remedies for digestive diseases, etc. The title compound II showed EC30 of 14 nM against carbachol-induced contraction of rat esophageal mucosal muscle.

IT 244788-92-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline derivs. for treatment of digestive diseases)
 RN 244788-92-9 CAPLUS
 CN 4-Quinazolinamine, 6-[3-[[[2-(4-morpholinyl)ethyl]amino]methyl]-1H-pyrrol-1-yl]-2-phenyl-N-propyl- (CA INDEX NAME)



IT 244789-54-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinazoline derivs. for treatment of digestive diseases)
 RN 244789-54-6 CAPLUS
 CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-phenyl-4-(propylamino)-7-quinazolinyl]- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 107 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:481266 CAPLUS
 DOCUMENT NUMBER: 131:139513
 TITLE: Nitrogen monoxide formation inhibitors
 INVENTOR(S): Taniguchi, Naoyuki; Kobayashi, Kaoru; Murota, Masayuki
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11209287	A	19990803	JP 1998-10973	19980123 <--
PRIORITY APPLN. INFO.:			JP 1998-10973	19980123
OTHER SOURCE(S):	MARPAT	131:139513		

GI




AB The title aminoquinazoline compds. (I: R1 = H, etc.; R2 = C1-6 alkyl, etc.; Z = methylene, etc.; CyB = heterocyclic group, etc.; R3 = C1-4 alkyl, etc.; R4 = alkoxy, etc.) are useful for inhibition of NO formation. I are useful for prevention and treatment of diseases such as septicemia.

IT 236388-81-1 236388-82-2 236388-83-3
236388-84-4 236388-85-5 236388-86-6
236388-87-7 236388-88-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen monooxide formation inhibitors)

RN 236388-81-1 CAPLUS


CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-6,7-dimethoxy-2-[2-(1-methylethyl)-1H-imidazol-1-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 236388-82-2 CAPLUS


CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-6,7-dimethoxy-2-(2-methyl-1H-imidazol-1-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 236388-83-3 CAPLUS

CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-(2-ethyl-4-methyl-1H-imidazol-1-yl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 236388-84-4 CAPLUS
 CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-(1H-imidazol-1-yl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 236388-85-5 CAPLUS
 CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-6,7-dimethoxy-2-[2-(1-methylethyl)-1H-imidazol-1-yl]- (CA INDEX NAME)




RN 236388-86-6 CAPLUS
 CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-6,7-dimethoxy-2-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 236388-87-7 CAPLUS
 CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-(2-ethyl-4-methyl-1H-imidazol-1-yl)-6,7-dimethoxy- (CA INDEX NAME)



RN 236388-88-8 CAPLUS
 CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-(1H-imidazol-1-yl)-6,7-dimethoxy- (CA INDEX NAME)



L7 ANSWER 108 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:409556 CAPLUS
 DOCUMENT NUMBER: 131:58845
 TITLE: Substituted 2-aryl-4-amino-quinazolines
 INVENTOR(S): Schindler, Ursula; Schindler, Peter; Schoenafinger, Karl; Strobel, Hartmut
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19756388	A1	19990624	DE 1997-19756388	19971218 <--
CA 2315205	A1	19990701	CA 1998-2315205	19981211 <--
WO 9932460	A1	19990701	WO 1998-EP8097	19981211 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9922708	A	19990712	AU 1999-22708	19981211 <--
EP 1040101	A1	20001004	EP 1998-966301	19981211 <--
EP 1040101	B1	20070425		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY				
JP 2001526273	T	20011218	JP 2000-525397	19981211 <--

AT 360622	T	20070515	AT 1998-966301	19981211
ES 2285798	T3	20071116	ES 1998-966301	19981211
US 6613772	B1	20030902	US 2000-581763	20000616 <--
PRIORITY APPLN. INFO.:			DE 1997-19756388	A 19971218
			WO 1998-EP8097	W 19981211

OTHER SOURCE(S): MARPAT 131:58845

AB Substituted 2-aryl-4-amino-quinazolines and their use as cardiovascular agents for treatment circulatory disease, blood pressure, angina, pectoris, heart insufficiency, thrombosis or atherosclerosis and to modulate the production of cGMP. Thus, 2-(4-chlorophenyl)-4-N-benzylpiperzino-6,7,8-trimethoxyquinazoline was prepared in a multistep process from Me 2-amino-3,4,5-trimethoxybenzoate and 4-chlorobenzoyl chloride and subsequently with N-benzylpiperazine.


IT 228118-66-9P 228118-67-0P 228118-68-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(for preparation of arylaminoquinazolines as cardiovascular agents)

RN 228118-66-9 CAPLUS


CN Quinazoline, 2-(4-chlorophenyl)-6,7-dimethoxy-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 228118-67-0 CAPLUS

CN 1,2-Ethanediamine, N2-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-bis(1-methylethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 228118-68-1 CAPLUS

CN Quinazoline, 2-(4-chlorophenyl)-6,7-dimethoxy-4-[4-(phenylmethyl)-1-

piperazinyll]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


IT 228118-58-9P 228118-59-0P 228118-60-3P
 228118-61-4P 228118-62-5P 228118-63-6P
 228118-69-2P 228118-70-5P 228118-71-6P
 228118-72-7P 228118-73-8P 228118-74-9P
 228118-75-0P 228118-76-1P 228118-77-2P
 228118-79-4P 228118-81-8P 228118-82-9P
 228118-83-0P 228118-84-1P 228118-85-2P
 228118-86-3P 228118-87-4P 228118-88-5P
 228118-89-6P 228118-90-9P 228118-91-0P
 228118-92-1P 228118-93-2P 228118-94-3P
 228118-95-4P 228118-96-5P 228118-97-6P
 228118-98-7P 228118-99-8P 228119-00-4P
 228119-01-5P 228119-02-6P 228119-03-7P
 228119-04-8P 228119-05-9P 228119-06-0P
 228119-07-1P 228119-08-2P 228119-11-7P
 228119-12-8P 228119-13-9P 228119-14-0P
 228119-15-1P 228119-17-3P 228119-18-4P
 228119-19-5P 228119-20-8P 228119-21-9P
 228119-22-0P 228119-23-1P 228119-24-2P
 228119-25-3P 228119-26-4P 228119-27-5P
 228119-28-6P 228119-29-7P 228119-30-0P
 228119-31-1P 228119-32-2P 228119-33-3P
 228119-34-4P 228119-35-5P 228119-36-6P
 228119-38-8P 228119-39-9P 228119-40-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of arylaminoquinazolines as cardiovascular agents)


RN 228118-58-9 CAPLUS

CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-[4-(phenylmethyl)-1-piperazinyll]- (CA INDEX NAME)




RN 228118-59-0 CAPLUS

CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-[4-(2-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 228118-60-3 CAPLUS


CN 1,2-Ethanediamine, N2-[2-(4-chlorophenyl)-6,7,8-trimethoxy-4-quinazolinyl]-N1,N1-bis(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 228118-61-4 CAPLUS


CN Ethanone, 2-[4-[2-(4-chlorophenyl)-6,7,8-trimethoxy-4-quinazolinyl]-1-piperazinyl]-1-(4-morpholinyl)- (CA INDEX NAME)



RN 228118-62-5 CAPLUS
 CN 1-Piperazineethanol, 4-[2-(4-chlorophenyl)-6,7,8-trimethoxy-4-quinazolinyl]- (CA INDEX NAME)




RN 228118-63-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7,8-trimethoxy-N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 228118-69-2 CAPLUS
 CN Ethanol, 2-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 228118-70-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-[4-(1H-imidazol-1-yl)butyl]-6,7-dimethoxy- (CA INDEX NAME)




RN 228118-71-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 228118-72-7 CAPLUS

CN 1-Piperazineethanol, 4-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-
(CA INDEX NAME)



RN 228118-73-8 CAPLUS


CN 1-Piperazineacetamide, 4-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-
N-(1-methylethyl)- (CA INDEX NAME)



RN 228118-74-9 CAPLUS


CN Acetamide, 2-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]-

(CA INDEX NAME)




RN 228118-75-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-(2,2,6,6-tetramethyl-4-piperidiny)- (CA INDEX NAME)




RN 228118-76-1 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]propyl]- (CA INDEX NAME)




RN 228118-77-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 228118-79-4 CAPLUS

CN Ethanone, 2-[4-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-1-piperazinyl]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 228118-81-8 CAPLUS

CN 1-Propanol, 3-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 228118-82-9 CAPLUS


CN Ethanol, 2-[2-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 228118-83-0 CAPLUS
 CN Glycine, N-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]- (CA INDEX NAME)




RN 228118-84-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N,N-dimethyl- (CA INDEX NAME)



RN 228118-85-2 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 228118-86-3 CAPLUS
 CN Ethanol, 2-[[6,7-dimethoxy-2-(4-methylphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 228118-87-4 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-(3-pyridinylmethyl)-
(CA INDEX NAME)




RN 228118-88-5 CAPLUS

CN Quinazoline, 6,7-dimethoxy-2-(4-methylphenyl)-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)




RN 228118-89-6 CAPLUS

CN 1,2-Ethanediamine, N2-[6,7-dimethoxy-2-(4-methylphenyl)-4-quinazolinyl]-
N1,N1-bis(1-methylethyl)- (CA INDEX NAME)




RN 228118-90-9 CAPLUS

CN Ethanol, 2-[[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]methylamino]-
(CA INDEX NAME)




RN 228118-91-0 CAPLUS

CN Ethanol, 2-[[6,7-dimethoxy-2-[4-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 228118-92-1 CAPLUS


CN 1-Piperazineethanol, 4-[6,7-dimethoxy-2-[4-(trifluoromethyl)phenyl]-4-quinazolinyl]- (CA INDEX NAME)




RN 228118-93-2 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(3-pyridinylmethyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 228118-94-3 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-4-(4-methyl-1-piperazinyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 228118-95-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-[2-(4-phenoxyphenyl)ethyl]- (CA INDEX NAME)




RN 228118-96-5 CAPLUS
 CN Glycine, N-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-, methyl ester (CA INDEX NAME)




RN 228118-97-6 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-6,7-dimethoxy-4-(4-morpholinyl)- (CA INDEX NAME)




RN 228118-98-7 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-2-(4-methylphenyl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 228118-99-8 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-4-(4-morpholinyl)-2-[4-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)



RN 228119-00-4 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-(4-pyridinylmethyl)-
 (CA INDEX NAME)




RN 228119-01-5 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-(2-pyridinylmethyl)-
 (CA INDEX NAME)




RN 228119-02-6 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 228119-03-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7,8-trimethoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 228119-04-8 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-(4-morpholinyl)- (CA INDEX NAME)




RN 228119-05-9 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-(1-piperazinyl)- (CA INDEX NAME)



RN 228119-06-0 CAPLUS
 CN Ethanol, 2-[[2-(4-chlorophenyl)-6,7,8-trimethoxy-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 228119-07-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7,8-trimethoxy-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 228119-08-2 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-[4-(1H-imidazol-1-yl)butyl]-6,7,8-trimethoxy- (CA INDEX NAME)




RN 228119-11-7 CAPLUS

CN Quinazoline, 2-[3,5-bis(trifluoromethyl)phenyl]-6,7,8-trimethoxy-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 228119-12-8 CAPLUS

CN 1,2-Ethanediamine, N2-[2-[3,5-bis(trifluoromethyl)phenyl]-6,7,8-trimethoxy-4-quinazolinyl]-N1,N1-bis(1-methylethyl)- (CA INDEX NAME)




RN 228119-13-9 CAPLUS

CN Quinazoline, 2-[3,5-bis(trifluoromethyl)phenyl]-6,7,8-trimethoxy-4-(4-morpholinyl)- (CA INDEX NAME)




RN 228119-14-0 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-6,7,8-trimethoxy-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 228119-15-1 CAPLUS


CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 228119-17-3 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-(1-oxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 228119-18-4 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-4-(1,1-dioxido-4-thiomorpholinyl)-6,7,8-trimethoxy- (CA INDEX NAME)




RN 228119-19-5 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-[(3-methoxyphenyl)methyl]-2-(4-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 228119-20-8 CAPLUS


CN 4-Quinazolinamine, 6,7-dimethoxy-N-[2-(3-methoxyphenyl)ethyl]-2-(4-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 228119-21-9 CAPLUS


CN 4-Quinazolinamine, 6,7-dimethoxy-2-(4-methylphenyl)-N-[(3-nitrophenyl)methyl]- (CA INDEX NAME)




RN 228119-22-0 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-[2-(2-methoxyphenyl)ethyl]-2-(4-methylphenyl)- (CA INDEX NAME)



RN 228119-23-1 CAPLUS
 CN Quinazoline, 2-(4-chlorophenyl)-6,7-dimethoxy-4-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 228119-24-2 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-2-(4-methylphenyl)-4-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 228119-25-3 CAPLUS

CN Quinazoline, 2-(4-chlorophenyl)-6,7-dimethoxy-4-(1-oxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 228119-26-4 CAPLUS

CN Quinazoline, 6,7-dimethoxy-2-(4-methylphenyl)-4-(1-oxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 228119-27-5 CAPLUS

CN Quinazoline, 2-(4-chlorophenyl)-6,7,8-trimethoxy-4-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 228119-28-6 CAPLUS

CN Quinazoline, 6,7-dimethoxy-2-(4-methylphenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 228119-29-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7,8-trimethoxy-N,N-dipropyl- (CA INDEX NAME)




RN 228119-30-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N,N-dipropyl- (CA INDEX NAME)




RN 228119-31-1 CAPLUS

CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-6,7,8-trimethoxy-N,N-dipropyl- (CA INDEX NAME)




RN 228119-32-2 CAPLUS

CN Quinazoline, 4-(2,6-dimethyl-4-morpholinyl)-6,7-dimethoxy-2-(4-methylphenyl)- (CA INDEX NAME)



RN 228119-33-3 CAPLUS


CN 4-Quinazolinamine, 6,7-dimethoxy-N-(3-methoxypropyl)-2-(4-methylphenyl)- (CA INDEX NAME)



RN 228119-34-4 CAPLUS


CN Quinazoline, 2-(4-chlorophenyl)-4-(2,6-dimethyl-4-morpholinyl)-6,7-

dimethoxy- (CA INDEX NAME)




RN 228119-35-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N-(3-methoxypropyl)-
(CA INDEX NAME)




RN 228119-36-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-6,7-dimethoxy-N,N-bis(2-methoxyethyl)-
(CA INDEX NAME)



RN 228119-38-8 CAPLUS


CN Quinazoline, 2-(4-chlorophenyl)-4-(hexahydro-1H-azepin-1-yl)-6,7-dimethoxy-
(CA INDEX NAME)



RN 228119-39-9 CAPLUS


CN Quinazoline, 2-(4-chlorophenyl)-4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6,7-dimethoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 228119-40-2 CAPLUS

CN Ethanol, 2-[[2-(4-chlorophenyl)-6,7,8-trimethoxy-4-quinazolinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L7 ANSWER 109 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:282208 CAPLUS


DOCUMENT NUMBER: 130:311787

TITLE: Preparation of benzisothiazoles as serotonin antagonists

INVENTOR(S): Lubisch, Wilfried; Dullweber, Uta; Starck, Dorothea;

Steiner, Gerd; Bach, Alfred; Emling, Franz;
Garcia-Ladona, Xavier; Teschendorf, Hans-Jurgen;
Wicke, Karsten
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920616	A1	19990429	WO 1998-EP6300	19981005 <--
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19746612	A1	19990429	DE 1997-19746612	19971022 <--
CA 2307199	A1	19990429	CA 1998-2307199	19981005 <--
AU 9911497	A	19990510	AU 1999-11497	19981005 <--
AU 748613	B2	20020606		
BR 9812948	A	20000808	BR 1998-12948	19981005 <--
EP 1034170	A1	20000913	EP 1998-954330	19981005 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
TR 200001080	T2	20010122	TR 2000-1080	19981005 <--
HU 2000003758	A2	20011028	HU 2000-3758	19981005 <--
HU 2000003758	A3	20011228		
JP 2001520224	T	20011030	JP 2000-516958	19981005 <--
NZ 503604	A	20020301	NZ 1998-503604	19981005 <--
TW 517052	B	20030111	TW 1998-87117331	19981020 <--
ZA 9809571	A	20000425	ZA 1998-9571	19981021 <--
MX 200003136	A	20010131	MX 2000-3136	20000330 <--
BG 104332	A	20010228	BG 2000-104332	20000411 <--
NO 2000001937	A	20000413	NO 2000-1937	20000413 <--
US 6346622	B1	20020212	US 2000-529828	20000420 <--
PRIORITY APPLN. INFO.:			DE 1997-19746612	A 19971022
			WO 1998-EP6300	W 19981005
OTHER SOURCE(S):			MARPAT 130:311787	
GI				




AB Title compds. [I; R = Z1Z2R5; R1,R2 = alkyl; R3,R4 = H, halo, alkyl, alkoxy, etc.; R5 = (hetero)aryl; Z1 = (heteroatom-interrupted) alkylene, etc.; Z2 = azacycloalkylene] were prepared as serotonin antagonists (no data). Thus, I [R = (CH2)3R6, R1 = R2 = Me, R3 = R4 = H](II; R6 = Cl) was condensed with 1-(5-tetralinyl)piperazine (preparation each given) to give II [R6 = 4-(5-tetralinyl)-1-piperazinyl].

IT 223586-67-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzisothiazoles as serotonin antagonists)

RN 223586-67-2 CAPLUS

CN Quinazoline, 4-[4-[3-(3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-2(3H)-
yl)propyl]-1-piperazinyl]-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 110 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:244638 CAPLUS

DOCUMENT NUMBER: 130:311813

TITLE: Preparation of piperazinylisoquinolines and analogs as
serotonin antagonists

INVENTOR(S): Ueno, Kohshi; Sasaki, Atsushi; Kawano, Koki; Okabe,
Tadashi; Kitazawa, Noritaka; Takahashi, Keiko;
Yamamoto, Noboru; Suzuki, Yuichi; Matsunaga, Manabu;
Kubota, Atsuhiko

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 740 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9918077	A1	19990415	WO 1998-JP4465	19981002 <--
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000053647	A	20000222	JP 1998-281752	19981002 <--
JP 3989102	B2	20071010		
EP 1020445	A1	20000719	EP 1998-945593	19981002 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6340759	B1	20020122	US 2000-509778	20000331 <--
US 20020013460	A1	20020131	US 2001-852850	20010511 <--
US 6790844	B2	20040914		
US 20040204421	A1	20041014	US 2004-796673	20040310
US 6875761	B2	20050405		

PRIORITY APPLN. INFO.:

JP 1997-284290

A 19971002

JP 1998-153416

T0 19980602

WO 1998-JP4465

W 19981002

US 2000-509778

A3 20000331


US 2001-852850

A3 20010511


OTHER SOURCE(S):

MARPAT 130:311813

GI



I



II

AB The title compds. I [ring A = benzene, pyridine, thiophene or furan ring; B = (un)substituted aryl, etc.; R1 = H, halo, etc.; R2 = 4-morpholinyl, etc.; R3 = H, halo, etc.; n = 0, or 1 - 6] are prepared I are central muscle relaxing drugs for treating, ameliorating or preventing spastic paralysis or ameliorating myotonia. In an in vitro test for 5HT1 receptor antagonism, the title compound II showed the Ki value of 21.2 nM.


IT 223551-49-3P 223551-50-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperazinyloquinolines and analogs as serotonin antagonists)

RN 223551-49-3 CAPLUS

CN Quinazoline, 4-(4-ethyl-1-piperazinyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 223551-50-6 CAPLUS
 CN Quinazoline, 4-(4-ethyl-1-piperazinyl)-2-(4-methoxyphenyl)-, hydrochloride
 (1:2) (CA INDEX NAME)




● 2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 111 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:130391 CAPLUS
 DOCUMENT NUMBER: 130:196662
 TITLE: 2,2'-Bridged bis-2,4-diaminoquinazolines as apamine-sensitive potassium channel blockers
 INVENTOR(S): Schohe-Loop, Rudolf; Seidel, Peter-Rudolf; Bullock, William; Hubsch, Walter; Feurer, Achim; Lerchen, Hans-Georg; Terstappen, Georg; Schuhmacher, Joachim; Vander, Staay Franz-Josef; Schmidt, Bernard; Fanelli, Richard J.; Chisholm, Jane C.; Mccarthy, Richard T.
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
 SOURCE: U.S., 16 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
US 5874438	A	19990223	US 1996-729128	19961011 <--
PRIORITY APPLN. INFO.:			US 1996-729128	19961011
OTHER SOURCE(S):	MARPAT 130:196662			
GI				




AB Title compds. I [A, A', D, D', E, E' = H, halogen, OH, NO₂, CF₃, OCF₃, alkyl, alkoxy; L = (un)substituted ≤20C alkylene, oxaalkylene, azaalkylene, thiaalkylene; R₁, R₂ = H, (un)substituted Ph, alkyl; R₁NLNR₂ = (un)substituted 5-8-membered heterocycle; R₃-R₆ = H, (un)substituted Ph, alkyl; NR₃R₄, NR₅R₆ = heterocyclic] were prepared for use as apamine-sensitive potassium channel blockers in treatment of dementia, depression, myotonic dystrophy, or asthma. Thus, 2,4-dichloroquinazoline was monoaminated and treated with 1,5-diazocane to give 1,5-bis(4-diethylaminoquinazolin-2-yl)-1,5-diazocane which had a K_i for inhibition of binding of apamine to bovine cerebral membrane of 340 nM/L.

IT 220747-11-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bridged bis-2,4-diaminoquinazolines as apamine-sensitive potassium channel blockers)

RN 220747-11-5 CAPLUS


CN 2,4-Quinazolinediamine, N2-[[2-[4-(diethylamino)-2-quinazolinyl]-2,3,3a,4,5,6,7,7a-octahydro-4,7-etheno-1H-isoindol-4-yl]methyl]-N4,N4-diethyl- (CA INDEX NAME)



IT 220747-60-4P 220747-66-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bridged bis-2,4-diaminoquinazolines as apamine-sensitive potassium channel blockers)


RN 220747-60-4 CAPLUS

CN 4-Quinazolinamine, 2,2'-(2,3-dihydro-1H-1,4-benzodiazepine-1,4(5H)-
diyl)bis[N,N-diethyl- (9CI) (CA INDEX NAME)



RN 220747-66-0 CAPLUS

CN 2,4-Quinazolinediamine, N2-[[2-[4-(diethylamino)-2-quinazolinyl]-
2,3,3a,4,5,6,7,7a-octahydro-4,7-etheno-1H-isoindol-4-yl]methyl]-N4,N4-
diethyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 112 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:89741 CAPLUS

DOCUMENT NUMBER: 130:276225

TITLE: Synthesis, Pharmacological Evaluation, and
Structure-Activity Relationship and Quantitative
Structure-Activity Relationship Studies on Novel
Derivatives of 2,4-Diamino-6,7-dimethoxyquinazoline
 α 1-Adrenoceptor Antagonists

AUTHOR(S): Leonardi, Amedeo; Motta, Gianni; Boi, Carlo; Testa,
Rodolfo; Poggesi, Elena; De Benedetti, Pier G.;
Menziani, M. Cristina


CORPORATE SOURCE: Recordati S.p.A., Milan, 20148, Italy
 SOURCE: Journal of Medicinal Chemistry (1999),
 42(3), 427-437
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A new series of novel piperazine and non-piperazine derivs. of 2,4-diamino-6,7-dimethoxyquinazoline was synthesized and evaluated for binding affinity toward α 1-adrenergic and other G-protein-coupled aminergic receptors. The α 1-adrenoceptor (AR) subtype selectivity was also investigated for the most interesting compds. Only 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2-isopropyl-6-methoxyphenoxy)acetyl]piperazine showed moderate selectivity toward the α 1b-AR subtype. Selected compds. were tested in vivo in a dog model indicating activity on blood pressure and on the lower urinary tract. 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(benzoylacetyl)piperazine showed in vivo potency close to that of prazosin. Powerful interpretative and predictive theor. QSAR models have been obtained. The theor. descriptors employed in the rationalization of the α 1-adrenergic binding affinity depict the key features for receptor binding which can be summarized in an electrostatic interaction between the protonated amine function and a primary nucleophilic site of the receptor, complemented by short-range attractive (polar and dispersive) and repulsive (steric) intermol. interactions. Moreover, on predictive grounds, the ad hoc derived size and shape QSAR model developed in a previous paper (Rastelli, G.; et al. J. Mol. Struct. 1991, 251, 307-318) proved to be successful in predicting nanomolar α 1-adrenergic binding affinity for 4-amino-6,7-dimethoxy-2-(1,2,3,4-tetrahydrobenz[f]isoquinolin-2-yl)quinazoline.

IT 222832-29-3P 222832-36-2P
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (synthesis and pharmacol. evaluation and structure-activity relationship and quant. structure-activity relationship studies on novel derivs. of diaminodimethoxyquinazoline α 1-adrenoceptor antagonists)

RN 222832-29-3 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 222832-36-2 CAPLUS


CN 4-Quinazolinamine, 2-(1,4-dihydrobenz[f]isoquinolin-3(2H)-yl)-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 113 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:48710 CAPLUS
 DOCUMENT NUMBER: 130:125085
 TITLE: Preparation of quinazoline analogs and related compounds for treating inflammatory conditions
 INVENTOR(S): Palanki, Moorthy S. S.; Suto, Mark J.
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901441	A1	19990114	WO 1998-US13483	19980629 <--
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5939421	A	19990817	US 1997-886198	19970701 <--
AU 9881754	A	19990125	AU 1998-81754	19980629 <--
US 6150372	A	20001121	US 1999-340557	19990628 <--
PRIORITY APPLN. INFO.:			US 1997-886198	A 19970701
			WO 1998-US13483	W 19980629
OTHER SOURCE(S):		MARPAT 130:125085		
GI				




AB The title compds. [I; R10 = II-IV; A = CR7, N; R1, R3 = H, (un)substituted C1-8 alkyl, C6-12 aryl; R2 = (un)substituted C1-8 alkyl, C6-12 aryl, etc.; R4 = H, C1-8 alkyl; R5-R8 = H, NO2, CN, etc.; R11 = H, (un)substituted C1-8 alkyl, C6-12 aryl; R12 = H, CO2R9, CONHR9; R9 = H, (un)substituted C1-8 alkyl, C6-12 aryl, etc.], having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory (such as rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, transplant rejection, sepsis, ARDS, and asthma) and autoimmune diseases (such as multiple sclerosis, psoriasis, inflammatory bowel disease, glomerulonephritis, uveitis, and chronic hepatitis), and trauma, oxidative stress, cell death, irradiation damage, ischemia, reperfusion, cancer and viral infection, were prepared. Thus, reaction of 4-chloro-2-(2'-thienyl)quinazoline (preparation given) with hydrazine in THF followed by treatment of the resulting intermediate with citraconic anhydride in chloroform afforded 98% V which showed IC50 of 0.07 μ M against AP-1 and IC50 of 0.04 μ M against NF κ B.

IT 219773-50-9P 219773-51-0P 219773-55-4P
 219773-56-5P 219773-60-1P 219773-64-5P
 219773-68-9P 219773-72-5P 219773-75-8P
 219773-78-1P 219773-81-6P 219773-85-0P
 219773-89-4P 219773-94-1P 219774-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline analogs and related compds. for treating inflammatory conditions)


RN 219773-50-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[2-(2-thienyl)-4-quinazolinyl]amino]-
 (CA INDEX NAME)




RN 219773-51-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[methyl[2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 219773-55-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-56-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]methylamino]-3-methyl- (CA INDEX NAME)




RN 219773-60-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[6-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-64-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[7-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-68-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[8-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-72-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 1-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-75-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[6,7,8-trimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 219773-78-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 1-[[5-fluoro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-81-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-[[5-chloro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-85-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[5-methyl-2-(2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 219773-89-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-[[7-(dimethylamino)-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (CA INDEX NAME)




RN 219773-94-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 219774-15-9 CAPLUS
 CN 2-Butenedioic acid, 2-methyl-, 1-[2-[6-methoxy-2-(2-thienyl)-4-quinazolinyl]hydrazide], (2Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 219774-16-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinazoline analogs and related compds. for treating inflammatory conditions)
 RN 219774-16-0 CAPLUS
 CN Quinazoline, 4-hydrazinyl-6-methoxy-2-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 114 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:745041 CAPLUS
 DOCUMENT NUMBER: 130:10618
 TITLE: Modulating serine/threonine protein kinase function with quinazoline-based compounds and their use as antitumor and anti-fibrotic agents
 INVENTOR(S): Tang, Peng C.; McMahon, Gerald; Weinberger, Heinz; Kutscher, Bernhard; App, Harald
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850370	A1	19981112	WO 1998-US9060	19980501 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9803669	A	19991101	ZA 1998-3669	19980430 <--
CA 2288778	A1	19981112	CA 1998-2288778	19980501 <--
AU 9872829	A	19981127	AU 1998-72829	19980501 <--
EP 981519	A1	20000301	EP 1998-920203	19980501 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6204267	B1	20010320	US 1998-71682	19980501 <--
JP 2001524128	T	20011127	JP 1998-548336	19980501 <--
IN 1998CA00786	A	20050318	IN 1998-CA786	19980504
US 20010014679	A1	20010816	US 2001-769360	20010126 <--
US 6911446	B2	20050628		
PRIORITY APPLN. INFO.:			US 1997-45351P	P 19970502
			US 1997-60152P	P 19970926
			US 1998-71682	A3 19980501
			WO 1998-US9060	W 19980501
OTHER SOURCE(S):			CASREACT 130:10618; MARPAT 130:10618	
GI				




AB The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compds (I). The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions (e.g., tumors, fibrotic disorders, or other signal transduction aberrations) in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compds. and pharmaceutical compns. comprising these compds. Syntheses and biol. activities are provided for 38 quinazoline-based compds.

IT 215925-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modulating serine/threonine protein kinase function with quinazoline-based compds. and their use as antitumor and anti-fibrotic agents)

RN 215925-73-8 CAPLUS

CN 4-Quinazolinamine, 5-phenoxy-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 115 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:721497 CAPLUS

DOCUMENT NUMBER: 130:3852

TITLE: Quinoline and quinazoline compounds useful in therapy of benign prostatic hyperplasia

INVENTOR(S): Collis, Alan John; Fox, David Nathan Abraham

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 875506	A1	19981104	EP 1998-302968	19980416 <--
EP 875506	B1	20030226		



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

AT 233242	T	20030315	AT 1998-302968	19980416 <--
ES 2190809	T3	20030816	ES 1998-302968	19980416 <--
CA 2236239	A1	19981101	CA 1998-2236239	19980429 <--
CA 2236239	C	20030318		
BR 9801506	A	20000208	BR 1998-1506	19980429 <--
JP 10316664	A	19981202	JP 1998-121990	19980501 <--
JP 3076786	B2	20000814		
MX 9803607	A	20000131	MX 1998-3607	19980504 <--
US 20030045525	A1	20030306	US 2002-252852	20020923 <--
US 6649620	B2	20031118		
US 20040034032	A1	20040219	US 2003-640314	20030813
PRIORITY APPLN. INFO.:			GB 1997-8917	A 19970501
			US 1998-67608	B1 19980428
			US 2000-591195	B1 20000609
			US 2002-252852	A3 20020923

OTHER SOURCE(S): MARPAT 130:3852


GI



AB Title compds. I [wherein R1 = C1-4 alkoxy (un)substituted by 1 or more F atoms; R2 = aryl or heteroaryl, (un)substituted by C1-4 alkyl or SO2NH2; R3 = 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least 1 heteroatom selected from N, O, and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least 1 heteroatom selected from N, O, and S, the ring system as a whole being (un)substituted by OH, C1-4 alkyl, C1-4 alkoxy, halo, and/or NHSO2-(C1-4 alkyl); X = CH or N; L = certain cyclic or chain amino groups; or L may be absent] and their pharmaceutically acceptable salts are useful in the treatment of a variety of disorders including benign prostatic hyperplasia (no data). Examples include syntheses of approx. 20 compds. I and a variety of intermediates. For instance, 5-hydroxy-4-methoxy-2-nitrobenzoic acid was converted to the Me ester (87%), followed by conversion to the 5-triflate (85%), Pd-catalyzed phenylation of the latter (99%), reduction of the nitro group to amino (99%), and 2-step cyclization with sodium cyanate (91%), to give 7-methoxy-6-phenylquinazoline-2,4-dione. Treatment of this with POCl3 and then methanolic NH3 gave 55% 4-amino-2-chloro-7-methoxy-6-phenylquinazoline, which was condensed with 1-(4-morpholinesulfonyl)-1,4-diazepane HCl (16%) to give title compound


II.HCl.

IT 215659-18-0P, 4-Amino-7-methoxy-6-phenyl-2-(5,6,7,8-tetrahydro-1,6-naphthyrid-6-yl)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(product; preparation of quinoline and quinazoline derivs. for therapy of benign prostatic hyperplasia)
RN 215659-18-0 CAPLUS
CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-6-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 116 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:711702 CAPLUS
DOCUMENT NUMBER: 130:63543
TITLE: Antibacterial effect of some 2,6-disubstituted 4-anilinoquinazolines
AUTHOR(S): Gottasova, R.; Kubikova, J.; Cipak, L.
CORPORATE SOURCE: Department of Biochemistry and Microbiology, Faculty of Chemical Technology, Slovak University of Technology, Bratislava, 812 37, Slovakia
SOURCE: Folia Microbiologica (Prague) (1998), 43(6), 679-682
CODEN: FOMIAZ; ISSN: 0015-5632
PUBLISHER: Institute of Microbiology, Academy of Sciences of the Czech Republic
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Two synthetic 2,6-disubstituted 4-anilinoquinazolines (I and II) exerted a significant effect on the Gram-pos. bacteria Bacillus subtilis and Staphylococcus aureus. None of 12 tested derivs. influenced Escherichia

coli, Proteus mirabilis, and Pseudomonas aeruginosa. Derivs. having the aromatic ring non-substituted or substituted by bromine, the pyrimidine ring by Ph, morpholine or piperidine and the aniline skeleton non-substituted or substituted by Me or amino group exerted a considerable antibacterial activity. II is considered as a potential antibacterial compound


IT 40288-70-8 94078-50-9 94078-54-3
94078-57-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibacterial effect of some disubstituted anilinoquinazolines)


RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 94078-50-9 CAPLUS

CN 4-Quinazolinamine, N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 94078-54-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chlorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)



RN 94078-57-6 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 117 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:603674 CAPLUS

DOCUMENT NUMBER: 129:325734

ORIGINAL REFERENCE NO.: 129:66247a,66250a

TITLE: A Novel Class of Adenosine A3 Receptor Ligands. 2. Structure Affinity Profile of a Series of Isoquinoline and Quinazoline Compounds

AUTHOR(S): Van Muijlwijk-Koezen, Jacqueline E.; Timmerman, Henk; Link, Regina; Van der Goot, Henk; IJzerman, Adriaan P.

CORPORATE SOURCE: Division of Medicinal Chemistry Leiden/Amsterdam Center for Drug Research Department of Pharmacochimistry, Vrije Universiteit, Amsterdam, 1081 HV, Neth.

SOURCE: Journal of Medicinal Chemistry (1998), 41(21), 3994-4000

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English


AB 1-Substituted 3-(2-pyridinyl)isoquinolines have been shown to form a novel class of adenosine A3 receptor ligands. In the present study further investigations of this new lead and the structure affinity relationships of this class of compds. are described. First, the influence of an amide group at position 1 of the isoquinoline ring on the adenosine A3 receptor affinity was determined. A carboxamide proved to be a useful spacer between the isoquinoline and a Ph ring. N-[2-(2-pyridinyl)isoquinolin-4-yl]benzamide (VUF8507) had an affinity of 200 nM at the adenosine A3 receptor. Second, we investigated the effects of substitution of the benzamide ring of VUF8507 with a series of mono- and disubstituted N-[3-(2-pyridinyl)isoquinoline]benzamides. The ratio of the tautomers of the benzamides was determined in the solid state and in solution by spectroscopic techniques (IR and NMR). Affinities were determined in radioligand binding assays at rat brain A1 and A2A receptors and at cloned human A3 receptor. The benzamides showed higher adenosine A3 receptor affinity than aliphatic amides. We propose that the adenosine A3 receptor affinity of the different benzamides is related to their presence in either the iminol or amide form. Ligands present in the iminol form showed relatively high adenosine A3 receptor affinity. Finally, we explored the influence of replacement of C4 of the isoquinoline ring by a nitrogen atom. Comparison of isoquinolines with the corresponding quinazolines revealed that both compds. showed similar adenosine A3 receptor affinity. These

investigations led to potent and selective human adenosine A3 receptor ligands with affinities in the nanomolar range. The subtype-selective compound 4-methoxy-N-[2-(2-pyridinyl)quinazolin-4-yl]benzamide (VUF8504) with an affinity of 17.0 nM at the human adenosine A3 receptor might become a useful tool in the pharmacol. characterization or the investigation of the physiol. function of this receptor.


IT 91748-43-5P 91748-44-6P 91748-45-7P
 91748-46-8P 91748-48-0P 215172-44-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (structure of isoquinoline and quinazoline compds. as adenosine A3 receptor ligands)
 RN 91748-43-5 CAPLUS
 CN Acetamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-44-6 CAPLUS
 CN Benzamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-45-7 CAPLUS
 CN Benzamide, N-benzoyl-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-46-8 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-48-0 CAPLUS
 CN Methanimidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 215172-44-4 CAPLUS
 CN Benzamide, 4-methoxy-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



IT 40172-82-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (structure of isoquinoline and quinazoline compds. as adenosine A3
 receptor ligands)
 RN 40172-82-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 118 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:490639 CAPLUS
 DOCUMENT NUMBER: 129:136176
 ORIGINAL REFERENCE NO.: 129:27845a,27848a
 TITLE: Quinoline and quinazoline compounds useful in therapy,
 particularly in the treatment of benign prostatic
 hyperplasia
 INVENTOR(S): Fox, David Nathan Abraham
 PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.; Fox, David Nathan
 Abraham
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9830560	A1	19980716	WO 1998-EP143	19980106 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 444013	B	20010701	TW 1997-86117203	19971118 <--
CA 2277473	A1	19980716	CA 1998-2277473	19980106 <--
CA 2277473	C	20030812		
EP 968208	A1	20000105	EP 1998-904058	19980106 <--
EP 968208	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AP 819	A	20000403	AP 1998-1175	19980106 <--
W: BW, GM, KE, MW, UG, ZW				
JP 2000507966	T	20000627	JP 1998-530565	19980106 <--
JP 3357677	B2	20021216		
NZ 336302	A	20000825	NZ 1998-336302	19980106 <--
HU 2000000942	A2	20010428	HU 2000-942	19980106 <--
HU 2000000942	A3	20020628		
CN 1093858	C	20021106	CN 1998-801748	19980106 <--
AT 242238	T	20030615	AT 1998-904058	19980106 <--
PT 968208	T	20030930	PT 1998-904058	19980106 <--
ES 2198695	T3	20040201	ES 1998-904058	19980106
CZ 295580	B6	20050817	CZ 1999-2436	19980106
SK 284779	B6	20051103	SK 1999-907	19980106
IL 130762	A	20051218	IL 1998-130762	19980106
HR 980010	B1	20020630	HR 1998-10	19980108 <--
BG 63918	B1	20030630	BG 1999-103560	19990707 <--
NO 9903396	A	19990709	NO 1999-3396	19990709 <--
NO 318609	B1	20050418		
US 6365599	B1	20020402	US 2000-586503	20000602 <--
HK 1025327	A1	20030711	HK 2000-104585	20000724 <--
US 20020040028	A1	20020404	US 2001-7753	20011113 <--
US 6521629	B2	20030218		
CN 1403453	A	20030319	CN 2001-143291	20011226 <--
US 20030130259	A1	20030710	US 2002-318902	20021213 <--
US 6653302	B2	20031125		
HK 1054389	A1	20051014	HK 2003-106677	20030917

PRIORITY APPLN. INFO.:

GB 1997-504	A 19970111
WO 1998-EP143	W 19980106
US 1999-341228	A3 19990707
US 2000-586503	A3 20000602
US 2001-7753	A3 20011113

OTHER SOURCE(S): MARPAT 129:136176
GI



AB I [R1 = C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 = H, C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 = 5- or 6-membered heterocyclic ring, the ring being optionally substituted; R4 = 4-, 5-, 6- or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; X = CH, N; L is absent or represents a N-containing cyclic group or chain], useful in treatment of benign prostatic hyperplasia, were prepared E.g., 4-amino-6,7-dimethoxy-2-[4-(4-morpholinecarbonyl)-1,4-diazepan-1-yl]-5-(oxazol-2-yl)quinoline was prepared


IT 210538-24-2P 210538-26-4P 210538-28-6P
210538-30-0P 210538-32-2P 210538-34-4P
210538-36-6P 210538-38-8P 210538-40-2P
210538-42-4P 210538-44-6P 210538-46-8P
210538-47-9P 210538-48-0P 210538-59-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoline and quinazoline derivs. useful in treatment of benign prostatic hyperplasia)


RN 210538-24-2 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-26-4 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-6,7-dimethoxy-5-(2-pyrimidinyl)- (CA INDEX NAME)




RN 210538-28-6 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-6,7-dimethoxy-5-(2-pyrimidinyl)- (CA INDEX NAME)




RN 210538-30-0 CAPLUS

CN 7-Isoquinolinesulfonamide, 2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro- (CA INDEX NAME)




RN 210538-32-2 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-dihydro-2H-isoindol-2-yl)-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-34-4 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-36-6 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 210538-38-8 CAPLUS

CN 4-Quinazolinamine, 2-[3,4-dihydro-7-(4-morpholinylsulfonyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-40-2 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydro-2-methylpyrido[4,3-d]pyrimidin-6(5H)-yl)-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-42-4 CAPLUS

CN 4-Quinazolinamine, 2-(5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-44-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)




RN 210538-46-8 CAPLUS


CN 4-Quinazolinamine, 2-[3,4-dihydro-7-(1-piperazinylsulfonyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-47-9 CAPLUS
 CN 4-Quinazolinamine, 2-[5-[(diethylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




RN 210538-48-0 CAPLUS
 CN Methanesulfonamide, N-[2-[4-amino-6,7-dimethoxy-5-(2-pyrimidinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (CA INDEX NAME)




RN 210538-59-3 CAPLUS
 CN 4-Quinazolinamine, 2-[7,8-dihydro-2-(4-morpholinyl)-1,6-naphthyridin-6(5H)-yl]-6,7-dimethoxy-5-(2-pyridinyl)- (CA INDEX NAME)




IT 192869-55-9P 210538-69-5P 210538-77-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinoline and quinazoline derivs. useful in treatment of benign prostatic hyperplasia)
 RN 192869-55-9 CAPLUS
 CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-5-iodo-6,7-dimethoxy- (CA INDEX NAME)



RN 210538-69-5 CAPLUS
 CN 4-Quinazolinamine, 2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-5-iodo-6,7-dimethoxy- (CA INDEX NAME)



RN 210538-77-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[2-[4-amino-6,7-dimethoxy-5-(2-pyridinyl)-2-quinazolinyl]-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 119 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:485716 CAPLUS

DOCUMENT NUMBER: 129:156410

ORIGINAL REFERENCE NO.: 129:31701a, 31704a

TITLE: A General Approach for the Prediction of the Intestinal Absorption of Drugs: Regression Analysis Using the Physicochemical Properties and Drug-Membrane Electrostatic Interaction

AUTHOR(S): Sugawara, Mitsuru; Takekuma, You; Yamada, Harumi; Kobayashi, Michiya; Iseki, Ken; Miyazaki, Katsumi

CORPORATE SOURCE: Department of Pharmacy Hokkaido University Hospital School of Medicine, Hokkaido University, Sapporo, 060, Japan

SOURCE: Journal of Pharmaceutical Sciences (1998), 87(8), 960-966

CODEN: JPMSAE; ISSN: 0022-3549


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A general method for predicting the intestinal absorption of a wide range of drugs using multiple regression anal. of their physicochem. properties and the drug-membrane electrostatic interaction was developed. The absorption rates of tested drugs from rat jejunum were measured by the in situ single-pass perfusion technique. The drugs used in this study were divided into three groups for regression anal., and a smaller "test" set of compds. was used to assess the predictive capacity of the regression equation. When the anal. was applied to each resp. group of drugs (i.e., anionic, cationic, and nonionized compds.), obtained regression coeffs. were 0.569, 0.821, 0.728 by using the organic solvent (n-octanol)/buffer partition coefficient, 0.730, 0.734, 0.914 using the permeation rate across a silicon membrane, and 0.790, 0.915, 0.941 using an EVA membrane, resp. However, smaller regression coeffs. of 0.377, 0.468, and 0.718 were obtained when these three groups of drugs were put together for prediction. Meanwhile, correlation was improved remarkably when drug-membrane electrostatic interactions, namely, hydrogen-bonding donor ($H\alpha$) and acceptor ($H\beta$) activity or index of electricity (E_c), were added to the other parameters of lipophilicity and permeation rate across the EVA membrane ($r = 0.880$ and 0.883 , resp.). Moreover, the equation obtained from these regression analyses was applicable even to the prediction of the absorption of the zwitterionic drugs. These results suggest that including the electrostatic interaction parameters in addition to lipophilicity and permeability across artificial membranes would afford a better prediction for the intestinal absorption of the vast majority of drugs.

IT 211117-00-9, ONO 1505
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (prediction of intestinal absorption of drugs by regression anal. using physicochem. properties and drug-membrane electrostatic interaction)
 RN 211117-00-9 CAPLUS
 CN Ethanol, 2-[2-[[6-methoxy-2-(1H-pyrrol-1-yl)-4-quinazolinyl]amino]ethoxy]-, methanesulfonate (1:1) (CA INDEX NAME)
 CM 1
 CRN 211116-99-3
 CMF C17 H20 N4 O3



CM 2
 CRN 75-75-2
 CMF C H4 O3 S



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 120 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:402413 CAPLUS
 DOCUMENT NUMBER: 129:81658
 ORIGINAL REFERENCE NO.: 129:16861a
 TITLE: Preparation of azetidinones as inhibitors of the enzymic activity of psa
 INVENTOR(S): Anderson, Benjamin A.; Becker, Gerald W.; Carty, James A.; Harn, Nancy K.; Hatfield, Lowell D.; et al.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Anderson, Benjamin A.; Becker, Gerald W.; Carty, James A.
 SOURCE: PCT Int. Appl., 184 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825895	A1	19980618	WO 1997-US22573	19971209 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP,				

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
 UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG

CA 2274958	A1	19980618	CA 1997-2274958	19971209 <--
AU 9855970	A	19980703	AU 1998-55970	19971209 <--
EP 944594	A1	19990929	EP 1997-952334	19971209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9714394	A	20000516	BR 1997-14394	19971209 <--
HU 2000000288	A2	20010129	HU 2000-288	19971209 <--
HU 2000000288	A3	20010428		
MX 9905473	A	20000131	MX 1999-5473	19990611 <--

PRIORITY APPLN. INFO.:

US 1996-33179P	P	19961213
US 1997-40362P	P	19970313
US 1997-40539P	P	19970313
US 1997-40543P	P	19970313
US 1997-44032P	P	19970313
US 1997-40804P	P	19970318
US 1997-40805P	P	19970318
US 1997-47054P	P	19970519
US 1997-47055P	P	19970519
US 1997-50721P	P	19970625
WO 1997-US22573	W	19971209

OTHER SOURCE(S): MARPAT 129:81658
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I; R1 = (un)substituted aryl, heterocycle; R2 = alkenyl, aryl, heterocycle; R3 = heterocycle, COOR, CSNHR4; R = alkenyl, alkyl, chcloalkyl, etc.; R4 = arylalkenyl, heterocycloalkenyl] their stereoisomers, pharmaceutical salts and solvates as well as certain intermediates are prepared and are tested as inhibitors of the enzymic activity of Prostate-Specific Antigen (PSA) as well as for treating prostatic cancer (Pca), Pca metastasis, benign prostatic hyperplasia (BPH) and breast cancer (Bc) with various compns. being employed in the forms of tablets, aerosols, ointments, sterile injectable solns., etc. Title compound II was prepared from 3-formylpyridine and 4-methoxyalanine followed by 2+2 cycloaddn. with III, deprotection, and acylation with phenoxycarbonyl chloride.

IT 209354-43-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azetidinones as inhibitors of the enzymic activity of psa)

RN 209354-43-8 CAPLUS

CN 2-Oxazolidinone, 3-[(3R,4R)-2-oxo-1-(2-phenyl-4-quinazolinyl)-4-[2-(3-pyridinyl)ethenyl]-3-azetidiny]-4-phenyl-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 121 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:398239 CAPLUS
 DOCUMENT NUMBER: 129:67793
 ORIGINAL REFERENCE NO.: 129:14075a,14078a
 TITLE: Preparation of heterocyclylsulfonamides as potassium channel blockers.
 INVENTOR(S): Brendel, Joachim; Lang, Hans Jochen; Gerlach, Uwe; Weidmann, Klaus
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 50 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 847996	A1	19980617	EP 1997-121437	19971205 <--
EP 847996	B1	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19652213	A1	19980618	DE 1996-19652213	19961216 <--
DE 19730326	A1	19990121	DE 1997-19730326	19970715 <--
IN 1997MA02740	A	20050304	IN 1997-MA2740	19971128
AT 234821	T	20030415	AT 1997-121437	19971205 <--
PT 847996	T	20030731	PT 1997-121437	19971205 <--
ES 2195071	T3	20031201	ES 1997-121437	19971205 <--
NO 9705887	A	19980617	NO 1997-5887	19971215 <--
ZA 9711245	A	19980617	ZA 1997-11245	19971215 <--
AU 9748373	A	19980618	AU 1997-48373	19971215 <--
AU 725699	B2	20001019		
CN 1185435	A	19980624	CN 1997-125504	19971215 <--
JP 10182610	A	19980707	JP 1997-345469	19971215 <--
US 5856338	A	19990105	US 1997-990455	19971215 <--
BR 9706142	A	19990518	BR 1997-6142	19971215 <--
HU 9702475	A2	19990628	HU 1997-2475	19971215 <--
HU 9702475	A3	20000128		
CA 2224885	A1	19980616	CA 1997-2224885	19971216 <--
PRIORITY APPLN. INFO.:			DE 1996-19652213	A 19961216
			DE 1997-19730326	A 19970715
OTHER SOURCE(S):	MARPAT 129:67793			

GI




AB Title compds. [I; X = O, S, SO, SO₂, NR₇, CR_{8a}R_{8b}, CO; R₇ = H, (CaH_{2a})R₉, etc.; a = 0-8; R₉ = H, CF₃, C₂F₅, C₃F₇, cycloalkyl, Me₂N, Et₂N, piperidinyl, pyrrolidinyl, morpholinyl, etc.; R₁R₇ = bond; R_{8a} = H, CF₃, C₂F₅, C₃F₇, alkyl, (substituted) Ph; R_{8b} = H, alkyl, OR₁₀, CO₂R₁₀, COR₁₀; R₁₀ = H, alkyl; Y = N, CR₁₁; R₁₁ = H, alkyl; R₁, R₂ = H, CF₃, C₂F₅, C₃F₇, F, Cl, OMe, alkyl, (substituted) Ph; R₁R₂ = C₂-10 alkylene; R₃ = R₁₂CnH_{2n}R₁₃, R₁₂CnH_{2n}, etc.; R₁₂ = H, Me, cycloalkyl, CF₃, C₂F₅, C₃F₇; R₁₃ = H, alkyl; R₁₂R₁₃ = bond; R₃R₄ = C₃-8 alkylene, etc.; R₄ = R₁₄CrH_{2r}, etc.; R₁₄ = Me, CF₃, C₂F₅, C₃F₇, cycloalkyl, OH, CO₂H, amino, piperidinyl, pyrrolidinyl, morpholinyl, etc.; R₅R₆ = CR₁₅:CR₁₆CR₁₇:CR₁₈, CR₁₅:CR₁₆CR₁₇:N, SCR₁₅:CR₁₆, etc.; R₁₅-R₁₈ = H, F, Cl, Br, iodo, alkyl, cycloalkyl, cyano, CF₃, C₂F₅, C₃F₇, N₃, NO₂, thienyl, (substituted) Ph, etc.], were prepared Thus, EtSO₂NHMe in DMA was stirred 4 h with NaH; 4-chloro-2-phenylquinazoline in DMA was added and the mixture was stirred 3 days to give 4-(N-ethylsulfonyl-N-methyl)amino-2-phenylquinazoline.

IT 209120-58-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclylsulfonamides as potassium channel blockers)

RN 209120-58-1 CAPLUS

CN Ethanesulfonamide, N-methyl-N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 122 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:304032 CAPLUS
 DOCUMENT NUMBER: 129:62431
 ORIGINAL REFERENCE NO.: 129:12765a,12768a
 TITLE: Computer modeling of size and shape descriptors of α 1-adrenergic receptor antagonists and quantitative structure-affinity/selectivity relationships
 AUTHOR(S): Montorsi, Monia; Menziani, M. Cristina; Cocchi, Marina; Fanelli, Francesca; De Benedetti, Pier G.

CORPORATE SOURCE: Dipartimento di Chimica, Universita di Modena, Modena,
41100, Italy
SOURCE: Methods (Orlando, Florida) (1998), 14(3),
239-254
CODEN: MTHDE9; ISSN: 1046-2023
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Computational chemical and mol. modeling procedures allow the authors to define and compute ad hoc size and shape descriptors on the different prototropic forms assumed by drugs in biotest solns. Together with exptl. data measured on a well-identified target receptor, these descriptors are essential elements for obtaining simple, consistent, comparable, and easily interpretable theor. quant. structure-activity relation (QSAR) models based on the ligand similarity-target receptor complementarity paradigm. In this context, quant. size and shape affinity/subtype selectivity relationships have been modeled for a large set of very heterogeneous α_1 -, α_1 b-, and α_1 d- adrenergic receptor antagonists. The linear QSAR models generated have been validated by predicting both binding affinity and selectivity of a test set of noncongeneric antagonists. The satisfactory results obtained highlight both the simplicity and the versatility of the approach presented.

IT 139644-60-3 173059-56-8

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(computer modeling of size and shape descriptors of α_1 -adrenergic receptor antagonists and quant. structure-affinity/selectivity relationships)


RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



RN 173059-56-8 CAPLUS

CN 4-Quinazolinamine, 2-[1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]-6,7-dimethoxy- (CA INDEX NAME)




REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 123 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:226895 CAPLUS
 DOCUMENT NUMBER: 128:304069
 ORIGINAL REFERENCE NO.: 128:60109a,60112a
 TITLE: Inhibitors for nitric oxide formation
 INVENTOR(S): Taniguchi, Naoyuki; Nakai, Hisao
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF


DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10087492	A	19980407	JP 1997-183227	19970625 <--
PRIORITY APPLN. INFO.:			JP 1996-164593	A 19960625
AB	Imidazolyl quinazoline, aminopyrimidine, and pyrimidine derivs. (Markush included) and their salts are claimed as inhibitors for nitric oxide formation for prevention and treatment of related diseases e.g. shock, hypotension, chronic rheumatism, ulcerative colitis, brain ischemia, tumor, insulin-dependent diabetes, etc. Examples of pharmaceutical tablets and injections were formulated.			
IT	157863-66-6 157863-67-7 157863-74-6 157863-90-6 157863-91-7 157863-96-2 170985-90-7 171661-64-6 171661-66-8 206750-62-1 206750-64-3 206750-65-4			
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitors for nitric oxide formation for treatment of related diseases)			
RN	157863-66-6 CAPLUS			
CN	4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)- (CA INDEX NAME)			



RN 157863-67-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-74-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)- (CA INDEX NAME)



RN 157863-91-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-96-2 CAPLUS


CN Ethanol, 2-[[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 170985-90-7 CAPLUS


CN Ethanol, 2-[[2-[[6-methoxy-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 171661-64-6 CAPLUS


CN Ethanol, 2-[[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



RN 171661-66-8 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 206750-62-1 CAPLUS
 CN Ethanol, 2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 206750-64-3 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 171661-66-8
 CMF C16 H19 N5 O3




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 206750-65-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylthio)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 124 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:219795 CAPLUS

DOCUMENT NUMBER: 128:257447

ORIGINAL REFERENCE NO.: 128:50967a, 50970a

TITLE: Preparation of nitrogenous heterocyclic compounds inhibiting phosphorylation of platelet-derived growth factors (PDGF) receptors

INVENTOR(S): Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 312 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814431	A1	19980409	WO 1997-JP3510	19971001 <--
W: AU, BG, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2239227	A1	19980409	CA 1997-2239227	19971001 <--
CA 2239227	C	20071030		
AU 9744708	A	19980424	AU 1997-44708	19971001 <--
AU 719392	B2	20000511		
EP 882717	A1	19981209	EP 1997-943133	19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1208404	A	19990217	CN 1997-191741	19971001 <--
JP 4073961	B2	20080409	JP 1998-516380	19971001
MX 9804356	A	20000831	MX 1998-4356	19980601 <--
US 6169088	B1	20010102	US 1998-88199	19980601 <--
US 6207667	B1	20010327	US 2000-481544	20000112 <--
US 20020068734	A1	20020606	US 2000-734918	20001213 <--
US 6472391	B2	20021029		
US 20030229077	A1	20031211	US 2002-227302	20020826 <--
US 6750218	B2	20040615		

PRIORITY APPLN. INFO.:

JP 1996-260743	A	19961001
WO 1997-JP3510	W	19971001
US 1998-88199	A3	19980601
US 2000-481544	A3	20000112
US 2000-734918	A3	20001213

OTHER SOURCE(S): MARPAT 128:257447

GI



AB Nitrogenous heterocyclic compds. of general formula [I; wherein V is oxygen or sulfur; W is 1,4-piperazinediyl or 1,4-homopiperazinediyl which may be substituted with unsubstituted alkyl on the ring; X is nitrogen or C-R9; Y is nitrogen or C-R8; Z is nitrogen or C-R7, with at least one of X, Y and Z being nitrogen; R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like; R2 is substituted alkyl, substituted or unsubstituted cycloalkyl or the like; R3, R4, R5 and R6 are each independently hydrogen, halogeno, substituted or unsubstituted alkyl, nitro, cyano, (un)substituted OH or NH2 or the like; R7, R8 = R1, halogeno or the like; R9 is hydrogen or acyl] and pharmacol. acceptable salts thereof are prepared These compds. inhibit the phosphorylation of PDGF acceptors and the abnormal proliferation or migration of cells and so are effective in preventing or treating cell proliferative diseases such as arterial sclerosis, vascular reocclusion diseases, cancer, and glomerulosclerosis. Thus, 6,7-dimethoxy-4-piperazinylquinazoline was dissolved in ethanol, followed by adding Ph isocyanate, and the resulting mixture was heated at reflux for 10 min to give 4(4-quinazolinyl)piperazine derivative (II; R = CONHPh). II (R = Q) in vitro showed IC50 of 0.03 μ M for inhibiting the phosphorylation of PDGF receptor. Pharmaceutical formulations, e.g. tablet containing II (R = N-p-nitrophenylcarbamoyl), were prepared


IT 205255-49-8P 205255-50-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrogenous heterocyclic compds. inhibiting phosphorylation of platelet-derived growth factors (PDGF) receptors)


RN 205255-49-8 CAPLUS

CN 1-Piperazinecarboxamide, N-(4-nitrophenyl)-4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 205255-50-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (CA INDEX NAME)




IT 181115-48-0 205259-64-9 205259-65-0

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of nitrogenous heterocyclic compds. inhibiting phosphorylation of platelet-derived growth factors (PDGF) receptors)

RN 181115-48-0 CAPLUS


CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)



RN 205259-64-9 CAPLUS
 CN Quinazoline, 6,7-dimethoxy-2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)



RN 205259-65-0 CAPLUS
 CN Quinazoline, 4-(hexahydro-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-2-phenyl-
 (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 125 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:789208 CAPLUS
 DOCUMENT NUMBER: 128:61473
 ORIGINAL REFERENCE NO.: 128:12039a,12042a
 TITLE: Synthesis and reactions of 2-substituted
 4(3H)-quinazolinethione derivatives of possible
 biological activity
 AUTHOR(S): El-Hashash, M. A.; Salman, A. S. S.; El-Ghaffar, N. F.
 Abd; Soliman, F. M. A.; Souka, L. M.; Dawood, N. T.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Ain-Shams
 University, Cairo, Egypt
 SOURCE: Al-Azhar Bulletin of Science (1996), 7(1,
 Pt. 1), 11-18

PUBLISHER: Al-Azhar University, Faculty of Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

CODEN: ABSCE7; ISSN: 1110-2535




AB Several functionally substituted thioquinazoline derivs. were synthesized from quinazolinethione I. Reaction of I with Et chloroacetate, Ph isocyanate, acrylonitrile, β -benzoylacrylic acid, copper bronze, and hydrazine hydrate were studied.

IT 200121-79-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactions of 4(3H)-quinazolinethiones)

RN 200121-79-5 CAPLUS

CN 4(1H)-Quinazolinone, 2-[4-[(hydroxyimino)(4-methoxy-3-methylphenyl)methyl]phenyl]-, hydrazone (9CI) (CA INDEX NAME)




IT 200121-81-9P 200121-82-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of 4(3H)-quinazolinethiones)

RN 200121-81-9 CAPLUS

CN Hydrazinecarboxamide, 2-[2-[4-[(hydroxyimino)(4-methoxy-3-methylphenyl)methyl]phenyl]-4-quinazolinyl]-N-phenyl- (CA INDEX NAME)



RN 200121-82-0 CAPLUS
 CN Hydrazinecarbothioamide, 2-[2-[4-[(hydroxyimino)(4-methoxy-3-methylphenyl)methyl]phenyl]-4-quinazolinyl]-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 126 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:713805 CAPLUS
 DOCUMENT NUMBER: 128:18928
 ORIGINAL REFERENCE NO.: 128:3599a,3602a
 TITLE: Antagonism to noradrenaline-induced lethality in rats is related to affinity for the α 1A-adrenoceptor subtype
 AUTHOR(S): Testa, Rodolfo; Guarneri, Luciano; Ibba, Marina; Angelico, Patrizia; Poggesi, Elena; Taddei, Carlo; Motta, Gianni; Leonardi, Amedeo
 CORPORATE SOURCE: Pharmaceutical RandD Division, RECORDATI S.p.A., Milan, 20148, Italy
 SOURCE: Life Sciences (1997), 61(22), 2177-2188
 CODEN: LIFSAK; ISSN: 0024-3205
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The potency of several α 1-adrenoceptor antagonists in preventing the noradrenaline-induced lethality in conscious rats, their binding affinity for the native α 1A- and α 1B-adrenoceptors, the recombinant animal α 1a-, α 1b- and α 1d-adrenoceptor subtypes, as well as their functional affinity for the α 1L-adrenoceptor subtype were evaluated. The potency of the tested compds. as antagonists of noradrenaline-induced lethality was correlated with the affinity for the α 1A- (and α 1a-) adrenoceptor subtype, but not with the affinity for the other subtypes. On the contrary, the hypotensive effects of the compds., assessed in anesthetized rats, were not clearly related

with the affinity for any of the $\alpha 1$ -subtypes. These results suggest that the $\alpha 1A$ -subtype plays a determining role in preventing lethality induced by noradrenaline in the rats, and that this activity is unrelated to the hypotensive effect of the compds., which cannot be clearly correlated with affinity for a particular $\alpha 1$ -adrenoceptor subtype.


IT 139644-60-3, Rec 0/0232

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(antagonism to noradrenaline-induced lethality relation to affinity for $\alpha 1A$ -adrenoceptor subtype)

RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 127 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:574584 CAPLUS

DOCUMENT NUMBER: 127:212475

ORIGINAL REFERENCE NO.: 127:41189a, 41192a

TITLE: N-(Heterocyclylaryl)hydrazine derivative for a principal color developer, silver halide photographic light-sensitive material and imaging method

INVENTOR(S): Okawa, Atsuhiko; Makuta, Toshiyuki; Taguchi, Toshiki

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 82 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09211818	A	19970815	JP 1996-331409	19961128 <--
US 5851749	A	19981222	US 1996-757730	19961126 <--
PRIORITY APPLN. INFO.:			JP 1995-334183	A 19951130
OTHER SOURCE(S):	MARPAT	127:212475		

GI





AB The title compds. [I; Z1 = acyl, CONH2, alkoxycarbonyl, aryloxycarbonyl, R1SO2, C(X):NR2; wherein R1 = alkyl, alkenyl, alkynyl, aryl, heterocyclyl; X = OR3, NR4R5; R2, R4, R5 = H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R3 = same as R1; or R2 and R3, or R4 and R5 are bonded together to form a ring; Q1 = a group of nonmetal atoms necessary to form a 5- or 6-membered ring together with the C atom; Q2 = heterocyclyl; Y = substitutable group; m = 1,2; n = 0-3] (e.g. II) are prepared. An imaging method involves development of an imagewise-exposed silver halide photog. light-sensitive material in the presence of above color developer I, in particular with a processing liquid containing above color developer I. A silver halide photog. light-sensitive material comprises at least one hydrophilic colloidal layer containing above color developer I formed on a support. Another imaging method involves development of the latter photog. material (1) by heat-treatment at 50-200° or (2) in a solution. These compds. provide new principal developers which form dyes excellent in coloration during development and give images of good coloration and stability and stable in hue even when couplers substituted at the coupling position are used.

IT 194790-65-3

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. color developer; N-(heterocyclylaryl)hydrazine derivs. for principal color developers, silver halide photog. light-sensitive material, and imaging method)

RN 194790-65-3 CAPLUS

CN Hydrazinecarboxamide, 2-[2-(2-benzothiazolyl)-4-quinazolinyl]-N-[3-[2,4-bis(1,1-dimethylpropyl)phenoxy]propyl]- (CA INDEX NAME)



L7 ANSWER 128 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:506728 CAPLUS
 DOCUMENT NUMBER: 127:121749
 ORIGINAL REFERENCE NO.: 127:23489a,23492a
 TITLE: Preparation of quinolines and quinazolines for
 treatment of benign prostatic hyperplasia
 INVENTOR(S): Collis, Alan John; Fox, David Nathan Abraham; Newman,
 Julie
 PATENT ASSIGNEE(S): Pfizer Research and Development Company, N.V./S.A, UK;
 Pfizer Inc.; Collis, Alan John; Fox, David Nathan
 Abraham; Newman, Julie
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723462	A1	19970703	WO 1996-EP5609	19961205 <--
W: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				

	SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
CA 2236814	A1	19970703	CA 1996-2236814 19961205 <--
CA 2236814	C	20010918	
AU 9713719	A	19970717	AU 1997-13719 19961205 <--
AU 708979	B2	19990819	
EP 877734	A1	19981118	EP 1996-943954 19961205 <--
EP 877734	B1	20000712	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO			
CN 1205693	A	19990120	CN 1996-199303 19961205 <--
JP 11501668	T	19990209	JP 1997-523272 19961205 <--
JP 3070958	B2	20000731	
BR 9612263	A	19990713	BR 1996-12263 19961205 <--
HU 9903560	A2	20000528	HU 1999-3560 19961205 <--
HU 9903560	A3	20000728	
AT 194598	T	20000715	AT 1996-943954 19961205 <--
ES 2151192	T3	20001216	ES 1996-943954 19961205 <--
PT 877734	T	20001229	PT 1996-943954 19961205 <--
ZA 9610784	A	19980622	ZA 1996-10784 19961220 <--
IN 1996DE02900	A	20050311	IN 1996-DE2900 19961220
US 6103738	A	20000815	US 1998-91370 19980617 <--
NO 9802913	A	19980730	NO 1998-2913 19980622 <--
GR 3034225	T3	20001229	GR 2000-401910 20000817 <--
US 20020049322	A1	20020425	US 2001-812083 20010319 <--
US 6642242	B2	20031104	
US 20030220332	A1	20031127	US 2003-455546 20030604 <--
US 6750214	B2	20040615	
PRIORITY APPLN. INFO.:			GB 1995-26546 A 19951223
			WO 1996-EP5609 W 19961205
			US 1998-91370 A3 19980617
			US 2000-613500 B1 20000710
			US 2001-812083 A3 20010319
OTHER SOURCE(S):	MARPAT 127:121749		
GI			

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; R1 = C1-4 alkoxy optically substituted by one or more F atoms; R2 = H, C1-6 alkoxy optionally substituted by one or more F atoms; R3 = H, halo, C1-4 alkoxy, CF3; R2R3 = OCH2, the methylene group being attached to the ortho-position of the pendant Ph ring; R4 = 4-6-membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring, (un)substituted 5-6-membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S; X = CH, N; L = a bond, II (wherein N is attached to the 2-position of the quinoline or quinazoline ring; A = a bond, CO, SO2; Z = CH, N; m = 0-2; n = 1-3), N(R6)(CH2)pZ'(R7)A' (wherein N is attached to the 2-position of the quinoline or quinazoline ring; A', Z' = A, Z; R6, R7 = H, C1-4 alkyl; p = 0-3)], useful in the treatment of inter alia benign prostatic hyperplasia, were prepared Thus, reacting N-benzyl-3S,4S-bis(tert-butyl dimethylsilyloxy)pyrrolidine with phosgene in PhMe followed by treatment of the intermediate with homopiperazine in THF, and reaction of the resulting 1-{1-[3S,4S-bis(tert-butyl dimethylsilyloxy)pyrrolidine]carbo nyl}-1,4-diazepane with 4-amino-2-chloro-6,7-dimethoxy-5-phenylquinazoline in the presence of Et3N in n-BuOH afforded (3S,4S)-III.HCl which showed pA2 of 8.5.

IT 192868-70-5P 192868-89-6P 192868-90-9P
192868-91-0P 192868-93-2P 192868-97-6P
192868-98-7P 192868-99-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolines and quinazolines for treatment of benign prostatic hyperplasia)


RN 192868-70-5 CAPLUS

CN 7-Isoquinolinesulfonamide, 2-(4-amino-6,7-dimethoxy-5-phenyl-2-quinazolinyl)-1,2,3,4-tetrahydro- (CA INDEX NAME)




RN 192868-89-6 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-6,7-dimethoxy-5-phenyl- (CA INDEX NAME)




RN 192868-90-9 CAPLUS

CN 4-Quinazolinamine, 2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-6,7-dimethoxy-5-phenyl- (CA INDEX NAME)




RN 192868-91-0 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-6,7-dimethoxy-5-phenyl-2-quinazolinyl)-2,3-dihydro-1H-isoindol-4-yl]- (CA INDEX NAME)




RN 192868-93-2 CAPLUS
 CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-6,7-dimethoxy-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 192868-97-6 CAPLUS
 CN 4-Quinazolinamine, 2-(5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-6,7-dimethoxy-5-phenyl- (CA INDEX NAME)




RN 192868-98-7 CAPLUS
 CN 4-Quinazolinamine, 2-(5,8-dihydro-4-methoxypyrido[3,4-d]pyrimidin-7(6H)-yl)-6,7-dimethoxy-5-phenyl- (CA INDEX NAME)



RN 192868-99-8 CAPLUS
 CN 4-Quinazolinamine, 2-(6,7-dihydro-2-methylthiazolo[5,4-c]pyridin-5(4H)-yl)-6,7-dimethoxy-5-phenyl- (CA INDEX NAME)



IT 192869-55-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of quinolines and quinazolines for treatment of benign
 prostatic hyperplasia)
 RN 192869-55-9 CAPLUS
 CN 4-Quinazolinamine, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-5-iodo-6,7-
 dimethoxy- (CA INDEX NAME)




L7 ANSWER 129 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:505658 CAPLUS
 DOCUMENT NUMBER: 127:115214
 ORIGINAL REFERENCE NO.: 127:22101a,22104a
 TITLE: Silver halide color photographic material
 INVENTOR(S): Makuta, Toshiyuki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 93 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09152691	A	19970610	JP 1995-334189	19951130 <--
PRIORITY APPLN. INFO.:			JP 1995-334189	19951130
OTHER SOURCE(S): MARPAT 127:115214				

AB In the title photog. material comprising a support having one or more
 photog. layers, at least one photog. layer contains color developer
 represented by R1NHNHR2 [R1 = aryl, etc.; R2 = alkyl, etc.; X = SO2,
 etc.], a dye-forming coupler, and an organic solvent with high b.p. The use
 of the title material gives high quality images with good storage
 stability.

IT 192515-19-8
 RL: NUU (Other use, unclassified); TEM (Technical or engineered material
 use); USES (Uses)
 (silver halide color photog. material)
 RN 192515-19-8 CAPLUS
 CN Hydrazinecarboxamide, N-[4-(dodecyloxy)phenyl]-2-(2-phenyl-4-quinazolinyl)-
 (CA INDEX NAME)



Me-(CH₂)₁₁-O

L7 ANSWER 130 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:253088 CAPLUS

DOCUMENT NUMBER: 126:293330

ORIGINAL REFERENCE NO.: 126:56805a, 56808a

TITLE: Fused pyrimidine synthesis and antiinflammatory testing of certain novel imidazo[1,2-c]quinazoline, pyrazolo[3,4-d]triazolo[3,4-b]pyrimidine, and pyrimido[2,1-a]phthalazine derivatives

AUTHOR(S): El-Kerdawy, Mohamed M.; El-Ashmawy, Mahmoud B.; Shehata, Ihsan A.; Barghash, Alaa Eldin M.; El-Bendary, Eman R.; El-Kashef, Hassan A.

CORPORATE SOURCE: Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt

SOURCE: Saudi Pharmaceutical Journal (1997), 5(1), 46-51

CODEN: SPJOEM; ISSN: 1319-0164

PUBLISHER: Saudi Pharmaceutical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB A number of heterocyclic compds. containing a pyrimidine nucleus, namely, imidazo[1,2,-c]quinazolines, pyrazolo[3,4-d]triazolo[3,4-b]pyrimidines and pyrimido[2,1-a]phthalazines, have been synthesized. Acidic moieties that characterize most nonsteroidal antiinflammatory drugs (NSAIDs) or ester groups, as potential pro-drug functionalities, have been incorporated. E.g., reaction of 1-aminophthalazine and DMAD gave 35% Me 2-oxo-2H-pyrimido[2,1-a]phthalazine-4-carboxylate. The potency of eight compds. to inhibit carrageenin-induced paw edema in rats has been evaluated.

IT 189064-74-2P 189064-77-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and antiinflammatory activity of fused pyrimidines)


RN 189064-74-2 CAPLUS

CN Glycine, N-[6-chloro-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 189064-77-5 CAPLUS
 CN L-Phenylalanine, N-[6-chloro-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 189064-76-4P 189064-78-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antiinflammatory activity of fused pyrimidines)
 RN 189064-76-4 CAPLUS
 CN Glycine, N-[6-bromo-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 189064-78-6 CAPLUS
 CN L-Phenylalanine, N-[6-bromo-2-(2-thienyl)-4-quinazolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 131 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:251867 CAPLUS

DOCUMENT NUMBER: 126:301412

ORIGINAL REFERENCE NO.: 126:58213a,58216a

TITLE: Relationships between the structure, cytotoxicity and hydrophobicity of quinazoline derivatives by quantitative structure-activity relationship.

AUTHOR(S): Jantova, S.; Balaz, S.; Stankovsky, S.; Spirkova, K.; Lukacova, V.

CORPORATE SOURCE: Faculty of Chemical Technology, Slovak Technical University, Bratislava, 812 37, Slovakia

SOURCE: Folia Biologica (Prague) (1997), 43(2), 83-89

CODEN: FOBLAN; ISSN: 0015-5500

PUBLISHER: Institute of Molecular Genetics

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Cytotoxicities of 93 quinazoline derivs. against HeLa cells were determined as the isoeffective concns. inhibiting, after a single dose, the protein synthesis of 50% of the control amount after 48 h incubation. The dependence of cytotoxicity on hydrophobicity of the studied derivs. has been described using a previously published model-based approach. The studied derivs. are classified into 9 classes each forming a smooth hydrophobicity-cytotoxicity curve. Owing to the acceptable agreement between the model and the data it can be inferred that: (1) the compds. except 2 derivs. bind to the receptors with approx. the same affinity; (2) the criterion for the classification is the different rate of metabolism. The results represent a basis for a rotational development of more potent quinazoline derivs.

IT 6484-29-3 29209-80-1 40288-70-8
94078-50-9 94078-57-6 153991-71-0
154475-60-2 154475-61-3 157980-29-5
169136-48-5 170463-25-9 177027-28-0
177027-31-5 177027-32-6 177027-33-7
189222-71-7 189223-05-0 189223-08-3
189223-11-8 189223-14-1 189223-17-4
189223-22-1 189223-33-4 189223-38-9
189223-39-0 189223-40-3 189223-41-4
189223-42-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure-cytotoxicity-hydrophobicity relations of quinazolines)

RN 6484-29-3 CAPLUS


CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)




RN 29209-80-1 CAPLUS
 CN 4(1H)-Quinazolinone, 8-methyl-2-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 40288-70-8 CAPLUS
 CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 94078-50-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 94078-57-6 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 153991-71-0 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 154475-60-2 CAPLUS
 CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-phenyl- (CA INDEX NAME)




RN 154475-61-3 CAPLUS
 CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (CA INDEX NAME)




RN 157980-29-5 CAPLUS
 CN Quinazoline, 2,4-di-1H-1,2,4-triazol-1-yl- (CA INDEX NAME)




RN 169136-48-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-(6-chloro-2-phenyl-4-quinazolinyl)-N-phenyl- (CA INDEX NAME)




RN 170463-25-9 CAPLUS
 CN Quinazoline, 4-(1H-imidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 177027-28-0 CAPLUS
 CN Quinazoline, 6-chloro-4-hydrazinyl-2-phenyl- (CA INDEX NAME)




RN 177027-31-5 CAPLUS
 CN Benzaldehyde, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 177027-32-6 CAPLUS
 CN Benzaldehyde, 4-(dimethylamino)-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 177027-33-7 CAPLUS
 CN Benzaldehyde, 4-nitro-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 189222-71-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-chlorophenyl)-8-methyl-2-phenyl- (CA INDEX NAME)




RN 189223-05-0 CAPLUS
 CN Quinazoline, 2-phenyl-4-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 189223-08-3 CAPLUS
 CN Quinazoline, 4-(2H-benzotriazol-2-yl)-2-phenyl- (CA INDEX NAME)




RN 189223-11-8 CAPLUS
 CN Quinazoline, 7-chloro-2-phenyl-4-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 189223-14-1 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-7-chloro-2-phenyl- (CA INDEX NAME)




RN 189223-17-4 CAPLUS
 CN Quinazoline, 4-(2H-benzotriazol-2-yl)-7-chloro-2-phenyl- (CA INDEX NAME)



RN 189223-22-1 CAPLUS
 CN Quinazoline, 2,4-bis(2H-benzotriazol-2-yl)- (CA INDEX NAME)




RN 189223-33-4 CAPLUS
 CN Benzaldehyde, 2-fluoro-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 189223-38-9 CAPLUS

CN Acetamide, N-[4-[[2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazinyldene]methyl]phenyl]- (CA INDEX NAME)




RN 189223-39-0 CAPLUS

CN Benzaldehyde, 5-bromo-2-fluoro-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 189223-40-3 CAPLUS

CN Benzaldehyde, 2-fluoro-5-nitro-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 189223-41-4 CAPLUS


CN Benzaldehyde, 5-acetyl-2-fluoro-, 1-[2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone] (CA INDEX NAME)



RN 189223-42-5 CAPLUS
 CN 1H-Indole-3-carboxaldehyde, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone
 (CA INDEX NAME)



L7 ANSWER 132 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:218276 CAPLUS
 DOCUMENT NUMBER: 126:317357
 ORIGINAL REFERENCE NO.: 126:61569a,61572a
 TITLE: Synthesis and antimicrobial activity of some
 bis(quinazoline) derivatives
 AUTHOR(S): Shiba, S. A.; El-Khamry, A. A.; Shaban, M. E.; Atia,
 K. S.
 CORPORATE SOURCE: Faculty Science, Ain Shams University, Cairo, Egypt
 SOURCE: Pharmazie (1997), 52(3), 189-194
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB Bis[quinazolin-4-on-2-yl]-1,3-phenylene (I) and its 3-N-substituted derivs. were prepared from the corresponding bis[3,1-benzoxazin-4-on-2-yl]-1,3-phenylene as precursor. Quinazolinone I was converted into several derivs. such as bis[quinazolin-4-thioxo-2-yl]-, bis[4-chloroquinazolin-2-yl]-, and bis[4-hydrazinoquinazolin-2-yl]-1,3-phenylene. Some of the prepared compds. show activity against Gram-pos. and Gram-neg. bacteria and yeasts.

IT 189294-42-6P 189294-45-9P 189294-46-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and antimicrobial activity of bis-quinazolines)


RN 189294-42-6 CAPLUS

CN 4(1H)-Quinazolinone, 2,2'-(1,3-phenylene)bis-, dihydrazone (9CI) (CA INDEX NAME)




RN 189294-45-9 CAPLUS

CN Benzaldehyde, (1,3-phenylenedi-2,4-quinazolinediyl)dihydrazone (9CI) (CA INDEX NAME)




RN 189294-46-0 CAPLUS

CN Benzaldehyde, 4-methoxy-, (1,3-phenylenedi-2,4-quinazolinediyl)dihydrazone (9CI) (CA INDEX NAME)



IT 189294-38-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of bis-quinazolines)
 RN 189294-38-0 CAPLUS
 CN 4-Quinazolinamine, 2,2'-(1,3-phenylene)bis[N-(4-chlorophenyl)- (CA INDEX NAME)



L7 ANSWER 133 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:18906 CAPLUS
 DOCUMENT NUMBER: 126:126498
 ORIGINAL REFERENCE NO.: 126:24269a,24272a
 TITLE: Structure-activity relationship studies of CNS agents. Part 29. N-Methylpiperazino-substituted derivatives of quinazoline, phthalazine and quinoline as novel α 1, 5-HT1A and 5-HT2A receptor ligands
 AUTHOR(S): Mokrosz, J. L.; Duszynska, B.; Charakchieva-Minol, S.; Bojarski, A. J.; Mokrosz, M. J.; Wydra, R. L.; Janda, L.; Strekowski, L.
 CORPORATE SOURCE: Inst. Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.
 SOURCE: European Journal of Medicinal Chemistry (1996)

), 31(12), 973-980
CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The receptor binding profiles ($\alpha 1$, 5-HT_{1A}, 5-HT_{2A}) of the title compds. and their analogs have been determined. It has been demonstrated that orientation of a local dipole moment of the heteroarom. ring system affects both the $\alpha 1$ and 5-HT_{2A} affinity of the investigated class of ligands. Distortion of the coplanar unfused heteroarom. ring system results in a decreased 5-HT_{2A} affinity. 4-(4-Methylpiperazino)-2-(2-thienyl)quinoline is the most active and selective $\alpha 1$ ligand (K_i = 4.9 nM) with a much lower affinity for 5-HT_{1A} (K_i = 3420 nM) and 5-HT_{2A} (K_i = 211 nM) receptors.


IT 106823-85-2 143871-26-5 186339-96-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of N-methylpiperazino-substituted derivs. of quinazoline, phthalazine and quinoline as $\alpha 1$, 5-HT_{1A} and 5-HT_{2A} receptor ligands)


RN 106823-85-2 CAPLUS

CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 143871-26-5 CAPLUS

CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)



RN 186339-96-8 CAPLUS

CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 134 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:675493 CAPLUS

DOCUMENT NUMBER: 126:26533

ORIGINAL REFERENCE NO.: 126:5285a,5288a

TITLE: Quinazoline derivatives suppress nitric oxide production by macrophages through inhibition of NOS II gene expression

AUTHOR(S): Fujiwara, Noriko; Okado, Ayako; Seo, Han Geuk; Fujii, Junichi; Kondo, Kigen; Taniguchi, Naoyuki

CORPORATE SOURCE: Department Biochemistry, Osaka University Medical School, Suita, 565, Japan

SOURCE: FEBS Letters (1996), 395(2,3), 299-303
CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have found three novel quinazolidine derivs. which inhibit the formation of nitrite dose-dependently in a murine macrophage cell line, RAW264.7. The decreased nitrite formation was due not to the inhibition of nitric oxide synthase activity but to suppression of NOS II mRNA and protein expression. In rat vascular smooth muscle cells (VSMC), however, these compound rather enhanced NOS II mRNA. These compds. also prevented LPS-stimulated heme oxygenase-1 (HO-1) and cyclooxygenase-2 (COx-2) gene expression in RAW264.7 cells, but again not in VSMC. The three quinazolidine derivs. specifically inhibit gene expression of NOS II, HO-1 and COX-2 only in macrophage cells, indicating that they are selective inhibitors of inducible gene expression in macrophages.


IT 157863-90-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quinazoline derivs. suppress nitric oxide production by macrophages through inhibition of NOS II gene expression)


RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-
(CA INDEX NAME)



L7 ANSWER 135 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:616981 CAPLUS
 DOCUMENT NUMBER: 126:361
 ORIGINAL REFERENCE NO.: 126:63a,66a
 TITLE: An exploration of the structure-activity relationships of 4-aminoquinolines: novel antimalarials with activity in vivo
 AUTHOR(S): Ismail, F. M. D.; Dascombe, M. J.; Carr, P.; North, S. E.
 CORPORATE SOURCE: Division of Chemical Sciences, Univ. of Hertfordshire, Hatfield, AL10 9AB, UK
 SOURCE: Journal of Pharmacy and Pharmacology (1996), 48(8), 841-850
 CODEN: JPPMAB; ISSN: 0022-3573
 PUBLISHER: Royal Pharmaceutical Society of Great Britain
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The structure-activity relationships of bisquinolines, a potentially important group of novel antimalarial drugs, were studied. The high-temperature (180-250°) synthesis of 4-aminoquinolines, including bisquinolines, by nucleophilic displacement was both fast and efficient. Several bisquinolines including (±)-trans-N1,N2-bis(7-trifluoroquinolin-4-yl)cyclohexane-1,2-diamine and 1R,2R-(-)-, 1S,2S-(+)-trans- and (±)-trans- and cis-N1,N2-bis(7-chloroquinolin-4-yl)cyclohexane-1,2-diamine exhibited potent activity against Plasmodium berghei in mice; (±)-trans-N1,N2-bis(7-chloroquinolin-4-yl)cyclohexane-1,2-diamine was orally active. The results indicate that these compds. conform to a putative receptor for quinoline antimalarials. In addition, a 7-haloquinoline linked by a heterocyclic bridge, at the 4-position, to another heterocycle (such as an acridine at the 9-position) maximally occupies the active site of the authors postulated target.
 IT 183477-50-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (exploration of structure-activity relationships of 4-aminoquinolines as novel antimalarials with activity in vivo)
 RN 183477-50-1 CAPLUS
 CN 1,2-Cyclohexanediamine, N,N'-bis(2-phenyl-4-quinazolinyl)-, trans- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



L7 ANSWER 136 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:580373 CAPLUS
 DOCUMENT NUMBER: 125:221864
 ORIGINAL REFERENCE NO.: 125:41469a, 41472a
 TITLE: Preparation of 4-aminopyrimidines and
 4-aminoquinazolines
 INVENTOR(S): Zielinski, Wojciech; Mazik, Monika
 PATENT ASSIGNEE(S): Politechnika Slaska, Pol.
 SOURCE: Pol., 5 pp.
 CODEN: POXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Polish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 169025	B1	19960531	PL 1992-296745	19921124 <--
PRIORITY APPLN. INFO.:			PL 1992-296745	19921124
OTHER SOURCE(S):		CASREACT 125:221864; MARPAT 125:221864		

GI



AB The title compds. [I and II; R = H, alkyl, aryl; R1, R3 = alkyl, aryl; R2 = H, alkyl, (substituted) Ph; R4 = H, alkyl, alkoxy, etc.], useful as potential anticancer agents, antihypertensives, antiviral (HIV-1) agents and fungicides (no data), were prepared by reaction of R5N:C(R1)X [R5 = R2CH:CR3, R4C6H4; X = Cl, Cl2P(O), etc.] with R2NC.tplbond.N followed by cyclization of the intermediate R5N:CN:C(X)NR2 (III). Refluxing the intermediate III (R5 = R2CH:CR3) in PhMe afforded compds. I while refluxing III (R5 = R4C6H4) in the presence of Lewis acids such as TiCl4 in C6H6 afforded compds. II.


IT 1022-44-2P 103051-13-4P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)

(preparation of 4-aminopyrimidines and 4-aminoquinazolines)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



RN 103051-13-4 CAPLUS

CN 4-Quinazolinamine, N,N,2-triphenyl- (CA INDEX NAME)



L7 ANSWER 137 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:567069 CAPLUS

DOCUMENT NUMBER: 125:221856

ORIGINAL REFERENCE NO.: 125:41465a, 41468a

TITLE: Preparation of quinazoline derivatives as adrenergic α 1C receptor antagonists

INVENTOR(S): Andrews, Robert Carl; Brown, Peter Jonathan; Deaton, David Norman; Drewry, David Harold; Foley, Michael Andrew; Garrison, Deanna T.; Marron, Brian Edward; Smalley, Terrence L.; Berman, Judd M.; Noble, Stewart Alywyn

PATENT ASSIGNEE(S): Glaxo Inc, USA

SOURCE: Brit. UK Pat. Appl., 190 pp.

CODEN: BAXXDU


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
GB 2295387	A	19960529	GB 1994-23635	19941123 <--
PRIORITY APPLN. INFO.:			GB 1994-23635	19941123
OTHER SOURCE(S):	MARPAT	125:221856		
GI				



AB Title compds. [I; R = Z1Z2 = R4; R1 = H, halo, alkyl, alkoxy, etc.; R4 = H, (di)(alkyl)amino, phenyl(oxy), etc.; R5,R6 = H, OH, halo, alkyl, alkoxy; Z1 = NH, 2-(piperazine-1,4-diyl)ethylimino, iminopyridine-5,2-diylimino, etc.; Z2 = bond, (un)substituted alkylene] were prepared as adrenergic α_1C receptor antagonists (no data). Thus, 4-chloro-2-phenylquinazoline was aminated by 4-amino-1-benzylpiperidine and the deprotected product N-alkylated by 5-(2-chloroethyl)-2-methoxybenzenesulfonamide (preparation given) to give title compound II.

IT 181112-98-1P 181113-01-9P 181113-04-2P
 181113-07-5P 181113-11-1P 181113-13-3P
 181113-14-4P 181113-17-7P 181113-21-3P
 181113-24-6P 181113-26-8P 181113-27-9P
 181113-31-5P 181113-33-7P 181113-35-9P
 181113-36-0P 181113-38-2P 181113-39-3P
 181113-41-7P 181113-43-9P 181113-45-1P
 181113-47-3P 181113-49-5P 181113-51-9P
 181113-53-1P 181113-57-5P 181113-59-7P
 181113-60-0P 181113-61-1P 181113-62-2P
 181113-63-3P 181113-65-5P 181113-66-6P
 181113-68-8P 181113-69-9P 181113-71-3P
 181113-72-4P 181113-73-5P 181113-75-7P
 181113-77-9P 181113-79-1P 181113-80-4P
 181113-82-6P 181113-84-8P 181113-85-9P
 181113-86-0P 181113-87-1P 181113-88-2P
 181113-89-3P 181113-90-6P 181113-92-8P
 181113-93-9P 181113-94-0P 181113-97-3P
 181114-01-2P 181114-03-4P 181114-05-6P
 181114-07-8P 181114-08-9P 181114-10-3P
 181114-12-5P 181114-13-6P 181114-15-8P
 181114-16-9P 181114-18-1P 181114-20-5P
 181114-21-6P 181114-24-9P 181114-26-1P
 181114-28-3P 181114-29-4P 181114-30-7P
 181114-31-8P 181114-32-9P 181114-33-0P
 181114-34-1P 181114-36-3P 181114-38-5P
 181114-40-9P 181114-42-1P 181114-43-2P
 181114-44-3P 181114-45-4P 181114-46-5P
 181114-48-7P 181114-49-8P 181114-51-2P
 181114-53-4P 181114-55-6P 181117-78-2P
 181230-25-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline derivs. as adrenergic α_1C receptor antagonists)

RN 181112-98-1 CAPLUS


CN Benzenesulfonamide, 5-[2-[hexahydro-4-(2-phenyl-4-quinazolinyl)-1H-1,4-

diazepin-1-yl]ethyl]-2-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181112-97-0


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-01-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[(2-phenyl-4-quinazolinyl)amino]-1-piperidiny]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-00-8


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-04-2 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[2-methyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-03-1


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-07-5 CAPLUS

CN Pyrazino[2,1-b][3]benzazepine, 1,2,3,4,6,7,12,12a-octahydro-2-(2-phenyl-4-quinazolinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-06-4


CMF C27 H26 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-11-1 CAPLUS

CN Pyrazino[1,2-b][2]benzazepine, 1,2,3,4,6,11,12,12a-octahydro-2-(2-phenyl-4-quinazolinyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-10-0


CMF C27 H26 N4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 181113-13-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 181113-14-4 CAPLUS
 CN Benzenesulfonamide, 5-[2-[hexahydro-3-[(2-phenyl-4-quinazolinyl)amino]-1H-azepin-1-yl]ethyl]-2-methoxy- (CA INDEX NAME)



RN 181113-17-7 CAPLUS
 CN Benzenesulfonamide, 5-[2-[3,5-dimethyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 181113-16-6
 CMF C29 H33 N5 O3 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 181113-21-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[3-methyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 181113-20-2


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-24-6 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[1-[(2-phenyl-4-quinazolinyl)amino]-4-piperidinyl]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 181113-23-5


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-26-8 CAPLUS

CN 2,4-Pyridinediamine, N2-methyl-N2-(phenylmethyl)-N4-(2-phenyl-4-quinazolinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 181113-25-7


CMF C27 H23 N5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 181113-27-9 CAPLUS

CN 2,5-Pyridinediamine, N2-methyl-N2-(phenylmethyl)-N5-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181113-31-5 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[methyl(2-phenyl-4-quinazolinyl)amino]-3-pyrrolidinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-30-4


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-33-7 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[3-methyl-3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2)
(CA INDEX NAME)

CM 1

CRN 181113-32-6


CMF C28 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-35-9 CAPLUS

CN Benzenesulfonamide, 5-[2-[3,4-dimethyl-3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-2-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-34-8


CMF C29 H33 N5 O3 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181113-36-0 CAPLUS
 CN Benzenesulfonamide, 5-[2-[2,5-dimethyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy- (CA INDEX NAME)




RN 181113-38-2 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[(2-phenyl-4-quinazolinyl)amino]cyclohexyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:2)
 (CA INDEX NAME)


CM 1

CRN 181113-37-1
 CMF C29 H33 N5 O3 S

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 181113-39-3 CAPLUS
CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181113-41-7 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[[1-(2-phenyl-4-quinazolinyl)-3-pyrrolidinyl]amino]ethyl]-, (R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181113-40-6

CMF C27 H29 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181113-43-9 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181113-42-8

CMF C27 H29 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181113-45-1 CAPLUS


CN Acetamide, N-[[2-methoxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]phenyl]sulfonyl]-, (S)-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 181113-44-0

CMF C29 H31 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181113-47-3 CAPLUS


CN Benzenesulfonamide, 2-hydroxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 181113-46-2

CMF C26 H27 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181113-49-5 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[[1-(2-phenyl-4-quinazolinyl)-3-pyrrolidinyl]amino]ethyl]-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181113-48-4

CMF C27 H29 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-51-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[5-(2-phenyl-4-quinazolinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 181113-50-8

CMF C28 H29 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 181113-53-1 CAPLUS
CN Benzenesulfonamide, 2-methoxy-5-[2-[methyl[2-[(2-phenyl-4-quinazolinyl)amino]ethyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-52-0
CMF C26 H29 N5 O3 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 181113-57-5 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[2-methyl-4-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (2S-trans)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 181113-56-4
 CMF C28 H31 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 181113-59-7 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[3-methyl-4-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (3S-trans)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181113-58-6
 CMF C28 H31 N5 O3 S


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 181113-60-0 CAPLUS

CN Phenol, 2-(phenylmethyl)-4-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-61-1 CAPLUS

CN Acetamide, N-[2-hydroxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]- (CA INDEX NAME)




RN 181113-62-2 CAPLUS

CN Ethanone, 1-[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]- (CA INDEX NAME)




RN 181113-63-3 CAPLUS

CN 2-Pyrrolidinone, 1-[1-oxo-6-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]hexyl]- (CA INDEX NAME)




RN 181113-65-5 CAPLUS
 CN 2-Imidazolidinone, 1-(methylsulfonyl)-3-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)
 CM 1
 CRN 181113-64-4
 CMF C24 H28 N6 O3 S




CM 2
 CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 181113-66-6 CAPLUS
 CN 2-Imidazolidinone, 1-(2,2-dimethyl-1-oxopropyl)-3-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 181113-68-8 CAPLUS
 CN 2-Piperidinone, 1-[1-oxo-4-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]butyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-67-7
 CMF C27 H31 N5 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 181113-69-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[[(2-phenyl-4-quinazolinyl)amino]methyl]-1-pyrrolidinyl]ethyl]-, dihydrochloride, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181113-71-3 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(2-phenyl-4-quinazolinyl)amino]methyl]-1-pyrrolidinyl]ethyl]-, (R)-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1


CRN 181113-70-2
 CMF C28 H31 N5 O3 S

Absolute stereochemistry.




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 181113-72-4 CAPLUS
CN Quinazoline, 4-[4-[3-(1H-indol-3-yl)propyl]-1-piperazinyl]-2-phenyl- (CA INDEX NAME)



RN 181113-73-5 CAPLUS
CN Benzenemethanol, 2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-75-7 CAPLUS

CN Methanesulfonamide, N-[[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1

CRN 181113-74-6


CMF C29 H33 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181113-77-9 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1


CRN 181113-76-8

CMF C32 H33 N5 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 181113-79-1 CAPLUS
CN Quinazoline, 4-[4-[2-(3-bromo-4-methoxyphenyl)ethyl]-1-piperazinyl]-2-phenyl-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181113-78-0
CMF C27 H27 Br N4 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 181113-80-4 CAPLUS


CN Benzenesulfonamide, 2-methoxy-N-[(phenylamino)carbonyl]-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 181113-82-6 CAPLUS
 CN Quinazoline, 4-[4-[2-[4-methoxy-3-(tetrahydro-2-furanyl)phenyl]ethyl]-1-piperazinyl]-2-phenyl-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)


CM 1

CRN 181113-81-5
 CMF C31 H34 N4 O2



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 181113-84-8 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-(2-methoxyphenyl)-4-quinazolinyl]-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (2:3) (CA INDEX NAME)

CM 1

CRN 181113-83-7

CMF C28 H31 N5 O4 S




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181113-85-9 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-[3-(trifluoromethyl)phenyl]-4-quinazolinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-86-0 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-(4-nitrophenyl)-4-quinazolinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-87-1 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-(3-methylphenyl)-4-quinazolinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-88-2 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-(4-pyridinyl)-4-quinazolinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181113-89-3 CAPLUS

CN Glycine, N-[[2-(2-methoxy-2-oxoethoxy)-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)




RN 181113-90-6 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[3-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)



RN 181113-92-8 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 181113-91-7
 CMF C27 H29 N5 O3 S




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 181113-93-9 CAPLUS

CN Benzenesulfonamide, 5-[2-[4-(8-chloro-2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy- (CA INDEX NAME)




RN 181113-94-0 CAPLUS

CN Benzenesulfonamide, 5-[2-[4-(7-chloro-2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy- (CA INDEX NAME)



RN 181113-97-3 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[4-[2-(1H-pyrrol-2-yl)-4-quinazolinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 181114-01-2 CAPLUS

CN Benzenesulfonamide, 5-[2-[3-[[2-(3-chloro-4-fluorophenyl)-4-quinazolinyl]amino]-1-pyrrolidinyl]ethyl]-2-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181114-03-4 CAPLUS

CN Benzenesulfonamide, 5-[2-[4-(5-chloro-2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-02-3


CMF C27 H28 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181114-05-6 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-(6-methoxy-2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-04-5


CMF C28 H31 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181114-07-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-[3-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 181114-06-7

CMF C28 H30 N8 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 181114-08-9 CAPLUS
CN 2,4-Pyrrolidinedione, 1-methyl-5-[4-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]butylidene]- (CA INDEX NAME)



RN 181114-10-3 CAPLUS
CN Benzenesulfonamide, 2-methoxy-N-methyl-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-09-0
CMF C28 H31 N5 O3 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-12-5 CAPLUS

CN Benzenesulfonamide, 2-methoxy-N,N-dimethyl-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-11-4

CMF C29 H33 N5 O3 S




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 181114-13-6 CAPLUS


CN Acetamide, N-[[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 181114-15-8 CAPLUS
 CN Acetamide, N-[[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]sulfonyl]-N-methyl-, 2,2,2-trifluoroacetate (1:2)
 (CA INDEX NAME)


CM 1

CRN 181114-14-7
 CMF C30 H33 N5 O4 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 181114-16-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)



RN 181114-18-1 CAPLUS


CN Benzamide, 3-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 181114-20-5 CAPLUS


CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CRN 181114-19-2
CMF C27 H28 N8 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 181114-21-6 CAPLUS
CN Quinazoline, 2-phenyl-4-[4-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 181114-24-9 CAPLUS
CN Quinazoline, 2-phenyl-4-[4-(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 181114-23-8
CMF C29 H30 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181114-26-1 CAPLUS

CN Cyclopropanecarboxamide, 2,2,3,3-tetramethyl-N-[3-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]propyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 181114-25-0

CMF C29 H37 N5 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-28-3 CAPLUS

CN 2-Furancarboxamide, tetrahydro-N-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-27-2


CMF C25 H29 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 181114-29-4 CAPLUS


CN Quinazoline, 4-[4-(3,3-diphenylpropyl)-1-piperazinyl]-2-phenyl- (CA INDEX NAME)



RN 181114-30-7 CAPLUS
 CN Quinazoline, 4-[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]-2-phenyl- (CA INDEX NAME)




RN 181114-31-8 CAPLUS
 CN Acetamide, 2-[[[2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]sulfonyl]amino]- (CA INDEX NAME)




RN 181114-32-9 CAPLUS

CN Quinazoline, 2-phenyl-4-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 181114-33-0 CAPLUS

CN 1H-Pyrrole-2-acetic acid, 1-methyl-5-[[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 181114-34-1 CAPLUS
 CN 1H-Pyrrole-2-acetamide, N,1-dimethyl-5-[[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 181114-36-3 CAPLUS
 CN Methanesulfonamide, N-[3-[1-hydroxy-2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]phenyl]-, (2Z)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 181114-35-2
 CMF C27 H29 N5 O3 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-38-5 CAPLUS

CN Benzoic acid, 2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, methyl ester, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 181114-37-4

CMF C29 H30 N4 O3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-40-9 CAPLUS

CN Benzamide, 2-methoxy-N-methyl-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-39-6

CMF C29 H31 N5 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-42-1 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-41-0

CMF C28 H29 N5 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-43-2 CAPLUS


CN Benzamide, 4-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181114-44-3 CAPLUS
 CN Quinazoline, 4-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-2-phenyl-
 (CA INDEX NAME)



RN 181114-45-4 CAPLUS
 CN Benzamide, 5-[1-hydroxy-2-[4-(2-phenyl-4-quinazolinyl)-1-
 piperazinyl]ethyl]-2-methoxy- (CA INDEX NAME)




RN 181114-46-5 CAPLUS
 CN Quinazoline, 2-phenyl-4-(3-phenyl-1-piperazinyl)- (CA INDEX NAME)



RN 181114-48-7 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[2-phenyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 181114-47-6
 CMF C33 H33 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 181114-49-8 CAPLUS

CN 2H-Pyrazino[2,1-a]isoquinoline, 1,3,4,6,7,11b-hexahydro-2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181114-51-2 CAPLUS

CN Benzenesulfonamide, 5-[2-[2,2-dimethyl-4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]-2-methoxy-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-50-1

CMF C29 H33 N5 O3 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 181114-53-4 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[[[1-(2-phenyl-4-quinazolinyl)-4-piperidinyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-52-3


CMF C27 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 181114-55-6 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[8-(2-phenyl-4-quinazolinyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 181114-54-5


CMF C29 H31 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 181117-78-2 CAPLUS

CN Benzenesulfonamide, 2-methoxy-5-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)



RN 181230-25-1 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[2-methyl-4-[(2-phenyl-4-quinazolinyl)amino]-1-pyrrolidinyl]ethyl]-, (2R-cis)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181230-24-0

CMF C28 H31 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 181114-56-7P 181114-57-8P 181114-58-9P
181114-59-0P 181114-64-7P 181114-65-8P
181114-71-6P 181114-72-7P 181114-77-2P
181114-78-3P 181114-83-0P 181114-84-1P
181114-85-2P 181114-88-5P 181114-90-9P
181114-91-0P 181114-92-1P 181114-96-5P
181114-97-6P 181114-99-8P 181115-00-4P
181115-24-2P 181115-25-3P 181115-27-5P
181115-29-7P 181115-48-0P 181115-58-2P
181115-59-3P 181115-63-9P 181115-64-0P
181115-66-2P 181115-68-4P 181115-69-5P
181115-70-8P 181230-26-2P 181230-27-3P
181230-31-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinazoline derivs. as adrenergic α 1C receptor antagonists)

RN 181114-56-7 CAPLUS


CN Quinazoline, 4-(hexahydro-1H-1,4-diazepin-1-yl)-2-phenyl- (CA INDEX NAME)




RN 181114-57-8 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 181114-58-9 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-4-piperidinyl- (CA INDEX NAME)




RN 181114-59-0 CAPLUS
 CN Quinazoline, 4-(3-methyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)




RN 181114-64-7 CAPLUS

CN Carbamic acid, [1-(2-phenyl-4-quinazolinyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 181114-65-8 CAPLUS

CN 4-Piperidinamine, 1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181114-71-6 CAPLUS

CN 4-Quinazolinamine, N-methyl-2-phenyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)




RN 181114-72-7 CAPLUS

CN 4-Quinazolinamine, N-methyl-2-phenyl-N-3-pyrrolidinyl- (CA INDEX NAME)




RN 181114-77-2 CAPLUS

CN 4-Quinazolinamine, N-[3-methyl-1-(phenylmethyl)-3-pyrrolidinyl]-2-phenyl- (CA INDEX NAME)




RN 181114-78-3 CAPLUS

CN 4-Quinazolinamine, N-(3-methyl-3-pyrrolidinyl)-2-phenyl- (CA INDEX NAME)




RN 181114-83-0 CAPLUS

CN 4-Quinazolinamine, N-[3,4-dimethyl-1-(phenylmethyl)-3-pyrrolidinyl]-2-phenyl- (CA INDEX NAME)




RN 181114-84-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dimethyl-3-pyrrolidinyl)-2-phenyl- (CA INDEX NAME)



RN 181114-85-2 CAPLUS


CN Quinazoline, 4-(2,5-dimethyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)



RN 181114-88-5 CAPLUS

CN 3-Pyrrolidinamine, 1-(2-phenyl-4-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181114-90-9 CAPLUS


CN 3-Pyrrolidinamine, 1-(2-phenyl-4-quinazolinyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181114-91-0 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 181114-92-1 CAPLUS


CN 1,2-Ethanediamine, N1-methyl-N2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 181114-96-5 CAPLUS

CN 3-Pyrrolidinamine, 5-methyl-1-[(4-methylphenyl)sulfonyl]-N-(2-phenyl-4-quinazolinyl)-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181114-97-6 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-3-pyrrolidinyl)-2-phenyl-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181114-99-8 CAPLUS

CN 4-Quinazolinamine, N-[4-methyl-1-(phenylmethyl)-3-pyrrolidinyl]-2-phenyl-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181115-00-4 CAPLUS

CN 4-Quinazolinamine, N-(4-methyl-3-pyrrolidinyl)-2-phenyl-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181115-24-2 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[[1-(1-phenylethyl)-3-pyrrolidinyl]methyl]-N-(phenylmethyl)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181115-25-3 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(phenylmethyl)-N-(3-pyrrolidinylmethyl)-,
 (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181115-27-5 CAPLUS
 CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(phenylmethyl)(2-phenyl-4-
 quinazolinyl)amino]methyl]-1-pyrrolidinyl]ethyl]-, (R)-, trifluoroacetate
 (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 181115-26-4
 CMF C35 H37 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 181115-29-7 CAPLUS


CN Benzenesulfonamide, 2-methoxy-5-[2-[3-[(phenylmethyl)(2-phenyl-4-quinazolinyl)amino]methyl]-1-pyrrolidinyl]ethyl]-, (S)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 181115-28-6

CMF C35 H37 N5 O3 S


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 181115-48-0 CAPLUS

CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (CA INDEX NAME)




RN 181115-58-2 CAPLUS

CN 1-Piperazinebutanol, 4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181115-59-3 CAPLUS

CN 1-Piperazinebutanal, 4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181115-63-9 CAPLUS

CN 1-Piperazinepropanamine, 4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 181115-64-0 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 181115-66-2 CAPLUS

CN 1-Piperazineethanamine, 4-(2-phenyl-4-quinazolinyl)-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 181115-65-1

CMF C20 H23 N5




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 181115-68-4 CAPLUS

CN Quinazoline, 4-(3,3-dimethyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)




RN 181115-69-5 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octane, 3-(phenylmethyl)-8-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 181115-70-8 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octane, 8-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 181230-26-2 CAPLUS

CN 3-Pyrrolidinamine, 5-methyl-1-[(4-methylphenyl)sulfonyl]-N-(2-phenyl-4-

quinazolinyl)-, (3S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181230-27-3 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-3-pyrrolidinyl)-2-phenyl-, (3S-cis)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 181230-31-9 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[[1-(1-phenylethyl)-3-pyrrolidinyl]methyl]-N-(phenylmethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 138 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:494195 CAPLUS

DOCUMENT NUMBER: 125:142765

ORIGINAL REFERENCE NO.: 125:26729a, 26732a


TITLE: Preparation of quinazolineamines and analogs as
endothelin converting enzyme inhibitors

INVENTOR(S): Ahn, Kyunghye; Cheng, Xue-Min; Doherty, Annette

PATENT ASSIGNEE(S): Marian; Elslager, Edward Faith; Kornberg, Brian; Lee, Chitase; Leonard, Daniele; Nikam, Sham Shribhar; Werbel, Leslie Morton
 SOURCE: Warner-Lambert Company, USA
 PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619474	A1	19960627	WO 1995-US15366	19951127 <--
W: CA, EE, JP, LT, LV, MX, SI				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5658902	A	19970819	US 1994-363104	19941222 <--
CA 2206046	A1	19960627	CA 1995-2206046	19951127 <--
EP 799221	A1	19971008	EP 1995-941477	19951127 <--
EP 799221	B1	20021030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
JP 10510834	T	19981020	JP 1995-519802	19951127 <--
AT 226951	T	20021115	AT 1995-941477	19951127 <--
PT 799221	T	20030331	PT 1995-941477	19951127 <--
ES 2186734	T3	20030516	ES 1995-941477	19951127 <--
US 5773444	A	19980630	US 1997-837176	19970414 <--
PRIORITY APPLN. INFO.:			US 1994-363104	A 19941222
			WO 1995-US15366	W 19951127

OTHER SOURCE(S): MARPAT 125:142765
 GI




AB Title compds. [e.g., I; R = (halo)alkyl, (hetero)aryl(alkyl); R1 = substituted alkyl, heterocyclyl, etc.; R2 = H or alkyl; NR1R2 = heterocyclyl; R3-R6 = H, halo, alkyl, alkoxy, etc.] were prepared Thus, 5-iodoanthranilic acid was cyclocondensed with a trichloroacetimidate and the chlorinated product aminated by 3-amino-1-ethylpiperidine to give I (R = CC13, R1 = 1-ethyl-3-piperidinyl, R3 = R5 = R6 = H, R4 = iodo) which had IC50 of 6.6µM in a EAhy926 cell-based assay.
 IT 179598-38-0P 179598-58-4P 179598-59-5P
 179598-60-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazolineamines and analogs as endothelin converting enzyme inhibitors)
 RN 179598-38-0 CAPLUS
 CN 4-Quinazolinamine, N-(1-ethyl-3-piperidinyl)-6-iodo-2-phenyl- (CA INDEX

NAME)




RN 179598-58-4 CAPLUS

CN 4-Quinazolinamine, N-(1-ethyl-3-piperidiny)-6-iodo-2-(4-methylphenyl)-
(CA INDEX NAME)




RN 179598-59-5 CAPLUS

CN 4-Quinazolinamine, N-(1-ethyl-3-piperidiny)-6-iodo-2-(4-methoxyphenyl)-
(CA INDEX NAME)




RN 179598-60-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(1-ethyl-3-piperidiny)-6-iodo-
(CA INDEX NAME)




L7 ANSWER 139 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:465793 CAPLUS
 DOCUMENT NUMBER: 125:221774
 ORIGINAL REFERENCE NO.: 125:41449a, 41452a
 TITLE: Annelation to the quinazoline ring. Preparation of some substituted 2H-imidazo- and 2,3-dihydropyrimido[1,2-c]quinazolines
 AUTHOR(S): Spirkova, Katarina; Stankovsky, Stefan
 CORPORATE SOURCE: Dep. of Organic Chemistry, Slovak Technical Univ., Bratislava, 812 37, Slovakia
 SOURCE: Collection of Czechoslovak Chemical Communications (1996), 61(6), 957-961
 PUBLISHER: CODEN: CCCCAK; ISSN: 0010-0765
 INSTITUTE of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 125:221774
 GI




AB Substituted 2H-imidazo[1,2-c]quinazolin-3-ones I (X = CH₂, CHMe; R = 7-Me, 9-Cl, 9-Br, H) and 2,3-dihydropyrimido[1,2-c]quinazolin-4-ones I (X = CH₂CH₂, R = H, 8-Me, 10-Br) were prepared by reaction of corresponding 3H-quinazoline-4-thiones with amino acid esters. IR, ¹H NMR and ¹³C NMR spectra of the compds. synthesized are presented.
 IT 181278-83-1P 181278-84-2P 181278-85-3P
 181278-86-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazo- and dihydropyrimidoquinazolines)
 RN 181278-83-1 CAPLUS
 CN β-Alanine, N-(6-chloro-2-phenyl-4-quinazolinyl)-, methyl ester (CA INDEX NAME)




RN 181278-84-2 CAPLUS
 CN Glycine, N-(8-methyl-2-phenyl-4-quinazolinyl)-, methyl ester (CA INDEX NAME)



RN 181278-85-3 CAPLUS
 CN Glycine, N-(6-chloro-2-phenyl-4-quinazolinyl)-, methyl ester (CA INDEX NAME)



RN 181278-86-4 CAPLUS
 CN Glycine, N-(6-bromo-2-phenyl-4-quinazolinyl)-, methyl ester (CA INDEX NAME)



L7 ANSWER 140 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:458023 CAPLUS
 DOCUMENT NUMBER: 125:105160
 ORIGINAL REFERENCE NO.: 125:19439a,19442a
 TITLE: Inhibitors of cGMP phosphodiesterase for the treatment of erectile dysfunction and other disorders
 INVENTOR(S): Campbell, Simon Fraser; Mackenzie, Alexander Roderick; Wood, Anthony
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.; Pfizer Inc.
 SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616644	A1	19960606	WO 1995-EP4066	19951016 <--
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2203379	A1	19960606	CA 1995-2203379	19951016 <--
CA 2203379	C	20060103		
EP 793486	A1	19970910	EP 1995-936507	19951016 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09512834	T	19971222	JP 1995-517126	19951016 <--
JP 2975990	B2	19991110		
JP 11343238	A	19991214	JP 1999-105626	19951016 <--
US 6300335	B1	20011009	US 1997-836670	19970522 <--
FI 9702205	A	19970523	FI 1997-2205	19970523 <--
US 20010044441	A1	20011122	US 2001-880141	20010613 <--
US 6656945	B2	20031202		
JP 2004091490	A	20040325	JP 2003-308939	20030901
US 20040087599	A1	20040506	US 2003-694644	20031027

PRIORITY APPLN. INFO.:

GB 1994-23910	A	19941126
JP 1996-517126	A3	19951016
JP 1999-105626	A3	19951016
WO 1995-EP4066	W	19951016
US 1997-836670	A3	19970522
US 2001-880141	A3	20010613


AB Compds. which are selective inhibitors of cGMP phosphodiesterase are useful in the treatment of erectile dysfunction (impotence) in male animals, including man. The cGMP phosphodiesterase inhibitors can also be used to treat female sexual dysfunction, premature labor, or dysmenorrhea. Specific compds., as well as compds. from other patents, are claimed.

IT 157863-27-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cGMP phosphodiesterase inhibitors for treatment of erectile dysfunction and other disorders)

RN 157863-27-9 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



L7 ANSWER 141 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:432466 CAPLUS

DOCUMENT NUMBER: 125:195567


ORIGINAL REFERENCE NO.: 125:36627a,36630a

TITLE: Synthesis and basicity of 4-(N,N-dimethylamino)-2-arylquinazolines


AUTHOR(S): Zielinski, Wojciech; Kudelko, Agnieszka; Holt, Elizabeth M.

CORPORATE SOURCE: Inst. Org. Chem. Technol., Silesian Technical Univ.,


SOURCE: Gliwice, 44-101, Pol.
 Heterocycles (1996), 43(6), 1201-1209
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The reaction of substituted N-phenylbenzimidoyl chlorides $\text{PhN:CClC}_6\text{H}_4\text{R}$ ($\text{R} = \text{H}, 4\text{-MeO}, 4\text{-NO}_2, 3\text{-Me}, 3\text{-NO}_2$, etc.) with N,N-dimethylcyanamide in the presence of titanium tetrachloride has yielded seven 4-(N,N-dimethylamino)-2-arylquinazolines, I. $\text{P}_\text{K}_\text{a}$ values have been determined for these compds. and analyzed in conjunction with the Hammett σ consts. to observe the influence of these substituents upon the basicity of 4-(N,N-dimethylamino)-2-arylquinazolines. The ρ value, single crystal x-ray anal., and ^{15}N -NMR spectra give evidence about the preferential site of protonation in such systems.
 IT 139474-19-4P 180906-16-5P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and basicity of (dimethylamino)arylquinazolines)
 RN 139474-19-4 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)



RN 180906-16-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N,N-dimethyl- (CA INDEX NAME)




IT 180906-17-6P 180906-18-7P 180906-19-8P

180906-20-1P 180906-21-2P 180906-22-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and basicity of (dimethylamino)arylquinazolines)


RN 180906-17-6 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 180906-18-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 180906-19-8 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 180906-20-1 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-(3-methylphenyl)- (CA INDEX NAME)




RN 180906-21-2 CAPLUS


CN 4-Quinazolinamine, 2-(3-chlorophenyl)-N,N-dimethyl- (CA INDEX NAME)



RN 180906-22-3 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-2-(3-nitrophenyl)- (CA INDEX NAME)



IT 180906-23-4P 180906-24-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and basicity of (dimethylamino)arylquinazolines)
 RN 180906-23-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N,N-dimethyl-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 180906-24-5 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)

CM 1


CRN 139474-19-4
 CMF C16 H15 N3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 180906-25-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)


RN 180906-25-6 CAPLUS

CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-N,N-dimethyl-, hydrochloride,
hydrate (1:2:1) (CA INDEX NAME)

CM 1

CRN 180906-16-5

CMF C17 H17 N3 O



CM 2

CRN 7732-18-5

CMF H2 O

H₂O

L7 ANSWER 142 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:367606 CAPLUS

DOCUMENT NUMBER: 125:5314

ORIGINAL REFERENCE NO.: 125:1207a,1210a

TITLE: Antibacterial effect of substituted
4-quinazolylylhydrazines and their arylhydrazones
determined by a modified microdilution method

AUTHOR(S): Jantova, S.; Hudecova, D.; Stankovsky, S.; Spirkova,
K.; Ruzekova, L.

CORPORATE SOURCE: Dep. Microbiol., Biochem. and Biol., Slovak Technical
Univ., Bratislava, 812 37, Slovakia

SOURCE: Folia Microbiologica (Prague) (1995), 40(6),
611-614

CODEN: FOMIAZ; ISSN: 0015-5632

PUBLISHER: Academia
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Eight 4-quinazolyldhydrazines (including I and II) and eleven of their arylhydrazones e.g. III and IV, have been tested for antibacterial activity and for structure-activity relationships by a modified microdilution method. III had the highest antibacterial effect, the MIC values being 100 mg/L for *Enterococcus faecalis*, 250 mg/L for *Staphylococcus aureus*, 200 mg/L for *Pseudomonas aeruginosa*, and 350 mg/L for *Escherichia coli*. The most effective derivs. were those with the benzene ring substituted with chlorine or Me group in position 6 or 8 and with pyrimidine ring substituted with a secondary amine in position 2. The modified microdilution method did not give rise to any statistically significant deviations in the MIC values for ampicillin in comparison with reported reference collection values.

IT 6484-29-3 29209-80-1 177027-28-0
177027-30-4 177027-31-5 177027-32-6
177027-33-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure-antibacterial activity relations of substituted quinazolyldhydrazines and their arylhydrazones)


RN 6484-29-3 CAPLUS

CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)




RN 29209-80-1 CAPLUS

CN 4(1H)-Quinazolinone, 8-methyl-2-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 177027-28-0 CAPLUS

CN Quinazoline, 6-chloro-4-hydrazinyl-2-phenyl- (CA INDEX NAME)




RN 177027-30-4 CAPLUS

CN 2-Furancarboxaldehyde, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 177027-31-5 CAPLUS

CN Benzaldehyde, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 177027-32-6 CAPLUS

CN Benzaldehyde, 4-(dimethylamino)-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)




RN 177027-33-7 CAPLUS
 CN Benzaldehyde, 4-nitro-, 2-(8-methyl-2-phenyl-4-quinazolinyl)hydrazone (CA INDEX NAME)



L7 ANSWER 143 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:995217 CAPLUS
 DOCUMENT NUMBER: 124:117340
 ORIGINAL REFERENCE NO.: 124:21857a, 21860a
 TITLE: Preparation of 4-amino-2-piperazinoquinazolines and analogs as α 1-adrenergic antagonists
 INVENTOR(S): Leonardi, Amedeo; Motta, Gianni; Boi, Carlo; Testa, Rodolfo
 PATENT ASSIGNEE(S): Recordati S.A. Chemical and Pharmaceutical Co., Switz.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9525726	A1	19950928	WO 1995-EP1001	19950317 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9518948	A	19951009	AU 1995-18948	19950317 <--
ZA 9502208	A	19951228	ZA 1995-2208	19950317 <--
EP 750614	A1	19970102	EP 1995-911342	19950317 <--
EP 750614	B1	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09511238	T	19971111	JP 1995-524370	19950317 <--
JP 3683911	B2	20050817		
IL 113024	A	20000726	IL 1995-113024	19950317 <--
ES 2158938	T3	20010916	ES 1995-911342	19950317 <--
PT 750614	T	20011031	PT 1995-911342	19950317 <--
TW 416951	B	20010101	TW 1995-84105132	19950523 <--
US 5798362	A	19980825	US 1996-716160	19960917 <--
GR 3036443	T3	20011130	GR 2001-401292	20010823 <--
PRIORITY APPLN. INFO.:			IT 1994-MI506	A 19940318
			WO 1995-EP1001	W 19950317
OTHER SOURCE(S):		MARPAT 124:117340		
GI				




AB Title compds. [I; R6 = Z1Z2(CR1R2)mR, NMeZR7, 4,4-diphenylpiperidino, etc.; R = aryl(oxy), diarylmethyl, aroyl, etc.; R1,R2 = H, alkyl; R7 = Ph, CHPh2, 4-(2-methoxyphenyl)piperazino; Z = alkylene; Z1 = 1,4-piperazinyllene; Z2 = bond, O, CO, CONH; m = 0-4; n = 0 or 1] were prepared. Thus, I (R6 = piperazino) was amidated by PhCOCH2CO2H to give I (R6 = Z1COCH2COPh, Z1 = 1,4-piperazinyllene) which had ED25 for blood pressure reduction of 56µg/kg i.v. in normotensed rats and 2.42mg/kg orally in spontaneously hypertensive rats.

IT 173059-26-2P 173059-56-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-amino-2-piperazinoquinazolines and analogs as α1-adrenergic antagonists)


RN 173059-26-2 CAPLUS

CN 4-Quinazolinamine, 2-[1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 173059-56-8 CAPLUS
 CN 4-Quinazolinamine, 2-[1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]-6,7-dimethoxy- (CA INDEX NAME)



L7 ANSWER 144 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:972738 CAPLUS
 DOCUMENT NUMBER: 124:175959
 ORIGINAL REFERENCE NO.: 124:32631a,32634a
 TITLE: The chemistry of 5-oxodihydroisoxazoles. XIV.
 Synthesis of 2-(1-aryltetrazol-5-yl)propanoic acids
 AUTHOR(S): Caiazza, Daniela; Prager, Rolf H.; Schafer, Karl
 CORPORATE SOURCE: Department Chemistry, Flinders University South
 Australia, Adelaide, 5001, Australia
 SOURCE: Australian Journal of Chemistry (1995),
 48(11), 1861-72
 CODEN: AJCHAS; ISSN: 0004-9425
 PUBLISHER: Commonwealth Scientific and Industrial Research
 Organization
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:175959
 GI




AB A number of N-arylisoxazol-5(2H)-ones (aryl = Ph, isoquinolin-1-yl, quinolin-2-yl, 2-phenylquinazolin-4-yl and benzothiazol-2-yl), e.g., I, have been reacted with lithium azide to give 2-(1-aryltetrazol-5-yl)acetic esters, e.g., II,, which have been C-methylated and hydrolyzed. The resulting 2-(1-aryltetrazol-5-yl)propanoic acids, e.g., III, had low antiinflammatory activity, as judged by inhibition of synthesis of prostaglandin PGE2 or tumor necrosis factor α .

IT 173470-63-8P 173470-64-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of (aryltetrazolyl)propanoic acids)


RN 173470-63-8 CAPLUS

CN 1H-Tetrazole-5-acetic acid, α,α -dimethyl-1-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)




RN 173470-64-9 CAPLUS


CN	1H-Tetrazole-5-acetic acid, α -methyl-1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)
----	--




IT 100422-74-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and antiinflammatory activity of (aryltetrazolyl)propanoic acids)
 RN 100422-74-0 CAPLUS
 CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)




IT 173470-53-6P 173470-62-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antiinflammatory activity of (aryltetrazolyl)propanoic acids)
 RN 173470-53-6 CAPLUS
 CN 1H-Tetrazole-5-acetic acid, 1-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



RN 173470-62-7 CAPLUS
 CN 1H-Tetrazole-5-acetic acid, α -methyl-1-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 145 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:908282 CAPLUS
 DOCUMENT NUMBER: 124:116467
 ORIGINAL REFERENCE NO.: 124:21689a,21692a
 TITLE: Influence of intramolecular hydrogen bond on azide-tetrazole equilibrium in 5-(2-hydroxyphenyl)tetrazolo[1,5-a]pyrimidine, -tetrazolo[1,5-c]pyrimidine, -tetrazolo[1,5-c]quinazoline, and 7-(2-hydroxyphenyl)tetrazolo[1,5-c]pyrimidine
 AUTHOR(S): Krivopalov, V. P.; Mamatyuk, V. I.; Nikolaenkova, E. B.
 CORPORATE SOURCE: Novosibirsk Inst. Org. Chem., Siberian Branch Russian Acad. Sci., Novosibirsk, 630090, Russia
 SOURCE: Izvestiya Akademii Nauk, Seriya Khimicheskaya (1995), (8), 1494-502
 CODEN: IASKEA
 PUBLISHER: Nauka
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 124:116467
 AB Intramol. hydrogen bonding between the phenolic hydroxyl and a nitrogen atom of the pyrimidine ring in the title compds. exerts a destabilizing effect on the tetrazole ring and shifts the azide-tetrazole equilibrium toward the azide form, especially in the case of tetrazolo[c]pyrimidine and -[c]quinazoline. An o-MeO group in the Ph ring stabilizes the tetrazole tautomer more than a p-MeO group.
 IT 63399-60-0
 RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
 (effect of intramol. hydrogen bond on azide-tetrazole equilibrium)
 RN 63399-60-0 CAPLUS
 CN Phenol, 2-(4-azido-2-quinazolinyl)- (CA INDEX NAME)




L7 ANSWER 146 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:902611 CAPLUS
 DOCUMENT NUMBER: 123:308670
 ORIGINAL REFERENCE NO.: 123:55159a,55162a
 TITLE: 1,1-(Quinazoline-2,4-diyl)bis(pyridinium)


INVENTOR(S): diperchlorate with defoliant activity
 Nuridzhanyan, Koren A.; Gudkov, Aleksej G.; Zubkova,
 Natalya F.; Gruzinskaya, Nina A.; Bukashkina, Zinaida
 V.; Fomina, Larisa M.; Razumovskij, Mikhail V.
 PATENT ASSIGNEE(S): Nauchno-Issledovatel'skij Institut Khimicheskikh
 Sredstv Zashchity Rastenij, Russia
 SOURCE: Russ. From: Izobreteniya 1994, (4), 83-4.
 CODEN: RUXXE7
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2008311	C1	19940228	RU 1991-4950292	19910626 <--
PRIORITY APPLN. INFO.:			SU 1991-4950292	A 19910626


AB Title only translated.
 IT 169944-41-6
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except
 adverse); BSU (Biological study, unclassified); BIOL (Biological study);
 USES (Uses)
 (defoliant)
 RN 169944-41-6 CAPLUS
 CN Pyridinium, 1,1'-(2,4-quinazolinediyl)bis-, diperchlorate (9CI) (CA INDEX
 NAME)
 CM 1
 CRN 169944-40-5
 CMF C18 H14 N4



CM 2
 CRN 14797-73-0
 CMF C1 O4



DOCUMENT NUMBER: 123:251045
 ORIGINAL REFERENCE NO.: 123:44743a, 44746a
 TITLE: Structure-activity relationships of some
 4-quinazolylythiosemicarbazides and their triazolo
 derivatives
 AUTHOR(S): Jantova, S.; Hudecova, D.; Spirkova, K.; Stankovsky,
 S.
 CORPORATE SOURCE: Faculty Chemical Technology, Slovak Technical
 University, Bratislava, 812 37, Slovakia
 SOURCE: Folia Microbiologica (Prague) (1994), 39(6),
 471-4
 CODEN: FOMIAZ; ISSN: 0015-5632
 PUBLISHER: Academia
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Eight 4-quinazolythiosemicarbazides and nine of their structural analogs have been tested for antibacterial effects and for structure activity relationships. 9-Chloro-5-morpholino-1,2,4-triazolo[4,3-c]quinazoline-3-thione (I) demonstrated the highest antibacterial effect (MIC of 1 mg/L for Escherichia coli and Proteus mirabilis and <1 mg/L for Staphylococcus aureus and Bacillus subtilis). The most effective derivs. have the carbon aromatic ring substituted with chlorine and the pyrimidine ring with morpholine or with secondary amine group.

IT 154475-60-2 154475-61-3 169136-48-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-bactericidal activity relations of
 quinazolylythiosemicarbazides and their triazolo derivs.)


RN 154475-60-2 CAPLUS

CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-phenyl-
 (CA INDEX NAME)




RN 154475-61-3 CAPLUS

CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (CA INDEX NAME)




RN 169136-48-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-(6-chloro-2-phenyl-4-quinazolinyl)-N-phenyl-
 (CA INDEX NAME)




L7 ANSWER 148 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:851876 CAPLUS
 DOCUMENT NUMBER: 123:256761
 ORIGINAL REFERENCE NO.: 123:45931a,45934a
 TITLE: Preparation and formulation of quinazoline derivatives
 as c-GMP phosphodiesterase and thromboxane A2
 synthetase inhibitors
 INVENTOR(S): Konishi, Yoshitaka; Kondo, Norimoto
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07188214	A	19950725	JP 1993-347333	19931224 <--
PRIORITY APPLN. INFO.:			JP 1993-347333	19931224
OTHER SOURCE(S):		MARPAT 123:256761		
GI				



IT 168904-35-6P 168904-36-7P

RN 168904-35-6 CAPLUS




CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(1-propyn-1-yl)-4-

CM 1

CRN 168904-35-6


CMF C18 H19 N5 O2



CM 2



CRN 75-75-2

CMF C H4 O3 S



L7 ANSWER 149 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:795361 CAPLUS
 DOCUMENT NUMBER: 124:29779
 ORIGINAL REFERENCE NO.: 124:5715a,5718a
 TITLE: 4-Aminoquinazoline derivatives as inhibitors of cGMP
 phosphodiesterase and TXA2 synthetase
 INVENTOR(S): Lee, Sung J.; Konishi, Yoshitaka; Macina, Orest T.;
 Kondo, Kigen; Yu, Dingwei T.
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 76,431,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5439895	A	19950808	US 1993-154691	19931119 <--
JP 06192235	A	19940712	JP 1993-197039	19930714 <--
CA 2100626	A1	19940116	CA 1993-2100626	19930715 <--
KR 191416	B1	19990615	KR 1993-13549	19930715 <--
AT 208771	T	20011115	AT 1993-305557	19930715 <--
ES 2167325	T3	20020516	ES 1993-305557	19930715 <--
PT 579496	T	20020531	PT 1993-305557	19930715 <--
JP 08099962	A	19960416	JP 1995-264667	19950920 <--
JP 2923742	B2	19990726		
PRIORITY APPLN. INFO.:			US 1992-913473	B2 19920715
			US 1993-76431	B2 19930614
OTHER SOURCE(S):	MARPAT	124:29779		
GI				



AB The compds. of the formula I and acid addition salts thereof, salts thereof, and hydrates thereof wherein R1 is hydrogen or C1-4 alkyl; Y is C1-6 alkylene; A is OR0 or S(O)pR0, in which R0 is C1-4 alkyl-hydroxy; p is 0-2; Z is single bond, methylene, ethylene, vinylene or ethynylene; CyB is (1) 7-membered, unsatd. or partially saturated, monocyclic hetero ring containing

as hetero atoms, one, two or three nitrogen atoms, (2) 6-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atoms, two

or

three nitrogen atoms, (3) 6-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atom, one nitrogen atom, (4) 4- or 5-membered, unsatd. or partially saturated, monocyclic hetero ring containing

as

hetero atoms, one, two or three nitrogen atoms, or (5) 4-7 membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero

atoms,

one or two oxygen atoms, or one or two sulfur atoms; R3 = e.g., H, C1-4 alkyl, C1-4 alkoxy; R4 = e.g., H, C1-4 alkyl, C1-4 alkoxy; and m and n independently are 1 or 2; with the proviso that (1) a CyB ring does not bond to Z through a nitrogen atom in the CyB ring when Z is vinylene or ethynylene, have inhibitory effect on cGMP-PDE, and addnl. on TXA2 synthetase. Thus, e.g., 2-(1-imidazolyl)-4-[2-(2-hydroxyethoxy)ethyl]amino-6-ethynylquinazoline.2HCl (II.2HCl) (prepared by desilylation of a silylacetylene precursor) exhibited inhibitory effect on cGMP-PDE and TXA2 synthetase with IC50 = 4.6 + 10-8 M and 1.33 + 10-6 M, resp. Pharmaceutical formulations were given.

IT 157862-69-6P 157862-70-9P 157862-71-0P
 157862-72-1P 157862-73-2P 157862-74-3P
 157862-75-4P 157862-76-5P 157862-77-6P
 157862-78-7P 157862-79-8P 157862-80-1P
 157862-81-2P 157862-82-3P 157862-83-4P
 157862-84-5P 157862-85-6P 157862-86-7P
 157862-87-8P 157862-88-9P 157862-89-0P
 157862-90-3P 157862-91-4P 157862-92-5P
 157862-93-6P 157862-94-7P 157862-95-8P
 157862-96-9P 157862-97-0P 157862-98-1P
 157862-99-2P 157863-00-8P 157863-01-9P
 157863-02-0P 157863-03-1P 157863-04-2P
 157863-05-3P 157863-06-4P 157863-07-5P


157863-08-6P 157863-09-7P 157863-10-0P
 157863-11-1P 157863-12-2P 157863-13-3P
 157863-14-4P 157863-15-5P 157863-16-6P
 157863-17-7P 157863-18-8P 157863-19-9P
 157863-20-2P 157863-21-3P 157863-22-4P
 157863-23-5P 157863-24-6P 157863-25-7P
 157863-26-8P 157863-27-9P 157863-29-1P
 157863-30-4P 157863-31-5P 157863-33-7P
 157863-34-8P 157863-36-0P 157863-39-3P
 157863-40-6P 157863-41-7P 157863-42-8P
 157863-43-9P 157863-45-1P 157863-46-2P
 157863-47-3P 157863-49-5P 157863-50-8P
 157863-51-9P 157863-52-0P 157863-53-1P
 157863-54-2P 157863-55-3P 157863-57-5P
 157863-58-6P 157863-59-7P 157863-61-1P
 157863-63-3P 157863-64-4P 157863-65-5P
 157863-66-6P 157863-67-7P 157863-68-8P
 157863-69-9P 157863-70-2P 157863-71-3P
 157863-72-4P 157863-73-5P 157863-74-6P
 157863-75-7P 157863-76-8P 157863-81-5P
 157863-83-7P 157863-85-9P 157863-87-1P
 157863-89-3P 157863-90-6P 157863-91-7P
 157863-92-8P 157863-93-9P 157863-94-0P
 157863-95-1P 157863-96-2P 157863-97-3P
 157863-99-5P 157864-00-1P 157864-01-2P
 157864-03-4P 157864-04-5P 157864-05-6P
 157864-06-7P 157864-07-8P 157864-08-9P
 157864-09-0P 157864-10-3P 157864-11-4P
 157864-12-5P 157864-13-6P 157864-14-7P
 157864-15-8P 157864-16-9P 157864-17-0P
 157864-18-1P 157864-19-2P 157864-20-5P
 157941-27-0P 157941-28-1P 157941-29-2P
 170985-89-4P 170985-90-7P 171661-62-4P
 171661-63-5P 171661-64-6P 171661-66-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(4-aminoquinazoline derivs. as inhibitors of cGMP phosphodiesterase and TXA2 synthetase)


RN 157862-69-6 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-70-9 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-71-0 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-72-1 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-73-2 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157862-74-3 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157862-75-4 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-76-5 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-77-6 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 157862-78-7 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 157862-79-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-80-1 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)



● 2 HCl


RN 157862-81-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-82-3 CAPLUS

CN Benzoic acid, 3-[[2-(3-pyridinyl)-4-quinazolinyl]amino]-, methyl ester
(CA INDEX NAME)




RN 157862-83-4 CAPLUS


CN Benzoic acid, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]- (CA INDEX NAME)



RN 157862-84-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 157862-85-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)-, hydrochloride
 (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-86-7 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-87-8 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-88-9 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 157862-89-0 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)-, hydrochloride
 (1:3) (CA INDEX NAME)




● 3 HCl

RN 157862-90-3 CAPLUS
 CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)- (CA
 INDEX NAME)



RN 157862-91-4 CAPLUS


CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157862-92-5 CAPLUS


CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157862-93-6 CAPLUS

CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)


(CA INDEX NAME)



● 2 HCl

RN 157862-94-7 CAPLUS


CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157862-95-8 CAPLUS


CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-(3-pyridinyl)-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 157862-96-9 CAPLUS


CN Benzenesulfonamide, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157862-97-0 CAPLUS


CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)- (CA INDEX NAME)



RN 157862-98-1 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)-, hydrochloride (1:2)


(CA INDEX NAME)



● 2 HCl


RN 157862-99-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157863-00-8 CAPLUS

CN 4-Quinazolinamine, 2-(6-chloro-3-pyridinyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-01-9 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-02-0 CAPLUS


CN 4-Quinazolinamine, N-phenyl-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-03-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-phenyl- (CA INDEX NAME)



RN 157863-05-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-06-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-07-5 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-08-6 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-09-7 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-10-0 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-11-1 CAPLUS
 CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-12-2 CAPLUS
 CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)-, hydrochloride
 (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-13-3 CAPLUS

CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-14-4 CAPLUS

CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-15-5 CAPLUS
 CN 4-Quinazolinamine, N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-
 (CA INDEX NAME)




RN 157863-16-6 CAPLUS
 CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX
 NAME)



RN 157863-17-7 CAPLUS


CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-18-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 157863-19-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 157863-20-2 CAPLUS

CN 4-Quinazolinamine, 6-iodo-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-21-3 CAPLUS
 CN 4-Quinazolinamine, 6-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157863-22-4 CAPLUS
 CN Benzoic acid, 3-[[2-(4-pyridinyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 157863-23-5 CAPLUS
 CN Acetamide, N-[4-[(phenylmethyl)amino]-2-(3-pyridinyl)-6-quinazolinyl]-
 (CA INDEX NAME)




RN 157863-24-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-25-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methyl-1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-26-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 157863-27-9 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-29-1 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 157863-30-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-31-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-33-7 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-34-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA

INDEX NAME)



RN 157863-36-0 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-39-3 CAPLUS


CN 6-Quinazolinesulfonamide, 2-(1H-imidazol-1-yl)-N,N-dimethyl-4-[(phenylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157863-40-6 CAPLUS


CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-41-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 157863-42-8 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2-furanyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-43-9 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride
(1:2) (CA INDEX NAME)




●2 HCl

RN 157863-45-1 CAPLUS
CN 6-Quinazolinesulfonamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-
[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157863-46-2 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenylethyl)-, hydrochloride
(1:2) (CA INDEX NAME)




●2 HCl

RN 157863-47-3 CAPLUS
CN 4-Quinazolinamine, N-(cyclohexylmethyl)-2-(1H-imidazol-1-yl)-,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-49-5 CAPLUS
 CN 6-Quinazolinecarboxamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-[(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-50-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-51-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-52-0 CAPLUS


CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-53-1 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-54-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-55-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-57-5 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(2-methoxyethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(phenylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-59-7 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N-(2-methoxyethyl)-2-(2-methyl-1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-61-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(2-methoxyethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-63-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)- (CA INDEX NAME)




RN 157863-64-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-65-5 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-66-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-
 (CA INDEX NAME)




RN 157863-67-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-
 , hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-68-8 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157863-69-9 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-70-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylthio)-N-(phenylmethyl)-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-71-3 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(3-methoxypropyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-72-4 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-, methyl ester (CA INDEX NAME)




RN 157863-73-5 CAPLUS

CN 6-Quinazolinecarboxylic acid, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-, methyl ester (CA INDEX NAME)




RN 157863-74-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 157863-75-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)



RN 157863-76-8 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 157863-81-5 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-24-6


CMF C18 H15 N5



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 157863-83-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(phenylmethyl)-,
 dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 157863-82-6
 CMF C20 H19 N5 O2



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 157863-85-9 CAPLUS
 CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(1H-imidazol-1-yl)-,
 methanesulfonate (2:3) (CA INDEX NAME)


CM 1

CRN 157863-84-8
 CMF C20 H19 N5 O2



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 157863-87-1 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenoxyethyl)-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 157863-86-0
CMF C19 H17 N5 O




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 157863-89-3 CAPLUS


CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)- (CA INDEX NAME)



RN 157863-91-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-92-8 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-93-9 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-94-0 CAPLUS
 CN 4-Quinazolinamine, N-(3-ethoxypropyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-95-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157863-96-2 CAPLUS


CN Ethanol, 2-[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-97-3 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-99-5 CAPLUS

CN 1,2-Ethanediamine, N2-[6-chloro-2-(3-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 157864-00-1 CAPLUS
 CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-01-2 CAPLUS
 CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157864-03-4 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-04-5 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157864-05-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)- (CA INDEX NAME)




RN 157864-06-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157864-07-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157864-08-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-

(methylsulfonyl)- (CA INDEX NAME)



RN 157864-09-0 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157864-10-3 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 157864-11-4 CAPLUS

CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-12-5 CAPLUS

CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]- (CA INDEX NAME)




RN 157864-13-6 CAPLUS

CN 6-Quinazolinemethanol, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 157864-14-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-[2-(triethylsilyl)ethynyl]- (CA INDEX NAME)




RN 157864-15-8 CAPLUS

CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-16-9 CAPLUS

CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 157864-17-0 CAPLUS

CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 157864-18-1 CAPLUS


CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157864-19-2 CAPLUS

CN Ethanone, 1-[2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-6-quinazolinyl]- (CA INDEX NAME)




RN 157864-20-5 CAPLUS

CN Ethanone, 1-[4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-6-quinazolinyl]- (CA INDEX NAME)




RN 157941-27-0 CAPLUS

CN Methanimidamide, N'-[[2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-6-quinazolinyl]sulfonyl]-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157941-28-1 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157941-29-2 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 170985-89-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-nitro-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 170985-90-7 CAPLUS
 CN Ethanol, 2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 171661-62-4 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(2-ethoxyethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 171661-63-5 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(2-ethoxyethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 171661-64-6 CAPLUS

CN Ethanol, 2-[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 171661-66-8 CAPLUS


CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



L7 ANSWER 150 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:761961 CAPLUS
 DOCUMENT NUMBER: 123:340173
 ORIGINAL REFERENCE NO.: 123:61059a,61062a
 TITLE: 4-Aminoquinazoline derivatives as inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterase and thromboxane A₂ synthetase
 INVENTOR(S): Lee, Sung J.; Konishi, Yoshitaka; Macina, Orest T.; Kondo, Kigen; Yu, Dingwei T.
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: U.S., 44 pp. Cont.-in-part of U.S. Ser. No. 76,431, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5436233	A	19950725	US 1993-154518	19931119 <--
JP 06192235	A	19940712	JP 1993-197039	19930714 <--
CA 2100626	A1	19940116	CA 1993-2100626	19930715 <--
KR 191416	B1	19990615	KR 1993-13549	19930715 <--
AT 208771	T	20011115	AT 1993-305557	19930715 <--
ES 2167325	T3	20020516	ES 1993-305557	19930715 <--
PT 579496	T	20020531	PT 1993-305557	19930715 <--
JP 08099962	A	19960416	JP 1995-264667	19950920 <--
JP 2923742	B2	19990726		

PRIORITY APPLN. INFO.: US 1992-913473 B2 19920715
 US 1993-76431 B2 19930614
 OTHER SOURCE(S): CASREACT 123:340173; MARPAT 123:340173
 GI



AB Title compds. I [R₁ is H, C₁-4 alkyl; Y is a single bond or C₁-6 alkylene; A is (i) CyA-(R₂)₁, (ii) OR₀ or S(O)_pR₀ in which R₀ is R_{0A} or R_{0B}; R_{0A} is CyA-(R₂)₁; R_{0B} is H or C₁-4 alkyl; p is 0-2; CyA is, e.g., (1) 3-7 membered, saturated or unsatd., monocyclic carbocyclic ring, (2) 7-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen atom, one nitrogen and one oxygen atoms, two nitrogen and one

oxygen atoms, or one nitrogen and two oxygen atoms, (3) 6-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen and one oxygen atoms, two nitrogen and one oxygen atoms, or one nitrogen and two oxygen atoms; R2 is R2A or R2B; R2A is, e.g., CF3, OCF3; R2B is, e.g., H, C1-4 alkyl, C1-4 alkoxy; Z is ZA or ZB, ZA is methylene, ethylene, vinylene, ethynylene; ZB is a single bond; CyB is, e.g., (1) 7-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atoms, one, two or three nitrogen atoms, (2) 6-membered, unsatd. or partially saturated, monocyclic hetero ring containing as hetero atoms, two or three nitrogen atoms, (3) 6-membered, unsatd. or partially saturated, monocyclic hetero ring containing as a hetero atom, one nitrogen atom; R3 = e.g., H, C1-4 alkyl; R4 = e.g., NHSO2R11, R11 = e.g., C1-4 alkyl; l, m, n are independently 1 or 2 (with provisos)] are provided as inhibitors of cGMP-PDE and TXA2 synthetase. Thus, e.g., treatment of 2-(1-imidazolyl)-4-(2-methoxyethyl)amino-6-(2-triethylsilylethynyl)quinazoline (preparation given) with tetrabutylammonium fluoride afforded 6-ethynyl-4-(2-methoxyethyl)amino-2-(1-imidazolyl)quinazoline (II); II.2HCl demonstrated inhibition of cGMP-PDE with and TXA2 synthetase with IC50 = 4.6 + 10-8 and 2.4 + 10-6 M, resp. Pharmaceutical formulations were given.


IT 157862-69-6P 157862-71-0P 157862-73-2P
 157862-75-4P 157862-77-6P 157862-79-8P
 157862-84-5P 157862-86-7P 157862-88-9P
 157862-90-3P 157862-92-5P 157862-97-0P
 157863-05-3P 157863-07-5P 157863-09-7P
 157863-11-1P 157863-13-3P 157863-16-6P
 157863-18-8P 157863-24-6P 157863-29-1P
 157863-63-3P 157863-66-6P 157863-68-8P
 157863-90-6P 157863-98-4P 157864-00-1P
 157864-03-4P 157864-05-6P 157864-08-9P
 157864-14-7P 157864-15-8P 157864-16-9P
 157864-17-0P 157941-29-2P 166039-55-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(4-aminoquinazoline derivs. as inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterase and thromboxane A2 synthetase)


RN 157862-69-6 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-71-0 CAPLUS


CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-73-2 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-75-4 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-77-6 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 157862-79-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-84-5 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 157862-86-7 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-88-9 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 157862-90-3 CAPLUS
 CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157862-92-5 CAPLUS
 CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-97-0 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157863-05-3 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-07-5 CAPLUS

CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-09-7 CAPLUS

CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-11-1 CAPLUS

CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-13-3 CAPLUS

CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-16-6 CAPLUS

CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157863-18-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 157863-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-29-1 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 157863-63-3 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)- (CA INDEX NAME)




RN 157863-66-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)- (CA INDEX NAME)




RN 157863-68-8 CAPLUS

CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)- (CA INDEX NAME)




RN 157863-98-4 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(2-methoxyethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157864-00-1 CAPLUS

CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-03-4 CAPLUS

CN Ethanol, 2-[2-[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-05-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)- (CA INDEX NAME)




RN 157864-08-9 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)- (CA INDEX NAME)




RN 157864-14-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-[2-(triethylsilyl)ethynyl]- (CA INDEX NAME)




RN 157864-15-8 CAPLUS


CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-16-9 CAPLUS
CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 157864-17-0 CAPLUS
CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 157941-29-2 CAPLUS
CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 166039-55-0 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]- (CA INDEX NAME)




IT 157862-70-9P 157862-72-1P 157862-74-3P
 157862-76-5P 157862-78-7P 157862-80-1P
 157862-81-2P 157862-82-3P 157862-83-4P
 157862-85-6P 157862-87-8P 157862-89-0P
 157862-91-4P 157862-93-6P 157862-94-7P
 157862-95-8P 157862-96-9P 157862-98-1P
 157862-99-2P 157863-00-8P 157863-01-9P
 157863-02-0P 157863-03-1P 157863-04-2P
 157863-06-4P 157863-08-6P 157863-10-0P
 157863-12-2P 157863-14-4P 157863-15-5P
 157863-17-7P 157863-19-9P 157863-20-2P
 157863-21-3P 157863-22-4P 157863-23-5P
 157863-25-7P 157863-26-8P 157863-27-9P
 157863-30-4P 157863-31-5P 157863-33-7P
 157863-34-8P 157863-36-0P 157863-39-3P
 157863-40-6P 157863-41-7P 157863-42-8P
 157863-43-9P 157863-45-1P 157863-46-2P
 157863-47-3P 157863-49-5P 157863-50-8P
 157863-51-9P 157863-52-0P 157863-53-1P
 157863-54-2P 157863-55-3P 157863-57-5P
 157863-58-6P 157863-59-7P 157863-61-1P
 157863-64-4P 157863-65-5P 157863-67-7P
 157863-69-9P 157863-70-2P 157863-71-3P
 157863-72-4P 157863-73-5P 157863-74-6P
 157863-75-7P 157863-76-8P 157863-81-5P
 157863-83-7P 157863-85-9P 157863-86-0P
 157863-87-1P 157863-89-3P 157863-91-7P
 157863-92-8P 157863-93-9P 157863-94-0P
 157863-95-1P 157863-96-2P 157863-97-3P
 157863-99-5P 157864-01-2P 157864-04-5P
 157864-06-7P 157864-07-8P 157864-09-0P
 157864-10-3P 157864-11-4P 157864-12-5P
 157864-13-6P 157864-18-1P 157864-19-2P
 157864-20-5P 157941-27-0P 157941-28-1P
 166039-56-1P 166039-63-0P 170985-89-4P
 170985-90-7P 170985-91-8P 170985-92-9P
 170985-93-0P 170985-97-4P 170985-98-5P
 170985-99-6P 170986-01-3P 170986-02-4P
 170986-03-5P 170986-04-6P 170986-05-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(4-aminoquinazoline derivs. as inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterase and thromboxane A2 synthetase)


RN 157862-70-9 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-72-1 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-74-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-76-5 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-78-7 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 157862-80-1 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 157862-81-2 CAPLUS
 CN 4-Quinazolinamine, N-phenyl-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-82-3 CAPLUS

CN Benzoic acid, 3-[[2-(3-pyridinyl)-4-quinazolinyl]amino]-, methyl ester
(CA INDEX NAME)




RN 157862-83-4 CAPLUS

CN Benzoic acid, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]- (CA
INDEX NAME)




RN 157862-85-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)-, hydrochloride
(1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-87-8 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-89-0 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 157862-91-4 CAPLUS
 CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-93-6 CAPLUS
 CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-94-7 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-95-8 CAPLUS
 CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-(3-pyridinyl)-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 157862-96-9 CAPLUS
 CN Benzenesulfonamide, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-98-1 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157862-99-2 CAPLUS
 CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157863-00-8 CAPLUS
 CN 4-Quinazolinamine, 2-(6-chloro-3-pyridinyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-01-9 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-02-0 CAPLUS
 CN 4-Quinazolinamine, N-phenyl-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-03-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-phenyl- (CA INDEX NAME)




RN 157863-06-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-08-6 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)-,


hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-10-0 CAPLUS


CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-12-2 CAPLUS

CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-14-4 CAPLUS

CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-15-5 CAPLUS

CN 4-Quinazolinamine, N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-
(CA INDEX NAME)




RN 157863-17-7 CAPLUS

CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)-,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-19-9 CAPLUS
 CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 157863-20-2 CAPLUS
 CN 4-Quinazolinamine, 6-iodo-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride
 (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-21-3 CAPLUS
 CN 4-Quinazolinamine, 6-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157863-22-4 CAPLUS
 CN Benzoic acid, 3-[[2-(4-pyridinyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 157863-23-5 CAPLUS
 CN Acetamide, N-[4-[(phenylmethyl)amino]-2-(3-pyridinyl)-6-quinazolinyl]-
 (CA INDEX NAME)




RN 157863-25-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methyl-1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-26-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)



RN 157863-27-9 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-30-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-31-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-33-7 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-34-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-36-0 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-39-3 CAPLUS


CN 6-Quinazolinesulfonamide, 2-(1H-imidazol-1-yl)-N,N-dimethyl-4-[(phenylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157863-40-6 CAPLUS


CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-41-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 157863-42-8 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2-furanyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-43-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-45-1 CAPLUS

CN 6-Quinazolinaminesulfonamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 157863-46-2 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-47-3 CAPLUS


CN 4-Quinazolinamine, N-(cyclohexylmethyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-49-5 CAPLUS

CN 6-Quinazolinecarboxamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-[(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-50-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-51-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-52-0 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-53-1 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-54-2 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-55-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-57-5 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(phenylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-59-7 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N-(2-methoxyethyl)-2-(2-methyl-1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-61-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-64-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-65-5 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-67-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157863-69-9 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




RN 157863-70-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylthio)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



RN 157863-71-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(3-methoxypropyl)-, hydrochloride (1:2) (CA INDEX NAME)




RN 157863-72-4 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-, methyl ester (CA INDEX NAME)




RN 157863-73-5 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-

imidazol-1-yl)-, methyl ester (CA INDEX NAME)




RN 157863-74-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylthio)ethyl]-
(CA INDEX NAME)




RN 157863-75-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)



RN 157863-76-8 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 157863-81-5 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-24-6


CMF C18 H15 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 157863-83-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(phenylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-82-6


CMF C20 H19 N5 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 157863-85-9 CAPLUS

CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(1H-imidazol-1-yl)-, methanesulfonate (2:3) (CA INDEX NAME)

CM 1

CRN 157863-84-8


CMF C20 H19 N5 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 157863-86-0 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenoxyethyl)- (CA INDEX NAME)




RN 157863-87-1 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenoxyethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-86-0


CMF C19 H17 N5 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 157863-89-3 CAPLUS


CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 157863-91-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-92-8 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-93-9 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-94-0 CAPLUS
 CN 4-Quinazolinamine, N-(3-ethoxypropyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-95-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157863-96-2 CAPLUS


CN Ethanol, 2-[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-97-3 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-99-5 CAPLUS

CN 1,2-Ethanediamine, N2-[6-chloro-2-(3-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 157864-01-2 CAPLUS
 CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157864-04-5 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157864-06-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157864-07-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157864-09-0 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 157864-10-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 157864-11-4 CAPLUS
 CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-12-5 CAPLUS
 CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]- (CA INDEX NAME)



RN 157864-13-6 CAPLUS
 CN 6-Quinazolinemethanol, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 157864-18-1 CAPLUS
 CN Ethanol, 2-[2-[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157864-19-2 CAPLUS
 CN Ethanone, 1-[2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-6-quinazolinyl]- (CA INDEX NAME)



RN 157864-20-5 CAPLUS
 CN Ethanone, 1-[4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-6-quinazolinyl]- (CA INDEX NAME)




RN 157941-27-0 CAPLUS
 CN Methanimidamide, N'-[[2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-6-quinazolinyl]sulfonyl]-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157941-28-1 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 166039-56-1 CAPLUS
 CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 166039-63-0 CAPLUS
 CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 170985-89-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-nitro-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 170985-90-7 CAPLUS
 CN Ethanol, 2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 170985-91-8 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(2-methoxyethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 170985-92-9 CAPLUS


CN 6-Quinazolinaminesulfonamide, 2-(1H-imidazol-1-yl)-N,N-dimethyl-4-[(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 170985-93-0 CAPLUS


CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 170985-97-4 CAPLUS

CN 6-Quinazolinesulfonamide, 2-(1H-imidazol-1-yl)-N,N-dimethyl-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 170985-98-5 CAPLUS

CN 6-Quinazolinesulfonamide, N-[(dimethylamino)methylene]-2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 170985-99-6 CAPLUS

CN 6-Quinazolinecarboxamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 170986-01-3 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 170986-02-4 CAPLUS

CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-(3-pyridinyl)-
(CA INDEX NAME)




RN 170986-03-5 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]-
(CA INDEX NAME)




RN 170986-04-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 170986-05-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



L7 ANSWER 151 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:746792 CAPLUS

DOCUMENT NUMBER: 123:132021

ORIGINAL REFERENCE NO.: 123:23145a,23148a

TITLE: Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities

AUTHOR(S): Lee, Sung J.; Konishi, Yoshitaka; Yu, Dingwei T.; Miskowski, Tamara A.; Riviello, Christopher M.; Macina, Orest T.; Frierson, Manton R.; Kondo, Kigen; Sugitani, Masafumi; et al.

CORPORATE SOURCE: Biofor Inc., Waverly, PA, 18471, USA

SOURCE: Journal of Medicinal Chemistry (1995), 38(18), 3547-57

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society


DOCUMENT TYPE: Journal

LANGUAGE: English


AB Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor

2-phenyl-4-anilinoquinazoline (I) was identified utilizing MultiCASE assisted drug design (MCADD) technol. Modification of I was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivs. of 2-(3-pyridyl)quinazoline and 2-(imidazol-1-yl)quinazoline exhibited more than 1000-fold selectivity for PDE V over the other four PDE isoenzymes. In addition, 3 cGMP-PDE inhibitors were found to have an addnl. property of thromboxane synthesis inhibitory activity.


IT 40288-70-8, 4-Anilino-2-phenylquinazoline
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (pyridyl- and imidazolylquinazolines as cyclic GMP phosphodiesterase and thromboxane synthesis inhibitors)
 RN 40288-70-8 CAPLUS
 CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




IT 40288-71-9P 77651-73-1P 94078-51-0P
 157862-70-9P 157862-72-1P 157862-74-3P
 157862-78-7P 157862-79-8P 157862-85-6P
 157862-89-0P 157862-93-6P 157862-97-0P
 157862-99-2P 157863-01-9P 157863-02-0P
 157863-03-1P 157863-04-2P 157863-10-0P
 157863-12-2P 157863-24-6P 157863-31-5P
 157863-33-7P 157863-35-9P 157863-36-0P
 157863-40-6P 157863-41-7P 157863-42-8P
 157863-46-2P 157863-47-3P 157863-70-2P
 166039-18-5P 166039-19-6P 166039-20-9P
 166039-21-0P 166039-22-1P 166039-23-2P
 166039-24-3P 166039-25-4P 166039-26-5P
 166039-27-6P 166039-28-7P 166039-29-8P
 166039-30-1P 166039-31-2P 166039-32-3P
 166039-33-4P 166039-34-5P 166039-35-6P
 166039-36-7P 166039-37-8P 166039-38-9P
 166039-39-0P 166039-40-3P 166039-41-4P
 166039-42-5P 166039-50-5P 166039-51-6P
 166039-52-7P 166039-53-8P 166039-54-9P
 166039-55-0P 166039-56-1P 166039-57-2P
 166039-58-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (pyridyl- and imidazolylquinazolines as cyclic GMP phosphodiesterase and thromboxane synthesis inhibitors)
 RN 40288-71-9 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 77651-73-1 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-propyl- (CA INDEX NAME)



RN 94078-51-0 CAPLUS
 CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-phenyl- (CA INDEX NAME)




RN 157862-70-9 CAPLUS
 CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-72-1 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-74-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-78-7 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-79-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157862-85-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)-, hydrochloride
(1:2) (CA INDEX NAME)



● 2 HCl

RN 157862-89-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)-, hydrochloride
(1:3) (CA INDEX NAME)



● 3 HCl

RN 157862-93-6 CAPLUS


CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 157862-97-0 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157862-99-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157863-01-9 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-02-0 CAPLUS


CN 4-Quinazolinamine, N-phenyl-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-03-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-phenyl- (CA INDEX NAME)




RN 157863-10-0 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-12-2 CAPLUS
 CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-31-5 CAPLUS


CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-33-7 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-35-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-nitro-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-36-0 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-40-6 CAPLUS
 CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-41-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 157863-42-8 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2-furanyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-46-2 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenylethyl)-, hydrochloride
(1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-47-3 CAPLUS
CN 4-Quinazolinamine, N-(cyclohexylmethyl)-2-(1H-imidazol-1-yl)-,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-70-2 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylthio)-N-(phenylmethyl)-,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 166039-18-5 CAPLUS
CN 4-Quinazolinamine, N-methyl-N,2-diphenyl-, hydrochloride (1:1) (CA INDEX
NAME)




● HCl


RN 166039-19-6 CAPLUS
 CN 4-Quinazolinamine, N-cyclohexyl-2-phenyl- (CA INDEX NAME)




RN 166039-20-9 CAPLUS
 CN 4-Quinazolinamine, N-cyclopentyl-2-phenyl- (CA INDEX NAME)



RN 166039-21-0 CAPLUS
 CN 4-Quinazolinamine, N-(2-chlorophenyl)-2-phenyl- (CA INDEX NAME)




RN 166039-22-1 CAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 166039-23-2 CAPLUS
 CN 4-Quinazolinamine, N-(3-nitrophenyl)-2-phenyl- (CA INDEX NAME)




RN 166039-24-3 CAPLUS
 CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 166039-25-4 CAPLUS

CN Benzoic acid, 3-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)



RN 166039-26-5 CAPLUS


CN Benzoic acid, 4-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (CA INDEX NAME)



RN 166039-27-6 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-3-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)


NAME)



● HCl


RN 166039-28-7 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1-pyrrolidinyl- (CA INDEX NAME)



RN 166039-29-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-phenyl- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 166039-30-1 CAPLUS

CN 4-Quinazolinamine, N-methyl-2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 166039-31-2 CAPLUS

CN 4-Quinazolinamine, N-[(2-chlorophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 166039-32-3 CAPLUS

CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 166039-33-4 CAPLUS


CN 4-Quinazolinamine, N-[(4-chlorophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 166039-34-5 CAPLUS
 CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 166039-35-6 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 166039-36-7 CAPLUS
 CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-phenyl- (CA INDEX NAME)




RN 166039-37-8 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-pyridinylmethyl)-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl


RN 166039-38-9 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 166039-39-0 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 166039-40-3 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 166039-41-4 CAPLUS
 CN Butanoic acid, 4-[(2-phenyl-4-quinazolinyl)amino]-, ethyl ester (CA INDEX NAME)



RN 166039-42-5 CAPLUS
 CN 1-Pentanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 166039-50-5 CAPLUS
 CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 166039-51-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[(2-furanyl)methyl]-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 166039-52-7 CAPLUS
 CN 4-Quinazolinamine, N-[2-(3-methyl-1H-pyrrol-1-yl)ethyl]-2-(3-pyridinyl)-
 (CA INDEX NAME)



RN 166039-53-8 CAPLUS


CN 4-Quinazolinamine, 6-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 166039-54-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 166039-55-0 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]- (CA INDEX NAME)



RN 166039-56-1 CAPLUS
 CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 166039-57-2 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(2-furanylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 166039-58-3 CAPLUS
 CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(1H-imidazol-1-yl)-6-methoxy-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


IT 166039-59-4P 166039-60-7P 166039-63-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (pyridyl- and imidazolylquinazolines as cyclic GMP phosphodiesterase
 and thromboxane synthesis inhibitors)
 RN 166039-59-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylthio)-N-(phenylmethyl)-
 (CA INDEX NAME)



RN 166039-60-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-
 (phenylmethyl)- (CA INDEX NAME)



RN 166039-63-0 CAPLUS
 CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L7 ANSWER 152 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:737316 CAPLUS

DOCUMENT NUMBER: 123:144272

ORIGINAL REFERENCE NO.: 123:25717a, 25720a

TITLE: Preparation of quinazolinylbenzyl phosphonates derivatives as hyperlipidemia, hypertension, and diabetes agents

INVENTOR(S): Kurogi, Yasuhisa; Miyata, Kazuyoshi; Nakamura, Shizuo; Kondo, Mitsuyoshi; Iwamoto, Takeshi; Naba, Chieko; Tsuda, Yoshihiko; Inoue, Yasuhide; Kanaya, Jun; Sato, Keigo

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500524	A1	19950105	WO 1994-JP883	19940531 <--
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2142597	A1	19950105	CA 1994-2142597	19940531 <--
CA 2142597	C	20040113		
AU 9468558	A	19950117	AU 1994-68558	19940531 <--
AU 664337	B2	19951109		
EP 655456	A1	19950531	EP 1994-917137	19940531 <--
EP 655456	B1	20000906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1112365	A	19951122	CN 1994-190513	19940531 <--
CN 1048018	C	20000105		
JP 2926274	B2	19990728	JP 1994-502639	19940531 <--
AT 196145	T	20000915	AT 1994-917137	19940531 <--
US 5624918	A	19970429	US 1995-387907	19950205 <--
PRIORITY APPLN. INFO.:			JP 1993-146528	A 19930617
			WO 1994-JP883	W 19940531

OTHER SOURCE(S): MARPAT 123:144272

GI



AB The preparation of title compds. I (A = O, S; R1, R2, R9, R10 = each independently H, lower alkoxy, nitro, lower alkyl, halogenated lower alkyl, halo; R3 = Ph, -B-R6 [B = O, S; R6 = H, lower alkyl, cycloalkyl, Ph, phenylated lower alkyl wherein Ph may be halogenated, phenoxyated lower alkyl, lower-alkoxy carbonyl-substituted lower alkyl, carboxylated lower alkyl or lower alkenyl, -NR7R8, R7, R8 = each independently H, lower alkyl, amino or cycloalkyl, R7R8 = combined together to form lower alkylene]; R4, R5 = each independently H, lower alkyl), useful as remedies for hyperlipidemia, hypertension, diabetes, and so forth, is described. Thus, reaction of o-aminobenzonitrile with 4-(EtO)2P(O)CH2C6H4COCl gave di-Et 4-[N-(2-cyanophenyl)carbamoyl]benzylphosphonate which on cyclization in the presence of MeOH gave p-substituted title compound I (R1, R2, R9, R10 = H, R3 = OMe, A = O, R4, R5 = Et). I lowered the triglycerides by 37-86% at 100 mg/kg P.O. in rats with Triton-induced hyperlipemia. Tablet, capsule, and granular formulation was also given.


IT 166394-39-4P 166394-40-7P 166394-41-8P
 166394-42-9P 166394-43-0P 166394-44-1P
 166394-45-2P 166394-46-3P 166394-47-4P
 166394-48-5P 166394-49-6P 166394-50-9P
 166394-51-0P 166394-52-1P 166394-53-2P
 166394-64-5P 166394-65-6P 166394-66-7P
 166394-67-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinylbenzyl phosphonates derivs. as hyperlipidemia, hypertension, and diabetes agents)


RN 166394-39-4 CAPLUS

CN Phosphonic acid, [[4-[4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-40-7 CAPLUS


CN Phosphonic acid, [[4-[4-(ethylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-41-8 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 166394-42-9 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(ethylamino)-2-quinazolinyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 166394-43-0 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-44-1 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(ethylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-45-2 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(butylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-46-3 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(cyclohexylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-47-4 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(cyclopentylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-48-5 CAPLUS


CN Phosphonic acid, [[4-[6-bromo-4-(1-piperidiny1)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-49-6 CAPLUS
 CN Phosphonic acid, [[4-(6-bromo-4-hydrazino-2-quinazolinyl)phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-50-9 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 166394-51-0 CAPLUS
 CN Phosphonic acid, [[4-[6-bromo-4-(ethylamino)-2-quinazolinyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 166394-52-1 CAPLUS
 CN Phosphonic acid, [[4-[6-chloro-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-53-2 CAPLUS
 CN Phosphonic acid, [[4-[6,7-dimethoxy-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 166394-64-5 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(methylamino)-2-quinazolinyl]phenyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




RN 166394-65-6 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(ethylamino)-2-quinazolinyl]phenyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




RN 166394-66-7 CAPLUS

CN Phosphonic acid, [[4-[6-bromo-4-(1-piperidiny1)-2-quinazolinyl]phenyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




RN 166394-67-8 CAPLUS


CN Phosphonic acid, [[4-[6-bromo-4-(dimethylamino)-2-quinazolinyl]phenyl]methyl]-, monoethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 153 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:716414 CAPLUS
 DOCUMENT NUMBER: 123:339969
 ORIGINAL REFERENCE NO.: 123:61015a,61018a
 TITLE: Azolylquinazolines: synthesis and biological activity
 AUTHOR(S): Bodajla, M.; Stankovsky, S.; Spirkova, K.; Jantova, S.; Hudecova, D.
 CORPORATE SOURCE: Faculty Chemical Technology, Slovak Technical University, Bratislava, SK-812 37, Slovakia
 SOURCE: Chemical Papers (1994), 48(6), 432-6
 CODEN: CHPAEG; ISSN: 0366-6352
 PUBLISHER: Slovak Academy of Sciences, Institute of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Preparation of some 2-phenyl-4-(azol-1-yl)quinazolines by reaction of the corresponding chloroquinazolines with the sodium salts of azoles is described. The IR, UV, and ¹H NMR spectra and the preliminary screening of biol. activity of final products are presented.
 IT 54608-51-4P 153991-71-0P 170463-25-9P
 170463-26-0P 170463-27-1P 170463-28-2P
 170463-29-3P 170463-30-6P 170463-31-7P
 170463-32-8P 170463-33-9P 170463-34-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and biol. activity of azolylquinazolines)
 RN 54608-51-4 CAPLUS
 CN Quinazoline, 4-(1H-benzotriazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 153991-71-0 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 170463-25-9 CAPLUS
 CN Quinazoline, 4-(1H-imidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 170463-26-0 CAPLUS
 CN Quinazoline, 2-phenyl-4-(1H-1,2,3-triazol-1-yl)- (CA INDEX NAME)




RN 170463-27-1 CAPLUS
 CN Quinazoline, 6-chloro-4-(1H-imidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 170463-28-2 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-6-chloro-2-phenyl- (CA INDEX NAME)




RN 170463-29-3 CAPLUS
 CN Quinazoline, 6-chloro-2-phenyl-4-(1H-1,2,3-triazol-1-yl)- (CA INDEX NAME)




RN 170463-30-6 CAPLUS
 CN Quinazoline, 4-(1H-benzotriazol-1-yl)-6-chloro-2-phenyl- (CA INDEX NAME)




RN 170463-31-7 CAPLUS
 CN Quinazoline, 6,8-dichloro-4-(1H-imidazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 170463-32-8 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-6,8-dichloro-2-phenyl- (CA INDEX NAME)



RN 170463-33-9 CAPLUS
 CN Quinazoline, 6,8-dichloro-2-phenyl-4-(1H-1,2,3-triazol-1-yl)- (CA INDEX NAME)



RN 170463-34-0 CAPLUS
 CN Quinazoline, 4-(1H-benzotriazol-1-yl)-6,8-dichloro-2-phenyl- (CA INDEX NAME)



L7 ANSWER 154 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:612182 CAPLUS
 DOCUMENT NUMBER: 123:198652
 ORIGINAL REFERENCE NO.: 123:35461a,35464a
 TITLE: Synthesis of certain benzoxazine and quinazoline derivatives as potential antiinflammatory agents
 AUTHOR(S): Kerdawy, M. M. El; Yousif, M. Y.; Emam, A. A. El; Moustafa, M. A.; El-Sherbeny, M. A.
 CORPORATE SOURCE: Faculty Pharmacy, University Mansoura, Mansura, Egypt
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 1-20
 CODEN: EJPSBZ; ISSN: 0301-5068


PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Substituted 2-(2-thienyl)-4H-3,1-benzoxazin-4-ones have been synthesized. Aminolysis of these compds. was achieved using 1-methylpiperazine, n-propylamine, hydroxylamine hydrochloride, p-anisidine, p-phenetidine, hydrazine hydrate, and ammonium acetate. Also prepared were tetrazoloquinazoline, triazoloquinazoline, and (thenylidenehydrazino)quinazoline derivs. Antiinflammatory screening for some compds. were carried out.

IT 167994-92-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiinflammatory activity of benzoxazine and quinazoline derivs.)

RN 167994-92-5 CAPLUS


CN Quinazoline, 6-chloro-4-hydrazinyl-2-(2-thienyl)- (CA INDEX NAME)



IT 167995-07-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and antiinflammatory activity of benzoxazine and quinazoline derivs.)

RN 167995-07-5 CAPLUS

CN 2-Thiophenecarboxaldehyde, 2-[6-chloro-2-(2-thienyl)-4-quinazolinyl]hydrazone (CA INDEX NAME)



L7 ANSWER 155 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:253820 CAPLUS

DOCUMENT NUMBER: 122:23985

ORIGINAL REFERENCE NO.: 122:4577a,4580a

TITLE: The heuristic-direct approach to theoretical quantitative structure-activity relationship analysis of α 1-adrenoceptor ligands

AUTHOR(S): Fanelli, F.; Menziani, M. C.; Cocchi, M.; Leonardi,


CORPORATE SOURCE: A.; De Benedetti, P. G.
Dipartimento di Chimica, Universita di Modena, V.
Campi 183, Modena, 41100, Italy
SOURCE: THEOCHEM (1994), 120(3), 265-76
CODEN: THEODJ; ISSN: 0166-1280
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The heuristic-direct quant. structure-activity relation approach was applied to 15 non-congeneric α 1-adrenergic receptor (α 1-AR) ligands interacting with the rat α 1A/D-AR subtype. The good linear correlations, which have been obtained between calculated binding energies and the pharmacol. affinities, allow one to predict the pharmacol. affinity of new ligands. Moreover, according to the α 1A/D-receptor model proposed, it has been possible to speculate on the amino acid residues which are mainly involved in the interaction with the ligands. This novel procedure constitutes a powerful tool for the design of new selective leads based on explicit intermol. interactions and for suggesting site-directed mutagenesis studies, to give, interactively, further support and improvement to the predictive and interpretative aspects of the model.

IT 139644-60-3
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(heuristic-direct approach to theor. QSAR anal. of α 1-adrenoceptor ligands)

RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)



L7 ANSWER 156 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:680606 CAPLUS

DOCUMENT NUMBER: 121:280606

ORIGINAL REFERENCE NO.: 121:51231a,51234a

TITLE: Synthesis of 4-aminoquinazoline derivatives

AUTHOR(S): Zielinski, W.; Mazik, M.

CORPORATE SOURCE: Inst. Org. Chem. Technol., Silesian Technical Univ., Gliwice, 44-101, Pol.

SOURCE: Polish Journal of Chemistry (1994), 68(3), 489-97

CODEN: PJCHDQ; ISSN: 0137-5083

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The reaction of N-phenylimidoyl chlorides, e.g. , PhN:CPHCl, with cyanamide and N,N-dimethylcyanamide was studied. At the first stage, linear products like 1-amino-1-chloro-3,5-diphenyl-2,4-diaza-1,3-butadienes were obtained. They underwent cyclization to 4-aminoquinazoline derivs.


IT 1022-44-2P 139474-19-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reaction of N-phenylimidoyl chlorides with cyanamides)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



RN 139474-19-4 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)



IT 158832-77-0P 158832-78-1P 158832-79-2P


158832-80-5P 158832-81-6P 158832-82-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(reaction of N-phenylimidoyl chlorides with cyanamides)


RN 158832-77-0 CAPLUS

CN 4-Quinazolinamine, N,N,6-trimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-78-1 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-79-2 CAPLUS


CN 4-Quinazolinamine, 6-bromo-N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 158832-80-5 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-6-nitro-2-phenyl- (CA INDEX NAME)



RN 158832-81-6 CAPLUS
 CN 4-Quinazolinamine, N,N,7-trimethyl-2-phenyl- (CA INDEX NAME)



RN 158832-82-7 CAPLUS
 CN 4-Quinazolinamine, 7-methoxy-N,N-dimethyl-2-phenyl- (CA INDEX NAME)



L7 ANSWER 157 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:645222 CAPLUS
 DOCUMENT NUMBER: 121:245222
 ORIGINAL REFERENCE NO.: 121:44471a,44474a
 TITLE: Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes
 AUTHOR(S): Clancy, Joanna; Tait-Kamradt, Amelia; Petitpas, Joan; Manousos, Mary; McGuirk, Paul R.; Subashi, Timothy; Watts, Paul; Wondrack, Lillian
 CORPORATE SOURCE: Central Res. Div., Pfizer, Inc., Groton, CT, 06340, USA
 SOURCE: Antimicrobial Agents and Chemotherapy (1994), 38(9), 2008-13

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human immunodeficiency virus type 1 infects human helper T lymphocytes by an interaction between gp120, the viral coat protein, and the T-cell receptor CD4. Two microtiter-based immunoassays, an ELISA (ELISA) and a particle concentration fluorescence assay, were developed to measure gp120-CD4 binding and were then used to screen a variety of compds. for the inhibition of this interaction. Addnl. protocols, called "consumption assays," were defined to distinguish inhibitors which functioned by sequestering either gp120 or CD4 to prevent the final effective bimol. interaction. Monoclonal antibodies of defined specificity and compds. known from other published studies to inhibit gp120-CD 4 binding were tested in an attempt to validate the assays used in the study. Once the capacity of these assays to detect known gp120-CD4 inhibitors was confirmed, they were used to screen synthetic agents and fermentation broths

for

novel compds. that might be used as human immunodeficiency virus receptor antagonists. A 2,4-diaminoquinazoline, CP-101,816-1, was found to inhibit this interaction (50% inhibitory concentration in ELISA, 32.5 µg/mL) and to interact more strongly with CD4 than with gp120 in the consumption assays. The identification of a novel inhibitor, a 2,4-diaminoquinazoline, confirmed that such assays are useful for the detection of human immunodeficiency virus type 1 receptor antagonists.


IT 158701-36-1, CP 101816-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HIV-1 surface glycoprotein gp120 binding to human T lymphocyte CD4 receptor inhibition by)

RN 158701-36-1 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L7 ANSWER 158 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:605373 CAPLUS


DOCUMENT NUMBER: 121:205373

ORIGINAL REFERENCE NO.: 121:37397a, 37400a

TITLE: 4-aminoquinazoline derivatives, and their use as

INVENTOR(S): Lee, Sung Jai; Konishi, Yoshitaka; Macina, Orest
 PATENT ASSIGNEE(S): Taras; Kondo, Kigen; Yu, Dingwei Tim
 SOURCE: Ono Pharmaceutical Co., Ltd., Japan
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 579496	A1	19940119	EP 1993-305557	19930715 <--
EP 579496	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06192235	A	19940712	JP 1993-197039	19930714 <--
CA 2100626	A1	19940116	CA 1993-2100626	19930715 <--
KR 191416	B1	19990615	KR 1993-13549	19930715 <--
AT 208771	T	20011115	AT 1993-305557	19930715 <--
ES 2167325	T3	20020516	ES 1993-305557	19930715 <--
PT 579496	T	20020531	PT 1993-305557	19930715 <--
JP 08099962	A	19960416	JP 1995-264667	19950920 <--
JP 2923742	B2	19990726		
PRIORITY APPLN. INFO.:			US 1992-913473	A 19920715
			US 1993-76431	A 19930614
OTHER SOURCE(S):			MARPAT 121:205373	
GI				



AB The title compds. I wherein R1 is H or alkyl; Y is bond or alkylene; A is (i) -CyAR2, (ii) -OR0 or -S(O)pR0, R0 = H, alkyl, etc., p is 0-2, (iii) -NR16R17, R16, R17 are H, alkyl; CyA is (1) a 3-7 membered monocyclic carbocyclic ring, (2) a 4-7 membered monocyclic hetero ring containing as hetero atoms, one N atom, one N and one O atoms, two N and one O atoms, or one N and two O atoms, (3) a 4-7 membered monocyclic hetero ring containing as hetero atoms, 1 or 2 O or S atoms, R2 is (1) H, (2) alkyl, (3) alkoxy, (4) -COOR5, in which R5 is H or alkyl, (5) -NR6R7, R6, R7 are H, alkyl, (6) -SO2NR6R7, (7) halogen, (8) CF3, (9) NO2 or (10) CF3O; Z is bond, methylene, ethylene, vinylene or ethynylene; CyB is a heterocyclic ring; R3 is H, alkyl, alkoxy, halogen or CF3; R4 is H, alkyl, alkoxy, etc., and acid addition salts thereof, salts thereof, and hydrates thereof were prepared and have inhibitory effect on cGMP-PDE, or addnl. on TXA2 synthetase. Thus, a representative prepared compound II had inhibitory activity IC50 of 3.6 x 10⁻⁷ on cGMP-PDE.


IT 157862-69-6P 157862-70-9P 157862-71-0P
 157862-72-1P 157862-73-2P 157862-74-3P
 157862-75-4P 157862-76-5P 157862-77-6P

157862-78-7P 157862-79-8P 157862-80-1P
 157862-81-2P 157862-82-3P 157862-83-4P
 157862-84-5P 157862-85-6P 157862-86-7P
 157862-87-8P 157862-88-9P 157862-89-0P
 157862-90-3P 157862-91-4P 157862-92-5P
 157862-93-6P 157862-94-7P 157862-95-8P
 157862-96-9P 157862-97-0P 157862-98-1P
 157862-99-2P 157863-00-8P 157863-01-9P
 157863-02-0P 157863-03-1P 157863-04-2P
 157863-05-3P 157863-06-4P 157863-07-5P
 157863-08-6P 157863-09-7P 157863-10-0P
 157863-11-1P 157863-12-2P 157863-13-3P
 157863-14-4P 157863-15-5P 157863-16-6P
 157863-17-7P 157863-18-8P 157863-19-9P
 157863-20-2P 157863-21-3P 157863-22-4P
 157863-23-5P 157863-24-6P 157863-25-7P
 157863-26-8P 157863-27-9P 157863-29-1P
 157863-30-4P 157863-31-5P 157863-33-7P
 157863-34-8P 157863-35-9P 157863-36-0P
 157863-39-3P 157863-40-6P 157863-41-7P
 157863-42-8P 157863-43-9P 157863-45-1P
 157863-46-2P 157863-47-3P 157863-49-5P
 157863-50-8P 157863-51-9P 157863-52-0P
 157863-53-1P 157863-54-2P 157863-55-3P
 157863-57-5P 157863-58-6P 157863-59-7P
 157863-60-0P 157863-61-1P 157863-63-3P
 157863-64-4P 157863-65-5P 157863-66-6P
 157863-67-7P 157863-68-8P 157863-69-9P
 157863-70-2P 157863-71-3P 157863-72-4P
 157863-73-5P 157863-74-6P 157863-75-7P
 157863-76-8P 157863-81-5P 157863-83-7P
 157863-85-9P 157863-87-1P 157863-89-3P
 157863-90-6P 157863-91-7P 157863-92-8P
 157863-93-9P 157863-94-0P 157863-95-1P
 157863-96-2P 157863-97-3P 157863-98-4P
 157863-99-5P 157864-00-1P 157864-01-2P
 157864-02-3P 157864-03-4P 157864-04-5P
 157864-05-6P 157864-06-7P 157864-07-8P
 157864-08-9P 157864-09-0P 157864-10-3P
 157864-11-4P 157864-12-5P 157864-13-6P
 157864-14-7P 157864-15-8P 157864-16-9P
 157864-17-0P 157864-18-1P 157864-19-2P
 157864-20-5P 157941-27-0P 157941-28-1P
 157941-29-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as cardiovascular agents)


RN 157862-69-6 CAPLUS

CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX
 NAME)



RN 157862-70-9 CAPLUS


CN 4-Quinazolinamine, 7-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157862-71-0 CAPLUS

CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX
NAME)



RN 157862-72-1 CAPLUS


CN 4-Quinazolinamine, 6-methyl-N-(phenylmethyl)-2-(3-pyridinyl)-,
hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-73-2 CAPLUS

CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX
NAME)




RN 157862-74-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157862-75-4 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)- (CA
 INDEX NAME)




RN 157862-76-5 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-77-6 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 157862-78-7 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 157862-79-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-80-1 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)
 (CA INDEX NAME)



● 2 HCl


RN 157862-81-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-82-3 CAPLUS

CN Benzoic acid, 3-[[2-(3-pyridinyl)-4-quinazolinyl]amino]-, methyl ester
(CA INDEX NAME)




RN 157862-83-4 CAPLUS

CN Benzoic acid, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]- (CA INDEX NAME)




RN 157862-84-5 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 157862-85-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(2-thienylmethyl)-, hydrochloride
(1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-86-7 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157862-87-8 CAPLUS
 CN 4-Quinazolinamine, N-[(3-chlorophenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157862-88-9 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 157862-89-0 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-(3-pyridinylmethyl)-, hydrochloride
 (1:3) (CA INDEX NAME)




● 3 HCl

RN 157862-90-3 CAPLUS
 CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)- (CA
 INDEX NAME)



RN 157862-91-4 CAPLUS


CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157862-92-5 CAPLUS


CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)- (CA INDEX NAME)



RN 157862-93-6 CAPLUS

CN 4-Quinazolinamine, N-(2-phenylethyl)-2-(3-pyridinyl)-, hydrochloride (1:2)


(CA INDEX NAME)



● 2 HCl

RN 157862-94-7 CAPLUS


CN 4-Quinazolinamine, 2-(3-pyridinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157862-95-8 CAPLUS


CN 4-Quinazolinamine, N-[[4-(dimethylamino)phenyl]methyl]-2-(3-pyridinyl)-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 157862-96-9 CAPLUS


CN Benzenesulfonamide, 4-[[[2-(3-pyridinyl)-4-quinazolinyl]amino]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157862-97-0 CAPLUS


CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)- (CA INDEX NAME)



RN 157862-98-1 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(4-pyridinyl)-, hydrochloride (1:2)


(CA INDEX NAME)



● 2 HCl


RN 157862-99-2 CAPLUS

CN 4-Quinazolinamine, N-phenyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 157863-00-8 CAPLUS

CN 4-Quinazolinamine, 2-(6-chloro-3-pyridinyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-01-9 CAPLUS

CN 4-Quinazolinamine, N-(phenylmethyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-02-0 CAPLUS


CN 4-Quinazolinamine, N-phenyl-2-(2-thienyl)- (CA INDEX NAME)




RN 157863-03-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-phenyl- (CA INDEX NAME)



RN 157863-05-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-06-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-07-5 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-08-6 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-09-7 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-10-0 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-11-1 CAPLUS
 CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-12-2 CAPLUS
 CN 4-Quinazolinamine, N-(cyclopropylmethyl)-2-(3-pyridinyl)-, hydrochloride
 (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-13-3 CAPLUS
 CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-14-4 CAPLUS
 CN 4-Quinazolinamine, N-[(3-methylphenyl)methyl]-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-15-5 CAPLUS
 CN 4-Quinazolinamine, N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-(3-pyridinyl)-
 (CA INDEX NAME)




RN 157863-16-6 CAPLUS
 CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)- (CA INDEX
 NAME)



RN 157863-17-7 CAPLUS


CN 4-Quinazolinamine, N-[(3-nitrophenyl)methyl]-2-(3-pyridinyl)-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-18-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)- (CA INDEX
NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 157863-19-9 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-3-isoxazolyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 157863-20-2 CAPLUS

CN 4-Quinazolinamine, 6-iodo-N-(phenylmethyl)-2-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-21-3 CAPLUS
 CN 4-Quinazolinamine, 6-fluoro-N-(phenylmethyl)-2-(3-pyridinyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 157863-22-4 CAPLUS
 CN Benzoic acid, 3-[[2-(4-pyridinyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 157863-23-5 CAPLUS
 CN Acetamide, N-[4-[(phenylmethyl)amino]-2-(3-pyridinyl)-6-quinazolinyl]-
 (CA INDEX NAME)




RN 157863-24-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-25-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-methyl-1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 157863-26-8 CAPLUS
 CN 4-Quinazolinamine, N-(phenylmethyl)-2-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 157863-27-9 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 157863-29-1 CAPLUS
 CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




RN 157863-30-4 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-31-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-33-7 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-34-8 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(1H-imidazol-1-yl)-N-(phenylmethyl)- (CA

INDEX NAME)



RN 157863-35-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-nitro-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-36-0 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-39-3 CAPLUS


CN 6-Quinazolinesulfonamide, 2-(1H-imidazol-1-yl)-N,N-dimethyl-4-[(phenylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157863-40-6 CAPLUS


CN 4-Quinazolinamine, N-(2-furanylmethyl)-2-(1H-imidazol-1-yl)-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-41-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-thienylmethyl)- (CA INDEX
NAME)



RN 157863-42-8 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2-furanyl)methyl]-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-43-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-45-1 CAPLUS

CN 6-Quinazolinaminesulfonamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157863-46-2 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenylethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-47-3 CAPLUS
 CN 4-Quinazolinamine, N-(cyclohexylmethyl)-2-(1H-imidazol-1-yl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-49-5 CAPLUS
 CN 6-Quinazolinecarboxamide, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-4-
 [(phenylmethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-50-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-51-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-52-0 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-53-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-54-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-55-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-57-5 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-iodo-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-58-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-59-7 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(2-methoxyethyl)-2-(2-methyl-1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-60-0 CAPLUS


CN Ethanol, 2-[[6-methoxy-2-(2-methyl-1H-imidazol-1-yl)-4-quinazolinyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-61-1 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,8-diiodo-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-63-3 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)- (CA INDEX NAME)



RN 157863-64-4 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-phenoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157863-65-5 CAPLUS


CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-66-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-, (CA INDEX NAME)




RN 157863-67-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylthio)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-68-8 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157863-69-9 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylthio)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-70-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylthio)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-71-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(3-methoxypropyl)-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157863-72-4 CAPLUS

CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-, methyl ester (CA INDEX NAME)




RN 157863-73-5 CAPLUS

CN 6-Quinazolinecarboxylic acid, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-, methyl ester (CA INDEX NAME)




RN 157863-74-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 157863-75-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)



RN 157863-76-8 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 157863-81-5 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(phenylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-24-6


CMF C18 H15 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 157863-83-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(phenylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 157863-82-6
CMF C20 H19 N5 O2



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 157863-85-9 CAPLUS
CN 4-Quinazolinamine, N-[(3,4-dimethoxyphenyl)methyl]-2-(1H-imidazol-1-yl)-, methanesulfonate (2:3) (CA INDEX NAME)


CM 1

CRN 157863-84-8
CMF C20 H19 N5 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 157863-87-1 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-phenoxyethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 157863-86-0


CMF C19 H17 N5 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 157863-89-3 CAPLUS


CN 6-Quinazolinecarboxylic acid, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 157863-90-6 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)- (CA INDEX NAME)



RN 157863-91-7 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxy-1,1-dimethylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 157863-92-8 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-methoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157863-93-9 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 157863-94-0 CAPLUS
 CN 4-Quinazolinamine, N-(3-ethoxypropyl)-2-(1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-95-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 157863-96-2 CAPLUS
 CN Ethanol, 2-[2-[[6-chloro-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-97-3 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6,7-dimethoxy-N-(2-methoxyethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157863-98-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(2-methoxyethyl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 157863-99-5 CAPLUS
 CN 1,2-Ethanediamine, N2-[6-chloro-2-(3-pyridinyl)-4-quinazolinyl]-N1,N1-dimethyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 157864-00-1 CAPLUS
 CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)



RN 157864-01-2 CAPLUS
 CN 6-Quinazolinol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157864-02-3 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(2-methoxyethyl)-2-(3-pyridinyl)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 157864-03-4 CAPLUS

CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-04-5 CAPLUS

CN	Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)
----	--




●2 HCl

RN 157864-05-6 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)- (CA INDEX NAME)




RN 157864-06-7 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157864-07-8 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfinyl)-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 157864-08-9 CAPLUS
 CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-

(methylsulfonyl)- (CA INDEX NAME)



RN 157864-09-0 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 157864-10-3 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-6-(methylsulfonyl)-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 157864-11-4 CAPLUS

CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 157864-12-5 CAPLUS

CN 6-Quinazolinemethanol, 2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]- (CA INDEX NAME)




RN 157864-13-6 CAPLUS

CN 6-Quinazolinemethanol, 4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 157864-14-7 CAPLUS

CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)-6-[2-(triethylsilyl)ethynyl]- (CA INDEX NAME)




RN 157864-15-8 CAPLUS

CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-[2-[tris(1-methylethyl)silyl]ethynyl]-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




RN 157864-16-9 CAPLUS

CN 4-Quinazolinamine, 6-ethynyl-2-(1H-imidazol-1-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 157864-17-0 CAPLUS

CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)



RN 157864-18-1 CAPLUS


CN Ethanol, 2-[2-[[6-ethynyl-2-(1H-imidazol-1-yl)-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 157864-19-2 CAPLUS

CN Ethanone, 1-[2-(1H-imidazol-1-yl)-4-[(2-methoxyethyl)amino]-6-quinazolinyl]- (CA INDEX NAME)




RN 157864-20-5 CAPLUS

CN Ethanone, 1-[4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-(1H-imidazol-1-yl)-6-quinazolinyl]- (CA INDEX NAME)




RN 157941-27-0 CAPLUS

CN Methanimidamide, N'-[[2-(1H-imidazol-1-yl)-4-[(phenylmethyl)amino]-6-quinazolinyl]sulfonyl]-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 157941-28-1 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-methoxy-4-quinazolinyl]amino]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 157941-29-2 CAPLUS
 CN Ethanol, 2-[2-[[2-(1H-imidazol-1-yl)-6-iodo-4-quinazolinyl]amino]ethoxy]- (CA INDEX NAME)




L7 ANSWER 159 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:605297 CAPLUS
 DOCUMENT NUMBER: 121:205297
 ORIGINAL REFERENCE NO.: 121:37381a,37384a
 TITLE: Synthesis of some azolylquinazolines
 AUTHOR(S): Bodajla, Michal; Stankovsky, Stefan; Spirkova, Katarina
 CORPORATE SOURCE: Dep. Organic Chem., Slovak Technical Univ., Bratislava, 812 37, Slovakia
 SOURCE: Collection of Czechoslovak Chemical Communications (1994), 59(6), 1463-6
 CODEN: CCCCAK; ISSN: 0010-0765
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:205297
 AB A series of pyrimidine ring substituted azolylquinazolines were prepared by reaction of 2,4-dichloroquinazoline with the corresponding azoles.
 IT 157980-27-3P 157980-28-4P 157980-29-5P

157980-30-8P 157980-31-9P 157980-32-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 157980-27-3 CAPLUS

CN Quinazoline, 2,4-di-1H-imidazol-1-yl- (CA INDEX NAME)




RN 157980-28-4 CAPLUS

CN Quinazoline, 2,4-bis(1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 157980-29-5 CAPLUS

CN Quinazoline, 2,4-di-1H-1,2,4-triazol-1-yl- (CA INDEX NAME)




RN 157980-30-8 CAPLUS


CN Quinazoline, 2,4-bis(1H-benzotriazol-1-yl)- (CA INDEX NAME)




RN 157980-31-9 CAPLUS
CN Quinazoline, 2-(1H-imidazol-1-yl)-4-(4-morpholinyl)- (CA INDEX NAME)



RN 157980-32-0 CAPLUS
CN Quinazoline, 2-(1H-benzimidazol-1-yl)-4-(4-morpholinyl)- (CA INDEX NAME)



L7 ANSWER 160 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:534008 CAPLUS
DOCUMENT NUMBER: 121:134008
ORIGINAL REFERENCE NO.: 121:24229a,24232a
TITLE: The chemistry of 5-oxodihydroisoxazoles. VIII.
Photolysis of 2-(heterocyclyl)isoxazol-5(2H)-ones
AUTHOR(S): Prager, Rolf H.; Singh, Yogendra; Weber, Ben
CORPORATE SOURCE: Sch. Phys. Sci., Flinders Univ., Adelaide, 5001,
Australia
SOURCE: Australian Journal of Chemistry (1994),
47(7), 1249-62
CODEN: AJCHAS; ISSN: 0004-9425
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:134008
GI



AB Photolysis of 2-(heterocyclyl)isoxazol-5(2H)-ones occurs readily at 300 nm. In alc. the products are the corresponding 2-alkoxy-3-


heterocyclcyclaminoacrylates, and, in the presence of 1 M trifluoroacetic acid, the corresponding imidazole annulated heterocycle. Examples are reported where the heterocycle is quinolin-2-yl (10 examples), e.g. I, isoquinolin-1-yl, benzoxazol-2-yl, benzothiazol-2-yl, quinazolin-1-yl and pyrimidin-2-yl.

IT 153704-59-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(photolysis of)

RN 153704-59-7 CAPLUS

CN 4-Isloxazolecarboxylic acid, 2,5-dihydro-3-methyl-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 161 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:323450 CAPLUS

DOCUMENT NUMBER: 120:323450

ORIGINAL REFERENCE NO.: 120:56909a,56912a

TITLE: Synthesis of 4-dialkylaminoquinazolines from the reaction of N-aryl nitrilium salts with dialkylcyanamides

AUTHOR(S): Al-Talib, Mahmoud

CORPORATE SOURCE: Dep. Chem., Yarmouk Univ., Irbid/J., Jordan

SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung (1993), 335(8), 711-13


CODEN: JPCCEM; ISSN: 0941-1216

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:323450

GI



AB The reaction of nitrilium salts I (R1 = H, Cl; R2 = Me, Ph, etc.) with dialkylcyanamides was reported to yield (dialkylamino)quinazolines II.

IT 139474-19-4P 155224-61-6P 155224-62-7P

155224-63-8P 155224-64-9P 155224-65-0P


155224-66-1P 155224-67-2P 155224-74-1P

155224-75-2P 155224-76-3P 155224-77-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, from nitrilium salt and dialkylcyanamide)

RN 139474-19-4 CAPLUS

CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)




RN 155224-61-6 CAPLUS

CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
N,N-dimethyl-2-phenyl-4-quinazolinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139474-19-4

CMF C16 H15 N3




CM 2

CRN 16941-91-6

CMF C16 Sb . H


CCI CCS



● H⁺

RN 155224-62-7 CAPLUS

CN 4-Quinazolinamine, N,N-bis(1-methylethyl)-2-phenyl- (CA INDEX NAME)




RN 155224-63-8 CAPLUS

CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
N,N-bis(1-methylethyl)-2-phenyl-4-quinazolinamine (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 155224-62-7

CMF C20 H23 N3




CM 2

CRN 16941-91-6

CMF C16 Sb . H


CCI CCS



● H^+

RN 155224-64-9 CAPLUS

CN 4-Quinazolinamine, 6-chloro-2-(4-chlorophenyl)-N,N-dimethyl- (CA INDEX
NAME)




RN 155224-65-0 CAPLUS

CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
6-chloro-2-(4-chlorophenyl)-N,N-dimethyl-4-quinazolinamine (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 155224-64-9

CMF C16 H13 Cl2 N3




CM 2

CRN 16941-91-6

CMF C16 Sb . H


CCI CCS



● H⁺

RN 155224-66-1 CAPLUS


CN 4-Quinazolinamine, 6-chloro-2-(4-chlorophenyl)-N,N-bis(1-methylethyl)-
(CA INDEX NAME)



RN 155224-67-2 CAPLUS
 CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
 6-chloro-2-(4-chlorophenyl)-N,N-bis(1-methylethyl)-4-quinazolinamine (1:1)
 (9CI) (CA INDEX NAME)


CM 1

CRN 155224-66-1
 CMF C20 H21 Cl2 N3




CM 2

CRN 16941-91-6
 CMF Cl6 Sb . H
 CCI CCS



● H⁺


RN 155224-74-1 CAPLUS
 CN 4-Quinazolinamine, N-(diphenylmethylene)-2-phenyl- (CA INDEX NAME)



RN 155224-75-2 CAPLUS
 CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
 N-(diphenylmethylene)-2-phenyl-4-quinazolinamine (1:1) (9CI) (CA INDEX
 NAME)


CM 1

CRN 155224-74-1
 CMF C27 H19 N3




CM 2

CRN 16941-91-6
 CMF C16 Sb . H
 CCI CCS




RN 155224-76-3 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(4-chlorophenyl)-N-(diphenylmethylene)- (CA
 INDEX NAME)



RN 155224-77-4 CAPLUS
 CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with
 6-chloro-2-(4-chlorophenyl)-N-(diphenylmethylene)-4-quinazolinamine (1:1)
 (9CI) (CA INDEX NAME)


CM 1

CRN 155224-76-3
CMF C27 H17 Cl2 N3




CM 2

CRN 16941-91-6
CMF Cl6 Sb . H
CCI CCS



● H⁺

L7 ANSWER 162 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:270303 CAPLUS
DOCUMENT NUMBER: 120:270303
ORIGINAL REFERENCE NO.: 120:47886h, 47887a
TITLE: Synthesis of some 1,2,4-triazolo[4,3-c]quinazolines
based on 4-quinazolylthiosemicarbazides
AUTHOR(S): Spirkova, Katarina; Stankovsky, Stefan; Dandarova,
Miloslava
CORPORATE SOURCE: Dep. Org. Chem., Slovak Tech. Univ., Bratislava, 812
37, Slovakia
SOURCE: Collection of Czechoslovak Chemical Communications (1994), 59(1), 222-6
CODEN: CCCCAK; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB The paper describes the cyclization reactions of substituted 1-(4'-quinazolinyl)-4-phenylthiosemicarbazides I (X = piperidyl, morpholinyl, 4-phenylpiperazinyl, Ph, Y = 6-Cl, 8-Me, Z = H, 4-NO₂). The thermal intramol. cyclization gives 2H-1,2,4-triazolo[4,3-c]quinazoline-3-thiones II. Heating of I with HgO gives 3-anilino-1,2,4-triazolo[4,3-c]quinazolines III. The IR and ¹H NMR spectra of the compds. synthesized are presented.

IT 29209-80-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (condensation of, with Ph isothiocyanate)

RN 29209-80-1 CAPLUS


CN 4(1H)-Quinazolinone, 8-methyl-2-phenyl-, hydrazone (9CI) (CA INDEX NAME)



IT 154475-60-2P 154475-61-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)


RN 154475-60-2 CAPLUS

CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-phenyl- (CA INDEX NAME)



RN 154475-61-3 CAPLUS

CN Hydrazinecarbothioamide, 2-(8-methyl-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (CA INDEX NAME)



L7 ANSWER 163 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:261498 CAPLUS

DOCUMENT NUMBER: 120:261498

ORIGINAL REFERENCE NO.: 120:46045a, 46048a

TITLE: Theoretical quantitative size and shape activity and selectivity analyses of 5-HT_{1A} serotonin and α ₁-adrenergic receptor ligands

AUTHOR(S): De Benedetti, P. G.; Cocchi, M.; Menziani, M. C.; Fanelli, F.

CORPORATE SOURCE: Dipartimento di Chimica, Universita degli Studi di Modena, Via Campi 183, 41100, Modena, Italy

SOURCE: THEOCHEM (1994), 111(1-3), 101-10
CODEN: THEODJ; ISSN: 0166-1280

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Quantum chemical reactivity indexes and mol. modeling derived size and shape descriptors have been computed for 18 5-HT_{1A} serotonin and α ₁-adrenergic receptor ligands. The quant. size-shape affinity-selectivity relationships obtained support the general validity and versatility of the ad hoc size-shape descriptors employed.

IT 154754-56-0

RL: BIOL (Biological study)
(α ₁-adrenergic receptor and serotonin 5_{1A} receptor binding affinity and selectivity of, size and shape in relation to)

RN 154754-56-0 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, conjugate monoacid (9CI) (CA INDEX NAME)




● H⁺


L7 ANSWER 164 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:257297 CAPLUS
 DOCUMENT NUMBER: 120:257297
 ORIGINAL REFERENCE NO.: 120:45303a, 45306a
 TITLE: Silver halide color photographic material
 INVENTOR(S): Clarke, David; Goddard, John DeMita; Stanley, Paul
 Louis Reginald; Milner, Nigel Edgewick
 PATENT ASSIGNEE(S): Kodak Ltd., UK; Eastman Kodak Co.
 SOURCE: Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 545491	A1	19930609	EP 1992-203683	19921128 <--
EP 545491	B1	19981014		
R: BE, CH, DE, FR, GB, IT, LI, NL				
US 5284739	A	19940208	US 1992-974038	19921110 <--
JP 05241282	A	19930921	JP 1992-322996	19921202 <--
JP 3136010	B2	20010219		


PRIORITY APPLN. INFO.: GB 1991-25688 A 19911203
 AB A Ag halide color photog. material with incorporated color developing agent and capable of forming excellent color images comprises ≥ 2 color-forming units sensitive to different regions of the spectrum, each comprising a Ag halide emulsion layer and, in or adjacent the layer, a photog. coupler, wherein the photog. material contains a ballasted heterocyclic sulfone hydrazide color developing agent having the formula RNHNHSO₂R₁ (R = a heterocyclic group which may be substituted; R₁ = alkyl, aryl, or heterocyclyl with R or R₁ containing a ballasting group of such size and configuration as to render the compound nondiffusible) incorporated therein in droplets of a high-boiling solvent.
 IT 85987-76-4
 RL: USES (Uses)
 (photog. developing agent, silver halide color photog. materials containing)
 RN 85987-76-4 CAPLUS
 CN 1-Hexadecanesulfonic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




L7 ANSWER 165 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:217607 CAPLUS
 DOCUMENT NUMBER: 120:217607
 ORIGINAL REFERENCE NO.: 120:38645a, 38648a
 TITLE: Amidinoyl isothiocyanates in the synthesis of condensed heterocycles. Preparation of quinazolino[3,4-c][1,3,5]-benzotriazepines and quinazolino[3,4-c][1,2,3,5]-benzotetraazepines
 AUTHOR(S): Stankovsky, S.; Derer, T.; Spirkova, K.
 CORPORATE SOURCE: Fac. Chem. Technol., Slovak Tech. Univ., Bratislava, Slovakia
 SOURCE: Monatshefte fuer Chemie (1993), 124(6-7), 733-8
 CODEN: MOCMB7; ISSN: 0026-9247
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:217607
 GI




AB When heated, amidinoyl isothiocyanates (I; X = CH, O) with 2-nitrophenyl isothiocyanate cyclize to 4-(2'-nitroanilino)quinazolines (II; R = NO₂, X = CH, O) and after reduction to 2'-amino derivs. (II; R = NO₂, X = CH, O). The latter serve as precursors to derivs. of the title compds.
 IT 153991-71-0P
 RL: PREP (Preparation)
 (formation in synthesis of condensed heterocycles, quinazolinobenzotriazepines and quinazolinobenzotetraazepines via cyclization of isothiocyanates)
 RN 153991-71-0 CAPLUS
 CN Quinazoline, 4-(1H-benzimidazol-1-yl)-2-phenyl- (CA INDEX NAME)



L7 ANSWER 166 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:217421 CAPLUS
 DOCUMENT NUMBER: 120:217421
 ORIGINAL REFERENCE NO.: 120:38601a,38604a
 TITLE: The chemistry of 5-oxodihydroisoxazoles. VII.
 Conversion of heterocyclisoxazol-5(2H)-ones to
 imidazoles by flash vacuum pyrolysis
 AUTHOR(S): Prager, Rolf H.; Singh, Yogendra
 CORPORATE SOURCE: Sch. Phys. Sci., Flinders Univ. South Australia,
 Adelaide, 5001, Australia
 SOURCE: Tetrahedron (1993), 49(36), 8147--58
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:217421
 GI



AB A number of 5-oxo-2,5-dihydroisoxazoles, substituted with nitrogen
 heterocycles at N-2, were subjected to flash vacuum pyrolysis. Annulated
 imidazoles are obtained in excellent yields, and are presumed to arise by
 intramol. cyclization of an imino carbene intermediate. The heterocycles
 annulated in this manner include isoquinoline, quinoline, benzothiazole,
 quinazoline, phenanthridine, pyrimidine and pyridine, e.g.
 imidazoquinoline I, pyrimidoquinoline II, and imidazobenzotriazole III.
 IT 153704-59-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (flash vacuum pyrolysis in preparation of annulated imidazoles)
 RN 153704-59-7 CAPLUS
 CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-3-methyl-5-oxo-2-(2-phenyl-4-
 quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 167 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:603427 CAPLUS
 DOCUMENT NUMBER: 119:203427
 ORIGINAL REFERENCE NO.: 119:36285a,36288a
 TITLE: Preparation of N-containing heterocyclic compounds as phosphodiesterase inhibitors.
 INVENTOR(S): Takase, Yasutaka; Watanabe, Nobuhisa; Matsui, Makoto; Ikuta, Hironori; Kimura, Teiji; Saeki, Takao; Adachi, Hideyuki; Tokumura, Tadakazu; Mochida, Hisatoshi; et al.
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 362 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9307124	A1	19930415	WO 1992-JP1258	19920930 <--
W: AU, CA, FI, HU, JP, KR, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
ZA 9207465	A	19930413	ZA 1992-7465	19920929 <--
CN 1071164	A	19930421	CN 1992-110792	19920929 <--
AU 9226851	A	19930503	AU 1992-26851	19920930 <--
AU 668363	B2	19960502		
EP 607439	A1	19940727	EP 1992-920913	19920930 <--
EP 607439	B1	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
HU 70854	A2	19951128	HU 1994-910	19920930 <--
JP 2818487	B2	19981030	JP 1993-506780	19920930 <--
JP 2000264885	A	20000926	JP 2000-70142	19920930 <--
JP 3477138	B2	20031210		
JP 2000273089	A	20001003	JP 2000-70138	19920930 <--
JP 3481900	B2	20031222		
AT 211734	T	20020115	AT 1992-920913	19920930 <--
US 5576322	A	19961119	US 1994-196110	19940218 <--
FI 9401417	A	19940325	FI 1994-1417	19940325 <--
NO 9401101	A	19940530	NO 1994-1101	19940325 <--
US 5693652	A	19971202	US 1995-408867	19950323 <--
JP 10095776	A	19980414	JP 1997-195696	19970722 <--
JP 3081172	B2	20000828		
US 5801180	A	19980901	US 1997-904260	19970731 <--
JP 2000264877	A	20000926	JP 2000-70130	20000314 <--

JP 3671131
PRIORITY APPLN. INFO.:

B2 20050713

JP 1991-320853	A 19910930
JP 1993-506780	A3 19920930
JP 1997-195696	A3 19920930
WO 1992-JP1258	A 19920930
US 1994-196110	A3 19940218
US 1995-408867	A3 19950323

OTHER SOURCE(S): MARPAT 119:203427

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R1-R4 = H, halo, (halo)alkyl, (un)substituted cycloalkyl, alkoxy, etc.; R5 = H, OH, hydrazino, alkyl, (un)substituted cycloalkyl, alkoxy, etc.; R6 = H, halo, OH, cyano, alkyl, alkoxy, alkenyl, etc.; A = benzene ring, pyridine ring, cyclohexane ring; B = pyridine ring, pyrimidine ring, imidazole ring], useful for treatment of ischemia, heart attack, hypertension, cardiac insufficiency, and asthma (no data), are prepared E.g., a mixture of 4-hydroxy-6-carbamoylquinazoline, SOCl₂, and POCl₃ was refluxed for 20 h to give 4-chloro-6-cyanoquinazoline. 4-(4-Methoxybenzyl)amino-6,7,8-trimethoxyquinazoline (also prepared) had an IC₅₀ of 1.0 μ M against phosphodiesterase in an in vitro study.


IT 150450-79-6P 150450-80-9P 150451-88-0P

150451-89-1P 150452-96-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as phosphodiesterase inhibitor)


RN 150450-79-6 CAPLUS

CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150450-80-9 CAPLUS


CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(2-propoxyphenyl)- (CA INDEX NAME)




RN 150451-88-0 CAPLUS
 CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 150451-89-1 CAPLUS
 CN 6-Quinazolinecarbonitrile, 4-[(1,3-benzodioxol-5-ylmethyl)amino]-2-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 150452-96-3 CAPLUS
 CN 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-2-(1H-tetrazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 168 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:533233 CAPLUS

DOCUMENT NUMBER: 119:133233

ORIGINAL REFERENCE NO.: 119:23765a,23768a

TITLE: The Influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures

AUTHOR(S): Ashby, J.; Paton, D.

CORPORATE SOURCE: Cent. Toxicol. Lab., ICI, Macclesfield/Ches., SK10 4TJ, UK

SOURCE: Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis (1993), 286(1), 3-74

CODEN: MUREAV; ISSN: 0027-5107

DOCUMENT TYPE: Journal

LANGUAGE: English

AB L. S. Gold et al. (1991) tabulated the results of rodent bioassays on 522 chems. and analyzed the data. The present study complements those analyses by providing a perspective from the viewpoint of the chemical structure of the carcinogens. The chemical structure of each of the carcinogens is displayed and the Gold database is represented with the test agents as the primary variable. The carcinogens are gathered into 6 chemical classes and each chemical is assessed for structural alerts to DNA reactivity. The database is then analyzed using an integration of the following parameters: bioassay in rat, mouse or both; structural alert status; chemical class; sites and multiplicity of carcinogenesis, and trans-species carcinogenicity. A series of figures is presented that enables rapid acquaintance with what represents the core database of rodent carcinogenicity. The several analyses presented combine in endorsing the reality of two broad classes of rodent carcinogen, presumed DNA-reactive and others (putative genotoxic and non-genotoxic carcinogens, but semantics have been largely avoided). H. M. Vainio et al. (1991) and his colleagues have tabulated 55 situations in which humans have succumbed to chemical induced cancer and have listed the tissues affected. This database of human carcinogens has been analyzed in the present study as done for the rodent carcinogen database, and comparisons made between the two. The predominance of putative genotoxic carcinogens in the human database was confirmed, as was the reality of putative non-genotoxic carcinogenicity in humans. It is concluded that putative genotoxic rodent carcinogenesis can be correlated both with chemical structure and the extent and nature of the induced effect, and that it is of clear relevance to humans. In contrast, it is concluded that putative non-genotoxic rodent carcinogenesis is more closely related to the test species than to the test chemical, and that it is essentially unpredictable in the absence of mechanistic models.


IT 33372-39-3

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)


(neoplasm from, of tissues, in laboratory animals, structure role in, human in relation to)

RN 33372-39-3 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




L7 ANSWER 169 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:495458 CAPLUS
 DOCUMENT NUMBER: 119:95458
 ORIGINAL REFERENCE NO.: 119:17217a,17220a
 TITLE: Novel 4-(pyrazol-1-yl)-, 1,2,4-triazolo[4,3-c]-, triazolo[1,5-c]- and tetrazolo[1,5-c]quinazolines: synthesis for potential biological activities
 AUTHOR(S): Shaban, Mohammed A. E.; Taha, Mamdouh A. M.; Sharshira, Essam E. M.
 CORPORATE SOURCE: Fac. Sci., Univ. Alexandria, Egypt
 SOURCE: Alexandria Journal of Pharmaceutical Sciences (1992), 6(2), 219-24
 CODEN: AJPSES; ISSN: 1110-1792
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:95458
 GI




AB Several 4-pyrazolylquinazolines, e.g., I, 1,2,4-triazolo[4,3-c]quinazolinones, e.g., II, and 1,2,4-triazolo[1,5-c]quinazolines, e.g., III, of potential biol. activity, were prepared by cyclization of 4-hydrazino-2-methyl- and -2-phenylquinazoline with mono- and 1,3-dicarbonyl compds. 5-Phenyl-1,2,4-triazolo[4,3-c]quinazolines were also obtained by an alternative route involving cyclization of 4-chloro-2-phenylquinazoline (IV) with aroylhydrazines. The tetrazolo[1,5-c]quinazolines were synthesized by cyclizing the amidrazones with HONO or by cyclization of IV with NaN₃.
 IT 145470-92-4P 145471-15-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)

RN 145470-92-4 CAPLUS
 CN 2,4-Pentanedione, mono[(2-phenyl-4-quinazolinyl)hydrazone] (9CI) (CA INDEX NAME)




RN 145471-15-4 CAPLUS
 CN Butanoic acid, 3-[(2-phenyl-4-quinazolinyl)hydrazone]-, ethyl ester (9CI) (CA INDEX NAME)




IT 91020-52-9P 91020-55-2P 91020-56-3P
 91020-57-4P 91020-59-6P 91020-61-0P
 145470-94-6P 145470-96-8P 145471-05-2P
 145471-06-3P 145471-07-4P 145471-08-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 91020-52-9 CAPLUS
 CN Benzoic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-55-2 CAPLUS
 CN Benzaldehyde, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-56-3 CAPLUS
 CN Benzaldehyde, 4-bromo-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA

INDEX NAME)




RN 91020-57-4 CAPLUS

CN Benzaldehyde, 4-chloro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)




RN 91020-59-6 CAPLUS


CN Benzaldehyde, 4-methoxy-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)



RN 91020-61-0 CAPLUS
 CN Benzaldehyde, 4-nitro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 145470-94-6 CAPLUS
 CN Quinazoline, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-phenyl- (CA INDEX NAME)




RN 145470-96-8 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-phenyl-2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 145471-05-2 CAPLUS

CN Benzoic acid, 4-methoxy-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 145471-06-3 CAPLUS


CN Benzoic acid, 4-chloro-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 145471-07-4 CAPLUS
 CN Benzoic acid, 4-bromo-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 145471-08-5 CAPLUS
 CN Benzoic acid, 4-nitro-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)



IT 6484-29-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactions of)
 RN 6484-29-3 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



L7 ANSWER 170 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:191598 CAPLUS
 DOCUMENT NUMBER: 118:191598
 ORIGINAL REFERENCE NO.: 118:32909a,32912a
 TITLE: The chemistry of 5-oxodihydroisoxazoles. IV.
 Reactions of some N-arylisoxazol-5-ones with
 nucleophiles
 AUTHOR(S): Ang, Kiah H.; Donati, Cosimo; Donkor, Augustine;
 Prager, Rolf H.
 CORPORATE SOURCE: Sch. Phys. Sci., Flinders Univ. South Australia,
 Adelaide, 5001, Australia
 SOURCE: Australian Journal of Chemistry (1992),
 45(12), 2037-48
 CODEN: AJCHAS; ISSN: 0004-9425
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 118:191598
 GI




AB The reactions of Et 2-aryl-5-oxo-2,5-dihydroisoxazole-4-carboxylates I (R = Ph, isoquinolin-1-yl, 2-phenylquinazolin-5-yl, and 5-nitropyridin-2-yl) with azide and amines, and other nucleophiles are described. The product formation is rationalized in terms of predominant initial attack by the nucleophile at C(3), or abstraction of H(3), of the isoxazole ring.

IT 100422-74-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with azide)

RN 100422-74-0 CAPLUS

CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 171 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:124487 CAPLUS

DOCUMENT NUMBER: 118:124487

ORIGINAL REFERENCE NO.: 118:21581a,21584a

TITLE: Synthesis and reactions of 2-(α -naphthyl)-4-(3H)-quinazolinone

AUTHOR(S): El-Farargy, A. F.; Hamad, M. M.; Said, S. A.; Haikal, A.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt

SOURCE: Egyptian Journal of Chemistry (1991), Volume

Date 1990, 33(3), 283-9


CODEN: EGJCA3; ISSN: 0367-0422

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 118:124487

GI




AB Quinazolinone I (R = H) was prepared via fusion of formamide with 2-(α -naphthyl)-3,1-(4H)-benzoxazin-4-one. I was treated with MeI in BuOH to give I (R = Me), which underwent fusion with phthalimide or succinic anhydride to give I (R = R¹, R²), resp. Condensation of I (R = Me) with PhCHO or 4-MeOC₆H₄CHO gave I (R = CH:CHPh, CH:CHC₆H₄OMe-4), resp. Chlorination of I (R = H) gave chloride II (R³ = Cl) which was treated with PhNH₂, NH₂NH₂, or NaN₃ to give II (R³ = NHPh, NHHN₂, N₃), resp. Alkylation of I (R = H) with Me₂SO₄ or ClCH₂CO₂Et gave ether II (R³ = OMe, OCH₂CO₂Et), resp. Further treatment of II (R³ = OCH₂CO₂Et) with amines gave amides II (R³ = OCH₂CONHR₄, R₄ = NH₂, NHPh, Ph, C₆H₄Me-4).

IT 133594-93-1P, 4-Anilino-2-(1-naphthyl)quinazoline
 133594-97-5P, 4-Hydrazino-2-(1-naphthyl)quinazoline
 133610-71-6P, 4-Azido-2-(1-naphthyl)quinazoline
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 133594-93-1 CAPLUS

CN 4-Quinazolinamine, 2-(1-naphthalenyl)-N-phenyl- (CA INDEX NAME)




RN 133594-97-5 CAPLUS




CN 4(1H)-Quinazolinone, 2-(1-naphthalenyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 133610-71-6 CAPLUS
 CN Quinazoline, 4-azido-2-(1-naphthalenyl)- (CA INDEX NAME)



L7 ANSWER 172 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:651324 CAPLUS
 DOCUMENT NUMBER: 117:251324
 ORIGINAL REFERENCE NO.: 117:43515a, 43518a
 TITLE: Some reactions with 4-carboxymethylthio-2-phenyl-5-acetylpyrimidine
 AUTHOR(S): El-Bahaie, S.; Bayoumy, B. E.; Assy, M. G.; El-Kafrawy, A.; Yousif, Sh.
 CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1991), 32(1-2), 415-20
 CODEN: EJPSBZ; ISSN: 0301-5068
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:251324
 GI



AB (Thienopyrimidinyl)benzoxazinone I was prepared Hydrazinolysis of I gave
the (thienopyrimidinyl)quinazolinone II. The
tetrazoloquinazolinylthieny[2,3-d]pyrimidine III was also prepared

IT 139436-19-4P 139436-20-7P 139436-21-8P


139436-22-9P 139436-23-0P 139436-24-1P

139436-25-2P 139436-26-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 139436-19-4 CAPLUS

CN 4-Quinazolinamine, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-N-
phenyl- (CA INDEX NAME)




RN 139436-20-7 CAPLUS


CN 4-Quinazolinamine, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-N-
(4-methoxyphenyl)- (CA INDEX NAME)




RN 139436-21-8 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-, hydrazone (9CI) (CA INDEX NAME)




RN 139436-22-9 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-, phenylhydrazone (9CI) (CA INDEX NAME)




RN 139436-23-0 CAPLUS
 CN Benzaldehyde, [2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)




RN 139436-24-1 CAPLUS
 CN Benzaldehyde, 4-methoxy-, [2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)




RN 139436-25-2 CAPLUS
 CN Benzoic acid, 2-[2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 139436-26-3 CAPLUS
 CN Benzoic acid, 4-chloro-, 2-[2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




L7 ANSWER 173 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:571366 CAPLUS
 DOCUMENT NUMBER: 117:171366
 ORIGINAL REFERENCE NO.: 117:29629a,29632a
 TITLE: A new synthesis of N-substituted-2-alkyl(or aryl)quinazolin-4-amines by amide base-mediated cyclization of carboximidamides derived from 2-(trifluoromethyl)benzenamine.
 AUTHOR(S): Patterson, Steven E.; Janda, Lubomir; Strekowski, Lucjan
 CORPORATE SOURCE: Dep. Chem., Georgia State Univ., Atlanta, GA, 30303, USA
 SOURCE: Journal of Heterocyclic Chemistry (1992), 29(4), 703-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:171366
 GI For diagram(s), see printed CA Issue.
 AB A one-pot preparation of carboximidamides (amidines), 2-CF₃C₆H₄N:C(NH₂)R₁ (R₁ = Me, Me₃C, Ph, 2-thienyl), involves treatment of amides, 2-CF₃C₆H₄NHCOR₁, with phosphorus pentachloride followed by the treatment of the resultant crude imidoyl chlorides, 2-CF₃C₆H₄N:CR₁Cl, with ammonia. Amidines, 2-CF₃C₆H₄N:C(NH₂)R₁ are cyclized to quinazolines I in lithium alkylamide- or dialkylamide-mediated reactions.
 IT 106823-85-2P 143871-26-5P 143871-27-6P
 143871-28-7P 144921-45-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (chemoselective preparation of)
 RN 106823-85-2 CAPLUS
 CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 143871-26-5 CAPLUS
 CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)




RN 143871-27-6 CAPLUS
 CN Quinazoline, 2-phenyl-4-(2,2,6,6-tetramethyl-1-piperidinyl)- (CA INDEX NAME)




RN 143871-28-7 CAPLUS
 CN 1,2-Ethanediamine, N,N-dimethyl-N'-[2-(2-thienyl)-4-quinazolinyl]- (9CI)
 (CA INDEX NAME)



RN 144921-45-9 CAPLUS
 CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-(3-thienyl)- (CA INDEX NAME)




IT 143871-32-3P 143871-33-4P 143871-34-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 143871-32-3 CAPLUS
 CN 1,2-Ethanediamine, N,N-dimethyl-N'-(2-phenyl-4-quinazolinyl)-,
 dihydrobromide (9CI) (CA INDEX NAME)




●2 HBr

RN 143871-33-4 CAPLUS
 CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-phenyl-, phosphate (2:3) (CA
 INDEX NAME)
 CM 1
 CRN 143871-26-5
 CMF C19 H20 N4




CM 2
 CRN 7664-38-2

CMF H3 O4 P



RN 143871-34-5 CAPLUS
CN 1,2-Ethanediamine, N,N-dimethyl-N'-[2-(2-thienyl)-4-quinazolinyl]-,
dihydrobromide (9CI) (CA INDEX NAME)





●2 HBr

L7 ANSWER 174 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:490317 CAPLUS
DOCUMENT NUMBER: 117:90317
ORIGINAL REFERENCE NO.: 117:15773a,15776a
TITLE: Preparation of 2,4-diaminoquinazolines for enhancing
antitumor activity
INVENTOR(S): Coe, Jotham Wadsworth; Fliri, Anton Franz; Kaneko,
Takushi; Larson, Eric Robert
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9207844	A1	19920514	WO 1991-US7254	19911010 <--
W: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2095213	A1	19920507	CA 1991-2095213	19911010 <--
AU 9190592	A	19920526	AU 1991-90592	19911010 <--
AU 644035	B2	19931202		
EP 556310	A1	19930825	EP 1992-900750	19911010 <--
EP 556310	B1	19950705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05507290	T	19931021	JP 1992-501815	19911010 <--
HU 64533	A2	19940128	HU 1993-1314	19911010 <--
BR 9107070	A	19940531	BR 1991-7070	19911010 <--
ES 2074867	T3	19950916	ES 1992-900750	19911010 <--
CN 1061411	A	19920527	CN 1991-108479	19911105 <--
ZA 9108767	A	19930505	ZA 1991-8767	19911105 <--
NO 9301635	A	19930505	NO 1993-1635	19930505 <--

US 5444062 A 19950822 US 1993-50047 19930505 <--
 PRIORITY APPLN. INFO.: US 1990-609986 A1 19901106
 WO 1991-US7254 A 19911010
 OTHER SOURCE(S): CASREACT 117:90317; MARPAT 117:90317
 GI




AB Title compds. [I; X, X1 = H, alkyl, alkoxy, Br, iodo, NO₂, amino, Me₂S⁺, aminomethyl, MeS, HOCH₂, (substituted) benzoylamino, alkanoylamino, 4-methylpiperazino, morpholino, piperazino, pyrrolidino, etc.; X2 = H, alkyl, alkoxy; XX1 = ethylenedioxy, methylenedioxy; R1 = alkoxyalkyl, cycloalkyl, benzodioxan-2-ylmethyl; R2 = H, alkyl, PhCH₂; R1R2 = (substituted) benzodiazepinyl, piperidino, decahydroisoquinol-2-yl, octahydroisoindol-2-yl, 1,2,3,4-tetrahydro-β-carbol-2-yl; R3 = cycloalkyl, benzodioxan-2-ylmethyl, (substituted) aralkyl, pyridylalkyl, alkoxyalkyl, indolylalkyl, tetrahydronaphthyl, indenyl, naphthyl, etc.; R4 = H, alkyl; R3R4N = (substituted) tetrahydroisoquinolyl, piperidino, piperazino], were prepared as p-glycoprotein inhibitors to reverse multidrug resistance (no data). Thus, 2,4-dichloro-6,7-dimethoxyquinazoline, 1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline, and Et₃N were stirred 16 h in dimethylacetamide to give 2-chloro-4-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)-6,7-dimethoxyquinazoline. The latter was heated with N-methyl-3,4-dimethoxyphenethylamine in ethoxyethoxyethanol to give title compound II.

IT 142716-15-2P 142716-18-5P 142716-19-6P
 142716-31-2P 142716-71-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as P-glycoprotein inhibitor)


RN 142716-15-2 CAPLUS

CN Quinazoline, 2,4-bis(3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 142716-18-5 CAPLUS
 CN Quinazoline, 2,4-bis(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 142716-19-6 CAPLUS
 CN Quinazoline, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-4-(3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 142716-31-2 CAPLUS
 CN Quinazoline, 2,4-bis(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)- (9CI)

(CA INDEX NAME)



RN 142716-71-0 CAPLUS

CN 4-Quinazolinamine, N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 175 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:151703 CAPLUS

DOCUMENT NUMBER: 116:151703

ORIGINAL REFERENCE NO.: 116:25677a, 25680a

TITLE: Reactions with 4-carboxymethylthio-2-phenyl-5-acetylpyrimidine

AUTHOR(S): El-Bahaie, Said; Bayoumy, Basher E.; Assy, M. G.; Yousif, S.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt






SOURCE: Polish Journal of Chemistry (1991), 65(5-6), 1059-64

CODEN: PJCHDQ; ISSN: 0137-5083

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Treating the title compound I sequentially with SOCl_2 , 2- $\text{H}_2\text{NC}_6\text{H}_4\text{CO}_2\text{H}$ in AcOH , and Ac_2O gave oxobenzoxazinylthienopyrimidine II ($\text{R} = \text{Q}$). Cyclocondensation of II with aromatic amines, hydrazines, NH_3 and glycine gave quinazolines III ($\text{R}_1 = \text{Ph}$, $\text{C}_6\text{H}_4\text{Br}-4$, $\text{C}_6\text{H}_4\text{OMe}-4$, NH_2 , NPh , $\text{CH}_2\text{CO}_2\text{H}$, H). Chlorination of III ($\text{R}_1 = \text{H}$) with $\text{PCl}_5\text{-POCl}_3$ led to a number of quinazolinylthienopyrimidine derivs., e.g., IV ($\text{R}_2 = \text{NPh}$, NHNHPh , NHN:CHPh , $\text{NHNHCOC}_6\text{H}_4\text{Cl}-4$), via substitution of IV ($\text{R}_2 = \text{Cl}$) and in some cases condensation with aldehydes or acylation with acid chlorides.

IT 139436-21-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)

RN 139436-21-8 CAPLUS

CN 4(1H)-Quinazolinone, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-, hydrazone (9CI) (CA INDEX NAME)



IT 139436-19-4P 139436-20-7P 139436-22-9P


139436-23-0P 139436-24-1P 139436-25-2P

139436-26-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 139436-19-4 CAPLUS


CN 4-Quinazolinamine, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-N-phenyl- (CA INDEX NAME)




RN 139436-20-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 139436-22-9 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-, phenylhydrazone (9CI) (CA INDEX NAME)



RN 139436-23-0 CAPLUS
 CN Benzaldehyde, [2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)




RN 139436-24-1 CAPLUS
 CN Benzaldehyde, 4-methoxy-, [2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazone (9CI) (CA INDEX NAME)




RN 139436-25-2 CAPLUS

CN Benzoic acid, 2-[2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)



RN 139436-26-3 CAPLUS

CN Benzoic acid, 4-chloro-, 2-[2-(4,5-dimethyl-2-phenylthieno[2,3-d]pyrimidin-6-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)



L7 ANSWER 176 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:143279 CAPLUS

DOCUMENT NUMBER: 116:143279

ORIGINAL REFERENCE NO.: 116:23956h,23957a

TITLE: Conformational analysis, molecular modeling and quantitative structure-activity relationship studies of 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline α 1-adrenergic antagonists

AUTHOR(S): Rastelli, Giulio; Fanelli, Francesca; Menziani, M. Cristina; Cocchi, Marina; De Benedetti, Pier G.

CORPORATE SOURCE: Dip. Chim., Univ. Modena, Modena, 41100, Italy


SOURCE: THEOCHEM (1991), 83, 307-18

CODEN: THEODJ; ISSN: 0166-1280

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Conformational anal. (AM1), modeling of the mol. shape (QUANTA 3.0) and quant. structure-activity relationship anal. were done on a set of 16 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline α 1-adrenoceptor antagonists (prazosin analogs) I (R = piperidinylcarbonyl derivs. etc.). Thus, the 2-substituents of the analogs considered are quite flexible. Furthermore, they suggest that, once the electronic requirements of the common quinazoline moiety are satisfied, the binding affinities are modulated by the mol. shape of the quinazoline 2-substituent, through the optimization of dispersive and steric interactions and the hydrophobic contribution.


IT 139644-60-3

RL: BIOL (Biological study)

(α 1-adrenergic antagonist activity and conformation of, QSAR study of)

RN 139644-60-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)




L7 ANSWER 177 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1992:128057 CAPLUS

DOCUMENT NUMBER: 116:128057


ORIGINAL REFERENCE NO.: 116:21659a,21662a
 TITLE: Hammett-Taft constants of substituted 2- and 4-quinazolinyl groups
 AUTHOR(S): Baram, S. G.; Shkurko, O. P.; Mamaev, V. P.
 CORPORATE SOURCE: Novosib. Inst. Org. Khim., Novosibirsk, USSR
 SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1991), (3), 686-90
 CODEN: IASKA6; ISSN: 0002-3353
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI



AB Substituent consts. σ_I and σ_{R0} for the title groups were inferred from ^{13}C NMR shifts of meta and para carbons of Ph groups in phenylquinazolines I ($R = \text{H}, \text{Cl}, \text{OMe}, \text{NMe}_2, \text{CN}, R_1 = \text{Ph}$ and vice versa). σ_I For the 4-quinazolinyl groups exceeded those for the 2-quinazolinyl groups.
 IT 139474-19-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and NMR of carbon-13 in)
 RN 139474-19-4 CAPLUS
 CN 4-Quinazolinamine, N,N-dimethyl-2-phenyl- (CA INDEX NAME)




IT 67824-27-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, with potassium cyanide)
 RN 67824-27-5 CAPLUS
 CN 4-Quinazolinaminium, N,N,N-trimethyl-2-phenyl-, chloride (9CI) (CA INDEX NAME)




● Cl⁻

L7 ANSWER 178 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:471523 CAPLUS
 DOCUMENT NUMBER: 115:71523
 ORIGINAL REFERENCE NO.: 115:12363a,12366a
 TITLE: Recent results on the cyclization tendency of
 diacyl-2-aminobenzamidoximes
 AUTHOR(S): Korbonits, Dezso; Kolonits, Pal
 CORPORATE SOURCE: Chinoin Pharm. Chem. Works, Budapest, H-1325, Hung.
 SOURCE: Acta Chimica Hungarica (1990), 127(6),
 795-802
 CODEN: ACHUDC; ISSN: 0231-3146
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 115:71523
 GI




AB O,N-Diacyl derivs. I (R, R1 = Ac, Bz) of 2-aminobenzamidoxime are converted to quinazoline-3-oxides, 4-quinazolinone oximes, 1,2,4-oxadiazoles or 3-aminoindazoles depending on the substitution on I and pH of the reaction. Thus, I (R = R1 = Ac) when treated with Na2CO3 in aqueous acetone gave oxadiazole II (R1 = Ac, R2 = Me), whereas with NaOH in aqueous EtOH, quinazoline-3-oxide III (R2 = Me) was obtained. Similarly I (R = R1 = Bz) reacted with Na2CO3 to give II (R1 = Bz, R2 = Ph), whereas with NaOH in aqueous EtOH indazole IV, and with EtOH in presence of acid III (R2 = Ph) were obtained. I (R = Ac, R1 = Bz) gave II (R1 = Bz, R2 = Me) with Na2CO3, whereas with NaOH in aqueous EtOH quinazolinone oxime V, and with EtOH in presence of acid III (R2 = PH) were obtained.
 IT 29083-90-7P 117998-85-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 29083-90-7 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-, 3-oxide (CA INDEX NAME)



RN 117998-85-3 CAPLUS
CN 4(1H)-Quinazolinone, 2-phenyl-, oxime (9CI) (CA INDEX NAME)




L7 ANSWER 179 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:207187 CAPLUS
DOCUMENT NUMBER: 114:207187
ORIGINAL REFERENCE NO.: 114:34947a,34950a
TITLE: Synthesis and reaction of 2-(α -naphthyl)-4-(3H)-quinazolinone
AUTHOR(S): El-Farargy, A. F.; Hamad, M. M.; Said, S. A.; Haikal, A.
CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt
SOURCE: Anales de Quimica (1990), 86(7), 782-5
CODEN: ANQUEX; ISSN: 1130-2283
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:207187
GI




AB Reaction of 2-(1-naphthyl)-3,1-[4H]benzoxazin-4-one with formamide in dry xylene gave 2-(1-naphthyl)quinazolinone I (R = H, 1-naphthyl (II)). II reacted with Me iodide, POCl₃/PCl₅, Et chloroacetate or di-Me sulfate to give I (R = Me, R₁ = 1-naphthyl (III)) and IV (R₁ = 1-naphthyl, R₂ = Cl, OCH₂CO₂Et, OMe) resp. The condensation of III with benzaldehyde or p-anisaldehyde gave styryl derivs. I (R = CH:CHR₃; R₃ = Ph, C₆H₄OMe-4). Treatment of IV (R₂ = OCH₂CO₂Et with hydrazine, Ph hydrazine, aniline and p-toluidine gave the corresponding amides IV (R₂ = OCH₂CONHR₄; R₄ = NH₂,


NHPh, Ph, C6H4Me-4) resp.
 IT 133594-93-1P 133594-97-5P 133610-71-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 133594-93-1 CAPLUS
 CN 4-Quinazolinamine, 2-(1-naphthalenyl)-N-phenyl- (CA INDEX NAME)



RN 133594-97-5 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(1-naphthalenyl)-, hydrazone (9CI) (CA INDEX NAME)





RN 133610-71-6 CAPLUS
 CN Quinazoline, 4-azido-2-(1-naphthalenyl)- (CA INDEX NAME)



L7 ANSWER 180 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:178874 CAPLUS
 DOCUMENT NUMBER: 112:178874
 ORIGINAL REFERENCE NO.: 112:30257a,30260a
 TITLE: Base-catalyzed rearrangement of isoxazolinyl
 heterocycles: synthesis of annelated pyrimidines
 AUTHOR(S): Donati, Cosimo; Janowski, Wit K.; Prager, Rolf H.;
 Taylor, Max R.; Vilkins, Louise M.
 CORPORATE SOURCE: Sch. Phys. Sci., Flinders Univ. South Australia,
 Bedford Park, 5042, Australia
 SOURCE: Australian Journal of Chemistry (1989),
 42(12), 2161-9

DOCUMENT TYPE:
LANGUAGE:
OTHER SOURCE(S):
GI

Journal
English
CASREACT 112:178874




AB The rearrangement of a number of title compds. by mild base is described, leading to pyrimido[2,1-a]isoquinoline, pyrimido[1,2-a]quinoline, pyrimido[2,1-b]benzothiazole, pyrimido[1,2-a]pyrimidine, pyrimido[1,2-b]pyridazine and pyrimido[1,2-c]quinazoline ring systems. Thus, isoquinolinylloxodihydroisoxazolecarboxylate I was treated with aqueous NaOH and then 2 M HCl to give 96% Et hydroxyoxopyrimidoisoquinolinecarboxylate II. A mechanism is suggested, and x-ray crystallog. evidence presented for the structure of II.

IT 100422-74-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(rearrangement of)

RN 100422-74-0 CAPLUS

CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 181 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:173827 CAPLUS

DOCUMENT NUMBER: 112:173827

ORIGINAL REFERENCE NO.: 112:29239a,29242a

TITLE: The structural basis of the mutagenicity of chemicals in Salmonella typhimurium: The Gene-Tox data base
AUTHOR(S): Klopman, Gilles; Frierson, Manton R.; Rosenkranz, Herbert S.

CORPORATE SOURCE: Dep. Chem., Case West. Reserve Univ., Cleveland, OH, 44106, USA

SOURCE: Mutation Research, Fundamental and Molecular

Mechanisms of Mutagenesis (1990), 228(1),
1-50

CODEN: MUREAV; ISSN: 0027-5107

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The CASE (Computer Automated Structure Evaluation) structure-activity methodol. has been applied to a Gene-Tox derived Salmonella mutagenicity data base consisting of 808 chems. Based upon qual. structural features, CASE identified 29 activating and 3 inactivating structural determinants which correctly predicted the probability of carcinogenicity of 93.7% of the known mutagens and nonmutagens in the data base (sensitivity = 0.998, and specificity = 0.704). Addnl., based upon a qual. structure-activity anal., CASE's performance was even better, leading to a sensitivity of 0.981 and a specificity of 1.000. Using the structural determinants identified in this data base, CASE gave excellent predictions of the mutagenicity of chems. not included in the data base. The identified biophores and biophobes can also be used to investigate the structural basis of the mutagenicity of various chemical classes.

IT 33372-39-3 33372-40-6 33389-36-5


57584-56-2 57584-57-3 58139-47-2

58139-48-3 58139-49-4 58139-50-7

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(mutagenicity of, Computer Automated Structure Evaluation for study of
structural determinants in relation to)


RN 33372-39-3 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX
NAME)




RN 33372-40-6 CAPLUS

CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA
INDEX NAME)




RN 33389-36-5 CAPLUS


CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-56-2 CAPLUS
 CN Ethanol, 2-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-57-3 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 58139-47-2 CAPLUS
 CN Ethanol, 2,2'-[[2-(2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 58139-48-3 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-2-(5-nitro-2-thienyl)- (CA INDEX NAME)




RN 58139-49-4 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-amino-2-thienyl)-4-quinazolinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 58139-50-7 CAPLUS
 CN 2-Thiophenamine, 5-[4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)



L7 ANSWER 182 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:138996 CAPLUS
 DOCUMENT NUMBER: 112:138996
 ORIGINAL REFERENCE NO.: 112:23499a,23502a
 TITLE: Base-induced di- and tri-merization of
 2,6-dicyanoaniline
 AUTHOR(S): Gorvin, John H.
 CORPORATE SOURCE: Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK
 SOURCE: Journal of Chemical Research, Synopses (1989
), (9), 294-5
 CODEN: JRPSDC; ISSN: 0308-2342
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 112:138996
 GI




AB Treating 2,6-dicyanoaniline with Me₃COK in DMSO gave .apprx.60% dimer I,
 whereas Li₂CO in DMSO gave .apprx.40% trimer II.

IT 125833-53-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and N-cyanophenylation of)

RN 125833-53-6 CAPLUS

CN 8-Quinazolinecarbonitrile, 4-amino-2-(2-amino-3-cyanophenyl)- (CA INDEX
 NAME)




IT 125833-54-7P 125833-55-8P 125833-56-9P

125833-57-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 125833-54-7 CAPLUS

CN 8-Quinazolinecarbonitrile, 4-amino-2-[3-cyano-2-[(4-
 cyanophenyl)amino]phenyl]- (CA INDEX NAME)




RN 125833-55-8 CAPLUS
 CN [2,8'-Biquinazoline]-8-carbonitrile, 4,4'-diamino-2'-(2-amino-3-cyanophenyl)- (CA INDEX NAME)



RN 125833-56-9 CAPLUS
 CN [2,8'-Biquinazoline]-8-carbonitrile, 4,4'-diamino-2'-(2-amino-3-cyanophenyl)-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 125833-55-8
 CMF C24 H15 N9




CM 2


CRN 64-19-7
 CMF C2 H4 O2




RN 125833-57-0 CAPLUS
 CN 6-Quinazolinecarbonitrile, 4-amino-2-(2-amino-5-cyanophenyl)- (CA INDEX NAME)




L7 ANSWER 183 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:118749 CAPLUS
 DOCUMENT NUMBER: 112:118749
 ORIGINAL REFERENCE NO.: 112:20118h, 20119a
 TITLE: Imidoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5-phenyl-s-triazolo[4,3-c]quinazolines
 AUTHOR(S): Stankovsky, S.; Boulmokh, A.
 CORPORATE SOURCE: Fac. Chem. Technol., Slov. Tech. Univ., Bratislava, CS-812 37, Czech.
 SOURCE: Chemical Papers (1989), 43(3), 433-8
 CODEN: CHPAEG; ISSN: 0366-6352
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB PhN:CPHNCS easily isomerizes to 2-phenyl-3H-quinazoline-4-thione (I, R = SH), which upon treatment with N₂H₄ converts to 2-phenyl-4-hydrazinoquinazoline (I, R = NHNH₂). This in turn has been converted by standard procedures to the corresponding 2-phenyl-4-quinazolyldiazones e.g. I (R = NHN:CHC₆H₄R₁-4; R₁ = Me₂N, MeO, H, Me, Cl, NO₂), starting compds. for oxidative cyclization to 3-aryl-5-phenyl-s-triazolo[4,3-c]quinazolines II.
 IT 6484-29-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and condensation of, with aromatic aldehydes)
 RN 6484-29-3 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)




IT 91020-55-2P 91020-57-4P 91020-59-6P
 91020-60-9P 91020-61-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of, with ferric chloride)
 RN 91020-55-2 CAPLUS
 CN Benzaldehyde, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)



RN 91020-57-4 CAPLUS
 CN Benzaldehyde, 4-chloro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
 INDEX NAME)




RN 91020-59-6 CAPLUS
 CN Benzaldehyde, 4-methoxy-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
 INDEX NAME)




RN 91020-60-9 CAPLUS

CN Benzaldehyde, 4-methyl-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-61-0 CAPLUS


CN Benzaldehyde, 4-nitro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)



IT 125558-21-6P 125558-22-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of, with ferric chloride or nitrobenzene)
 RN 125558-21-6 CAPLUS
 CN Benzaldehyde, 4-(dimethylamino)-, (2-phenyl-4-quinazolinyl)hydrazone (9CI)
 (CA INDEX NAME)




RN 125558-22-7 CAPLUS
 CN 2-Furancarboxaldehyde, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX
 NAME)



L7 ANSWER 184 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:35882 CAPLUS
 DOCUMENT NUMBER: 112:35882
 ORIGINAL REFERENCE NO.: 112:6213a,6216a
 TITLE: Preparation and testing of quinazoline derivatives as agrochemical fungicides.
 INVENTOR(S): Dreikorn, Barry Allen; Suhr, Robert George; Jourdan, Glen Phil; Wright, Ian Glaisby
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Eur. Pat. Appl., 65 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 326329	A2	19890802	EP 1989-300657	19890125 <--
EP 326329	A3	19900912		
EP 326329	B1	19981028		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
IL 89027	A	19930131	IL 1989-89027	19890123 <--
AU 8928747	A	19890803	AU 1989-28747	19890124 <--
AU 632994	B2	19930121		
AT 172725	T	19981115	AT 1989-300657	19890125 <--
ES 2121737	T3	19981216	ES 1989-300657	19890125 <--
ZA 8900623	A	19891227	ZA 1989-623	19890126 <--
DK 8900370	A	19890730	DK 1989-370	19890127 <--
DK 170817	B1	19960129		
FI 8900421	A	19890730	FI 1989-421	19890127 <--
JP 01226877	A	19890911	JP 1989-19403	19890127 <--
JP 2776864	B2	19980716		
BR 8900365	A	19890919	BR 1989-365	19890127 <--
CN 1035825	A	19890927	CN 1989-100469	19890127 <--
CN 1052379	C	20000517		
HU 49791	A2	19891128	HU 1989-425	19890127 <--
HU 207643	B	19930528		
KR 129754	B1	19980409	KR 1989-870	19890127 <--
US 5411963	A	19950502	US 1993-93975	19930719 <--
PRIORITY APPLN. INFO.:			US 1988-150102	A 19880129
			US 1989-324056	B1 19890316
OTHER SOURCE(S):	CASREACT 112:35882			
GI				




AB The title compds. I (R1-R4 = H, halo, C1-4 alkyl, branched C3-4 alkyl, etc.; Y = H, Cl, etc.; Z = H, Cl, OMe, Me, etc.), useful as fungicides, were prepared. Some I have also demonstrated insecticidal and miticidal activity. Treatment of 2-[4-(tert-butyl)phenyl]ethanol with NaH in DMF, followed by reaction with 4-chloroquinazoline, gave 28.4% 4-[2-[4-(tert-butyl)phenyl]ethoxy]quinazoline (II). II at 400 ppm gave 90-100% control of Erysiphe graminis tritici.

IT 124427-33-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of, as fungicide)

RN 124427-33-4 CAPLUS

CN 4-Quinazolinamine, N-[2-(5-chloro-2-thienyl)ethyl]-2-phenyl- (CA INDEX NAME)



L7 ANSWER 185 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:632731 CAPLUS

DOCUMENT NUMBER: 111:232731

ORIGINAL REFERENCE NO.: 111:38661a, 38664a

TITLE: pH-dependent alternative ring closure of monoacyl 2-aminobenzamidoximes. A new 2-aminobenzimidazole synthesis [Erratum to document cited in CA110(1):8158T]

AUTHOR(S): Korbonits, Dezso; Kolonits, Pal


CORPORATE SOURCE: Chinoi Pharm. Chem. Works, Budapest, H-1325, Hung.

SOURCE: Journal of Chemical Research, Synopses (1989), (10), 328


CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal


LANGUAGE: English
 AB Errors in Schemes 1 and 2 have been corrected The errors were not reflected in the abstract or the index entries.
 IT 29083-90-7P 117998-85-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (Erratum))
 RN 29083-90-7 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-, 3-oxide (CA INDEX NAME)



RN 117998-85-3 CAPLUS
 CN 4(1H)-Quinazolinone, 2-phenyl-, oxime (9CI) (CA INDEX NAME)



L7 ANSWER 186 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:423475 CAPLUS
 DOCUMENT NUMBER: 111:23475
 ORIGINAL REFERENCE NO.: 111:4085a,4088a
 TITLE: Ring transformation of 1,2-disubstituted
 4(1H)-quinazolinone oximes to 3,5-disubstituted
 1,2,4-oxadiazoles
 AUTHOR(S): Korbonits, Dezso; Kanzel-Szvoboda, Ida; Gonczi, Csaba;
 Simon, Kalman; Kolonits, Pal
 CORPORATE SOURCE: Chinoin Pharm. Chem. Works, Budapest, H-1325, Hung.
 SOURCE: Chemische Berichte (1989), 122(6), 1107-12
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:23475
 GI




AB In basic medium, cyclization of 2-H₂NC(:NOR)C₆H₄NHCH₂Ph (R = Bz, Ac) gave oxadiazoles I (R₁ = Me, Ph), while heating in H₂O gave 2-amino-1-benzylbenzimidazole. Reaction of 2-NCC₆H₄N(CH₂Ph)COR with H₂NOH or treatment of 2-H₂NC(:NOR)C₆H₄NBzCH₂Ph with acid gave quinazolone oximes II (R₁ = Me, Ph), which on heating isomerizes to I. The crystal structure of II (R₁ = Ph) was determined

IT 1022-44-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



L7 ANSWER 187 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:38944 CAPLUS

DOCUMENT NUMBER: 110:38944

ORIGINAL REFERENCE NO.: 110:6491a,6494a

TITLE: Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators

AUTHOR(S): Fenton, Garry; Newton, Christopher G.; Wyman, Barry M.; Bagge, Philip; Dron, Donald I.; Riddell, David; Jones, Graham D.

CORPORATE SOURCE: Dagenham Res. Cent., Rhone Poulenc Ltd., Dagenham Essex, RM10 7XS, UK


SOURCE: Journal of Medicinal Chemistry (1989), 32(1), 265-72
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:38944

GI



AB The preparation and plasma lipid altering characteristics of a series of 4H-3,1-benzoxazin-4-ones I (R = Me, Br, Cl, iodo, H, etc.; R₁ = 4-Me₃C, 3-Me₃C, 2-Me₃C, 4-Me₃CCH₂, H) are described. Thus, 2,5-H₂N(Br)C₆H₃CO₂H was treated with 4-Me₃CC₆H₄COCl in pyridine and then Ac₂O to give 51% I (R = Br, R₁ = 4-Me₃C). Hypocholesterolemic, hypotriglyceridemic, and high-d.-lipoprotein elevating properties are found for derivs. bearing a 4-(1,1-dimethylethyl)phenyl group at the 2-position, and this activity is

displayed in both hypercholesterolemic and in normolipidemic rats when the ring system is substituted at position 6 with H, Me, Cl, or iodo groups, and is optimal when the 6-position is substituted by a bromine atom. Evidence is presented suggesting that a metabolite or degradation product is responsible for the changes in lipoprotein concentration observed with active mols.


of this type. Synthesis of anticipated degradation products of the active mols. gave products displaying the expected in vivo activity, but no improvement in the narrow therapeutic margin of the best compound, I (R = Br, R1 = 4-Me3C) was obtained.

IT 117145-77-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipidemic activity of)

RN 117145-77-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N,6-dimethyl- (CA INDEX NAME)



L7 ANSWER 188 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:8158 CAPLUS

DOCUMENT NUMBER: 110:8158

ORIGINAL REFERENCE NO.: 110:1495a,1498a

TITLE: PH-Dependent alternative ring closure of monoacyl 2-aminobenzamidoximes. A new 2-aminobenzimidazole synthesis

AUTHOR(S): Korbonits, Dezso; Kolonits, Pal

CORPORATE SOURCE: Chinoim Pharm. Chem. Works, Budapest, H-1325, Hung.

SOURCE: Journal of Chemical Research, Synopses (1988), (7), 209


CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:8158

GI




AB Cyclization of 2-BzNHC₆H₄C(:NOH)NH₂ in acidic medium gave quinazoline oxide I, whereas in basic medium quinazolinone oxime II was obtained. Similarly, cyclization of 2-H₂NC₆H₄C(NH₂):NOBz in acid medium gave I, whereas in basic medium the oxadiazole III which isomerized to indazole IV, and in water 2-aminobenzimidazole were obtained. PH selectivity was less pronounced with acetyl derivs. of 2-H₂NC₆H₄C(:NOH)NH₂.

IT 29083-90-7P 117998-85-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 29083-90-7 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-, 3-oxide (CA INDEX NAME)



RN 117998-85-3 CAPLUS

CN 4(1H)-Quinazolinone, 2-phenyl-, oxime (9CI) (CA INDEX NAME)



L7 ANSWER 189 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:56101 CAPLUS

DOCUMENT NUMBER: 108:56101

ORIGINAL REFERENCE NO.: 108:9377a,9380a

TITLE: Preparation of 2-(azolylmethyl)-2-aryl-4-
[(piperazinylphenoxy)methyl]-1,3-dioxolanes as
antimycotics and fungicides

INVENTOR(S): Kampe, Klaus Dieter; Raether, Wolfgang; Dittmar,
Walter; Haenel, Heinz

PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 37 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3609596	A1	19871001	DE 1986-3609596	19860321 <--
EP 237963	A2	19870923	EP 1987-103589	19870312 <--
EP 237963	A3	19890322		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
IL 81934	A	19901223	IL 1987-81934	19870318 <--
HU 47102	A2	19890130	HU 1987-1219	19870319 <--
US 4824846	A	19890425	US 1987-28087	19870319 <--
DK 8701439	A	19870922	DK 1987-1439	19870320 <--
NO 8701167	A	19870922	NO 1987-1167	19870320 <--
AU 8770421	A	19870924	AU 1987-70421	19870320 <--
AU 590691	B2	19891109		
JP 62240680	A	19871021	JP 1987-64429	19870320 <--
ZA 8702055	A	19871028	ZA 1987-2055	19870320 <--
CA 1290333	C	19911008	CA 1987-532657	19870320 <--
PRIORITY APPLN. INFO.:			DE 1986-3609596	A 19860321
OTHER SOURCE(S):	MARPAT 108:56101			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = CH, N; Ar = naphthyl, (halo)thienyl, (un)substituted Ph; R1 = C1-3 alkyl, Cl, F; Y = heterocyclic moieties Q-Q4; R2 = alkyl, (un)substituted Ph, phenylalkyl; R3 = H, (cycloalkyl)alkyl, (un)substituted Ph, phenylalkyl; R4 = H, alkyl, PhCH2; R5 = H, cyano; R3R4 = alkylene, CH:CHCH:CH; R6, R8, R12 = H, alkyl, (un)substituted Ph; R7 = H, Me, CF3, PhCH2; R7R8 = (CH2)4; R9 = H, Me, Et; R10 = H, cyano, alkoxycarbonyl; R11 = alkyl, CF3, alkoxy, halo; n = 0-2; m = 0, 1] and their physiol. acceptable salts were prepared as medical and agrochem. fungicides (no data). 1-[6-(2-Cyclopentylethyl)-2-ethyl-4-pyrimidinyl]-4-(4-hydroxy-3,5-dimethylphenyl)piperazine (preparation given) and cis-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-4-[[(methylsulfonyl)oxy]methyl]-1,3-dioxolane were heated for 3.5 h in aqueous NaOH/PhMe containing Bu4NBr to give 81% [(piperazinylphenoxy)methyl]dioxolane II.

IT 112189-92-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of dioxolane antimycotics)

RN 112189-92-1 CAPLUS

CN Phenol, 4-[4-(2-phenyl-4-quinazolinyl)-1-piperazinyl]- (CA INDEX NAME)



IT 112237-24-8P 112237-42-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antimycotic and fungicide)

RN 112237-24-8 CAPLUS


CN Quinazoline, 4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-3,5-dimethylphenyl]-1-piperazinyl]-2-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 112237-42-0 CAPLUS
CN Quinazoline, 4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]-2-phenyl-, cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A




PAGE 2-A



L7 ANSWER 190 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1987:84568 CAPLUS
 DOCUMENT NUMBER: 106:84568
 ORIGINAL REFERENCE NO.: 106:13885a,13888a
 TITLE: Acylcarbodiimides. V. Preparation of
 (N-alkylbenzimidoyl)- and (N-
 arylbenzimidoyl)carbodiimides; their rearrangement to
 aminoquinazolines and dihydro-1,3,5-triazines
 AUTHOR(S): Goerdeler, Joachim; Eggers, Wolfgang
 CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Bonn, Bonn, D-5300/1,
 Fed. Rep. Ger.
 SOURCE: Chemische Berichte (1986), 119(12), 3737-48
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 106:84568
 GI




AB Imidoylcarbodiimides RN:CR1N:C:NR2 (I; R = Me, Et, Me_2CH , cyclohexyl, PhCH_2 , Ph; R1 = Ph, p- $\text{O}_2\text{NC}_6\text{H}_4$; R2 = C1-C4 alkyl, Ph, 2,6- $\text{Me}_2\text{C}_6\text{H}_3$) were prepared from imidoylthioureas RN:CR1NHC(S)NHR_2 directly or via iminothiadiazolines II. Many I rearranged to aminoquinazolines III (for R = Ph) or dihydrotriazines IV [for R = $\text{R}_3\text{R}_4\text{CH}$ (MeCH, Me_2C , PhCH)]. The latter reaction was studied mechanistically. IV reacted thermally with elimination of primary amine to give pyrimidines V [R5 = H, R6 = H, Me or $\text{R}_5\text{R}_6 = (\text{CH}_2)_4$].
 IT 77651-72-0P 106185-26-6P 106185-27-7P
 106185-28-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 77651-72-0 CAPLUS
 CN 4-Quinazolinamine, N-methyl-2-phenyl- (CA INDEX NAME)




RN 106185-26-6 CAPLUS

CN 4-Quinazolinamine, N-(1,1-dimethylethyl)-2-phenyl- (CA INDEX NAME)




RN 106185-27-7 CAPLUS

CN 4-Quinazolinamine, N-methyl-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 106185-28-8 CAPLUS

CN 4-Quinazolinamine, N-cyclohexyl-2-(4-nitrophenyl)- (CA INDEX NAME)



L7 ANSWER 191 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:84257 CAPLUS

DOCUMENT NUMBER: 106:84257

ORIGINAL REFERENCE NO.: 106:13821a,13824a

TITLE: Heterocyclic amplifiers of phleomycin. VI. Some phenylpurines, phenylpteridines, phenylquinazolines and related compounds

AUTHOR(S): Brown, Desmond J.; Mori, Kenya

CORPORATE SOURCE: John Curtin Sch. Med. Res., Aust. Natl. Univ., Canberra, 2601, Australia

SOURCE: Australian Journal of Chemistry (1985), 38(3), 467-74


CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:84257

GI




AB Phenylpurines I, phenylpteridines II, and phenylquinazolines III [R = Ph, SCH₂CH₂NMe₂, NHCH₂CH₂NMe₂, Cl, H, SMe, 4-pyridyl, S(CH₂)₃NMe₂; R₁ = SCH₂CH₂NMe₂, Cl, NHCH₂CH₂NMe₂, NH₂, Ph, H, SMe, S(CH₂)₃NMe₂; R₂ = H, SCH₂CH₂NMe₂, Ph; R₃ = H, Me] were prepared by various routes. I (R = Ph, R₁ = SCH₂CH₂NMe₂, R₂ = H), II (R = Ph, R₁ = NHCH₂CH₂NMe₂, R₃ = Me), and III (R = Ph, R₁ = SCH₂CH₂NMe₂) have considerable activity as amplifiers of phleomycin-G in vitro.

IT 106823-85-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and phleomycin amplifying activity of)

RN 106823-85-2 CAPLUS

CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




IT 18602-79-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 18602-79-4 CAPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-(2-phenyl-4-quinazolinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



L7 ANSWER 192 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:442833 CAPLUS
 DOCUMENT NUMBER: 105:42833
 ORIGINAL REFERENCE NO.: 105:7101a,7104a
 TITLE: 4-Pyridinium quinazoline derivatives
 INVENTOR(S): Holyoke, Caleb W.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co. , USA
 SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4502880	A	19850305	US 1983-463473	19830203 <--
PRIORITY APPLN. INFO.:			US 1983-463473	19830203
OTHER SOURCE(S):	MARPAT	105:42833		
GI				




AB The title compds. I and II [R, R1 = H, F, Cl, Br, C1-4 alkyl; R2 = C1-4 alkyl; n = 0, 1, 2,; X- = agriculturally suitable anion] were prepared as cotton defoliants. Thus, 2,4-dichloroquinazoline was treated with pyridine to give I (R = R1 = R2 = H, R3 = Cl, X = Cl) (III). At 250 g/ha III defoliated cotton by 52% after 1 wk.

IT 96795-27-6P 96795-35-6P 96795-36-7P
 96795-37-8P 96795-38-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as cotton defoliant)


RN 96795-27-6 CAPLUS

CN Pyridinium, 1,1'-(2,4-quinazolinediyl)bis-, dichloride (9CI) (CA INDEX NAME)




●2 Cl⁻

RN 96795-35-6 CAPLUS
 CN Pyridinium, 1,1'-(6-chloro-2,4-quinazolinediyl)bis-, dichloride (9CI) (CA INDEX NAME)




●2 Cl⁻

RN 96795-36-7 CAPLUS
 CN Pyridinium, 1,1'-(6-methyl-2,4-quinazolinediyl)bis-, dichloride (9CI) (CA INDEX NAME)




●2 Cl⁻

RN 96795-37-8 CAPLUS
 CN Pyridinium, 1,1'-(2,4-quinazolinediyl)bis[2,4-dimethyl-, dichloride (9CI)
 (CA INDEX NAME)



●2 Cl⁻


RN 96795-38-9 CAPLUS
 CN Pyridinium, 1,1'-(7-chloro-2,4-quinazolinediyl)bis-, dichloride (9CI) (CA
 INDEX NAME)



●2 Cl⁻

L7 ANSWER 193 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:88467 CAPLUS
 DOCUMENT NUMBER: 104:88467
 ORIGINAL REFERENCE NO.: 104:14035a,14038a
 TITLE: Central nervous system active compounds. XV.
 2-Arylisoxazol-5(2H)-ones
 AUTHOR(S): Hung, Tran V.; Janowski, Wit K.; Prager, Rolf H.
 CORPORATE SOURCE: Dep. Org. Chem., Univ. Adelaide, Adelaide, 5001,
 Australia
 SOURCE: Australian Journal of Chemistry (1985),
 38(6), 931-7
 CODEN: AJCHAS; ISSN: 0004-9425
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 104:88467

GI




AB Et 5-oxo-2,5-dihydroisoxazole-4-carboxylate was treated with a number of chlorinated heterocycles to yield the corresponding substitution products I (R = isoquinolinyl, quinolinyl, purinyl, pyrimidinyl, pyridinyl, pyridazinyl, benzothiazolyl, quinazolinyl, triazinyl). I generally cause loss of motor control in mice, but are relatively toxic.

IT 100422-74-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and central nervous system activity of)

RN 100422-74-0 CAPLUS

CN 4-Isioxazolecarboxylic acid, 2,5-dihydro-5-oxo-2-(2-phenyl-4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



L7 ANSWER 194 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:523502 CAPLUS

DOCUMENT NUMBER: 103:123502

ORIGINAL REFERENCE NO.: 103:19757a,19760a

TITLE: Quinazoline and isoquinoline derivatives

INVENTOR(S): Timmerman, Hendrik; Van der Goot, Henderikus

PATENT ASSIGNEE(S): AKZO N. V. , Neth.

SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 135975	A2	19850403	EP 1984-201386	19840928 <--
EP 135975	A3	19850612		
EP 135975	B1	19880914		


R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
 WO 8501501 A1 19850411 WO 1984-EP312 19840928 <--
 W: AU, DK, JP, US
 AU 8435518 A 19850423 AU 1984-35518 19840928 <--
 AU 572585 B2 19880512
 ZA 8407673 A 19850529 ZA 1984-7673 19840928 <--
 JP 61500019 T 19860109 JP 1984-503906 19840928 <--
 AT 37183 T 19880915 AT 1984-201386 19840928 <--
 CA 1255674 A1 19890613 CA 1984-464249 19840928 <--
 US 4694000 A 19870915 US 1984-679000 19841206 <--
 DK 8406043 A 19850411 DK 1984-6043 19841217 <--
 PRIORITY APPLN. INFO.: NL 1983-3328 A 19830929
 EP 1984-201386 A 19840928
 WO 1984-EP312 A 19840928
 OTHER SOURCE(S): MARPAT 103:123502
 GI




AB Quinazolines and isoquinolines I (R, R1 = H, alkyl, alkoxy, halo, F3C; R2 = (un)substituted 2-pyridyl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl; X = N, CH; Z = O, NH), useful as bactericides, protozoacides, and inhibitors of Mycoplasma (no data) were prepared. Thus, 2-H2NC6H4CONH2 was treated with 2-pyridinecarbonitrile to give 61% 4-amino-2-(2-pyridyl)quinazoline which was acylated with Ac2O to give 23% I (R = R1 = H, R2 = 2-pyridyl, R3 = Me, X = N, Z = O). The microbicidal activities of I are increased by the addition of Cu salts (no data).
 IT 91748-44-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amination of)
 RN 91748-44-6 CAPLUS
 CN Benzamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




IT 40172-82-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of)
 RN 40172-82-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)




IT 91748-43-5P 91748-46-8P 91748-48-0P
 91748-50-4P 91748-51-5P 91748-52-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 91748-43-5 CAPLUS
 CN Acetamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-46-8 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-48-0 CAPLUS
 CN Methanimidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-50-4 CAPLUS
 CN Ethanimidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 91748-51-5 CAPLUS
 CN Benzenecarboximidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-52-6 CAPLUS
 CN Ethanimidamide, 2,2,2-trifluoro-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




L7 ANSWER 195 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:523411 CAPLUS
 DOCUMENT NUMBER: 103:123411
 ORIGINAL REFERENCE NO.: 103:19741a,19744a
 TITLE: Thermolysis of 4-azidopyrimidines and 4-azidoquinazolines
 AUTHOR(S): Giammanco, Lorenzo; Invidiata, Francesco Paolo
 CORPORATE SOURCE: Ist. Chim. Farm. Tossicol., Univ. Palermo, Palermo, 90123, Italy
 SOURCE: Heterocycles (1985), 23(6), 1459-64
 CODEN: HTCYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 103:123411
 AB A facile thermolysis of 4-azidopyrimidines and 4-azidoquinazolines leading, by ring contraction, in excellent yields to 1-cyanoimidazoles and benzimidazoles is reported.
 IT 98296-28-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reaction of, with sodium nitrite)
 RN 98296-28-7 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(3-pyridinyl)-, hydrazone (9CI) (CA INDEX NAME)



IT 98296-32-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and thermolysis of)
 RN 98296-32-3 CAPLUS
 CN Quinazoline, 4-azido-2-(3-pyridinyl)- (CA INDEX NAME)



IT 63399-59-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (thermolysis of)
 RN 63399-59-7 CAPLUS
 CN Quinazoline, 4-azido-2-phenyl- (CA INDEX NAME)




L7 ANSWER 196 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:454096 CAPLUS
 DOCUMENT NUMBER: 103:54096
 ORIGINAL REFERENCE NO.: 103:8721a,8724a
 TITLE: Pharmacodynamic 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-3,4-dehydropiperidine derivatives
 INVENTOR(S): Konig, Jan; Rajsner, Miroslav; Trcka, Vaclav; Macova, Svetluse
 PATENT ASSIGNEE(S): Czech.
 SOURCE: Czech., 4 pp.
 CODEN: CZXXA9
 DOCUMENT TYPE: Patent
 LANGUAGE: Czech

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 218028	B1	19830225	CS 1981-6718	19810911 <--
PRIORITY APPLN. INFO.:			CS 1981-6718	19810911

GI




AB Eight title compds. I (R = H, Cl, F, Me, CMe₃) were prepared by refluxing 2-chloro-4-amino-6,7-dimethoxyquinazoline with the appropriate 4-aryl-3,4-dehydropiperidine in Me₂CH(CH₂)₂OH and isolated as the HCl salts. I had at 1-5 mg/kg orally prolonged hypotensive activity in rats and monkeys.

IT 97429-86-2P 97429-87-3P 97429-88-4P
97429-89-5P 97429-90-8P 97429-91-9P
97429-92-0P 97429-93-1P 97429-97-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 97429-86-2 CAPLUS

CN 4-Quinazolinamine, 2-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




RN 97429-87-3 CAPLUS

CN 4-Quinazolinamine, 2-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 97429-88-4 CAPLUS
 CN 4-Quinazolinamine, 2-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 97429-89-5 CAPLUS
 CN 4-Quinazolinamine, 2-[4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 97429-90-8 CAPLUS
 CN 4-Quinazolinamine, 2-[4-(2-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 97429-91-9 CAPLUS


CN 4-Quinazolinamine, 2-[3,6-dihydro-4-(3-methylphenyl)-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 97429-92-0 CAPLUS


CN 4-Quinazolinamine, 2-[3,6-dihydro-4-(4-methylphenyl)-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 97429-93-1 CAPLUS

CN 4-Quinazolinamine, 2-[4-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-1(2H)-pyridinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 97429-97-5 CAPLUS
 CN 4-Quinazolinamine, 2-[3,6-dihydro-4-(4-methylphenyl)-1(2H)-pyridinyl]-6,7-dimethoxy- (CA INDEX NAME)




L7 ANSWER 197 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:45876 CAPLUS
 DOCUMENT NUMBER: 102:45876
 ORIGINAL REFERENCE NO.: 102:7217a,7220a
 TITLE: Synthesis of 4-aminopyrimidines from 1,2,4-oxadiazoles. I. New general method for the preparation of 4-aminoquinazolines and their hetero analogs
 AUTHOR(S): Korbonits, Dezso; Kiss, Pal; Simon, Kalman; Kolonits, Pal
 CORPORATE SOURCE: Chinoin Pharm. Chem. Works, Budapest, H-1325, Hung.
 SOURCE: Chemische Berichte (1984), 117(11), 3183-93
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 102:45876
 GI For diagram(s), see printed CA Issue.
 AB Catalytic hydrogenation of 1,2,4-oxadiazoles I [R = H; R1 = (un)substituted alkyl, Ph; A = benzene, pyrazole, 1,2,3-triazole, pyridine, pyrimidine residue] gave 2-amino-N-acylarenecarboxamidines II which were dehydrated to give condensed 4-aminopyrimidines III. The corresponding secondary amines (I, A = benzene residue; R = Et, R1 = Me; R = R1 = Me) gave 4-iminoquinazolines IV. Reduction and dehydration of I (A = benzene residue, R = Ac, Bz, R1 = Me, Ph) gave, via a somewhat different pathway, 4-(acylamino)quinazolines V (R2 = Me, Ph).
 IT 1022-44-2P 94078-81-6P 94078-82-7P
 94078-92-9P 94078-93-0P 94078-94-1P
 94098-58-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 1022-44-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 94078-81-6 CAPLUS
 CN Acetamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 94078-82-7 CAPLUS
 CN Benzamide, N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 94078-92-9 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methylphenyl)- (CA INDEX NAME)




RN 94078-93-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 94078-94-1 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 94098-58-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-methoxyphenyl)- (CA INDEX NAME)



L7 ANSWER 198 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:24579 CAPLUS
 DOCUMENT NUMBER: 102:24579
 ORIGINAL REFERENCE NO.: 102:4055a,4058a
 TITLE: Preparation of substituted 2-phenyl-4-anilinoquinazolines through imidoylecarbodiimides
 AUTHOR(S): Stankovsky, S.; Mrazova, D.
 CORPORATE SOURCE: Dep. Org. Chem., Slovak Tech. Univ., Bratislava, CS-812 37, Czech.
 SOURCE: Chemické Zvesti (1984), 38(4), 549-55
 CODEN: CHZVAN; ISSN: 0366-6352
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 102:24579
 GI




AB 4-RC₆H₄N:CP_hNHCSNHC₆H₄R₁-4 (I, R, R₁ = H, Me, Cl) were prepared in 50-70% yields by treating 4-RC₆H₄N:CP_hNCS with 4-R₁C₆H₄NH₂. Oxidative cyclization of I with HgO gave 56-68% quinazolines II.

IT 40288-70-8P 94078-50-9P 94078-51-0P
 94078-52-1P 94078-53-2P 94078-54-3P
 94078-55-4P 94078-56-5P 94078-57-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 94078-50-9 CAPLUS

CN 4-Quinazolinamine, N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 94078-51-0 CAPLUS


CN 4-Quinazolinamine, N-(4-chlorophenyl)-2-phenyl- (CA INDEX NAME)




RN 94078-52-1 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




RN 94078-53-2 CAPLUS
 CN 4-Quinazolinamine, 6-methyl-N,2-diphenyl- (CA INDEX NAME)




RN 94078-54-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-chlorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 94078-55-4 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(4-chlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 94078-56-5 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N,2-diphenyl- (CA INDEX NAME)




RN 94078-57-6 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-N-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)




L7 ANSWER 199 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:551814 CAPLUS
 DOCUMENT NUMBER: 101:151814
 ORIGINAL REFERENCE NO.: 101:22979a,22982a
 TITLE: Triazines and related products. Part 27. Thermolysis
 of 4-anilino-1,2,3-benzotriazines
 AUTHOR(S): Baig, Ghouse Unissa; Stevens, Malcolm F. G.; Vaughan,
 Keith
 CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, B4 7ET, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions
 1: Organic and Bio-Organic Chemistry (1972-1999) (1984), (5), 999-1003
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:151814
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Thermolysis of benzotriazine I in refluxing morpholine for 7 h gave
 benzotriazine II in addition to the major product, amidine III. The yield of
 II increased in high boiling nonnucleophilic solvents. Decomposition of II in
 hot AcOH gave 4-(4-cyanophenyl)-2-phenylquinazoline derivs.
 IT 92000-85-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrogenation of)
 RN 92000-85-6 CAPLUS
 CN Benzonitrile, 4-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]- (CA INDEX
 NAME)




IT 92000-86-7P 92000-88-9P 92000-89-0P
 92000-90-3P 92000-92-5P 92000-93-6P
 92000-94-7P 92000-95-8P 92000-96-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 92000-86-7 CAPLUS
 CN Benzonitrile, 4-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-,
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 92000-88-9 CAPLUS
 CN Benzonitrile, 4-[(2-phenyl-4-quinazolinyl)amino]-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl


RN 92000-89-0 CAPLUS
 CN Benzonitrile, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 92000-90-3 CAPLUS
 CN Benzonitrile, 4-[[2-(2-hydroxyphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 92000-92-5 CAPLUS
 CN Benzonitrile, 4-[[2-(2-iodophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 92000-93-6 CAPLUS

CN Benzonitrile, 4-[[2-(2-bromophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 92000-94-7 CAPLUS


CN Benzonitrile, 4-[[2-(2-bromophenyl)-4-quinazolinyl]amino]-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr


RN 92000-95-8 CAPLUS

CN Benzonitrile, 4-[[2-[2-[(2-hydroxy-1-naphthalenyl)azo]phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 92000-96-9 CAPLUS


CN Benzonitrile, 4-[[2-(2-azidophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



IT 92000-91-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, diazotization, and cyclization of)
 RN 92000-91-4 CAPLUS
 CN Benzonitrile, 4-[[2-(2-aminophenyl)-4-quinazolinyl]amino]- (CA INDEX
 NAME)



L7 ANSWER 200 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:510863 CAPLUS
 DOCUMENT NUMBER: 101:110863
 ORIGINAL REFERENCE NO.: 101:16933a,16936a
 TITLE: Synthesis and copper dependent antimycoplasmal
 activity of quinazolinylamidines and amides: a case
 of concentration quenching
 AUTHOR(S): Linschoten, Marcel R.; Gaisser, H. Dieter; Van der
 Goot, Hendricks; Timmerman, Hendrick
 CORPORATE SOURCE: Dep. Pharmacochem., Vrije Univ., Amsterdam, 1081 HV,
 Neth.
 SOURCE: European Journal of Medicinal Chemistry (1984
), 19(2), 137-42
 CODEN: EJMCA5; ISSN: 0009-4374
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:110863
 GI




AB The title compds. I (R = H, Me, Ph, CF₃, 2-pyridyl, Z = NH; R = Me, Ph, CF₃, Z = O) were prepared from the amine or from the chloroquinoline. In the absence of Cu, I (R = Me, Ph, CF₃, Z = NH) showed concentration quenching of their antimycoplasmal activity, i.e. decreasing toxicity with increasing concentration. The presence of 10 µg Cu/mL enhanced the activity of I manyfold. In the presence of Cu I, except I (R = H, Z = NH), were more effective than tylosin.

IT 40172-82-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation or hydrolysis of)

RN 40172-82-5 CAPLUS


CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)



IT 91748-42-4P 91748-43-5P 91748-46-8P
 91748-48-0P 91748-50-4P 91748-51-5P
 91748-52-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antimycoplasmal activity of, copper presence effect on)


RN 91748-42-4 CAPLUS

CN 2-Pyridinecarboximidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-43-5 CAPLUS

CN Acetamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-46-8 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-48-0 CAPLUS

CN Methanimidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-50-4 CAPLUS

CN Ethanimidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-51-5 CAPLUS


CN Benzenecarboximidamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 91748-52-6 CAPLUS
 CN Ethanimidamide, 2,2,2-trifluoro-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



IT 91748-45-7P 91748-49-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 91748-45-7 CAPLUS
 CN Benzamide, N-benzoyl-N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 91748-49-1 CAPLUS
 CN Methanimidamide, N,N'-bis[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 91748-44-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, chlorination-ammoniation, and antimycoplasmal activity of)

RN 91748-44-6 CAPLUS

CN Benzamide, N-[2-(2-pyridinyl)-4-quinazolinyl]- (CA INDEX NAME)



L7 ANSWER 201 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:510436 CAPLUS

DOCUMENT NUMBER: 101:110436

ORIGINAL REFERENCE NO.: 101:16852h,16853a

TITLE: Synthesis of 2-cyano-4-nitroaniline. II. Preparation of 2-cyano-4-nitroaniline by ammonolysis

AUTHOR(S): Gheorghe, Pompilia; Savulescu, Angela

CORPORATE SOURCE: Cent. Cercetari Color., Icechim, Bucharest, Rom.

SOURCE: Revistade Chimie (Bucharest, Romania) (1984), 35(2), 105-8

CODEN: RCBUAU; ISSN: 0034-7752

DOCUMENT TYPE: Journal

LANGUAGE: Romanian

AB 1-Chloro-2-cyano-4-nitrobenzene and 2-cyano-4-nitroanisole were treated with NH₃ to yield the title aniline, higher yields were obtained from the chlorobenzene derivative Also obtained were 5-nitroanthranilamide and 2-(2-amino-5-nitrophenyl)-4-amino-6-nitroquinazoline.


IT 91620-55-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of)

RN 91620-55-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-amino-5-nitrophenyl)-6-nitro- (CA INDEX NAME)




L7 ANSWER 202 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:455051 CAPLUS
 DOCUMENT NUMBER: 101:55051
 ORIGINAL REFERENCE NO.: 101:8556h,8557a
 TITLE: Quinazoline derivatives from 2-phenyl-4-quinazolinylhydrazine
 AUTHOR(S): El-Sherief, Hassan Ahmed; Mahmoud, Abdalla Mohamed; Esmail, Ahmed Ahmed
 CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt
 SOURCE: Bulletin of the Chemical Society of Japan (1984), 57(4), 1138-42
 CODEN: BCSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:55051
 GI




AB HCO₂H, AcCl and BzCl were treated with 2-phenyl-4-quinazolinylhydrazine (I) under mild conditions to afford the corresponding hydrazides which were converted into triazoloquinazolines II (R = H, Me, Ph) by heating over their m.ps. Reaction of I with RCHO (R = Ph, 4-BrC₆H₄, 4-ClC₆H₄, 3-ClC₆H₄, 4-MeOC₆H₄, 4-MeC₆H₄, 4-O₂NC₆H₄, 3-O₂C₆H₄, 2-thienyl) produced the corresponding hydrazones which give the corresponding II on pyrolysis. CS₂ underwent ring closure with I to 5-phenyl-1,2,4-triazolo[4,3-c]quinazoline-3-thiol which was readily converted into the corresponding alkylthio compds. by treatment with alkyl halides. Further, 4-(4-arylmethylene-5-oxo-2-phenyl-2-imidazolinylamino)-2-phenylquinazolines were obtained via the condensation of 4-arylmethylene-2-phenyl-2-oxazolin-5-ones with I.
 IT 6484-29-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with benzaldehydes, triazoloquinzaolines from)
 RN 6484-29-3 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)




IT 91020-53-0P 91020-54-1P 91020-55-2P
 91020-56-3P 91020-57-4P 91020-58-5P
 91020-59-6P 91020-60-9P 91020-61-0P
 91020-62-1P 91020-63-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of, triazoloquinazoline from)
 RN 91020-53-0 CAPLUS
 CN Acetic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-54-1 CAPLUS
 CN Hydrazinecarboxaldehyde, 2-(2-phenyl-4-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 91020-55-2 CAPLUS
 CN Benzaldehyde, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-56-3 CAPLUS
 CN Benzaldehyde, 4-bromo-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-57-4 CAPLUS

CN Benzaldehyde, 4-chloro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)




RN 91020-58-5 CAPLUS

CN Benzaldehyde, 3-chloro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)




RN 91020-59-6 CAPLUS

CN Benzaldehyde, 4-methoxy-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-60-9 CAPLUS

CN Benzaldehyde, 4-methyl-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




RN 91020-61-0 CAPLUS

CN Benzaldehyde, 4-nitro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)




RN 91020-62-1 CAPLUS

CN Benzaldehyde, 3-nitro-, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA
INDEX NAME)



RN 91020-63-2 CAPLUS

CN 2-Thiophenecarboxaldehyde, (2-phenyl-4-quinazolinyl)hydrazone (9CI) (CA INDEX NAME)




IT 91020-52-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and isomerization of)

RN 91020-52-9 CAPLUS

CN Benzoic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)



IT 91020-64-3P 91020-79-0P 91020-80-3P

91020-81-4P 91020-82-5P 91020-83-6P

91020-84-7P 91020-85-8P 91020-86-9P


91020-87-0P 91020-88-1P 91020-89-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 91020-64-3 CAPLUS

CN Acetic acid, 2-acetyl-1-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-79-0 CAPLUS

CN 2-Propenoic acid, 2-(benzoylamino)-3-phenyl-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-80-3 CAPLUS

CN 2-Propenoic acid, 2-(benzoylamino)-3-(4-chlorophenyl)-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-81-4 CAPLUS


CN 2-Propenoic acid, 2-(benzoylamino)-3-(2-methoxyphenyl)-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)



RN 91020-82-5 CAPLUS
 CN 2-Propenoic acid, 2-(benzoylamino)-3-(4-methoxyphenyl)-,
 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-83-6 CAPLUS
 CN 2-Propenoic acid, 2-(benzoylamino)-3-(4-nitrophenyl)-,
 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-84-7 CAPLUS

CN 2-Propenoic acid, 2-(benzoylamino)-3-(2-thienyl)-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-85-8 CAPLUS

CN 2-Propenoic acid, 2-(benzoylamino)-3-(2-furanyl)-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 91020-86-9 CAPLUS

CN 4H-Imidazol-4-one, 3,5-dihydro-2-phenyl-5-(phenylmethylene)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 91020-87-0 CAPLUS

CN 4H-Imidazol-4-one, 5-[(4-chlorophenyl)methylene]-3,5-dihydro-2-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 91020-88-1 CAPLUS

CN 4H-Imidazol-4-one, 3,5-dihydro-5-[(4-methoxyphenyl)methylene]-2-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 91020-89-2 CAPLUS

CN 4H-Imidazol-4-one, 3,5-dihydro-2-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]-5-(2-thienylmethylene)- (CA INDEX NAME)



L7 ANSWER 203 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:211631 CAPLUS
 DOCUMENT NUMBER: 100:211631
 ORIGINAL REFERENCE NO.: 100:32147a,32150a
 TITLE: Pyrazolone azo dyes
 AUTHOR(S): Crawley, M. W.
 CORPORATE SOURCE: Kodak Ltd., UK
 SOURCE: Research Disclosure (1984), 239, 109 (No. 23938)
 CODEN: RSDSBB; ISSN: 0374-4353
 DOCUMENT TYPE: Journal; Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 239038		19840310	RD 1984-239038	19840310 <--
PRIORITY APPLN. INFO.:			RD 1984-239038	19840310
GI				




AB Metalizable pyrazolone azo dyes, particularly useful in photog. color image transfer materials, are represented by the general structure I, where R is an (un)substituted carbocyclic or heterocyclic aromatic group, and R1 and R2 are each an (un)substituted alkyl, carbocyclic aromatic, or heterocyclic aromatic group. A typical dye, I (R = 5-nitro-2-pyridyl, R1 = Ph, R2 = Me) [90352-83-3] was prepared in 93% yield condensing 3-methyl-1-phenylpyrazole-4,5-dione [881-05-0] with (5-nitro-2-pyridyl)hydrazine [6343-98-2] in HOAc at room temperature Four other I were prepared by the same method.

IT 90352-77-5
 RL: USES (Uses)

(dye, for diffusion-transfer color photog., preparation of)
 RN 90352-77-5 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 3-methyl-1-phenyl-, 4-[(2-phenyl-4-quinazolinyl)hydrazone] (9CI) (CA INDEX NAME)




IT 6484-29-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with methylphenylpyrazoledione)
 RN 6484-29-3 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



L7 ANSWER 204 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:121102 CAPLUS
 DOCUMENT NUMBER: 100:121102
 ORIGINAL REFERENCE NO.: 100:18433a,18436a
 TITLE: Quinazoline derivatives
 PATENT ASSIGNEE(S): Showa Denko K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58172379	A	19831011	JP 1982-53734	19820402 <--
PRIORITY APPLN. INFO.:			JP 1982-53734	19820402
OTHER SOURCE(S):		CASREACT 100:121102		

GI



AB Thirteen quinazoline derivs. (I; R, R2 = alkyl; R1 = alkoxy carbonyl; R3 = H, alkyl, aryl; R4 = alkoxy, dialkylaminoalkoxy, 1-piperidinoalkoxy, H2N, etc.), effective antihypertensives at 100 $\mu\text{g/kg}$, were prepared. Thus, 12 mL NH₃-saturated EtOH was added to 200 mg chloro derivative I (R = R2 = R3 =

Me, R1 = EtO₂C, R4 = Cl) in EtOH at 70° to give quant. amino derivative I (R4 = H₂N, others same).


IT 89200-71-5P 89200-72-6P 89200-73-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antihypertensive activity of)


RN 89200-71-5 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-4-(dimethylamino)-6,8-dimethyl-, ethyl ester (CA INDEX NAME)




RN 89200-72-6 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-4-[4-(4-chlorophenyl)-1-piperazinyl]-6,8-dimethyl-, ethyl ester (CA INDEX NAME)




RN 89200-73-7 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-4-[4-(ethoxycarbonyl)-1-piperazinyl]-6,8-dimethyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

IT 89200-75-9P 89200-76-0P 89200-77-1P
 89200-78-2P 89200-79-3P 89200-80-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 89200-75-9 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 4-amino-2-(2-chlorophenyl)-6,8-dimethyl-, ethyl ester (CA INDEX NAME)




RN 89200-76-0 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-4-(ethylamino)-6,8-dimethyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 89200-77-1 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-6,8-dimethyl-4-(4-phenyl-1-piperidinyl)-, ethyl ester (CA INDEX NAME)




RN 89200-78-2 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-6,8-dimethyl-4-(1-piperazinyl)-, ethyl ester (CA INDEX NAME)




RN 89200-79-3 CAPLUS

CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-6,8-dimethyl-4-[4-(phenylmethyl)-1-piperazinyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 89200-80-6 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 2-(2-chlorophenyl)-4-[4-(2-chlorophenyl)-1-piperazinyl]-6,8-dimethyl-, ethyl ester (CA INDEX NAME)



L7 ANSWER 205 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:594917 CAPLUS
 DOCUMENT NUMBER: 99:194917
 ORIGINAL REFERENCE NO.: 99:30007a,30010a
 TITLE: Reactions with 4-[p-(substituted cinnamoyl)anilino]-2-phenylquinazolines
 AUTHOR(S): Mahmoud, A. M.; El-Sherief, H. A. H.; Esmail, A. A.
 CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt
 SOURCE: Acta Chimica Hungarica (1983), 113(3), 247-56
 CODEN: ACHUDC; ISSN: 0231-3146
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 99:194917
 GI



I



II


AB Chalcone analogs I [R = (un)substituted Ph, 1-C₁₀H₇, 2-furyl, 2-thienyl], prepared in 68-85% yields by condensation of RCHO with the corresponding acetophenone derivative, were cyclocondensed with N₂H₄.H₂O, PhNHNH₂, and NH₂OH.HCl to give 60-75% and 69-80%, resp., of II [X = NR₁ (R₁ = H, Ph); R = p-BrC₆H₄, p-ClC₆H₄, p-MeOC₆H₄, p-Me₂NC₆H₄] and II (X = O, R = p-ClC₆H₄, p-MeOC₆H₄, p-Me₂NC₆H₄). Addnl. products were obtained from I by bromination and subsequent substitution reactions and by cyclocondensation with MeCOCH₂CO₂Et.

IT 87771-83-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with aldehydes)

RN 87771-83-3 CAPLUS

CN Ethanone, 1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




IT 87771-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)


RN 87771-99-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)



IT 87771-85-5P 87771-86-6P 87771-87-7P
 87771-88-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reactions of)
 RN 87771-85-5 CAPLUS
 CN 2-Propen-1-one, 3-(4-bromophenyl)-1-[4-[(2-phenyl-4-
 quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 87771-86-6 CAPLUS
CN 2-Propen-1-one, 3-(4-chlorophenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 87771-87-7 CAPLUS
CN 2-Propen-1-one, 3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 87771-88-8 CAPLUS
CN 2-Propen-1-one, 3-[4-(dimethylamino)phenyl]-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




IT 87771-84-4P 87771-89-9P 87771-90-2P
 87771-91-3P 87771-92-4P 87771-93-5P
 87771-94-6P 87771-95-7P 87771-96-8P
 87771-97-9P 87771-98-0P 87772-00-7P
 87772-01-8P 87772-02-9P 87772-03-0P
 87772-04-1P 87772-05-2P 87772-06-3P
 87772-07-4P 87772-08-5P 87772-09-6P
 87772-11-0P 87772-12-1P 87772-13-2P
 87772-14-3P 87785-52-2P 87785-53-3P
 87785-54-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 87771-84-4 CAPLUS


CN 2-Propen-1-one, 3-phenyl-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-
 (CA INDEX NAME)



RN 87771-89-9 CAPLUS

CN 2-Propen-1-one, 3-(4-methylphenyl)-1-[4-[(2-phenyl-4-quinazoliny)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

RN 87771-90-2 CAPLUS

CN 2-Propen-1-one, 3-(4-nitrophenyl)-1-[4-[(2-phenyl-4-quinazoliny)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 87771-91-3 CAPLUS

CN 2-Propen-1-one, 3-(2-fluorophenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 87771-92-4 CAPLUS
CN 2-Propen-1-one, 3-(2,4-dimethoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 87771-93-5 CAPLUS
CN 2-Propen-1-one, 3-(2,4-dichlorophenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 87771-94-6 CAPLUS

CN 2-Propen-1-one, 3-(2-chloro-6-nitrophenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 87771-95-7 CAPLUS

CN 2-Propen-1-one, 3-(1-naphthalenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 87771-96-8 CAPLUS

CN 2-Propen-1-one, 3-(2-furanyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 87771-97-9 CAPLUS

CN 2-Propen-1-one, 1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-3-(2-thienyl)- (CA INDEX NAME)




RN 87771-98-0 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-00-7 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)



RN 87772-01-8 CAPLUS


CN 4-Quinazolinamine, N-[4-[5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)



RN 87772-02-9 CAPLUS

CN 1H-Pyrazole, 5-(4-bromophenyl)-4,5-dihydro-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 87772-03-0 CAPLUS
CN 1H-Pyrazole, 1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 87772-04-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-bromophenyl)-4,5-dihydro-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-05-2 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-06-3 CAPLUS

CN 4-Quinazolinamine, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-07-4 CAPLUS

CN 4-Quinazolinamine, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-3-isoxazolyl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-08-5 CAPLUS

CN 4-Quinazolinamine, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-isoxazolyl]phenyl]-2-phenyl- (CA INDEX NAME)




RN 87772-09-6 CAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 6-(4-methoxyphenyl)-2-oxo-4-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 87772-11-0 CAPLUS
 CN 1-Propanone, 2-bromo-3-methoxy-3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 87772-12-1 CAPLUS

CN 1-Propanone, 2-bromo-3-ethoxy-3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 87772-13-2 CAPLUS


CN 1-Propanone, 3-(4-methoxyphenyl)-2,3-di-4-morpholinyl-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)

c1ccc2nc(C3=CC=CC=C3)c(NC4=CC=C(C(=O)CN(C5CCOCC5)C6=CC=CC=C6)CC7CCOCC7)c2c1

OMe

RN	87772-14-3	CAPLUS	
CN	1-Propanone, 3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2,3-bis(phenylthio)-		(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 87785-52-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[5-[4-(dimethylamino)phenyl]-4,5-dihydro-3-isoxazolyl]phenyl]-2-phenyl- (CA INDEX NAME)



RN 87785-53-3 CAPLUS


CN 3-Cyclohexene-1-carboxylic acid, 6-(4-chlorophenyl)-2-oxo-4-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 87785-54-4 CAPLUS

CN 1-Propanone, 3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2,3-di-1-piperidinyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




IT 87772-10-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation, alcoholysis, and amination of)
RN 87772-10-9 CAPLUS
CN 1-Propanone, 2,3-dibromo-3-(4-methoxyphenyl)-1-[4-[(2-phenyl-4-
quinazolinyl)amino]phenyl]- (CA INDEX NAME)




L7 ANSWER 206 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:430710 CAPLUS
 DOCUMENT NUMBER: 99:30710
 ORIGINAL REFERENCE NO.: 99:4750h, 4751a
 TITLE: Forming a photographic dye image
 INVENTOR(S): Bailey, Joseph; Clarke, David; Crawley, Michael
 William; Marsden, Peter Douglas; Sidhu, Jasbir
 PATENT ASSIGNEE(S): Kodak Ltd., UK; Eastman Kodak Co.
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8300939	A1	19830317	WO 1982-GB263	19820902 <--
W: JP, US				
RW: BE, CH, DE, FR, GB, NL				
CA 1247916	A1	19890103	CA 1982-410528	19820831 <--
JP 58501339	T	19830811	JP 1982-502683	19820902 <--
JP 04047811	B	19920805		
EP 87446	A1	19830907	EP 1982-902681	19820902 <--
EP 87446	B1	19860709		
R: BE, CH, DE, FR, GB, LI, NL				

US 4481268	A	19841106	US 1983-499754	19830429 <--
PRIORITY APPLN. INFO.:			GB 1981-26620	A 19810902
			WO 1982-GB263	W 19820902
OTHER SOURCE(S):	MARPAT 99:30710			
GI				



I



II


AB Photog. azo or azomethine dye images of superior fastness are produced by color coupling development process which leads to the formation of dyes which are bi-, tri- or higher-dentate metal complexes. Thus, a solution containing I 7, N,N-diethylauramide 14, and 2-butoxyethoxyethyl acetate 16 g (60-100°) was mixed with a solution containing 12.5% gelatin 56.6 and diisopropyl naphthalenesulfonate 9.6 g (50°), homogenized, cooled, washed (at pH = 6 for 6 h), and adjusted to 100 g (pH = 5) to give a dispersion containing 7% I and 7% gelatin. A poly(ethylene terephthalate) support was coated with a AgCl emulsion containing the above dispersion, imagewise exposed, developed in a solution containing II 10 mg in 5 cm³ 10% Na₂CO₃ at 21°, rinsed with 10% Na₂CO₃, bleach-fixed, and metalized for 2-5 min at 21° in a solution containing NiSO₄·7H₂O 10, Na₂CO₃ 4 g, 0.880 NH₃ solution 20, and H₂O 180 cm³ to give a dye image with λ_{max} = 472 nm.

IT 85987-55-9P 85987-75-3P 85987-76-4P
85987-77-5P 85987-78-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and photog. applications of)


RN 85987-55-9 CAPLUS

CN Benzenesulfonic acid, 4-methyl-, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA
INDEX NAME)




RN 85987-75-3 CAPLUS

CN Methanesulfonic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 85987-76-4 CAPLUS

CN 1-Hexadecanesulfonic acid, 2-(2-phenyl-4-quinazolinyl)hydrazide (CA INDEX NAME)




RN 85987-77-5 CAPLUS

CN Benzenesulfonic acid, 4-methyl-, 2-[2-(4-chlorophenyl)-4-quinazolinyl]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85987-78-6 CAPLUS
 CN Benzenesulfonic acid, 4-methyl-, 2-[2-(4-nitrophenyl)-4-quinazolinyl]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L7 ANSWER 207 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:143349 CAPLUS
 DOCUMENT NUMBER: 98:143349
 ORIGINAL REFERENCE NO.: 98:21841a,21844a
 TITLE: Some reactions of 3-[2'-(4'H,2',1')-benzoxazin-4'-onyl]coumarins and 3-(2'-quinazol-4'-onyl)coumarins
 AUTHOR(S): El-Hashash, M. A.; Kaddah, A. M.; El-Kady, M.; Ammer, M. M.
 CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Pakistan Journal of Scientific and Industrial Research
(1982), 25(4), 104-8
CODEN: PSIRAA; ISSN: 0030-9885
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 98:143349
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensation of benzoxazinylcoumarins I (R = H, Br; X = O) with NH₄OAc or HCONH₂ at 190° gave I (X = NH). Treatment of I (R = H, X = NH) with BzCl or POCl₃ gave quinazolinylcoumarins II (R₁ = BzO, Cl), and ring cleavage of I (X = O) with anilines gave coumarincarboxanilides III (R₂ = Me, Cl, CO₂H). Condensation of I (X = O, NH) with N₂H₄ gave salicylaldehyde azines and the pyrazolinone IV, and Michael addition of I (R = H, X = O) with MeCOCH₂CO₂Et gave pyranobenzopyrandione V whereas addition with MeCOCH₂COMe gave dihydrocoumarin VI. Cyclocondensation of NaN₃ and I (R = H, X = O) gave tetrazole VII.

IT 85226-80-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85226-80-8 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[4-(phenylamino)-2-quinazolinyl]- (CA INDEX NAME)




L7 ANSWER 208 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:34562 CAPLUS
DOCUMENT NUMBER: 98:34562
ORIGINAL REFERENCE NO.: 98:5409a,5412a
TITLE: Hydroxide-catalyzed synthesis of heterocyclic aromatic amine derivatives from nitriles
AUTHOR(S): Smyrl, Norman R.; Smithwick, Robert W., III
CORPORATE SOURCE: Oak Ridge Y-12 Plant, Oak Ridge, TN, 37830, USA
SOURCE: Journal of Heterocyclic Chemistry (1982),
19(3), 493-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 98:34562
AB A wide variety of heterocyclic aromatic amine derivs. were prepared from nitriles by use of hydroxide catalysts. Nitrile dimers (3-aminocrotononitrile and dicyandiamide) and a dimer analog (anthranilonitrile) react with monomeric nitriles in the presence of hydroxide to form resp., aminopyrimidines, diaminotriazines and aminoquinazolines.

IT 1022-44-2P 83702-21-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



RN 83702-21-0 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)- (CA INDEX NAME)



L7 ANSWER 209 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:402056 CAPLUS

DOCUMENT NUMBER: 97:2056

ORIGINAL REFERENCE NO.: 97:431a,434a

TITLE: Studies on the induction of sex-linked recessive lethal mutations in *Drosophila melanogaster* by nitroheterocyclic compounds

AUTHOR(S): Kramers, P. G. N.

CORPORATE SOURCE: Dep. Radiat. Genet. Chem. Mutagen., State Univ. Leiden, Leiden, Neth.

SOURCE: Mutation Research, Genetic Toxicology Testing (1982), 101(3), 209-36


CODEN: MRGTE4; ISSN: 0165-1218

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Nitroheterocyclic compds. (24) were investigated for their capacity to induce sex-linked recessive lethals in *Drosophila*, by the adult feeding technique, and in some cases injection or larval-feeding methods. Out of 5-nitroimidazoles, ZK 26173 [67664-93-1] and ZK 25095 (moxnidazole) [30185-92-3] were clearly active, whereas nimorazole [6506-37-2] and ronidazole [7681-76-7] were marginally mutagenic. Out of 10 5-nitrofurans, nitrovin [804-36-4], furazolidone [67-45-8], and furaltadone [139-91-3] were unambiguously mutagenic, whereas nitrofurantoin [67-20-9] was a borderline case. Nitrofurans were active at lower mol. concns. than nitroimidazoles. Out of a group of 5 related nitro compds. (2 nitrothiophenes, picrolonic acid [550-74-3], nitridazole [61-57-4] and 4-NQO [56-57-5]), only 4-NQO was clearly mutagenic, when fed to larvae. Expts. with germ-free flies showed that, for ZK 26173 and furazolidone, the gut flora of *Drosophila* did not play a role in the activation of the compds. to mutagenic metabolites. Furazolidone, 4-NQO, ZK 26173, ZK 25095, and furaltadone were tested in mal and cin strains, both of which lack xanthine dehydrogenase and aldehyde oxidase. The latter enzyme and xanthine oxidase are known to carry out nitro reduction in mammalian tissues. For ZK 26173, the mutation frequencies were drastically reduced in the enzyme-deficient strains, indicating the


involvement of one of these enzymes in the activation of this substance.
 IT 33372-40-6 33389-36-5
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (mutagenicity of, sex-linked recessive lethal mutation in *Drosophila*
melanogaster in relation to)
 RN 33372-40-6 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA
 INDEX NAME)



RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



L7 ANSWER 210 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:122738 CAPLUS
 DOCUMENT NUMBER: 96:122738
 ORIGINAL REFERENCE NO.: 96:20157a,20160a
 TITLE: Phosphoramides. XVII. A new synthesis of
 quinazolinamines
 AUTHOR(S): Nielsen, Knud Erik; Pedersen, Erik B.
 CORPORATE SOURCE: Dep. Chem., Odense Univ., Odense, DK-5230, Den.
 SOURCE: Chemica Scripta (1981), 18(5), 242-4
 CODEN: CSRPB9; ISSN: 0004-2056
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 96:122738
 GI



AB Quinazolinamines I (R = Me, Me3C, Ph; R1 = Me, Pr, EtCHMe, Ph) were prepared
 in 12-81% yield by heating acylaminobenzonitriles II in a reagent mixture of
 P2O5, an amine hydrochloride, and N,N-dimethylcyclohexylamine at
 180-240°. In that reagent mixture I could also be obtained by


heating 2-H₂NC₆H₄CN together with an acylating reagent which could be HCO₂(CH₂)₄Me, HCONEt₂, or BzOH.

IT 1022-44-2P 40288-70-8P 77651-73-1P
77651-74-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 77651-73-1 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-propyl- (CA INDEX NAME)



RN 77651-74-2 CAPLUS

CN 4-Quinazolinamine, N-(2-methylpropyl)-2-phenyl- (CA INDEX NAME)



L7 ANSWER 211 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:85578 CAPLUS

DOCUMENT NUMBER: 96:85578

ORIGINAL REFERENCE NO.: 96:14055a,14058a


TITLE: 2-Aryl-4-substituted quinazolines

INVENTOR(S): Chen, Ying Ho

PATENT ASSIGNEE(S): A. H. Robins Co., Inc., USA

SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4306065	A	19811215	US 1979-105161	19791219 <--
US 4377582	A	19830322	US 1981-266257	19810522 <--
PRIORITY APPLN. INFO.:			US 1979-105161	A3 19791219
OTHER SOURCE(S):	CASREACT 96:85578; MARPAT 96:85578			
GI				




AB 4-Chloroquinazolines reacted with amines to yield the resp. 4-amino derivs. I [n = 1, 2, 3; R = H, alkyl, alkoxy, NO₂, amino, halo; R₁ = substituted 1-piperazinyl, (un)substituted 1-piperidinyl, substituted amino], useful as antihypertensives (no data, formulations given). 2-Phenyl-4-chloroquinazoline was treated with 2,6-dimethylpiperazine and subsequent neutralization gave I (n = 1, R = H, R₁ = 3,5-dimethyl-1-piperazinyl).

IT 80858-48-6P 80858-49-7P 80858-50-0P
 80858-51-1P 80858-52-2P 80858-53-3P
 80858-54-4P 80858-55-5P 80858-56-6P
 80858-57-7P 80858-58-8P 80858-59-9P
 80858-60-2P 80858-61-3P 80858-63-5P
 80858-64-6P 80858-65-7P 80858-66-8P
 80858-68-0P 80858-69-1P 80874-34-6P
 80874-35-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 80858-48-6 CAPLUS


CN Quinazoline, 4-(3,5-dimethyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)



RN 80858-49-7 CAPLUS


CN Cyclohexanecarbonitrile, 4-[[(2-phenyl-4-quinazolinyl) amino] methyl]- (CA

INDEX NAME)




RN 80858-50-0 CAPLUS

CN 4-Piperidinol, 1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 80858-51-1 CAPLUS

CN 3-Pyrrolidinol, 1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 80858-52-2 CAPLUS

CN 1-Propanol, 2-methyl-2-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 80858-53-3 CAPLUS


CN Quinazoline, 4-(3,5-dimethyl-1-piperazinyl)-2-phenyl-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

RN 80858-54-4 CAPLUS


CN Quinazoline, 4-(4-hexyl-1-piperazinyl)-2-phenyl-, dihydrochloride (9CI)
(CA INDEX NAME)



●2 HCl


RN 80858-55-5 CAPLUS

CN Quinazoline, 4-(4-hexyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)




RN 80858-56-6 CAPLUS

CN 3-Piperidinemethanol, 1-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 80858-57-7 CAPLUS

CN Quinazoline, 4-[3-(2-methoxyphenoxy)-1-pyrrolidinyl]-2-phenyl- (CA INDEX NAME)




RN 80858-58-8 CAPLUS

CN Quinazoline, 2-phenyl-4-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 80858-59-9 CAPLUS
 CN 1-Piperazineethanol, 4-(2-phenyl-4-quinazolinyl)-, dihydrochloride (9CI)
 (CA INDEX NAME)




●2 HCl

RN 80858-60-2 CAPLUS
 CN 2-Propanol, 1-(2-methoxyphenoxy)-3-[(2-phenyl-4-quinazolinyl)amino]- (CA
 INDEX NAME)




RN 80858-61-3 CAPLUS
 CN 1-Piperazinepropanol, α -[(2-methoxyphenoxy)methyl]-4-(2-phenyl-4-quinazolinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 80858-63-5 CAPLUS
CN 1-Piperazinepropanol, α -[(2-methoxyphenoxy)methyl]-4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 80858-64-6 CAPLUS
CN 1-Piperazineethanol, α -[(2-ethoxyphenoxy)methyl]-4-(2-phenyl-4-quinazolinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



CN 1-Piperazineethanol, α -[(2-ethoxyphenoxy)methyl]-4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




CN 2-Propanol, 1-(4-chloro-3-methylphenoxy)-3-[ethyl(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 80858-68-0 CAPLUS

CN 2-Propanol, 1-(3,5-dimethylphenoxy)-3-[(2-phenyl-4-quinazolinyl)amino]-
(CA INDEX NAME)




RN 80858-69-1 CAPLUS

CN 2-Propanol, 1-phenoxy-3-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 80874-34-6 CAPLUS

CN 1-Piperazineethanol, 2,6-dimethyl-4-(2-phenyl-4-quinazolinyl)- α -[(2-propenyloxy)methyl]- (9CI) (CA INDEX NAME)



RN 80874-35-7 CAPLUS

CN 2-Propanol, 1-(4-chloro-3-methylphenoxy)-3-[ethyl(2-phenyl-4-quinazolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



L7 ANSWER 212 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:8146 CAPLUS

DOCUMENT NUMBER: 96:8146

ORIGINAL REFERENCE NO.: 96:1469a,1472a

TITLE: Chromogenic quinazoline compounds and their use as color constituents in pressure-sensitive or heat-sensitive recording materials

INVENTOR(S): Fletcher, Ian John

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 33716	A1	19810812	EP 1981-810019	19810126 <--
EP 33716	B1	19830525		
R: AT, BE, CH, DE, FR, GB, IT				
FI 8004067	A	19810801	FI 1980-4067	19801230 <--
FI 70036	B	19860131		
FI 70036	C	19860912		
US 4480096	A	19841030	US 1981-227294	19810122 <--
AT 3547	T	19830615	AT 1981-810019	19810126 <--
CA 1162193	A1	19840214	CA 1981-369639	19810129 <--
BR 8100571	A	19810818	BR 1981-571	19810130 <--
ES 498980	A1	19820501	ES 1981-498980	19810130 <--
JP 56120768	A	19810922	JP 1981-12263	19810131 <--
JP 01056103	B	19891128		
US 4435003	A	19840306	US 1982-421205	19820922 <--

PRIORITY APPLN. INFO.:

CH 1980-780	A	19800131
CH 1980-5411	A	19800715
US 1981-227294	A3	19810122
EP 1981-810019	A	19810126

OTHER SOURCE(S): MARPAT 96:8146
GI



AB Chromogenic compds. of general structure I are prepared, where R represents an optionally substituted p-aminophenyl or carbazol-3-yl group, R1 represents H, alkoxy, aryloxy, amino, or thio ether derivative, and ring A may be substituted. I give sublimation- and lightfast yellow, orange, or red colors when in contact with acidic developers. Thus, reaction of 4-chloro-2-[4-(dimethylamino)phenyl]quinazoline [79916-53-3] with NaOMe in refluxing MeOH gave I (R = C6H4NMe2-p, R1 = OMe) [79916-30-6], a yellow color former. Twenty other I were prepared


IT 79916-31-7P 79916-32-8P 79916-37-3P

RL: PREP (Preparation)


(manufacture of, as color former for heat- and pressure-sensitive recording materials)

RN 79916-31-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 79916-32-8 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)



RN 79916-37-3 CAPLUS
CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N,N-dimethyl- (CA INDEX NAME)




L7 ANSWER 213 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:208812 CAPLUS
DOCUMENT NUMBER: 94:208812
ORIGINAL REFERENCE NO.: 94:34155a,34158a
TITLE: Synthesis of cyano-substituted heterocycles by tetraethylammonium cyanide
AUTHOR(S): Hermann, Klaus; Simchen, Gerhard
CORPORATE SOURCE: Inst. Org. Chem. Biochem. Isotopenforsch., Univ. Stuttgart, Stuttgart, D-7000/80, Fed. Rep. Ger.
SOURCE: Liebigs Annalen der Chemie (1981), (2), 333-41
CODEN: LACHDL; ISSN: 0170-2041
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 94:208812
AB RCN (R = optionally substituted 2-pyridinyl, 4-pyrimidinyl, 4-quinazolinyl, 2-quinazolinyl, 2-quinoxaliny) were prepared by treating RC1 with NMe3 and treating RN+Me3 Cl- with Et4N+ CN- to give RCN.
IT 67824-27-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with tetraethylammonium cyanide)
RN 67824-27-5 CAPLUS
CN 4-Quinazolinaminium, N,N,N-trimethyl-2-phenyl-, chloride (9CI) (CA INDEX NAME)




● Cl⁻


L7 ANSWER 214 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:208804 CAPLUS
 DOCUMENT NUMBER: 94:208804
 ORIGINAL REFERENCE NO.: 94:34155a,34158a
 TITLE: Phosphoramides. XIII. Phosphorus pentoxide-amine hydrochloride mixtures as reagents in the synthesis of 4(3H)-quinazolinones and 4-quinazolinamines
 AUTHOR(S): Nielsen, Knud Erik; Pedersen, Erik B.
 CORPORATE SOURCE: Dep. Chem., Odense Univ., Odense, DK-5230, Den.
 SOURCE: Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1980), B34(9), 637-42
 CODEN: ACBOCV; ISSN: 0302-4369
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 94:208804
 GI




AB Quinazolinones I (R = Me, Ph, Pr; R₁ = H, Me, Et, NH₂, Pr, Bu, Me₂CHCH₂, EtCHMe) were prepared by heating o-MeO₂CC₆H₄NHCOR and the R₁NH.HCl with P₂O₅ and N,N-dimethylcyclohexylamine at 180 °. Quinazolinamines II and R₁NHCR:NR₁ were isolated as by-products. Carboxamides were believed to be reaction intermediates. By raising the temperature to 250 °, II was obtained in a preparative yield.
 IT 1022-44-2P 77651-72-0P 77651-73-1P
 77651-74-2P 77651-75-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 1022-44-2 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 77651-72-0 CAPLUS
CN 4-Quinazolinamine, N-methyl-2-phenyl- (CA INDEX NAME)




RN 77651-73-1 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-propyl- (CA INDEX NAME)



RN 77651-74-2 CAPLUS
CN 4-Quinazolinamine, N-(2-methylpropyl)-2-phenyl- (CA INDEX NAME)





RN 77651-75-3 CAPLUS
CN 4-Quinazolinamine, N-butyl-2-phenyl- (CA INDEX NAME)




L7 ANSWER 215 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:167486 CAPLUS
DOCUMENT NUMBER: 94:167486
ORIGINAL REFERENCE NO.: 94:27207a,27210a

TITLE: New chemotherapeutic nitroheterocycles active against
 5-nitroimidazole-resistant strains of trichomonads
 AUTHOR(S): Meingassner, J. G.; Nesvadba, H.; Mieth, H.
 CORPORATE SOURCE: Sandoz Forschungsinst., Vienna, Austria
 SOURCE: Arzneimittel-Forschung (1981), 31(1), 6-8
 CODEN: ARZNAD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Four 4-substituted 2-imidazolylquinazoline derivs. were synthesized and tested against *Trichomonas vaginalis*. All 4 compds. were highly active against metronidazole [443-48-1]-sensitive and metronidazole-resistant strains of trichomonads. The compds., referred to as 81.987 (I) [77093-25-5], 82.492 (II) [77093-24-4], 82.726 [77093-26-6], and 82.727 [77093-27-7], showed high therapeutic efficacy when applied orally to mice or intravaginally to rats infected with trichomonads.
 IT 77093-25-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and trichomonocidal activity of)
 RN 77093-25-5 CAPLUS
 CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 216 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:604604 CAPLUS
 DOCUMENT NUMBER: 93:204604
 ORIGINAL REFERENCE NO.: 93:32649a,32652a
 TITLE: Hetarylnitrenes. 7. Cyclic carbodiimides by rearrangements of nitrenes
 AUTHOR(S): Wentrup, Curt; Thetaz, Celestin; Tagliaferri, Enrico; Lindner, Hans Joerg; Kitschke, Brigitte; Winter, Hans Wilhelm; Reisenauer, Hans Peter
 CORPORATE SOURCE: Fachber. Chem., Univ. Marburg/Lahn, Marburg, D-3550, Fed. Rep. Ger.
 SOURCE: Angewandte Chemie (1980), 92(7), 556-7
 CODEN: ANCEAD; ISSN: 0044-8249
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 93:204604
 GI



AB The cyclic carbodiimide I was identified as an intermediate in thermolysis of the condensed tetrazoles II and III to give IV and V.


4-Azido-2-phenylquinazoline was prepared by sublimation and condensation of II, but 3-azido-2-phenylquinoxaline was only weakly detected in the reaction of III to give IV.

IT 63399-59-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and thermolysis of)

RN 63399-59-7 CAPLUS

CN Quinazoline, 4-azido-2-phenyl- (CA INDEX NAME)




IT 1022-44-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



L7 ANSWER 217 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:76445 CAPLUS

DOCUMENT NUMBER: 92:76445

ORIGINAL REFERENCE NO.: 92:12595a,12598a

TITLE: Synthesis of shangrolin analogs as antimalarials

AUTHOR(S): Li, Ying; Li, Liang-Quan; Chen, Yi-Xin; Wang, De-Sheng; Gai, Yuan-Zhu; Yu, Pei-Lin; Zheng, Ya-Ping
CORPORATE SOURCE: Shanghai Inst. Mater. Med., Acad. Sin., Shanghai, Peop. Rep. China


SOURCE: Yaoxue Xuebao (1979), 14(2), 108-15

CODEN: YHHPAL; ISSN: 0513-4870

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI




AB Shangrolin analogs I (R = Q, Q1; R1 = H, Cl, MeO; R2 = H, MeO; R1R2 = OCH2O; R4 = R5 = R8 = H, Me; R6 = H, 1-pyrrolidinylmethyl (Q2); R7 = H, Q2, 1-adamantylaminomethyl; R9 = H, 2-, 3-ClC6H4) were prepared by amination of I (R = Cl) and Mannich reaction of I (R = Q; R6 = R7 = H). Pteridine analog of shangrolin and 1,3-bis[4-(6,8-dichloroquinazolin-4-yl)piperazin-1-yl]propane were also prepared I (R = Q; R1 = R2 = R3 = R5 = R8 = H; R4 = Me, R6 = R7 = Q2 and R1R2 = OCH2O; R3 = R4 = R5 = R7 = R8 = H, R6 = Q2) were more active than shangrolin against *P. berghei* in mice.

IT 72700-45-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antimalarial activity of)

RN 72700-45-9 CAPLUS

CN Ethanol, 2-[(2-phenyl-4-quinazolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 218 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:586405 CAPLUS

DOCUMENT NUMBER: 91:186405

ORIGINAL REFERENCE NO.: 91:29887a,29890a

TITLE: Antitumor activity, biomimetic oxidation and metabolism of heteroalicyclic triazenes

AUTHOR(S): Stevens, Malcolm F. G.; Gescher, Andreas; Turnbull, Colin P.

CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK


SOURCE: Biochemical Pharmacology (1979), 28(6), 769-76

CODEN: BCPCA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Triazenoquinazolines, with variations in the quinazoline nucleus or triazene side-chain, generally had no antitumor activity; e.g., I [71825-17-7] was inactive against L1210 lymphoid leukemia in mice. The aminoquinazoline series, however, were the most toxic agents against human epidermoid carcinoma of the nasopharynx in cell culture, with ED50 values of 1.2-2.3 $\mu\text{g}/\text{mL}$; e.g., I had an ED50 of 1.5 $\mu\text{g}/\text{mL}$. Substitution in the quinazoline nucleus by Br atoms or replacement of the aminoquinazoline by a 2,4-diamino-s-triazin-6-yl fragment decreased the chemotherapeutic effect. 1-(4-Chlorophenylazo)piperidine (II) [62499-15-4], when oxidized with KMnO_4 in aqueous acetone at pH 6-9, yielded 8 oxidation products, similar to those produced by oxidation of II via the Udenfriend process or by incubation with rat liver homogenates or fortified microsomes, the major product being 1-(4-chlorophenylazo)piperidin-2-one [62499-17-6] (5% yield). Oxidation of 1-(4-chlorophenylazo)pyrrolidine [62499-16-5] with KMnO_4 in aqueous acetone or incubation with liver homogenates or microsomes yielded 3 products, e.g. 1-(4-chlorophenylazo)pyrrolidin-2-one [65568-22-1] (5% yield). KMnO_4 oxidation of III [54762-78-6] yielded a bis(chlorophenyl)triazene, 4-chloroaniline [106-47-8], and a morpholin-3-ol compound (25%); the latter was formed from III upon incubation with liver homogenates or microsomes, but was not formed in vivo.


IT 62888-12-4 71825-06-4 71825-07-5
71825-08-6 71825-09-7 71825-15-5
71825-17-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of)


RN 62888-12-4 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-[(4-methyl-1-piperidinyl)azo]phenyl]- (9CI) (CA INDEX NAME)




RN 71825-06-4 CAPLUS

CN 4-Quinazolinamine, 5-methyl-2-[2-(1-pyrrolidinylazo)phenyl]- (9CI) (CA INDEX NAME)




RN 71825-07-5 CAPLUS

CN 4-Quinazolinamine, 5-methyl-2-[2-(4-morpholinylazo)phenyl]- (9CI) (CA INDEX NAME)




RN 71825-08-6 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,3-diethyl-1-triazenyl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 71825-09-7 CAPLUS


CN 4-Quinazolinamine, 2-[2-(3,3-dipropyl-1-triazenyl)phenyl]-5-methyl- (9CI)
(CA INDEX NAME)




RN 71825-15-5 CAPLUS
CN 4-Quinazolinamine, 2-[2-[[4-[[2-(1-amino-3-isoquinolinyl)phenyl]azo]-1-piperazinyl]azo]phenyl]- (9CI) (CA INDEX NAME)



RN 71825-17-7 CAPLUS
CN 4-Quinazolinamine, 5-methyl-2-[2-(1-piperidinylazo)phenyl]- (9CI) (CA INDEX NAME)



DOCUMENT NUMBER: 91:157681
ORIGINAL REFERENCE NO.: 91:25453a, 25456a
TITLE: Heterocyclic compounds. XII. Quinazoline derivatives as potential antifertility agents
AUTHOR(S): Manhas, M. S.; Hoffman, W. A., III; Bose, A. K.
CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, 07030, USA
SOURCE: Journal of Heterocyclic Chemistry (1979), 16(4), 711-15
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 91:157681
GI



AB Acylation of 2-H₂NC₆H₄CONH₂ by RCOCl [R = 4-MeOC₆H₄, 4-MeOC₆H₄CH:CPh, α -benzylidene-3,4-dimethoxybenzyl, 3,4-methylenedioxyphenyl] gave 2-(RCONH)C₆H₄CONH₂, which cyclized in refluxing Ph₂O to give the corresponding quinazolinones I. Chlorination of I by POCl₃ followed by substitution reaction with 2-pyrrolidinoethanol Na salt gave ethoxyquinazolines II (R as defined above; R₁ = H). Hydrogenation of Me 3,4,5-trimethoxy-2-nitrobenzoate over Pt/C followed by acylation with 4-MeOC₆H₄COCl gave Me 2-(p-methoxybenzamido)-3,4,5-trimethoxybenzoate, which underwent cyclocondensation in refluxing C₆H₆ containing NaOMe to give the benzoxazinone III (X = O). Treatment of III (X = O) with NH₃ in MeOH under pressure gave III (X = NH), which underwent chlorination and substitution reaction with pyrrolidinoethanol Na salt to give II (R = 4-MeOC₆H₄; R₁ = MeO). Reaction of I (R = 4-MeOC₆H₄) with P₂S₅ gave the corresponding quinazolinethione, which underwent S-methylation with Me iodide and then substitution reaction with 3-MeOC₆H₄NH₂ to give the anilinoquinazoline IV. II (R = 4-MeOC₆H₄, α -benzylidene-3,4,5-trimethoxybenzyl, 3,4-methylenedioxyphenyl; R₁ = H) and IV possessed low level postcoital contraceptive activity in rats.


IT 71622-66-7P 71622-69-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71622-66-7 CAPLUS


CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-(4-methoxyphenyl)- (CA INDEX

NAME)



RN 71622-69-0 CAPLUS

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-(4-methoxyphenyl)-,
monohydriodide (9CI) (CA INDEX NAME)



● HI

L7 ANSWER 220 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:474567 CAPLUS

DOCUMENT NUMBER: 91:74567

ORIGINAL REFERENCE NO.: 91:12057a,12060a

TITLE: Formation and thermal transformations of extended
dipolar imidoylazimines

AUTHOR(S): Barr, John J.; Storr, Richard C.

CORPORATE SOURCE: Robert Robinson Lab., Liverpool Univ., Liverpool, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions
1: Organic and Bio-Organic Chemistry (1972-1999) (1979), (1), 185-91


CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 91:74567

GI



I



III


AB Heating benzocinnolines I (R = aryl), readily obtained from benzocinnoline N-imide (II) and imidoyl chlorides, gave benzocinnoline N-arylimides by 1,5-dipolar cyclization and retro dipolar cycloaddn. I (R = Me, Et) were unstable and underwent a 1,6-H shift to give ultimately III (R = H, Me). Treating II with MeSCPh:N+HMe iodide gave I (R = H) which was subsequently converted into I (R = acyl, CPh:NCHMe₂, CPh:NPh). On heating, I (R = acyl) gave benzocinnoline (IV) and oxadiazoles, I (R = CPh:NCHMe₂) gave IV and 2-phenyl-4-(isopropylamino)quinazoline, and I (R = CPh:NPh) gave IV, 1,3,5-triphenyl-1,2,4-triazole, and 2,4-diphenylquinazoline.

IT 71028-42-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71028-42-7 CAPLUS

CN 4-Quinazolinamine, N-(1-methylethyl)-2-phenyl- (CA INDEX NAME)



L7 ANSWER 221 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:439514 CAPLUS

DOCUMENT NUMBER: 91:39514

ORIGINAL REFERENCE NO.: 91:6449a,6452a

TITLE: Copper complexes of phenanthroline, isoquinoline, and quinazoline derivatives useful in combatting mycoplasma infections

INVENTOR(S): Nauta, W. T.

PATENT ASSIGNEE(S): Gist-Brocades N. V., Neth.

SOURCE: Ger. Offen., 62 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2826526	A1	19790104	DE 1978-2826526	19780616 <--
NL 7713938	A	19790619	NL 1977-13938	19771215 <--
GB 2002746	A	19790228	GB 1978-27117	19780616 <--
DK 7802750	A	19781218	DK 1978-2750	19780619 <--
SE 7807001	A	19781218	SE 1978-7001	19780619 <--
BE 868249	A1	19781219	BE 1978-188676	19780619 <--
NL 7806573	A	19781219	NL 1978-6573	19780619 <--

FR 2401155	A1	19790323	FR 1978-18282	19780619 <--
US 4269834	A	19810526	US 1978-916541	19780619 <--
CA 1102329	A1	19810602	CA 1978-305746	19780619 <--
FR 2422659	A1	19791109	FR 1979-6395	19790313 <--
PRIORITY APPLN. INFO.:			GB 1977-25539	A 19770617
			NL 1977-13938	A 19771215
OTHER SOURCE(S):	MARPAT 91:39514			
GI				



I




II

AB Cu complexes of I [R = H, alkyl, halogen; R1 = H, halogen, Ph, (alkyl-substituted) NH2; n = 1-4; A = (substituted) pyridyl or 2-imidazolyl; X = N, alkylidene] or II (R2 = R3 = H, halogen, alkyl, alkoxy, NH2; R4 = H, alkyl, halogen; m = 1-6) were prepared for use as antimycoplasic agents (test data tabulated). Thus, 2-MeC6H4CN was added to K in liquid NH3, followed by the addition of 1-methyl-2-cyano-1H-imidazole to give I (Rn = H, R1 = NH2, X = CH, A = 1-methyl-2-imidazolyl), which reacted with CuNO2 to give the Cu(I) complex.

IT 69767-95-9P 69767-99-3P 69768-00-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and copper complex formation of)

RN 69767-95-9 CAPLUS


CN 4-Quinazolinamine, 2-(1-methyl-1H-imidazol-2-yl)-, dihydrochloride (9CI)
 (CA INDEX NAME)



● 2 HCl


RN 69767-99-3 CAPLUS

CN 4-Quinazolinamine, 2-(1-ethenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl

RN 69768-00-9 CAPLUS
CN 4-Quinazolinamine, 2-(1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


IT 69767-39-1P 69767-41-5P 69768-01-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69767-39-1 CAPLUS
CN 4-Quinazolinamine, 2-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 69767-41-5 CAPLUS
CN 4-Quinazolinamine, 2-(1-ethenyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 69768-01-0 CAPLUS
 CN 4-Quinazolinamine, 2-(6-amino-2-pyridinyl)- (CA INDEX NAME)




L7 ANSWER 222 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:6336 CAPLUS
 DOCUMENT NUMBER: 90:6336
 ORIGINAL REFERENCE NO.: 90:1157a,1160a
 TITLE: Synthesis of antimalarials by a new route to
 4-quinolinols, 4-quinazolinones, and 4-cinnolinol
 1-oxides
 AUTHOR(S): Noland, Wayland E.
 CORPORATE SOURCE: Dep. Chem., Univ. Minnesota, Minneapolis, MN, USA
 SOURCE: U. S. NTIS, AD Rep. (1977), AD-A054407, 44
 pp. Avail.: NTIS
 From: Gov. Rep. Announce. Index (U. S.) 1978, 78(17),
 110
 CODEN: XADRCH; ISSN: 0099-8575
 DOCUMENT TYPE: Report
 LANGUAGE: English
 AB Six 4-[[4-(diethylamino)-1-methylbutyl]amino]-3-phenylquinolines and three
 4-[[4-(diethylamino)-1-methylbutyl]amino]-3-phenylquinazolines and 100
 intermediates were prepared and submitted for testing. All six of the
 quinoline antimalarials showed some evidence of activity, and four of
 them, containing 4-methoxy-4-unsubstituted 4-bromo and 4-nitro substituents in
 the 3-Ph group were classed as active in mice, though only the methoxy
 derivative was classed as active at a dosage (320 mg/kg) below that at which
 some toxic deaths were observed. Three of the compds., were classed as active
 in chicks at dosages (80, 320, and 320 mg/kg, resp.) where no toxic deaths
 were observed. Although all three were submitted, only one of the quinazoline
 antimalarials, the 6-chloro-2-Ph derivative was tested in mice; it showed
 strong evidence of activity, but not quite sufficient to be classed as
 active.
 IT 47546-42-9DP, derivs.
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antimalarials)
 RN 47546-42-9 CAPLUS
 CN 1,4-Pentanediamine, N1,N1-diethyl-N4-(2-phenyl-4-quinazolinyl)- (CA INDEX
 NAME)



L7 ANSWER 223 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1978:563503 CAPLUS
 DOCUMENT NUMBER: 89:163503
 ORIGINAL REFERENCE NO.: 89:25341a,25344a
 TITLE: [1,2,3]Triazoloazine/(diazomethyl)azine valence
 tautomers from 5-azinyltetrazoles
 AUTHOR(S): Wentrup, Curt
 CORPORATE SOURCE: Fachber. Chem., Univ. Marburg, Marburg, Fed. Rep. Ger.
 SOURCE: Helvetica Chimica Acta (1978), 61(5),
 1755-64
 CODEN: HCACAV; ISSN: 0018-019X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 89:163503
 GI



AB Condensed triazoles I (RR1 = CH:CHCH:CH, CH:NCH:CH, o-C6H4N:CPh) were
 obtained by thermolysis of tetrazoles II (R2 = 2-pyridyl, 2-pyrazinyl,
 2-phenyl-4-quinazolinyl). The intermediate 2-pyridyldiazomethane was also
 captured with fumaronitrile as 3-(2-pyridyl)-1,2-
 cyclopropanedicarbonitrile.
 IT 67824-27-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, with cyanide)
 RN 67824-27-5 CAPLUS
 CN 4-Quinazolinaminium, N,N,N-trimethyl-2-phenyl-, chloride (9CI) (CA INDEX
 NAME)



● Cl⁻

L7 ANSWER 224 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:89484 CAPLUS

DOCUMENT NUMBER: 88:89484

ORIGINAL REFERENCE NO.: 88:14019a,14022a

TITLE: Triazines and related products. Part 20. Oxidation of 1-(arylaazo)piperidines with potassium permanganate
AUTHOR(S): Gescher, Andreas; Turnbull, Colin P.; Stevens, Malcolm F. G.

CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (18), 2078-83

CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 88:89484


AB Oxidation of 1-(4-chlorophenylazo)piperidine with aqueous KMnO₄ gave 4-chloroaniline (I), 1,3-bis(4-chlorophenyl)triazene, and the oxidized triazenes 1-(4-chlorophenylazo)piperidin-2-one (II), -4-one, -3-ol, and -4-ol, and 1-(4-chlorophenylazo)-1,2,3,4-tetrahydropyridine. Oxidation of 4-amino-2-[2-(piperidin-1-ylazo)phenyl]quinazoline (III) yielded 4-amino-2-(2-aminophenyl)quinazoline and 1-[2-(4-aminoquinazolin-2-yl)phenylazo]piperidin-2-one. Hydrolysis of II with 0.1N KOH in the dark gave I and valerolactone (IV). IV was also obtained as an oxidation product from treatment of III and N-nitrosopiperidine with KMnO₄. A mechanism for the oxidns. is given.

IT 52698-01-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)

RN 52698-01-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-piperidinylazo)phenyl]- (9CI) (CA INDEX NAME)



IT 65568-21-0P 65568-24-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 65568-21-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-piperidinylazo)phenyl]-, monobenzoate (9CI)
(CA INDEX NAME)

CM 1


CRN 52698-01-8

CMF C19 H20 N6




CM 2


CRN 65-85-0
CMF C7 H6 O2



RN 65568-24-3 CAPLUS
CN 2-Piperidinone, 1-[[2-(4-amino-2-quinazolinyl)phenyl]azo]- (9CI) (CA INDEX NAME)



L7 ANSWER 225 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:584175 CAPLUS
DOCUMENT NUMBER: 87:184175
ORIGINAL REFERENCE NO.: 87:29087a,29090a
TITLE: Acyl carbodiimides, II. Preparation, stability, and addition reactions of imidoacylcarbodiimides
AUTHOR(S): Goerdeler, Joachim; Lohmann, Helmut
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Bonn, Bonn, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1977), 110(9), 2996-3009
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 87:184175
GI




AB RN:CR1NHCSNHR2 (R = Me, CHMe2, Ph, 2,6-Me2C6H3, 1-naphthyl; R1 = Ph, 4-ClC6H4, 4-O2NC6H4; R2 = cyclohexyl, Ph, CMe3, 2,6-Me2C6H3, Me), prepared from RN:CR1Cl, NaSCN, and R2NH2 in Me2CO at 0°, reacted with cyanuric chloride in CH2Cl2, containing NEt3 with H2S elimination to give RN:CR1N:C:NR2 (I), some of which could be isolated. The stability of I was substituent dependent. Thus, alkyl groups at R were especially destabilizing and the 2,6-Me2C6H3 group at R was strongly stabilizing. I (R = R1 = R2 = Ph) tended to isomerize to the quinazoline derivative II. I added nucleophilic HX compds. (H2O, EtOH, PhOH, EtSH, PhSH, PhNH2, cyclohexylamine) to give RN:CR1NHCONHR2 and 2,6-Me2C6H3N:C(C6H4NO2-4)NHCX:NR2 and formed cycloaddn. compds. III [R1 = 4-ClC6H4, 4-O2NC6H4, R2 = cyclohexyl, Me; X = CPh2, NR3 (R3 = Ph)] and IV [R1 = 4-O2NC6H4, R2 = cyclohexyl; X = NR3 (R3 = Bz, 4-O2NC6H4CO, EtO2C] with Ph2C:C:O, PhOCN, BzNCO, 4-O2NC6H4NCO, and EtO2CNCS.

IT 40288-70-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)



L7 ANSWER 226 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:535380 CAPLUS

DOCUMENT NUMBER: 87:135380

ORIGINAL REFERENCE NO.: 87:21485a,21488a

TITLE: Quinazoline derivatives

INVENTOR(S): Nesvadba, H.; Reinshagen, H.

PATENT ASSIGNEE(S): Sandoz Ltd., Switz.

SOURCE: Belg., 31 pp.
CODEN: BEXXAL

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 841669	A1	19761110	BE 1976-166912	19760510 <--
CH 612432	A5	19790731	CH 1975-6041	19750512 <--
DK 7601974	A	19761113	DK 1976-1974	19760503 <--
FI 7601232	A	19761113	FI 1976-1232	19760503 <--
NO 7601537	A	19761115	NO 1976-1537	19760504 <--

SE 7605158	A	19761113	SE 1976-5158	19760505 <--
SE 409455	B	19790820		
SE 409455	C	19791129		
US 4055642	A	19771025	US 1976-683291	19760505 <--
NL 7604894	A	19761116	NL 1976-4894	19760507 <--
GB 1551117	A	19790822	GB 1976-18778	19760507 <--
CA 1071626	A1	19800212	CA 1976-252103	19760510 <--
JP 51138689	A	19761130	JP 1976-53730	19760511 <--
AT 7603421	A	19800815	AT 1976-3421	19760511 <--
FR 2310756	A1	19761210	FR 1976-14235	19760512 <--
FR 2310756	B1	19781020		
CH 617691	A5	19800613	CH 1978-12678	19781129 <--
PRIORITY APPLN. INFO.:			CH 1975-6041	A 19750512
GI				




AB Amebicidal and trichomonacidal (no data) imidazolylquinazolines I (R = H, 7-Cl, 6-Me, 6-Cl; R1 = aminoalkoxy, aminoalkylthio, aminoalkylamino) (24 compds.) were prepared. Thus, imidazole II was condensed with 2-H₂NC₆H₄CO₂H, the quinazolinone chlorinated, and I (R = H, R1 = Cl) treated with diethanolamine to give I (R = H, R1 = OCH₂CH₂NHCH₂CH₂OH).

IT 61717-11-1P 61717-15-5P 61717-16-6P
 61717-17-7P 61717-19-9P 61717-23-5P
 61717-24-6P 61717-25-7P 61717-26-8P
 61717-31-5P 63881-27-6P 63881-28-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 61717-11-1 CAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboximidic acid, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (CA INDEX NAME)




RN 61717-16-6 CAPLUS

CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 61717-17-7 CAPLUS

CN 2-Furancarboximidic acid, 5-nitro-, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-19-9 CAPLUS

CN Ethanol, 2-[[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 61717-23-5 CAPLUS

CN 1-Piperazineethanol, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]- (CA INDEX NAME)




RN 61717-24-6 CAPLUS

CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 61717-25-7 CAPLUS

CN 1H-Imidazole-2-carboximidic acid, 1-methyl-5-nitro-, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-26-8 CAPLUS

CN Quinazoline, 4,4'-(1,4-piperazinediyl)bis[2-(1-methyl-5-nitro-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 61717-31-5 CAPLUS


CN Ethanol, 2,2'-[[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)



RN 63881-27-6 CAPLUS
 CN Ethanol, 2-[methyl[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 63881-28-7 CAPLUS
 CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-thiomorpholinyl)- (CA INDEX NAME)



L7 ANSWER 227 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:452548 CAPLUS
 DOCUMENT NUMBER: 87:52548
 ORIGINAL REFERENCE NO.: 87:8319a,8322a
 TITLE: Effect of intramolecular hydrogen bonding on
 azide-tetrazole tautomerism
 AUTHOR(S): Krivopalov, V. P.; Mamaev, V. P.
 CORPORATE SOURCE: Novosib. Inst. Org. Khim., Novosibirsk, USSR
 SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1977), (4), 966-7
 CODEN: IASKA6; ISSN: 0002-3353
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian

GI




AB IR data for I-II and III-IV (R = H, OH) systems indicated that azide formation in the III-IV system was favored when R = OH owing to intramol. H bonding. The relative amts. of I and II depended on the medium.

IT 63399-59-7 63399-60-0

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(tautomerism of)


RN 63399-59-7 CAPLUS

CN Quinazoline, 4-azido-2-phenyl- (CA INDEX NAME)



RN 63399-60-0 CAPLUS

CN Phenol, 2-(4-azido-2-quinazolinyl)- (CA INDEX NAME)



L7 ANSWER 228 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:189864 CAPLUS

DOCUMENT NUMBER: 86:189864


ORIGINAL REFERENCE NO.: 86:29781a,29784a

TITLE: Triazines and related products. Part 19.
4-Amino-2[2-(piperidin-1-ylazo)phenyl]quinazoline and its analogs

AUTHOR(S): Gescher, Andreas; Stevens, Malcolm F. G.; Turnbull, Colin P.

CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions
 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (2), 107-14
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 86:189864
 GI




AB 4,2-R(NC)C₆H₃NH₂ (R = H, Br) reacted with NaH in Me₂SO to give the aminophenylquinazolines I. Nitrosation of I (R = H, Br) gave unstable diazonium salts, which cyclized to give the quinazolino[3,2-c]-[1,2-c][1,2,3]benzotriazines (III), which are implicated as intermediates in the reactions of 4,2-R(NC)C₆H₃N:NNHC₆H₃(CN)R-2,4 (IV). Thus reaction of IV (R = H, Br) with 2-, 3-, and 4-methylpiperidine gave 72-90% title compds. V (NR₁R₂ = 2-, 3-, 4-methylpiperidino, resp.) by a cyclization, ring cleavage, and amine addition sequence. V (R = H, NR₁R₂ = piperidino) (VI) behaved as a masked diazonium compound and decomposed in mineral acid, AcOH containing Cu-bronze, hot ethylene glycol, on photolysis in MeOH or EtOH, or on reduction. The triazene linkage of VI is resistant to alc. KOH but the 4-aminoquinazoline nucleus is hydrolyzed to the corresponding quinazolin-4(3H)-one system. Methylation of VI with MeI in THF gave an N-1 methiodide which hydrolyzed to the corresponding 1-methylquinazolin-4-(1H)-one in aqueous alkali. The unusual properties of this and other 1-methylquinazolin-4(1H)-ones is attributed to their dipolar character, which renders the 1-Me group liable to removal in acidic conditions.

IT 62888-16-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and cyclization of)

RN 62888-16-8 CAPLUS


CN Benzenediazonium, 2-(4-amino-6-bromo-2-quinazolinyl)-4-bromo-, chloride, dihydrochloride (9CI) (CA INDEX NAME)




● Cl⁻

● 2 HCl

IT 62888-15-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and diazotization of)
 RN 62888-15-7 CAPLUS
 CN 4-Quinazolinamine, 2-(2-amino-5-bromophenyl)-6-bromo- (CA INDEX NAME)



IT 62888-13-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidation of)
 RN 62888-13-5 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(3,3-dimethyl-1-triazenyl)phenyl]- (9CI) (CA
 INDEX NAME)




IT 62888-14-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation and reactions of)

RN 62888-14-6 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-(1-piperidinylazo)phenyl]- (9CI)
(CA INDEX NAME)



IT 62888-00-0P 62888-03-3P 62888-06-6P

62888-07-7P 62888-08-8P 62888-09-9P


62888-10-2P 62888-11-3P 62888-12-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 62888-00-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-[(2-methyl-1-piperidinyl)azo]phenyl]- (9CI) (CA
INDEX NAME)




RN 62888-03-3 CAPLUS

CN 4-Quinazolinamine, 2-[2-[(hexahydro-1H-azepin-1-yl)azo]phenyl]- (9CI) (CA
INDEX NAME)




RN 62888-06-6 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-(3-bromophenyl)- (CA INDEX NAME)




RN 62888-07-7 CAPLUS

CN 2-Naphthalenol, 1-[[2-(4-amino-6-bromo-2-quinazolinyl)-4-bromophenyl]azo]-
(9CI) (CA INDEX NAME)




RN 62888-08-8 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-(1-pyrrolidinylazo)phenyl]- (9CI)
(CA INDEX NAME)




RN 62888-09-9 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-(4-morpholinylazo)phenyl]- (9CI)
(CA INDEX NAME)




RN 62888-10-2 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-[(2-methyl-1-piperidiny)azo]phenyl]- (9CI) (CA INDEX NAME)




RN 62888-11-3 CAPLUS

CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-[(3-methyl-1-piperidiny)azo]phenyl]- (9CI) (CA INDEX NAME)




RN 62888-12-4 CAPLUS


CN 4-Quinazolinamine, 6-bromo-2-[5-bromo-2-[(4-methyl-1-piperidiny)azo]phenyl]- (9CI) (CA INDEX NAME)



IT 52698-01-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactions of)
 RN 52698-01-8 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(1-piperidinyldiazo)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 229 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:189863 CAPLUS
 DOCUMENT NUMBER: 86:189863
 ORIGINAL REFERENCE NO.: 86:29781a,29784a
 TITLE: Triazines and related products. Part 18.
 Decomposition of 1,2,3-benzotriazines and related
 triazines with sodium azide in acetic acid: a
 convenient route to azidoarenes
 AUTHOR(S): Gescher, Andreas; Stevens, Malcolm F. G.; Turnbull,
 Colin P.
 CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions
 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (2), 103-6
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 86:189863
 GI



AB The benzotriazinones I (R = H, Ph, 2-MeC₆H₄, 2-O₂NC₆H₄, 4-O₂NC₆H₄, 2-amino-3,4-dihydro-4-oxo-6-methylpyrimidinyl) decomposed on boiling in AcOH containing NaN₃ or NaI to give 65-88% 2-N₃C₆H₄CONHR and 85-90% 2-IC₆H₄CONHR (R = H, Ph, 4-O₂NC₆H₄), resp. Certain azidoarenes with nucleophilic ortho-substituents, formed from the decomposition of 1,2,3-benzotriazines and related aryltriazenes, cyclized with elimination of N under the reaction conditions described. Thus treatment of triazinobenzotriazines II (R = H, Me, Br) with AcOH-NaN₃ gave the o-azidophenyl-s-triazines III, which subsequently cyclized to give 70-80% triazinoindazoles IV. 1,3-Bis-o-nitrophenyltriazene in AcOH-NaN₃ gave benzofuran N-oxide and 2-O₂NC₆H₄NH₂.


IT 52698-01-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(decomposition of, with acetic acid containing sodium azide or sodium iodide)

RN 52698-01-8 CAPLUS

CN 4-Quinazolinamine, 2-[2-(1-piperidinylazo)phenyl]- (9CI) (CA INDEX NAME)




IT 62786-11-2P 62786-13-4P 62786-14-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 62786-11-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-azidophenyl)- (CA INDEX NAME)



RN 62786-13-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2-iodophenyl)- (CA INDEX NAME)



RN 62786-14-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2-iodophenyl)-, monohydriodide (9CI) (CA INDEX NAME)



● HI


L7 ANSWER 230 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:183779 CAPLUS
 DOCUMENT NUMBER: 86:183779
 ORIGINAL REFERENCE NO.: 86:28785a,28788a
 TITLE: Antibacterial activity of nitropyrroles,
 nitrothiophenes, and aminothiophenes in vitro
 AUTHOR(S): Wang, Ching Y.; Chiu, Chung W.; Muraoka, Keiji;
 Michie, Preston D.; Bryan, George T.
 CORPORATE SOURCE: Med. Sch., Univ. Wisconsin, Madison, WI, USA
 SOURCE: Antimicrobial Agents and Chemotherapy (1975
), 8(2), 216-19
 CODEN: AMACCQ; ISSN: 0066-4804
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The antibacterial activities of nitropyrroles, nitrothiophenes, and
 aminothiophenes were studied. Replacement of the nitro group with an
 amino group enhanced the activity of the thiophene compds. Nitropyrroles

had higher antibacterial activities than nitrothiophenes.

IT 33372-39-3 33372-40-6 33389-36-5
 57584-56-2 57584-57-3 58139-48-3
 58139-50-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (bactericidal activity of)


RN 33372-39-3 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-40-6 CAPLUS

CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33389-36-5 CAPLUS

CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-56-2 CAPLUS

CN Ethanol, 2-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-57-3 CAPLUS


CN 1,2-Propanediol, 3-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 58139-48-3 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-2-(5-nitro-2-thienyl)- (CA INDEX NAME)




RN 58139-50-7 CAPLUS
 CN 2-Thiophenamine, 5-[4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)



L7 ANSWER 231 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:121366 CAPLUS
 DOCUMENT NUMBER: 86:121366
 ORIGINAL REFERENCE NO.: 86:19171a,19174a
 TITLE: 2-(3,4-Dichlorophenyl)-4-(substituted amino)quinazolines
 INVENTOR(S): Alaimo, Robert J.
 PATENT ASSIGNEE(S): Morton-Norwich Products, Inc., USA
 SOURCE: U.S., 3 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3997538	A	19761214	US 1975-644619	19751229 <--
PRIORITY APPLN. INFO.:			US 1975-644619	A 19751229

GI



AB Quinazolines I [R = pyrrolidinopropyl, (CH₂)₃N(CH₂CH₂OH)₂, CH₂CH(OH)CH₂OH, CH₂CH(OH)CH₂NEt₂, (CH₂)₃OH] were prepared by aminating 4-chloro-2-(3,4-dichlorophenyl)quinazoline. I had min. inhibitory concns. against Staphylococcus aureus of 6.25-25 µg/mL.


IT 62220-45-5P 62220-46-6P 62220-47-7P

62220-48-8P 62220-49-9P 62220-50-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 62220-45-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 62220-46-6 CAPLUS

CN Ethanol, 2,2'-[[3-[[2-(3,4-dichlorophenyl)-4-quinazolinyl]amino]propyl]imino]bis- (9CI) (CA INDEX NAME)




RN 62220-47-7 CAPLUS


CN 1,2-Propanediol, 3-[[2-(3,4-dichlorophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 62220-48-8 CAPLUS
 CN 2-Propanol, 1-[[2-(3,4-dichlorophenyl)-4-quinazolinyl]amino]-3-(diethylamino)- (CA INDEX NAME)




RN 62220-49-9 CAPLUS
 CN 2-Propanol, 1-[[2-(3,4-dichlorophenyl)-4-quinazolinyl]amino]-3-(diethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 62220-50-2 CAPLUS
 CN 1-Propanol, 3-[[2-(3,4-dichlorophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



L7 ANSWER 232 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:72696 CAPLUS
 DOCUMENT NUMBER: 86:72696
 ORIGINAL REFERENCE NO.: 86:11527a,11530a
 TITLE: Quinazoline derivatives
 INVENTOR(S): Nesvadba, Hans; Reinshagen, Hellmuth
 PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 21 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2619110	A1	19761125	DE 1976-2619110	19760503 <--
CH 612432	A5	19790731	CH 1975-6041	19750512 <--
DK 7601974	A	19761113	DK 1976-1974	19760503 <--
FI 7601232	A	19761113	FI 1976-1232	19760503 <--
NO 7601537	A	19761115	NO 1976-1537	19760504 <--
SE 7605158	A	19761113	SE 1976-5158	19760505 <--
SE 409455	B	19790820		
SE 409455	C	19791129		
US 4055642	A	19771025	US 1976-683291	19760505 <--
NL 7604894	A	19761116	NL 1976-4894	19760507 <--
GB 1551117	A	19790822	GB 1976-18778	19760507 <--
CA 1071626	A1	19800212	CA 1976-252103	19760510 <--
JP 51138689	A	19761130	JP 1976-53730	19760511 <--
AT 7603421	A	19800815	AT 1976-3421	19760511 <--
FR 2310756	A1	19761210	FR 1976-14235	19760512 <--
FR 2310756	B1	19781020		
CH 617691	A5	19800613	CH 1978-12678	19781129 <--
PRIORITY APPLN. INFO.:			CH 1975-6041	A 19750512
GI				




I

AB Imidazolylquinazolines (I; R = e.g., HOCH2CH2NH, HOCH2CH2NHCH2CH2O, Et2NCH2CH2S, morpholino, 4-methyl-1-piperazinyl; R1 = H, Me; R2 = H, Cl), useful as amebicides and trichomonacides, are prepared by reaction of 4-chloro-2-(1-methyl-5-nitro-2-imidazolyl)quinazolines with the appropriate alcs., thiols, or amines. The 4-chloro derivs. are obtained from the 4(3H)-quinazolinones which are prepared by cyclocondensation of an anthranilic acid with an alkyl 1-methyl-5-nitro-2-imidazolecarboximidate. Thus, reaction of I (R = Cl, R1 = R2 = H) with HN(CH2CH2OH)2 in DMF 1.5 h at 100° gives I (R = HOCH2CH2NHCH2CH2O, R1 = R2 = H).

IT 61717-11-1P 61717-15-5P 61717-16-6P
 61717-17-7P 61717-19-9P 61717-23-5P
 61717-24-6P 61717-25-7P 61717-26-8P
 61717-31-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)


RN 61717-11-1 CAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboximidic acid, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-15-5 CAPLUS

CN 4-Quinazolinamine, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (CA INDEX NAME)




RN 61717-16-6 CAPLUS

CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 61717-17-7 CAPLUS

CN 2-Furancarboximidic acid, 5-nitro-, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-19-9 CAPLUS

CN Ethanol, 2-[[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 61717-23-5 CAPLUS

CN 1-Piperazineethanol, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]- (CA INDEX NAME)




RN 61717-24-6 CAPLUS

CN Quinazoline, 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-(4-morpholinyl)- (CA INDEX NAME)




RN 61717-25-7 CAPLUS

CN 1H-Imidazole-2-carboximidic acid, 1-methyl-5-nitro-, 2-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]hydrazide (CA INDEX NAME)




RN 61717-26-8 CAPLUS


CN Quinazoline, 4,4'-(1,4-piperazinediyl)bis[2-(1-methyl-5-nitro-1H-imidazol-2-yl)]- (CA INDEX NAME)



RN 61717-31-5 CAPLUS
 CN Ethanol, 2,2'-[[2-(1-methyl-5-nitro-1H-imidazol-2-yl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)



L7 ANSWER 233 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:29740 CAPLUS
 DOCUMENT NUMBER: 86:29740
 ORIGINAL REFERENCE NO.: 86:4759a,4762a
 TITLE: New synthesis of 4-tosylimino-3,4-dihydroquinazoline derivatives
 AUTHOR(S): Ried, Walter; Heine, Birgit; Merkel, Wulf; Kothe, Norbert
 CORPORATE SOURCE: Inst. Org. Chem., Univ. Frankfurt, Frankfurt/Main, Fed. Rep. Ger.
 SOURCE: Synthesis (1976), (8), 534-5
 CODEN: SYNTBF; ISSN: 0039-7881
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 86:29740
 GI




AB Tosyliminoquinazolines I [R = morpholino, R1 = H, Me; R = 4-R2C6H4 (R2 = H, MeO, NO2), R1 = H] were prepared in 50-85% yields by treating quinazolinethiones II (R = morpholino, R1 = H, Me) in dioxane or II [R = 4-R2C6H4 (R2 = H, MeO, NO2), R1 = H] neat with p-SCNSO2C6H4Me.

IT 50871-62-0P 61335-57-7P 61364-51-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 50871-62-0 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 61335-57-7 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[2-(4-nitrophenyl)-4-quinazolinyl]- (CA INDEX NAME)




RN 61364-51-0 CAPLUS
 CN Benzenesulfonamide, N-[2-(4-methoxyphenyl)-4-quinazolinyl]-4-methyl- (CA
 INDEX NAME)




L7 ANSWER 234 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:591941 CAPLUS
 DOCUMENT NUMBER: 85:191941
 ORIGINAL REFERENCE NO.: 85:30690h,30691a
 TITLE: Tautomerism of heterocyclic compounds, V. The
 reactions of chloroformamidines and
 N-phenylbenzimidoyl chloride with N-cyanoamidines and
 1-cyanoguanidine
 AUTHOR(S): Ried, Walter; Kothe, Norbert
 CORPORATE SOURCE: Inst. Org. Chem., Univ. Frankfurt/Main,
 Frankfurt/Main, Fed. Rep. Ger.
 SOURCE: Chemische Berichte (1976), 109(8), 2706-15
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 85:191941
 GI For diagram(s), see printed CA Issue.
 AB Chloroformamidines (I; R = H, o-Me, p-Cl, etc.) are treated with
 R1C(NH2)NCN (R1 = CCl3, Ph, Me) to yield II, III, and IV (R, R1 as above).
 I are treated with NCN:C(NH2)2 to yield V (R as above). A mechanism
 involving VI as the initial intermediate was postulated for the formation

of III.
 IT 55434-76-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55434-76-9 CAPLUS
 CN Benzenecarboximidamide, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




L7 ANSWER 235 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:572499 CAPLUS
 DOCUMENT NUMBER: 85:172499
 ORIGINAL REFERENCE NO.: 85:27533a, 27536a
 TITLE: Comparative carcinogenicity of 5-nitrothiophenes and 5-nitrofurans in rats
 AUTHOR(S): Cohen, Samuel M.; Erturk, E.; Bryan, George T.
 CORPORATE SOURCE: Cent. Health Sci., Univ. Wisconsin, Madison, WI, USA
 SOURCE: Journal of the National Cancer Institute (1940-1978) (1976), 57(2), 277-82
 CODEN: JNCIAM; ISSN: 0027-8874
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The carcinogenicity of five 5-nitrothiophenes with heterocyclic substituents at the 2-position of the thiophene ring was investigated by feeding the chems. to Sprague-Dawley rats and comparing the type and incidence of lesions with those appearing after exposure to two 5-nitrofurans. Benign and malignant mammary tumors and intestinal tract sarcomas were the most frequent lesions induced by 5-nitrothiophenes. 4-Bis(2-hydroxyethyl)amino-2-(5-nitro-2-thienyl)quinazoline (I) [33372-39-3] caused a 100% incidence of mammary adenocarcinomas in 28 female rats at risk; it induced 3 benign and 5 malignant mammary tumors and 13 small intestine sarcomas in 20 male rats. A high incidence of similar lesions was observed in male and female rats fed the corresponding 5-nitrofuran analogue, 4-bis(2-hydroxyethyl)amino-2-(5-nitro-2-furyl)quinazoline [5055-20-9]. In marked contrast, 4 of 28 female rats receiving 4-bis(2-hydroxyethyl)amino-2-(2-thienyl)quinazoline [58139-47-2], which lacks the nitro group at the 5-position on the thiophene ring, had solitary benign mammary tumors. Addnl.

5-nitrothiophenes demonstrating significant oncogenic activity for female rats were 4-morpholino-2-(5-nitro-2-thienyl)quinazoline [58139-48-3], 4-(2-hydroxyethylamino)-2-(5-nitro-2-thienyl)quinazoline [33389-36-5], 4-(2,3-dihydroxypropylamino)-2-(5-nitro-2-thienyl)quinazoline [33372-40-6], and 1,2-dihydro-2-(5-nitro-2-thienyl)quinazolin-4(3H)-one [33389-33-2]. Another nitrofuran, 4,6-dimethyl-2-(5-nitro-2-furyl)-pyrimidine [59-35-8], provided the following types of neoplasms in 30 female rats at risk: squamous cell carcinomas of the forestomach (30), sarcomas of the intestine (21), adenocarcinomas of the mammary gland (12), and transitional cell carcinomas of the kidney (2).


IT 5055-20-9 33372-39-3 33372-40-6
 33389-36-5 58139-47-2 58139-48-3
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (carcinogenicity of)
 RN 5055-20-9 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-39-3 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-40-6 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 58139-47-2 CAPLUS
 CN Ethanol, 2,2'-[[2-(2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 58139-48-3 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-2-(5-nitro-2-thienyl)- (CA INDEX NAME)



L7 ANSWER 236 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:560155 CAPLUS
 DOCUMENT NUMBER: 85:160155
 ORIGINAL REFERENCE NO.: 85:25645a,25648a
 TITLE: 4-Aminoquinazoline derivatives
 INVENTOR(S): Nesvadba, Hans; Reinshagen, Hellmuth
 PATENT ASSIGNEE(S): Sandoz Ltd., Switz.
 SOURCE: Patentschrift (Switz.), 3 pp.
 CODEN: SWXXAS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 578556	A5	19760813	CH 1973-2448	19730220 <--
PRIORITY APPLN. INFO.: GI			CH 1973-2448	A 19730220




AB Reaction of 4-chloro-2-(5-nitro-2-thiazolyl)quinazoline with 1-methylpiperazine gives bactericidal I; by quaternization of I with MeI the dimethylpiperazinylium iodide is obtained.

IT 60726-44-5P 60726-45-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)


RN 60726-44-5 CAPLUS

CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-(5-nitro-2-thiazolyl)- (CA INDEX NAME)




RN 60726-45-6 CAPLUS

CN Piperazinium, 1,1-dimethyl-4-[2-(5-nitro-2-thiazolyl)-4-quinazolinyl]-, iodide (9CI) (CA INDEX NAME)



● I⁻

L7 ANSWER 237 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:104695 CAPLUS
 DOCUMENT NUMBER: 84:104695
 ORIGINAL REFERENCE NO.: 84:17047a,17050a
 TITLE: Tetrazoloazines. Nitrogen-15 nuclear magnetic resonance and infrared absorption spectroscopy
 AUTHOR(S): Thetaz, Celestin; Wehrli, F. W.; Wentrup, Curt
 CORPORATE SOURCE: Inst. Chim. Org., Univ. Lausanne, Lausanne, Switz.
 SOURCE: Helvetica Chimica Acta (1976), 59(1), 259-64
 CODEN: HCACAV; ISSN: 0018-019X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Halo azines, e.g., 2-bromopyridine, react with alkali azide to give tetrazoloazines via direct nucleophilic substitution of the halogen atom. 15N NMR and ir data were given.
 IT 58534-08-0
 RL: PRP (Properties)
 (NMR of)
 RN 58534-08-0 CAPLUS
 CN Quinazoline, 4-(azido-15N2)-2-phenyl- (9CI) (CA INDEX NAME)




L7 ANSWER 238 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:54689 CAPLUS
 DOCUMENT NUMBER: 84:54689
 ORIGINAL REFERENCE NO.: 84:8973a,8976a
 TITLE: Mutagenicity of nitrofurans, nitrothiophenes, nitropyrroles, nitroimidazole, aminothiophenes, and aminothiazoles in Salmonella typhimurium
 AUTHOR(S): Wang, Ching Yung; Muraoka, Keiji; Bryan, George T.
 CORPORATE SOURCE: Cent. Health Sci., Univ. Wisconsin, Madison, WI, USA
 SOURCE: Cancer Research (1975), 35(12), 3611-17
 CODEN: CNREA8; ISSN: 0008-5472
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Thirty-two heterocyclic compds., including 24 nitroheterocycles, 7 aminoheterocycles and derivs., and 1 thiophene lacking a nitro group, were tested for mutagenic activity in S. typhimurium TA98 and TA100. All the nitroheterocycles (11 new), including nitrofurans, nitrothiophenes, nitropyrroles, and 1 nitroimidazole, were mutagenic in TA100 and 13 were also mutagenic in TA98. 5-Nitro-2-furoic acid [645-12-5] (a noncarcinogen) was mutagenic in TA100. Seven carcinogenic nitroheterocycles were mutagenic in both strains. Seven aminoheterocycles (4 new), aminothiophenes, and aminothiazole derivs., and 1 thiophene without a nitro group were not mutagenic. Both TA98 and TA100 were uvrB and lacked the ability of excision repair of DNA. Among the 24 mutagenic nitroheterocycles, only 13 exhibited bacterial killing effects, suggesting that more than 1 mechanism may be involved in the interaction of nitroheterocycles with bacterial DNA.
 IT 33372-39-3 33372-40-6 33389-36-5
 57584-56-2 57584-57-3 58139-47-2
 58139-48-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(mutagenic activity of)


RN 33372-39-3 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-40-6 CAPLUS

CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33389-36-5 CAPLUS

CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-56-2 CAPLUS

CN Ethanol, 2-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-57-3 CAPLUS


CN 1,2-Propanediol, 3-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 58139-47-2 CAPLUS
 CN Ethanol, 2,2'-[[2-(2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 58139-48-3 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-2-(5-nitro-2-thienyl)- (CA INDEX NAME)



IT 58139-49-4P 58139-50-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation) (preparation and mutagenic activity of)
 RN 58139-49-4 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-amino-2-thienyl)-4-quinazolinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 58139-50-7 CAPLUS
 CN 2-Thiophenamine, 5-[4-(4-morpholinyl)-2-quinazolinyl]- (CA INDEX NAME)



L7 ANSWER 239 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:26640 CAPLUS

DOCUMENT NUMBER: 84:26640

ORIGINAL REFERENCE NO.: 84:4371a, 4374a

TITLE: Nitroreduction of carcinogenic 5-nitrothiophenes by rat tissues

AUTHOR(S): Wang, Ching Yung; Chiu, Chung Wai; Bryan, George T.

CORPORATE SOURCE: Med. Sch., Univ. Wisconsin, Madison, WI, USA

SOURCE: Biochemical Pharmacology (1975), 24(17), 1563-8

CODEN: BCPCA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Rat tissue cytosols and microsomes catalyzed nitroreductn. of anthelmintic and carcinogenic 5-nitrothiophenes, e.g. 4-(2,3-dihydroxypropylamino)-2-(5-nitro-2-thienyl)quinazoline (I). Cytosol and microsomal nitroreductase [9037-41-6] activities were hypoxanthine- and NADPH-dependent, resp., and were both inhibited by air. Nitroreductn. of 5-nitrothiophenes, which was also catalyzed by milk xanthine oxidase [9002-17-9], was higher in small intestine and liver preps. than in kidney or stomach preps., suggesting that the former 2 organs are the main organs for metabolism of 5-nitrothiophenes. Only 25-50% of reduced 5-nitrothiophenes was converted to the corresponding amine, probably by the same enzymes (xanthine oxidase and cytochrome c reductase) involved in the reduction of 5-nitrofurans. A procedure for the photometric determination of 5-nitro- and 5-aminothiophenes


is described.

IT 57584-56-2P 57584-57-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and uv spectrum of)


RN 57584-56-2 CAPLUS

CN Ethanol, 2-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 57584-57-3 CAPLUS


CN 1,2-Propanediol, 3-[[2-(5-amino-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



IT 33372-40-6 33389-36-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reduction of, by animal tissue)
 RN 33372-40-6 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA
 INDEX NAME)




RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




L7 ANSWER 240 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1975:593208 CAPLUS
 DOCUMENT NUMBER: 83:193208
 ORIGINAL REFERENCE NO.: 83:30389a,30392a
 TITLE: 1,2,4-Triazino[4,3-c]- and [2,3-c]quinazolines. II
 AUTHOR(S): Trepanier, Donald L.; Sunder, Shyam
 CORPORATE SOURCE: Dow Lepetit, USA, Dow Chem. Co., Midland, MI, USA
 SOURCE: Journal of Heterocyclic Chemistry (1975),
 12(2), 321-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 83:193208
 GI For diagram(s), see printed CA Issue.
 AB The triazine I (R = H) was cyclized with R1COR2 [R1 = Ph, substituted
 phenyl, Me(CH2)4, R2 = H, Me] to give the triazinoquinazolines II. I (R =
 H) was acylated with R3COCl (R3 = Ph, substituted phenyl) to give I (R =
 R3CO), which were cyclized to III. II (R1R2 = O) was obtained from I (R =
 H) and MeNCO followed by cyclization. I (R = H) and HONO gave IV. Some
 of the triazinoquinazolines were antiinflammatory and analgesic (no data).
 IT 57046-45-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of)

RN 57046-45-4 CAPLUS
CN 4(1H)-Quinazolinone, 2-phenyl-, (2-hydroxyethyl)methylhydrazone (9CI) (CA INDEX NAME)




L7 ANSWER 241 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:588196 CAPLUS
DOCUMENT NUMBER: 83:188196
ORIGINAL REFERENCE NO.: 83:29505a,29508a
TITLE: Derivatives of imidazo[1,2-c]quinazolines and their inhibitory action on platelet aggregation
AUTHOR(S): Cardellini, M.; Franchetti, P.; Grifantini, M.; Martelli, S.; Petrelli, F.
CORPORATE SOURCE: Ist. Chim. Farm. Chim. Org., Univ. Camerino, Camerino, Italy
SOURCE: Farmaco, Edizione Scientifica (1975), 30(7), 536-46
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Italian
OTHER SOURCE(S): CASREACT 83:188196
GI For diagram(s), see printed CA Issue.
AB Assay of 35 title compds. for their ability to inhibit ADP-induced platelet aggregation in rabbit platelet-rich plasma showed that activity was not limited to 5,6-dihydroimidazo[1,2-c]quinazolines (I; R = alkyl or aryl; R1 = Me, Et, or H) but was found in other derivs. Among the nonsubstituted, hydrogenated compds., the most active was 2,3-dihydroimidazo[1,2-c]quinazoline [1010-62-4]. The activity of I in which R = aryl depended on the position and type of substituent group on the ring; the most active was I(R = p-Me-C6H4; R1 = H) [56948-51-7]. I in which R was o-, m-, or p-HOC6H4 were inactive. Disubstituted I (R = R1 = Me or Et) was also inactive. Aggregation-inhibiting activity remained after opening of the quinazoline ring, as in 2-(o-aminophenyl)imidazole (II) [29528-25-4]. I were synthesized by the acid-catalyzed condensation of II with the appropriate aldehydes or ketones. Two routes for the synthesis of II are also given.
IT 56948-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and isomerization of)
RN 56948-20-0 CAPLUS
CN Quinazoline, 4-(1-aziridiny1)-2-phenyl- (CA INDEX NAME)




L7 ANSWER 242 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1975:479282 CAPLUS
 DOCUMENT NUMBER: 83:79282
 ORIGINAL REFERENCE NO.: 83:12454h,12455a
 TITLE: Bactericidal and antihypertensive 4-aminoquinazoline compounds
 INVENTOR(S): Nauta, Wijbe T.
 PATENT ASSIGNEE(S): N. V. Koninklijke Pharmaceutische Fabrieken Voorheen Brocades-Stheeman & Pharmacia, Neth.
 SOURCE: Brit., 4 pp. Division of Brit. 1,390,014.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1390015	A	19750409	GB 1974-47849	19720505 <--

PRIORITY APPLN. INFO.: GB 1974-47849 A 19720505
 GI For diagram(s), see printed CA Issue.
 AB Ten title compds. I (R = pyrrolidyl, 2-, 3-, and 4-pyridyl, 2-furyl, 1-methyl-2-pyrrolyl; R1 = H, Cl, MeO; R2 = H, MeO) were prepared from 2-aminobenzonitriles by treatment with heterocyclic nitriles. Thus, I (R = pyrrolidyl, R1 = R2 = H) was prepared from 2-H2NC6H4CN in Et2O by refluxing with 1-pyrrolidinenitrile 4 hr under N in the presence of PhBr-Li followed by treatment with H2O. I showed bactericidal activity (no data) towards Mycoplasma gallisepticum and Pasteurella multocida. The antihypertensive activities of I were assessed in rats (no data).
 IT 40172-82-5P 40172-83-6P 40172-84-7P
 40172-87-0P 40172-88-1P 40172-89-2P
 40172-98-3P 40172-99-4P 56503-36-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (bactericide and antihypertensive, preparation of)
 RN 40172-82-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)




RN 40172-83-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 40172-84-7 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(2-pyridinyl)- (CA INDEX NAME)



RN 40172-87-0 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-pyridinyl)- (CA INDEX NAME)




RN 40172-88-1 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-pyridinyl)-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 40172-89-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1-methyl-1H-pyrrol-2-yl)-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 40172-98-3 CAPLUS
CN 4-Quinazolinamine, 2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 40172-99-4 CAPLUS
CN 4-Quinazolinamine, 2-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 56503-36-7 CAPLUS
CN 4-Quinazolinamine, 2-(2-furanyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L7 ANSWER 243 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1975:170822 CAPLUS
 DOCUMENT NUMBER: 82:170822
 ORIGINAL REFERENCE NO.: 82:27301a,27304a
 TITLE: Tautomerism of heterocyclic compounds. IV. On the reactions of chloroformamidines and imidoyl chlorides with cyanamides
 AUTHOR(S): Ried, Walter; Kothe, Norbert; Merkel, Wulf
 CORPORATE SOURCE: Inst. Org. Chem., Univ. Frankfurt, Frankfurt/Main, Fed. Rep. Ger.
 SOURCE: Chemische Berichte (1975), 108(1), 181-90
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 82:170822
 GI For diagram(s), see printed CA Issue.
 AB The chloroformamidines I (Rn = H, 2-Me, 4-Cl, or benzo[b]) reacted with H2NCN in 2:1 molar ratio to give 32-56% quinazolines II. The reaction of I (Rn = H, 2-Me, 4-Cl, or 4-Ph) with 4-cyanomorpholine led to the dimorpholino compds. III.
 IT 55434-76-9P 55434-82-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 55434-76-9 CAPLUS
 CN Benzenecarboximidamide, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 55434-82-7 CAPLUS
 CN Benzenecarboximidamide, N-methyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




L7 ANSWER 244 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1975:72914 CAPLUS
 DOCUMENT NUMBER: 82:72914
 ORIGINAL REFERENCE NO.: 82:11655a,11658a
 TITLE: Synthesis and spectral study of 2-phenyl-4-(3'-N,N-dimethylaminomethyl-4'-hydroxyanilino)quinazoline derivatives
 AUTHOR(S): Patel, J. G.; Bhide, B. H.; Patel, S. R.
 CORPORATE SOURCE: Dep. Chem., Sardar Patel Univ., Vallabh Vidyanagar, India
 SOURCE: Journal of the Indian Chemical Society (1974), 51(7), 674-6
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB The quinazolines I (R = Et₂NCH₂, Me₂NCH₂, piperidinomethyl) were prepared by Mannich reaction of I (R = H) with amines. I (R = H) was prepared by condensation of p-HOC₆H₄NH₂ with 4-chloroquinazolines. The uv spectra of I were determined to check for tautomerism; no conclusion was drawn.
 IT 54665-94-0P 54665-95-1P 54665-96-2P 54665-97-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and Mannich reaction of)
 RN 54665-94-0 CAPLUS
 CN Phenol, 4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 54665-95-1 CAPLUS
 CN Phenol, 4-[(7-chloro-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 54665-96-2 CAPLUS
 CN Phenol, 4-[(6-chloro-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 54665-97-3 CAPLUS
 CN Phenol, 4-[(6-methoxy-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




IT 54666-36-3P 54666-37-4P 54666-38-5P
 54666-39-6P 54666-40-9P 54666-41-0P
 54666-42-1P 54666-43-2P 54666-44-3P
 54666-45-4P 54666-46-5P 54666-47-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and uv spectra of)
 RN 54666-36-3 CAPLUS
 CN Phenol, 2-[(diethylamino)methyl]-4-[(2-phenyl-4-quinazolinyl)amino]- (CA

INDEX NAME)




RN 54666-37-4 CAPLUS

CN Phenol, 2-[(dimethylamino)methyl]-4-[(2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 54666-38-5 CAPLUS

CN Phenol, 4-[(2-phenyl-4-quinazolinyl)amino]-2-(1-piperidinylmethyl)- (CA INDEX NAME)




RN 54666-39-6 CAPLUS

CN Phenol, 4-[(7-chloro-2-phenyl-4-quinazolinyl)amino]-2-[(diethylamino)methyl]- (CA INDEX NAME)




RN 54666-40-9 CAPLUS

CN Phenol, 4-[(7-chloro-2-phenyl-4-quinazolinyl)amino]-2-[(dimethylamino)methyl]- (CA INDEX NAME)




RN 54666-41-0 CAPLUS

CN Phenol, 4-[(7-chloro-2-phenyl-4-quinazolinyl)amino]-2-(1-piperidinylmethyl)- (CA INDEX NAME)




RN 54666-42-1 CAPLUS

CN Phenol, 4-[(6-chloro-2-phenyl-4-quinazolinyl)amino]-2-[(diethylamino)methyl]- (CA INDEX NAME)




RN 54666-43-2 CAPLUS

CN Phenol, 4-[(6-chloro-2-phenyl-4-quinazolinyl)amino]-2-[(dimethylamino)methyl]- (CA INDEX NAME)




RN 54666-44-3 CAPLUS

CN Phenol, 4-[(6-chloro-2-phenyl-4-quinazolinyl)amino]-2-(1-piperidinylmethyl)- (CA INDEX NAME)




RN 54666-45-4 CAPLUS

CN Phenol, 2-[(diethylamino)methyl]-4-[(6-methoxy-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 54666-46-5 CAPLUS

CN Phenol, 2-[(dimethylamino)methyl]-4-[(6-methoxy-2-phenyl-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 54666-47-6 CAPLUS

CN Phenol, 4-[(6-methoxy-2-phenyl-4-quinazolinyl)amino]-2-(1-piperidinylmethyl)- (CA INDEX NAME)



L7 ANSWER 245 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1975:43327 CAPLUS

DOCUMENT NUMBER: 82:43327


ORIGINAL REFERENCE NO.: 82:6897a,6900a

TITLE: Novel synthesis of a benzimidazo[1,2-c]benzopyrimidine

by photolysis of 4-(benzotriazol-1-yl)-2-phenylquinazoline
 AUTHOR(S): Hubert, A. J.
 CORPORATE SOURCE: Inst. Chim., Univ. Liege, Liege, Belg.
 SOURCE: Journal of Heterocyclic Chemistry (1974),
 11(5), 737-8
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 82:43327
 GI For diagram(s), see printed CA Issue.
 AB A novel synthesis of 6-phenylbenzimidazo[1,2-c]benzopyrimidine (I) by
 photolysis of 4-(benzotriazol-1-yl)-2-phenylquinazoline (II) is described.
 The acid-catalyzed thermolysis of II gives extensive degradation to
 2-phenyl-4-quinazolinone.
 IT 54608-51-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and photolysis of)
 RN 54608-51-4 CAPLUS
 CN Quinazoline, 4-(1H-benzotriazol-1-yl)-2-phenyl- (CA INDEX NAME)



L7 ANSWER 246 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:486076 CAPLUS
 DOCUMENT NUMBER: 81:86076
 ORIGINAL REFERENCE NO.: 81:13623a,13626a
 TITLE: Antimalarials. 2. α -Di-n-butylaminomethyl-2-(p-chlorophenyl)-5-quinazolinemethanol
 AUTHOR(S): Cruickshank, Philip A.; Hymans, William E.
 CORPORATE SOURCE: Chem. Res. Dev. Cent., FMC Corp., Princeton, NJ, USA
 SOURCE: Journal of Medicinal Chemistry (1974),
 17(4), 468-9
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The title compound (I) [52171-80-9] was prepared and tested against Plasmodium
 berghei in mice and P. gallinaceum in chicks. I cured P. berghei in mice
 at 480 mg/kg, but caused severe photosensitivity.
 IT 52171-74-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antimalarial activity of)
 RN 52171-74-1 CAPLUS
 CN 5-Quinazolinecarboxylic acid, 2-(4-chlorophenyl)-4-[2-[(4-methylphenyl)sulfonyl]hydrazino]-, methyl ester, monohydrochloride (9CI)
 (CA INDEX NAME)



L7 ANSWER 247 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:413549 CAPLUS
 DOCUMENT NUMBER: 81:13549
 ORIGINAL REFERENCE NO.: 81:2183a,2186a
 TITLE: 2-(or 4)-Aminoquinazoline derivatives
 INVENTOR(S): Danilewicz, John C.; Kemp, John E. G.; Wright, James Robert
 PATENT ASSIGNEE(S): Pfizer Corp.
 SOURCE: Ger. Offen., 31 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2345064	A1	19740411	DE 1973-2345064	19730906 <--
DE 2345064	B2	19790308		
DE 2345064	C3	19791025		
ZA 7305660	A	19740731	ZA 1973-5660	19730820 <--
IN 139088	A1	19760508	IN 1973-CA1920	19730821 <--
AU 7359606	A	19750227	AU 1973-59606	19730824 <--
DK 131725	B	19750825	DK 1973-4782	19730830 <--
CA 995673	A1	19760824	CA 1973-180089	19730831 <--
JP 49085078	A	19740815	JP 1973-98934	19730904 <--
US 3960861	A	19760601	US 1973-394491	19730905 <--
BE 804558	A1	19740306	BE 1973-135402	19730906 <--
GB 1383409	A	19750212	GB 1972-41992	19730906 <--
AT 7307745	A	19751015	AT 1973-7745	19730906 <--
AT 330785	B	19760726		
DE 2366106	B1	19790621	DE 1973-2366106	19730906 <--
DE 2366106	C2	19800214		
NL 7312350	A	19740312	NL 1973-12350	19730907 <--
NL 161152	B	19790815		
NL 161152	C	19800115		
FR 2198751	A1	19740405	FR 1973-32315	19730907 <--
ES 418612	A1	19760716	ES 1973-418612	19730908 <--

SU 555850	A3	19770425	SU 1975-2095549	19750108 <--
IN 141109	A1	19770122	IN 1975-CA1357	19750711 <--
US 4044136	A	19770823	US 1976-663627	19760303 <--
PRIORITY APPLN. INFO.:			GB 1972-41992	A 19720909
			US 1973-394491	A3 19730905

GI For diagram(s), see printed CA Issue.


AB Antihypertensive tetrahydroisoquinolinyl (amino)quinazolines (40 compds.) including I (R = R3 = H, R1 = OMe, R2 = OMe, OCHMe2, OEt, OCH2-CH : CH2; R = R3 = H, R1 = OEt, R2 = OMe, OEt; R = R1 = H, R2 = R3 = OMe; R = Me, R1 = R2 = OMe, R3 = H) were prepared. Thus, 12 g I (R = R3 = H, R1 = R2 = OMe) was obtained by treating 12 g 4-amino-2-chloro-6,7-dimethoxyquinazoline with 9.6 g 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline.

IT 52758-88-0P 52758-89-1P 52758-90-4P
 52758-91-5P 52758-92-6P 52758-93-7P
 52758-94-8P 52758-95-9P 52758-96-0P
 52758-97-1P 52758-98-2P 52758-99-3P
 52759-00-9P 52759-07-6P 52759-10-1P
 52759-11-2P 52759-12-3P 52759-15-6P
 52759-36-1P 52759-37-2P 52759-38-3P
 52759-39-4P 52759-45-2P 52759-46-3P
 52759-47-4P 52759-48-5P 52759-49-6P
 52759-50-9P 52759-51-0P 52759-52-1P
 52759-53-2P 52759-54-3P 52781-46-1P
 52781-47-2P 52903-18-1P 52903-21-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 52758-88-0 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dihydro-7,8-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 52758-89-1 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-90-4 CAPLUS
 CN 7-Isoquinolinol, 2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-6-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-91-5 CAPLUS
 CN 6-Isoquinolinol, 2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-7-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-92-6 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2,3,8,9-tetrahydro-1,4-dioxino[2,3-g]isoquinolin-7(6H)-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-93-7 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-5,6-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-94-8 CAPLUS
 CN 4-Quinazolinamine, 2-(6-ethoxy-3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-95-9 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6-methoxy-7-propoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-96-0 CAPLUS
 CN 4-Quinazolinamine, 2-[3,4-dihydro-6-methoxy-7-(1-methylethoxy)-2(1H)-isoquinolinyl]-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-97-1 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-7-nitro-2(1H)-isoquinolinyl)-6,7-dimethoxy- (CA INDEX NAME)




RN 52758-98-2 CAPLUS
 CN 4-Quinazolinamine, 2-(6,7-diethoxy-3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52758-99-3 CAPLUS
 CN 8-Isoquinolinol, 2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-7-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-00-9 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7,8-trimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 52759-07-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 52759-10-1 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7,8-trimethoxy- (CA INDEX NAME)



RN 52759-11-2 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-6,7,8-trimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-12-3 CAPLUS

CN 4-Quinazolinamine, 2-(3,4-dihydro-7,8-dimethoxy-2(1H)-isoquinolinyl)-6,7,8-trimethoxy- (CA INDEX NAME)




RN 52759-15-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-36-1 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-5,6,7-trimethoxy-2(1H)-isoquinolinyl)-6,7,8-trimethoxy- (CA INDEX NAME)




RN 52759-37-2 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-diethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-38-3 CAPLUS
 CN 4-Quinazolinamine, 6,7-diethoxy-2-(7-ethoxy-3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-39-4 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6-methoxy-7-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-45-2 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(1,3,4,5-tetrahydro-7,8-dimethoxy-2H-2-benzazepin-2-yl)- (CA INDEX NAME)




RN 52759-46-3 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 52759-47-4 CAPLUS


CN 4-Quinazolinamine, 2-(7-ethoxy-3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 52759-48-5 CAPLUS

CN 4-Quinazolinamine, 2-[3,4-dihydro-6-methoxy-7-(2-propenyloxy)-2(1H)-isoquinolinyl]-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-49-6 CAPLUS
 CN 4-Quinazolinamine, 2-[3,4-dihydro-6-methoxy-7-(2-pyridinyloxy)-2(1H)-isoquinolinyl]-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-50-9 CAPLUS
 CN 4-Quinazolinamine, 2-(8-ethoxy-3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-51-0 CAPLUS
 CN 4-Quinazolinamine, 2-(7-amino-3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 52759-52-1 CAPLUS
 CN Acetamide, N-[2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-53-2 CAPLUS
 CN 2-Furancarboxamide, N-[2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52759-54-3 CAPLUS
 CN Carbamic acid, [2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52781-46-1 CAPLUS
 CN 4-Quinazolinamine, 2-(3,4-dihydro-5,6,7-trimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52781-47-2 CAPLUS
 CN 4-Quinazolinamine, 2-(7-butoxy-3,4-dihydro-6-methoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52903-18-1 CAPLUS
 CN 7-Quinazolinol, 4-amino-2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 52903-21-6 CAPLUS
 CN 4-Quinazolinamine, 2-(5,6-dimethoxy-2H-isoindol-2-yl)-6,7-dimethoxy- (CA INDEX NAME)



L7 ANSWER 248 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:403894 CAPLUS
 DOCUMENT NUMBER: 81:3894
 ORIGINAL REFERENCE NO.: 81:635a,638a
 TITLE: Triazines and related products. XIII. Decomposition of 4-arylamino-1,2,3-benzotriazines and their precursors in secondary amines
 AUTHOR(S): Stevens, Malcolm F. G.
 CORPORATE SOURCE: Dep. Pharm., Univ. Aston, Birmingham, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1974), (5), 615-20
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB 4-(Arylamino)-1,2,3-benzotriazines with secondary amines gave 80-90% N,N,N'-trisubstituted 2-aminobenzamidines. E.g., 4-(p-cyanoanilino)-1,2,3-benzotriazine with piperidine gave 88% benzamidine I. 4-(o-Aminoanilino)-1,2,3-benzotriazine with HO(CH2)2OH or piperidine gave 2-(2-aminophenyl)benzimidazole. The reactions may proceed by nucleophilic attack at C-4 by the amines. 2-NCC6-H4N:NNHC6H4CN-4 with piperidine gave I. 2-NCC6H4N:NNHC6H4CN-2 with secondary amines gave (triazenylphenyl)-quinazolines, e.g. II.
 IT 52698-01-8P 52698-02-9P 52698-03-0P
 52698-04-1P 52698-05-2P 52768-16-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 52698-01-8 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(1-piperidinylazo)phenyl]- (9CI) (CA INDEX NAME)




RN 52698-02-9 CAPLUS
 CN 4-Quinazolinamine, 2-[2-(1-pyrrolidinylazo)phenyl]- (9CI) (CA INDEX NAME)




RN 52698-03-0 CAPLUS

CN 4-Quinazolinamine, 2-[2-(3,3-diethyl-1-triazenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 52698-04-1 CAPLUS


CN 4-Quinazolinamine, 2-[2-(3,3-dipropyl-1-triazenyl)phenyl]- (9CI) (CA INDEX NAME)




RN 52698-05-2 CAPLUS

CN 4-Quinazolinamine, 2,2'-[1,4-piperazinediylbis(azo-2,1-phenylene)]bis- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 52768-16-8 CAPLUS
CN 4-Quinazolinamine, 2-[2-(4-morpholinylazo)phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 249 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:403870 CAPLUS
DOCUMENT NUMBER: 81:3870
ORIGINAL REFERENCE NO.: 81:630h, 631a
TITLE: Heterocyclic quinones. XXII. Synthesis and
antimicrobial action of substituted
2-phenylquinazolinequinones


AUTHOR(S): Karpova, N. B.; Tsizin, Yu. S.; Rudzit, E. A.;
 CORPORATE SOURCE: Radkevich, T. P.; Kulikova, D. A.; Luk'yanov, A. V.
 Inst. Med. Parazit. Trop. Med. im. Martsinovskogo,
 Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1974),
 8(2), 21-4
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB The quinazolinols I (R = Me₂N, PhNH, MeNH) were oxidized by O in MeOH
 containing copper acetate and R₁H (R₁ = morpholino, piperidino) to give the
 corresponding quinazolinediones II. Reduction of II (R = R₁ = piperidino) by
 Zn in refluxing Ac₂O-pyridine gave the diacetoxyquinazoline III. II (R =
 MeNH, R₁ = piperidino; R = R₁ = piperidino) possessed antibacterial
 activity at 0.19-25 µg/ml. Seven isomeric quinazolinediones IV (R =
 MeO, piperidino; R₁ = HO, MeO, BuNH, MeNH, piperidino, morpholino) were
 tested for antibacterial activity and IV (R = HO, R₁ = piperidino) was
 effective at ≥6.25 µg/ml.
 IT 34637-65-5 43182-42-9 43182-43-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation-amination of)
 RN 34637-65-5 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(phenylamino)- (CA INDEX NAME)



RN 43182-42-9 CAPLUS
 CN 6-Quinazolinol, 4-(methyamino)-2-phenyl- (CA INDEX NAME)




RN 43182-43-0 CAPLUS
 CN 6-Quinazolinol, 4-(dimethylamino)-2-phenyl- (CA INDEX NAME)



IT 52599-44-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 52599-44-7 CAPLUS

CN 5,6-Quinazolinediol, 2-phenyl-4,8-di-1-piperidinyl-, diacetate (ester)
(9CI) (CA INDEX NAME)



L7 ANSWER 250 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:120986 CAPLUS
DOCUMENT NUMBER: 80:120986
ORIGINAL REFERENCE NO.: 80:19479a,19482a
TITLE: 4-Aminoquinazolines
INVENTOR(S): Simpson, William Ronald J.
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 31 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2338669	A1	19740221	DE 1973-2338669	19730731 <--
US 3819628	A	19740625	US 1972-276794	19720731 <--
NL 7310392	A	19740204	NL 1973-10392	19730726 <--
BE 802996	A4	19740130	BE 1973-134043	19730730 <--
JP 49045083	A	19740427	JP 1973-85072	19730730 <--
FR 2194437	A2	19740301	FR 1973-27985	19730731 <--
PRIORITY APPLN. INFO.:			US 1972-276794	A 19720731
			BE 1970-746756	A 19700302

GI For diagram(s), see printed CA Issue.


AB Aminoquinazolines I (X = piperazino, NH(CH₂)₃, NH(CH₂)₃NHCH₂CH₂OR, R = H, NO₂) active against angina pectoris, were prepared Thus 2,3,4,5-H₂N(MeO)3C₆HCO₂Me, was converted to the amide, benzoylated, and the 2,3,4,5-BzNH(MeO)3C₆HCONH₂ cyclized to the quinazolinone II, which was chlorinated and treated with the amine to give I. The nitrate esters were prepared by esterifying the alcs. either before or after reaction with the chloroquinazoline.

IT 52515-83-0P 52515-84-1P 52515-85-2P
52515-86-3P 52515-87-4P 52515-88-5P
52625-31-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 52515-83-0 CAPLUS


CN 1-Piperazineethanol, 4-(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 52515-84-1 CAPLUS
 CN 1-Piperazineethanol, 4-(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 52515-85-2 CAPLUS
 CN 1-Piperazineethanol, 4-(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)-, nitrate (ester), dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 52515-86-3 CAPLUS
 CN 1-Pentanol, 5-[(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 52515-87-4 CAPLUS
 CN Ethanol, 2,2'-[[3-[(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)amino]propyl]imino]bis- (9CI) (CA INDEX NAME)




RN 52515-88-5 CAPLUS
 CN Ethanol, 2,2'-[[3-[(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)amino]propyl]imino]bis-, dinitrate (ester), dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 52625-31-7 CAPLUS
 CN 1-Pentanol, 5-[(6,7,8-trimethoxy-2-phenyl-4-quinazolinyl)amino]-, nitrate (ester), monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L7 ANSWER 251 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:27195 CAPLUS
 DOCUMENT NUMBER: 80:27195
 ORIGINAL REFERENCE NO.: 80:4485a,4488a
 TITLE: Heterocyclic quinones. XX. N-Substituted
 2-phenyl-4-aminoquinazolinequinones
 AUTHOR(S): Karpova, N. B.; Tsizin, Yu. S.
 CORPORATE SOURCE: Inst. Med. Parazitol. Trop. Med. im. Martsinovskogo,
 Moscow, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1973
), (10), 1403-8
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB Quinazolinequinones (I; R1 = NH2, BuNH, Me2N, morpholino, piperidino; NR2
 = piperidino, Me2N) were obtained in 65-79% yields by oxidation of
 quinazolinols II. Pyrimidophenazines III (R1 = NH2, piperidino; R =
 piperidino, OH) were obtained by condensation of the appropriate I with
 o-(NH2)2-C6H4. Base-catalyzed hydrolysis of I yielded 75-94% quinones IV
 (R1 = NH2, Me2N, piperidino). Addnl. prepared were furodiquinazoline V and
 VI.
 IT 34637-63-3 34637-64-4 41533-79-3
 43182-43-0 51127-81-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of)
 RN 34637-63-3 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 34637-64-4 CAPLUS
 CN 6-Quinazolinol, 4-(butylamino)-2-phenyl- (CA INDEX NAME)




RN 41533-79-3 CAPLUS
 CN 6-Quinazolinol, 4-amino-2-phenyl- (CA INDEX NAME)



RN 43182-43-0 CAPLUS
 CN 6-Quinazolinol, 4-(dimethylamino)-2-phenyl- (CA INDEX NAME)



RN 51127-81-2 CAPLUS
 CN 6-Quinazolinol, 4-(diethylamino)-2-phenyl- (CA INDEX NAME)




L7 ANSWER 252 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:14890 CAPLUS
 DOCUMENT NUMBER: 80:14890
 ORIGINAL REFERENCE NO.: 80:2501a,2504a
 TITLE: 1,6-Cyclization of (phenylimino)methylimino cumulenes.
 Formation of quinazoline derivatives
 AUTHOR(S): Augart, Karl D.; Kresze, Guenter; Schoenberger, Nobert
 CORPORATE SOURCE: Org.-Chem. Lab., Tech. Univ. Muenchen, Munich, Fed.
 Rep. Ger.
 SOURCE: Justus Liebig's Annalen der Chemie (1973), 9,
 1457-66
 CODEN: JLACBF; ISSN: 0075-4617
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 80:14890
 GI For diagram(s), see printed CA Issue.

AB Reaction of $RnC_6H_5-nN:CR_1-NH_2$ (I; $R_n = H, 4-Cl, 3-MeO$, or 3,4-benzo; $R_1 = Ph, NMe_2$, or SMe) with $4-MeC_6H_4SO_2N:CCl_2$ gave the quinazolines II. Reaction of I with CCl_3CHO followed by treatment with Ac_2O gave the quinazolines III ($R_3 = H$ or Ac) and IV.

IT 50871-62-0P 50871-63-1P 50871-64-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 50871-62-0 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)




RN 50871-63-1 CAPLUS

CN Benzenesulfonamide, N-(6-chloro-2-phenyl-4-quinazolinyl)-4-methyl- (CA INDEX NAME)




RN 50871-64-2 CAPLUS


CN Benzenesulfonamide, N-(7-methoxy-2-phenyl-4-quinazolinyl)-4-methyl- (CA INDEX NAME)




L7 ANSWER 253 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:492149 CAPLUS
 DOCUMENT NUMBER: 79:92149
 ORIGINAL REFERENCE NO.: 79:14967a,14970a
 TITLE: Synthesis and antimicrobial action of N-substituted 2-phenyl-4-amino-6-hydroxyquinazolines
 AUTHOR(S): Tsizin, Yu. S.; Karpova, N. B.; Luk'yanov, A. V.; Rudzit, E. A.; Kulikova, D. A.; Radkevich, T. P.
 CORPORATE SOURCE: Inst. Med. Parazitol. Trop. Med. im. Martsinovskogo, Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1973), 7(7), 16-19
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB Seventeen 2-phenyl-6-quinazolinols [I; R1 = PhNH, p-MeOC6H4NH, m-, p-ClC6H4NH, MeNH, Me2N, Me(CH2)11NH, piperidino, morpholino, 4-methyl-1-piperazinyl, NH2, H, OH, OMe; R2 = H, OH, OMe) were prepared by known methods and their bactericidal activity determined I (R1 = Me2N, R2 = OH) was effective against diphtheria, staphylococcus, and anthrax at 1.56-3.12 µg/ml while I (R1 = BuNH, R2 = OH) was effective against tuberculosis at 0.39-0.78 µg/ml.
 IT 34637-61-1 34637-62-2 34637-63-3
 34637-64-4 40288-70-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (bactericidal activity of)
 RN 34637-61-1 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N,2-diphenyl- (CA INDEX NAME)




RN 34637-62-2 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(1-piperidinyl)- (CA INDEX NAME)




RN 34637-63-3 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 34637-64-4 CAPLUS
 CN 6-Quinazolinol, 4-(butylamino)-2-phenyl- (CA INDEX NAME)




RN 40288-70-8 CAPLUS
 CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




IT 34637-65-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (bactericidal activity of)
 RN 34637-65-5 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(phenylamino)- (CA INDEX NAME)




IT 41533-79-3P 43182-41-8P 43182-42-9P
 43182-43-0P 43182-47-4P 43182-54-3P
 43182-55-4P 43182-56-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)
 RN 41533-79-3 CAPLUS
 CN 6-Quinazolinol, 4-amino-2-phenyl- (CA INDEX NAME)




RN 43182-41-8 CAPLUS
 CN 6-Quinazolinol, 4-[(4-methoxyphenyl)amino]-2-phenyl- (CA INDEX NAME)




RN 43182-42-9 CAPLUS
 CN 6-Quinazolinol, 4-(methylamino)-2-phenyl- (CA INDEX NAME)




RN 43182-43-0 CAPLUS
 CN 6-Quinazolinol, 4-(dimethylamino)-2-phenyl- (CA INDEX NAME)



RN 43182-47-4 CAPLUS
 CN 6-Quinazolinol, 4-(4-methyl-1-piperazinyl)-2-phenyl- (CA INDEX NAME)




RN 43182-54-3 CAPLUS
 CN 6-Quinazolinol, 4-[(4-chlorophenyl)amino]-2-phenyl-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 43182-55-4 CAPLUS
 CN 6-Quinazolinol, 4-[(3-chlorophenyl)amino]-2-phenyl-, monohydrochloride
 (9CI) (CA INDEX NAME)



● HCl

RN 43182-56-5 CAPLUS
 CN 6-Quinazolinol, 4-(dodecylamino)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L7 ANSWER 254 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:465472 CAPLUS
 DOCUMENT NUMBER: 79:65472
 ORIGINAL REFERENCE NO.: 79:10579a,10582a
 TITLE: Photostability and molecular structure
 AUTHOR(S): Otterstedt, Jan E. A.
 CORPORATE SOURCE: Res. Dev. Div., E. I. du Pont de Nemours and Co.,
 Inc., Wilmington, DE, USA
 SOURCE: Journal of Chemical Physics (1973), 58(12),
 5716-25
 CODEN: JCPSA6; ISSN: 0021-9606
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Photostability defined as the inverse of the quantum yield of a photochem. reaction, is assumed to be proportional to the rate of internal conversion. The rate of internal conversion is inversely proportional to the energy difference between the first excited state and the ground state. In intramolecularly H-bonded π systems, the photoexcited enol form rearranges itself to an excited keto form. SCF LCAO MO calcns. indicate that the energy difference between the first excited state and the ground state is smaller in the keto form than in the enol form. Expts. are reported in support of these theoretical considerations. Weak, strongly red-shifted fluorescence is observed at 77°K for several photostable quinazolines, pyrimidines, quinolines, pyrazines, benzotriazoles, and benzophenones with an o-hydroxyphenyl group ortho to a

ring N or a carbonyl group. For some compds. a moderately red-shifted fluorescence is observed as well. No phosphorescence is detected. None of the compounds fluoresce at room temperature When intramolecular H bonding is destroyed by, e.g., methylation, the compound shows phosphorescence and moderately red-shifted fluorescence. With data from the literature, the increase in photostability due to enol-keto tautomerism in the excited state is estimated The increase agrees with the exptl. results.

IT 25171-37-3
 RL: PRP (Properties)
 (photostability of, enol-ketone tautomerism in relation to)

RN 25171-37-3 CAPLUS

CN Phenol, 2-[4-(dimethylamino)-2-quinazolinyl]- (CA INDEX NAME)



L7 ANSWER 255 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:136213 CAPLUS

DOCUMENT NUMBER: 78:136213

ORIGINAL REFERENCE NO.: 78:21881a,21884a

TITLE: Conversion of indoles into quinazolines. New quinazoline synthesis

AUTHOR(S): Yoneda, Fumio; Higuchi, Masatsugu; Nonaka, Reiko

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan

SOURCE: Tetrahedron Letters (1973), (5), 359-60
 CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 78:136213

AB 3-Nitroso-2-phenylindole (I) with excess POCl3 or p-MeC6H4SO3H in sulfolane at 200° for 1 hr gave 90 or 68% 2-phenyl-4(3H)-quinazolinone, resp. The reaction proceeds by a second order Beckmann rearrangement of the imino oxime tautomer of I. I with excess POCl3 and PhNH2 or PhCH2NH2 gave 50 or 65%, resp., of 4-anilino- or 4-(benzylamino)-2-phenylquinazoline.

IT 40288-70-8P 40288-71-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 40288-70-8 CAPLUS

CN 4-Quinazolinamine, N,2-diphenyl- (CA INDEX NAME)




RN 40288-71-9 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-(phenylmethyl)- (CA INDEX NAME)



L7 ANSWER 256 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:124627 CAPLUS
 DOCUMENT NUMBER: 78:124627
 ORIGINAL REFERENCE NO.: 78:20027a,20030a
 TITLE: N-Substituted 2-phenyl-4,8-diaminoquinazoline5,6-quinones
 INVENTOR(S): Tsizin, Yu. S.; Karpova, N. B.; Luk'yanov, A. V.; Rudzit, E. A.
 PATENT ASSIGNEE(S): Ordzhonikidze, S., All-Union Scientific-Research Chemical-Pharmaceutical Institute
 SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1972, 49(32), 186.
 CODEN: URXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	SU 330745		19721023	SU	19700722 <--
AB	2-Phenyl-4-chloro-6-acetoxyquinazoline or an N-substituted 2-phenyl-4-amino-6-hydroxyquinazoline was oxidized with O in the presence of Cu acetate and a secondary amine in an organic-solvent medium, e.g. MeOH, to give the title compds.				
IT	41533-79-3D, 6-Quinazolinol, 4-amino-2-phenyl-, N-substituted derivs.				
	RL: RCT (Reactant); RACT (Reactant or reagent) (oxidation and amination of)				
RN	41533-79-3 CAPLUS				
CN	6-Quinazolinol, 4-amino-2-phenyl- (CA INDEX NAME)				



L7 ANSWER 257 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:72195 CAPLUS
 DOCUMENT NUMBER: 78:72195
 ORIGINAL REFERENCE NO.: 78:11481a,11484a
 TITLE: 4-Amino-2-(5-nitro-2-thienyl)quinazolines and their intermediate 4-chloro-2-(5-nitro-2-thienyl)quinazolines
 INVENTOR(S): Alaimo, Robert J.
 PATENT ASSIGNEE(S): Morton-Norwich Products, Inc.

SOURCE: U.S., 3 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3705898	A	19721212	US 1970-5924	19700126 <--
ZA 7008715	A	19720830	ZA 1970-8715	19701229 <--
IL 35942	A	19730829	IL 1970-35942	19701231 <--
SE 373369	B	19750203	SE 1971-544	19710118 <--
CA 955942	A1	19741008	CA 1971-103218	19710120 <--
BE 761872	A1	19710722	BE 1971-98839	19710121 <--
NL 7100953	A	19710728	NL 1971-953	19710125 <--
DE 2103286	A	19710805	DE 1971-2103286	19710125 <--
FR 2081456	A5	19711203	FR 1971-2362	19710125 <--
FR 2081456	A1	19711203		
DK 124134	B	19720918	DK 1971-299	19710125 <--
CH 555855	A	19741115	CH 1971-1126	19710126 <--
GB 1292417	A	19721011	GB 1971-1292417	19710419 <--
GB 1292418	A	19721011	GB 1971-1292418	19710419 <--
DK 126789	B	19730820	DK 1972-1425	19720324 <--
			US 1970-5924	A 19700126

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.


AB 5-Nitro-2-thiophenecarboxaldehyde in EtOH containing HCl reacted with o-H₂NC₆H₄CONH₂ to give 1,2-dihydro-2-(5-nitro-2-thienyl)quinazolin-4(3H)-one, which was refluxed with p-benzoquinone and DMF in EtOH to yield the 1,2-didehydro derivative (I). Treatment of I with POCl₃ and PCl₅ gave 4-chloro-2-(5-nitro-2-thienyl)quinazoline, which reacted with HO(CH₂)₂NH₂ in DMF to give 83% 4-(2-hydroxyethylamino)-2-(5-nitro-2-thienyl)quinazoline (II; R = H, R₁ = CH₂CH₂OH). Analogously, 11 other II, e.g. R, R₁ = Et, (CH₂)₄OH, CH₂CH(OH)CH₂OH, (CH₂)₃OH; RR₁N = piperazino, were prepared

IT 33372-36-0P 33372-37-1P 33372-38-2P
 33372-39-3P 33372-40-6P 33372-41-7P
 33372-42-8P 33372-43-9P 33372-44-0P
 33372-45-1P 33372-46-2P 33372-49-5P
 33372-50-8P 33389-36-5P 33389-37-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 33372-36-0 CAPLUS

CN 1-Butanol, 4-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-37-1 CAPLUS

CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-thienyl)- (CA INDEX NAME)



RN 33372-38-2 CAPLUS


CN 1-Piperazineethanol, 4-[2-(5-nitro-2-thienyl)-4-quinazolinyl]-, dihydrochloride (8CI, 9CI) (CA INDEX NAME)



● 2 HCl


RN 33372-39-3 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-40-6 CAPLUS


CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-41-7 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(5-nitro-2-thienyl)-, (2-hydroxyethyl)hydrazone
 (9CI) (CA INDEX NAME)




RN 33372-42-8 CAPLUS
 CN Ethanol, 2-[2-[3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]propoxy]ethoxy]-
 xy]- (CA INDEX NAME)




RN 33372-43-9 CAPLUS
 CN 2-Propanol, 1,1'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA
 INDEX NAME)




RN 33372-44-0 CAPLUS
 CN 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-
 quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-45-1 CAPLUS
 CN Ethanol, 2-[butyl[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-46-2 CAPLUS
 CN 1-Propanol, 3-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-49-5 CAPLUS
 CN 1,2-Propanediol, 3-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-50-8 CAPLUS
 CN Ethanol, 2,2'-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)



RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33389-37-6 CAPLUS
 CN Ethanol, 2-[ethyl[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




L7 ANSWER 258 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:72180 CAPLUS
 DOCUMENT NUMBER: 78:72180
 ORIGINAL REFERENCE NO.: 78:11481a,11484a
 TITLE: Pyrimidine derivatives
 PATENT ASSIGNEE(S): N. V. Koninklijke Pharmaceutische Fabrieken Voorheen
 Brocades-Stheeman & Pharmacia
 SOURCE: Neth. Appl., 19 pp.
 CODEN: NAXXAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Dutch
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 7206067	A	19721109	NL 1972-6067	19720505 <--
JP 56001315	B	19810113	JP 1972-44512	19720504 <--
NO 139270	C	19790131	NO 1972-1600	19720505 <--
NO 139270	B	19781023		
SE 406197	C	19790510	SE 1972-5960	19720505 <--
SE 406197	B	19790129		
PRIORITY APPLN. INFO.:			GB 1971-13802	A 19710507

GI For diagram(s), see printed CA Issue.
 AB Aminoquinazolines (I, R = NMe₂, NEt₂, pyrrolidino, 2-furyl, 2-pyridyl, 1-methyl-2-pyrrolyl, 4-(2-furoyl)-1-piperazinyl; R₁ = R₂ = H, OMe; R₁ = Cl, R₂ = H) were prepared by treating the corresponding o-aminobenzonitrile with RCN and PhLi. Thus, reaction of o-H₂NC₆H₄CN with Et₂NCN and PhLi gave I (R = NEt₂, R₁ = R₂ = H).
 IT 40172-82-5P 40172-83-6P 40172-84-7P
 40172-85-8P 40172-86-9P 40172-87-0P
 40172-88-1P 40172-89-2P 40172-98-3P
 40172-99-4P 40173-00-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 40172-82-5 CAPLUS
 CN 4-Quinazolinamine, 2-(2-pyridinyl)- (CA INDEX NAME)




RN 40172-83-6 CAPLUS
 CN 4-Quinazolinamine, 2-(3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 40172-84-7 CAPLUS
 CN 4-Quinazolinamine, 6-chloro-2-(2-pyridinyl)- (CA INDEX NAME)



RN 40172-85-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)- (CA INDEX NAME)




RN 40172-86-9 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 40172-87-0 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-pyridinyl)- (CA INDEX NAME)




RN 40172-88-1 CAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 40172-89-2 CAPLUS
 CN 4-Quinazolinamine, 2-(1-methyl-1H-pyrrol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 40172-98-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 40172-99-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 40173-00-0 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L7 ANSWER 259 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1972:475186 CAPLUS
 DOCUMENT NUMBER: 77:75186
 ORIGINAL REFERENCE NO.: 77:12423a,12426a
 TITLE: Condensation of some aldehydes with
 O-benzoyl-o-aminobenzamidoxime
 AUTHOR(S): Goncalves, Huguet; Bon, Maryse; Barrans, Jean;
 Foulcher, Christian
 CORPORATE SOURCE: Lab. Chim. Phys. II, Univ. Paul Sabatier, Toulouse,
 Fr.
 SOURCE: Comptes Rendus des Seances de l'Academie des Sciences,
 Serie C: Sciences Chimiques (1972),
 274(21), 1750-2
 CODEN: CHDCAQ; ISSN: 0567-6541
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI For diagram(s), see printed CA Issue.
 AB Tetrahydroquinazolines (I) and quinazolines (II) were prepared by reaction
 of o-H₂NC₆H₄C(:NOBz)NH₂ with RCHO. I was also prepared by reaction of its
 oxime analog with Bz₂O. Six I (R = Et, Pr, Bu, Ph, C₆H₄Cl-p or -o) and 2
 II (R = CHMe₂, C₆H₄NO₂-p) were prepared
 IT 37471-18-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 37471-18-4 CAPLUS
 CN 4-Quinazolinamine, 2-(4-nitrophenyl)- (CA INDEX NAME)



L7 ANSWER 260 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1972:107933 CAPLUS
 DOCUMENT NUMBER: 76:107933
 ORIGINAL REFERENCE NO.: 76:17356h,17357a
 TITLE: Anthelmintic 2-(5-nitro-2-thienyl)-4-(substituted
 amino)quinazolines
 AUTHOR(S): Alaimo, Robert J.; Hatton, Christopher J.
 CORPORATE SOURCE: Res. Dev. Dep., Norwich Pharm. Co., Norwich, NY, USA
 SOURCE: Journal of Medicinal Chemistry (1972),
 15(1), 108-9
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Of 19 anthelmintic 2-(5-nitro-2-thienyl)-4-(substituted amino)quinazolines (I), synthesized by displacement of the activated Cl atom in 4-chloro-2-(5-nitro-2-thienyl)quinazolines by various amines, 4-[(2-hydroxyethyl)amino]-2-(5-nitro-2-thienyl)quinazoline [33389-36-5] (I, R=R1=H, R2 = CH2CH2OH) exhibited the strongest activity against the helminthic parasites *Ascaris suum* and *Syphacia obvelata* and against the tapeworm *Hymenolepis nana* in mice. The chloroquinazolines were synthesized from 5-nitro-2-thiophenecarboxaldehyde and anthranilamides, affording dihydroquinazolinones which were oxidized with p-benzoquinone and chlorinated with PCl5 in POC13.

IT 33372-36-0 33372-37-1 33372-38-2
33372-39-3 33372-40-6 33372-42-8
33372-43-9 33372-44-0 33372-46-2
33372-49-5 33372-50-8 33389-36-5
33389-37-6 35771-24-5 35771-25-6
35771-26-7 35787-59-8 35787-63-4
35787-64-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(anthelmintic activity of)


RN 33372-36-0 CAPLUS

CN 1-Butanol, 4-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-37-1 CAPLUS

CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-thienyl)- (CA INDEX NAME)




RN 33372-38-2 CAPLUS

CN 1-Piperazineethanol, 4-[2-(5-nitro-2-thienyl)-4-quinazolinyl]-, dihydrochloride (8CI, 9CI) (CA INDEX NAME)




● 2 HCl


RN 33372-39-3 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)



RN 33372-40-6 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-42-8 CAPLUS
 CN Ethanol, 2-[2-[3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]propoxy]ethoxy]- (CA INDEX NAME)




RN 33372-43-9 CAPLUS
 CN 2-Propanol, 1,1'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)

INDEX NAME)




RN 33372-44-0 CAPLUS

CN 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-46-2 CAPLUS

CN 1-Propanol, 3-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-49-5 CAPLUS

CN 1,2-Propanediol, 3-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-50-8 CAPLUS


CN Ethanol, 2,2'-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33389-37-6 CAPLUS
 CN Ethanol, 2-[ethyl[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 35771-24-5 CAPLUS
 CN 2-Propanol, 1-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 35771-25-6 CAPLUS
 CN 1-Propanol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 35771-26-7 CAPLUS

CN 2-Butanol, 4-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 35787-59-8 CAPLUS

CN Quinazoline, 4-(1-methylhydrazino)-2-(5-nitro-2-thienyl)- (9CI) (CA INDEX NAME)




RN 35787-63-4 CAPLUS

CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]propylamino]- (CA INDEX NAME)




RN 35787-64-5 CAPLUS


CN Ethanol, 2-[1-[2-(5-nitro-2-thienyl)-4-quinazolinyl]hydrazino]- (9CI) (CA INDEX NAME)




L7 ANSWER 261 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1972:14467 CAPLUS
 DOCUMENT NUMBER: 76:14467
 ORIGINAL REFERENCE NO.: 76:2363a,2366a
 TITLE: Synthesis of substituted 2-phenyl-6-hydroxyquinazolines
 AUTHOR(S): Tsizin, Yu. S.; Karpova, N. B.; Efimova, O. V.
 CORPORATE SOURCE: Inst. Med. Parazitol. Trop. Med. im. Martsinovskogo, Moscow, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1971), 7(3), 418-20
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB 2-Phenyl-6-methoxyquinazolin-4-one (I) was obtained by condensation of benzoyl-p-anisidine with Et urethane. Demethylation of I gave II. II was acetylated and treated with SOCl₂ to form (III, R = OAc, R₁ = Cl) which, heated with alc. primary and secondary amines gave III (R = OH; R₁ = NEt₂, morpholino, BuNH, and PhNH.
 IT 27228-26-8P 27414-19-3P 34637-57-5P
 34637-60-0P 34637-61-1P 34637-62-2P
 34637-63-3P 34637-64-4P 34637-65-5P
 34637-67-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 27228-26-8 CAPLUS
 CN Quinazoline, 6-methoxy-2-phenyl-4-(1-piperidinyl)- (CA INDEX NAME)



RN 27414-19-3 CAPLUS
 CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 34637-57-5 CAPLUS
 CN Benzenesulfonic acid, 4-methyl-, 2-(6-methoxy-2-phenyl-4-quinazolinyl)hydrazide, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 34637-60-0 CAPLUS
 CN 4-Quinazolinamine, N-butyl-6-methoxy-2-phenyl- (CA INDEX NAME)




RN 34637-61-1 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N,2-diphenyl- (CA INDEX NAME)




RN 34637-62-2 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(1-piperidinyl)- (CA INDEX NAME)




RN 34637-63-3 CAPLUS
 CN 6-Quinazolinol, 4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




RN 34637-64-4 CAPLUS
 CN 6-Quinazolinol, 4-(butylamino)-2-phenyl- (CA INDEX NAME)



RN 34637-65-5 CAPLUS
 CN 6-Quinazolinol, 2-phenyl-4-(phenylamino)- (CA INDEX NAME)



RN 34637-67-7 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, 2-[6-(acetyloxy)-2-phenyl-4-quinazolinyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L7 ANSWER 262 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:14466 CAPLUS

DOCUMENT NUMBER: 76:14466

ORIGINAL REFERENCE NO.: 76:2363a,2366a

TITLE: Synthesis of substituted quinazolines. II. Use of diethyl oxalate in quinazoline synthesis

AUTHOR(S): George, T.; Tahilramani, R.; Mehta, D. V.

CORPORATE SOURCE: CIBA Res. Cent., Goregaon, India

SOURCE: Indian Journal of Chemistry (1971), 9(10), 1077-80

CODEN: IJOCAP; ISSN: 0019-5103

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Starting from 2-carbethoxy-4-quinazolinone the corresponding hydrazide was prepared and reacted with aromatic acid chlorides to give the aroyl hydrazides. Cyclization of the latter, using POCl₃ gives 2-[2-aryl(1,3,4-oxadiazolyl)]-4-chloroquinazoline. 2-(Hydroxymethyl)-4-quinazolinone, synthesized by reacting anthranilamide with Et glycolate, was used for the synthesis of 2,4-substituted quinazolines. 2-Carbethoxy-3-methyl-4-quinazolinone was also synthesized by the reaction of N-methylantranilamide with di-Et oxalate, and a few derivs. prepared Reaction of N-(β-hydroxyethyl)antranilamide with di-Et oxalate gives the tricyclic compound 3,4-dihydro-1H,6H-1,4-oxazino[3,4-b]quinazoline-1,6-dione which on reaction with amines affords 4-quinazolinone derivs.

IT 34632-77-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 34632-77-4 CAPLUS

CN 4(1H)-Quinazolinone, 2-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-, dimethylhydrazone (9CI) (CA INDEX NAME)




L7 ANSWER 263 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:551829 CAPLUS
 DOCUMENT NUMBER: 75:151829
 ORIGINAL REFERENCE NO.: 75:23949a,23952a
 TITLE: Diuretic 4-aminoquinazolines.
 INVENTOR(S): Robba, Max F.; Marcy, Rene H. P.; Duval, Denise J. C.
 PATENT ASSIGNEE(S): Innothera
 SOURCE: Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2106510	A	19710826	DE 1971-2106510	19710211 <--
FR 2077803	A5	19711105	FR 1970-5371	19700216 <--
FR 2077803	B1	19730316		
US 3772295	A	19731113	US 1971-115797	19710216 <--
JP 50010866	B	19750424	JP 1971-6550	19710216 <--
GB 1298313	A	19721129	GB 1971-1298313	19710419 <--
			FR 1970-5371	A 19700216

PRIORITY APPLN. INFO.:


GI For diagram(s), see printed CA Issue.
 AB 4-Aminoquinazolines (I), useful as natriuretic and chlorouretic agents, were prepared from 4-quinazolones by reaction with POCl₃ to give I (R₁=Cl) and reaction with amines. Thus, 4-quinazolinone was refluxed with POCl₃ and PCl₅ 4 hr to give 72% I (R=R₂=H, R₁=Cl), which was refluxed with m-F₃CC₆H₄NH₂ in absolute EtOH 3 hr to give, after reaction with HO₂CCO₂H, 4-[m-(trifluoromethyl)anilino] quinazoline oxalate [I oxalate (R=R₂=H, R₁=m-F₃CC₆H₄NH)]. Similarly prepared were 12 addnl. I. The toxicity of I was tested in mice, e.g. 600 or 900 mg/kg 4-(furfurylamino)-2-(α-thienyl)quinazoline (II) killed 33 or 100% mice, resp., 5 days after i.p. administration. The diuretic activity of I was tested in rats, e.g. 100 mg II/kg increased the urine volume 5.5 fold with respect to that of untreated rats.
 IT 34116-17-1P 34116-18-2P 34116-19-3P
 34116-20-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 34116-17-1 CAPLUS
 CN Quinazoline, 7-chloro-4-[(tetrahydrofurfuryl)amino]-2-(2-thienyl)- (8CI)
 (CA INDEX NAME)




RN 34116-18-2 CAPLUS
 CN Quinazoline, 7-chloro-4-(furfurylamino)-2-(2-thienyl)- (8CI) (CA INDEX NAME)



RN 34116-19-3 CAPLUS
 CN Quinazoline, 4-(furfurylamino)-2-(2-thienyl)- (8CI) (CA INDEX NAME)



RN 34116-20-6 CAPLUS
 CN Quinazoline, 4-[(tetrahydrofurfuryl)amino]-2-(2-thienyl)- (8CI) (CA INDEX NAME)



L7 ANSWER 264 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:498586 CAPLUS
 DOCUMENT NUMBER: 75:98586
 ORIGINAL REFERENCE NO.: 75:15589a,15592a
 TITLE: Microbicidal 2-(5-nitro-2-thienyl)-4-aminoquinazolines
 INVENTOR(S): Alaimo, Robert J.
 PATENT ASSIGNEE(S): Norwich Pharmacal Co.
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2103286	A	19710805	DE 1971-2103286	19710125 <--
US 3705898	A	19721212	US 1970-5924	19700126 <--
PRIORITY APPLN. INFO.:			US 1970-5924	A 19700126

GI For diagram(s), see printed CA Issue.

AB Title compds. (I), especially useful as anthelmintics, were prepared by reaction


of 4-chloro-2-(5-nitro-2-thienyl)quinazolines with amines. Thus, 5-nitro-2-thiophenecarboxaldehyde was refluxed in EtOH and HCl with o-H₂NC₆H₄CONH₂ 1 hr to give 82.5% 1,2-dihydro-2-(5-nitro-2-thienyl)-4(3H)-quinazolinone, which was refluxed in EtOH, DMF, and p-benzoquinone 6 hr to give 66% 2-(5-nitro-2-thienyl)-4(3H)-quinazolinone (II). II was refluxed with POCl₃ and PCl₅ to give 89.0% 4-chloro-2-(5-nitro-2-thienyl)quinazoline, which reacted with HOCH₂CH₂NH₂ in DMF 5.5 hr at 100° to give 83% I (R = CH₂CH₂OH, R₁ = R₂ = H). Similarly prepared were 14 addnl. I, e.g. (R-R₂ given): NHCH₂CH₂OH, H, H; 3-morpholinopropyl, H, H; CH₂CHMeOH, CH₂CHMeOH, H; CH₂CH(OH)CH₂OH, H, Cl.

IT 33372-36-0P 33372-37-1P 33372-38-2P
 33372-39-3P 33372-40-6P 33372-41-7P
 33372-42-8P 33372-43-9P 33372-44-0P
 33372-45-1P 33372-46-2P 33372-49-5P
 33372-50-8P 33389-36-5P 33389-37-6P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 33372-36-0 CAPLUS


CN 1-Butanol, 4-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 33372-37-1 CAPLUS
 CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-thienyl)- (CA INDEX NAME)




RN 33372-38-2 CAPLUS
 CN 1-Piperazineethanol, 4-[2-(5-nitro-2-thienyl)-4-quinazolinyl]-, dihydrochloride (8CI, 9CI) (CA INDEX NAME)




● 2 HCl


RN 33372-39-3 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-40-6 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-41-7 CAPLUS
 CN 4(1H)-Quinazolinone, 2-(5-nitro-2-thienyl)-, (2-hydroxyethyl)hydrazone (9CI) (CA INDEX NAME)



RN 33372-42-8 CAPLUS
 CN Ethanol, 2-[2-[3-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]propoxy]ethoxy]- (CA INDEX NAME)




RN 33372-43-9 CAPLUS
 CN 2-Propanol, 1,1'-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)




RN 33372-44-0 CAPLUS

CN 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-45-1 CAPLUS

CN Ethanol, 2-[butyl[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-46-2 CAPLUS

CN 1-Propanol, 3-[(2-hydroxyethyl)[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-49-5 CAPLUS


CN 1,2-Propanediol, 3-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 33372-50-8 CAPLUS
 CN Ethanol, 2,2'-[[6-chloro-2-(5-nitro-2-thienyl)-4-quinazolinyl]imino]bis-
 (CA INDEX NAME)



RN 33389-36-5 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 33389-37-6 CAPLUS
 CN Ethanol, 2-[ethyl[2-(5-nitro-2-thienyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



L7 ANSWER 265 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:434814 CAPLUS
 DOCUMENT NUMBER: 75:34814
 ORIGINAL REFERENCE NO.: 75:5501a,5504a
 TITLE: Rearrangement of 3-amino-1-benzylindazole to
 4-amino-2-phenylquinazoline
 AUTHOR(S): Finch, Neville; Gschwend, Heinz W.
 CORPORATE SOURCE: Res. Dep., CIBA Pharm. Co., Summit, NJ, USA
 SOURCE: Journal of Organic Chemistry (1971), 36(11),
 1463-5

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Attempts to prepare 3-amino-1-benzylindazole by cyclization of o-(1-benzylhydrazino)-benzonitrile yielded instead a rearranged and oxidized product 4-amino-2-phenylquinazoline. A mechanism for this transformation is proposed. The intermediates postulated were synthesized and subjected to rearrangement conditions. Some comments are made about the chemistry of dihydroquinazolines.

IT 1022-44-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



L7 ANSWER 266 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:100610 CAPLUS

DOCUMENT NUMBER: 74:100610

ORIGINAL REFERENCE NO.: 74:16391a,16394a

TITLE: Substituted 4-aminoquinazolines, for coloring plastics

PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.

SOURCE: Fr. Demande, 9 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2016729		19700508	FR 1969-29650	19690829 <--
DE 1795271			DE	
GB 1228536			GB	
US 3689489		19720905	US	19690813 <--
PRIORITY APPLN. INFO.:			DE	19680831

GI For diagram(s), see printed CA Issue.


AB The title compds. (I, R = NH₂, H, or Ph; R₁ = NO₂ or CN; R₂ = NO₂ or H), yellow to red colorants for plastics, were prepared by heating 2,3,5-X(R₁)(R₂)C₆H₂CN (X = MeO or Cl) with RC(NH₂):NH in MeOH at 60° or in DMF at 130°. Thus, 2,3,5-MeO(O₂N)₂-C₆H₂CN and (H₂N)₂C:NH gave 90% I (R = NH₂, R₁ = R₂ = NO₂). Similarly, 3 other I were prepared

IT 31910-84-6P


RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 31910-84-6 CAPLUS


CN Quinazoline, 4-amino-6,8-dinitro-2-phenyl- (8CI) (CA INDEX NAME)




L7 ANSWER 267 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:53704 CAPLUS
 DOCUMENT NUMBER: 74:53704
 ORIGINAL REFERENCE NO.: 74:8657a,8660a
 TITLE: Cyclic amidines. XXII. Novel isomerism of disubstituted tricycloquinazolines and molecular orientations in carcinogenesis
 AUTHOR(S): Partridge, Maurice W.; Brunswick, D. J.; Vipond, H. J.
 CORPORATE SOURCE: Univ. Nottingham, Nottingham, UK
 SOURCE: Journal of the Chemical Society [Section] C: Organic (1970), (19), 2641-7
 CODEN: JSOOAX; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB Certain disubstituted tricycloquinazolines, such as I and II, exhibit an unusual structural isomerism originating from the modification of the symmetry of tricycloquinazoline by substitution. Mol. orientations specific for carcinogenesis, consistent with differences in the carcinogenic activities of such isomers and other 2-substituted tri-cycloquinazolines were deduced.
 IT 30380-10-0P 30380-11-1P 30380-12-2P
 30380-13-3P 30380-14-4P 30380-15-5P
 30380-16-6P 30380-17-7P 30380-18-8P
 30380-19-9P 30380-20-2P 30380-21-3P
 30380-22-4P 30380-23-5P 30380-24-6P
 30380-25-7P 30380-26-8P 30391-21-0P
 30391-22-1P 30391-23-2P 30391-24-3P
 30391-25-4P 30391-26-5P 30391-27-6P
 30391-28-7P 30391-29-8P 30391-30-1P
 30391-31-2P 30391-32-3P 30391-33-4P
 30391-34-5P 30391-35-6P 30391-36-7P
 30391-37-8P 30391-38-9P 30391-39-0P
 30391-40-3P 30391-41-4P 30391-42-5P
 30391-43-6P 30391-44-7P 30391-45-8P
 30563-96-3P 30563-97-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 30380-10-0 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-ethyl-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30380-11-1 CAPLUS
 CN m-Toluic acid, 6-[[2-(o-aminophenyl)-6-methyl-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-12-2 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-bromo-4-quinazolinyl]-5-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-13-3 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-6-bromo-4-quinazolinyl]-4-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-14-4 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-6-bromo-4-quinazolinyl]-5-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-15-5 CAPLUS
 CN p-Toluic acid, 2-[[2-(o-aminophenyl)-7-bromo-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-16-6 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-methyl-4-quinazolinyl]-4-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-17-7 CAPLUS
 CN m-Toluic acid, 6-[[2-(o-aminophenyl)-7-bromo-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




RN 30380-18-8 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-methyl-4-quinazolinyl]-5-bromo-, methyl ester (8CI) (CA INDEX NAME)




RN 30380-19-9 CAPLUS
 CN p-Toluic acid, 2-[[2-(o-aminophenyl)-6-bromo-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




RN 30380-20-2 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-6-methyl-4-quinazolinyl]-4-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-21-3 CAPLUS
 CN m-Toluic acid, 6-[[2-(o-aminophenyl)-6-bromo-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-22-4 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-6-methyl-4-quinazolinyl]-5-bromo-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-23-5 CAPLUS
 CN p-Toluic acid, 2-[[2-(o-aminophenyl)-7-fluoro-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)



RN 30380-24-6 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-methyl-4-quinazolinyl]-4-fluoro-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-25-7 CAPLUS
 CN m-Toluic acid, 6-[[2-(o-aminophenyl)-6-fluoro-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30380-26-8 CAPLUS

CN Anthranilic acid, N-[2-(o-aminophenyl)-6-methyl-4-quinazolinyl]-5-fluoro-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-21-0 CAPLUS

CN Anthranilic acid, 4-chloro-N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-22-1 CAPLUS

CN Anthranilic acid, 4-bromo-N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-23-2 CAPLUS

CN Anthranilic acid, N-[2-(o-nitrophenyl)-7-(trifluoromethyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-24-3 CAPLUS

CN Anthranilic acid, N-[7-ethyl-2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-25-4 CAPLUS


CN Anthranilic acid, 3,5-dimethyl-N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-26-5 CAPLUS
 CN p-Toluic acid, 2-[[6-methyl-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-27-6 CAPLUS
 CN m-Toluic acid, 6-[[6-methyl-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-28-7 CAPLUS
 CN Anthranilic acid, 5-bromo-N-[7-bromo-2-(o-nitrophenyl)-4-quinazolinyl]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-29-8 CAPLUS
 CN Anthranilic acid, 4-bromo-N-[6-bromo-2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-30-1 CAPLUS
 CN Anthranilic acid, 5-bromo-N-[6-bromo-2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-31-2 CAPLUS
 CN p-Toluic acid, 2-[[7-bromo-2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-32-3 CAPLUS
 CN Anthranilic acid, 4-bromo-N-[7-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-33-4 CAPLUS
 CN m-Toluic acid, 6-[[7-bromo-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-34-5 CAPLUS
 CN Anthranilic acid, 5-bromo-N-[7-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-35-6 CAPLUS
 CN p-Toluic acid, 2-[[6-bromo-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)



RN 30391-36-7 CAPLUS
 CN Anthranilic acid, 4-bromo-N-[6-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-37-8 CAPLUS
 CN m-Toluic acid, 6-[[6-bromo-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-38-9 CAPLUS

CN Anthranilic acid, 5-bromo-N-[6-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-39-0 CAPLUS

CN p-Toluic acid, 2-[[7-fluoro-2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-40-3 CAPLUS


CN Anthranilic acid, 4-fluoro-N-[7-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-41-4 CAPLUS
 CN m-Toluic acid, 6-[[6-fluoro-2-(o-nitrophenyl)-4-quinazolinyl]amino]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-42-5 CAPLUS
 CN Anthranilic acid, 5-fluoro-N-[6-methyl-2-(o-nitrophenyl)-4-quinazolinyl]-,
 methyl ester (8CI) (CA INDEX NAME)




RN 30391-43-6 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-4-chloro-, methyl
 ester (8CI) (CA INDEX NAME)




RN 30391-44-7 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-4-bromo-, methyl ester (8CI) (CA INDEX NAME)




RN 30391-45-8 CAPLUS
 CN Anthranilic acid, N-[2-(o-aminophenyl)-7-(trifluoromethyl)-4-quinazolinyl]-, methyl ester (8CI) (CA INDEX NAME)



RN 30563-96-3 CAPLUS
 CN m-Toluic acid, 6-[[7-methyl-2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)



RN 30563-97-4 CAPLUS
 CN m-Toluic acid, 6-[[2-(o-aminophenyl)-7-methyl-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)



L7 ANSWER 268 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:31687 CAPLUS
 DOCUMENT NUMBER: 74:31687
 ORIGINAL REFERENCE NO.: 74:5093a,5096a
 TITLE: 7-Amino-5-imino-8(5H)-quinolones, 6-amino-8-imino-5(8H)-quinolones, and 7-alkyl-4,6-dihydroxy-5,8-quinolinediones as potential antiprotozoal agents
 AUTHOR(S): Bullock, Frank J.; Tweedie, John F.
 CORPORATE SOURCE: Arthur D. Little, Inc., Cambridge, MA, USA
 SOURCE: Journal of Heterocyclic Chemistry (1970), 7(5), 1125-30
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Oxidation of 7-amino-8-hydroxyquinoline-5-sulfonic acid with silver oxide in DMF and in the presence of aryl amines provided a series of 7-amino-5-arylimino-8(5H)-quinolones. Reaction of 8-dialkylamino-5,6-quinolinediones with triethyloxonium tetrafluoroborate gave a series of unstable but synthetically useful enolethers. These reacted with amines to give 6-amino-8-imino-5(8H)-quinolones, isolated and characterized as tetrafluoroborate salts. PMR studies showed these to be vinylogous amidinium salts, analogous to those previously obtained with 2-amino-1,4-naphthoquinone imines. 4,6-Dihydroxy-5,8-quinolinedione


underwent free radical alkylation to give a 7-alkyl-4,6-dihydroxy-5,8-quinolinedione. Evaluation of the new compds. against various Plasmodium species in rodents, birds, and mosquitoes revealed no significant antimalarial activity.

IT 17254-14-7P 25171-37-3P 25171-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17254-14-7 CAPLUS

CN Phenol, o-(4-amino-2-quinazolinyl)- (8CI) (CA INDEX NAME)




RN 25171-37-3 CAPLUS

CN Phenol, 2-[4-(dimethylamino)-2-quinazolinyl]- (CA INDEX NAME)



RN 25171-40-8 CAPLUS

CN Acetamide, N-[2-(o-hydroxyphenyl)-4-quinazolinyl]- (8CI) (CA INDEX NAME)



L7 ANSWER 269 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:12455 CAPLUS

DOCUMENT NUMBER: 74:12455

ORIGINAL REFERENCE NO.: 74:2009a,2012a

TITLE: Photostable o-hydroxyphenylquinazolines

AUTHOR(S): Pater, Richard

CORPORATE SOURCE: Org. Chem. Dep., E. I. du Pont de Nemours and Co.,
Wilmington, DE, USA

SOURCE: Journal of Heterocyclic Chemistry (1970),
7(5), 1113-24

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The correlation between intrinsic photostability and the structure of several intramol. H-bonded heterocycles containing suitable o-hydroxyphenyl groups is discussed in terms of the changes in resonance energy resulting from a reversible keto-enol rearrangement in the lowest excited singlet state in such compds. The influence of intramol. H bonding, resonance and steric effects on photostability in o-hydroxyphenylquinazolines as elucidated with the aid of spectroscopic methods is discussed.

IT 25171-37-3

RL: PRP (Properties)
(photostability of)

RN 25171-37-3 CAPLUS

CN Phenol, 2-[4-(dimethylamino)-2-quinazolinyl]- (CA INDEX NAME)




IT 17254-14-7P 25171-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17254-14-7 CAPLUS

CN Phenol, o-(4-amino-2-quinazolinyl)- (8CI) (CA INDEX NAME)



RN 25171-40-8 CAPLUS

CN Acetamide, N-[2-(o-hydroxyphenyl)-4-quinazolinyl]- (8CI) (CA INDEX NAME)



L7 ANSWER 270 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1970:530965 CAPLUS

DOCUMENT NUMBER: 73:130965


ORIGINAL REFERENCE NO.: 73:21344h,21345a

TITLE: Acetylation of o-aminobenzamidoxime

AUTHOR(S): Goncalves, Huguette; Mathis, Ferdinand; Foulcher, Christian
 CORPORATE SOURCE: Lab. Chim. Phys. II, Fac. Sci., Toulouse, Fr.
 SOURCE: Bulletin de la Societe Chimique de France (1970), (7), 2599-614
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 OTHER SOURCE(S): CASREACT 73:130965
 GI For diagram(s), see printed CA Issue.
 AB The diformyl, diacetyl, dibenzoyl, and O-benzoyl derivs. of o-aminobenzamidoxime (I) were prepared and deacylated to give 1,2,4-oxadiazoles or quinazoline 3-oxides. For example, the dibenzoyl and diacetyl derivs., prepared by treating I with BzCl and Ac2O, resp., were heated at their m. ps. to give II (R1 = Ph, Me; R2 = Ac, Bz) but hot evaporation of a MeOH solution of the diformyl derivative of I gave III. The structures of the oxadiazoles and quinazolines were proven chemical and spectrographically (ir and NMR spectra).
 IT 29083-90-7P 29378-32-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 29083-90-7 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-, 3-oxide (CA INDEX NAME)



RN 29378-32-3 CAPLUS
 CN Quinazoline, 4-amino-2-phenyl-, 3-oxide, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L7 ANSWER 271 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:520586 CAPLUS
 DOCUMENT NUMBER: 73:120586
 ORIGINAL REFERENCE NO.: 73:19651a,19654a
 TITLE: Benzodiazines. XV. Synthesis and properties of some quinazoline and tetrazolo[1,5-c]quinazoline derivatives with substituents in the benzene ring
 AUTHOR(S): Golomolzin, B. V.; Postovskii, I. Ya.
 CORPORATE SOURCE: Ural. Politekh. Inst. im. Kirova, Sverdlovsk, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970)

), (6), 855-8

CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE:

Journal

LANGUAGE:

Russian

GI For diagram(s), see printed CA Issue.


AB N-(p-Tolyl)benzimidoyl chloride (0.1 mole) in 100 ml dry C₆H₆ was treated with 32 g Pb(NCS)₂ and the mixture refluxed 2 hr to give 85-90% N-(p-tolyl)benzimidoyl thiocyanate (I), m. 75-80°. Similarly was obtained N-(o-tolyl)benzimidoyl thiocyanate (II), oil. I or II (0.1 mole) was refluxed 2 hr in 60 ml m-xylene to give 39% or 35% III (R = 6- or 8-Me, X = S) (IV), m. 234-5° or 241-3°. IV (0.02 mole) in 10% KOH (2-3-fold excess) was treated with stirring with 30% H₂O₂ at 80° to give 90% III (R = 6- or 8-Me, X = O) (V), m. 256-8° or 252-4°. A mixture of V (0.02 mole), 6 ml POCl₃, 9 ml PhNMe₂, and 100 ml anhydrous C₆H₆ was refluxed 2 hr to give 95% VI (R = 6- or 8-Me, R₁ = Cl) (VII), m. 111-12° or 99-101°. IV (0.02 mole), refluxed 6-8 hr in 150 ml EtOH with 15-fold excess of NH₂NH₂·H₂O gave 75% or 65% VIII (R = 6- or 8-Me) (IX), m. 208-10° or 215-17°. IX were also obtained from VII. IX (0.01 mole) in 2N HCl treated with 0.01 mole NaNO₂ gave 82% or 87% X (R = 6- or 8-Me) (XI), m. 175-6° and 168-9°. XI was also obtained from IX, refluxed in EtOH with NaN₃. A solution of 1 g IX in 500 ml H₂O was treated under reflux during 1 hr with 1.3 g KMnO₄ and the mixture refluxed 5 hr to give 12% XII, m. 310-13°. The same result was obtained by oxidation in AcOH with KMnO₄ during 2.5 hr. Some polarographic and ir data are given.

IT 29083-94-1P 29209-80-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 29083-94-1 CAPLUS

CN Quinazoline, 4-hydrazino-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 29209-80-1 CAPLUS

CN 4(1H)-Quinazolinone, 8-methyl-2-phenyl-, hydrazone (9CI) (CA INDEX NAME)



L7 ANSWER 272 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1970:520585 CAPLUS

DOCUMENT NUMBER: 73:120585

ORIGINAL REFERENCE NO.: 73:19651a,19654a

TITLE: Condensation of o-aminobenzamidoxime with some aldehydes

AUTHOR(S): Goncalves, Huguette; Foulcher, Christian; Mathis, Ferdinand
 CORPORATE SOURCE: Lab. Chim.-Phys. II, Fac. Sci., Toulouse, Fr.
 SOURCE: Bulletin de la Societe Chimique de France (1970), (7), 2615-28
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI For diagram(s), see printed CA Issue.
 AB When 1 equivalent of o-aminobenzamidoxime (I) was treated with 1 or 2 equivalent of p-methoxybenzaldehyde or PhCH:CHCHO, II or III (R = p-MeOC6H4 or PhCH:CH, resp.) was formed, resp. I treated with EtCHO, PrCHO, PhCH2CHO, BzH, m-or p-O2NC6H4CHO, or o- or p-ClC6H4CHO, gave, regardless of the mole ratio, only IV (R = Et, Pr, PhCH, Ph, m- or p-O2NC6H4, or o- or p-ClC6H4, resp.) The acetylation of II and IV by Ac2O was studied. A detailed ir and NMR anal. of II, III, IV and their derivs. is included.
 IT 29083-90-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 29083-90-7 CAPLUS
 CN 4-Quinazolinamine, 2-phenyl-, 3-oxide (CA INDEX NAME)



L7 ANSWER 273 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:121484 CAPLUS
 DOCUMENT NUMBER: 72:121484
 ORIGINAL REFERENCE NO.: 72:21847a,21850a
 TITLE: Benzodiazines. XI. Covalent hydration in a series of benzosubstituted derivatives of tetrazolo[1,5-c]quinazoline
 AUTHOR(S): Postovskii, I. Ya.; Golomolzin, B. V.
 CORPORATE SOURCE: Ural. Politekh. Inst. im. Kirova, Sverdlovsk, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (1), 100-2
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB Boiling 0.01 mole 2-phenyl-4-chloro-6-bromoquinazoline (I) with 0.05 mole H2NNH2.H2O in 50 ml C6H6 gave 90% 2-phenyl-4-hydrazino-6-bromoquinazoline (II), m. 226-8° (decomposition) (EtOH). A mixture of 0.01 mole I, 0.01 mole NaN3, 100 ml EtOH, and 2 ml H2O boiled 1 hr gave 95% 5-phenyl-9-bromotetrazolo[1,5-c]quinazoline (III), m. 160-61° (iso-PrOH). III was also prepared by treating 0.01 mole II in 50 ml concentrated H2SO4 and 50 ml H2O with aqueous 0.01 mole NaNO2 at 80°. III (0.01 mole) was boiled with 150 ml 1:1 HCl-H2O 3 hr, the precipitate was filtered off, and the filtrate gave, after treatment with NH3, 6% 2-phenyl-6-bromo-4-quinazolone (IV), m. 303-5° (iso-PrOH). The precipitate dissolved in NH3 and precipitated with HCl gave 75% 5,6-dihydro-5-phenyl-5-hydroxy-9-bromotetrazolo[1,5-c]quinazoline (V), m. 251-52° (decomposition)


(iso-PrOH). V boiled with 10% KOH 4 hr and neutralized with AcOH gave 50% 5-(2-amino-5-bromophenyl)tetrazole (VI), m. 205-6° (H₂O), which, treated with BzCl in C₅H₅N gave V. VI boiled with Ac₂O 20 min gave 70% 5-methyl-5-hydroxy-9-bromo-5,6-dihydrotetrazolo[1,5-c]quinazoline (VII), m. 205-6° (aqueous iso-PrOH). III boiled with 10% KOH 5 hr gave VI. Mechanism of the covalent hydration of III is discussed.

IT 27398-48-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27398-48-7 CAPLUS

CN Quinazoline, 6-bromo-4-hydrazino-2-phenyl- (8CI) (CA INDEX NAME)



L7 ANSWER 274 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:121480 CAPLUS

DOCUMENT NUMBER: 72:121480

ORIGINAL REFERENCE NO.: 72:21847a,21850a

TITLE: Benzodiazines. X. Luminescent properties of some quinazoline derivatives

AUTHOR(S): Golomolzin, B. V.; Shcherak, L. D.; Postovskii, I. Ya.

CORPORATE SOURCE: Ural. Politekh. Inst. im. Kirova, Sverdlovsk, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1969), (6), 1131-3

CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.


AB Refluxing of 0.1 mole p-MeOC₆H₄N:CPhCl with 32 g Pb(NCS)₂ in 100 ml absolute EtOH on a water bath 2 hr gave 80-5% oily p-MeOC₆H₄N:CPhN:C:S (I). I (0.1 mole) refluxed 2 hr in 60 ml m-xylene yielded 40% II (R = S), m. 222-3° (C₆H₆). Addition of 30% H₂O₂ to 0.02 mole II (R = S) in 10% KOH (0.06-0.08 mole) at 80° afforded 90% II (R = O), m. 247-8° (iso-PrOH) which gave, with POCl₃, III (R = Cl), m. 126-8°. Treatment of 0.01 mole III (R = Cl) with 0.02 mole piperidine in dry benzene at room temperature 1 hr gave III (R = piperidino) (IV), m. 121-3° (EtOH). Similarly was prepared, from III (R = Cl) and morpholine, III (R = morpholino) (V), m. 94-6° (EtOH). IV and V exhibit, in uv light, violet fluorescence in crystals and in solns. in hydrocarbons. Uv and fluorescence spectra of IV and V in hexane and benzene are discussed.

IT 27228-26-8P 27414-19-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27228-26-8 CAPLUS

CN Quinazoline, 6-methoxy-2-phenyl-4-(1-piperidinyl)- (CA INDEX NAME)



RN 27414-19-3 CAPLUS
 CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-phenyl- (CA INDEX NAME)




L7 ANSWER 275 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:97625 CAPLUS
 DOCUMENT NUMBER: 72:97625
 ORIGINAL REFERENCE NO.: 72:17697a,17700a
 TITLE: Determination of untreated whole milk effects on in vitro antibacterial activity
 AUTHOR(S): Van Natta, J. P.; Lo, P. W.; Chang, Timothy Scott
 CORPORATE SOURCE: Res. Develop. Dep., Norwich Pharmacal Co., Norwich, NY, USA
 SOURCE: Applied Microbiology (1970), 19(2), 220-3
 CODEN: APMBAY; ISSN: 0003-6919
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effect of fresh whole milk without pasteurization or other pretreatment on in vitro antibacterial activity of selected compds. was determined in broth dilution The milk was collected by hand directly from dairy goats, or by syringe or cannula from bovine quarters showing low bacterial counts. Antibacterial activity was determined in 50% (v/v) milk-broth medium against sensitive mastitisetiologic strains of Streptococcus agalactiae and Staphylococcus aureus. The indicator sale 2,3,5-triphenyltetrazolium chloride was incorporated in the milk-broth medium to determine inoculum growth. Contaminant interference was circumvented through early as well as late readings and comparisons with uninoculated control tubes, with and without the test compds. Application of the method with more than 75 compds., including nitrofurans, antibiotics, and other chems. uncovered marked degrees of milk interference. The method warrants routine use among preliminary screens to relate in vitro with in vivo observations of antimicrobial activity. Similar procedures may be used with serum, skim milk, or mastitis-milk media for separating effects due to protein, lipid, or other elements in product evaluation.
 IT 5489-93-0 27465-08-3 27465-09-4
 27465-10-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(antibiotic activity of, milk effect on)

RN 5489-93-0 CAPLUS


CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-furanyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



●₂ HCl

RN 27465-08-3 CAPLUS


CN Quinazoline, 2-(5-nitro-2-furyl)-4-[[2-(1-pyrrolidinyl)ethyl]amino]-,
hydrochloride (7CI, 8CI) (CA INDEX NAME)



●_x HCl


RN 27465-09-4 CAPLUS

CN Quinazoline, 4-[[2-(dimethylamino)ethyl]amino]-2-(5-nitro-2-furyl)-,
hydrochloride (7CI, 8CI) (CA INDEX NAME)



●x HCl

RN 27465-10-7 CAPLUS
 CN Quinazoline, 4-[[3-(diethylamino)propyl]amino]-2-(5-nitro-2-furyl)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



●x HCl


L7 ANSWER 276 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:90511 CAPLUS
 DOCUMENT NUMBER: 72:90511
 ORIGINAL REFERENCE NO.: 72:16456h,16457a
 TITLE: 2-(o-Hydroxyphenyl)quinazoline ultraviolet absorbers
 INVENTOR(S): Otterstedt, Jan E. A.; Pater, Richard
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co.
 SOURCE: Ger. Offen., 71 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1935382	A	19700205	DE 1969-1935382	19690711 <--
US 3637693	A	19720125	US 1968-744310	19680712 <--
NL 6910724	A	19700114	NL 1969-10724	19690711 <--
FR 2012863	A5	19700327	FR 1969-23691	19690711 <--
GB 1249370	A	19711013	GB 1969-1249370	19690711 <--
CH 538526	A	19730815	CH 1969-10654	19690711 <--
CH 6917707	D	19730928	CH 1969-17707	19690711 <--
CH 547385	B5	19740329		
CA 949568	A1	19740618	CA 1969-56832	19690711 <--
PRIORITY APPLN. INFO.:			US 1968-744310	A 19680712


GI For diagram(s), see printed CA Issue.
 AB 2-(o-Hydroxyphenyl)quinazoline uv light stabilizers (I, where R and R1 are H or other substituents with Hammett p-σ-values of -0.67 to 0.25, R2 is H or a substituent besides OH with a Hammett p-σ-value of -0.67 to 0.25, and R3 is H or a substituent with a Hammett p-σ-value of

-0.67 to 0.78. Thus, 3.06 g 2-(o-hydroxyphenyl)quinazoline-4-carboxylic acid in 25 ml quinoline was heated for 3 hr at 160°. The quinoline was removed in vacuo to give 2-(o-hydroxyphenyl)quinazoline m. 132-3° (EtOH). A mixture of 1.93 g o-(salicyloylamino)acetophenone, 8 g NH₃, and 50ml absolute EtOH was heated at 180° for 24 hr to give 2-(o-hydroxyphenyl)-4-methylquinazoline, m. 118-19° (EtOH). A mixture of 6 g 2,4-dichloroquinazoline, 7.4 g p-methylanisole, and 8g AlCl₃ in 50 ml dichlorobenzene was heated for 19 hr at 176-82° to give 2,4-bis(2-hydroxy-5-methylphenyl)quinazoline, m. 202-4° (PhMe). A mixture of 12 g 2-(o-hydroxyphenyl)-4(3H)-quinazolinone, 50 g NH₃, and 120 ml EtOH was heated at 200-20° for 24 hr to give 2-(o-hydroxyphenyl)-4-aminoquinazoline, m. 222-3° (EtOH). A mixture of 2,4-bis(2,4-dihydroxyphenyl)-quinazoline 1.73, PrBr 1.30, and Na₂CO₃ 1.08 g in 15 ml Me Cellosolve was heated for 30 min periods at 60-70°, 70-80°, 80-95°, and 95-100° and for 45 min at 110° to give 2,4-bis(2-hydroxy-4-propoxyphenyl)quinazoline m. 149-50° (HOAc). Similarly prepared were I (R, R₁, R₂, R₃, and m.p. given): H, H, Ph, H, 171-2°; HO, H, 2,4-dihydroxyphenyl, H, 290-2°; HO, H, 2,4-dihydroxyphenyl, Me, 290-2°; MeO, H, 2,4-dimethoxyphenyl, H, 178-9°; PrO, H, 2,4-dipropoxyphenyl, H, 143.5-4.5°; BuO, H, 2-hydroxy-4-butoxyphenyl, H, 142-3°; octyloxy, H, 2-hydroxy-4-octyloxyphenyl, H, 67-8°; octadecyloxy, H, 2-hydroxy-4-octadecyloxy, H, 89-90°; EtO₂CCH₂O, H, 2,4-bis(ethoxycarbonylmethoxy)phenyl, H, 89-90°; EtO₂CCH₂O, H, 2,4-bis(ethoxycarbonylmethoxy)phenyl, H, 137-9°; MeO₂CCH₂O, H, 2,4-bis(methoxycarbonylmethoxy)phenyl, H, 152-4°; HOCH₂CH₂O, H, 2,4-bis(β-hydroxyethoxy)phenyl, H, 193-4°; H, H, Cl, H, 157°; H, H, Me₂N, H, 147-8.5°; H, H, MeO, H, 117-18°; H, H, allyloxy, H, 104.5-5.5°; H, H, MeCONH, H, 232-3°; H, Me, 5-acetoxy-2-methylphenyl, H, 217-18°; H, Me, 5-(methacryloyloxy)-2-methylphenyl, H, 170-1°. I had high inherent photostability; i.e. they effectively dispersed the light energy absorbed, and were suitable for use as uv light stabilizers and photostabilizers for such polymers as poly(vinyl butyral), polyamides, polypropylene, and poly(vinyl fluoride) films, fibers, and textiles.


IT 17254-14-7P 25171-37-3P 25171-40-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17254-14-7 CAPLUS
 CN Phenol, o-(4-amino-2-quinazolinyl)- (8CI) (CA INDEX NAME)



RN 25171-37-3 CAPLUS
 CN Phenol, 2-[4-(dimethylamino)-2-quinazolinyl]- (CA INDEX NAME)




RN 25171-40-8 CAPLUS
 CN Acetamide, N-[2-(o-hydroxyphenyl)-4-quinazolinyl]- (8CI) (CA INDEX NAME)




L7 ANSWER 277 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:31830 CAPLUS
 DOCUMENT NUMBER: 72:31830
 ORIGINAL REFERENCE NO.: 72:5837a,5840a
 TITLE: Bactericidal 4-(o-, m-, and p-hydroxyanilino)-2-(5-nitro-2-furyl)quinazolines
 PATENT ASSIGNEE(S): Norwich Pharmacal Co.
 SOURCE: Brit., 3 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1168430		19691022	GB 1969-4748	19690128 <--
DE 1909522			DE	
FR 2005591			FR	
US 3542784		19701124	US	19680405 <--
ZA 6900771		19690000	ZA	<--
PRIORITY APPLN. INFO.:			US	19680405


GI For diagram(s), see printed CA Issue.
 AB The title compds. (I) in which the OH may be in the 2-, 3-, or 4-position show high in vitro antibacterial activity. A mixture of 35 g II and 28.5 g o-HOC6H4NH2 in 500 ml Me2NCHO was heated on the steam-bath 2 hr to give 35 g I (2-OH) (III), m. 275° (decomposition). Similarly were prepared I (3-OH) (IV), m. 284° (decomposition) and I (4-OH), m. 286-8° (decomposition). I were particularly effective in vitro against animal pathogens.
 IT 24912-15-0P 24912-16-1P 24912-17-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 24912-15-0 CAPLUS
 CN Phenol, p-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- (8CI) (CA INDEX NAME)



RN 24912-16-1 CAPLUS
 CN Phenol, m-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- (8CI) (CA INDEX NAME)



RN 24912-17-2 CAPLUS
 CN Phenol, o-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- (8CI) (CA INDEX NAME)



L7 ANSWER 278 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1969:68419 CAPLUS
 DOCUMENT NUMBER: 70:68419
 ORIGINAL REFERENCE NO.: 70:12809a,12812a
 TITLE: Hypotensive and bronchodilatory quinolines, isoquinolines, and quinazolines
 INVENTOR(S): Cronin, Timothy H.; Hess, Hans J. E.
 PATENT ASSIGNEE(S): Pfizer, Chas., and Co., Inc.

SOURCE: S. African, 114 pp.
 CODEN: SFXXAB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6706512		19680306	ZA	<--
DE 1695593			DE	
DE 1795787			DE	
GB 1199768			GB	
US 3517005		19700623	US	19671026 <--
US 3594480		19710720	US	19700312 <--
US 3702849		19721114	US	19700317 <--
US 3812127		19740521	US 1972-259113	19720602 <--
			US	19661031

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 70:68419

GI For diagram(s), see printed CA Issue.

AB A mixture of 5 g. 2-ethyl-4-chloro-6,7-dimethoxyquinazoline and 7.43 g. piperazine-1-carboxylic acid, iso-Bu ester in 50 ml. absolute EtOH was refluxed 1 hr. and worked up to give 79.5% 4-(2-ethyl-6,7-dimethoxyquinazolin-4-yl)-piperazine-1-carboxylic acid iso-Bu ester, m. 96-7° (hexane); HCl salt m. 218-20°. A solution of di-Et sodiomalonate in HCONMe₂ (DMF) was prepared from 11.5 g. 50% NaH-mineral oil dispersion from which the mineral oil had been removed with hexane, 32.0 g. of di-Et malonate, and 100 ml. DMF. To this was added 51.8 g. 2,4-dichloro-6,7-dimethoxy-quinazoline, and the mixture heated at 60° 40 hrs. and worked up to give 80% di-Et (2-chloro-6,7-dimethoxyquinazol-4-yl)malonate (I), m. 160.5-2.5° (EtOH). A suspension of 30 g. I in 300 ml. N NaOH was refluxed 1 hr. and filtered to give 46.5% 2-chloro-4-methyl-6,7-dimethoxyquinazoline (II), m. 183-5° (MeOH). A stainless steel pressure vessel was charged with 4.0 g. II, 40 ml. NH(Et)₂, and 40 ml. EtOH, and heated at 130° 3 hrs. and worked up to give 51% 2-diethylamino-4-methyl-6,7-dimethoxyquinazoline, m. 95-7°; HCl salt m. 220-1°. The following III (R = R₁ = MeO and R₂ = H) were prepared (R₃, R₄, m.p., and m.p. HCl salt given): H, Me, 206.8° (EtOH), 264-5°; H, Et, 223-4° (MeOH), 261-2°; H, Pr, 207-8° (EtOAc), 246-8°; H, iso-Pr, 248-50° (EtOH), 250° (decomposition); H, cyclopropyl, 237-9° (EtOAc), 253.5-4.0° (decomposition); H, Ph, 236-8°, 259-60°; H, PhCH₂, 230-1° (EtOH), 250°; H, 2-phenylethyl, 190-1° (H₂O), 239-41°; Et, Et, 112-14°, 224°; Pr, Pr, 147-8° (MeOH-H₂O), 207° (decomposition); Me, Me, 158-60°, -; and H, H, 205-7° (H₂O), 275°. Also prepared were the following III (R = R₁ = MeO, R₃ = R₄ = H) (R₂, m.p., and m.p. HCl salt given): Et, 238-9° (EtOH), 278-80°; CF₃, 284-6° (MeOH), 258-9° (decomposition); Et, -, 262-3° (decomposition); Pr, 224-6° (MeOH), 258-60° (decomposition); iso-Pr, 217-18°, 255-7°; tert-Bu, -, 272-3° (decomposition); Ph, 203-4° (MeOH), 258-60° (decomposition); PhCH₂, -, -; and PhEt, -, 270-1° (decomposition). Also prepared were the following III, (R, R₁, R₂, R₃, R₄, m.p., and m.p. HCl salt given); CH₂:CHO, CH₂:CHO, H, H, H, 234-6° (EtOH-Et₂O), 278-81°; H, MeO, H, H, H, 270-1° (MeOH), 255-6°; and iso-Pr, iso-Pr, H, H, H, 147-8°, 250-1°. Also prepared were the following IV (R = R₁ = MeO, R₂ = H) (R₃, m.p., and m.p. HCl salt given): H, 150-1° (EtOAc), 299-30°; iso-BuCO, 125-6° (C₆H₆-hexane), -; Me, 159-60° (CH₂Cl₂-isoPr₂O), 300-1° (decomposition); CH₂:CHCH₂, 128-30° (isoPr₂O), 239-42° (decomposition); Ph, 152.5-60° (MeOH-H₂O), 221-3° (decomposition);

HOCH₂CH₂, 155.8° (EtOAc), 230-3.5° (decomposition); 6,7-dimethoxy-4-quinazolyl, 264-5° (CHCl₃MeOH), 253-5° (decomposition); OH, 201-2.5° (iso-PrOH), 233° (decomposition); Ac, 186° (iso-PrOH-iso-Pr₂O), 224-5° (decomposition); EtO, 150-1° (C₆H₆-hexane), 216-17°; Me₂CHO, 172-3° (C₆H₆-hexane), 210-11°; BuCO, 130.5-33° (EtOAc-hexane), 209-10°; Me(CH₂)₆CO, 136-8° (MeOH-H₂O), 157-8° (decomposition); Bz, 221-3° (MeOH), 183-5°; CH₂:CHCO, 127-9° (C₆H₆-hexane), 102-4°; 2-furoyl, 159-61° (C₆H₆-hexane), 222-3°; Me₂CONH, 147-8.5° (C₆H₆-iso-Pr₂O), 167-8°; CF₃CO, 191-2° (CH₂Cl₂-iso-Pr₂O), 225-6°; CCl₃CO, 84-8° (DMF-H₂O), 243-4°; MeSO₂, 239-40° (CHCl₃-MeOH), 256° (decomposition); PhSO₂, 186-7° (C₆H₆), 236-7° (decomposition). Also prepared were 4-(6,7-dimethoxyquinazolin-4-yl)homopiperazine-1-carboxylic acid, m. 146.5-48° (EtOAc) [iso-Bu ester m. 109-12° [(iso-Pr)₂O-hexane]]; and the following IV (R = R₁ = MeO, R₂ = H, R₃ = O₂CR₄) (R₄, m.p., and m.p. HCl salt given): Et, 145-7° (C₆H₆-hexane), 215-16°; Pr, 131-3° (MeOH-H₂O), 229° (decomposition); iso-Pr, -, -; Bu, 129-30° (MeOH-H₂O), 199-200°; iso-Bu, 151-2° (MeOH), 217°; pentyl, 153-4° (MeOH), 212-12.5° (decomposition); hexyl, 143.5-45° (MeOH-H₂O), 187-7.5°; tetrahydrofurfuryl, 139-40° (C₆H₆-hexane), -; Ph, 154-5° (Me₂CO), 231°; benzyl, 132-3.5° (MeOH-H₂O), 198-9°; Me₂CClCH₂, 158-9° (Me₂CO-H₂O), -; Me₂C(OH)CH₂, 199-200° (CHCl₃-EtAc), -; 2-methyl-2-propenyl, -, 210-13°; and 2-dimethylaminoethyl, 100-4° (EtOAc-hexane), 230-2°. Also prepared were 2-amino-6,7-diisopropoxyquinazoline, m. 147.5-8.5° (HCl salt m. 250-1°); 2-amino-4-methyl-6,7-dimethoxyquinazoline, m. 218-20° [HCl salt m. 282-3° (decomposition)]; and 2-dimethylamino-4-methyl-6,7-dimethoxyquinazoline, m. 131-3° (HCl salt m. 258°). Also prepared were the following 2-(4-substituted-1-piperazinyl)-4-methyl-6,7-dimethoxyquinazoline (substituent, m.p., and m.p. HCl salt given): CO₂Et, 153-5°, 247°; and CO₂Ph, 201-3°, 237.5-40.0°. Also prepared were the following IV (R = R₁ = MeO, R₃ = CO₂Bu-iso (R₂, m.p., and m.p. HCl salt given): Me, 131-2° (MeOH-H₂O), 228° (decomposition); CF₃, 132-3° (EtOH), 169-71°; Pr, 100-2° (hexane), 202-4°; iso-Pr, 102-4° (hexane), 198-9.5°; tert Bu, 89-91° (hexane), 180-1.5°; Ph, 164-6° (MeOH), 227-8° (decomposition); PhCH₂, 62-4° (CH₂Cl₂-hexane), 198-9°; Ph-CH₂CH₂, 100-1°, (C₆H₆-hexane), 190-1°; and H, -, 217° (decomposition). Also prepared were esters of 4-(6,7-dimethoxyquinoline-4-yl)piperazine-1-carboxylic acid (alc. group of ester and m.p. given): iso-Bu, 172-3° (EtOH); and CH₂C(OH)Me₂, 172-3° (EtOAc). Also prepared are the following 1-amino-6,7-dimethoxy-isoquinolines (amino group, m.p., and m.p. HCl salt given): iso-PrNH, 138-40° (MeOH), 200-4°; Me₂N, 72-5°, 148-51°; and Et₂N, 137-8.5° (Me₂CO-H₂O), 189-91°. Also prepared were the following 1-(4-substituted-1-piperazinyl)-6,7-dimethoxyisoquinolines (4-substituent, m.p., and m.p. HCl salt given): Me, 163-6° (EtOAc), 220-5°; Ph, 138-41° (MeOH), 222-8°; Ac, 137-8° (CH₂Cl₂-iso-Pr₂O), 157-8° (decomposition); and CO₂Et, 146-7° (CH₂Cl₂-iso-Pr₂O), 135-7° (decomposition). Also prepared were esters of 4-(6,7-dimethoxyisoquinolin-1-yl)piperazine-1-carboxylic acid (alc. group of ester, m.p., and m.p. HCl salt given): CH₂CH₂Cl, 137.5-38° (MeOH-H₂O), 105-6° (decomposition); CHMe₂, 155-6° (MeOH), 102-4° (decomposition); CH₂CH₂Me, 137-8° (MeOH), 120-3° (decomposition); (CH₂)₂NEt₂, 103-4°, (iso-Pr₂O), 78-91°; (CH₂)₂NMe₂, 115° (CH₂Cl₂-iso-Pr₂O), 169-72° (decomposition); (CH₂)₂NH₂, 134-7° (EtOAc-hexane), 173-5° (decomposition); (CH₂)₂OMe, 119-20° (EtOAc-hexane), 103-5° (decomposition);


iso-Bu, 130-2° (MeOH), -; Me₂C(OH)CH₂, 133-4° (EtOAc-hexane), -; and Me₂NCH₂CH₂, 115° (CH₂Cl₂-iso-Pr₂O), -. All title compds. exhibited bronchodilator activity, while III and the 2-aminoquinoxaline derivs. were better hypotensives. Extensive test data were given.

IT 21580-38-1P 21580-39-2P 21580-54-1P
21580-55-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 21580-38-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-, isobutyl ester (8CI) (CA INDEX NAME)



RN 21580-39-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-, isobutyl ester, hydrochloride (8CI) (CA INDEX NAME)




●x HCl

RN 21580-54-1 CAPLUS

CN 4-Quinazolinamine, 6,7-dimethoxy-2-phenyl- (CA INDEX NAME)



RN 21580-55-2 CAPLUS
 CN Quinazoline, 4-amino-6,7-dimethoxy-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)



● x HCl

L7 ANSWER 279 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1969:4142 CAPLUS
 DOCUMENT NUMBER: 70:4142
 ORIGINAL REFERENCE NO.: 70:781a,784a
 TITLE: 1-Aryl-4-imino-1,2-dihydroquinazolines
 INVENTOR(S): Blatter, Herbert M.; Carney, Richard W. J.; De Stevens, George
 PATENT ASSIGNEE(S): CIBA Corp.
 SOURCE: U.S., 7 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3403153	A	19680924	US 1967-624211	19670320 <--
PRIORITY APPLN. INFO.:			US 1967-624211	A 19670320

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) are prepared by action of R₃NH₂ on quinazolinium salts (II), or by catalytic dehydrogenation of III or IV, in which R₁ is aryl, R₂ is alkyl, or aryl, R₃ is H, alkyl, or aryl, R₄ is lower alkyl, X is O or S, and Y- is an anion. Benzoylation of 33.3 g. 4-FC₆H₄NH₂ in 100 ml. C₅H₅N with 42.1 g. BzCl gave 4-FC₆H₄NHCOPh (V), m. 183-7° (EtOH). V (46 g.) and 100 ml. SOCl₂, refluxed 3 hrs., gave 4-FC₆H₄N:-CClPh (VI), b₂₀ 182°. VI (4.66 g.) in 25 ml. Et₂O, added to 4.56 g. 2-HOC₆H₄CO₂Me and 1.35 g. NaOMe in 50 ml. anhydrous MeOH, at room temperature

30

min., gave 4-RC₆H₄N:CPh(OC₆H₄CO₂Me-2) (VII, R = F) (VIIa), m. 126-30° (EtOH). VIIa (85 g.), 10 min. at 275°, gave 2-MeO₂CC₆H₄N(Bz)(C₆H₄F-4), m. 110-16° (MeOH), which was hydrolyzed to give N-benzoyl-N-(4-fluorophenyl)anthranilic acid (VIIIa), m. 176-8° (Et₂O). Refluxing 20 g. VIIIa and 100 ml. POCl₃ 19 hrs.

gave 1-(4-fluorophenyl)-2-phenyl-3,4-dihydro-4-quinazolinone (IXa), m. 289-90° (Me2COC6H14). A mixture of 10.5 g. IX, 8.9 g. P2S5 and 150 ml. xylene, refluxed 2 hrs., cooled, and treated with 60 ml. 10% NaOH gave 1-(4-fluorophenyl)-2-phenyl-3,4-dihydroquinazoline-4-thione (X), m. 293-6° (Me2CO). Action of 15 ml. MeI on X 1.5 hrs. gave II (R1 = 4-FC6H4, R2 = Ph, XR4 = SMe, Y- = I-) (IIa), m. 270-90° (decomposition) (Me2CO). To 2 g. IIa in 20 ml. Me2NCHO was added 0.75 g. PrNH2, giving after 15 min. at room temperature I (R1 = 4-FC6H4, R2 = Ph, R3 = Pr) (Ia), m. 234-5° (Me2CO). MeNH2 was bubbled through 0.7 g. IIa in 15 ml. Me2NCHO until the color changed from deep red to pale yellow. After 15 min., H2O was added, giving a precipitate of I (R1 = 4-FC6H4, R2 = Ph, R3 =

Me),


(Ib), m. 228-30° (Et2O). IIa and Me2NH gave 1-(4-fluorophenyl)-4-dimethylamino-2-phenylquinazolinium iodide, m. 275-6° (Me2CO). Also prepared from IIa were I (R1 = 4-FC6H4, R2 = Ph) (R3 and m.p. given): Me2NCH2CH2, 181-3° (Et2O-C5H12); 4-phenylpiperazinoethyl, 244-6° (decomposition) (Me2CO); CH2CO2H, -; H, - (Me2CO-Et2O); Et, 234-6° (Me2CO-Et2O); iso-Pr, 217-19° (Et2O); Bu, 195-7° (Me2CO); sec-Bu, 190-8° (MeOH); tert-Bu, 204-13 (MeOH); n-C5H11, 182-4° (Me2CO); 4-FC6H4, 210-13° (Et2O); EtO2CCH2, 213-15° (Me2CO); allyl, 229-30° (MeOH); 4-FC6H4CH2, 195-6° (Me2CO-C6H14); cyclopropyl, 243-4° (MeOH); and cyclopropylmethyl, 223-5° (MeOH). II (R1 = 4-MeOC6H4, R2 = Ph, XR4 = SMe, Y- = I-) (IIb) was prepared similarly to IIa, starting with 2-HOC6H4CO2Me, 4-MeOC6H4N:CClPh and NaOMe, to give VII (R = MeO) (VIIb), m. 115-17° (EtOH). VIIb was heated at 275° to give 2-MeO2CC6H4NBz(C6H4OMe-4), m. 151-3° (Me2CO-C6H14), which was hydrolyzed to give N-benzoyl-N-(4-methoxyphenyl)anthranilic acid (VIIIb), m. 184-7° (Me2CO-C6H14). Heating the amide of VIIIb at 300° gave 1-(4-methoxyphenyl)-2-phenyl-1,4-dihydro-4-quinazolinone (IXb), m. 240-3° (EtOH), which gave IIb on treatment with P2S5 followed by MeI. Other I prepared from II were (R1, R2, R3, and m.p. given): Ph, Ph, sec-Bu, 199° (MeOH); Ph, Ph, allyl, 224-6° (MeOH); Ph, Ph, cyclopropyl, 222-3° (MeOH); Ph, Ph, 4-FC6H4CH2, 187-8° (MeOH); 4-ClC6H4, Ph, sec-Bu, 199-204° (MeOH); 4-ClC6H4, Ph, tert-Bu, 217-18° (MeOH); and 4-Me-OC6H4, Ph, cyclopropyl, -. Ia was also prepared by dehydrogenation of 0.5 g. III (R1 = 4-Fc6H4, R2 = Ph, R3 = Pr) on 0.1 g. 10% Pd-C in 100 ml. cyclohexane under reflux 24 hrs., or by 0.2 g. S in Me2NCHO under reflux 30 min. I are antiinflammatory agents.

IT 22261-51-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 22261-51-4 CAPLUS

CN Quinazolinium, 4-(dimethylamino)-1-(p-fluorophenyl)-2-phenyl-, iodide
(8CI) (CA INDEX NAME)



● I⁻

L7 ANSWER 280 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:419205 CAPLUS

DOCUMENT NUMBER: 69:19205

ORIGINAL REFERENCE NO.: 69:3623a,3626a

TITLE: 4-Aminopyrimidines

INVENTOR(S): Blatter, Herbert M.

PATENT ASSIGNEE(S): CIBA Corp.

SOURCE: U.S., 10 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	US 3340260		19670905	US 1966-591700	19630919 <--
GI	For diagram(s), see printed CA Issue.				
AB	<p>The title compds. (I), useful analgesic agents, are prepared Thus, 60 ml. absolute EtOH was added to a solution of 4.76 g. 4-mercapto-2-phenylquinazoline (II) in 60 ml. 2-morpholinoethylamine (III) and the mixture refluxed 2 hrs. to give 4-(2-morpholinoethylamino)-2-phenylquinazoline, (IIIa), m. 139-40.5°; IIIa.2HCl.1.5H₂O m. 285° (decomposition). A mixture of 23.9 g. N-phenylbenzamide and 22 g. SOCl₂ was refluxed 6 hrs. to give 19.5 g. N-phenylbenzimidoyl chloride (IV), m. 40°. A mixture of 47.5 g. IV and 97 g. Pb(NCS)₂ in 500 ml. benzene was refluxed 2 hrs., the mixture worked up, treated with 500 ml. toluene, and refluxed 24 hrs. to give II, m. 226-8°. II was also prepared by refluxing a mixture of 4.4 g. 2-phenylquinazol-4-one and 4.4 g. P₄S₅ in 50 ml. xylene for 2 hrs. Absolute EtOH (15 ml.) was added to a mixture of 1.19 g. II and 15 ml. of 2-(N,N-diethylamino)ethylamine and refluxed 4 hrs. to give 4-[2-(N,N-diethylamino)ethyl]amino-2-phenylquinazoline-2HCl, m. 269-7°. A mixture of 1.34 g. 4-mercapto-6-methoxy-2-phenylquinazoline and 10 ml. III was refluxed 2 hrs. to give 6-methoxy-4-(2-morpholinoethylamino)-2-phenylquinazoline, m. 182-4°. A mixture of 81 g. N-(4-methoxyphenyl)benzamide and 50 ml. SOCl₂ was refluxed 6 hrs. to give N-(4-methoxyphenyl)-benzimidoyl chloride (V), 57-60°. A mixture of 13 g. V and 16 g. Pb(NCS)₂ in 200 ml. benzene was treated as above to give 6-methoxy-4-mercapto-2-phenylquinazoline, m. 233-5°. A solution of 1.19 g. II in 15 ml. 2-(N,N-dimethylamino)ethylamine was treated with 15 ml. EtOH and the mixture</p>				

refluxed 4 hrs. The mixture was worked up and treated with a solution of HCl in isopropanol to give 4-[2-(N,N-dimethylamino)ethyl]amino-2-phenylquinazoline-2HCl (VI); VI.2HCl.1.5H₂O m. 272-4°. A solution of 2.38 g. II in 15 ml. 2-piperidinoethylamine was treated with 15 ml. EtOH and the mixture refluxed 4 hrs. to give 4-(2-piperidino-ethylamino)-2-phenylquinazoline (VII), m. 120-2°. Similarly prepared were the following I (R, R₁, n, R₂, and m.p. given): 7-F, Ph, 2, morpholino, 124-6°; H, Ph, 2, Pr₂N, 118-19°; H, 3,4,5-(MeO)₃C₆H₂, 2, morpholino, 229-30°; 2-Ph, H, 2, piperazino, 235-7°; 6-benzyloxy, Ph, 2, morpholino, 124-6°; 8-F, Ph, 2, morpholino, 142-4°; 2-Ph, H, 2, pyrrolidino, 92-4°; 7-F, 2-ClC₆H₄, 2, morpholino, 131-3°; H, 2-thienyl, 2, morpholino, 150-2°. A solution of 6-benzyloxy-4-[N-(2-morpholinoethyl)amino]-2-phenylquinazoline in 50 ml. EtOH was treated with H under atmospheric pressure in the presence of

0.5

mg. Pd catalyst containing 10% Pd-C to give 6-hydroxy-4-[N-(2-morpholinoethyl)amino]-2-phenylquinazoline, m. 250-3°. A mixture of 0.7 g. 4-mercapto-2-(4-pyridyl)quinazoline and 10 ml. III in 10 ml. EtOH was refluxed 4 hrs. to give 4-[N-(2-morpholinoethyl)amino]-2-(4-pyridyl)quinazoline, m. 163-5°. A mixture of 10.7 g. 4-pyridinecarboxaldehyde and 13.6 g. anthranilamide in 100 ml. EtOH was refluxed 15 min. to give 2-(4-pyridylmethylimino)benzamide (VIII), m. 178-81°. A solution of 12 g. VIII in 240 ml. EtOH was treated with 24 ml. 2N aqueous solution NaOH and the mixture refluxed 16 hrs. to give 2-(4-pyridyl)-3,4-dihydroquinazolin-4-one (IX), m. 280-2°. A mixture of 0.5 g. IX and 0.5 g. P₄S₅ in 100 ml. xylene was refluxed 2 hrs. and 15 ml. 2N aqueous solution NaOH was added to give 4-mercapto-2-(4-pyridyl)quinazoline, m. 236-8°. Similarly prepared was 2-(2-chlorophenyl)-4-[N-(2-morpholinoethyl)amino]quinazoline, m. 114-16°. Treatment of 2-[(2-chlorophenyl)methylimino]benzamide with NaOH gave 2-(2-chlorophenyl)-3,4-dihydroquinazolin-4-ol (X). Oxidation of X with KMnO₄ gave 2-(2-chlorophenyl)-3,4-dihydroquinazolin-4-one, m. 176-8°, which was then treated with P₄S₅ in xylene to give 2-(2-chlorophenyl)-4-mercaptoquinazoline, m. 208-10°. A mixture of 1.1 g. 4-[N-(2-morpholinoethyl)amino]-2-phenylquinazoline in 10 ml. propionic acid anhydride was treated with 4 drops pyridine and the mixture refluxed 2 hrs. to give 4-[N-(2-morpholinoethyl)amino]-N-propionyl-2-phenylquinazoline, m. 100-3°.

IT

18590-60-8P 18590-62-0P 18590-64-2P
18590-65-3P 18590-67-5P 18590-69-7P
18590-70-0P 18590-74-4P 18590-77-7P
18602-70-5P 18602-74-9P 18602-75-0P
18602-79-4P 18602-80-7P 18602-81-8P
18602-83-0P 18602-84-1P 18701-39-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN

18590-60-8 CAPLUS


CN

4-Quinazolinamine, 2-phenyl-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 18590-62-0 CAPLUS

CN Quinazoline, 8-fluoro-4-[(2-morpholinoethyl)amino]-2-phenyl- (8CI) (CA INDEX NAME)




RN 18590-64-2 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 18590-65-3 CAPLUS
 CN Quinazoline, 2-(o-chlorophenyl)-7-fluoro-4-[(2-morpholinoethyl)amino]-
 (8CI) (CA INDEX NAME)



RN 18590-67-5 CAPLUS
 CN 4-Quinazolinethiol, 4-[(2-morpholinoethyl)amino]-2-(2-thienyl)- (8CI) (CA
 INDEX NAME)




RN 18590-69-7 CAPLUS
 CN 6-Quinazolinol, 4-[(2-morpholinoethyl)amino]-2-phenyl- (8CI) (CA INDEX
 NAME)




RN 18590-70-0 CAPLUS

CN 4-Quinazolinamine, N-[2-(4-morpholinyl)ethyl]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 18590-74-4 CAPLUS

CN Quinazoline, 2-(o-chlorophenyl)-4-[(2-morpholinoethyl)amino]- (8CI) (CA INDEX NAME)




RN 18590-77-7 CAPLUS

CN Propionamide, N-(2-morpholinoethyl)-N-(2-phenyl-4-quinazolinyl)- (8CI)
(CA INDEX NAME)




RN 18602-70-5 CAPLUS

CN 4-Quinazolinamine, N-[[2-(4-morpholinyl)ethyl]amino]-2-phenyl- (9CI) (CA
INDEX NAME)



RN 18602-74-9 CAPLUS


CN Quinazoline, 4-[[2-(diethylamino)ethyl]amino]-2-phenyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl


RN 18602-75-0 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-morpholinoethyl)amino]-2-phenyl- (8CI) (CA INDEX NAME)



RN 18602-79-4 CAPLUS


CN 1,2-Ethanediamine, N,N-dimethyl-N'-(2-phenyl-4-quinazolinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 18602-80-7 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 18602-81-8 CAPLUS

CN Quinazoline, 7-fluoro-4-[(2-morpholinoethyl)amino]-2-phenyl- (8CI) (CA INDEX NAME)




RN 18602-83-0 CAPLUS

CN Quinazoline, 4-[[2-(dipropylamino)ethyl]amino]-2-phenyl- (8CI) (CA INDEX NAME)




RN 18602-84-1 CAPLUS

CN Quinazoline, 4-[(2-morpholinoethyl)amino]-2-(3,4,5-trimethoxyphenyl)-
(8CI) (CA INDEX NAME)



RN 18701-39-8 CAPLUS

CN Quinazoline, 6-(benzyloxy)-4-[(2-morpholinoethyl)amino]-2-phenyl- (8CI)
(CA INDEX NAME)



L7 ANSWER 281 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:68858 CAPLUS

DOCUMENT NUMBER: 68:68858

ORIGINAL REFERENCE NO.: 68:13283a,13286a

TITLE: Abnormal products from phenolic oxidation of a
dihydroxy-1-benzyl-1,2,3,4-tetrahydroisoquinoline

AUTHOR(S): Kametani, Tetsuji; Noguchi, Isao

CORPORATE SOURCE: Pharm. Inst. Sch. Med. Tohoku Univ., Sendai, Japan

SOURCE: Journal of the Chemical Society [Section] C: Organic

(1968), (4), 447-51
CODEN: JSOOAX; ISSN: 0022-4952

DOCUMENT TYPE: Journal
LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Phenolic oxidation of 1,2,3,4-tetrahydro-7-hydroxy-1-(3 - hydroxy - 4,5 - dimethoxybenzyl)-6-methoxy-2-methylisoquinoline unexpectedly afforded 3-hydroxy-4,5-dimethoxybenzaldehyde and a cyclopent[ij]isoquinolinone (I), whose structures were elucidated by spectral detns.

IT 17254-14-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17254-14-7 CAPLUS

CN Phenol, o-(4-amino-2-quinazolinyl)- (8CI) (CA INDEX NAME)



L7 ANSWER 282 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:49551 CAPLUS

DOCUMENT NUMBER: 68:49551

ORIGINAL REFERENCE NO.: 68:9594h,9595a

TITLE: Cyclic amidines. XXI. Tricycloquinazoline-14C and hydroxytricycloquinazolines

AUTHOR(S): Dean, Harvey G.; Grout, R. J.; Partridge, M. W.; Vipond, Hilton J.

CORPORATE SOURCE: Univ. Nottingham, Nottingham, UK

SOURCE: Journal of the Chemical Society [Section] C: Organic
(1968), (2), 142-4
CODEN: JSOOAX; ISSN: 0022-4952

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB The four isomeric hydroxytricycloquinazolines were synthesized. Hydroxyl radical oxidation of tricycloquinazoline (I) was shown to yield the 2- and 3-hydroxy derivs. Tricycloquinazoline-14C was prepared in three steps from Na14CN.


IT 17330-46-0P 17330-47-1P 17330-48-2P

17330-49-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17330-46-0 CAPLUS

CN o-Anisamide, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- (8CI) (CA INDEX NAME)




RN 17330-47-1 CAPLUS

CN o-Anisamide, 6-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- (8CI) (CA INDEX NAME)




RN 17330-48-2 CAPLUS

CN m-Anisic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




RN 17330-49-3 CAPLUS


CN m-Anisic acid, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (8CI) (CA INDEX NAME)




L7 ANSWER 283 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1967:432680 CAPLUS
 DOCUMENT NUMBER: 67:32680
 ORIGINAL REFERENCE NO.: 67:6191a,6194a
 TITLE: Triazines and related products. I.
 1,3-Di-o-cyanophenyltriazenes
 AUTHOR(S): Stevens, Malcolm F. G.
 CORPORATE SOURCE: Heriot-Watt Univ., Edinburgh, UK
 SOURCE: Journal of the Chemical Society [Section] C: Organic
 (1967), (11), 1096-8
 CODEN: JSOOAX; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 67:32680
 GI For diagram(s), see printed CA Issue.
 AB 12-Imino-12H-[1]benzo-vic-triazino[3,4-a]quinazoline (I) was prepared by
 alumina-catalyzed cyclization of 1,3-di-o-cyanophenyltriazenes and its
 properties compared with those of the isomeric 7-imino-7H-[1]benzo-vic-
 triazino[4,3-b]quinazoline. The triazino[3,4-a]quinazoline is involved as
 an intermediate in certain reactions of 1,3-di-o-cyanophenyltriazenes;
 thus, the triazene affords, on reduction with SnCl₂ in EtOH,
 11-aminoindazolo[3,2-b]quinazoline.
 IT 16288-67-8P 16288-69-0P 16288-70-3P
 16288-71-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 16288-67-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-aminophenyl)- (CA INDEX NAME)




RN 16288-69-0 CAPLUS
 CN 2-Naphthol, 1-[[o-(4-amino-2-quinazolinyl)phenyl]azo]- (8CI) (CA INDEX NAME)



RN 16288-70-3 CAPLUS
 CN Quinazoline, 4-amino-2-(o-hydrazinophenyl)- (8CI) (CA INDEX NAME)



RN 16288-71-4 CAPLUS
 CN Benzaldehyde, [o-(4-amino-2-quinazolinyl)phenyl]hydrazone (8CI) (CA INDEX NAME)



L7 ANSWER 284 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1966:490697 CAPLUS
 DOCUMENT NUMBER: 65:90697
 ORIGINAL REFERENCE NO.: 65:16981h,16982a-f
 TITLE: 4-Substituted 2-(5-nitro-2-furyl)quinazolines
 INVENTOR(S): Burch, H. A.
 PATENT ASSIGNEE(S): Norwich Pharmacal Co.
 SOURCE: 17 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----
BE 672504	19660316	BE 1967-2504	19651118 <--
PRIORITY APPLN. INFO.:		US	19641214


GI For diagram(s), see printed CA Issue.

AB The title products with general formula (I), useful as antibacterials, are prepared CaCO₃ (5 g.) is added to a solution of 6.8 g. o-aminobenzamide in 30 cc. HCONMe₂. A solution of 8.75 g. 5-nitrofuroyl chloride in 20 cc. HCONMe₂ is added with stirring. The mixture is heated for 1 hr., filtered, and cooled. The precipitate is filtered, and crystallized from HCONMe₂ to give 3.9 g.


2-(5-nitro-2-furyl)-4(3H)-quinazolinone (II). II (198 g.) is added slowly with stirring to a solution of 159 g. PCl₅ in 790 cc. POCl₃. The mixture is refluxed for 1 hr., cooled, diluted with 3000 cc. petroleum ether, and cooled again. The precipitate is filtered off and purified by extraction with toluene in a Soxhlet apparatus. The toluene solution is cooled, and the precipitate filtered to give 106 g. 4-chloro-2-(5-nitro-2-furyl)quinazoline (III), m. 196.5-8.5°. A solution of 30 g. III and 26.5 g. HOCHMeCH₂NH(CH₂)₂OH in 750 cc. HCONMe₂ is heated on a steam bath for 1 hr., diluted with water, and cooled. The precipitate is filtered off to give 18 g. 4-[2-hydroxyethyl (2-hydroxy-1-propyl)amino]-2-(5-nitro-2-furyl)quinazoline, m. 165-6° (all m.ps. are corrected) (iso-PrOH). A solution of 40 g. III and 40 g. (HOCHMeCH₂)₂NH in 500 cc. HCONMe₂ is heated on a steam bath for 2 hrs., diluted with water, and cooled to give 39 g. 4-bis(2-hydroxy-1-propyl)amino-2-(5-nitro-2-furyl)quinazoline, m. 169-70°. In the same way, 40 g. III, 36 g. N-butylethanolamine, and 500 cc. HCONMe₂ give 39 g. 4-butyl(2-hydroxyethyl)amino-2-(5-nitro-2-furyl)quinazoline, m. 120-1°; 30.2 g. III, 26.3 g. diethanolamine, and 300 cc. HCONMe₂ give 22 g. 4-bis(2-hydroxyethyl)amino-2-(5-nitro-2-furyl)quinazoline, m. 167-8°; 35 g. III, 23.1 g. 3-methoxypropylamine, and 500 cc. HCONMe₂ give 33 g. 4-(3-methoxypropylamino)-2-(5-nitro-2-furyl)quinazoline, m.p. 143-5°; 35 g. III, 42 g. diethoxyethylamine, and 1000 cc. HCONMe₂ give 40 g. 4-bis(2-ethoxyethyl)amino-2-(5-nitro-2-furyl)quinazoline, m. 60-1°; 30.2 g. III, 15 g. 2-ethanolamine, and 800 cc. HCONMe₂ give 31 g. 4-(2-hydroxyethyl)amino-2-(5-nitro-2-furyl)quinazoline, m. 221-3°; and 35 g. III, 25 g. N-isopropylethanolamine, and 500 cc. HCONMe₂ give 21 g. 4-[(2-hydroxyethyl)isopropylamino]-2-(5-nitro-2-furyl)quinazoline, m. 157-9°. A mixture of 50 g. III, 34 g. N-methylethanolamine, and 1000 cc. benzene is refluxed for 1 hr., and cooled. The precipitate is filtered, suspended in cool water, and alkalized with aqueous NaOH to give 40 g. 4-[(2-hydroxyethyl) methylamino]-2-(5-nitro-2-furyl)-quinazoline, m. 151-2° (HCONMe₂-water). A mixture of 40 g. III, 22.5 g. 2-methoxyethylamine, and 1000 cc. benzene is refluxed for 1 hr., cooled, and diluted with petroleum ether to give 26 g. 4-(2-methoxyethyl)amino-2-(5-nitro-2-furyl)quinazoline, m.p. 160-2° (MeOH). A mixture of 30.2 g. III, 36 g. 3-aminopropyl-4-morpholine, and 750 cc. benzene is refluxed for 1.5 hrs., cooled, and diluted with petroleum ether. The precipitate is filtered, suspended in water, and alkalized with aqueous NaOH. The precipitate is filtered to give 42 g. 4-[3-(4-morpholino)propyl]amino-2-(5-nitro-2-furyl)quinazoline (IV), m. 170.0-1.5°. A solution of 40 g. IV in 500 cc. anhydrous AcOH is saturated with dry HCl while cooling, and diluted with ether to give 30 g. IV.2HCl, m. 211-13°. A solution of 35 g. III, and 19.5 g. 3-amino-1-propanol in 500 cc. HCONMe₂ is heated on a steam bath for 1 hr., diluted with water to give 22 g. 4-(3-hydroxy-1-propylamino)-2-(5-nitro-2-furyl)quinazoline, m.p. 180-3° (MeCN). A mixture of 40 g. III, 28.5 g. 80% 2-hydroxyethylhydrazine, and 500 cc. HCONMe₂ is left at room temperature for 15 min. and heated at 40°, and then at 60°. The solution is diluted with water to give 35.5 g. 4-[1-(2-hydroxyethyl)hydrazino]-2-(5-

nitro-2-furyl)quinazoline, m.p. 190-1° (MeNO₂).


IT 5019-69-2P, Ethanol, 2-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5019-74-9P, 2-Propanol, 1,1'-[[2-(5-nitro-2-furyl)-4-
quinazolinyl]imino]di- 5019-79-4P, Ethanol, 2-[1-[2-(5-nitro-2-
furyl)-4-quinazolinyl]hydrazino]- 5055-18-5P, Ethanol,
2-[isopropyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5055-19-6P, Ethanol, 2-[butyl[2-(5-nitro-2-furyl)-4-
quinazolinyl]amino]- 5055-20-9P, Ethanol, 2,2'-[[2-(5-nitro-2-
furyl)-4-quinazolinyl]imino]di- 5055-21-0P, 2-Propanol,
1-[(2-hydroxyethyl)[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5055-30-1P, Quinazoline, 4-[(2-methoxyethyl)amino]-2-(5-nitro-2-
furyl)- 5055-31-2P, Quinazoline, 4-[(3-methoxypropyl)amino]-2-(5-
nitro-2-furyl)- 5055-33-4P, Quinazoline, 4-[bis(2-
ethoxyethyl)amino]-2-(5-nitro-2-furyl)- 5085-66-5P, 1-Propanol,
3-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5094-03-1P,
Ethanol, 2-[methyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5489-93-0P, Quinazoline, 4-[(3-morpholinopropyl)amino]-2-(5-nitro-
2-furyl)-, dihydrochloride 10460-86-3P, Quinazoline,
4-[(3-morpholinopropyl)amino]-2-(5-nitro-2-furyl)-
RL: PREP (Preparation)
(preparation of)
RN 5019-69-2 CAPLUS
CN Ethanol, 2-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5019-74-9 CAPLUS
CN 2-Propanol, 1,1'-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]imino]bis- (CA
INDEX NAME)




RN 5019-79-4 CAPLUS
CN Ethanol, 2-[1-[2-(5-nitro-2-furanyl)-4-quinazolinyl]hydrazino]- (9CI) (CA
INDEX NAME)




RN 5055-18-5 CAPLUS
 CN Ethanol, 2-[(1-methylethyl)[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]-
 (CA INDEX NAME)




RN 5055-19-6 CAPLUS
 CN Ethanol, 2-[butyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX
 NAME)



RN 5055-20-9 CAPLUS
 CN Ethanol, 2,2'-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]imino]bis- (CA INDEX
 NAME)




RN 5055-21-0 CAPLUS
 CN 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-furanyl)-4-
 quinazolinyl]amino]- (CA INDEX NAME)




RN 5055-30-1 CAPLUS

CN 4-Quinazolinamine, N-(2-methoxyethyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)




RN 5055-31-2 CAPLUS

CN 4-Quinazolinamine, N-(3-methoxypropyl)-2-(5-nitro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 5055-33-4 CAPLUS

CN 4-Quinazolinamine, N,N-bis(2-ethoxyethyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)




RN 5085-66-5 CAPLUS


CN 1-Propanol, 3-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 5094-03-1 CAPLUS
 CN Ethanol, 2-[methyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5489-93-0 CAPLUS
 CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-furanyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 10460-86-3 CAPLUS
 CN Quinazoline, 4-[(3-morpholinopropyl)amino]-2-(5-nitro-2-furyl)- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 285 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1966:403982 CAPLUS

DOCUMENT NUMBER: 65:3982

ORIGINAL REFERENCE NO.: 65:710h, 711a-d

TITLE: Benzodiazines. VI. Synthesis of 2-substituted-4-hydrazinoquinazolines, 5-substituted [3,4-c]-s-triazolo-, and [1,5-c]tetrazoloquinazolines
 AUTHOR(S): Postovskii, I. Ya.; Vereschagina, N. N.; Mertsalov, S. L.

CORPORATE SOURCE: S. M. Kirov Ural Polytech. Inst., Sverdlovsk
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1966), (1), 130-5

CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian


GI For diagram(s), see printed CA Issue.

AB cf. CA 63, 13256g. 2-R-substituted quinazol-4-ones (I), -4-chloroquinazolines (II), and -4-hydrazinoquinazolines (III) were prepared. Treatment of II with CS(NH₂)₂ gave the corresponding isothiuronium salts, which on treatment with NaOH gave 2-R-substituted-quinazoline-4-thiones (IV). III with HNO₂ gave 5-R-substituted[1,5-c]tetrazoloquinazolines (V), with CH(OEt)₃ gave 5-R-substituted[3,4-c]-s-triazoloquinazolines (VI). V treated with HCl gave I (a, R = Me) (b, R = Ph) (c, R = α -furyl) (d, R = γ -pyridyl). Thus, 12.5 g. thioisonicotinamide and 12.5 g. anthranilic acid was heated at 150-60° 1 hr. to give 7.5 g. Id, m. 250° (dioxane). IIa-c were prepared according to Scarborough et al. (CA 57, 7263h). IIa m. 86-8° (heptane); IIb m. 124-6° (heptane); IIc m. 122-4° (heptane). A mixture of 7.5 g. Id, 60 cc. POCl₃, and 10 g. PCl₅ was boiled 4 hrs., POCl₃ distilled, the mixture poured onto ice, neutralized with NH₃, and filtered, the precipitate washed with H₂O and


dried, the residue extracted with boiling C₆H₆, and the extract filtered and evaporated gave 6.5 g., IId, m. 164-6° (heptane). II (0.02 mole) in C₆H₆ was stirred and cooled, 5-fold excess NH₂NH₂.H₂O in C₆H₆ added, and the mixture stirred 2 hrs. gave III. II (0.01 mole), 0.01 mole CS(NH₂)₂, and 50 cc. EtOH boiled 1 hr. and evaporated, the residue dissolved in NaOH, the mixture filtered, and the filtrate acidified with AcOH gave IV. The following III and IV were prepared (R, III m.p., III % yield, IV m.p., and IV % yield given): Me, 180-2° (CHCl₃), 80, 217-18° (EtOH), -; Ph, 214-15° (CHCl₃), 81, 216-18° (EtOH), 63; α -furyl, 249-50° (dioxane), 76, 219-20° (dioxane), 85; γ -pyridyl, 200-2° (CHCl₃), 97, -, -. Treatment of IIa with NH₂NH₂.H₂O in EtOH gave 50% N,N'-bis(2-methylquinazolyl)-4-hydrazine (VII), m. 280° (isoPrOH). III (0.002 mole) boiled 1 hr. with 5-fold excess CH(OEt)₃ gave VI. NaNO₂ (0.002 mole) was added to 0.002

mole III in 2N HCl at 3-5° and the mixture stirred 1 hr. to give V. V were also prepared by treating II with NaN₃ in EtOH. The following VI and V were prepared (R, VI m.p., VI % yield, V m.p., and V % yield given): Me, >280°, 50, 163-5°, 60; Ph, 204-6°, 97, 162-3°, 70; α-furyl, 260-2°, 98, 194-6°, 73; γ-pyridyl, 206-7°, 80, 200-2°, 80. Boiling IV with 15-fold excess NH₂NH₂.H₂O in EtOH until no more H₂S evolved (8-10 hrs.) gave III. Treatment of V with HCl (1:1) 3 hrs. gave I. The compds. with R = Me differ considerably from the others, both in color and in stability of the intermediate reaction products.


IT 6484-29-3P, Quinazoline, 4-hydrazino-2-phenyl- 6484-31-7P
 , Quinazoline, 4-hydrazino-2-(4-pyridyl)- 6505-41-5P,
 Quinazoline, 2-(2-furyl)-4-hydrazino-
 RL: PREP (Preparation)
 (preparation of)
 RN 6484-29-3 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



RN 6484-31-7 CAPLUS
 CN Quinazoline, 4-hydrazinyl-2-(4-pyridinyl)- (CA INDEX NAME)




RN 6505-41-5 CAPLUS
 CN Quinazoline, 2-(2-furyl)-4-hydrazino- (7CI, 8CI) (CA INDEX NAME)




L7 ANSWER 286 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1966:104206 CAPLUS
 DOCUMENT NUMBER: 64:104206
 ORIGINAL REFERENCE NO.: 64:19608c-d
 TITLE: Nitrofuryl heterocycles. IV. 4-Amino-2-(5-nitro-2-furyl)quinazoline derivatives
 AUTHOR(S): Burch, Homer A.

CORPORATE SOURCE: Chem. Div., Norwich Pharmacal Co., Norwich, NY
 SOURCE: Journal of Medicinal Chemistry (1966), 9(3),
 408-10
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 64:104206
 AB cf. CA 64, 19596c. Thirty-five 4-(substituted amino)-2-(5-nitro-2-furyl)quinazolines were prepared and found to possess broad in vitro antibacterial activity against a variety of organisms. Several compds. were also active in vivo against Staphylococcus aureus infections. The most active compound contained the 4-bis(2-hydroxyethyl)amino group. A new mol. grouping responsible for enhancing the antibacterial activity of nitrofurans is postulated.
 IT 5055-22-1 5055-26-5 5055-27-6
 5055-30-1
 (Derived from data in the 7th Collective Formula Index (1962-1966))
 RN 5055-22-1 CAPLUS
 CN 1,2-Ethanediamine, N,N-dimethyl-N'-[2-(5-nitro-2-furanyl)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 5055-26-5 CAPLUS
 CN 1,3-Propanediamine, N,N-diethyl-N'-[2-(5-nitro-2-furanyl)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 5055-27-6 CAPLUS
 CN 4-Quinazolinamine, 2-(5-nitro-2-furanyl)-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 5055-30-1 CAPLUS
CN 4-Quinazolinamine, N-(2-methoxyethyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)



IT 5019-75-0, Ethanol, 2-[2-[3-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]propoxy]ethoxy]-
(others at q)
RN 5019-75-0 CAPLUS
CN Ethanol, 2-[2-[3-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]propoxy]ethoxy]- (CA INDEX NAME)




IT 5019-67-0P, Quinazoline, 2-(5-nitro-2-furyl)-4-
[(tetrahydrofurfuryl)amino]- 5019-68-1P, Quinazoline,
4-(furfurylmethylamino)-2-(5-nitro-2-furyl)- 5019-69-2P,
Ethanol, 2-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5019-70-5P
, 2-Propanol, 1-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5019-71-6P, 1-Propanol, 2-methyl-2-[[2-(5-nitro-2-furyl)-4-
quinazolinyl]amino]- 5019-72-7P, 1,2-Propanediol,
3-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5019-73-8P,
Ethanol, 2-[benzyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]-
5019-74-9P, 2-Propanol, 1,1'-[[2-(5-nitro-2-furyl)-4-
quinazolinyl]imino]di- 5019-76-1P, Quinazoline,

4-[[2-(diethylamino)ethyl]methylamino]-2-(5-nitro-2-furyl)-, hydrochloride
 5019-77-2P, 1-Piperazineethanol, 4-[2-(5-nitro-2-furyl)-4-quinazolinyl]- 5019-78-3P, Quinazoline, 4-(1-methylhydrazino)-2-(5-nitro-2-furyl)- 5019-79-4P, Ethanol, 2-[1-[2-(5-nitro-2-furyl)-4-quinazolinyl]hydrazino]- 5055-17-4P, Ethanol, 2-[ethyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5055-18-5P, Ethanol, 2-[isopropyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5055-19-6P, Ethanol, 2-[butyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5055-20-9P, Ethanol, 2,2'-[[2-(5-nitro-2-furyl)-4-quinazolinyl]imino]di- 5055-21-0P, 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5055-23-2P, Quinazoline, 4-[[3-(dimethylamino)propyl]amino]-2-(5-nitro-2-furyl)-, hydrochloride 5055-24-3P, Quinazoline, 4-[[2-(dimethylamino)ethyl]methylamino]-2-(5-nitro-2-furyl)-, hydrochloride 5055-25-4P, Quinazoline, 4-[[2-(diethylamino)ethyl]amino]-2-(5-nitro-2-furyl)-, hydrochloride 5055-28-7P, Quinazoline, 2-(5-nitro-2-furyl)-4-[[3-(1-pyrrolidinyl)propyl]amino]-, hydrochloride 5055-29-8P, Quinazoline, 4-(4-methyl-1-piperazinyl)-2-(5-nitro-2-furyl)-, hydrochloride 5055-31-2P, Quinazoline, 4-[(3-methoxypropyl)amino]-2-(5-nitro-2-furyl)- 5055-32-3P, Quinazoline, 4-morpholino-2-(5-nitro-2-furyl)- 5055-33-4P, Quinazoline, 4-[bis(2-ethoxyethyl)amino]-2-(5-nitro-2-furyl)- 5085-66-5P, 1-Propanol, 3-[[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5094-03-1P, Ethanol, 2-[methyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino]- 5094-04-2P, Quinazoline, 2-(5-nitro-2-furyl)-4-[[4-(1-pyrrolidinyl)butyl]amino]-, hydrochloride 5118-19-4P, 1,2,3,4,5-Hexanepentol, 6-[methyl[2-(5-nitro-2-furyl)-4-quinazolinyl]amino] 5489-93-0P, Quinazoline, 4-[(3-morpholinopropyl)amino]-2-(5-nitro-2-furyl)-, dihydrochloride 27465-08-3P, Quinazoline, 2-(5-nitro-2-furyl)-4-[[2-(1-pyrrolidinyl)ethyl]amino]-, hydrochloride 27465-09-4P, Quinazoline, 4-[[2-(dimethylamino)ethyl]amino]-2-(5-nitro-2-furyl)-, hydrochloride 27465-10-7P, Quinazoline, 4-[[3-(diethylamino)propyl]amino]-2-(5-nitro-2-furyl)-, hydrochloride
 RL: PREP (Preparation)

(preparation of)


RN 5019-67-0 CAPLUS

CN 4-Quinazolinamine, 2-(5-nitro-2-furanyl)-N-[(tetrahydro-2-furanyl)methyl]-
 (CA INDEX NAME)




RN 5019-68-1 CAPLUS


CN 4-Quinazolinamine, N-(2-furanylmethyl)-N-methyl-2-(5-nitro-2-furanyl)-
 (CA INDEX NAME)




RN 5019-69-2 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5019-70-5 CAPLUS
 CN 2-Propanol, 1-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5019-71-6 CAPLUS
 CN 1-Propanol, 2-methyl-2-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5019-72-7 CAPLUS
 CN 1,2-Propanediol, 3-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5019-73-8 CAPLUS
 CN Ethanol, 2-[[2-(5-nitro-2-furanyl)-4-quinazolinyl] (phenylmethyl) amino]-
 (CA INDEX NAME)



RN 5019-74-9 CAPLUS
 CN 2-Propanol, 1,1'-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]imino]bis- (CA
 INDEX NAME)




RN 5019-76-1 CAPLUS
 CN 1,2-Ethanediamine, N,N-diethyl-N-methyl-N-[2-(5-nitro-2-furanyl)-4-
 quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 5019-77-2 CAPLUS
 CN 1-Piperazineethanol, 4-[2-(5-nitro-2-furanyl)-4-quinazolinyl]- (CA INDEX

NAME)




RN 5019-78-3 CAPLUS

CN Quinazoline, 4-(1-methylhydrazino)-2-(5-nitro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 5019-79-4 CAPLUS

CN Ethanol, 2-[1-[2-(5-nitro-2-furanyl)-4-quinazolinyl]hydrazino]- (9CI) (CA INDEX NAME)




RN 5055-17-4 CAPLUS

CN Ethanol, 2-[ethyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5055-18-5 CAPLUS

CN Ethanol, 2-[(1-methylethyl)[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]-
(CA INDEX NAME)




RN 5055-19-6 CAPLUS

CN Ethanol, 2-[butyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5055-20-9 CAPLUS

CN Ethanol, 2,2'-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]imino]bis- (CA INDEX NAME)



RN 5055-21-0 CAPLUS


CN 2-Propanol, 1-[(2-hydroxyethyl)[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 5055-23-2 CAPLUS

CN 1,3-Propanediamine, N,N-dimethyl-N'-[2-(5-nitro-2-furanyl)-4-quinazolinyl]-


, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 5055-24-3 CAPLUS


CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-[2-(5-nitro-2-furanyl)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 5055-25-4 CAPLUS


CN 1,2-Ethanediamine, N,N-diethyl-N'-[2-(5-nitro-2-furanyl)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 5055-28-7 CAPLUS

CN 4-Quinazolinamine, 2-(5-nitro-2-furanyl)-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 5055-29-8 CAPLUS
 CN Quinazoline, 4-(4-methyl-1-piperazinyl)-2-(5-nitro-2-furanyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 5055-31-2 CAPLUS
 CN 4-Quinazolinamine, N-(3-methoxypropyl)-2-(5-(nitro-2-furanyl)- (9CI) (CA
 INDEX NAME)




RN 5055-32-3 CAPLUS
 CN Quinazoline, 4-(4-morpholinyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)




RN 5055-33-4 CAPLUS
 CN 4-Quinazolinamine, N,N-bis(2-ethoxyethyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)




RN 5085-66-5 CAPLUS
 CN 1-Propanol, 3-[[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 5094-03-1 CAPLUS
 CN Ethanol, 2-[methyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 5094-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(5-nitro-2-furanyl)-N-[4-(1-pyrrolidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 5118-19-4 CAPLUS
 CN Hexitol, 1-deoxy-1-[methyl[2-(5-nitro-2-furanyl)-4-quinazolinyl]amino]-
 (CA INDEX NAME)




RN 5489-93-0 CAPLUS
 CN 4-Quinazolinamine, N-[3-(4-morpholinyl)propyl]-2-(5-nitro-2-furanyl)-,
 dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 27465-08-3 CAPLUS
 CN Quinazoline, 2-(5-nitro-2-furyl)-4-[[2-(1-pyrrolidinyl)ethyl]amino]-,
 hydrochloride (7CI, 8CI) (CA INDEX NAME)




●_x HCl

RN 27465-09-4 CAPLUS
 CN Quinazoline, 4-[[2-(dimethylamino)ethyl]amino]-2-(5-nitro-2-furyl)-,
 hydrochloride (7CI, 8CI) (CA INDEX NAME)



●_x HCl


RN 27465-10-7 CAPLUS
 CN Quinazoline, 4-[[3-(diethylamino)propyl]amino]-2-(5-nitro-2-furyl)-,
 hydrochloride (7CI, 8CI) (CA INDEX NAME)



●_x HCl

L7 ANSWER 287 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1966:104205 CAPLUS
 DOCUMENT NUMBER: 64:104205
 ORIGINAL REFERENCE NO.: 64:19607h,19608a-c


monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 5055-30-1 CAPLUS

CN 4-Quinazolinamine, N-(2-methoxyethyl)-2-(5-nitro-2-furanyl)- (CA INDEX NAME)



L7 ANSWER 288 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:36424 CAPLUS
DOCUMENT NUMBER: 64:36424
ORIGINAL REFERENCE NO.: 64:6797h,6798a-c
TITLE: Anthraquinone pigments
PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik A.-G.
SOURCE: 6 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
NL 299516		19650825	NL	<--

PRIORITY APPLN. INFO.: DE 19590502

AB Pigments of the aminoanthraquinone series are obtained by the copolymn. of an acrylamidoanthraquinone with a suitable monomer. CH₂:CMeCONH₂ (I) (19 parts) and 1 part 1-amino-2-acetyl-4-acrylamidoanthraquinone (II) in 85 parts BuOH treated at 80-90° with 0.2 part [Me₂C(CN)N:]₂ (III) in 5 parts BuOH, stirred 7 h. at 80-90°, treated with an addnl. 0.2 part III in 5 parts BuOH, and stirred 6 h. gave 20 parts deep blue pigment powder. CH₂:CMeCO₂Me (19.5 parts), 0.5 part II, and 0.2 part III gave similarly during 7 h. at 80° a blue powder. I 19,


1-acrylamido-4-[(2-phenyl-4-quinazolinyl)amino]anthraquinone, III 0.5, and BuOH 80 parts gave similarly 19.8 parts deep blue pigment. Styrene 29, 1-acrylamido-5-benzamidoanthraquinone 1, III 1.5, and N-methylpyrrolidone 120 parts heated 11 h. at 85° and diluted with 700 parts MeOH yielded 19.2 parts orange pigment. I 18, CH₂:CHSO₃H 1, II 1, III 0.5, and BuOH 120 parts heated 6.5 h. at 85-90° gave 19 parts deep blue powder. Butyrolactone (IV) 200, CH₂:CHCl 100, 1-acrylamidoanthraquinone (V) 7.5, and condensation product (VI) 0.5 part of 95% pentaerythritol and 5% glycerol with 4-5 mol equivs. epichlorohydrin and 0.2 part Bz2O2 heated 33 h. at 55° yielded an orange pigment. CH₂:CCl₂ 80, V 6, VI 0.6, Bz2O2 0.5, and IV 200 parts treated 30 h. at 65-70° with a stream of N gave 36 parts yellow pigment. I 18, V 1.5, 4-acrylamidoanthraquinone-1(N)-2-benzacridone 0.5, and HCONMe₂ 100 parts stirred 2 h. at 85-90° with 0.5 part III in 10 parts HCONMe₂ yielded 8.8 parts green pigment.

IT 5003-45-2

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 5003-45-2 CAPLUS

CN Acrylamide, N-[4-[(2-phenyl-4-quinazolinyl)amino]-1-anthraquinonyl]- (7CI, 8CI) (CA INDEX NAME)



IT 618858-40-5, Acrylamide, N-[4-[(2-phenyl-4-quinazolinyl)amino]-1-anthraquinonyl]-, polymer with methacrylamide (pigments from)


RN 618858-40-5 CAPLUS

CN Acrylamide, N-[4-[(2-phenyl-4-quinazolinyl)amino]-1-anthraquinonyl]-, polymer with methacrylamide (7CI) (CA INDEX NAME)

CM 1


CRN 5003-45-2

CMF C31 H20 N4 O3



CM 2

CRN 79-39-0
CMF C4 H7 N O



L7 ANSWER 289 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1966:36423 CAPLUS
 DOCUMENT NUMBER: 64:36423
 ORIGINAL REFERENCE NO.: 64:6797g-h
 TITLE: Fiber-reactive blue dye
 INVENTOR(S): Gamlen, George A.; Morris, Cyril; Scott, Donald F.; Twitchett, Harry J.
 PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
 SOURCE: 7 pp.; Addn. to Brit. 937,182 (CA 60, 4282g)
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1012625		19651208	GB 1963-14456	19630410 <--

PRIORITY APPLN. INFO.: GB 19630410


GI For diagram(s), see printed CA Issue.

AB A mixture of H2O 40, pyridine 4, and I (X = Cl) 4 parts is stirred for 15 mins. at 80°, cooled to 15° and diluted with acetone to give I (X = 1-pyridinium), blue on cotton when applied with an acid-binding agent.

IT 5003-45-2
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 5003-45-2 CAPLUS

CN Acrylamide, N-[4-[(2-phenyl-4-quinazolinyl)amino]-1-anthraquinonyl]- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 290 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:471983 CAPLUS

DOCUMENT NUMBER: 63:71983

ORIGINAL REFERENCE NO.: 63:13256f-h,13257a

TITLE: Benzodiazines. VII. 1-(2-R-quinazoly1)-4-R'-thiosemicarbazides and their properties

AUTHOR(S): Vereshchagina, N. N.; Postovskii, I. Ya.; Mertsalov, S. L.

CORPORATE SOURCE: S. M. Kirov Polytech. Inst., Sverdlovsk

SOURCE: Zhurnal Organicheskoi Khimii (1965), 1(6), 1154-8

CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian


AB cf. CA 61, 8307f. Heating the appropriate mustard oils with 2-R-4-hydrazinoquinazoline in EtOH 1 hr. gave 1-(2-R-quinazoly1)-4-R'-thiosemicarbazides (I) (R and R' shown): Me, Ph, decomposed 190-2°; Me, p-ClC6H4, decomposed 195-7°; Me, CH2:CHCH2, decomposed 210-11°; Ph, Ph (II), decomposed 198-9°; Ph, p-ClC6H4 (III), decomposed 200-1°; Ph, CH2:CHCH2, decomposed 220-2°; 4-pyridyl, Ph (IV), m. 197-8°; 4-pyridyl, p-ClC6H4, m. 204-6°; 4-pyridyl, CH2:CHCH2, m. 223-5°. IV contained 1 mole dioxane and H2O in a yellow form, which changed to normal red form that was free of solvents on being treated with EtOH or Me2NCHO. Heating the products I (R' = Ph) with aqueous HCl 1-8 hrs. gave 3-(2-aminophenyl)-4-phenyl-1,2,4-triazoline-5-thione (V), m. 252-4°, which with MeI gave the Me ether, m. 140-3°, while p-O2NC6H4CHO gave yellow azomethine C21H15N5O2S, m. above 250°. Similar hydrolysis of the p-chlorophenyl analogs gave 3-(o-aminophenyl)-4-(p-chlorophenyl)-1,2,4-triazoline-5-thione, m. 267-9°. The allyl members above hydrolyzed with HCl to 2-methyl-4-quinazolone and 2-phenyl-4-quinazolone, resp. Anthranilhydrazide and phenyl mustard oil heated in MeOH 1 hr. gave 2-aminobenzoyl-4-phenylthiosemicarbazide, decomposed 167-8°, which heated with aqueous HCl or NaOH gave V. II or III heated to 230-40° gave 5-phenyltriazolo[3,2-c]quinazolinethione, m. 250-4°. The 4-pyridyl analogs above pyrolyzed similarly to 5-(4-pyridyl)triazolo[3,4-c]quinazolinethione, m. above 280°.

IT 3455-24-1P, Semicarbazide, 4-phenyl-1-(2-phenyl-4-quinazolinyl)-3-thio- 3455-25-2P, Semicarbazide, 4-(p-chlorophenyl)-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio- 3645-09-8P, Semicarbazide, 4-(p-chlorophenyl)-1-(2-phenyl-4-quinazolinyl)-3-thio- 4079-97-4P, Semicarbazide, 4-phenyl-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio- 4628-41-5P, Semicarbazide, 4-allyl-1-(2-phenyl-4-quinazolinyl)-3-

thio- 4833-67-4P, Semicarbazide, 4-allyl-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio-
 RL: PREP (Preparation)
 (preparation of)


RN 3455-24-1 CAPLUS

CN Semicarbazide, 4-phenyl-1-(2-phenyl-4-quinazolinyl)-3-thio- (7CI, 8CI)
 (CA INDEX NAME)




RN 3455-25-2 CAPLUS

CN Semicarbazide, 4-(p-chlorophenyl)-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio-
 (7CI, 8CI) (CA INDEX NAME)




RN 3645-09-8 CAPLUS

CN Semicarbazide, 4-(p-chlorophenyl)-1-(2-phenyl-4-quinazolinyl)-3-thio-
 (7CI, 8CI) (CA INDEX NAME)




RN 4079-97-4 CAPLUS

CN Semicarbazide, 4-phenyl-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio- (7CI, 8CI) (CA INDEX NAME)




RN 4628-41-5 CAPLUS

CN Semicarbazide, 4-allyl-1-(2-phenyl-4-quinazolinyl)-3-thio- (7CI, 8CI) (CA INDEX NAME)



RN 4833-67-4 CAPLUS

CN Semicarbazide, 4-allyl-1-[2-(4-pyridyl)-4-quinazolinyl]-3-thio- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 291 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:423901 CAPLUS

DOCUMENT NUMBER: 63:23901

ORIGINAL REFERENCE NO.: 63:4209d-g

TITLE: Preparation of N-(2,3-dimethylphenyl)anthranilic acid and its salts

INVENTOR(S): Scherrer, Robert A.

PATENT ASSIGNEE(S): Parke, Davis & Co.

SOURCE: 6 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1190951		19650415	DE	
NL 292083			NL	
PRIORITY APPLN. INFO.:			CA	19620918


GI For diagram(s), see printed CA Issue.

AB The title compound (I) was prepared by hydrolysis of II, III, IV, and V with excess alkaline reagent. The starting materials were prepared by introducing 1 or 2 2,3-dimethylphenoxy groups in a quinazoline or dibenzodiazocine nucleus and carrying out a thermal rearrangement of the 2,3-dimethylphenyl groups to an adjoining N atom. 2,4-Dichloroquinazoline (18 g.) was added to Na 2,3-dimethylphenolate (from 24 g. 2,3-dimethylphenol and 9.6 g. 55% NaH) in 90 ml. diethylene glycol dimethyl ether. After the exothermic reaction had ceased, the mixture was refluxed 5 hrs. to give 2,4-bis(2,3-dimethylphenoxy)quinazoline (VI), m. 177-8° (aqueous ethanol). VI (8.9 g.) was heated to 320-33° in a N atmospheric for 3 hrs. to yield 1,3-bis(2,3-dimethylphenyl)-2,4(1H,3H)-quinazolinedione, which was refluxed with 37 g. 50% NaOH in 100 ml. ethanol for 10 hrs. to give I, m. 229-30°. The following intermediates were similarly prepared (m.p. given): 2-(2,3-dimethylphenyl)-4(3H)-quinazoline, 272-3°; 1-(2,3-dimethylphenyl)-2,4(1H,3H)-quinazolinedione, 270°; 2-chloro-4-pyrrolidinylquinazoline, 172°; 4-pyrrolidinyl-2-(2,3-dimethylphenyl)quinazoline, 125°; 5,12-bis(2,3-dimethylphenyl)dibenzo[b,f][1,5]diazocine, 210-15°; N-(2,3-dimethylphenyl)isatoic anhydride, 197-8°; 2-(2,3-dimethylphenyl)-4-carbostyryl, 194-5°; N-(2,3-dimethylphenyl)isatin, 188°; 2-hydroxymethyl-2',3'-dimethyldiphenylamine, 65-7°; N-(2,3-dimethylphenyl)-1,2-dihydro-4H-3,1-benzoxazine, 61-3°; N-(2,3-dimethylphenyl)-1,2-dihydro-4H-3,1-benzoxazine-4-on, 82-3°. The sodium salt of I was prepared by dissolving I in ethanol, adding the equivalent amount of aqueous or ethanolic

NaOH and concentrating the mixture in vacuo. I and its salts are effective as analgesics and in the treatment of inflammations.

IT 1970-10-1P, Quinazoline, 4(1-pyrrolidinyl)-2-(2,3-xylyl)-
RL: PREP (Preparation)
(preparation of)

RN 1970-10-1 CAPLUS
CN Quinazoline, 4-(1-pyrrolidinyl)-2-(2,3-xyllyl)- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 292 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:93275 CAPLUS

DOCUMENT NUMBER: 62:93275

ORIGINAL REFERENCE NO.: 62:16737d-g

TITLE: Biochemical and morphologic properties of a new
lactating mammary tumor line in the rat

AUTHOR(S): Hilf, Russell; Michel, Inge; Bell, Carlton; Freeman,
James J.; Borman, Aleck

CORPORATE SOURCE: Squibb Inst. of Med. Res., New Brunswick, NJ

SOURCE: Cancer Research (1965), 25, 286-99

CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new transplantable mammary adenocarcinoma of the Fischer rat was studied, which arose spontaneously from the R3230AB, a fast growing, lactating tumor. The new subline, R3230AC, is autonomous, responsive, and is composed primarily of epithelial cell elements. A copious lactational state is achieved in response to estrogen treatment and lactation is accompanied by a decrease in tumor growth rate. Androgen treatment will also decrease tumor growth rate. Biochem. studies showed that 2- to 3-fold increase in glucose-6-phosphate dehydrogenase and TPN-malic enzyme activities accompanied the estrogen-induced lactational response. Androgen treatment depressed the activities of these dehydrogenase enzymes below control levels. Isocitric dehydrogenase activity was not significantly altered. No significant anaerobic glucose utilization in vitro was obtained by R3230AC tumor, nor did treatment with estrogen alter the utilization of glucose substrate, but in vitro malic acid substrate utilization was demonstrated and estrogen treatment increased malic acid utilization. The new tumor was compared to mammary glands of the same animals. Estrogen treatment markedly increased glucose-6-phosphate dehydrogenase, TPN-malic enzyme and isocitric dehydrogenase activities. Mammary glands did not utilize glucose in vitro under anaerobic conditions, but they did utilize malic acid substrate under these conditions. The data suggest that R3230AC tumor is a transplantable breast neoplasm with certain biochem. and morphologic characteristics similar to normal breast tissue.

IT 102287-24-1 104998-19-8

(Derived from data in the 7th Collective Formula Index (1962-1966))


RN 102287-24-1 CAPLUS

CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester, Ac deriv. (7CI) (CA INDEX NAME)

CM 1


CRN 98024-45-4

CMF C22 H17 F N4 O2




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 104998-19-8 CAPLUS
CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-methoxy-, methyl ester, acetyl deriv. (7CI) (CA INDEX NAME)



D1-Ac

IT 2475-75-4P, m-Anisic acid, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester
RL: PREP (Preparation)
(preparation of)
RN 2475-75-4 CAPLUS
CN Benzoic acid, 5-methoxy-2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)



L7 ANSWER 293 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:93274 CAPLUS

DOCUMENT NUMBER: 62:93274

ORIGINAL REFERENCE NO.: 62:16737b-d

TITLE: Further studies on the influence of peripheral ring substitution on the carcinogenicity of tricycloquinazoline

AUTHOR(S): Baldwin, R. W.; Cunningham, G. J.; Dean, H. G.; Partridge, M. W.; Surtees, S. J.; Vipond, H. J.

CORPORATE SOURCE: Univ. Nottingham, UK

SOURCE: Biochemical Pharmacology (1965), 14(3), 323-31

CODEN: BCPA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English


AB 3-Ethyl-, 3-tert-butyl-, 3-methoxy-, and 2-fluoro derivs. of tricycloquinazoline (TCQ) were unequivocally synthesized. Detns. of their epidermal carcinogenic activities and further studies on 2-methyl-TCQ were carried out. The inactivity of 2-methyl-TCQ, both as a carcinogen and as an initiator, was confirmed, whereas 2-fluoro-TCQ was found to be active in both respects. Substitution in the 2-position of TCQ is therefore not in itself sufficient to abolish activity, and, moreover, covalent bonding of the 2-position to a receptor is not involved in TCQ carcinogenesis. Results with 3-methoxy-TCQ indicated that this substituent does not have a specific structural effect on activity. Decreases in the skin carcinoma incidence observed with 3-ethyl and 3-tert-butyl-TCQ as compared with 3-methyl-TCQ afford further support for the hypothesis that activity in TCQ and its derivs. is controlled by stereochem. factors related to the coplanar area of the mol. Comparative reassessment of the activities of all known TCQ derivs. and analogs implies a highly specific orientation of the carcinogen at the tissue receptor.

IT 2475-70-9 2475-74-3 102287-24-1
104998-19-8

(Derived from data in the 7th Collective Formula Index (1962-1966))


RN 2475-70-9 CAPLUS

CN Benzoic acid, 2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-4-fluoro-, methyl ester (CA INDEX NAME)



RN 2475-74-3 CAPLUS

CN Benzoic acid, 4-fluoro-2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




RN 102287-24-1 CAPLUS

CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester, Ac deriv. (7CI) (CA INDEX NAME)

CM 1


CRN 98024-45-4

CMF C22 H17 F N4 O2




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 104998-19-8 CAPLUS
CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-methoxy-, methyl ester, acetyl deriv. (7CI) (CA INDEX NAME)




D1-Ac


IT 2475-72-1, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-methoxy-, methyl ester 98024-45-4, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester (acetyl derivative)
RN 2475-72-1 CAPLUS
CN Benzoic acid, 2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-5-methoxy-, methyl ester (CA INDEX NAME)




RN 98024-45-4 CAPLUS
CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester (7CI) (CA INDEX NAME)



IT 2475-69-6P, Anthranilic acid, 5-tert-butyl-N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester 2475-72-1P, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-methoxy-, methyl ester 2475-73-2P, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-ethyl-, methyl ester 2475-75-4P, m-Anisic acid, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester 2475-76-5P, Anthranilic acid, 5-ethyl-N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester 4310-07-0P, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-tert-butyl-, methyl ester 98024-45-4P, Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester
 RL: PREP (Preparation)
 (preparation of)
 RN 2475-69-6 CAPLUS
 CN Benzoic acid, 5-(1,1-dimethylethyl)-2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




RN 2475-72-1 CAPLUS
 CN Benzoic acid, 2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-5-methoxy-, methyl ester (CA INDEX NAME)




RN 2475-73-2 CAPLUS

CN Benzoic acid, 2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-5-ethyl-, methyl ester (CA INDEX NAME)




RN 2475-75-4 CAPLUS

CN Benzoic acid, 5-methoxy-2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




RN 2475-76-5 CAPLUS

CN Benzoic acid, 5-ethyl-2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)




RN 4310-07-0 CAPLUS

CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-tert-butyl-, methyl ester (7CI, 8CI) (CA INDEX NAME)




RN 98024-45-4 CAPLUS


CN Anthranilic acid, N-[2-(o-aminophenyl)-4-quinazolinyl]-5-fluoro-, methyl ester (7CI) (CA INDEX NAME)




ACCESSION NUMBER: 1965:93273 CAPLUS
 DOCUMENT NUMBER: 62:93273
 ORIGINAL REFERENCE NO.: 62:16737a-b
 TITLE: Content of cobalt in the blood and organs of patients with uterine myoma depending on the speed of neoplastic growth
 AUTHOR(S): Gerasimovich, G. I.
 SOURCE: Akusherstvo i Ginekol. (1965), 41(1), 115-18
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB Cobalt was determined repeatedly according to Sandell (Colorimetric Determination of Traces of Metals, New York: Interscience Pubs., 1950, 224 pp.) in blood, plasma, erythrocytes, and tissue samples (myoma, myometrium, ovaries) of diseased women, of women killed accidentally and from blood donors. Normal values of Co in whole blood was 8.13, in blood plasma 9.98, and in erythrocytes 6.39 γ %. In cases of myoma with a low tumor growth rate, lower Co values (blood 6.95, plasma 8.09, erythrocytes 5.85 γ %) were found; while in cases of fast growing tumors, higher Co values were found (8.95, 11.48, 6.31 γ %, resp.). In samples of tissue withdrawn during operation, increased Co values were found in myomas in comparison with normal myometrium. In cases with fast-growing myomas, a higher Co content was found, not only in the tumor, but also in the myometrium and ovaries.
 IT 2475-70-9 2475-74-3
 (Derived from data in the 7th Collective Formula Index (1962-1966))
 RN 2475-70-9 CAPLUS
 CN Benzoic acid, 2-[[2-(2-aminophenyl)-4-quinazolinyl]amino]-4-fluoro-, methyl ester (CA INDEX NAME)



RN 2475-74-3 CAPLUS
 CN Benzoic acid, 4-fluoro-2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (CA INDEX NAME)



L7 ANSWER 295 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:31527 CAPLUS
 DOCUMENT NUMBER: 62:31527
 ORIGINAL REFERENCE NO.: 62:5611e-f
 TITLE: An autoradiographic and histochemical investigation of the gut mucopolysaccharides of the purple sea urchin (*Strongylocentrotus purpuratus*)
 AUTHOR(S): Holland, Nicholas D.; Nimitz, Aquinas
 CORPORATE SOURCE: Stanford Univ., Pacific Grove, CA
 SOURCE: Biological Bulletin (Woods Hole, MA, United States) (1964), 127(2), 280-93
 CODEN: BIBUBX; ISSN: 0006-3185
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A neutral mucopolysaccharide (I) was found in the connective tissue-muscle layer of all gut regions. In the inner epithelium, I was found in unicellular glands located in all gut regions preceding the junction of the esophagus and stomach. Many of the I of unicellular glands are acidic. Of these, some are sulfated and others are not. Autoradiograms show that some gland cells which contain acidic sulfated I first incorporate sulfate in the middle third of the cell. In some cases, the initially sulfated materials are refractory to specific histochem. tests for sulfated acid I, perhaps because they are masked by combination with protein. 20 references.
 IT 890-95-9
 (Derived from data in the 7th Collective Formula Index (1962-1966))
 RN 890-95-9 CAPLUS
 CN Quinazoline, 4-amino-2-(o-aminophenyl)-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 296 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:31526 CAPLUS
 DOCUMENT NUMBER: 62:31526
 ORIGINAL REFERENCE NO.: 62:5611d-e
 TITLE: Phospholipids of various subcellular fractions from the larvae of the blow fly *Phormia regina*
 AUTHOR(S): Taylor, James F.; Hodgson, Ernest
 CORPORATE SOURCE: Univ. of North Carolina, Raleigh
 SOURCE: Annals of the Entomological Society of America (1964), 57(6), 795-6
 CODEN: AESAAI; ISSN: 0013-8746
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The phospholipid profiles of mitochondria, microsomes, soluble fraction, and


the residue do not differ from the profile found for the whole organism by chromatography.

IT 890-95-9

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 890-95-9 CAPLUS

CN Quinazoline, 4-amino-2-(o-aminophenyl)-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 297 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1965:3106 CAPLUS

DOCUMENT NUMBER: 62:3106

ORIGINAL REFERENCE NO.: 62:561f-g

TITLE: Cyclic Amidines. XVIII. The synthesis of tricycloquinazolines by cyclodehydrogenation

AUTHOR(S): Partridge, M. W.; Slorach, S. A.; Vipond, H. J.

SOURCE: Journal of the Chemical Society (1964), (Oct.), 3670-3

CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Cyclization of 2-o-aminophenyl-4-arylaminquinazolines with HC(OEt)₃ yields 7-arylaminotriazabenz[a]anthracenes (I) which, on cyclodehydrogenation, afford tricycloquinazolines, e.g. II.

IT 855-89-0P, Quinazoline, 2-(o-aminophenyl)-4-(p-bromoanilino)-
856-01-9P, Phenol, o-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-
857-68-1P, Formanilide, 2'-(4-anilino-2-quinazolinyl)-
859-13-2P, Phenol, o-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-
859-14-3P, Quinazoline, 4-(p-bromoanilino)-2-(o-nitrophenyl)-
860-40-2P, Quinazoline, 2-(o-aminophenyl)-4-(2-naphthylamino)-
862-07-7P, Quinazoline, 4-(2-naphthylamino)-2-(o-nitrophenyl)-
863-07-0P, 1-Naphthoic acid, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester
863-08-1P, 2-Naphthoic acid, 3-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester
863-93-4P, 2-Naphthoic acid, 3-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester
976-20-5P, Quinazoline, 2-(p-aminophenyl)-4-anilino-
1062-47-1P, 1-Naphthoic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester
RL: PREP (Preparation)


(preparation of)

RN 855-89-0 CAPLUS


CN Quinazoline, 2-(o-aminophenyl)-4-(p-bromoanilino)- (7CI, 8CI) (CA INDEX NAME)




RN 856-01-9 CAPLUS
 CN Phenol, o-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- (7CI, 8CI) (CA INDEX NAME)




RN 857-68-1 CAPLUS
 CN Formanilide, 2'-(4-anilino-2-quinazolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 859-13-2 CAPLUS
 CN Phenol, o-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- (7CI, 8CI) (CA INDEX NAME)




RN 859-14-3 CAPLUS
 CN Quinazoline, 4-(p-bromoanilino)-2-(o-nitrophenyl)- (7CI, 8CI) (CA INDEX NAME)




RN 860-40-2 CAPLUS
 CN Quinazoline, 2-(o-aminophenyl)-4-(2-naphthylamino)- (7CI, 8CI) (CA INDEX NAME)




RN 862-07-7 CAPLUS
 CN Quinazoline, 4-(2-naphthylamino)-2-(o-nitrophenyl)- (7CI, 8CI) (CA INDEX NAME)




RN 863-07-0 CAPLUS
 CN 1-Naphthoic acid, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI, 8CI) (CA INDEX NAME)




RN 863-08-1 CAPLUS
 CN 2-Naphthoic acid, 3-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI, 8CI) (CA INDEX NAME)




RN 863-93-4 CAPLUS
 CN 2-Naphthoic acid, 3-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI, 8CI) (CA INDEX NAME)



RN 976-20-5 CAPLUS
 CN Quinazoline, 2-(p-aminophenyl)-4-anilino- (7CI, 8CI) (CA INDEX NAME)



RN 1062-47-1 CAPLUS
 CN 1-Naphthoic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 298 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:3105 CAPLUS
 DOCUMENT NUMBER: 62:3105
 ORIGINAL REFERENCE NO.: 62:561d-e
 TITLE: Cyclic Amidines. XVII. 4-Imino-1,2,3-benzotriazines
 AUTHOR(S): Partridge, M. W.; Stevens, M. F. G.
 CORPORATE SOURCE: Univ. Nottingham, UK
 SOURCE: Journal of the Chemical Society (1964),
 (Oct.), 3663-9
 CODEN: JCSOA9; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.


AB cf. CA 59, 5170e. 4-Imino-1,2,3-benzotriazines (I) afford, on reduction, 3-aminoindazoles (e.g. II) and on decomposition in acid, 6-aminophenan-thridines. The reactions of o-cyanophenyltriazenes were studied.

IT 890-95-9P, Quinazoline, 4-amino-2-(o-aminophenyl)-, dihydrochloride 964-17-0P, Quinazoline, 4-amino-2-(o-nitrophenyl)-, hydrochloride 1022-44-2P, Quinazoline, 4-amino-2-phenyl- 1032-50-4P, Quinazoline, 4-amino-2-(o-nitrophenyl)- 1061-33-2P, Quinazoline, 4-amino-2-(o-nitrophenyl)-, picrate

RL: PREP (Preparation)
(preparation of)

RN 890-95-9 CAPLUS


CN Quinazoline, 4-amino-2-(o-aminophenyl)-, dihydrochloride (7CI, 8CI) (CA INDEX NAME)



● 2 HCl

RN 964-17-0 CAPLUS


CN Quinazoline, 4-amino-2-(o-nitrophenyl)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)




● HCl

RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 1032-50-4 CAPLUS
CN Quinazoline, 4-amino-2-(o-nitrophenyl)- (7CI, 8CI) (CA INDEX NAME)



RN 1061-33-2 CAPLUS
CN Quinazoline, 4-amino-2-(o-nitrophenyl)-, picrate (7CI, 8CI) (CA INDEX NAME)


CM 1

CRN 1032-50-4
CMF C14 H10 N4 O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L7 ANSWER 299 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1964:492876 CAPLUS
DOCUMENT NUMBER: 61:92876
ORIGINAL REFERENCE NO.: 61:16204a-d
TITLE: Vat dyes
PATENT ASSIGNEE(S): CIBA Ltd.
SOURCE: 36 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 635078		19640117	BE	<--
GB 1027565			GB	
PRIORITY APPLN. INFO.:			CH	19620718


GI For diagram(s), see printed CA Issue.

AB Anthraquinone derivs. containing a heterocyclic nucleus are prepared Thus, a mixture of I 10 and 100% H2SO4 220 was stirred for 3 hrs. at room temperature, poured on ice, the precipitate filtered and suspended in H2O 1000 at 70-80°, neutralized with aqueous NaOH, NaCl 50 parts added, and the sulfonated dye filtered and vacuum-dried. It dyes cotton green. Similarly, other vat dyes were prepared (reactants and shade given): 2-biphenyl-4-chloro-6,7-phthaloylquinazoline, 1-aminoanthraquinone (II), H2SO4, orange; aminoacedianthrone (III), tetrachloropyrimidine (IV), 4-PhC6H4NH2 (V), H2SO4, violet; III, IV, V, H2NCH2CH2OH, H2SO4, brown; 4-aminoanthraquinone-2,1(N)-acridone (Va), 2,3-dichloroquinoxaline-6-carboxylic acid (VI) (m. 278°), olive-green; Va, VI, V, ruby red; aminodibenzanthrone (VII), 1,4-dichlorophthalazine (VIIa), H2SO4, blue; VII, VIIa, V, H2SO4, blue; II, VI, orange; Pz-dihydroxypyrazinoanthraquinone, SOCl2, 1-aminoanthraquinone-6-carboxylic acid, orange; III, IV, 27% oleum, brown; VII, 2,4-dichloroquinazoline, 2% oleum, blue; 2-(1,4-diamino-2-anthraquinonyl-5,6-phthaloylbenzothiazole, 2-biphenyl-4-chloroquin-azoline (VIII), H2SO4, gray. 2-H2NC6H4CO2H and 4-PhC6H4COCl are condensed to form 2-(4-PhC6H4CONH)C6H4CO2H, m. 244-8°, which with urea gave 2-biphenyl-4-quinazolone, m. 282-4°, and this compound and PCl5 formed VIII.

IT 106977-84-8 107988-55-6
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 106977-84-8 CAPLUS


CN Anthra[2,3-d]thiazole-5,10-dione, 2-[1-amino-4-[[2-(4-biphenyl)-4-quinazolinyl]amino]-2-anthraquinonyl]-, sulfo deriv., sodium salt (7CI) (CA INDEX NAME)






RN 107988-55-6 CAPLUS

CN Anthraquinone, 1,1'-iminobis[4-[[2-(4-biphenyl)-4-quinazolinyl]amino]-, disulfo deriv., sodium salt (7CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 856308-75-3, Anthraquinone, 1,1'-iminobis[4-[[2-(4-biphenyl)l]-4-quinazolinyl]amino]-
(disulfo derivative, Na salt)
RN 856308-75-3 CAPLUS
CN Anthraquinone, 1,1'-iminobis[4-[[2-(4-biphenyl)l]-4-quinazolinyl]amino]-
(7CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



IT 856308-19-5, Anthra[2,3-d]thiazole-5,10-dione,
2-[1-amino-4-[[2-(4-biphenyl)-4-quinazolinyl]amino]-2-anthraquinonyl]-
(sulfo derivative, Na salt)
RN 856308-19-5 CAPLUS
CN Anthra[2,3-d]thiazole-5,10-dione, 2-[1-amino-4-[(2-[1,1'-biphenyl]-4-yl-4-
quinazolinyl)amino]-9,10-dihydro-9,10-dioxo-2-anthracenyl]- (CA INDEX
NAME)



L7 ANSWER 300 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1964:411794 CAPLUS
DOCUMENT NUMBER: 61:11794
ORIGINAL REFERENCE NO.: 61:1980g-h,1981a-d
TITLE: Bis[4 - (anthraquinonylamino) - 2 -
quinazolylyl]azobenzenes and -azobiphenyls
INVENTOR(S): Weidinger, Hans; Haese, Gottfried
PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik A.-G.
SOURCE: 15 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 634560		19640106	BE	<--
FR 1361777			FR	
GB 1043348			GB	
US 3157631			US	
PRIORITY APPLN. INFO.:			DE	19620706

GI For diagram(s), see printed CA Issue.

AB Bis(4-chloro-2-quinazolylyl)azobenzenes and -azobiphenyls are treated with an aminoanthraquinone to give dyes of the general formula I which give fast, full, brilliant colors on cotton. Thus, o-H₂NC₆H₄CONH₂ 100 in 2N Na₂CO₃ 700 is treated with a solution of 4-O₂NC₆H₄COC₁ 136 in C₆H₆ 140 to give 2-(4-nitrophenyl)-4-hydroxyquinazoline (II) 178-85 parts, m. 352-4°. A mixture of II 133.5 in a solution of KOH 50 in H₂O 2000 is treated with NaOH 300 in H₂O 1625, heated at 85°, treated with glucose 100 parts, heated 30 min. at 90-5°, treated with 50 parts addnl. glucose, and heated for 1 hr. at 90-5° to give 4,4'-bis(4-hydroxy-2-quinazolylyl)azobenzene (III), m. >350°. A mixture of III 20 and PhNO₂ 120 parts is treated for 5 hrs. at 180° with COCl₂ to give 18-20 parts 4,4'-bis(4-chloro-2-quinazolylyl)azobenzene (IV), m. >350°. A mixture of IV 9, 2-aminoanthraquinone (V) 8.1, and PhNO₂ 120-50 parts is heated for 3 hrs. at 190°, cooled, filtered, and the precipitate washed with MeOH to give I (R = p-C₆H₄, X = anthraquinon-2-ylamino), yellow on cotton. Similarly prepared are dyes from IV and the following amines (color of dye on cotton given): 1-amino-3-chloroanthraquinone, golden orange; 1-aminoanthraquinone (VI), orange; 1-amino-5-(benzoylamino)anthraquinone (VII), brown-orange; 5-aminoanthrapyrimidine (VIII), brown; 1-amino-2-[2-(2-aminophenyl)-5-oxadiazolylyl] anthraquinone (IX), red; 1-amino-4-(benzoylamino)anthraquinone (X), bordeaux; 1,4-diamino-2-(2-phenyl-5-oxadiazolylyl)anthraquinone (XI), blue-green; 1,4-diamino-2-acetylanthraquinone (XII), blue-green; 4-aminoanthraquinone-1(N)-2-benzacridone (XIII), green; 1'-chloro-4'-aminoanthraquinone-1(N)-2-benzacridone (XIV), gray; dyes from I (R = m-C₆H₄, X = Cl) and the following amines (color on cotton given): V, yellow; VII, brown-orange; IX, red; X, red-violet; XI, blue; XIII, blue-green; XIV, blue-gray; VI, orange; dyes from I (R = 4,4' - biphenylylene, X = Cl) and the following amines (color on cotton given): VI, yellow; V, yellow; VII, yellow; XII, blue-green; XIII, green; dyes from IV and the following amine mixts. (color on cotton given): VII and VIII, brown; VII and XIII, olive; XII and XIII, blue green; VII and XII, olive; VI and VIII, brown. Also prepared are the following intermediates (m.p. given): 2-(3-nitrophenyl)-4-hydroxyquinazoline, 340-2°; I (R = m-C₆H₄, X = OH), 350°; I (R = m-C₆H₄, X = Cl), 300-10° 2-[(4'-nitro-4-biphenylylcarbonyl)amino]benzamide, 245-50°; 2-(4'-nitro-4-biphenylyl)4-hydroxyquinazoline, 325-30°; I (R = 4,4'-biphenylylene, X = OH),


350°; I (R = 4,4'-biphenylylene, X = Cl), 324-6°.

IT 107387-41-7

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 107387-41-7 CAPLUS


CN Anthraquinone, 1,1'-[azobis(p-phenylene-2,4-quinazolinediylimino)]bis[5-benzamido- (7CI) (CA INDEX NAME)



IT 106713-05-7P, Anthraquinone, 1,1'-[azobis(m-phenylene-2,4-quinazolinediylimino)]di- 106713-06-8P, Anthraquinone, 1,1'-[azobis(p-phenylene-2,4-quinazolinediylimino)]di- 106784-84-3P, Anthraquinone, 2,2'-[azobis(p-phenylene-2,4-quinazoline-diylimino)]di- 107101-22-4P, Anthraquinone, 1,1'-[azobis(4',4'-biphenylylene-2,4-quinazolinediylimino)]di- 107420-02-0P, Anthraquinone, 5-benzamido-1,1'-[azobis(p-phenylene-2,4-quinazolinediylimino)]di- 107928-72-3P, Naphth[2,3-c]acridan-5,8,14-trione, 6,6'-[azobis(p-phenylene-2,4-quinazolinediylimino)]bis-
RL: PREP (Preparation)
(preparation of)


RN 106713-05-7 CAPLUS

CN Anthraquinone, 1,1'-[azobis(m-phenylene-2,4-quinazolinediylimino)]di- (7CI) (CA INDEX NAME)




RN 106713-06-8 CAPLUS


CN Anthraquinone, 1,1'-[azobis(p-phenylene-2,4-quinazolinediylimino)]di- (7CI) (CA INDEX NAME)




RN 106784-84-3 CAPLUS
 CN Anthraquinone, 2,2'-[azobis(p-phenylene-2,4-quinazolinediylimino)]di- (7CI) (CA INDEX NAME)




RN 107101-22-4 CAPLUS
 CN Anthraquinone, 1,1'-[azobis(4',4-biphenylylene-2,4-quinazolinediylimino)]di- (7CI) (CA INDEX NAME)



RN 107420-02-0 CAPLUS
 CN Anthraquinone, 5-benzamido-1,1'-[azobis(p-phenylene-2,4-quinazolinediylimino)]di- (7CI) (CA INDEX NAME)



RN 107928-72-3 CAPLUS
 CN Naphth[2,3-c]acridan-5,8,14-trione, 6,6'-[azobis(p-phenylene-2,4-quinazolinediylimino)]bis- (7CI) (CA INDEX NAME)



L7 ANSWER 301 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1963:428562 CAPLUS
 DOCUMENT NUMBER: 59:28562
 ORIGINAL REFERENCE NO.: 59:5170e-h,5171a-e
 TITLE: Cyclic amidines. XVI. Tetraazanaphtho[1,2,3-fg]naphthacenes
 AUTHOR(S): Parfitt, R. T.; Partridge, M. W.; Vipond, H. J.
 CORPORATE SOURCE: Univ. Nottingham, Nottingham, UK
 SOURCE: Journal of the Chemical Society (1963) 3062-6
 CODEN: JCSOA9; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 59:28562
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 57, 12490c. Some title compds., isomeric with tricycloquinazoline (I), were synthesized for examination of their carcinogenic activity. 9,10,15,15b-tetraazanaphtho[1,2,3-fg]naphthacene(II) is a weak epidermal carcinogen, while I is intermediate in activity between 1,2;5,6-dibenzanthracene and 3,4-benzopyrene. This contrast provides

further evidence of the importance of the stereochem. fit in I carcinogenesis. The 4a,9,10,15-isomer (III) of II is too insol. in appropriate solvents for biol. testing. 2-Anilino-4-chloroquinazoline (4 g.) and 2.4 g. o-H₂NC₆H₄CO₂Me shaken 0.5 hr. in 50 cc. dry Me₂CO gave 2-anilino-4-(o-methoxycarbonylanilino)quinazoline-HCl (IV.HCl), m. 360-4° (EtOH); IV (from IV.HCl with alc. NH₃) m. 210-12° (aqueous AcOH). IV heated 1 hr. at 210° and then extracted with BuOH yielded 6-anilino-7H-5,6a,12-triazabenz[a]anthracen-7-one (V), m. 190-2°. 4-Hydroxy-2-[o-(3-phenylureido)phenyl]quinazoline (VI) (0.5 g.) in 15 cc. POCl₃ kept 12 hrs. or refluxed 1 hr. and poured onto 200 g. crushed ice yielded 74% V. 2-(o-Aminophenyl)-4-hydroxyquinazoline (VII) (5 g.) in 300 cc. dry C₆H₆ refluxed 1 hr. with 3 g. PhNCO yielded 6.1 g. VI, m. 304-6° (aqueous HCO₂H). VI fused 15 min. at 220-30° with NaOH gave 71% 2,4-dihydroxyquinazoline, m. 349-55°. VII (5 g.) in 400 cc. dry C₆H₆ and 10 g. cyclohexyl isocyanate refluxed 6 hrs. yielded 98% 2-[o(3-cyclohexylureido)] analog of VI, m. 242-4° (HCO₂H). V (1 g.) added at about 100° to a melt of 0.4 g. NaCl and 2 g. AlCl₃, heated 1 hr. at 320°, cooled, powdered, extracted with H₂O at 65°, and the extract treated with 50 cc. saturated aqueous NaNO₃ yielded II.HNO₃, dark red prisms, m. 216-18°

(precipitated


from H₂O with HNO₃). II.HNO₃ in H₂O treated with Et₃N and extracted with CHCl₃ gave II, dark green needles, m. 296-8° (CHCl₃), which sublimed at 265-70°/0.1 mm. gave prisms, m. 296-8°. II digested 2 days with N HCl-AcOH gave II.HCl, dark red needles, m. 328-30°; II picrate, green, m. 259-60° (AcOH). II with H₃PO₄ in Et₂O yielded during 10 days a deliquescent phosphate, dark red needles, m. 154-6°. II (0.4 g.) in 25 cc. AcOH refluxed 15 min. with 5 cc. 30% aqueous H₂O₂ and basified with NH₄OH yielded 0.17 g. N-oxide of II, pale yellow prisms, m. 276-7° (aqueous HCONMe₂). VI (0.5 g.) and 0.6 g. NaCl-AlCl₃ heated 1 hr. at 320° gave II, isolated as 25 mg. II.HNO₃. VIII (R = OH) (IX) (1.3 g.), 0.52 g. PhNH₂, and 2 g. NaCl-AcCl₃ heated 1 hr. at 320° yielded 0.12 g. II. (o-H₂NC₆H₄)CO (1.06 g.) and 1 g. 2,4-dichloroquinazoline in 20 cc. AcOH refluxed (0.5 hr. gave II, isolated as 0.75 g. II.HCl. II refluxed 8 hrs. with 4N HCl, 12 hrs. with 11N HCl, 5 hrs. with 5N NaOH, 5 hrs. with 10N NaOH, 24 hrs. with 2N HNO₃, 4 hrs. with 1.5N CrO₃, and 24 hrs. with 2N alkaline KMnO₄ showed 100, 42, 96, 24, 14, 41, and 20% recovery, resp. V (1 g.) in 6 cc. PhNO₂ and 0.45 g. POCl₃ refluxed 15 hrs., basified with NH₃, steam-distd, to remove the PhNO₂, and the tarry residue chromatographed on Al₂O₃ yielded 75 mg. I, m. 317-19°. VI (0.5 g.) in 20 cc. 100% H₃PO₄ heated 6 hrs. at 223° and poured into H₂O gave 15 mg. I. 2,4-Dianilinoquinazoline-HCl (20 g.) refluxed 4 hrs. with 50 g. KOH in 250 cc. (CH₂OH)₂, cooled, diluted with H₂O, acidified, and the precipitate extracted with EtOH gave from

the extract


9.5 g. 2-anilino-4-hydroxyquinazoline, m. 260-2° (AcOH), which was also obtained in 61% yield by hydrolysis with alc. KOH; Ac derivative m. 201-3°. 4-Ethoxy-2-(o-carbethoxyanilino)quinazoline (X) (0.5 g.) and 5 cc. PhNH₂ heated 6 hrs. at 180° and diluted with 5 cc. Me₂CO yielded 0.29 g. 5-anilino-12H-6,7,12a-triazabenz[a]anthracen-12-one (XI), yellow prisms, m. 298-300° (EtOCH₂CH₂OH); the mother liquor deposited 0.07 g. 4-OH analog of X, m. 210-12°, resolidifying and remelting at 290-6°. 11,12-Dihydro-11,12-dioxo-5H-5,6,11a-triazanaphthacene (XII) (2 g.) in 50 cc. POCl₃ heated 6 hrs. at 120-40°, poured onto crushed ice, and extracted with CHCl₃ yielded 0.44 g. 6,12-dihydro-5,12dioxo-5H-6,7,12a-triaza[a]anthracene, m. 254-6°, and 1.4 g. unchanged XII. 4-Chloro-2-(o-nitrophenyl)quinazoline (XIII) (0.5 g.) and 5 g. MeNH₂.AcOH heated 1 hr. at 180°, extracted with H₂O, the insol. residue dissolved in EtOH, and basified gave 0.46 g. 4-methylamino-2-(o-nitrophenyl)quinazoline (XIV), m. 169-71° (aqueous EtOH); picrate m. 279-81°. XIII (2.9 g.), 0.83 g. PhNH₂, and 0.5 cc HCl in 150 cc. Me₂CO refluxed 0.5 hr. and cooled gave

3.1 g. 4-anilino-HCl analog of XIV, m. 192-5° (decomposition) (MeOH); free base m. 177-8° (decomposition) (BuOH). 5,6-Diazanaphthacene-11,12-diol (2 g.), 8 g. PCl₅, and 12 cc. POCl₃ heated 3 hrs. at 120-40°, kept 12 hrs., filtered rapidly, the filter residue mixed with 5 g. 2-aminopyridine, kept molten 0.5 hr., cooled, and extracted with H₂O left 0.17 g. III, yellow prisms, m. 370-2° (AcOH and sublimed). III with 2N aqueous-alc. H₂SO₄ gave the sulfate, yellow needles, m. 326-30° (decomposition). 11-Chloro-5,6-diazanaphthacen-12-ol (0.55 g.), 0.5 g. Cu powder, and 5 g. 2-aminopyridine refluxed 4 hrs. yielded 0.11 g. III. The ultraviolet absorption maximum of XI, the 5-piperidino analog of XI, and IX are recorded.

IT 94688-16-1P, Quinazoline, 4-anilino-2-(o-nitrophenyl)-
 94879-05-7P, Quinazoline, 4-(methylanino)-2-(o-nitrophenyl)-
 94879-06-8P, Quinazoline, 4-(methylanino)-2-(o-nitrophenyl)-,
 picrate 106300-56-5P, Quinazoline, 4-anilino-2-(o-nitrophenyl)-,
 hydrochloride
 RL: PREP (Preparation)
 (preparation of)
 RN 94688-16-1 CAPLUS
 CN Quinazoline, 4-anilino-2-(o-nitrophenyl)- (7CI) (CA INDEX NAME)




RN 94879-05-7 CAPLUS
 CN 4-Quinazolinamine, N-methyl-2-(2-nitrophenyl)- (CA INDEX NAME)



RN 94879-06-8 CAPLUS
 CN Quinazoline, 4-(methylanino)-2-(o-nitrophenyl)-, picrate (7CI) (CA INDEX NAME)

CM 1


CRN 94879-05-7
 CMF C15 H12 N4 O2



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7



RN 106300-56-5 CAPLUS

CN Quinazoline, 4-anilino-2-(o-nitrophenyl)-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

L7 ANSWER 302 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1962:462771 CAPLUS

DOCUMENT NUMBER: 57:62771

ORIGINAL REFERENCE NO.: 57:12490c-i,12491a-i,12492a-d

TITLE: Cyclic amidines. XV. Derivatives of tricycloquinazoline

AUTHOR(S): Partridge, M. W.; Vipond, H. J.; Waite, J. A.

CORPORATE SOURCE: Univ. Nottingham, UK

SOURCE: Journal of the Chemical Society (1962) 2549-56

CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. CA 55, 9422a. Unsym. substituted tricycloquinazolines, required for examination of the relevance of the symmetry of tricycloquinazoline to its

carcinogenic activity, were synthesized by a number of routes.

5-Fluoroisatin (15 g.) in 150 ml. 2.5N NaOH treated dropwise with 27 ml. 30% H₂O₂, heated 15 min. at 80-90°, filtered through C, and the filtrate treated with concentrated HCl gave 7 g. 5,2-F(H₂N)C₅H₃-CO₂H, m. 182-3° (xylene). 2-NCC₅H₄NH₂ (I) (11.8 g.) in 40 ml. dry C₆H₆ and 20 ml. pyridine shaken 1 hr. with 20 g. 2-O₂NC₆H₄COC₁ (II) in 70 ml. C₆H₆, the C₆H₆ distilled, and the residue treated with 300 ml. H₂O gave 16.4 g. 4,2 R(NC)C₆H₃NHCOC₆H₄NO₂-2 (III) (R = H), m. 205-6° (EtOH). Similarly were prepared 61% III (R = Me), m. 185-6° (EtOH), and 58% III (R = Br), m. 190-7° (AcOH or BuOH). II (65 g.) in 200 ml. C₆H₆ added during 10 min. to 49 g. 5,2-Me(H₂N)C₆H₃CO₂H in 500 ml. 0.8N NaOH with stirring, the mixture stirred 30 min., and the aqueous layer adjusted to pH 4 with AcOH gave 69 g. x,2-R(2-O₂-NC₆H₄CONH)C₆H₃CO₂H (IV) (R = 5-Me), m. 229.5-31.0° (BuOH). The following IV were prepared similarly (R, % yield, m.p., recrystn. solvent given): 3-Me, 209-10°, EtOH; 5-Br, 75, 251-2 BuOH; 5-F, 70, 252-3°, EtOH. IV (R = 5-Me) (68 g.) boiled 1 hr. with 200 ml. Ac₂O gave 58 g. V (R = Me, R' = H), m. 186.5-8.0° (AcOH). The following V were prepared similarly (R, R', % yield, m.p., recrystn. solvent given): H, Me, 86, 186-7 AcOH; Br, H, 86, 145-6°, EtOH; F, H, 92, 170-1°, AcOH. Method A. III (R = H) (5 g.) in 15 ml. dioxane and 100 ml. 20% aqueous NaOH refluxed 1 hr. with 60 ml. 30% H₂O₂, the solution treated with 25 ml. 30% H₂O₂, refluxed 30 min., diluted with 500 ml. H₂O, neutralized with AcOH, and made alkaline with


aqueous NH₃

gave 4.35 g. VI (R = R' = H) (VIa), m. 227-8° (PhMe). Method B. V (R = R' = H) (30 g.) and 150 g. urea heated 30 min. at 180-90° and poured into 1.25 l. H₂O with stirring gave 26 g. Via, m. 227-9° (BuOH). By the foregoing methods were prepared the following VI (R, R', method, % yield, m.p., recrystn. solvent given): Me, H, A, 88, 271-3° BuOH; Me, H, B, 92, 271-3°, BuOH; H, Me, B, 74, 286-8°, AcOH; Br, H, A, 90, 279-80°, AcOH; Br, H, B, 79, 279-80 AcOH; F, H, B, 68, 248-9°, MeOCH₂CH₂OH (VII). VIa (2.7 g.) in 20 ml. 2N NaOH treated gradually with 10.5 g. Na₂S₂O₄ at 80° while maintaining the pH above 9 by further addns. of 2N NaOH, after 30 min. the solution cooled, and neutralized with AcOH gave 1.4 g. VIII (R = R' = H) (VIIIa) m. 239-41°. Raney Ni added portion-wise to 2.7 g. VIa and 4 ml. 80% N₂H₄.H₂O (IX) in 80 ml. EtOH at 60-5° until effervescence subsided and the mixture filtered deposited 1.56 g. VIIIa, m. 240-1°; 2-(2-nitrobenzoyl) derivative (X) (formed with II) m. 272-3°. Reduction of the VI with Raney Ni and IX in EtOH or BuOH gave the following VIII (R, R', % yield, m.p., recrystn. solvent given): Me, H (XI), 76, 223-4° [HCl salt m. 279-81° (2N HCl)], iso-PrOH; H, Me (XII), 78, 259-60°, BuOH; Br, H, (XIII), 67, 264-5°, BuOH; F, H (XIV), 68, 266-7°, EtOH. VIIIa (1 g.) refluxed 90 min. in 25 ml. pyridine with 1.4g. 2-phthalimidobenzoyl chloride, diluted with H₂O, and the alkali-sol, fraction worked up gave 1.1 g. 2-(2-phthalimidobenzoyl) derivative (XV) of VIIIa, m. 316-18° (PhMe). Reduction of X with Raney Ni and IX in EtOH gave 24% 2-(2-amino-benzoyl) derivative (XVI) of VIIIa, m. 314-16° (BuOH). XV (0.3 g.) in 20 ml. VII refluxed 2 hrs. with 0.5 ml. 80% IX and the solution neutralized with HCl gave 0.11 g. XVI. XI (0.75 g.) and 0.6 g. II in 16 ml. dry C₆H₆ and 25 ml. pyridine refluxed 90 min., the C₆H₆ removed, and the residual solution diluted with H₂O gave 0.87 g. corresponding amide (XVII), m. 272-3° (BuOH); the mother liquors deposited 0.045 g. compound, probably the secondary amide, m. 24950°. Reduction of XVII with Raney Ni and IX gave 58% 2-(2-aminobenzoyl) derivative (XVIII) of XI, m. 317-20° (BuOH); Ac derivative m. 295-7° (BuOH). Catalytic reduction of XVII in AcOH over PtO₂ gave 52% XVIII. From VIIIa and 2-(4-MeC₆H₄SO₂NH)C₆H₄COC₁ was prepared 61% corresponding amide (XIX), m. 266-7° (BuOH). VIa (2.7 g.), 0.73 g. HCONMe₂, and 15 ml. SOCl₂ boiled 75 min., cooled, and poured onto 100 g. crushed ice with stirring gave 2.7 g. 4-chloro-2-(2-nitrophenyl)quinazoline (XX), m. 179-81° (anhydrous


Me₂CO). VIa (40 g.) and 160 ml. POCl₃ heated 2.5 hrs. at 140°, filtered hot, and the filtrate kept at 0° gave 20.6 g. XX, m. 179-81°; from the mother liquor was obtained 9.3 g. XX, m. 178-80°. XX (2.85 g.), 1.51 g. 2-H₂NC₆H₄CO₂Me, and 0.2 ml. concentrated HCl in 150 ml. Me₂CO refluxed 1 hr. gave 4 g. XXI (R = CO₂Me, R' = R'' = H) (XXII) HCl salt, m. 232-3° (MeOH); XXII (obtained from XXII.HCl in MeOH with aqueous NH₃) m. 187-8° (AcOH). The following XXI were prepared similarly (R, R', R'', % yield, m.p., m.p. of HCl salt given): CO₂H, H, H, 70, 309-11°, 253-5°; CN, H, H, 74, 186-7°, -; CO₂Me, Me, H, 74, 196-7°, 173-5° (decomposition) (containing EtOH of crystallization); CO₂Me, H, Me, 69, 214-15°, 217-19° (decomposition); CN, H, Me, 83, 197-9°, 192-3° (decomposition) (containing AcOH of crystallization); CN, H, OMe, 76, 197-8°, 161-2°. XXII (2.2 g.) in 150 ml. AcOH shaken with H and 0.01 g. PtO₂, filtered, the filtrate evaporated, the residue extracted with acid, and the extract basified gave 1.3 g. XXIII (R = CO₂Me, R' = R'' = H) (XXIV), m. 192-3° (BuOH); HCl salt m. 176-8 (2N HCl); Ac derivative m. 212-13° (AcOH). Reduction of XXII with Raney Ni and IX in BuOH as described above gave 76% XXIV, m. 191-3°. By the latter reductive procedure were prepared the following XXIII (R, R', R'', % yield, m.p., recrystn. solvent given): CO₂Me, Me, H (XXV), 75, 152-3°, MeOH; CO₂Me, H, Me (XXVI), 90, 182-3°, BuOH; CN, H, Me (XXVII), 59, 195-6° (decomposition), PhMe; CN, H, OMe (XXVIII), 60, 201-3° (decomposition), BuOH. I (3 g.) and 8 g. Me anthranilate ptoluenesulfonate heated 40 min. at 210° and the product extracted with hot acid and alkali gave 1.02 g. tricycloquinazo-line (XXIX), m. 317-20°, having the characteristic bands between 245 and 455 μ neutralization of the acid and alkaline exts. gave 0.4 g. 5-amino-11-hydroxyphenhomazine, isomeric with VIIIA, m. 213-15° (MeOH) [di-Ac derivative m. 238-9° (AcOH)]. VIIIA (0.6 g.), 0.3 g. I, and 0.1 g. 4-MeC₆H₄SO₃H heated 45 min. at 210°, the powdered product washed with warm 2N HCl and 2N NaOH, and extracted with C₆H₆ gave 0.49 g. XXIX, m. 318-20°. The following derivs. of XXIX were prepared similarly by the latter method (reactants, derivative of XXIX formed, % yield, m.p. given): XII and I, 1-Me (XXX), 31, 292-4°; VIIIA and 5,2-Me(NC) C₆H₃NH₂, 2-Me (XXXI), 31, 278-9 (XXVII heated 1 hr. at 210° underwent cyclization and gave 30% XXXI, m. 278-80°); VIIIA and 4,2-Me(NC)C₆H₃NH₂ (XXXII) (obtained in 47% yield by pyrolysis of 5-methylisatin 3-oxime), 3-Me (XXXIII), 31, 266-7 XI and I, 3-Me, 33, 266-7°; VIIIA and 3,2-Me(NC)C₆H₃NH₂, 4-Me (XXXIV), 20, 246-8°; VIIIA and 4,2-Br(NC)C₆H₃NH₂ (XXXV), 3-Br, 34, 290-1°; XIII and I, 3-Br, 35, 290-1°; VIIIA and 4,2-F(NC)C₆H₃NH₂ (XXXVI) [b₁₅ 130 m. 94-5° (H₂O)], 3-F, 30, 322-3°; XI and XXXII, 3,8-Me₂, 42, 273-5°; XIII and XXXV, 3,8-Br₂, 18, 325-6°; XIV and XXXVI, 3,8-F₂, 29, 336-8°. XVI (0.1 g) and 0.4 g. P₂O₆ in 15 ml. xylene boiled 90 min. and subsequently treated with H₂O gave 20 mg. XXIX, m. 317-20°. XVIII and XIX treated similarly gave 23% XXXIII, m. 264-6°, and 17% XXIX, m. 318-20°, resp. XXII treated similarly gave 23% XXXIII, m. 264-6°, and 17% XXIX, m. 318-20°, resp. XXII treated similarly gave (from the acid-soluble fraction) 30% recovered XXII and (as the acid-insol. fraction) 14% XXIX, m. 319-20°. XXII (0.5 g.) and 25 g. 100% H₃PO₄ heated 3 hrs. at 160° (optimum time and temperature) and poured into 70 ml. H₂O gave 0.34 g. XXIX, m. 319-20° (PhMe). Similar treatment of XXVI and XXV gave 80% XXXI, m. 278-9°, and 70% XXXIII, m. 266-7 resp. XXXII.4-MeC₆H₄SO₃H heated 45 min. at 210° gave 11% 3,8,13-trimethyltricycloquinazoline, m. 388-90° (xylene). XXVIII (1 g.) heated 2 hrs. at 255° gave 0.73 g. 2-methoxytricycloquinazoline (XXXVII), m. 250-1° (PhMe). XXXVII demethylated by boiling 1 hr. with aqueous HBr gave 92% 2-hydroxytricycloquinazoline, m. 367-9 (aqueous pyridine). From preliminary

biol. observations, the most significant indication was that XXXI was almost noncarcinogenic, whereas XXX, XXXIII, and XXXIV were carcinogenic. Spectral data for the tricycloquinazolines were recorded.

IT 94873-30-0P, Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]- 95024-95-6P, Benzoic acid, p-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester 95139-11-0P, p-Tolunitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- 95139-13-2P, p-Anisonitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- 95162-70-2P, p-Tolunitrile, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- 95162-72-4P, p-Anisonitrile, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- 95225-67-5P, p-Toluic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester 95435-27-1P, p-Toluic acid, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester 96060-81-0P, m-Toluic acid, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester 96262-63-4P, m-Toluic acid, 6-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester 100088-90-2P, Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]-, hydrochloride 100266-70-4P, p-Tolunitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, hydrochloride 100266-71-5P, p-Anisonitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, hydrochloride 100322-03-0P, p-Toluic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride 100410-65-9P, m-Toluic acid, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride 104534-33-0P, Benzoic acid, p-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride 107159-62-6P, Benzoic acid, p-[[2-(o-acetamidophenyl)-4-quinazolinyl]amino]-, methyl ester 856308-38-8P, Anthranilonitrile, N-[2-(o-nitrophenyl)-4-quinazolinyl]- 856308-77-5P, Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester, hydrochloride 856308-80-0P, Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]-, methyl ester
 RL: PREP (Preparation)
 (preparation of)
 RN 94873-30-0 CAPLUS
 CN Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]- (7CI) (CA INDEX NAME)




RN 95024-95-6 CAPLUS
 CN Benzoic acid, p-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI) (CA INDEX NAME)




RN 95139-11-0 CAPLUS

CN p-Tolunitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- (7CI) (CA INDEX NAME)




RN 95139-13-2 CAPLUS

CN p-Anisonitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]- (7CI) (CA INDEX NAME)




RN 95162-70-2 CAPLUS

CN p-Tolunitrile, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- (7CI) (CA INDEX NAME)




RN 95162-72-4 CAPLUS

CN p-Anisonitrile, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]- (7CI) (CA INDEX NAME)




RN 95225-67-5 CAPLUS

CN p-Toluic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI) (CA INDEX NAME)




RN 95435-27-1 CAPLUS

CN p-Toluic acid, 2-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI) (CA INDEX NAME)




RN 96060-81-0 CAPLUS

CN m-Toluic acid, 6-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester
(7CI) (CA INDEX NAME)




RN 96262-63-4 CAPLUS

CN m-Toluic acid, 6-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester
(7CI) (CA INDEX NAME)



RN 100088-90-2 CAPLUS


CN Anthranilic acid, N-[2-(o-nitrophenyl)-4-quinazolinyl]-, hydrochloride
(7CI) (CA INDEX NAME)



●x HCl

RN 100266-70-4 CAPLUS


CN p-Tolunitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

RN 100266-71-5 CAPLUS


CN p-Anisonitrile, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, hydrochloride (7CI) (CA INDEX NAME)



●_x HCl

RN 100322-03-0 CAPLUS


CN p-Toluic acid, 2-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride (7CI) (CA INDEX NAME)



● HCl


RN 100410-65-9 CAPLUS

CN m-Toluic acid, 6-[[2-(o-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride (7CI) (CA INDEX NAME)




● x HCl

RN 104534-33-0 CAPLUS
 CN Benzoic acid, p-[[2-(o-aminophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride (7CI) (CA INDEX NAME)




● HCl

RN 107159-62-6 CAPLUS
 CN Benzoic acid, p-[[2-(o-acetamidophenyl)-4-quinazolinyl]amino]-, methyl ester (7CI) (CA INDEX NAME)




RN 856308-38-8 CAPLUS

CN Benzonitrile, 2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 856308-77-5 CAPLUS


CN Benzoic acid, 2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 856308-80-0 CAPLUS

CN Benzoic acid, 2-[[2-(2-nitrophenyl)-4-quinazolinyl]amino]-, methyl ester
(CA INDEX NAME)



L7 ANSWER 303 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1962:73498 CAPLUS

DOCUMENT NUMBER: 56:73498

ORIGINAL REFERENCE NO.: 56:14287d-h

TITLE: Reaction of 2,4-dichloro-5-nitropyrimidine with amines

AUTHOR(S): Taylor, Edward C.; Thompson, Malcolm J.

CORPORATE SOURCE: Princeton Univ., Princeton, NJ

SOURCE: Journal of Organic Chemistry (1961), 26,
5224-6

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB 2,4-Dichloro-5-nitropyrimidine (I) (31.5 g.) in 120 ml. dioxane stirred 3 hrs. at 0-5° with 80 ml. 25% MeNH₂ in 60 ml. AcOH, diluted with 350 ml. ice H₂O, kept 2 hrs. at 0°, and filtered, gave 17.5 g. crude product which by infrared spectrum was shown to be a mixture of 70-80% 2-chloro-4-methylamino-5-nitropyrimidine (II) and 30-20% 4-chloro-2-methylamino-5-nitropyrimidine (III). Recrystn. gave pure II, m. 85-6° (aqueous alc.). Fractional crystallization of the less soluble of the 2 products gave 2-3 g. III, m. 122°. Repetition of the reaction with I and methylamine acetate at 15-20° gave 20.2 g. crude product. This contained II and III in about the same ratio. The alc. insol. residue of 1.1 g. was 2,4-bis(methylamino)-5-nitropyrimidine (IV), m. 261-3°. II (2 g.) and 50 ml. 10% alc.-NH₃ left 4 hrs. at room temperature gave 1.63 g. 2-amino-4-methylamino-5-nitropyrimidine, m. 249-50°. III (0.5 g.) in 10 ml. MeOH containing 0.1 g. Na refluxed 0.5 hr. gave 45% 2-methylamino-4-methoxy-5-nitropyrimidine (IVa), m. 207-8°. III (0.35 g.) and 20 ml. N NaOH heated 1 hr. gave 0.045 g. IV and acidification of the filtrate gave 31% 2-methylamino-5-nitro-4(3H)-pyrimidone (V), m. 326° (decomposition). V was obtained by hydrolysis of IVa with concentrated HCl 2 hrs. on the steam bath. II (0.5 g.) and 20 ml.

N


NaOH heated 1 hr. gave 0.026 g. IV and acidification of the filtrate gave 0.21 g. 4-methylamino-5-nitro-2(1H)-pyrimidone (VI), m. 325° (decomposition). VI was also obtained by hydrolysis of

2-methoxy-4-methylamino-

5-nitropyrimidine. 2-Chloro-4-amino-5-nitropyrimidine (0.5 g.) and 40 ml. 0.5N NaOH heated 45 min. gave 45% 5-nitrocytosine, m. above 360°.

I (10 g.) in 50 ml. alc. added rapidly to 200 ml. alc.-NH₃, the mixture heated to boiling, left 0.5 hr., and filtered gave 7.65 g. 2,4-diamino-5-nitropyrimidine, m. above 350°. Infrared and ultraviolet spectra were given for these compds.

IT 93716-72-4
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 93716-72-4 CAPLUS
CN 4-Quinazolinamine, 6-nitro-2-(4-nitrophenyl)- (CA INDEX NAME)



L7 ANSWER 304 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1962:73497 CAPLUS

DOCUMENT NUMBER: 56:73497

ORIGINAL REFERENCE NO.: 56:14286d-i,14287a-d

TITLE: Reaction of nitriles with o-aminonitriles: a convenient synthesis of fused 4-aminopyrimidines

AUTHOR(S): Taylor, Edward C.; Borrer, Alan L.

CORPORATE SOURCE: Princeton Univ., Princeton, NJ

SOURCE: Journal of Organic Chemistry (1961), 26, 4967-74

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The base-catalyzed condensation of various aromatic and heterocyclic o-aminonitriles with nitriles to give 4-aminoquinazolines, 4-aminopyrazolo[3,4]pyrimidines, 4-aminopyrido [2,3-d] pyrimidines, and 6-aminopurines (adenines) was described. The scope, limitations, mechanism, and synthetic utility of this reaction were discussed. KNO₃ (1.7 g.) in 15 ml. concentrated H₂SO₄ treated portionwise with 3.25 g. 3-bromobenzamide below 35°, the solution stirred 1.5 hrs. at room temperature, poured over crushed ice, and recrystd. gave 2.05 g. 5-bromo-2-nitrobenzamide (I), m. 185-6°. I (20.9 g.) in 50 ml. C₅H₅N treated in 45 min. with 15.3 g. POCl₃, stirred an addnl. 15 min., poured on ice, and separated gave 13.5 g. 5-bromo-2-nitrobenzonitrile (II), m. 117-19° (alc.). II (7.7 g.) added in small amts. below 35° to 20 g. mossy Sn in 22.5 ml. 25% HCl, after 5 hrs. the mixture diluted, decanted, made basic, extracted with Et₂O, and evaporated gave 4 g. 2-amino-5-bromobenzonitrile (IIa), m. 92-4°. The o-aminonitrile, nitrile, and a solvent were sealed in a hydrogenation bomb, the mixture heated as specified, and the product isolated either by direct filtration or by evaporation in vacuo followed by recrystn. of the residue from the specified solvent. The following fused 4-aminopyrimidines were thus obtained (o-aminonitrile, nitrile, product, solvent, time in hrs., temperature of reaction, recrystn. solvent, m.p. of product, % yield given): 2-aminobenzonitrile (III), PhCN, 2-phenyl-4-aminoquinazoline, MeOH-NH₃, 20, 200°, aqueous alc., 145.5-6.5°, 39; III, MeCN, 2-methyl-5-amino-quinazoline, MeOH-NH₃, 24, 210°, H₂O, 228-9°, 26; IIa, PhCN, 2-phenyl-4-amino-6-bromoquinazoline, MeOH-NH₃, 20, 190°, aqueous alc., 224-6°, 31; IIa, 4-nitrobenzonitrile, 2-(4-nitrophenyl)-4-amino-6-bromoquinazoline, MeOH-NH₃, 4, 190°, EtOCH₂CH₂OH, 283-5°, 44; 2-aminonicotinonitrile, nicotinonitrile, 2-(3-pyridyl)-4-aminopyrido[2,3-d]pyrimidine, MeOH-NH₃, 5, 200°, sublimed 312-14°, 56; 2-aminonicotinonitrile, nicotinonitrile, 2-(3-pyridyl)-4-aminopyrido[2,3-d]pyrimidine, alc.-NaOEt, 6, reflux, -, -, 50; 3-amino-4-cyanopyrazole, 3-amino-4-cyanopyrazole, 4-amino-6-(3-amino-4-pyrazolyl)pyrazolo[3,4-d]pyrimidine, MeOH-NH₃, 20, 200°, aqueous Me₂S, 334-8°, 63.5;

1-methyl-4-cyano-5-aminopyrazole, 1-methyl-4-cyano-5-aminopyrazole, 1-methyl-4-amino-6-[4-(1-methyl-5-aminopyrazyl)] pyrazolo [3,4-d] pyrimidine, MeOH-NH₃, 20, 200°, sublimed, 255-7°, 41.5; 1-phenyl-4-cyano-5-aminopyrazole, 1-phenyl-4-cyano-5-aminopyrazole, 1-phenyl-4-amino-6-[4-(1-phenyl-5-aminopyrazyl)] pyrazolo[3,4-d]pyrimidine, MeOH-NH₃, 20, 200°, aqueous alc., 255-7°, 43; 1-methyl-4-amino-5-cyanoimidazole, PhCN, 2-phenyl-7-methyladenine, MeOH-NH₃, 20, 200°, HOCNMe₂, 328-9°, 50. The following 4-aminopyrazolo[3,4-d]pyrimidines were similarly obtained (substituents at 5 and 2, solvent, time in hrs., temperature, recrystn. solvent, m.p., and % yield given): H, 3-pyridyl, MeOH-NH₃, 20, 200°, HCONMe₂, 338-9° (decomposition), 83; H, p-O₂NC₆H₄, MeOH-NH₃, 20, 200°, HCONMe₂, 360°, 83; H, PhCH₂, MeOH-NH₃, 20, 200°, HCONMe₂, 296-8°, 61.5; H, Ph, MeOH-NH₃, 20, 200°, aqueous HCONMe₂, 275-7°, 69; H, Me, MeOH-NH₃, 24, 200°, aqueous HCONMe₂, 300°, 77.5; Me, 3-pyridyl, MeOH-NH₃, 20, 200°, HCONMe₂, 262-3°, 71; Me, 3-pyridyl, alc.-NaOEt, 3, reflux, HCONMe₂, 262-3°, 80; Me, p-O₂NC₆H₄, MeOH-NH₃, 20, 200°, HCONMe₂, 297-8°, 51; Me, PhCH₂, MeOH-NH₃, 20, 200°, alc., 206-7°, 71.5; Me, Ph, MeOH-NH₃, 20, 200°, alc., 199-200°, 59.5; Me, Ph, alc.-NaOEt, 5, reflux, alc., 199-200°, 64; Me, Me, MeOH-NH₃, 48, 200°, aqueous MeOH, 260-1°, 65.5; Ph, 3-pyridyl, MeOH-NH₃, 20, 200°, aqueous HCONMe₂, 239-40°, 71.5; Ph, 3-pyridyl, alc.-NaOEt, 3, reflux, aqueous HCONMe₂, 239-40°, 91.5; Ph, p-O₂NC₆H₄, MeOH-NH₃, 20, 200°, HCONMe₂, 300-1°, 67; Ph, PhCH₂, MeOH-NH₃, 20, 200°, aqueous HCONMe₂, 220-1°, 57; Ph, Ph, MeOH-NH₃, 20, 200°, aqueous HCONMe₂, 224-5°, 71; Ph, Ph, alc.-NaOEt, 5, reflux, aqueous HCONMe₂, 224-5°, 72; Ph, Me, MeOH-NH₃, 48, 200°, aqueous alc. 246-8°, 73.5. III (0.71 g.), 0.98 g. 2-amino-5-nitrobenzonitrile, 0.89 g. 4-nitrobenzonitrile, and 25 ml. MeOH-NH₃ warmed 2 hrs. at 185° in a bomb, the mixture filtered, collected solid washed, dried, and crystallized gave 0.91 g. impure 2-(4-nitrophenyl)-4-amino-6-nitroquinazoline, m. 298-301°; evaporation of the filtrate afforded a further 0.12 g. product. The aqueous extract afforded 0.1 g. 2-amino-5-nitrobenzonitrile, m. 204-6°.


IT 1022-44-2P, Quinazoline, 4-amino-2-phenyl- 92103-98-5P,
Quinazoline, 4-amino-6-bromo-2-(p-nitrophenyl)- 93716-72-4P,
Quinazoline, 4-amino-6-nitro-2-(p-nitrophenyl)- 93716-83-7P,
Quinazoline, 4-amino-6-bromo-2-phenyl-

RL: PREP (Preparation)

(preparation of)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)




RN 92103-98-5 CAPLUS


CN Quinazoline, 4-amino-6-bromo-2-(p-nitrophenyl)- (7CI) (CA INDEX NAME)



RN 93716-72-4 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 93716-83-7 CAPLUS
 CN 4-Quinazolinamine, 6-bromo-2-phenyl- (CA INDEX NAME)




L7 ANSWER 305 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1961:144313 CAPLUS
 DOCUMENT NUMBER: 55:144313
 ORIGINAL REFERENCE NO.: 55:27383a-c
 TITLE: N-Substituted 1,4-, 1,5-, and 1,8-diaminoanthraquinones
 INVENTOR(S): Ebel, Friedrich; Weidinger, Hans
 PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik Akt.-Ges.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1099543		19610216	DE 1957-B52258	19570508 <--


AB The title compds. were obtained if 1,4- (I), 1,5- (Ia), or 1,8-diaminoanthraquinone, in the presence of a saturated lactam, was treated with 2-phenyl-6-chloroquinazoline (II) or 2-phenyl-4-anilino-6-chloro-1,3,5-triazine- (III), m. 160-4°, at elevated temps. Suitable lactams were pyrrolidone (IV), piperidone, caprolactam (V), and capryllactam (or their alkyl derivs.). Thus, I 50 and N-Me derivative (IVa) of IV 450 parts kept 1 hr. at 95°, cooled to 60°, filtered, and washed with IVa and MeOH gave 1-amino-4-(2-phenyl-4-quinazolinyl)aminoanthraquinone-HCl (VI) 84 parts, blue-violet crystals. VI dissolved in H2SO4 was added to ice H2O with stirring to obtain the free base of VI, blue, m. 273-8°. Similarly prepared was the 5-(2-pbenyl-4-quinazolinyl) analog of VI, m. 303-4°; HCl salt was

copper colored. To Ia 24 and IVa 240 was added III 28 parts at 120° within 1 hr. (stirring) and the mixture kept 2 hrs. After being cooled, the mixture was diluted with H2O to give 1-amino-5-(2-phenyl-4-anilino-1,3,5-triazin-6-ylamino)anthraquinone-HCl red, m. 283-5°. The compds. were useful as intermediates in the preparation of dyes.


IT 116027-31-7P, Anthraquinone, 1-amino-5-[(2-phenyl-4-quinazolinyl)amino]- 116028-61-6P, Anthraquinone, 1-amino-4-[(2-phenyl-4-quinazolinyl)amino]- 121600-19-9P, Anthraquinone, 1-amino-4-[(2-phenyl-4-quinazolinyl)amino]-, hydrochloride 121991-09-1P, Anthraquinone, 1-amino-5-[(2-phenyl-4-quinazolinyl)amino]-, hydrochloride
 RL: PREP (Preparation)
 (preparation of)
 RN 116027-31-7 CAPLUS
 CN Anthraquinone, 1-amino-5-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)



RN 116028-61-6 CAPLUS
 CN Anthraquinone, 1-amino-4-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 121600-19-9 CAPLUS
 CN Anthraquinone, 1-amino-4-[(2-phenyl-4-quinazolinyl)amino]-, hydrochloride (6CI) (CA INDEX NAME)



● HCl

RN 121991-09-1 CAPLUS
 CN Anthraquinone, 1-amino-5-[(2-phenyl-4-quinazolinyl)amino]-, hydrochloride
 (6CI) (CA INDEX NAME)



● HCl

L7 ANSWER 306 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1961:112219 CAPLUS
 DOCUMENT NUMBER: 55:112219
 ORIGINAL REFERENCE NO.: 55:21152e-h
 TITLE: Piperazinium salts
 INVENTOR(S): Rudner, Bernard
 PATENT ASSIGNEE(S): W. R. Grace & Co.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2967865		19610110	US 1958-761295	19580916 <--

AB Several N-aminopiperazinium compds. were prepared having significant

pharmacol. properties. N'-Benzhydryl-N-methylpiperazine (27 g.) in 800 ml. CHCl₃ was treated with gaseous ClNH₂ from a Sisler generator (CA 49, 16374c). Filtration gave 32.6 g. solid containing about 60% product and 40% NH₄Cl. Evaporation of the filtrate gave 9.1 g. addnl. crude product. The combined solids were recrystd. from isopropanol after filtration from undissolved NH₄Cl to give N-amino-N-methyl-N'-benzhydrylpiperazinium chloride (I), m. about 230°; the piperazinium picrate m. about 174°; piperazinium hexafluorophosphate m. about 194°.

N-Methyl-N'-(p-chlorobenzhydryl)piperazine (28 g.) was chloraminated in the same manner as above. Filtration gave 39.8 g. mixed product and NH₄Cl and 5.6 g. addnl. crude product on evaporation of the filtrate. The combined solids were extracted with ether, taken up in isopropanol, the solution

filtered,

and the alc. evaporated The residue was dissolved in aqueous Na₂CO₃, treated with


activated C, filtered, and evaporated to dryness. The product was purified by crystallization from isopropanol to give hygroscopic N-amino-N-methyl-N'-(p-chlorobenzhydryl)piperazinium chloride (II).H₂O, m. and 138° .apprx. 106°; II sulfate m. 175-6°; II nitrate m. .apprx.

144°. The nitrate was hygroscopic and decomposed with the evolution of gas on heating near its m.p. Pharmacol. studies showed the compds. to be antihypertensive and antihistaminic agents.

IT 55434-76-9P, Benzamidine, N'-phenyl-N-(2-phenyl-4-quinazolinyl)-
RL: PREP (Preparation)
(preparation of)

RN 55434-76-9 CAPLUS

CN Benzenecarboximidamide, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



L7 ANSWER 307 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:112218 CAPLUS

DOCUMENT NUMBER: 55:112218

ORIGINAL REFERENCE NO.: 55:21152b-e

TITLE: Quinazolines

INVENTOR(S): Meerwein, Hans

PATENT ASSIGNEE(S): Schering Akt.-Ges.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1074047		19600128	DE	<--

GI For diagram(s), see printed CA Issue.

AB N:CR.N:CR'.C:C:CH:CH:CH (I) [R is alkyl or aryl, R' is the radical derived from R'CN (II)], were prepared by heating II, RCR':NR''' (III) (R'' is Cl or alkoxy, R''' is aryl, unsubstituted on at least one ortho position), and a Friedel-Crafts catalyst (IV) (method A) or RCONHR''', SOCl₂, or PCl₅, II, and IV (method B) or II and the nitrilium compds. from III (R'' = Cl) and IV (method C) or III and the addition compds. from II and

IV (method D), in suitable solvents at 90-160°. Thus, (method B) heating 19.7 g. BzNHPh in 50 ml. II (R' = Ph) (V) with 13 g. SOCl₂ and 13.3 g. AlCl₃ 1 hr. at 150° (HCl and SO₂ evolved), treating the cooled mixture with NaOH, and distilling excess V with steam gave 85.7% I (R = R' = Ph) (VI), m. 119-20° (EtOH), also prepared (method A) from V, III (R = R''' = Ph, R'' = Cl, OMe and OEt resp.), and AlCl₃ in 96%, 86%, and 93% yield. The addition compound from V with ZnCl₂ was heated in o-Cl₂C₆H₄ (VII) 10 min. at 100° with III (R = R''' = Ph, R'' = Cl) to give approx. 100% VI (method D). The following I were prepared (R, R', method, R'', R''', solvent, IV, m.p., crystallization solvent, and % yield given): Ph,


Me,

C, Cl, Ph, MeCN, TiCl₄, 90°, EtOH, 85; Ph, Br, C, Cl, Ph, PhNO₂, SnCl₄, 129°, AcOEt, 70.8; CC₁₃, Ph, A, Cl, Ph, V, AlCl₃, 129°, EtOH, 78.8; Ph, CHPh₂, A, Cl, Ph, PhNO₂, AlCl₃, 132°, EtOH, 94; Me, Ph, A, OEt, Ph, V, AlCl₃, 47° (b1 191°), -, 72; Ph, SMe, C, Cl, Ph, PhNO₂, SnCl₄, 94°, EtOH, 98; Ph, Ph₂N, A, Cl, Ph, VII, SnCl₄, 156°, EtOH, -; Ph, PhN:C(Ph)NH, C, Cl, Ph, VII, SnCl₄, 196.5-7.0, Am₂O, 88. I (R = Ph, R' = Ph₂N) hexachlorostannate, m. 276-9° (PhCN).

IT 55434-76-9P, Benzamidine, N'-phenyl-N-(2-phenyl-4-quinazolinyl)-103051-13-4P, Quinazoline, 4-diphenylamino-2-phenyl-125904-49-6P, Quinazoline, 4-diphenylamino-2-phenyl-, chlorostannate(IV)
RL: PREP (Preparation)
(preparation of)


RN 55434-76-9 CAPLUS

CN Benzenecarboximidamide, N-phenyl-N'-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



RN 103051-13-4 CAPLUS

CN 4-Quinazolinamine, N,N,2-triphenyl- (CA INDEX NAME)




RN 125904-49-6 CAPLUS

CN Quinazoline, 4-diphenylamino-2-phenyl-, chlorostannate(IV) (6CI) (CA INDEX NAME)

CM 1


CRN 103051-13-4

CMF C26 H19 N3



CM 2

CRN 19512-65-3
CMF Cl6 Sn . 2 H
CCI CCS



● 2 H⁺

L7 ANSWER 308 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1961:99472 CAPLUS
 DOCUMENT NUMBER: 55:99472
 ORIGINAL REFERENCE NO.: 55:18737b-i,18738a-i,18739a
 TITLE: Hydrazino derivatives of some heterocyclic series
 AUTHOR(S): Libermann, D.; Rouaix, A.
 SOURCE: Bulletin de la Societe Chimique de France (1959) 1793-8
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 55:99472
 GI For diagram(s), see printed CA Issue.
 AB The mono- and dihydrazino derivs. of substituted and unsubstituted pyrimidines, quinazolines, quinoxalines, purines, and pyridazines were prepared from the corresponding mercapto or halo derivs. The thiouracil (10 g.), 30 g. powdered P2S5, and 200 cc. tetrahydronaphthalene heated 2 hrs. at 170° with stirring, cooled, the precipitate air-dried, extracted repeatedly with boiling EtOH, and the extract concentrated, and cooled gave the following N:C(SH).N:C(SH).CR:CR' (I) (R, R', m.p., and % yield given): H, Ph, 268-70°, 74; H, PhCH2, 250-1°, 56; RR' = tetramethylene, 346-8°, 73.5; Me, Ph, 280-1°, 84 (in this case the precipitate was treated with 800 cc. H2O and 2.5N Na2CO3 and the filtered solution acidified with aqueous HCl). I refluxed 10-15 hrs. with a large excess 99.5% N2H4.H2O (II) (8 times the weight of I) in EtOH, cooled, the precipitate air-dried, and recrystd. from EtOH gave the following N:C(NHNH2).N:C(NHNH2).CR:CR' (R, R', m.p., and % yield given): H, Ph, 164-5°, 70; H, PhCH2, 154-5°, 55; RR' = tetramethylene, 210-11°, 50; Me, Ph, 203-4°, 70. 4-Hydroxyquinazoline (prepared by the method of Chapman,

et al., CA 42, 182b) (7.3 g.) and 12.5 g. purified P2S5 in 75 cc. anhydrous C5H5N refluxed 1 hr., the hot solution poured into 500 cc. hot H2O, and cooled gave 7 g. N:CR.N:CR'.C:C.CH:CH.CH:CH (III) (R = H, R' = SH) (IV), m. 320°. IV heated 45 min. with 350 cc. absolute EtOH containing 20 cc. II, the solution decolorized with Norit, filtered hot, and the filtrate cooled gave 5 g. III (R = H, R' = NHNH2), m. 176° (decomposition). 2-Phenylquinazolone (m. 237°) (prepared by the method of Endicott, et al., CA 40, 57483) (5 g.) and 5.5 g. purified P2S5 in 300 cc. anhydrous C5H5N refluxed 2 hrs., the hot solution poured into 800 cc. hot H2O, and cooled gave 4.2 g. III (R = Ph, R' = SH) (V), m. 221°. V (2.2 g.) and 3 cc. II in 75 cc. absolute EtOH refluxed 2 hrs., decolorized with Norit, filtered hot, and the solution concentrated to 1/3 its volume gave 1.8 g. III

(R =

Ph, R' = NHNH2), m. 213° (decomposition). From NaOCN and 2H2NC6H4CO2Me was prepared III (R = R' = OH) (VI), m. 354-5°. To 35 g. VI and 105 cc. POCl3 was added very slowly 16 cc. PhNMe2, the mixture refluxed 5 hrs., allowed to cool to 40-50°, and poured slowly with stirring into 500 g. crushed ice and 300 cc. H2O to give 30 g. III (R = R' = Cl) (VII), m. 118-19°. VII (30 g.) and 55 cc. II in 350 cc. absolute EtOH refluxed 4 hrs. gave 15 g. III (R = R' = NHNH2), m. 219-20° (decomposition), giving with BzH a dihydrazone, m. 286°. OHCCO2Et (18 g.) and 18 g. o-C6H4(NH2)2 in 50 cc. EtOH refluxed 12 hrs. gave 5.3 g. N:CR.CH:N.C:C.CH:CH.CH:CH (VIII) (R = OH), m. 103-4°. VIII (R = OH) (5.3 g.) and 25 cc. POCl3 refluxed 1 hr., the excess POCl3 removed in vacuo, the residue treated with ice H2O, extracted with Et2O, the extract

washed

with 5% aqueous NaHCO3, dried, evaporated, the residue dissolved in hot EtOH,

the

solution decolorized with C, concentrated, and chilled gave 3.9 g. VIII (R =

Cl),


m. 50-2°. VIII (R = Cl) and 20 cc. 99.5% II in 30 cc. absolute EtOH refluxed 8 hrs. gave 3.2 g. VIII (R = NHNH2), m. 165-6°; HCl salt m. 238-40° (decomposition). Caffeine (VIIIa) (15 g.) dissolved by refluxing in 2:1 PhNO2-CCl4, the solution treated with 0.1 g. iodine followed during 30 min. with 25 g. Br in 25 cc. 2:1 PhNO2-CCl4, refluxed 2.5 hrs., refrigerated overnight, the precipitate (7 g.) air dried, washed with EtOH (concentration of the mother liquor yielded an addnl. 8 g.) and the combined portions recrystd. from EtOH gave 14 g. 8-bromocaffeine (IX), m. 210°. IX (10 g.) and 50 cc. 99.5% II in 75 cc. absolute EtOH refluxed 8 hrs. gave 8 g. 8-hydrazinocaffeine, m. 316°. VIIIa dissolved in 1:1 PhNO2-CCl4, treated with a little iodine, heated to mild boiling, and treated with a vigorous current of Cl gave 7,8-dichlorocaffeine (X), m. 150° (EtOH). X (10 g.) dissolved in 75 cc. EtOH by refluxing, treated with 20 cc. 99.5% II, and refluxed 3 hrs. gave 7 g. 8-hydrazinotheophylline, m. 320° (decomposition). 8-Bromotheophylline (2 g.) and 8 cc. 99.5% II heated 5 hrs. at 150° in a sealed tube gave 1.3 g. 1,1-bis(8-theophyllinyl)hydrazine, m. 416°. To 20 g. BzCH2CH2CO2H was added 10 cc. 85% II with stirring, the mixture kept overnight, the resulting product ground and washed with H2O, and recrystd. from 1.5 l. H2O to give 15 g. CPh:N.NH.CO.CHR.CH2 (XI) (R = H), m. 151°. Crude XI (R = Br) [obtained by treating XI (R = H) in AcOH with Br] (6 g.) dissolved in the cold in 30 cc. POCl3, the solution heated 1.5 hrs. in a H2O bath, cooled, poured over 200 g. crushed ice, and after 1 hr. treated with 500 cc. H2O gave 3.5 g. crude CPh:N.N:CR.CH:CH (XII) (R = Cl), m. 144° (EtOH). XII (R = Cl) (2.5 g.) and 10 cc. 85% II heated 3 hrs. in a boiling H2O bath, the mixture diluted with 20 cc. H2O, and heated 1 more hr. in the H2O bath gave 2.25 g. crude XII (R = NHNH2), m. 151-2° (H2O). 3-Pyridazone [obtained by decarboxylation of CR':N.N:CR.CH:CH (XIII) (R = OH, R' = CO2H) (XIV)] (3 g.) and 10 cc. POCl3 heated 2 hrs. at 65-70° in a H2O bath, the excess POCl3 removed in vacuo at below 60°, the residue cooled, poured over 50 g. crushed ice with stirring, adjusted to pH 8-9 with solid Na2CO3, and the product

isolated with Et₂O gave 3.5 g. XIII (R = Cl, R' = H) (XIVa), m. 35°. XIVa (3.5 g.) and 4 cc. 85% II heated 2 hrs. in a H₂O bath, evaporated on a H₂O bath, the residual sirup heated gently with absolute EtOH, and the cooled solution acidified with alc. HCl gave 2.25 g. XIII (R = NHNH₂, R' = H) di-HCl salt, m. 210-12° (decomposition). To 200 g. AcCH₂CH₂CO₂H was added portionwise 100 g. 98% II with stirring and cooling to give 169 g. 6-methyl-3-pyridazinone (XV), m. 105°. XV (210 g.) in 500 cc. AcOH treated dropwise during 2-3 hrs. with 305 g. Br (cooling if necessary to keep the temperature below 40-50°), stirred 6 hrs., and kept overnight gave 308 g. Br derivative (XVI) of XV, m. 190-2°. XVI (308 g.) in 600 cc. H₂O heated in a boiling H₂O bath, treated gradually with aqueous KOH until neutrality, the solution evaporated on a H₂O bath, the residue exhaustively extracted (10-12 times) with boiling EtOAc (after each extraction the decanted extract was cooled, the precipitate filtered off, and the filtrate used for the following extraction) gave 170 g. XIII (R = OH, R' = Me) (XVII), m. 145-7°. XVII (200 g.) in 2 l. concentrated H₂SO₄ treated portionwise during 3 hrs. with 536 g. powdered K₂Cr₂O₇ (the temperature rose slowly and when it reached 35-40° the mixture was cooled with ice H₂O to maintain the temperature at 40°), the mixture stirred 6-7 hrs., kept overnight, poured slowly over 7 kg. crushed ice with stirring, and kept 2 hrs. gave 190 g. XIV, m. 256-7°. XIV (105 g.) refluxed 14 hrs. with 550 cc. absolute EtOH and 150 cc. 20% alc. HCl (if solution was not complete, a small amount of alc. HCl was added) and cooled overnight gave 90 g. XIII (R = OH, R' = CO₂Et) (XVIII), m. 129-30°. XVIII (150 g.) dissolved in 1 l. POCl₃ at 150°, refluxed 30 min., cooled to 70°, the excess POCl₃ removed in vacuo (2 hrs.; towards the end the bath temperature was raised to 120°), and the residue treated repeatedly with crushed ice and saturated aqueous Na₂CO₃ gave 140 g. XIII (R = Cl, R' = CO₂Et) (XIX), m. 152-3° (H₂O). XIX (140 g.) in 560 cc. absolute EtOH saturated with NH₃ treated 2 hrs. at room temperature with NH₃ and refrigerated overnight gave 115 g. XIII (R = Cl, R' = CONH₂) (XX), m. 249°. XX (105 g.) and 70 g. 98% II in 1 l. EtOH refluxed 30 min., the mixture cooled, centrifuged, and the precipitate boiled 15 min. with 800 cc. H₂O and then several min. with 200 cc. H₂O gave 58 g. XIII (R = NHNH₂, R' = CONH₂), m. 249-50° (decomposition). XIX (92 g.) refluxed 2 hrs. with 1220 cc. absolute EtOH and 122 g. 99% II gave XIII (R = NHNH₂, R' = CONHNH₂), m. 251-2° (decomposition) (H₂O).

IT 6484-29-3P, Quinazoline, 4-hydrazino-2-phenyl-
 RL: PREP (Preparation)
 (preparation of)

RN 6484-29-3 CAPLUS

CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)




TITLE: Dimerization of 2-amino-5-nitrobenzonitrile
AUTHOR(S): Taylor, Edward C., Jr.; Knopf, Robert J.; Borrer, Alan L.
CORPORATE SOURCE: Princeton Univ., Princeton, NJ
SOURCE: Journal of the American Chemical Society (1960), 82, 3152-7
CODEN: JACSAT; ISSN: 0002-7863


DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB 2-Chloro-5-nitrobenzonitrile (3.6 g.) and 20 ml. MeOH-NH₃ was heated 3 hrs. at 150-70° to give 2.1 g. 2-amino-5-nitrobenzonitrile (I) and 0.25 g. 2-(2-amino-5-nitrophenyl)-4-amino-6-nitroquinazoline (II), m. above 360°. At 190° 29% I and 71% II were obtained. I and liquid NH₃ heated 3 hrs. at 180° gave 70% II. A cooled mixture of 0.5 g. II, 8.5 ml. 95% EtOH, and 3 ml. H₂SO₄ was treated with 0.25 g. NaNO₂ and refluxed 30 min. with evolution of AcH. Cooling and filtration gave 0.43 g. 2-(3-nitrophenyl)-4-amino-6-nitroquinazoline (III), m. 315°. Refluxing I, 3-nitrobenzoyl chloride, and pyridine gave 69% N-(2-cyano-4-nitrophenyl)-3-nitrobenzamide (IV), m. 216-7°. A cooled mixture of II in 50% H₂SO₄ was treated with NaNO₂ in H₂O and boiled to give 87% 2-(3-nitrophenyl)-6-nitro-4(3H)-quinazolone (V), m. 345-6°. Similar treatment of III gave 88% V. A mixture of 0.5 g. IV, 10 ml. 16% NaOH, and 20 ml. 3% H₂O₂ was refluxed 1 hr., 5 ml. 3% H₂O₂ added, and the mixture refluxed 30 min. to give 0.46 g. V. I with 2-chlorobenzoyl chloride in pyridine gave 95% N-(2-cyano-4-nitrophenyl)-2-chlorobenzamide (VI), m. 186-7°. VI with NaOH and H₂O₂ gave 90% 2-(2-chlorophenyl)-6-nitro-4(3H)-quinazolone (VII), m. 278-9°. To 0.61 g. KNO₃ in 10 ml. concentrated H₂SO₄ was added 1.6 g. VII and the mixture stirred 45 min. at 90°. Treatment with ice gave 1.8 g. 2-(2-chloro-5-nitrophenyl)-6-nitro-4(3H)-quinazoline (VIII), m. 324-5°. Refluxing II in 50% H₂SO₄ for 2.5 hrs. gave 60% 2-(2-amino-5-nitrophenyl)-6-nitro-4(3H)-quinazolone (IX), m. above 360°. VIII with concentrated NH₄OH 150° for 15 hrs. gave 93% IX. To 7.6 g. KNO₃ in 50 ml. H₂SO₄ was added 13.05 g. 3-bromobenzonitrile to give 12.7 g. 2-nitro-5-bromobenzonitrile (X), m. 115-17°. To 20 g. mossy Sn in 22.4 ml. 25% HCl was added 7.7 g. X to give 4.45 g. 2-amino-5-bromobenzonitrile, m. 96-7°. A mixture of 2.36 g. 2-aminobenzonitrile (XI), 3.7 g. 4-nitrobenzonitrile (XIa) and 20 ml. MeOH-NH₃ was heated at 180-90° for 3.5 hrs. to give 2.5 g. 2-(4-nitrophenyl)-4-aminoquinazoline (XII), m. 220-1°. XI with 4-nitrobenzoyl chloride (XIa) in pyridine gave N-(2-cyanophenyl)-4-nitrobenzamide (XIII), m. 229-30°. XII with H₂SO₄ and NaNO₂ gave 75% 2-(4-nitrophenyl)-4(3H)-quinazolone (XIV), m. 351-2°. XIII with NaOH and H₂O₂ gave 50% XIV. I, XIa, and MeOH-NH₃ were heated 3.5 hrs. at 180-90° to give 87% 2-(4-nitrophenyl)-4-amino-6-nitroquinazoline (XV), m. 303-4°. I, XIIa, and C₅H₅N gave 77% N-(2-cyano-4-nitrophenyl)-4-nitrobenzamide (XVI), m. 199.0-9.5°. XV with H₂SO₄ and NaNO₂ gave 78% 2-(4-nitrophenyl)-6-nitro-4(3H)-quinazolone (XVII), m. 317-18°. XVI with NaOH and H₂O₂ gave 48% XVII.


IT 37471-18-4P, Quinazoline, 4-amino-2-(p-nitrophenyl)-
91620-55-2P, Quinazoline, 4-amino-2-(2-amino-5-nitrophenyl)-6-nitro-
93716-72-4P, Quinazoline, 4-amino-6-nitro-2-[p-nitrophenyl]-
108012-95-9P, Quinazoline, 4-amino-6-nitro-2-[m-nitrophenyl]-
RL: PREP (Preparation)
(preparation of)
RN 37471-18-4 CAPLUS
CN 4-Quinazolinamine, 2-(4-nitrophenyl)- (CA INDEX NAME)




RN 91620-55-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-amino-5-nitrophenyl)-6-nitro- (CA INDEX NAME)



RN 93716-72-4 CAPLUS
 CN 4-Quinazolinamine, 6-nitro-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 108012-95-9 CAPLUS
 CN Quinazoline, 4-amino-6-nitro-2-(m-nitrophenyl)- (6CI) (CA INDEX NAME)




L7 ANSWER 310 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1961:5198 CAPLUS
 DOCUMENT NUMBER: 55:5198
 ORIGINAL REFERENCE NO.: 55:1009g-i,1010a-d
 TITLE: Vat dyes for dyeing fibers, fabrics, and other structures consisting of high molecular weight substances containing carboxamide groups
 INVENTOR(S): Ebel, Friedrich; Schuhmacher, Alfred; Kling, Karl E.
 PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik Akt.-Ges.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	DE 1046565		19581218	DE	<--
AB	<p>The dyes are 4-aminoquinazolines with the amino group substituted by a vatable radical and the 2-position substituted by a vatable or nonvatable radical. They are prepared by reaction of vatable ring systems containing NH₂ groups with monohaloquinazolines or their derivs. having the halogen atoms in the 4-position. Thus, the following 4-chloroquinazolines were prepared as intermediates for the preparation of these dyes (color and</p>				
m.p.	<p>given): 2-(o-chlorophenyl) (I) (colorless, 124-5°); 2-(2,4-dichlorophenyl) (II) (colorless 133-4°); 2-(m-trifluoromethylphenyl) (III) (colorless 86-8°); 2-(p-methoxyphenyl) (IV) (colorless 125.5-6.5°); 2-(o-methoxyphenyl) (V) (colorless 100-1°); and 2-(anthraquinonyl) (VI) (yellow 276-8°). Thus, stirring at 180° a mixture of 107 parts of 2-phenyl-4-chloroquinazoline (VII), 114.5 parts of 1-amino-5-chloroanthraquinone (VIII), and 1700 parts of PhNO₂ for 2 hrs., cooling, filtering, washing with MeOH, and drying gives 132 parts of red crystals. It dyes poly(hexamethylenediammonium adipate) (IX) fibers yellow orange shades. Similarly, vat dyes were prepared from the following components (shades on polyamides given): 2-aminoanthraquinone (X) and VII yellow; X and I, yellow; X and V, yellow; X and III, yellow; X and IV, yellow; 1-aminoanthraquinone (XI) and VII, yellowish orange; XI and I, yellowish orange; XI and V, yellow; XI and III, yellowish orange; XI and II, yellowish orange; XI and IV, yellowish orange; 8-amino-4-benzamidoanthraquinone (XII) and VII, orange; XII and I, orange; XII and V, orange; XII and III, orange; XII and II, orange; XII and IV, orange; 1-amino-4-benzamidoanthraquinone (XIII) and VII, claret; XIII and I, claret; XIII and V, claret; XIII and III, claret; XIII and II, claret; XIII and IV, claret; VIII and I, orange; VIII and V, yellowish orange; VIII and III, orange; VIII and II, orange; VIII and IV, orange; 1-amino-6-chloroanthraquinone (XIV) and VII, yellowish orange; XIV and V, yellowish orange; 1-amino-6,7-dichloroanthraquinone (XV) and VII, yellowish orange; XV and V, yellowish orange; 1-amino-4-chloroanthraquinone (XVI) and VII, orange; XVI and I, orange; 1,4-diamino-2-acetylanthraquinone (XVII) and VII, blue; XVII and I, blue; XVII and V, greenish blue; XVII and III, blue; XVII and II, blue; XVII and IV, blue; 4-amino-2,1(N)-1',2'(N)-benzacridone (XVIII) and VII, turquoise blue; XVIII and III, grayish blue; 1-amino-4-methoxyanthraquinone (XIX) and VII, red; XIX and I, red; XIX and V, red; XIX and III, red; XIX and II, red; XIX and IV, red; VI and XII with II and XII, brown; VI and XIII, dark brown; VI and XIII with II and XIII, reddish brown; VI and 5-benzamido-7-chloro-8-aminoanthraquinone, reddish brown; X, II, and XII, gray brown; XI, II, and XII, brown; VI and 7-chloro-8-amino-4-benzamidoanthraquinone pale red brown; and XII, II, and XII, dark claret.</p>				
IT	<p>3888-59-3 108520-52-1 108520-53-2 (Derived from data in the 6th Collective Formula Index (1957-1961))</p>				
RN	<p>3888-59-3 CAPLUS</p>				
CN	<p>Naphth[2,3-c]acridan-5,8,14-trione, 6-[[2-(α,α,α-trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)</p>				





RN 108520-52-1 CAPLUS

CN Anthraquinone, 1-benzamido[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)



RN 108520-53-2 CAPLUS

CN Anthraquinone, 1-benzamido[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




IT 2356-27-6P, Anthraquinone, 1-chloro-5-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 2560-95-4P, Anthraquinone, 1-methoxy-4-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 3825-15-8P, Anthraquinone, 2-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 3872-28-4P, Anthraquinone, 1-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 7604-25-3P, Anthraquinone, 1-benzamido-4-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 7604-26-4P, Anthraquinone, 1-benzamido-5-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- 103037-11-2P, Anthraquinone, 6,7-dichloro-1-[(2-phenyl-4-quinazolinyl)amino]- 103165-54-4P, Anthraquinone, 1-methoxy-4-[(2-phenyl-4-quinazolinyl)amino]- 103985-83-7P, Anthraquinone, 1-chloro-5-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- 103985-84-8P, Anthraquinone, 1-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- 104178-10-1P, Anthraquinone, 1-chloro-5-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- 104178-11-2P, Anthraquinone, 2-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- 104179-61-5P, Anthraquinone, 1-chloro-4-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- 104179-62-6P, Anthraquinone, 1-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- 104297-81-6P, Anthraquinone, 6,7-dichloro-1-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 104297-82-7P, Anthraquinone, 1-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]-4-methoxy- 104297-83-8P, Anthraquinone, 1-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-4-methoxy- 104395-80-4P, Anthraquinone, 6-chloro-1-[[2-[o-methoxyphenyl]-4-quinazolinyl]amino]- 104508-87-4P, Anthraquinone, 1-benzamido-5-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]- 104508-88-5P, Anthraquinone, 1-benzamido-4-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 104508-89-6P, Anthraquinone, 1-benzamido-5-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 104509-84-4P, Anthraquinone, 1-benzamido-4-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]- 105946-28-9P, Anthraquinone, 1-methoxy-4-[[2-[p-methoxyphenyl]-4-quinazolinyl]amino]- 105947-33-9P, Anthraquinone, 1-methoxy-4-[[2-[o-methoxyphenyl]-4-quinazolinyl]amino]- 115605-21-5P, Anthraquinone, 1-chloro-5-[(2-phenyl-4-quinazolinyl)amino]- 115605-22-6P, Anthraquinone, 6-chloro-1-[(2-phenyl-4-quinazolinyl)amino]-

115606-03-6P, Anthraquinone, 1-chloro-4-[(2-phenyl-4-quinazolinyl)amino]- 116027-87-3P, Anthraquinone, 2-[(2-phenyl-4-quinazolinyl)amino]- 116028-56-9P, Anthraquinone, 1-[(2-phenyl-4-quinazolinyl)amino]- 117072-08-9P, Anthraquinone, 6-chloro-1-[[2-[p-methoxyphenyl]-4-quinazolinyl]amino]- 117072-14-7P, Anthraquinone, 1-chloro-5-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 117874-82-5P, Anthraquinone, 1-benzamido-5-[(2-phenyl-4-quinazolinyl)amino]- 117875-03-3P, Anthraquinone, 1-benzamido-4-[(2-phenyl-4-quinazolinyl)amino]- 122218-73-9P, Naphth[2,3-c]acridan-5,8,14-trione, 6-[(2-phenyl-4-quinazolinyl)amino]- 856625-09-7P, Anthraquinone, 2-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]- 856625-16-6P, Anthraquinone, 2-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 856625-24-6P, Anthraquinone, 1-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]- 856625-31-5P, Anthraquinone, 1-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- 857200-58-9P, Anthraquinone, 1-benzamido-5-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- 857200-64-7P, Anthraquinone, 1-benzamido-4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- 857200-73-8P, Anthraquinone, 1-benzamido-5-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- 857200-80-7P, Anthraquinone, 1-benzamido-4-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-
 RL: PREP (Preparation)

(preparation of)


RN 2356-27-6 CAPLUS

CN Anthraquinone, 1-chloro-5-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)




RN 2560-95-4 CAPLUS


CN Anthraquinone, 1-methoxy-4-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)




RN 3825-15-8 CAPLUS
 CN Anthraquinone, 2-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)



RN 3872-28-4 CAPLUS
 CN Anthraquinone, 1-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)




RN 7604-25-3 CAPLUS
 CN Anthraquinone, 1-benzamido-4-[[2-(α,α,α -trifluoro-m-tolyl)-4-quinazolinyl]amino]- (6CI, 8CI) (CA INDEX NAME)




RN 7604-26-4 CAPLUS

CN Benzamide, N-[9,10-dihydro-9,10-dioxo-5-[[2-[3-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-1-anthracenyl]- (CA INDEX NAME)




RN 103037-11-2 CAPLUS

CN Anthraquinone, 6,7-dichloro-1-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 103165-54-4 CAPLUS

CN Anthraquinone, 1-methoxy-4-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 103985-83-7 CAPLUS

CN Anthraquinone, 1-chloro-5-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)




RN 103985-84-8 CAPLUS

CN Anthraquinone, 1-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)




RN 104178-10-1 CAPLUS

CN Anthraquinone, 1-chloro-5-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 104178-11-2 CAPLUS

CN Anthraquinone, 2-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- (6CI) (CA
INDEX NAME)




RN 104179-61-5 CAPLUS


CN Anthraquinone, 1-chloro-4-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 104179-62-6 CAPLUS
CN Anthraquinone, 1-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)



RN 104297-81-6 CAPLUS
CN Anthraquinone, 6,7-dichloro-1-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)




RN 104297-82-7 CAPLUS
CN Anthraquinone, 1-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]-4-methoxy- (6CI) (CA INDEX NAME)




RN 104297-83-8 CAPLUS

CN Anthraquinone, 1-[[2-(o-chlorophenyl)-4-quinazolinyl]amino]-4-methoxy-
(6CI) (CA INDEX NAME)




RN 104395-80-4 CAPLUS

CN Anthraquinone, 6-chloro-1-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 104508-87-4 CAPLUS

CN Anthraquinone, 1-benzamido-5-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 104508-88-5 CAPLUS

CN Anthraquinone, 1-benzamido-4-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 104508-89-6 CAPLUS


CN Anthraquinone, 1-benzamido-5-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)



RN 104509-84-4 CAPLUS
 CN Anthraquinone, 1-benzamido-4-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]-
 (6CI) (CA INDEX NAME)




RN 105946-28-9 CAPLUS
 CN Anthraquinone, 1-methoxy-4-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]-
 (6CI) (CA INDEX NAME)




RN 105947-33-9 CAPLUS

CN Anthraquinone, 1-methoxy-4-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]-
(6CI) (CA INDEX NAME)




RN 115605-21-5 CAPLUS

CN Anthraquinone, 1-chloro-5-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA
INDEX NAME)



RN 115605-22-6 CAPLUS


CN Anthraquinone, 6-chloro-1-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA
INDEX NAME)



RN 115606-03-6 CAPLUS


CN Anthraquinone, 1-chloro-4-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA

INDEX NAME)




RN 116027-87-3 CAPLUS

CN Anthraquinone, 2-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 116028-56-9 CAPLUS

CN Anthraquinone, 1-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 117072-08-9 CAPLUS


CN Anthraquinone, 6-chloro-1-[[2-(p-methoxyphenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)




RN 117072-14-7 CAPLUS
 CN Anthraquinone, 1-chloro-5-[[2-(o-methoxyphenyl)-4-quinazolinyl]amino]- (6CI) (CA INDEX NAME)



RN 117874-82-5 CAPLUS
 CN Anthraquinone, 1-benzamido-5-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 117875-03-3 CAPLUS
 CN Anthraquinone, 1-benzamido-4-[(2-phenyl-4-quinazolinyl)amino]- (6CI) (CA INDEX NAME)




RN 122218-73-9 CAPLUS

CN Naphth[2,3-c]acridan-5,8,14-trione, 6-[(2-phenyl-4-quinazolinyl)amino]-
(6CI) (CA INDEX NAME)




RN 856625-09-7 CAPLUS

CN 9,10-Anthracenedione, 2-[[2-(4-methoxyphenyl)-4-quinazolinyl]amino]- (CA
INDEX NAME)




RN 856625-16-6 CAPLUS

CN 9,10-Anthracenedione, 2-[[2-(2-methoxyphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 856625-24-6 CAPLUS

CN 9,10-Anthracenedione, 1-[[2-(4-methoxyphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 856625-31-5 CAPLUS

CN 9,10-Anthracenedione, 1-[[2-(2-methoxyphenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 857200-58-9 CAPLUS

CN Benzamide, N-[5-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]-9,10-dihydro-9,10-dioxo-1-anthracenyl]- (CA INDEX NAME)




RN 857200-64-7 CAPLUS

CN Benzamide, N-[4-[[2-(2,4-dichlorophenyl)-4-quinazolinyl]amino]-9,10-dihydro-9,10-dioxo-1-anthracenyl]- (CA INDEX NAME)




RN 857200-73-8 CAPLUS

CN Benzamide, N-[5-[[2-(2-chlorophenyl)-4-quinazolinyl]amino]-9,10-dihydro-9,10-dioxo-1-anthracenyl]- (CA INDEX NAME)



RN 857200-80-7 CAPLUS
 CN Benzamide, N-[4-[[2-(2-chlorophenyl)-4-quinazolinyl]amino]-9,10-dihydro-9,10-dioxo-1-anthracenyl]- (CA INDEX NAME)



L7 ANSWER 311 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1960:50460 CAPLUS
 DOCUMENT NUMBER: 54:50460
 ORIGINAL REFERENCE NO.: 54:9938i,9939a-e
 TITLE: Pyrimidines. VI. Derivatives of quinazoline
 AUTHOR(S): Claesen, M.; Vanderhaeghe, H.
 CORPORATE SOURCE: Univ. Louvain
 SOURCE: Bulletin des Societes Chimiques Belges (1959), 68, 220-4
 CODEN: BSCBAG; ISSN: 0037-9646
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

AB cf. C.A. 52, 1178f. The addition of 6 g. 2,4-dichloroquinazoline (I) to a mixture of 1.4 g. Na in 50 ml. of an alc., followed by 2 hrs. reflux, yielded the dialkoxy derivs. listed: MeO, m. 72-5°, EtO (II), m. 55°; PrO, 45-7°; and BuO. The above listed dialkoxy compds. were used to prepare the corresponding 2-alkoxy-4-hydroxy compds. by refluxing 6 hrs. 4 g. of the dialkoxy derivative in a solution of 0.5 g. Na in

ml. EtOH. The products were isolated by cooling, diluting with H₂O, and acidifying with AcOH. The m.ps. were as follows: MeO, 214-18°; EtO, 179°; PrO, 149-50°; and BuO, 135-7°. A mixture of 1.2 g. 2-chloro-4-hydroxyquinazoline (III), 2 g. K₂CO₃, 2 ml. 85% hydrazine hydrate (IV), and 6 ml. H₂O was refluxed 2 hrs. Cooling and acidifying yielded 0.7 g. 2-hydrazino-4-hydroxyquinazoline (V), decomposing 360°. The reaction of 20 ml. 50% IV with 2.5 g. I at reflux for 1.5 hrs. yielded 1.4 g. 2,4-dihydrazinoquinazoline (VI), m. 226-7°. VI and 2-hydrazino-4-ethoxyquinazoline were obtained by treating 2-chloro-4-ethoxyquinazoline with IV 3 hrs. at 37°. The reaction of II with IV in absolute EtOH at room temperature 11 days or at 37° 18 hrs. yielded VI. 2-Hydrazino-4-aminoquinazoline, m. 232°, was obtained in the same manner as V except that 2-chloro-4-aminoquinazoline (VII) was used as a starting material. The reaction of 3.6 g. VII with a solution of 0.46 g. Na in 100 ml. of an absolute alc. yielded the following 2-alkoxy derivs.: MeO, 203-5°; EtO, 136-7°; PrO, 154-6°, and BuO, 129-31°. The products were isolated by evaporation of the solution and treatment with H₂O. 4-Hydrazinoquinazoline (VIII), m. 186-7°, was obtained by refluxing 3.5 g. 4-chloroquinazoline in a mixture of 10 ml. 90% IV and 4 ml. dioxane for 1.5 hrs. Cooling and recrystn. (C₅H₅N) yielded 1.55 g. product. The HCl salt of VIII, m. 193-4°, was prepared by the addition of the stoichiometric amount of an alc. HCl solution

A

mixture of 0.62 g. 2-chloroquinazoline in 6 ml. MeOH was treated with 1 ml. 100% IV and refluxed 2.5 hrs. Cooling yielded 0.15 g. of 2-hydrazinoquinazoline, m. 132-3°. A mixture of 5 g. benzoylanthranil and 1 g. NaOAc was heated at 240-50° in vacuo 0.75 hr. After extraction with a hot 5% Na₂CO₃ solution and washing with H₂O and

EtOH,

3.4 g. 2-phenyl-4-quinazolone (IX), m. 233-4°, was obtained. A mixture of 15 g. IX, 20 g. PCl₅, and 60 ml. POCl₃ was refluxed 2 hrs. The mixture was concentrated, treated with 500 ml. C₆H₆, and neutralized with 5% aqueous

NaHCO₃. The C₆H₆ solution was concentrated to 30 ml. and petr. ether was added to

precipitate 13.2 g. 2-phenyl-4-chloroquinazoline (X), m. 126-7°. Refluxing 2.5 hrs. 6 ml. 100% IV with 6 g. X in 25 ml. dioxane yielded 4 g. 2-phenyl-4-hydrazinoquinazoline, m. 216-17°.


IT 6484-29-3P, Quinazoline, 4-hydrazino-2-phenyl-

RL: PREP (Preparation)

(preparation of)

RN 6484-29-3 CAPLUS

CN Quinazoline, 4-hydrazinyl-2-phenyl- (CA INDEX NAME)



L7 ANSWER 312 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1957:34884 CAPLUS

DOCUMENT NUMBER: 51:34884

ORIGINAL REFERENCE NO.: 51:6647h-i, 6648a-i, 6649a

TITLE: Syntheses in the quinazolone series. II. Synthesis of quino- and quinazoquinazolones

AUTHOR(S): Stephen, T.; Stephen, Henry

CORPORATE SOURCE: Univ. Witwatersrand, Johannesburg, S. Afr.
SOURCE: Journal of the Chemical Society (1956)
4173-7

CODEN: JC SOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. C.A. 50, 15540g. The synthesis of quinazolones was extended to the condensation of Me anthranilate (I) and of NH₄ anthranilate (II) with cyclic imidoyl chlorides; i.e., compds. containing N: CCl as part of a ring structure, viz., 2-chlorolepidine (III) and its derivs. and 4-Cl (IV) and 4-chloro-2-phenylquinazoline (V). In the condensation of III and its derivs. with I, it was found that if equimolar proportions of the reactants were used the yield was 10-30% lower than if one molar excess of I was used. The condensation was carried out as follows: III or a derivative (1 equivalent) were heated with 2 equivs. I in an oil bath, and when

separation of

I.HCl was complete the mixture made alkaline, and steam distilled to remove excess

I and any unchanged III. III (1.7 g.) and 2.7 g. I heated 10 min. at 130° gave 1.5 g. Me N-2'-lepidylanthranilate (VI), m. 149° (from alc.). III (1.7 g.) and 2.7 g. I heated 15 min. at 170° yielded 5-methylquino[2,1-b]quinazol-12-one (VII), yellow needles, m. 213°; platinichloride, buff. VI was readily soluble in concentrated HCl but from refluxing HCl the HCl salt of VII separated, this on treatment with H₂O and neutralization liberated free VII. An alc. solution of VI refluxed 0.5 hr. with 10% NaOH and acidified gave N-2'-lepidylanthranilic acid, needles, m. 203-4°. 2-Chloro-4,6-dimethylquinoline (VIII) (1 g.) and 1.6 g. I 0.5 hr. at 140° gave 50% Me N-(4,6-dimethyl-2-quinolyl)anthranilate (IX) and 0.4 g. recovered VIII. IX crystallized as needles, m. 162.5° (from 75% dioxane). Attempts to improve the yield gave mixts. of IX and 3,5-dimethylquino[2,1-b]quinazol-12-one (X). Refluxing the reactants several hrs. in dry dioxane gave no reaction. X obtained in 93% yield after 15 min. treatment at 170°, m. 199°. 2-Chloro-4,7-dimethylquinoline (XI) (1 g.) and 1.6 g. I 0.5 hr. at 140° gave 80% Me N-(4,7-dimethyl-2-quinolyl)anthranilate (XII), white needles, m. 172° (from 75% dioxane). Condensation at 170-90° gave an inseparable mixture of XII and the quinazolone (XIII), which was entirely converted to XIII by refluxing concentrated HCl or hydrolyzed to N-(4,7-dimethyl-2-quinolyl)anthranilic acid (XIV). Condensation of 1 g. 2-chloro-4,8-dimethylquinoline (XV) with 1.6 g. I 10 min. at 140° gave 80% Me N-(4,8-dimethylquinolyl)anthranilate, needles, m. 170°. The following analogs of VII were prepared (substituent, temperature of reaction, time in min., % yield, and m.p. given): 2-Me (XVa), 200-20°, -, 100, 194.5°; 2-MeO (XVI), 200-20°, 10, 96, 230°; 2-EtO (XVII), 200-20°, 10, 95, 193°. Analogs of XIV were prepared from the ester and(or) the quinoquinazolone by hydrolysis with NaOH in refluxing aqueous dioxane. These acids were converted to quinoquinazolones when sublimed or refluxed with Ac₂O (product, starting material, time of hydrolysis in hrs., m.p. given): 4,6-di-Me, IX, 0.5, 236°; XIV, XII and XIII, 0.5, 242°; 4-Me, 7-MeO (XVIII), XVI, 1, 218°; 4-Me, 7-EtO (XIX), XVII, 1, 188°. These acids, except XIX, were converted to quinoquinazolones. No condensation occurred between 2-chloro-6-ethoxylepidine and I below 150°, or when refluxed in solvents such as PhMe, or xylene 2-4 hrs. Condensation at 150-70° resulted in mixts. converted to XVII by refluxing with HCl, or hydrolyzed to XIX by NaOH. 2-Chloro-6-methoxylepidine (XX) (2 g.) and 2.7 g. I did not condense below 150°, but 0.5 hr. at 150-60° gave mixts. of the ester and XVI, but when refluxed with concentrated HCl gave only XVI. Condensation of XX with I 10 min. at 200-20° gave 96% XVI, canary yellow needles, m. 230° (from dioxane). XV (1 g.) and excess I heated to the b.p. gave N-(4,8-dimethyl-2-quinolyl)anthranilic acid (XXI).

Thus, the ester first formed failed to undergo ring closure but dry HCl hydrolyzed the ester group. XXI crystallized as needles, m. 240° (from dioxane). Ring closure by heating above the m.p. or refluxing with Ac2O failed. The ester in dioxane on hydrolysis with 10% NaOH gave XXI.


Refluxing XXI with concentrated HCl gave the HCl salt as cream colored crystals.

IV (3 g.) left 1 hr. in Me2CO with 5.6 g. I yielded 5.6 g. solids which on addition of NH3 gave Me N-4'-quinazolinylanthranilate (XXII), needles, m. 211° (from dioxane); HCl salt, m. 195°. The Me2CO filtrate and washings gave 2.5 g. unchanged I. XXII heated at its m.p. until effervescence ceased afforded quinazo[4,3-b]quinazol-8-one (XXIII), m. 197°. IV (2 g.) in 20 ml. Me2CO treated at 0° with 2 g. II in Me2CO gave an immediate precipitate of NH4Cl and after 1 hr. the solid removed, and the filtrate concentrated giving N-4'-quinazolinylanthranilic acid (XXIV), m. 248° (decomposition), which gave a platinichloride. XXIV heated at 250° gave XXIII. V (2 g.) and 2.7 g. I refluxed 2 hrs. in PhMe gave Me N-(2-phenyl-4-quinazolinyl)anthranilate (XXV), needles, m. 179° (from dioxane). XXV refluxed 1 hr. with Ac2O gave 6-phenylquinazo[4,3-b]quinazol-8-one (XXVI), m. 292°. XXV (0.5 g.) refluxed 0.5 hr. in dioxane with 10% NaOH gave N-(2-phenyl-4-quinazolinyl)anthranilic acid (XXVII), yellow needles, m. 255° (decomposition) (from aqueous dioxane). V (1.2 g.) in Me2CO at 0° treated with 0.8 g. II in Me2CO at 0°, left 1 hr., the filtrate evaporated, the product refluxed with H2O to remove anthranilic acid, and treated with NH3 gave 2-phenylquinazol-4-one (XXVIII). Acidification of the NH3 solution gave XXVII. XXVII heated at 255-60° gave a mixture, showing that it did not readily cyclize, probably due to steric hindrance by the 2-Ph group. Refluxing XXVII with Ac2O 1 hr. gave XXVI. V (0.6 g.) and 0.7 g. anthranilic acid refluxed 1 hr. in PhMe gave a compound, m. 240-5° (from aqueous dioxane). The product treated with cold NH4OH gave an insol. portion identified as XXVIII. The NH3 solution on acidification deposited XXVII, m. 255°.

IT 102452-36-8P, Anthranilic acid, N-(2-phenyl-4-quinazolinyl)-, methyl ester 102467-08-3P, Anthranilic acid, N-(2-phenyl-4-quinazolinyl)-
RL: PREP (Preparation)
(preparation of)


RN 102452-36-8 CAPLUS

CN Anthranilic acid, N-(2-phenyl-4-quinazolinyl)-, methyl ester (6CI) (CA INDEX NAME)



RN 102467-08-3 CAPLUS

CN Anthranilic acid, N-(2-phenyl-4-quinazolinyl)- (6CI) (CA INDEX NAME)



L7 ANSWER 313 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1956:77929 CAPLUS

DOCUMENT NUMBER: 50:77929

ORIGINAL REFERENCE NO.: 50:14773i,14774a-i,14775a-e

TITLE: Nitrilium salts. II. A new quinazoline synthesis

AUTHOR(S): Meerwein, Hans; Laasch, Peter; Mersch, Rudolf; Nentwig, Joachim

CORPORATE SOURCE: Univ. Marburg, Germany

SOURCE: Chemische Berichte (1956), 89, 224-38

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 50:77929

GI For diagram(s), see printed CA Issue.

AB Warming 5.8 g. N-phenylbenzonitrilium hexachlorotitanate (I.TiCl₆) in 10 cc. MeCN a few min. at 65-70°, making the mixture alkaline, and extracting it with Et₂O gives 85% 2-phenyl-4-methylquinazoline (II), needles, m. 90°; similarly, heating I.SnCl₆ 10 min. with PhCN gives 96.5% 2,4-diphenylquinazoline (III), m. 119-20°. Heating 2.4 g. PhCN.ZnCl₂ and 2.1 g. benzanilide imide chloride (IV) in 20 cc. o-C₆H₄Cl₂ 10 min. at 100° and decomposing the oil formed with H₂O gives 100% III; with PhCN.SnCl₄, III.SnCl₆, yellow needles, m. 201-3°, is obtained. When 21.6 g. IV in 50 cc. PhCN is treated with 13.3 g. AlCl₃ the temperature rises to 130°; the mixture is kept a few min. at 110-20°, decomposed with 20% NaOH, filtered, and the oil steam distilled, leaving 96% III. N-phenylbenzimidino Me treated similarly to IV 20 min. at 160-70° formed 86% III. Boiling 10.8 g. IV in 60 cc. MeCN a few min. with 6.5 g. SnCl₄ and decomposing the mixture with NaOH gives 62.5% II. Adding 6.7 g. AlCl₃ to 10.8 g. IV in 25 cc. EtCN and boiling the mixture a few min. gives 88% 2-phenyl-4-ethylquinazoline, m. 45° (picrate, red-yellow crystals, m. 139°). Heating 4 g. N-phenylacetimino Et ether in 30 cc. PhCN with 3.5 g. AlCl₃, 20 min. at 170-80°, steam distilling the mixture, and extracting the residue with Et₂O gives 72% 2-methyl-4-phenylquinazoline, b₁₁ 191°, m. 47°. Adding 6.7 g. AlCl₃ to 10.8 g. IV and 9.7 g. Ph₂CHCN in 30 cc. PhNO₂, heating the mixture a few min. at 120-30°, adding H₂O, and steam distilling the organic layer leaves 94% 2-phenyl-4-diphenylmethylquinazoline, m. 132°. Heating 2.6 g. N-phenyltrichloroacetamide chloride in 3 cc. MeCN with 3 g. SnCl₄ 10 min. at 125° gives 71% 2-trichloromethyl-4-methylquinazoline, long needles, m. 144°; with AlCl₃ the yield is 58%, with TiCl₄, 65%. Adding 5.3 g. BrCN to a cooled mixture of 11 g. IV in 20 cc. PhNO₂ and 6.5 g. SnCl₄ and 30 cc. PhNO₂ and heating the mixture in a sealed tube 10 min. at 150° gives 86.3% 2-phenyl-4-bromoquinazoline (V) hexachlorostannate, m. 214-16°; free V, shiny needles, m. 129°. Adding in 3 portions with shaking 7.3 g. MeCNS to 21.5 g. IV and 15 g. SnCl₄ in 70 cc. PhNO₂ causes a rise in the temperature to 100-20° and the separation of 98% 2-phenyl-4-

methylthioquinazoline (VI) hexachlorostannate, large yellow crystals, m. 278-81°, which, decomposed with NaOH, gives VI, needles, m. 94°. Warming 13 g. trichloroacetanilide imide chloride in 40 cc. PhNO₂ with 3.6 g. MeCNS and 6.5 g. SnCl₄ 10 min. at 150° and decomposing the filtered precipitate with NaOH gives 90% 2-trichloromethyl-4-methylthioquinazoline, long yellowish needles, m. 138°. Heating 13 g. N-(2-naphthyl)benzimidazole chloride in 50 cc. PhCN with 6.8 g. AlCl₃ 20 min. at 150-60° and adding ice-H₂O give 87.5% 2,4-diphenyl-5,6-benzoquinazoline, needles, m. 153°; 7,8-benzo isomer, 90.5%, m. 160°. That ring closure occurs at the 1- and not at the 3-position is shown by the fact that N-(α-chloro-2-naphthyl)-benzimidazole chloride under the same conditions does not give a quinazoline. Adding 4 g. SnCl₄ to 5 g. Ph₂NCN and 5.5 g. IV in 60 cc. o-C₆H₄Cl₂, heating the mixture 0.5 hr. at 160°, and pouring it onto ice gives 95.5% 2-phenyl-4-diphenylaminoquinazoline hexachlorostannate, fine deep yellow needles, m. 276-9°, which, boiled with alkali, gives the free base, shiny leaflets, m. 156°. Heating 5 g. NCCO₂Et, 11.5 g. IV, and 13 g. SnCl₄ in 30 cc. o-C₆H₄Cl₂ 10 min. at 140°, adding 20% NaOH, steam distilling, and acidifying the hot filtered solution with dilute HCl

gives

52% 2-phenylquinazoline-4-carboxylic acid, pale yellow crystals, m. 151° (CO₂ evolution). Heating 7.5 g. N-(vic-m-xylyl)benzonitrilium tetrachloroaluminate and 2.1 g. PhCN in 15 cc. o-C₆H₄Cl₂ 10 min. at 150° gives 62.5% [2,6-Me₂C₆H₃N:CPhN:CPh]AlCl₄, yellow crystals, m. above 400°; the corresponding ZnCl₃ compound, 67.5%, yellow crystals; both compds. decompose with H₂O with the formation of 2,6-Me₂C₆H₃NHBz, m. 172°. Warming 15.5 g. PhN₂BF₄ (VII) with 30 cc. MeCNS slowly to 70° causes a vigorous reaction; keeping the temperature below 100° and then heating it 5 min. at 110° gives 41% 2,4-dimethylthioquinazoline (VIII).BF₄, m. 205° (decomposition) (free base, needles, m. 67-8°; picrate m. 171°); with PhN₂.SnCl₆ in lieu of VII 54.5% VIII is obtained; 6-Me homolog (IX) of VIII, 49%, m. 104-5°. Heating V with alc. NH₃ 1 hr. at 150° gives o-C₆H₄.N:CR.N:CR' (X, R = Ph, R' = NH₂), 100%, m. 142-3°. V and CuCN boiled 8 hrs. in PhNO₂ gives 87% X (R = Ph, R' = CN), m. 166-7°. VIII boiled 2 hrs. with 10% alc. KOH gives 92% X (R = MeS, R' = OH), m. 219°; 3hrs. with 4% alc. NaOMe gives 85% OMe analog, m. 56°; VIII 3 hrs. at 150° with saturated alc. NH₃, 81% NH₂ analog, m. 233-4°; VIII 2 hrs. with 5% PhNH₂-EtOH, 85% X (R = MeS, R' = PhNH), m. 179°. VIII and saturated alc. NH₃ at 230° gives 81% X (R = R' = NH₂), m. 249-50°. The following addnl. X are prepared (R, R', % yield, m.p. given): Ph, 2-ClC₆H₄, 90.5, 163°; Ph, CC13, 32.5, 109°; CC13, Ph, 78.8, 129°; CC13, 2-ClC₆H₄, 62.5, 133°; CC13, CC13, 18.5, 133°; CHCl₂, Ph, 74.4, 185°; CH Cl₂, 2-ClC₆H₄, 51.5, 134°. The following quinazolines were prepared: 8-methyl-2,4-diphenyl, 97.5%, m. 124.5°; 6,8-dichloro-2,4-diphenyl, 94%, m. 200-1°; 8-methyl-2-phenyl-4-benzyl, 73.5%, m. 183-4°; 6-chloro-2-phenyl-4-benzyl, 83.3%, m. 195°; 6,8-dichloro-2-phenyl-4-diphenylmethyl, 75.5%, m. 310°. The following X are prepared by heating the appropriate aryldiazonium fluoborate: 2,4-diphenyl, 58%, m. 119-20°; 6-Me homolog, 69.5%, m. 177°; 6-Cl analog, 78%, m. 184-5°; 5,6- or 6,7-Me₂ homolog, 22%, m. 173-4°; 5,7-Me₂ homolog, 57.5%, m. 154-5°; 2,4-dibenzyl-5,8-dimethyl, 42%, m. 98-9°. Heating 22 g. 2,5-Me₂C₆H₃N₂BF₄ with 20 cc. MeCN at 60-70° until the N evolution has ceased and keeping the mixture 2 days give 51.5% bisfluoborate of the 2',5'-dimethylanil of 2,5,8-trimethyl-4-acetonylquinazoline (XI), yellow crystals, m. above 200° (free base, liberated with NaOH, yellow plates, m. 126-7°; di-HCl salt, m. 148-50°; monopicrate, brick-red crystals, m. 180°; methiodide, red-yellow prisms, m. 215°). Heating with acids splits XI into p-xylylidine and 2,5,8-trimethyl-4-acetonylquinazoline, yellowish needles, m. 135°


(picrate, m. 205°). In 2 of 10 expts. the primarily formed 2,4,5,8-tetramethylquinazoline was obtained in small yield and isolated as the picrate, yellow needles, m. 207-8°. Warming sym-m-xylyl-, asym-o-xylyl-, and pseudocumyldiazonium fluoborates with MeCN gives the corresponding anils in 64, 53, and 63% yield, resp. Treating 10.8 g. IV in 30 cc. MeCN with 6.7 g. AlCl₃ and heating the mixture a few min. at the boil give 88% anil (XII) of 2-phenyl-4-phenacylquinazoline, yellow crystals, m. 214-15°, also obtained when equimolar amts. of II and IV are condensed in PhNO₂ in the presence of AlCl₃; XII is quite stable toward alkali and acids. When 11.5 g. IV and 4.4 g. NCCH₂CO₂Et in 30 cc. PhNO₂ are treated with 13 g. SnCl₄ and the mixture, after the initial exothermic reaction has ceased, is heated 5 min. at 120°, then made alkaline, and steam distilled, 45.5% anil of 2-phenyl-4-(α -carboxyphenacyl)quinazoline, orange-red rosettes, m. 335°, is obtained; it is stable toward boiling alkali and acids.

IT 1022-44-2P, Quinazoline, 4-amino-2-phenyl- 103051-13-4P,
Quinazoline, 4-diphenylamino-2-phenyl- 125904-49-6P,
Quinazoline, 4-diphenylamino-2-phenyl-, chlorostannate(IV)
RL: PREP (Preparation)

(preparation of)


RN 1022-44-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl- (CA INDEX NAME)



RN 103051-13-4 CAPLUS

CN 4-Quinazolinamine, N,N,2-triphenyl- (CA INDEX NAME)




RN 125904-49-6 CAPLUS

CN Quinazoline, 4-diphenylamino-2-phenyl-, chlorostannate(IV) (6CI) (CA INDEX NAME)

CM 1

CRN 103051-13-4

CMF C26 H19 N3




CM 2

CRN 19512-65-3

CMF Cl6 Sn . 2 H

CCI CCS



● 2 H⁺

L7 ANSWER 314 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1954:18366 CAPLUS

DOCUMENT NUMBER: 48:18366

ORIGINAL REFERENCE NO.: 48:3369a-g

TITLE: Antimalarials. I. Quinazoline series

AUTHOR(S): Dass, Ramji; Vig, O. P.; Gupta, I. S.; Narang, K. S.

SOURCE: Journal of Scientific & Industrial Research (1952), 11B, 461-3

CODEN: JSIRAC; ISSN: 0022-4456

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB o-H₂NC₆H₄CONH₂ (I) was condensed with o- or p-ClC₆H₄COC1

(II), and the products cyclized to the quinazolines, and converted with PCl₅ and POCl₃ to the 4-Cl derivs. which were condensed with substituted aryl amines. I (4.4 g.) in 50 ml. C₆H₆ and 10 ml. C₅H₅N slowly treated with 5.0 g. II, the mixture warmed 20 min. on a H₂O bath, filtered, and the residue washed with Na₂CO₃ solution and crystallized from 70% EtOH gave 5 g. o-(o-chlorobenzamido)benzamide (III), m. 199.5°.

III (2 g.) in 20 ml. absolute EtOH treated with 0.5 g. KOH, the mixture heated 40 min., diluted with 200 ml. H₂O, cooled, filtered, and the filtrate acidified with HOAc, boiled, cooled, and filtered, gave 1.5 g.

2-(o-chlorophenyl)-4-quinazolinone (IV), m. 183° (from 40%

EtOH). PCl₅ (6 g.), 10 ml. POCl₃, and 2 g. IV refluxed 3 hrs., the P compds. removed by vacuum distillation, 15 ml. dry C₆H₆ added, then distilled

off,


the process repeated, and the product crystallized from 60-80° petr. ether gave 1.0 g. 2-(o-chlorophenyl)-4-chloroquinazoline (V), m.

126°. V (1.0 g.) in 20 ml. dry C₆H₆ added to 1.05 g. PhCH₂NH₂, the mixture refluxed 1 hr., the C₆H₆ removed, the residue crystallized from EtOH containing HCl, the HCl salt washed with Et₂O and C₆H₆, dissolved in EtOH, treated with 2 ml. 1% KOH, and the product crystallized from 9% EtOH gave 1.2 g. 2-(o-chlorophenyl)-4-benzylaminoquinazoline, m. 188°.


Similarly were prepared the following 2-(o-chlorophenyl)quinazolines (4-substituent, m.p., and crystallization solvent given): p-toluidino, 170°, absolute EtOH; p-anisidino (HCl salt), 148°, diluted EtOH; p-ethoxyanilino, 234-6°, absolute EtOH; o-toluidino (HCl salt), 174°, 60% EtOH; o-anisidino (HCl salt), 156°, 60% EtOH; o-ethoxy, 146°, 80% EtOH; p-chloroanilino (HCl salt),

257°, 80% EtOH; p-bromoanilino, 197°, absolute EtOH;
 p-hydroxyanilino (HCl salt), 304°, absolute EtOH; N-methyl-p-toluidino
 (HCl salt), 258°, absolute EtOH; N-ethyl-p-toluidino (HCl salt),
 168.5°, 50% EtOH; N-methyl-o-toluidino (HCl salt),
 163°, 40% EtOH; N-ethyl-o-toluidino (HCl salt),
 174°, 50% EtOH; N-ethyl-p-methoxyanilino (HCl salt), 182-4°,
 diluted EtOH. 2-(p-Chlorophenyl)quinazolines (4-substituent, m.p., and
 crystallization solvent given): benzylamino (HCl salt), 300°, diluted EtOH;
 p-anisidino, 158°, 80% EtOH; p-ethoxyanilino, 105°, diluted
 EtOH; o-toluidino, 145°, absolute EtOH; o-anisidino
 (HCl salt), 270°, absolute EtOH; o-ethoxyanilino, 177°,
 diluted EtOH; p-chloroanilino, 197°, 70% MeOH; p-bromoanilino,
 220°, C₆H₆; p-hydroxyanilino (HCl salt), 296°, absolute EtOH;
 N-methyl-p-toluidino, 170°, diluted EtOH; N-ethyl-p-toluidino-,
 181°, absolute EtOH; N-methyl-o-toluidino-, 168°. Me₂CO;
 N-ethyl-o-toluidino, 120°, diluted EtOH;
 N-ethyl-p-anisidino, 124°, 60% EtOH; and p-toluidino, 148°,
 90% EtOH.


IT 347366-40-9, Quinazoline, 2-[o-chlorophenyl]-4-p-hydroxyanilino-
 347366-41-0, Quinazoline, 4-p-anisidino-2-(o-chlorophenyl)-
 371218-83-6, Quinazoline, 4-o-anisidino-2-(o-chlorophenyl)-
 446829-22-7, Quinazoline, 2-[p-chlorophenyl]-4-p-hydroxyanilino-
 860192-17-2, Quinazoline, 2-(o-chlorophenyl)-4-[N-methyl-p-
 toluidino]- 860192-19-4, Quinazoline, 2-(o-chlorophenyl)-4-[N-
 methyl-o-toluidino]- 860192-21-8, Quinazoline,
 2-(o-chlorophenyl)-4-[N-ethyl-p-toluidino]- 860192-23-0,
 Quinazoline, 2-(o-chlorophenyl)-4-[N-ethyl-o-toluidino]-
 (hydrochlorides)
 RN 347366-40-9 CAPLUS
 CN Phenol, 4-[[2-(2-chlorophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 347366-41-0 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 371218-83-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(2-methoxyphenyl)- (CA INDEX NAME)




RN 446829-22-7 CAPLUS
 CN Phenol, 4-[[2-(4-chlorophenyl)-4-quinazolinyl]amino]- (CA INDEX NAME)




RN 860192-17-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-methyl-N-(4-methylphenyl)- (CA INDEX NAME)




RN 860192-19-4 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-methyl-N-(2-methylphenyl)- (CA
 INDEX NAME)




RN 860192-21-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-ethyl-N-(4-methylphenyl)- (CA
 INDEX NAME)




RN 860192-23-0 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-ethyl-N-(2-methylphenyl)- (CA
 INDEX NAME)




IT 329226-08-6P, Quinazoline, 2-[o-chlorophenyl]-4-p-toluidino-
 347366-42-1P, Quinazoline, 2-[o-chlorophenyl]-4-p-phenetidino-
 371215-23-5P, Quinazoline, 4-p-bromoanilino-2-[o-chlorophenyl]-
 371932-21-7P, Quinazoline, 4-p-anisidino-2-(p-chlorophenyl)-
 371938-93-1P, Quinazoline, 4-p-chloroanilino-2-(p-chlorophenyl)-
 371939-56-9P, Quinazoline, 4-p-bromoanilino-2-[p-chlorophenyl]-
 371945-50-5P, Quinazoline, 2-[p-chlorophenyl]-4-p-toluidino-
 371946-47-3P, Quinazoline, 4-benzylamino-2-(o-chlorophenyl)-
 420833-75-6P, Quinazoline, 2-[o-chlorophenyl]-4-o-phenetidino-
 421573-59-3P, Quinazoline, 2-[p-chlorophenyl]-4-p-phenetidino-
 421581-29-5P, Quinazoline, 2-(p-chlorophenyl)-4-o-toluidino-
 451462-12-7P, Quinazoline, 2-[p-chlorophenyl]-4-o-phenetidino-
 473800-21-4P, Quinazoline, 2-(o-chlorophenyl)-4-o-toluidino-,
 hydrochloride 855404-05-6P, Phenol, p-[2-[p-chlorophenyl]-4-
 quinazolinylamino]-, hydrochloride 855404-06-7P, Phenol,
 p-[2-[o-chlorophenyl]-4-quinazolinylamino]-, hydrochloride
 857759-95-6P, Quinazoline, 4-benzylamino-2-(p-chlorophenyl)-,
 hydrochloride 857760-11-3P, Quinazoline, 2-(p-chlorophenyl)-4-[N-
 ethyl-o-toluidino]- 857760-13-5P, Quinazoline,
 2-(p-chlorophenyl)-4-[N-ethyl-p-toluidino]- 858235-71-9P,
 Quinazoline, 4-p-chloroanilino-2-(o-chlorophenyl)-, hydrochloride
 858236-30-3P, Quinazoline, 2-(p-chlorophenyl)-4-N-ethyl-p-
 anisidino- 858236-33-6P, Quinazoline, 2-(o-chlorophenyl)-4-N-
 ethyl-p-anisidino-, hydrochloride 860192-13-8P, Quinazoline,
 2-(p-chlorophenyl)-4-[N-methyl-p-toluidino]- 860192-15-0P,
 Quinazoline, 2-(p-chlorophenyl)-4-[N-methyl-o-toluidino]-
 860720-51-0P, Quinazoline, 4-o-anisidino-2-(p-chlorophenyl)-,
 hydrochloride
 RL: PREP (Preparation)
 (preparation of)
 RN 329226-08-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(4-methylphenyl)- (CA INDEX NAME)




RN 347366-42-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 371215-23-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromophenyl)-2-(2-chlorophenyl)- (CA INDEX NAME)




RN 371932-21-7 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 371938-93-1 CAPLUS
 CN 4-Quinazolinamine, N,2-bis(4-chlorophenyl)- (CA INDEX NAME)




RN 371939-56-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromophenyl)-2-(4-chlorophenyl)- (CA INDEX NAME)




RN 371945-50-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(4-methylphenyl)- (CA INDEX NAME)




RN 371946-47-3 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 420833-75-6 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(2-ethoxyphenyl)- (CA INDEX NAME)




RN 421573-59-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 421581-29-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(2-methylphenyl)- (CA INDEX NAME)




RN 451462-12-7 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(2-ethoxyphenyl)- (CA INDEX NAME)



RN 473800-21-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(2-methylphenyl)-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 855404-05-6 CAPLUS


CN Phenol, 4-[[2-(4-chlorophenyl)-4-quinazolinyl]amino]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl


RN 855404-06-7 CAPLUS

CN Phenol, 4-[[2-(2-chlorophenyl)-4-quinazolinyl]amino]-, hydrochloride (1:1)
(CA INDEX NAME)




● HCl

RN 857759-95-6 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(phenylmethyl)-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl


RN 857760-11-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-ethyl-N-(2-methylphenyl)- (CA
 INDEX NAME)



RN 857760-13-5 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-ethyl-N-(4-methylphenyl)- (CA
 INDEX NAME)




RN 858235-71-9 CAPLUS
 CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(4-chlorophenyl)-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

RN 858236-30-3 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-ethyl-N-(4-methoxyphenyl)- (CA
 INDEX NAME)




RN 858236-33-6 CAPLUS
CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-ethyl-N-(4-methoxyphenyl)-,
hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 860192-13-8 CAPLUS
CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-methyl-N-(4-methylphenyl)- (CA
INDEX NAME)



RN 860192-15-0 CAPLUS
CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-methyl-N-(2-methylphenyl)- (CA
INDEX NAME)



RN 860720-51-0 CAPLUS
 CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(2-methoxyphenyl)-, hydrochloride
 (1:1) (CA INDEX NAME)




● HCl

L7 ANSWER 315 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1954:8414 CAPLUS
 DOCUMENT NUMBER: 48:8414
 ORIGINAL REFERENCE NO.: 48:1581h-i
 TITLE: Chemotherapy of experimental relapsing fever in mice
 with antibiotics and synthetic compounds
 AUTHOR(S): Thompson, Paul E.; Walker, D. F.; Dunn, Mary C.
 CORPORATE SOURCE: Parke, Davis & Co., Detroit, MI
 SOURCE: Journal of the American Pharmaceutical Association
 (1912-1977) (1953), 42, 647-52
 CODEN: JPHAA3; ISSN: 0003-0465
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB Out of 4 antibiotics and 206 synthetic compds., only subtilin, methylated
 subtilin, bacitracin, and melarsen oxide were effective in suppressing the
 spirochetemia in standardized relapsing fever infections in mice.
 IT 5431-48-1, Quinazoline, 4-(4-diethylamino-1-methylbutylamino)-2-
 phenyl-, diphosphate
 (antispicrochetal action of)
 RN 5431-48-1 CAPLUS
 CN 1,4-Pentanediamine, N1,N1-diethyl-N4-(2-phenyl-4-quinazolinyl)-, phosphate
 (1:2) (CA INDEX NAME)

CM 1


CRN 47546-42-9
 CMF C23 H30 N4



CM 2

CRN 7664-38-2

CMF H3 O4 P



L7 ANSWER 316 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1954:8413 CAPLUS

DOCUMENT NUMBER: 48:8413

ORIGINAL REFERENCE NO.: 48:1581g-h

TITLE: The effects of administration of sodium iodate to man and animals

AUTHOR(S): Murray, Margaret M.

CORPORATE SOURCE: Univ. London

SOURCE: Bull. World Health Organization (1953), 9, 211-16

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB Mice tolerated single oral doses of 250 mg. NaIO₃/kg. and rabbits tolerated 10 mg./kg. in twice-weekly oral doses for 6 wk. Chronic oral administration twice weekly at the 1 mg./kg. level produced no signs of ill health or histol. changes in rabbits. NaCl containing 0.005% NaIO₃ should be safe for man based on a weekly intake of 70 g. of salt.

IT 5431-48-1, Quinazoline, 4-(4-diethylamino-1-methylbutylamino)-2-phenyl-, diphosphate
(antispasmodic action of)


RN 5431-48-1 CAPLUS

CN 1,4-Pentanediamine, N1,N1-diethyl-N4-(2-phenyl-4-quinazolinyl)-, phosphate (1:2) (CA INDEX NAME)

CM 1

CRN 47546-42-9


CMF C23 H30 N4



CM 2

CRN 7664-38-2

CMF H3 O4 P



L7 ANSWER 317 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1951:21795 CAPLUS

DOCUMENT NUMBER: 45:21795

ORIGINAL REFERENCE NO.: 45:3852g-i,3853a

TITLE: Furylquinazolines. IV. Nucleophilic reactivity of the 2-furyl-4-alkoxyquinazolines

AUTHOR(S): Andrisano, R.; Modena, G.

CORPORATE SOURCE: Univ. Bologna, Italy

SOURCE: Bollettino Scientifico della Facolta di Chimica

Industriale di Bologna (1950), 8, 7-9

CODEN: BSFCAY; ISSN: 0366-3205

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB cf. preceding abstract 2-Furyl-4-chloroquinazoline (I) (C.A. 45, 1600f), refluxed for 0.5 hr. with 0.05 atom Na in 20-30 cc. of an aliphatic alc., poured into H₂O after cooling, and extracted with Et₂O, yields the corresponding 4-alkoxy derivative Thus, the following 2-furyl-4-alkoxyquinazolines (II) are prepared: MeO, prisms from ligroin, m. 65° (picrate, prisms from EtOH, m. 170°); EtO, needlelike prisms from ligroin, m. 83° (picrate, prisms from EtOH, m. 183.4°); PrO, characterized as the picrate, needlelike prisms from EtOH, m. 143.5°; iso-PrO, characterized as the picrate, prisms from EtOH, m. 164°. Similarly, by refluxing 0.02 mol. I, 0.05 atom Na, 8 cc. PhCH₂OH, and 20 cc. dioxane for 1 hr. was prepared 2-furyl-4-benzyloxyquinazoline (III), oil, characterized as the picrate, prisms from EtOH, m. 171°. Also, 2-furyl-4-phenoxyquinazoline (IV), prisms from ligroin, m. 135°. These compds. are hydrolyzed to 2-furyl-4-hydroxyquinazoline by refluxing with aqueous NaOH until they are completely dissolved; the rate of hydrolysis decreases in the order II > IV > III. Refluxing II, III, or IV with a Na alcoholate in the corresponding alc. or in dioxane yields the corresponding 4-alkoxy derivative In general, II are converted to their higher or lower homologs; IV easily yields II and III, but is not formed by this reaction. IV (3.3 g.) and 3 g. Et₂N(CH₂)₃CHMeNH₂ heated at 150° for 1.5 hrs., washed with 10% aqueous NaOH, and distilled in vacuo, yield 2-furyl-4-(5-diethylamino-2-pentylamino)quinazoline, characterized as the picrate, needles from EtOH, m. 179°.

IT 858236-39-2P, Quinazoline, 7-chloro-2-(2-furyl)-4-p-toluidino-

858236-41-6P, Quinazoline, 7-chloro-2-(2-furyl)-4-phenetidino-


860191-81-7P, Quinazoline, 4-(anisidino)-7-chloro-2-(2-furyl)-

RL: PREP (Preparation)


(preparation of)

RN 858236-39-2 CAPLUS


CN 4-Quinazolinamine, 7-chloro-2-(2-furanyl)-N-(4-methylphenyl)- (CA INDEX NAME)



RN 858236-41-6 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-N-(4-ethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)



RN 860191-81-7 CAPLUS
 CN 4-Quinazolinamine, 7-chloro-2-(2-furanyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



L7 ANSWER 318 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1951:21794 CAPLUS
 DOCUMENT NUMBER: 45:21794
 ORIGINAL REFERENCE NO.: 45:3852c-g
 TITLE: Furylquinazolines. III. 4-Substituted

2-furyl-4-chloroquinazolines
 AUTHOR(S): Andrisano, R.; Modena, G.
 CORPORATE SOURCE: Univ., Bologna, Italy
 SOURCE: Gazzetta Chimica Italiana (1950), 80, 321-4
 CODEN: GCITA9; ISSN: 0016-5603

DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 45:21794


AB cf. C.A. 45, 1601d; following abstract In view of the high anti-malarial power of 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinazoline (cf. Price, et al., C.A. 40, 5747.4), its 2-(2-furyl) derivative (I) was prepared 4,2-Cl(H₂N)C₆H₃CO₂H (10 g.) and 12 g. Et 2-furancarboximidate [cf. Ber. 25, 1416(1892)], heated 2 hrs. at 200°, the product taken up in MeOH, filtered, and the residue purified by AcOH, yield 2-(2-furyl)-4-hydroxy-7-chloroquinazoline (II), m. 276°. II (10 g.) in 80 cc. POCl₃ and 14 g. PCl₅, refluxed 90 min., distilled in vacuo, the residue taken up in ice water, neutralized with NH₄OH, filtered, and the residue extracted with C₆H₆, yields 9.5 g. (88%) of 2-(2-furyl)-4,7-dichloroquinazoline (III), m. 137°. III (5.3 g.) and 6.4 g. H₂NCHMeCH₂CH₂CH₂NEt₂ in 80 cc. C₆H₆, neutralized by Na₂CO₃, refluxed 3 hrs., and the product steam-distilled, yield almost 100 % I, m. 112°. With alc. picric acid, it forms a picrate, C₃₃H₃₃O₁₅N₁₀Cl, m. 199°. Since the Cl in the 4-position in III, like that in the chloroquinazolines already described (cf. C.A. 45, 1600f) is reactive with nucleophilic agents, 6 compds. were prepared by replacement of the Cl. III (0.01 mol.) and NaOMe (from 0.03 atom Na in 40 cc. MeOH), refluxed 30 min., diluted with water, and the precipitate purified by ligroin, yields 2-(2-furyl)-4-methoxy-7-chloroquinazoline, m. 130°. III (0.01 mol.) in 20 cc. dioxane and NaOPh (from 0.03 atom Na in 12 g. PhOH), refluxed 30 min., poured into water, NaOH added, and the precipitate purified by aqueous EtOH, yield 100% of

the 4-phenoxy analog, m. 140°. Four arylamino derivs. were prepared in high yields by refluxing 0.01 mol. III and 0.02 mol. of the resp. arylamine 1 hr. in C₆H₆, making alkaline with Na₂CO₃, and steam-distilling 2-(2-Furyl)-4-phenylamino-7-chloroquinazoline, m. 170° (from EtOH); 4-tolylamino analog, m. 201° (from ligroin); 4-methoxyphenylamino analog, m. 189° (from EtOH); 4-ethoxyphenylamino analog, m. 180° (from EtOH).

IT 858235-29-7P, Quinazoline, 7-chloro-4-(4-diethylamino-1-methylbutylamino)-2-(2-furyl)- 860191-83-9P, Quinazoline, 4-anilino-7-chloro-2-(2-furyl)-
 RL: PREP (Preparation)
 (preparation of)


RN 858235-29-7 CAPLUS

CN 1,4-Pentanediamine, N4-[7-chloro-2-(2-furanyl)-4-quinazolinyl]-N1,N1-diethyl- (CA INDEX NAME)



RN 860191-83-9 CAPLUS

CN 4-Quinazolinamine, 7-chloro-2-(2-furanyl)-N-phenyl- (CA INDEX NAME)



L7 ANSWER 319 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1951:8789 CAPLUS

DOCUMENT NUMBER: 45:8789

ORIGINAL REFERENCE NO.: 45:1601c-g

TITLE: Furylquinazolines. II. 4-Substituted
2-furyl-6-methylquinazolines

AUTHOR(S): Andrisano, R.; Modena, G.

CORPORATE SOURCE: Univ., Bologna, Italy

SOURCE: Bollettino Scientifico della Facolta di Chimica

Industriale di Bologna (1950), 8, 1-3

CODEN: BSFCAY; ISSN: 0366-3205

DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

AB cf. preceding abstract 5,2-Me(H₂N) C₆H₃CO₂Me (22 g.) and 24 g. Et 2-furanacetimidate (cf. Pinner, Ber. 25, 1416(1892)), heated at 200° for 1.5 hrs., taken up in MeOH after cooling, filtered, washed, and dried, yield 18.5 g. (61%) 2-furyl-4-hydroxy-6-methylquinazoline (I), silky needles from EtOH, m. 257°. I (16.8 g.) is refluxed with 100 cc. POCl₃ and 24 g. PCl₅ for 1.5 hrs., the excess POCl₃PCl₅ removed under reduced pressure, the residue taken up with H₂O and ice, neutralized with NH₄OH, filtered, washed, and dried to yield after recrystn. from C₆H₆ 14 g. (77%) 4-Cl analog (II), prisms from ligroin, m. 144°. Refluxing 5 g. II and 6.5 g. Et₂N(CH₂)₃CHMeNH₂ in 75 cc. C₆H₆, and removing the C₆H₆ and excess base with steam gives in almost quant. yield the 4-(5-diethylamino-2-pentylamino) analog, needles, b₉ 280°, m. 144° (from ligroin); picrate, needles from EtOH, m. 180°. II (0.01 mol.), refluxed with 0.03 atom Na in 40 cc. MeOH for 0.5 hr. and poured into H₂O, yields almost quantitatively the 4-MeO analog, colorless prisms from ligroin, m. 116°. Similarly, 0.01 mol. II, 0.03 atom Na, and 12 g. PhOH in 20 cc. dioxane give the 4-PhO analog, colorless prisms from ligroin, m. 141°. The following 2-furyl-4-arylamino-6-methylquinazolines are obtained in almost quant. yield by refluxing 0.01 mol. II with 0.02 mol. of the corresponding arylamine in 40 ml. C₆H₆, making alkaline with Na₂CO₃, and removing the solvent and excess amine with steam: PhNH, needles from aqueous EtOH, m. 180°; MeC₆H₄NH, needles from EtOH, m. 140°; p-MeOC₆H₄NH, needles from ligroin, m. 156°; p-EtOC₆H₄NH, silky needles from MeOH, m. 126°.


IT 857760-27-1P, Quinazoline, 4-(4-diethylamino-1-methylbutylamino)-2-(2-furyl)-6-methyl- 860191-75-9P, Quinazoline, 4-(anisidino)-2-(2-furyl)-6-methyl- 860720-50-9P, Quinazoline, 4-anilino-2-(2-furyl)-6-methyl-
RL: PREP (Preparation)
(preparation of)

RN 857760-27-1 CAPLUS


CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[2-(2-furanyl)-6-methyl-4-quinazolinyl]- (CA INDEX NAME)



RN 860191-75-9 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)



RN 860720-50-9 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-6-methyl-N-phenyl- (CA INDEX NAME)



L7 ANSWER 320 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1951:8788 CAPLUS
 DOCUMENT NUMBER: 45:8788
 ORIGINAL REFERENCE NO.: 45:1600f-i,1601a-c
 TITLE: Furylquinazolines. I. 4-Substituted
 2-furylquinazolines
 AUTHOR(S): Andrisano, Renato; Modena, G.
 CORPORATE SOURCE: Univ. Bologna, Italy
 SOURCE: Gazzetta Chimica Italiana (1950), 80, 228-33
 CODEN: GCITA9; ISSN: 0016-5603
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

AB cf. following abstract In view of the plasmocidal action of quinazoline derivs. containing a pentylamine side chain (cf. Endicott, et al., C.A. 40, 5748.3; Price, et al., C.A. 40, 5747.4), some 2-furylquinazoline derivs. were prepared to study their anti-malarial activity and the comparative influence on their pharmacol. properties of the Ph and furan ring in the quinazoline nucleus. o-H₂NC₆H₄CO₂Me (20 g.) and 20 g.

OC4H3C(:NH)OEt [cf. Ber. 25, 1416(1892)], heated 3 hrs. at 210-20°, taken up in MeOH, filtered, and the residue purified by EtOH, yields 74% of 2-furyl-4-hydroxyquinazoline (I), m. 220°. Also, 10.3 g. o-H2NC6H4CO2H and 9.5 g. OC4H3C(:S)NH2 [Hantzsch, Ber. 25, 1314(1892)], heated at 150° until no more H2S is evolved, and the product treated as before, yield approx. 74% I. I (10 g.) in 80 cc. POC13 and 14 g. PC15, heated 100 min. (no temperature given), distilled in vacuo, the residue neutralized with NH4OH, mixed with ice water, and the crystallized product dried and extracted with C6H6, yield 9 g. (80%) of 2-furyl-4-chloroquinazoline (II). Hydrolysis by 5% alc. KOH yields I. II (4.1 g.) and 5 g. H2NCHMe(CH2)3NEt2 in 60 cc. C6H6, refluxed 3 hrs., made alkaline with Na2CO3, and steam-distilled, leave a pasty residue which could

not


be crystallized even after distillation in vacuo (b16 286°). However, with alc. picric acid it formed, after purification by EtOH, a dipicrate, C33H34O15N10, m. 179°, and with H3PO4 a monohydrated diphosphate, C21H36O10N4P2, m. 210°. The wts. of these corresponded to an almost 100% yield of 2-furyl-4-(4-diethylamino-1-methylbutylamino)quinazoline (III). III is also formed by the same procedure, but in the presence of PhOH without solvent. II (0.01 mol.) and alc. NaOMe (from 0.03 atom Na in 40 cc. MeOH), refluxed 1 hr., diluted with water, extracted with Et2O, the extract evaporated, and the oil residue distilled

in vacuo (b16 212°), give, after purification by ligroin, a good yield of 2-furyl-4-methoxyquinazoline, m. 65°. II (0.01 mol.) and NaOPh (from 0.03 atom Na, 12 g. PhOH, and 20 cc. dioxane), refluxed 1 hr., poured into water, and NaOH added, give, after purification by ligroin, almost 100% of 2-furyl-4-phenoxyquinazoline (IV), m. 135°. Alc. II, treated while refluxing with anhydrous NH3 for 1 hr., diluted with water, and the precipitate purified by EtOH, yields almost 100% 2-furyl-4-aminoquinazoline, m. 225°. II (0.01 mol.) in C6H6 and 0.02 mol. of arylamine in 40 cc. C6H6, refluxed 1 hr., made alkaline with Na2CO3, steam-distilled, and the residues purified by EtOH, yielded almost 100% of the following 2-furyl-4-(arylamino)quinazolines: NHPH, m. 115°; NHC6H4Me, m. 133°; NHC6H4OMe, m. 110°; NHC6H4OEt, m. 105°. The extreme reactivity of the Cl in II is similar to the behavior of Cl in 2,4,1-(O2N)2C10H5Cl (cf. Mangini and Frenguelli, C.A. 32, 1258.3) and the Cl in 4-chloroquinazoline (cf. Tomisek and Christensen, C.A. 32, 1259.1). This is in harmony with the theory of Bonino and the expts. of Mangini and Frenguelli (Atti accad. sci. Bologna [10] 1, 201(1944); C.A. 33, 5398.6), and of the pharmacol. expts. of Erlenmeyer (C.A. 41, 1671g) concerning the analogy between the heterocyclic N atom and the aromatic CNO2 group, which, by strongly polarizing the electronic cloud in relation to the nuclear CCl group, increase the tendency toward replacement of the Cl.


IT 857760-25-9, Quinazoline, 4-(4-diethylamino-1-methylbutylamino)-2-(2-furyl)-
(and derivs.)

RN 857760-25-9 CAPLUS


CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[2-(2-furanyl)-4-quinazolinyl]- (CA INDEX NAME)




IT 40172-85-8P, Quinazoline, 4-amino-2-(2-furyl)-
 157863-04-2P, Quinazoline, 4-anilino-2-(2-furyl)-
 860191-77-1P, Quinazoline, 4-(anisidino)-2-(2-furyl)-
 RL: PREP (Preparation)
 (preparation of)
 RN 40172-85-8 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)- (CA INDEX NAME)



RN 157863-04-2 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-phenyl- (CA INDEX NAME)




RN 860191-77-1 CAPLUS
 CN 4-Quinazolinamine, 2-(2-furanyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



L7 ANSWER 321 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1947:20688 CAPLUS
 DOCUMENT NUMBER: 41:20688
 ORIGINAL REFERENCE NO.: 41:4156f-i, 4157a-b
 TITLE: 6- and 7-Chloro-4-(1-diethylamino-4-pentylamino)-2-(p-methoxyphenyl)quinazoline dihydrochlorides
 AUTHOR(S): McKee, R. L.; McKee, M. K.; Bost, R. W.
 CORPORATE SOURCE: Univ. North Carolina, Chapel Hill
 SOURCE: Journal of the American Chemical Society (1947), 69, 940-2
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

- AB 4,2-Cl(O₂N)C₆H₃CN (54.5 g.), added slowly to 220 g. SnCl₂ in 185 cc. concentrated HCl and 50 cc. AcOH at 25-30° and the mixture allowed to stand overnight, gives 73% 2-amino-4-chlorobenzonitrile (I), m. 161-2°; Fe and AcOH give 4,2-Cl(H₂N)C₆H₃CONH₂. I (17.5 g.) in 50 cc. C₅H₅N, treated dropwise with 41.3 g. p-MeOC₆H₄COCl, the mixture diluted with H₂O to 1 l., the gummy precipitate stirred with 100 cc. warm Me₂CO and 50 cc. 20% NaOH, diluted to 1 l., and the filtrate made just alkaline (phenolphthalein), gives 4.5 g. of the monoanisoyl derivative (II), m. 169-70°; the insol. portion, refluxed with 75 cc. Me₂CO and 50 cc. MeOH, gives a residue (6 g.) of the dianisoyl derivative (III), m. 216-17°; the extract yields 31 g. of a mixture of anisoylation products. II, III, or the mixture, refluxed 1 h. in 8 times its weight of 5% NaOH containing twice its weight of dioxane and twice its weight of 30% H₂O₂, gives 59% (on basis of I) of 7-chloro-2-(p-methoxyphenyl)-4-quinazoline (IV), m. 310-12° (decomposition). IV (10.5 g.) and 7.6 g. PCl₅ in 50 cc. POCl₃, refluxed 40 h., 35 cc. xylene added and 60 cc. solvent removed by distillation, the product treated with 21 g. Et₂N(CH₂)₃CHMeNH₂, and the mixture refluxed 4 h., give 91% of 7-chloro-4-(1-diethylamino-4-pentylamino)-2-(p-methoxyphenyl)quinazoline (as the di-HCl salt), m. 233-5° (decomposition). 7-Chloroisatoic anhydride (20 g.) and 100 cc. concentrated NH₄OH, refluxed 1 h. and the resulting solid extracted with Me₂CO, give 45% 5,2-Cl(NH₂)C₆H₃CONH₂ (V); the NH₄OH filtrate, neutralized with dilute AcOH, gives 4 g. 5-chloro-2-ureidobenzoic acid (VI), m. 184-5° and then 306-15°; heated 10 min. at 200°, VI gives 6-chlorobenzoylurea, m. 321-4°. V (8.5 g.) in 25 cc. C₅H₅N, treated slowly with 11 g. p-MeOC₆H₄COCl, the mixture heated 4 h. on the steam bath, and the resulting product refluxed 1 h. in 200 cc. 5% NaOH and 25 cc. dioxane, gives 84% 6-chloro-2-(p-methoxyphenyl)-4-quinazoline, m. 289-90°; this yields as above 57% 2-(p-methoxyphenyl)-4-(1-diethylamino-4-pentylamino)-6-chloroquinazoline-2HCl, m. 261-3° (decomposition).
- IT 5427-59-8P, Quinazoline, 6-chloro-4-(4-diethylamino-1-methylbutylamino)-2-(p-methoxyphenyl)-, dihydrochlorides
5431-76-5P, Quinazoline, 7-chloro-4-(4-diethylamino-1-methylbutylamino)-2-(p-methoxyphenyl)-, dihydrochlorides
RL: PREP (Preparation)
(preparation of)
- RN 5427-59-8 CAPLUS
- CN Quinazoline, 6-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]-2-(p-methoxyphenyl)-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

- RN 5431-76-5 CAPLUS
- CN 1,4-Pentanediamine, N₄-[7-chloro-2-(4-methoxyphenyl)-4-quinazolinyl]-N₁,N₁-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 322 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1947:15226 CAPLUS

DOCUMENT NUMBER: 41:15226

ORIGINAL REFERENCE NO.: 41:3108f-i

TITLE: Some basically substituted quinazolines

AUTHOR(S): McKee, R. L.; McKee, M. K.; Bost, R. W.

CORPORATE SOURCE: Univ. of N. Carolina, Chapel Hill

SOURCE: Journal of the American Chemical Society (1946), 68, 1902-3

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB 2,4-H₂N(MeO)C₆H₃CN (10.5 g.) in 40 cc. C₅H₅N, treated dropwise with 13.7 g. p-ClC₆H₄COCl with stirring and cooling and the mixture heated 5 hrs. on the steam bath, gives 64% 2-(p-chlorobenzamido)-4-methoxybenzonitrile (I), m. 173-5°. I (5 g.) in 13 cc. dioxane, treated with 20 g. NaOH in 100 cc. H₂O and then with 60 cc. 30% H₂O₂, the mixture refluxed 1 hr., 25 cc. H₂O₂ added, and the refluxing continued 30 min., gives 81% (70% conversion) 2-(p-chlorophenyl)-4-hydroxy-7-methoxyquinazoline (II), m. 315-16°. II (7.5 g.) and 5.4 g. PCl₅ in 50 cc. POCl₃, refluxed 40 hrs., 15 cc. xylene added, the solvent distilled off, and the residue heated 6 hrs. with 29.5 g. Et₂N(CH₂)₃CHMeNH₂, give 27% 2-(p-chlorophenyl)-4-(1-diethylamino-4-pentylamino)-7-methoxyquinazoline-2HCl, m. 235-6° (decomposition). 6,3,4-O₂N(MeO)2C₆H₂CN (56 g.) with 204 g. SnCl₂·2H₂O in 100 cc. concentrated HCl and 350 cc. AcOH at a temperature below 40° gives 83% 6-aminoveratronitrile (III), m. 92-3.5°. III (15 g.) in 100 cc. Me₂CO and 200 cc. H₂O containing 6.8 g. NaOH, treated with 14.5 g. p-ClC₆H₄COCl, gives 46% 6-(p-chlorobenzamido)veratronitrile (IV), m. 216-17°. IV with H₂O₂ as above gives 82% 2-(p-chlorophenyl)-6,7-dimethoxy-4-hydroxyquinazoline, m. 313-14°; treated with PCl₅ in POCl₃ and then with Et₂N(CH₂)₃CHMeNH₂ in C₅H₅N, this yields 30% 2-(p-chlorophenyl)-4-(1-diethylamino-4-pentylamino)-6,7-dimethoxyquinazoline-2HCl, m. 227-9° (decomposition).

IT 858236-34-7P, Quinazoline, 2-(p-chlorophenyl)-4-(4-diethylamino-1-methylbutylamino)-7-methoxy-, dihydrochloride 858236-36-9P, Quinazoline, 2-(p-chlorophenyl)-4-(4-diethylamino-1-methylbutylamino)-6,7-dimethoxy-, dihydrochloride

RL: PREP (Preparation)
(preparation of)


RN 858236-34-7 CAPLUS

CN 1,4-Pentanediamine, N₄-[2-(4-chlorophenyl)-7-methoxy-4-quinazolinyl]-N₁,N₁-diethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 858236-36-9 CAPLUS
 CN 1,4-Pentanediamine, N4-[2-(4-chlorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N1,N1-diethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


L7 ANSWER 323 OF 323 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1946:29348 CAPLUS
 DOCUMENT NUMBER: 40:29348
 ORIGINAL REFERENCE NO.: 40:5748b-e
 TITLE: Quinazoline derivatives. I. The synthesis of 4-(4'-diethylamino-1-methylbutylamino) quinazoline (SN 11,534) and the corresponding 2-phenylquinazoline (SN 11,535)
 AUTHOR(S): Endicott, Margaret M.; Wick, Emily; Mercury, Marie L.; Sherrill, Mary L.
 CORPORATE SOURCE: Mount Holyoke Coll., South Hadley, MA
 SOURCE: Journal of the American Chemical Society (1946), 68, 1299-301
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 40:29348
 AB o-H₂NC₆H₄CO₂H (137.1 g.) and 75.6 g. HCO₂H, heated 4 h. at 120-5°, give 90% of 4-quinazolone (I), m. 215.5-16.5° (m.ps. corrected). I (14.6 g.), 30 g. PCl₅, and 120 mL. POCl₃, heated 2 h. at 115-18°, give 62.5% of 4-chloroquinazoline (II), m. 96.5-7.5° (picrate, yellow, m. 170-70.5°). II (8.2 g.) and 17.4 g. of Et₂N(CH₂)₃CHMeNH₂ in C₆H₆, refluxed 2-3 h., give 98-9% of

4-(4-diethylamino-1-methylbutylamino)quinazoline (SN 11,534), m. 101-1.5° (picrate, yellow, m. 186.5-7.5°; diphosphate, with 1 mol. H2O, m. 141-2°, decomp. 145°, 95%). o-H2NC6H4CO2Me (or Et ester) (0.2 mol) and 0.22 mol PhC(:NH)OMe (or Et derivative), heated 2 h. at 210-20°, give 30-40% of 2-phenyl-4-quinazolone (III), m. 235-6°; o-H2NC6H4CO2H and PhCSNH2, heated 2 h. at 135-60°, give 50% of III. III, PCl5, and POCl3, heated 2 h. at 125-30°, give 76.8% of 4-chloro-2-phenylquinazoline (IV), m. 124-4.5° (picrate, yellow, m. 191-2°). IV and Et2N(CH2)3CHMeNH2 in C6H6, refluxed 6-7 h., give 85.5% of 4-(4-diethylamino-1-methylbutylamino)-2-phenylquinazoline (SN 11,535), yellow oil, b0.05 0.06 187-8° (picrate, bright yellow, m. 163-3.5°; diphosphate, with 1 mol. H2O, m. 221-4° (decomposition, uncor.), 95.3%).

IT 47546-42-9, Quinazoline, 4-(4-diethylamino-1-methylbutylamino)-2-phenyl-
(and salts)

RN 47546-42-9 CAPLUS

CN 1,4-Pentanediamine, N1,N1-diethyl-N4-(2-phenyl-4-quinazolinyl)- (CA INDEX NAME)



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1768.23

2131.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-258.40

-258.40

STN INTERNATIONAL LOGOFF AT 15:06:09 ON 05 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
 IPC display formats
 NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental
 spectra
 NEWS 4 MAR 31 CA/CAPplus and CASREACT patent number format for U.S.
 applications updated
 NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI
 NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued
 NEWS 8 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
 predefined hit display formats
 NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced
 NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements
 NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family
 searching
 NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
 sequence search option
 NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts
 NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents
 NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character
 patent numbers for U.S. applications
 NEWS 16 JUN 19 CAS REGISTRY includes selected substances from
 web-based collections
 NEWS 17 JUN 25 CA/CAPplus and USPAT databases updated with IPC
 reclassification data
 NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
 patent records
 NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
 options to display authors and affiliated
 organizations
 NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist
 Assistant and BLAST plug-in
 NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL
 NEWS 22 JUL 28 CA/CAPplus patent coverage enhanced
 NEWS 23 JUL 28 EPFULL enhanced with additional legal status
 information from the epoline Register
 NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS 25 JUL 28 STN Viewer performance improved
 NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:09:31 ON 05 AUG 2008

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HOME' AT 15:13:44 ON 05 AUG 2008

FILE 'HOME' ENTERED AT 15:13:44 ON 05 AUG 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 15:14:01 ON 05 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3

DICTIONARY FILE UPDATES: 4 AUG 2008 HIGHEST RN 1038507-75-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\bmcldowell\My Documents\misc\10552426specie.str



```

chain nodes :
19
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18 20 21 22 23 24 25 26
27 28
ring/chain nodes :
11
chain bonds :
7-11 9-13 11-19 11-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18 20-21 20-24 21-22 22-23 23-24 23-25 24-28 25-26 26-27 27-28

exact/norm bonds :
7-11 11-20 20-21 20-24 21-22 22-23
exact bonds :
9-13 11-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18 23-24 23-25 24-28 25-26 26-27 27-28
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

```

L1 STRUCTURE UPLOADED

```

=> s 11 exact sam
SAMPLE SEARCH INITIATED 15:14:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

```

```

100.0% PROCESSED          2 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE **COMPLETE**
                        BATCH  **COMPLETE**
PROJECTED ITERATIONS:   2 TO      124
PROJECTED ANSWERS:      0 TO      0

```

L2 0 SEA EXA SAM L1

=> s l1 exact full

FULL SEARCH INITIATED 15:14:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA EXA FUL L1

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

60.31

60.94

FILE 'CAPLUS' ENTERED AT 15:14:50 ON 05 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2008 VOL 149 ISS 6

FILE LAST UPDATED: 4 Aug 2008 (20080804/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 ibib abs hitstr

MISSING OPERATOR L3 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l3

L4 1 L3

=> d l4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:902403 CAPLUS

DN 141:374752

TI Heterocyclic compound modulators of kinases, particularly Tie-2 kinase, and use in the treatment of kinase-dependent diseases

IN Ibrahim, Mohamed; Leahy, James; Sangalang, Joan C.; Schnepf, Kevin; Shi, Xian; Nuss, John

PA Exelixis, Inc., USA

SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092196	A2	20041028	WO 2004-US10858	20040408
	WO 2004092196	A3	20050317		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004230928	A1	20041028	AU 2004-230928	20040408
	CA 2520323	A1	20041028	CA 2004-2520323	20040408
	EP 1610774	A2	20060104	EP 2004-749893	20040408
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	JP 2006523238	T	20061012	JP 2006-509820	20040408
	US 20070161651	A1	20070712	US 2005-552426	20051007
PRAI	US 2003-461446P	P	20030409		
	WO 2004-US10858	A	20040408		
OS	MARPAT 141:374752				

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.69

62.63

STN INTERNATIONAL LOGOFF AT 15:15:26 ON 05 AUG 2008